

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 759.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPTO)

Matches 43; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1149 ATTGCTTGGCCCATCTTCATGTCGAGCGCTCTCT 1191
 Db 43 ATTGCTTGGCCCATCTTCATGTCGAGCGCTCTCT 1

RESULT 3
 CL680542/c
 LOCUS
 DEFINITION CL680542 24 bp DNA linear GSS 09-JUL-2004
 PRI0129C.F01.2 - PRI0129C.BR (24) Mixed stage fosmid library of P.
 pacificus var. California Pristionchus pacificus genomic, genomic
 survey sequence.

ACCESSION CL680542
 VERSION CL680542
 KEYWORDS GI:50187453

SOURCE Pristionchus pacificus
 ORGANISM Pristionchus pacificus
 Neodiplogasteridae; Pristionchus.

REFERENCE 1 (bases 1 to 24)
 Srinivasan,J., Otto,G.W., Kahlow,U., Geisler,R. and Sommer,R.J.

JOURNAL AppAB: an Acedb database for the nematode satellite organism
 Pristionchus pacificus
 Nucleic Acids Res. 32 (1), D421-D422 (2004)
 COMMENT Contact: Sommer RJ
 Evolutionary Biology
 Max-Planck-Institute for Developmental Biology
 Spemannstr. 37-39, Tuebingen D-72076, Germany
 Tel: 00497071601371
 Fax: 00497071601498
 Email: ralf.sommer@tuebingen.mpg.de

This library was generated at Caltech, Pasadena, USA and end
 sequenced at Vancouver, Canada.
 Seq primer: T7
 Class: fosmid ends.

FEATURES
 source Location/Qualifiers

1..24
 /organism="Pristionchus pacificus"
 /mol_type="genomic DNA"
 /strain="California"
 /db_xref="taxon:54126"
 /clone_lib="Mixed stage fosmid library of P. pacificus
 var. California"
 /note="Vector: pGclfos-5 Fosmid vector"

Query Match 0.8%; Score 18.2; DB 1; Length 24;
 Best Local Similarity 87.0%; Pred. No. 5.1;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 5 GGGACGCCAGCGCGCGGCTGC 27
 Db 24 GGTAGCGCCAGCGCGGCGCAGC 2

RESULT 4
 CF921149 20 bp mRNA linear EST 05-NOV-2003
 LOCUS gmrhfw3-06.A05.1.047 Soybean root hair subtraced cDNA library
 DEFINITION gmrhfw3 Glycine max cDNA, mRNA sequence.
 CF921149
 CF921149.1 GI:38191943

ACCESSION CF921149
 VERSION CF921149
 KEYWORDS EST.
 SOURCE Glycine max (soybean)
 ORGANISM Glycine max

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eustosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
 Glycine.

REFERENCE 1 (bases 1 to 20)
 Schellier,B.E., Huang,S., Liu,X., Nguyen,H., Duke,M. and Stacey,G.
 TITLE Expressed sequence tags from soybean root hair subtractive cDNA
 library

JOURNAL Unpublished (2003)
 COMMENT Contact: Gary Stacey
 University of Missouri
 108 Waters Hall, Columbia, MO 65211, USA
 Tel: 573-884-4752
 Fax: 573-882-0588
 Email: stacey@missouri.edu
 Single pass sequence

Seq primer: T7
 FEATURES
 source Location/Qualifiers

1..20
 /organism="Glycine max"
 /mol_type="mRNA"
 /cultivar="Williams 82"
 /db_xref="taxon:3847"
 /tissue_type="root hairs"
 /clone_lib="Soybean root hair subtraced cDNA library
 gmrhfw3"
 /note="Organ: root hairs; Vector: PCR-1 Topo; cDNA clones
 generated from soybean root hair tissue treated with
 Bradyrhizobium japonicum for 3 hours."

Query Match 0.7%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 6.7;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 447 GTGCTCCAGTGGGCTCTGT 465
 Db 1 GTGCTCCAGGAGGTTCTGT 19

RESULT 5
 AA954509 19 bp mRNA linear EST 23-JUN-1998
 LOCUS on81d05.s1 Soares_NFL_T.GBC.S1 Homo sapiens cDNA clone
 IMAGE:1563081 3' similar to TR:Q24035 Q24035 ENA POLYPEPTIDE.
 ;contains element MSRI repetitive element ; mRNA sequence.

ACCESSION AA954509
 VERSION AA954509
 KEYWORDS GI:3118204

SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1 (bases 1 to 19)
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 JOURNAL National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgaps-remail.nih.gov

This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lln.gov) for further information.
 Trace considered overall poor quality
 Insert Length: 754 Std Error: 0.00
 Seq primer: -40m3 fwd. ET from Amersham
 High quality sequence stop: 1.

FEATURES
 source Location/Qualifiers
 1..19
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:1563081"
 /lab_host="DH10B"
 /clone_lib="Soares_NFL_T.GBC.S1"
 /note="Organ: pooled; Vector: pT73D-Pac (Pharmacia) with
 a modified polylinker; Site 1: Not 1; Site 2: Eco RI;
 Equal amounts of plasmid DNA from three normalized
 libraries (fetal lung NH419W, testis NHT, and B-cell)
 NCI-CGAP (GCBI) were mixed, and ss circles were made in
 vitro. Following HAP purification, this DNA was used as
 tracer in a subtractive hybridization reaction. The driver
 was PCR-amplified cDNAs from pools of 5,000 clones made

from the same 3 libraries. The pools consisted of
I.M.A.G.E. clones 297480-302087, 682632-687239,
726408-728711, and 729096-731399. Subtraction by Benito
Soares and M. Fatima Bonaldo."

Query Match

Best Local Similarity 94.1%; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 147 CCTGTGGCCCGGGGGCC 163
Db 1 CCCAGGCCCGGGGGCC 17

Search completed: August 8, 2005, 10:02:53
Job time : 0.001 secs

THIS PAGE BLANK (USPTO)

107	24	1.0	24	1	US-10-013-906A-293	Sequence 293, App	c 180	20	0.8	20	1	US-10-643-801-30	Sequence 30, Appl
108	24	1.0	24	1	US-10-013-906A-294	Sequence 294, App	c 181	20	0.8	20	1	US-10-643-801-31	Sequence 31, Appl
109	24	1.0	24	1	US-10-015-388A-293	Sequence 293, App	c 182	20	0.8	20	1	US-10-643-801-32	Sequence 32, Appl
110	24	1.0	24	1	US-10-015-388A-294	Sequence 294, App	c 183	20	0.8	20	1	US-10-643-801-33	Sequence 33, Appl
111	24	1.0	24	1	US-10-012-753A-293	Sequence 293, App	c 184	20	0.8	20	1	US-10-643-801-34	Sequence 34, Appl
112	24	1.0	24	1	US-10-012-753A-294	Sequence 294, App	c 185	20	0.8	20	1	US-10-643-801-35	Sequence 35, Appl
113	24	1.0	24	1	US-10-015-385A-293	Sequence 293, App	c 186	20	0.8	20	1	US-10-643-801-36	Sequence 36, Appl
114	24	1.0	24	1	US-10-015-385A-294	Sequence 294, App	c 187	20	0.8	20	1	US-10-643-801-37	Sequence 37, Appl
115	24	1.0	24	1	US-10-007-236A-293	Sequence 293, App	c 188	20	0.8	20	1	US-10-643-801-38	Sequence 38, Appl
116	24	1.0	24	1	US-10-007-236A-294	Sequence 294, App	c 189	20	0.8	20	1	US-10-643-801-39	Sequence 39, Appl
117	24	1.0	24	1	US-10-015-389A-293	Sequence 293, App	c 190	20	0.8	20	1	US-10-643-801-40	Sequence 40, Appl
118	24	1.0	24	1	US-10-015-389A-294	Sequence 294, App	c 191	20	0.8	20	1	US-10-643-801-41	Sequence 41, Appl
119	24	1.0	24	1	US-10-015-519A-293	Sequence 293, App	c 192	20	0.8	20	1	US-10-643-801-42	Sequence 42, Appl
120	24	1.0	24	1	US-10-015-519A-294	Sequence 294, App	c 193	20	0.8	20	1	US-10-643-801-43	Sequence 43, Appl
121	24	1.0	24	1	US-10-013-915A-293	Sequence 293, App	c 194	20	0.8	20	1	US-10-643-801-44	Sequence 44, Appl
122	24	1.0	24	1	US-10-013-915A-294	Sequence 294, App	c 195	20	0.8	20	1	US-10-643-801-45	Sequence 45, Appl
123	24	1.0	24	1	US-10-015-394A-293	Sequence 293, App	c 196	20	0.8	20	1	US-10-643-801-46	Sequence 46, Appl
124	24	1.0	24	1	US-10-015-394A-294	Sequence 294, App	c 197	20	0.8	20	1	US-10-643-801-47	Sequence 47, Appl
125	24	1.0	24	1	US-10-015-390A-293	Sequence 293, App	c 198	20	0.8	20	1	US-10-643-801-48	Sequence 48, Appl
126	24	1.0	24	1	US-10-015-390A-294	Sequence 294, App	c 199	20	0.8	20	1	US-10-643-801-49	Sequence 49, Appl
127	24	1.0	24	1	US-10-006-746A-293	Sequence 293, App	c 200	20	0.8	20	1	US-10-643-801-50	Sequence 50, Appl
128	24	1.0	24	1	US-10-006-746A-294	Sequence 294, App	c 201	20	0.8	20	1	US-10-643-801-51	Sequence 51, Appl
129	24	1.0	24	1	US-10-026-254A-293	Sequence 293, App	c 202	20	0.8	20	1	US-10-643-801-52	Sequence 52, Appl
130	24	1.0	24	1	US-10-026-254A-294	Sequence 294, App	c 203	20	0.8	20	1	US-10-643-801-53	Sequence 53, Appl
131	24	1.0	24	1	US-10-011-795A-293	Sequence 293, App	c 204	20	0.8	20	1	US-10-643-801-54	Sequence 54, Appl
132	24	1.0	24	1	US-10-011-795A-294	Sequence 294, App	c 205	20	0.8	20	1	US-10-643-801-55	Sequence 55, Appl
133	24	1.0	24	1	US-10-012-231A-293	Sequence 293, App	c 206	20	0.8	20	1	US-10-643-801-56	Sequence 56, Appl
134	24	1.0	24	1	US-10-012-231A-294	Sequence 294, App	c 207	20	0.8	20	1	US-10-643-801-57	Sequence 57, Appl
135	24	1.0	24	1	US-10-015-395A-293	Sequence 293, App	c 208	20	0.8	20	1	US-10-643-801-58	Sequence 58, Appl
136	24	1.0	24	1	US-10-015-395A-294	Sequence 294, App	c 209	20	0.8	20	1	US-10-643-801-59	Sequence 59, Appl
137	24	1.0	24	1	US-10-012-149A-293	Sequence 293, App	c 210	20	0.8	20	1	US-10-643-801-60	Sequence 60, Appl
138	24	1.0	24	1	US-10-012-149A-294	Sequence 294, App	c 211	20	0.8	20	1	US-10-643-801-61	Sequence 61, Appl
139	24	1.0	24	1	US-10-643-801-6	Sequence 6, Appl1	c 212	20	0.8	20	1	US-10-643-801-71	Sequence 71, Appl
140	23.4	1.0	25	1	US-10-719-900-684231	Sequence 684231, Sequence 761465,	c 213	20	0.8	20	1	US-10-643-801-72	Sequence 72, Appl
141	23.4	1.0	25	1	US-10-719-900-761465	Sequence 761465, Sequence 19410, A	c 214	20	0.8	20	1	US-10-643-801-73	Sequence 73, Appl
142	23.4	1.0	25	1	US-10-719-956-19410	Sequence 19410, A Sequence 102353,	c 215	20	0.8	20	1	US-10-643-801-74	Sequence 74, Appl
143	23.4	1.0	25	1	US-10-719-956-102353	Sequence 102353, Sequence 145295,	c 216	20	0.8	20	1	US-10-643-801-75	Sequence 75, Appl
144	23.4	1.0	25	1	US-10-719-956-145295	Sequence 145295, Sequence 323131	c 217	20	0.8	20	1	US-10-643-801-76	Sequence 76, Appl
145	23.4	1.0	25	1	US-10-719-956-323131	Sequence 323131, Sequence 22, Appl	c 218	20	0.8	20	1	US-10-643-801-77	Sequence 77, Appl
146	23	1.0	23	1	US-10-278-733-22	Sequence 22, Appl Sequence 25, Appl	c 219	20	0.8	20	1	US-10-643-801-78	Sequence 78, Appl
147	22	0.9	22	1	US-10-324-618-25	Sequence 25, Appl Sequence 73, Appl1	c 220	20	0.8	20	1	US-10-643-801-79	Sequence 79, Appl
148	22	0.9	22	1	US-10-643-801-5	Sequence 5, Appl1 Sequence 23, Appl	c 221	20	0.8	20	1	US-10-643-801-80	Sequence 80, Appl
149	22	0.9	22	1	US-10-643-801-7	Sequence 7, Appl1 Sequence 16467, A	c 222	20	0.8	20	1	US-10-643-801-81	Sequence 81, Appl
150	22	0.9	22	1	US-10-883-760-23	Sequence 23, Appl Sequence 881307, A	c 223	20	0.8	20	1	US-10-643-801-82	Sequence 82, Appl
151	21.8	0.9	25	1	US-10-719-900-16467	Sequence 16467, A Sequence 881307,	c 224	20	0.8	20	1	US-10-643-801-83	Sequence 83, Appl
152	21.8	0.9	25	1	US-10-719-900-811307	Sequence 811307, Sequence 881307,	c 225	20	0.8	20	1	US-10-643-801-84	Sequence 84, Appl
153	21.8	0.9	25	1	US-10-719-900-881307	Sequence 881307, Sequence 19409, A	c 226	20	0.8	20	1	US-10-643-801-85	Sequence 85, Appl
154	21.8	0.9	25	1	US-10-719-956-19409	Sequence 19409, A Sequence 102354,	c 227	20	0.8	20	1	US-10-643-801-86	Sequence 86, Appl
155	21.8	0.9	25	1	US-10-719-956-102354	Sequence 102354, Sequence 145296,	c 228	20	0.8	20	1	US-10-643-801-87	Sequence 87, Appl
156	21.8	0.9	25	1	US-10-719-956-145296	Sequence 145296, Sequence 630251,	c 229	20	0.8	20	1	US-10-643-801-88	Sequence 88, Appl
157	21.8	0.9	25	1	US-10-719-956-630251	Sequence 630251, Sequence 16468, A	c 230	20	0.8	20	1	US-10-643-801-89	Sequence 89, Appl
158	20.2	0.8	25	1	US-10-719-900-16468	Sequence 16468, A Sequence 263580,	c 231	20	0.8	20	1	US-10-643-801-90	Sequence 90, Appl
159	20.2	0.8	25	1	US-10-719-900-263580	Sequence 263580, Sequence 407646,	c 232	20	0.8	20	1	US-10-643-801-91	Sequence 91, Appl
160	20.2	0.8	25	1	US-10-719-900-407646	Sequence 407646, Sequence 539350,	c 233	20	0.8	20	1	US-10-643-801-92	Sequence 92, Appl
161	20.2	0.8	25	1	US-10-719-900-539350	Sequence 539350, Sequence 539351,	c 234	20	0.8	20	1	US-10-643-801-93	Sequence 93, Appl
162	20.2	0.8	25	1	US-10-719-900-539351	Sequence 539351, Sequence 811305,	c 235	20	0.8	20	1	US-10-643-801-94	Sequence 94, Appl
163	20.2	0.8	25	1	US-10-719-900-811305	Sequence 811305, Sequence 832328,	c 236	20	0.8	20	1	US-10-643-801-95	Sequence 95, Appl
164	20.2	0.8	25	1	US-10-719-900-832328	Sequence 832328, Sequence 881308,	c 237	20	0.8	20	1	US-10-643-801-96	Sequence 96, Appl
165	20.2	0.8	25	1	US-10-719-900-881308	Sequence 881308, Sequence 70482, A	c 238	20	0.8	20	1	US-10-643-801-97	Sequence 97, Appl
166	20.2	0.8	25	1	US-10-719-956-70482	Sequence 70482, A Sequence 630252,	c 239	20	0.8	20	1	US-10-643-801-143	Sequence 143, App
167	20.2	0.8	25	1	US-10-719-956-630252	Sequence 630252, Sequence 26, Appl	c 240	20	0.8	20	1	US-10-643-801-144	Sequence 144, App
168	20	0.8	20	1	US-10-324-618-26	Sequence 26, Appl Sequence 379, App	c 241	20	0.8	20	1	US-10-643-801-145	Sequence 145, App
169	20	0.8	20	1	US-10-307-817-379	Sequence 379, App Sequence 20, Appl	c 242	20	0.8	20	1	US-10-643-801-146	Sequence 146, App
170	20	0.8	20	1	US-10-643-801-20	Sequence 20, Appl Sequence 21, Appl	c 243	20	0.8	20	1	US-10-643-801-147	Sequence 147, App
171	20	0.8	20	1	US-10-643-801-21	Sequence 21, Appl Sequence 22, Appl	c 244	20	0.8	20	1	US-10-643-801-148	Sequence 148, App
172	20	0.8	20	1	US-10-643-801-22	Sequence 22, Appl Sequence 23, Appl	c 245	20	0.8	20	1	US-10-643-801-149	Sequence 149, App
173	20	0.8	20	1	US-10-643-801-23	Sequence 23, Appl Sequence 24, Appl	c 246	20	0.8	20	1	US-10-643-801-150	Sequence 150, App
174	20	0.8	20	1	US-10-643-801-24	Sequence 24, Appl Sequence 25, Appl	c 247	20	0.8	20	1	US-10-643-801-151	Sequence 151, App
175	20	0.8	20	1	US-10-643-801-25	Sequence 25, Appl Sequence 26, Appl	c 248	20	0.8	20	1	US-10-643-801-152	Sequence 152, App
176	20	0.8	20	1	US-10-643-801-26	Sequence 26, Appl Sequence 27, Appl	c 249	20	0.8	20	1	US-10-643-801-153	Sequence 153, App
177	20	0.8	20	1	US-10-643-801-27	Sequence 27, Appl Sequence 28, Appl	c 250	20	0.8	20	1	US-10-643-801-154	Sequence 154, App
178	20	0.8	20	1	US-10-643-801-28	Sequence 28, Appl Sequence 29, Appl	c 251	20	0.8	20	1	US-10-643-801-155	Sequence 155, App
179	20	0.8	20	1	US-10-643-801-29	Sequence 29, Appl Sequence 29, Appl	c 252	20	0.8	20	1	US-10-643-801-156	Sequence 156, App

253	20	0.8	20	1	US-10-643-801-157	Sequence 157, App	16.8	0.7	20	1	US-10-818-939-27	Sequence 27, Appl
254	20	0.8	20	1	US-10-643-801-158	Sequence 158, App	16.8	0.7	20	1	US-10-643-801-106	Sequence 106, App
255	20	0.8	20	1	US-10-643-801-159	Sequence 159, App	16.8	0.7	20	1	US-10-643-801-109	Sequence 109, App
256	20	0.8	20	1	US-10-643-801-160	Sequence 160, App	16.8	0.7	20	1	US-10-643-801-113	Sequence 113, App
257	20	0.8	20	1	US-10-643-801-161	Sequence 161, App	16.8	0.7	20	1	US-10-643-801-114	Sequence 114, App
258	20	0.8	20	1	US-10-643-801-162	Sequence 162, App	16.8	0.7	20	1	US-10-643-801-122	Sequence 122, App
259	20	0.8	20	1	US-10-643-801-163	Sequence 163, App	16.8	0.7	20	1	US-10-643-801-215	Sequence 215, App
260	20	0.8	20	1	US-10-643-801-164	Sequence 164, App	16.8	0.7	20	1	US-10-643-801-216	Sequence 216, App
261	20	0.8	20	1	US-10-643-801-165	Sequence 165, App	16.8	0.7	20	1	US-10-643-801-220	Sequence 220, App
262	20	0.8	20	1	US-10-643-801-166	Sequence 166, App	16.8	0.7	21	1	US-09-005-243-16	Sequence 16, Appl
263	20	0.8	20	1	US-10-643-801-167	Sequence 167, App	16.8	0.7	21	1	US-09-224-683-16	Sequence 16, Appl
264	20	0.8	20	1	US-10-643-801-168	Sequence 168, App	16.8	0.7	21	1	US-10-113-916-13	Sequence 13, Appl
265	20	0.8	20	1	US-10-643-801-169	Sequence 169, App	16.8	0.7	21	1	US-10-175-608-16	Sequence 16, Appl
266	20	0.8	20	1	US-10-643-801-170	Sequence 170, App	16.8	0.7	21	1	US-10-791-074-13	Sequence 13, Appl
267	20	0.8	20	1	US-10-643-801-171	Sequence 171, App	16.8	0.7	21	1	US-10-620-644-16	Sequence 16, Appl
268	20	0.8	20	1	US-10-643-801-172	Sequence 172, App	16.8	0.7	22	1	US-10-491-786-41	Sequence 41, Appl
269	20	0.8	20	1	US-10-643-801-173	Sequence 173, App	16.4	0.7	21	1	US-10-223-598-39	Sequence 39, Appl
270	20	0.8	20	1	US-10-643-801-174	Sequence 174, App	16.4	0.7	21	1	US-10-786-720-1409	Sequence 1409, Ap
271	20	0.8	20	1	US-10-643-801-182	Sequence 182, App	16.4	0.7	21	1	US-10-786-720-2516	Sequence 2516, Ap
272	20	0.8	20	1	US-10-643-801-183	Sequence 183, App	16.4	0.7	21	1	US-10-751-736-41385	Sequence 41385, A
273	20	0.8	20	1	US-10-643-801-184	Sequence 184, App	16.4	0.7	21	1	US-10-751-736-42150	Sequence 42150, A
274	20	0.8	20	1	US-10-643-801-185	Sequence 185, App	16.4	0.7	21	1	US-10-751-736-42150	Sequence 42150, A
275	20	0.8	20	1	US-10-643-801-186	Sequence 186, App	16.4	0.7	21	1	US-10-751-736-42150	Sequence 42150, A
276	20	0.8	20	1	US-10-643-801-187	Sequence 187, App	16.4	0.7	21	1	US-10-751-736-42150	Sequence 42150, A
277	20	0.8	20	1	US-10-643-801-188	Sequence 188, App	16.2	0.7	21	1	US-10-800-077-359	Sequence 359, App
278	20	0.8	20	1	US-10-643-801-189	Sequence 189, App	16.2	0.7	21	1	US-10-625-153-4	Sequence 4, Appl
279	20	0.8	20	1	US-10-643-801-190	Sequence 190, App	16.2	0.7	21	1	US-10-786-720-20417	Sequence 20417, A
280	20	0.8	20	1	US-10-643-801-191	Sequence 191, App	16.2	0.7	21	1	US-10-751-736-15119	Sequence 15119, A
281	20	0.8	20	1	US-10-643-801-192	Sequence 192, App	16.2	0.7	21	1	US-10-751-736-19221	Sequence 19221, A
282	20	0.8	20	1	US-10-643-801-193	Sequence 193, App	16.2	0.7	21	1	US-10-751-736-42616	Sequence 42616, A
283	20	0.8	20	1	US-10-643-801-194	Sequence 194, App	16.2	0.7	21	1	US-10-751-736-43132	Sequence 43132, A
284	20	0.8	20	1	US-10-643-801-195	Sequence 195, App	16.2	0.7	21	1	US-10-751-736-43411	Sequence 43411, A
285	20	0.8	20	1	US-10-643-801-196	Sequence 196, App	16	0.7	17	1	US-10-712-677-391	Sequence 391, App
286	20	0.8	20	1	US-10-643-801-197	Sequence 197, App	16	0.7	19	1	US-10-483-289A-85	Sequence 85, Appl
287	20	0.8	20	1	US-10-643-801-198	Sequence 198, App	15.8	0.7	19	1	US-10-180-781-80	Sequence 80, Appl
288	20	0.8	20	1	US-10-643-801-199	Sequence 199, App	15.8	0.7	20	1	US-08-771-737-8	Sequence 8, Appl
289	20	0.8	20	1	US-10-643-801-200	Sequence 200, App	15.8	0.7	20	1	US-09-954-936-8	Sequence 8, Appl
290	20	0.8	20	1	US-10-643-801-201	Sequence 201, App	15.8	0.7	20	1	US-10-972-607-12	Sequence 12, Appl
291	20	0.8	20	1	US-10-643-801-202	Sequence 202, App	15.8	0.7	20	1	US-10-376-566-63	Sequence 63, Appl
292	20	0.8	20	1	US-10-643-801-203	Sequence 203, App	15.8	0.7	20	1	US-10-455-229-22	Sequence 22, Appl
293	20	0.8	20	1	US-10-643-801-204	Sequence 204, App	15.8	0.7	20	1	US-10-628-841-12	Sequence 12, Appl
294	20	0.8	20	1	US-10-643-801-205	Sequence 205, App	15.8	0.7	20	1	US-10-749-075-8	Sequence 8, Appl
295	20	0.8	20	1	US-10-643-801-206	Sequence 206, App	15.8	0.7	20	1	US-10-643-801-111	Sequence 11, App
296	20	0.8	20	1	US-10-643-801-207	Sequence 207, App	15.8	0.7	20	1	US-10-257-158A-6237	Sequence 6237, Ap
297	20	0.8	20	1	US-10-643-801-208	Sequence 208, App	15.8	0.7	21	1	US-10-432-422-20	Sequence 20, Appl
298	20	0.8	20	1	US-10-643-801-209	Sequence 209, App	15.8	0.7	21	1	US-10-786-720-12520	Sequence 12520, A
299	20	0.8	20	1	US-10-643-801-210	Sequence 210, App	15.8	0.7	21	1	US-10-786-720-12521	Sequence 12521, A
300	20	0.8	20	1	US-10-643-801-211	Sequence 211, App	15.8	0.7	21	1	US-10-786-720-12522	Sequence 12522, A
301	20	0.8	20	1	US-10-643-801-212	Sequence 212, App	15.8	0.7	21	1	US-10-786-720-20416	Sequence 20416, A
302	20	0.8	20	1	US-10-643-801-213	Sequence 213, App	15.8	0.7	21	1	US-10-786-720-20418	Sequence 20418, A
303	19.4	0.8	25	1	US-10-719-956-301629	Sequence 301629,	15.8	0.6	17	1	US-10-751-736-18485	Sequence 18485, A
304	19.2	0.8	25	1	US-10-719-900-885846	Sequence 885846,	15.8	0.7	21	1	US-10-751-736-14042	Sequence 14042, A
305	19.2	0.8	25	1	US-10-809-189-52073	Sequence 52073, A	15.8	0.7	21	1	US-10-751-736-44617	Sequence 44617, A
306	19.2	0.8	25	1	US-10-956-157-170437	Sequence 170437,	15.8	0.7	21	1	US-10-847-918-1719	Sequence 12719, A
307	19.2	0.8	25	1	US-10-719-956-226834	Sequence 226834,	15.4	0.6	17	1	US-09-866-108-2021	Sequence 2021, Ap
308	18.8	0.8	25	1	US-10-719-900-194173	Sequence 194173,	15.4	0.6	17	1	US-09-866-108-2842	Sequence 2842, Ap
309	18.8	0.8	25	1	US-10-719-900-903590	Sequence 903590,	15.4	0.6	17	1	US-10-238-700-2	Sequence 2, Appl
310	18.8	0.8	25	1	US-10-719-956-30682	Sequence 30682, A	15.4	0.6	17	1	US-10-712-677-330	Sequence 390, App
311	18.8	0.8	25	1	US-10-719-956-451896	Sequence 451896,	15.4	0.6	17	1	US-10-723-361-2021	Sequence 2021, Ap
312	18.4	0.8	20	1	US-10-643-801-108	Sequence 108, App	15.4	0.6	17	1	US-10-723-361-2842	Sequence 2842, Ap
313	18.4	0.8	20	1	US-10-643-801-110	Sequence 110, App	15.4	0.6	17	1	US-10-498-468-1757	Sequence 1757, Ap
314	18.4	0.8	20	1	US-10-643-801-115	Sequence 115, App	15.4	0.6	17	1	US-10-498-468-1759	Sequence 1759, Ap
315	18.4	0.8	20	1	US-10-643-801-117	Sequence 117, App	15.4	0.6	17	1	US-10-724-270-2	Sequence 2, Appl
316	18.4	0.8	20	1	US-10-643-801-119	Sequence 119, App	15.4	0.6	17	1	US-10-353-461-2	Sequence 13, Appl
317	18.4	0.8	20	1	US-10-643-801-217	Sequence 217, App	15.4	0.6	20	1	US-10-303-266-15	Sequence 15, Appl
318	17.4	0.7	19	1	US-10-278-733-24	Sequence 24, Appl	15.4	0.6	20	1	US-10-874-242-13	Sequence 13, Appl
319	17.4	0.7	20	1	US-10-643-801-141	Sequence 141, App	15.2	0.6	20	1	US-09-373-938-10	Sequence 10, Appl
320	17.2	0.7	22	1	US-10-229-834A-11	Sequence 11, Appl	15.2	0.6	20	1	US-09-784-674-552	Sequence 552, App
321	17.2	0.7	22	1	US-10-806-782-20	Sequence 20, Appl	15.2	0.6	20	1	US-09-784-674-553	Sequence 553, App
322	17	0.7	21	1	US-10-349-143-11680	Sequence 11680, A	15.2	0.6	20	1	US-10-080-797-8	Sequence 8, Appl
323	16.8	0.7	20	1	US-09-733-294A-40	Sequence 40, Appl	15.2	0.6	20	1	US-10-057-550-80	Sequence 80, Appl
324	16.8	0.7	20	1	US-10-174-175-15	Sequence 15, Appl	15.2	0.6	20	1	US-10-037-182-22	Sequence 22, Appl
325	16.8	0.7	20	1	US-10-174-175-52	Sequence 52, Appl	15.2	0.6	20	1	US-10-045-360-16	Sequence 16, Appl

C 399	15.2	0.6	20	1	US-10-176-277-16	Sequence 16, Appl
C 400	15.2	0.6	20	1	US-10-176-277-20	Sequence 20, Appl
C 401	15.2	0.6	20	1	US-10-176-277-53	Sequence 53, Appl
C 402	15.2	0.6	20	1	US-10-176-277-56	Sequence 56, Appl
C 403	15.2	0.6	20	1	US-10-186-157-76	Sequence 76, Appl
C 404	15.2	0.6	20	1	US-10-289-762-3356	Sequence 3356, Ap
C 405	15.2	0.6	20	1	US-10-210-838-36	Sequence 36, Appl
C 406	15.2	0.6	20	1	US-10-210-838-141	Sequence 141, Appl
C 407	15.2	0.6	20	1	US-10-348-346-16	Sequence 16, Appl
C 408	15.2	0.6	20	1	US-10-273-826-24	Sequence 24, Appl
C 409	15.2	0.6	20	1	US-10-274-347-24	Sequence 24, Appl
C 410	15.2	0.6	20	1	US-10-280-183A-459	Sequence 459, App
C 411	15.2	0.6	20	1	US-10-300-424-77	Sequence 77, Appl
C 412	15.2	0.6	20	1	US-10-300-424-124	Sequence 124, Appl
C 413	15.2	0.6	20	1	US-10-300-399-28	Sequence 28, Appl
C 414	15.2	0.6	20	1	US-10-300-399-105	Sequence 105, App
C 415	15.2	0.6	20	1	US-10-688-706-316	Sequence 316, App
C 416	15.2	0.6	20	1	US-10-688-706-2458	Sequence 2458, Ap
C 417	15.2	0.6	20	1	US-10-316-459-16	Sequence 16, Appl
C 418	15.2	0.6	20	1	US-10-316-459-94	Sequence 94, Appl
C 419	15.2	0.6	20	1	US-10-671-395-1546	Sequence 1546, Ap
C 420	15.2	0.6	20	1	US-10-666-909-14	Sequence 14, Appl
C 421	15.2	0.6	20	1	US-10-666-909-62	Sequence 62, Appl
C 422	15.2	0.6	20	1	US-10-744-055-16	Sequence 16, Appl
C 423	15.2	0.6	20	1	US-10-877-231-552	Sequence 552, App
C 424	15.2	0.6	20	1	US-10-877-231-553	Sequence 553, App
C 425	15.2	0.6	20	1	US-10-643-801-107	Sequence 107, App
C 426	15.2	0.6	20	1	US-10-643-801-116	Sequence 116, App
C 427	15.2	0.6	20	1	US-10-831-901A-1717	Sequence 1717, Ap
C 428	15.2	0.6	20	1	US-10-831-901A-1718	Sequence 1718, Ap
C 429	15.2	0.6	20	1	US-10-831-901A-1719	Sequence 1719, Ap
C 430	15.2	0.6	20	1	US-10-831-901A-1720	Sequence 1720, Ap
C 431	15.2	0.6	20	1	US-10-018-320A-13	Sequence 13, Appl
C 432	15	0.6	17	1	US-09-861-077-153	Sequence 153, App
C 433	15	0.6	17	1	US-09-861-077-155	Sequence 155, App
C 434	15	0.6	17	1	US-10-156-306-6949	Sequence 6949, Ap
C 435	15	0.6	17	1	US-10-156-306-6950	Sequence 6950, Ap
C 436	15	0.6	17	1	US-10-238-700-2764	Sequence 2764, Ap
C 437	15	0.6	17	1	US-10-498-462-1758	Sequence 1758, Ap
C 438	15	0.6	17	1	US-10-724-270-1443	Sequence 1443, Ap
C 439	15	0.6	20	1	US-09-938-689-14	Sequence 14, Appl
C 440	14.8	0.6	18	1	US-08-887-505-145	Sequence 145, Appl
C 441	14.8	0.6	18	1	US-10-297-068-352	Sequence 352, App
C 442	14.8	0.6	18	1	US-10-813-203-1	Sequence 1, Appl
C 443	14.8	0.6	19	1	US-08-983-605-55	Sequence 55, Appl
C 444	14.8	0.6	19	1	US-09-901-484A-476	Sequence 476, App
C 445	14.8	0.6	19	1	US-09-966-147-22	Sequence 22, Appl
C 446	14.8	0.6	19	1	US-09-853-926-476	Sequence 476, App
C 447	14.8	0.6	19	1	US-09-864-954D-8	Sequence 8, Appl
C 448	14.8	0.6	19	1	US-10-045-360-17	Sequence 17, Appl
C 449	14.8	0.6	19	1	US-10-374-469-22	Sequence 22, Appl
C 450	14.8	0.6	19	1	US-10-698-597-22	Sequence 22, Appl
C 451	14.8	0.6	19	1	US-10-348-346-17	Sequence 17, Appl
C 452	14.8	0.6	19	1	US-10-683-990-57	Sequence 57, Appl
C 453	14.8	0.6	19	1	US-10-683-990-154	Sequence 154, App
C 454	14.8	0.6	19	1	US-10-744-055-17	Sequence 17, Appl
C 455	14.8	0.6	19	1	US-10-923-115-3	Sequence 3, Appl
C 456	14.8	0.6	19	1	US-10-923-115-119	Sequence 119, App
C 457	14.8	0.6	19	1	US-10-888-226-288	Sequence 288, App
C 458	14.8	0.6	19	1	US-10-888-226-702	Sequence 702, App
C 459	14.8	0.6	19	1	US-10-505-030-4	Sequence 4, Appl
C 460	14.8	0.6	19	1	US-10-697-527-55	Sequence 55, Appl
C 461	14.8	0.6	19	1	US-10-923-522-6	Sequence 6, Appl
C 462	14.8	0.6	19	1	US-10-923-522-269	Sequence 269, App
C 463	14.8	0.6	19	1	US-10-923-522-568	Sequence 568, App
C 464	14.8	0.6	19	1	US-10-923-522-887	Sequence 887, App

ALIGNMENTS

RESULT 1
US-09-908-975-16614/C

; Sequence 16614, Application US/09908975		; Publication No. US20030165843A1	
; GENERAL INFORMATION:		; APPLICANT: SHOSHAN, Avi	
; APPLICANT: WASSERMAN, Alon		; APPLICANT: MINTZ, Eli	
; APPLICANT: FAJLER, Slomchon		; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLIC	
; FILE REFERENCE: 36688-0005		; CURRENT FILING DATE: 2001-07-20	
; PRIOR FILING DATE: 2001-05-02		; PRIOR APPLICATION NUMBER: US 60/221,607	
; NUMBER OF SEQ ID NOS: 32337		; SOFTWARE: PatentIn version 3.0	
; SEQ ID NO 16614		; LENGTH: 60	
; TYPE: DNA		; ORGANISM: Homo sapiens	
; ORGANISM: Homo sapiens		; US-09-908-975-16614	
Query Match		2.5%; Score 60; DB 1; Length 60;	
Best Local Similarity		100.0%; Pred. No. 0.2;	
Matches		60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Db		1767 ACTTCTCATACAGCCCTTTATTCACATACCCACGCTGCTAGTCTGAAACTGCA 1826	
60 ACTTCTCATACAGCCCTTTATTCACATACCCACGCTGCTAGTCTGAAACTGCA 1			
RESULT 2		US-10-324-618-27	
; Sequence 27, Application US/10324618		; Publication No. US20030170691A1	
; GENERAL INFORMATION:		; APPLICANT: Gimeno, Ruth	
; APPLICANT: Wu, Zhidan		; APPLICANT: Kapeller-Liebermann, Rosana	
; APPLICANT: Hubbard, Brian K.		; TITLE OF INVENTION: HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2	
; FILE REFERENCE: MP101-263P2RM		; CURRENT FILING DATE: 2002-12-19	
; PRIOR FILING DATE: 2002-12-19		; PRIOR APPLICATION NUMBER: 60/341,947	
; PRIOR FILING DATE: 2002-09-19		; PRIOR APPLICATION NUMBER: 60/411,859	
; NUMBER OF SEQ ID NOS: 65		; SOFTWARE: FastSeq for Windows Version 4.0	
; SEQ ID NO 27		; LENGTH: 28	
; TYPE: DNA		; ORGANISM: Artificial Sequence	
; FEATURE:		; OTHER INFORMATION: 86606 probe	
; US-10-324-618-27			
Query Match		1.2%; Score 28; DB 1; Length 28;	
Best Local Similarity		100.0%; Pred. No. 46;	
Matches		28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Db		1800 CCACGCTGCTAGTCTGAAACTGCAG 1827	
1 CCACGCTGCTAGTCTGAAACTGCAG 28			
RESULT 3		US-10-307-817-378	

```
; Sequence 378, Application US/10307817
; Publication No. US20040058338A1
; GENERAL INFORMATION:
; APPLICANT: Agee et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-502C
; CURRENT APPLICATION NUMBER: US/10/307,817
; CURRENT FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 682
; SOFTWARE: CuraSeqlist version 0.1
; SEQ ID NO 378
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-307-817-378

Query Match
Best Local Similarity 100.0%; Score 26; DB 1; Length 27;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1167 ATCTTCATGTCGAGGCTCTTCTC 1192
DB 2 ATCTTCATGTCGAGGCTCTTCTC 27

RESULT 4
US-10-719-900-684232
; Sequence 684232, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 684232
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-684232

Query Match
Best Local Similarity 100.0%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1469 GTCATGGGTGTCTGTGGGTTATTTA 1493
DB 1 GTCATGGGTGTCTGTGGGTTATTTA 25

RESULT 5
US-10-719-900-761464
; Sequence 761464, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 761464
; LENGTH: 25
; TYPE: DNA
```

```
; ORGANISM: Mus musculus
US-10-719-900-761464

Query Match
Best Local Similarity 100.0%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1314 TACATGAGGCGCTGTGAAGCTCT 1338
DB 1 TACATGAGGCGCTGTGAAGCTCT 25

RESULT 6
US-10-719-956-323130
; Sequence 323130, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 323130
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-323130

Query Match
Best Local Similarity 100.0%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1296 GACCTGTACACACCATGTACATGG 1320
DB 1 GACCTGTACACACCATGTACATGG 25

RESULT 7
US-09-946-374-293
; Sequence 293, Application US/09946374
; Publication No. US20030073129A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PICI
; CURRENT APPLICATION NUMBER: US/09/946,374
; CURRENT FILING DATE: 2001-09-04
; PRIOR APPLICATION NUMBER: 60/098716
```

[illegible]

;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1041 GCTGACCTGCTCCATCTACTCC 1064
Db 1 GCTGACCTGCTCCATCTACTCC 24
RESULT 8
US-09-946-374-294/c
; Sequence 294, Application US/09946374
; Publication No. US20030073129A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tuma, Daniel
; APPLICANT: Williams, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: F2830F1C1
; CURRENT APPLICATION NUMBER: US/09/946,374
; PRIOR FILING DATE: 2001-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01

;; PRIOR APPLICATION NUMBER: 60/098803
;; PRIOR FILING DATE: 1998-09-02
;; PRIOR APPLICATION NUMBER: 60/098821
;; PRIOR FILING DATE: 1998-09-02
;; PRIOR APPLICATION NUMBER: 60/098843
;; PRIOR FILING DATE: 1998-09-02
;; PRIOR APPLICATION NUMBER: 60/099536
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099596
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099598
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099602
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099642
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099741
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099754
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099763
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099792
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099808
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099812
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099815
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099816
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/100385
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100388
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100390
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100584
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100627
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100661
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100662
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100664
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100683
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100684
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100710
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100711
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100849
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100930
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101014
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101068
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101071
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101279
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: 60/101471

```

; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103463
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14

```

```

; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1463 GGAGGTGCATGGGTGCTGTGGG 1486
Db      24  GGAGGTGCATGGGTGCTGTGGG 1

```

```

RESULT 9
US-10-006-856A-293
; Sequence 293, Application US/10006856A
; Publication No. US20030044841A1
GENERAL INFORMATION:

```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C14
; CURRENT APPLICATION NUMBER: US/10/006,856A
; CURRENT FILING DATE: 2002-05-10
; NUMBER OF SEQ ID NOS: 477
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-856A-293

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1041 GCTGACCTGCTTCCCATCTACTCC 1064
Db      1    GCTGACCTGCTTCCCATCTACTCC 24

```

```

RESULT 10
US-10-006-856A-294/C
; Sequence 294, Application US/10006856A

```

```
/ Publication No. US20030044841A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C14
/ CURRENT APPLICATION NUMBER: US/10/006,856A
/ CURRENT FILING DATE: 2002-05-10
/ NUMBER OF SEQ ID NOS: 477
/ Prior Application removed - See File Wrapper or Palm
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
/ US-10-006-856A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTCAATGGGTCTGTGTGGG 1486
DB      24 GGAAGTGTCAATGGGTCTGTGTGGG 1

RESULT 11
/ US-10-006-818A-293
/ Sequence 293, Application US/10006818A
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C14
/ CURRENT APPLICATION NUMBER: US/10/006,818A
/ CURRENT FILING DATE: 2001-12-06
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
/ US-10-006-818A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGCTTCCATCTACTCC 1064
DB      1 GCTGACCTGCTTCCATCTACTCC 24

RESULT 12
/ US-10-006-818A-294/c
/ Sequence 294, Application US/10006818A
/ Publication No. US20030054406A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C14
/ CURRENT APPLICATION NUMBER: US/10/006,818A
/ CURRENT FILING DATE: 2001-12-06
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
/ US-10-006-818A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTCAATGGGTCTGTGTGGG 1486
DB      24 GGAAGTGTCAATGGGTCTGTGTGGG 1

RESULT 13
/ US-10-006-485A-293
/ Sequence 293, Application US/10006485A
/ Publication No. US20030064062A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

1	FILE OF INVENTION: Acids Encoding the Same	2	PRIOR FILING DATE: 1998-09-17
2	FILE REFERENCE: P28301C9	3	PRIOR APPLICATION NUMBER: 60/100930
3	CURRENT APPLICATION NUMBER: US/10/006,485A	4	PRIOR FILING DATE: 1998-09-17
4	CURRENT FILING DATE: 2001-12-06	5	PRIOR APPLICATION NUMBER: 60/101014
5	PRIOR APPLICATION NUMBER: 60/098716	6	PRIOR FILING DATE: 1998-09-18
6	PRIOR FILING DATE: 1998-09-01	7	PRIOR APPLICATION NUMBER: 60/101068
7	PRIOR APPLICATION NUMBER: 60/098723	8	PRIOR FILING DATE: 1998-09-18
8	PRIOR FILING DATE: 1998-09-01	9	PRIOR APPLICATION NUMBER: 60/101071
9	PRIOR APPLICATION NUMBER: 60/098749	10	PRIOR FILING DATE: 1998-09-18
10	PRIOR FILING DATE: 1998-09-01	11	PRIOR APPLICATION NUMBER: 60/101279
11	PRIOR APPLICATION NUMBER: 60/098750	12	PRIOR FILING DATE: 1998-09-22
12	PRIOR FILING DATE: 1998-09-01	13	PRIOR APPLICATION NUMBER: 60/101471
13	PRIOR APPLICATION NUMBER: 60/098803	14	PRIOR FILING DATE: 1998-09-23
14	PRIOR FILING DATE: 1998-09-02	15	PRIOR APPLICATION NUMBER: 60/101472
15	PRIOR APPLICATION NUMBER: 60/098821	16	PRIOR FILING DATE: 1998-09-23
16	PRIOR FILING DATE: 1998-09-02	17	PRIOR APPLICATION NUMBER: 60/101474
17	PRIOR APPLICATION NUMBER: 60/098843	18	PRIOR FILING DATE: 1998-09-23
18	PRIOR FILING DATE: 1998-09-02	19	PRIOR APPLICATION NUMBER: 60/101475
19	PRIOR APPLICATION NUMBER: 60/099536	20	PRIOR FILING DATE: 1998-09-23
20	PRIOR FILING DATE: 1998-09-09	21	PRIOR APPLICATION NUMBER: 60/101476
21	PRIOR APPLICATION NUMBER: 60/099596	22	PRIOR FILING DATE: 1998-09-23
22	PRIOR FILING DATE: 1998-09-09	23	PRIOR APPLICATION NUMBER: 60/101477
23	PRIOR APPLICATION NUMBER: 60/099598	24	PRIOR FILING DATE: 1998-09-23
24	PRIOR FILING DATE: 1998-09-09	25	PRIOR APPLICATION NUMBER: 60/101479
25	PRIOR APPLICATION NUMBER: 60/099602	26	PRIOR FILING DATE: 1998-09-23
26	PRIOR FILING DATE: 1998-09-09	27	PRIOR APPLICATION NUMBER: 60/101738
27	PRIOR APPLICATION NUMBER: 60/099642	28	PRIOR FILING DATE: 1998-09-24
28	PRIOR FILING DATE: 1998-09-09	29	PRIOR APPLICATION NUMBER: 60/101741
29	PRIOR APPLICATION NUMBER: 60/099741	30	PRIOR FILING DATE: 1998-09-24
30	PRIOR FILING DATE: 1998-09-10	31	PRIOR APPLICATION NUMBER: 60/101743
31	PRIOR APPLICATION NUMBER: 60/099754	32	PRIOR FILING DATE: 1998-09-24
32	PRIOR FILING DATE: 1998-09-10	33	PRIOR APPLICATION NUMBER: 60/101915
33	PRIOR APPLICATION NUMBER: 60/099763	34	PRIOR FILING DATE: 1998-09-24
34	PRIOR FILING DATE: 1998-09-10	35	PRIOR APPLICATION NUMBER: 60/101916
35	PRIOR APPLICATION NUMBER: 60/099792	36	PRIOR FILING DATE: 1998-09-24
36	PRIOR FILING DATE: 1998-09-10	37	PRIOR APPLICATION NUMBER: 60/102207
37	PRIOR APPLICATION NUMBER: 60/099808	38	PRIOR FILING DATE: 1998-09-29
38	PRIOR FILING DATE: 1998-09-10	39	PRIOR APPLICATION NUMBER: 60/102240
39	PRIOR APPLICATION NUMBER: 60/099812	40	PRIOR FILING DATE: 1998-09-29
40	PRIOR FILING DATE: 1998-09-10	41	PRIOR APPLICATION NUMBER: 60/102307
41	PRIOR APPLICATION NUMBER: 60/099815	42	PRIOR FILING DATE: 1998-09-29
42	PRIOR FILING DATE: 1998-09-10	43	PRIOR APPLICATION NUMBER: 60/102330
43	PRIOR APPLICATION NUMBER: 60/099816	44	PRIOR FILING DATE: 1998-09-29
44	PRIOR FILING DATE: 1998-09-10	45	PRIOR APPLICATION NUMBER: 60/102331
45	PRIOR APPLICATION NUMBER: 60/100385	46	PRIOR FILING DATE: 1998-09-29
46	PRIOR FILING DATE: 1998-09-15	47	PRIOR APPLICATION NUMBER: 60/102484
47	PRIOR APPLICATION NUMBER: 60/100388	48	PRIOR FILING DATE: 1998-09-30
48	PRIOR FILING DATE: 1998-09-15	49	PRIOR APPLICATION NUMBER: 60/102487
49	PRIOR APPLICATION NUMBER: 60/100390	50	PRIOR FILING DATE: 1998-09-30
50	PRIOR FILING DATE: 1998-09-15	51	PRIOR APPLICATION NUMBER: 60/102570
51	PRIOR APPLICATION NUMBER: 60/100584	52	PRIOR FILING DATE: 1998-09-30
52	PRIOR FILING DATE: 1998-09-16	53	PRIOR APPLICATION NUMBER: 60/102571
53	PRIOR APPLICATION NUMBER: 60/100627	54	PRIOR FILING DATE: 1998-09-30
54	PRIOR FILING DATE: 1998-09-16	55	PRIOR APPLICATION NUMBER: 60/102684
55	PRIOR APPLICATION NUMBER: 60/100661	56	PRIOR FILING DATE: 1998-10-01
56	PRIOR FILING DATE: 1998-09-16	57	PRIOR APPLICATION NUMBER: 60/102687
57	PRIOR APPLICATION NUMBER: 60/100662	58	PRIOR FILING DATE: 1998-10-01
58	PRIOR FILING DATE: 1998-09-16	59	PRIOR APPLICATION NUMBER: 60/102955
59	PRIOR APPLICATION NUMBER: 60/100664	60	PRIOR FILING DATE: 1998-10-02
60	PRIOR FILING DATE: 1998-09-16	61	PRIOR APPLICATION NUMBER: 60/103258
61	PRIOR APPLICATION NUMBER: 60/100683	62	PRIOR FILING DATE: 1998-10-06
62	PRIOR FILING DATE: 1998-09-17	63	PRIOR APPLICATION NUMBER: 60/103314
63	PRIOR APPLICATION NUMBER: 60/100684	64	PRIOR FILING DATE: 1998-10-07
64	PRIOR FILING DATE: 1998-09-17	65	PRIOR APPLICATION NUMBER: 60/103315
65	PRIOR APPLICATION NUMBER: 60/100710	66	PRIOR FILING DATE: 1998-10-07
66	PRIOR FILING DATE: 1998-09-17	67	PRIOR APPLICATION NUMBER: 60/103328
67	PRIOR APPLICATION NUMBER: 60/100711	68	PRIOR FILING DATE: 1998-10-07
68	PRIOR FILING DATE: 1998-09-17	69	PRIOR APPLICATION NUMBER: 60/103395
69	PRIOR APPLICATION NUMBER: 60/100848	70	PRI

```
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28
```

Query Match 1.0%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Freq. No. 82; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1041 GGTGACCTGGTCCCATCTACTCC 1064
Db 1 GCTGACCTGGTCCCATCTACTCC 24
```

RESULT 14

```
;; Sequence 294, Application US/10006485A
;; Publication No. US20030064062A1
;; GENERAL INFORMATION:
;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnovers, Luc
;; APPLICANT: Baton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; TITLE OF INVENTION: Secretion and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: P2830P1C9
;; CURRENT APPLICATION NUMBER: US/10/006,485A
;; PRIOR FILING DATE: 2001-12-06
;; PRIOR APPLICATION NUMBER: 60/098716
;; PRIOR FILING DATE: 1998-09-01
;; PRIOR APPLICATION NUMBER: 60/098723
```

```
;; PRIOR FILING DATE: 1998-09-01
;; PRIOR APPLICATION NUMBER: 60/098749
;; PRIOR FILING DATE: 1998-09-01
;; PRIOR APPLICATION NUMBER: 60/098750
;; PRIOR FILING DATE: 1998-09-01
;; PRIOR APPLICATION NUMBER: 60/098803
;; PRIOR FILING DATE: 1998-09-02
;; PRIOR APPLICATION NUMBER: 60/098821
;; PRIOR FILING DATE: 1998-09-02
;; PRIOR APPLICATION NUMBER: 60/098843
;; PRIOR FILING DATE: 1998-09-02
;; PRIOR APPLICATION NUMBER: 60/099536
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099596
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099598
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099602
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099642
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099741
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099754
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099763
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099792
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099808
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099812
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099815
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099816
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/100385
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100388
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100390
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100584
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100627
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100661
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100662
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100664
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100683
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100684
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100710
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100711
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100849
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100930
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101014
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101068
;; PRIOR FILING DATE: 1998-09-18
```

PRIOR APPLICATION NUMBER: 60/101071
 PRIOR FILING DATE: 1998-09-18
 PRIOR APPLICATION NUMBER: 60/101279
 PRIOR FILING DATE: 1998-09-22
 PRIOR APPLICATION NUMBER: 60/101471
 PRIOR FILING DATE: 1998-09-23
 PRIOR APPLICATION NUMBER: 60/101472
 PRIOR FILING DATE: 1998-09-23
 PRIOR APPLICATION NUMBER: 60/101474
 PRIOR FILING DATE: 1998-09-23
 PRIOR APPLICATION NUMBER: 60/101475
 PRIOR FILING DATE: 1998-09-23
 PRIOR APPLICATION NUMBER: 60/101476
 PRIOR FILING DATE: 1998-09-23
 PRIOR APPLICATION NUMBER: 60/101477
 PRIOR FILING DATE: 1998-09-23
 PRIOR APPLICATION NUMBER: 60/101479
 PRIOR FILING DATE: 1998-09-23
 PRIOR APPLICATION NUMBER: 60/101738
 PRIOR FILING DATE: 1998-09-24
 PRIOR APPLICATION NUMBER: 60/101741
 PRIOR FILING DATE: 1998-09-24
 PRIOR APPLICATION NUMBER: 60/101743
 PRIOR FILING DATE: 1998-09-24
 PRIOR APPLICATION NUMBER: 60/101915
 PRIOR FILING DATE: 1998-09-24
 PRIOR APPLICATION NUMBER: 60/101916
 PRIOR FILING DATE: 1998-09-24
 PRIOR APPLICATION NUMBER: 60/102207
 PRIOR FILING DATE: 1998-09-29
 PRIOR APPLICATION NUMBER: 60/102240
 PRIOR FILING DATE: 1998-09-29
 PRIOR APPLICATION NUMBER: 60/102307
 PRIOR FILING DATE: 1998-09-29
 PRIOR APPLICATION NUMBER: 60/102330
 PRIOR FILING DATE: 1998-09-29
 PRIOR APPLICATION NUMBER: 60/102331
 PRIOR FILING DATE: 1998-09-29
 PRIOR APPLICATION NUMBER: 60/102484
 PRIOR FILING DATE: 1998-09-30
 PRIOR APPLICATION NUMBER: 60/102487
 PRIOR FILING DATE: 1998-09-30
 PRIOR APPLICATION NUMBER: 60/102570
 PRIOR FILING DATE: 1998-09-30
 PRIOR APPLICATION NUMBER: 60/102571
 PRIOR FILING DATE: 1998-09-30
 PRIOR APPLICATION NUMBER: 60/102684
 PRIOR FILING DATE: 1998-10-01
 PRIOR APPLICATION NUMBER: 60/102687
 PRIOR FILING DATE: 1998-10-01
 PRIOR APPLICATION NUMBER: 60/102965
 PRIOR FILING DATE: 1998-10-02
 PRIOR APPLICATION NUMBER: 60/103258
 PRIOR FILING DATE: 1998-10-06
 PRIOR APPLICATION NUMBER: 60/103314
 PRIOR FILING DATE: 1998-10-07
 PRIOR APPLICATION NUMBER: 60/103315
 PRIOR FILING DATE: 1998-10-07
 PRIOR APPLICATION NUMBER: 60/103338
 PRIOR FILING DATE: 1998-10-07
 PRIOR APPLICATION NUMBER: 60/103395
 PRIOR FILING DATE: 1998-10-07
 PRIOR APPLICATION NUMBER: 60/103396
 PRIOR FILING DATE: 1998-10-07
 PRIOR APPLICATION NUMBER: 60/103401
 PRIOR FILING DATE: 1998-10-07
 PRIOR APPLICATION NUMBER: 60/103449
 PRIOR FILING DATE: 1998-10-07
 PRIOR APPLICATION NUMBER: 60/103633
 PRIOR FILING DATE: 1998-10-08
 PRIOR APPLICATION NUMBER: 60/103678
 PRIOR FILING DATE: 1998-10-08
 PRIOR APPLICATION NUMBER: 60/103679

PRIOR FILING DATE: 1998-10-08
 PRIOR APPLICATION NUMBER: 60/103711
 PRIOR FILING DATE: 1998-10-08
 PRIOR APPLICATION NUMBER: 60/104257
 PRIOR FILING DATE: 1998-10-14
 PRIOR APPLICATION NUMBER: 60/104987
 PRIOR FILING DATE: 1998-10-20
 PRIOR APPLICATION NUMBER: 60/105000
 PRIOR FILING DATE: 1998-10-20
 PRIOR APPLICATION NUMBER: 60/105002
 PRIOR FILING DATE: 1998-10-20
 PRIOR APPLICATION NUMBER: 60/105104
 PRIOR FILING DATE: 1998-10-21
 PRIOR APPLICATION NUMBER: 60/105169
 PRIOR FILING DATE: 1998-10-22
 PRIOR APPLICATION NUMBER: 60/105266
 PRIOR FILING DATE: 1998-10-22
 PRIOR APPLICATION NUMBER: 60/105693
 PRIOR FILING DATE: 1998-10-26
 PRIOR APPLICATION NUMBER: 60/105694
 PRIOR FILING DATE: 1998-10-26
 PRIOR APPLICATION NUMBER: 60/105807
 PRIOR FILING DATE: 1998-10-27
 PRIOR APPLICATION NUMBER: 60/105881
 PRIOR FILING DATE: 1998-10-27
 PRIOR APPLICATION NUMBER: 60/105882
 PRIOR FILING DATE: 1998-10-27
 PRIOR APPLICATION NUMBER: 60/106023
 PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 82;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTGATGGTGTCTGTGGG 1486
 Db 24 GGAAGTGTCTGATGGTGTCTGTGGG 1

RESULT 15
 US-10-013-907A-293
 Sequence 293, Application US/10013907A
 Publication No. US20030064925A1
 GENERAL INFORMATION:
 APPLICANT: Baker, Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Desnoyers, Luc
 APPLICANT: Eaton, Dan I.
 APPLICANT: Ferrara, Napoleone
 APPLICANT: Fong, Sherman
 APPLICANT: Gao, Wei-Qiang
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, Christopher J.
 APPLICANT: Gurney, Austin L.
 APPLICANT: Hillan, Kenneth J.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 FILE REFERENCE: P2830PIC34
 CURRENT APPLICATION NUMBER: US/10/013,907A
 PRIOR FILING DATE: 2001-12-10
 Prior Application removed - See File Wrapper or Palm
 NUMBER OF SEQ ID NOS: 477
 SEQ ID NO 293
 LENGTH: 24
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic oligonucleotide probe
 US-10-013-907A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 16

US-10-013-907A-294/c
Sequence 294, Application US/10013907A
Publication No. US20030064925A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC34
CURRENT APPLICATION NUMBER: US/10/013,907A
CURRENT FILING DATE: 2001-12-10
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-907A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTGATGGGTCTGTGGG 1486
DB 24 GGAAGTGTGATGGGTCTGTGGG 1

RESULT 17

US-10-015-499A-293
Sequence 293, Application US/10015499A
Publication No. US20030065142A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC34
CURRENT APPLICATION NUMBER: US/10/015,499A
CURRENT FILING DATE: 2001-12-11
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-499A-294

FILE REFERENCE: P2830PIC42
CURRENT APPLICATION NUMBER: US/10/015,499A
CURRENT FILING DATE: 2001-12-11
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 293
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-499A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 18

US-10-015-499A-294/c
Sequence 294, Application US/10015499A
Publication No. US20030065142A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC42
CURRENT APPLICATION NUMBER: US/10/015,499A
CURRENT FILING DATE: 2001-12-11
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-499A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTGATGGGTCTGTGGG 1486
DB 24 GGAAGTGTGATGGGTCTGTGGG 1

RESULT 19

US-10-015-393A-293
Sequence 293, Application US/10015393A
Publication No. US20030069179A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc

```

; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C46
; CURRENT APPLICATION NUMBER: US/10/015,393A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-393A-293

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

```

```

RESULT 20
US-10-015-393A-294/c
; Sequence 294, Application US/10015393A
; Publication No. US20030069179A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C46
; CURRENT APPLICATION NUMBER: US/10/015,393A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-393A-294

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1463 GGAAGTGCATGGTGTCTGTGGG 1486
Db      24 GGAAGTGCATGGTGTCTGTGGG 1

```

```

RESULT 21
US-10-015-869A-293
; Sequence 293, Application US/10015869A
; Publication No. US20030073130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C45
; CURRENT APPLICATION NUMBER: US/10/015,869A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-869A-293

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

```

```

RESULT 22
US-10-015-869A-294/c
; Sequence 294, Application US/10015869A
; Publication No. US20030073130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C45
; CURRENT APPLICATION NUMBER: US/10/015,869A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm

```


PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarly 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTTCCTACTCTCC 1064
DB 1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 26
US-10-006-116A-294/C
Publication No. US20030082626A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferreira, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C15
CURRENT APPLICATION NUMBER: US/10/006,116A
PRIOR FILING DATE: 2001-12-16
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741

PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24

```
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105633
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807

; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTATGGGTGTCTGTGGG 1486
Db      24 GGAGTGTATGGGTGTCTGTGGG 1

RESULT 27
US-10-006-117A-293
; Sequence 293, Application US/10006117A
; Publication No. US20030082627A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC13
; CURRENT APPLICATION NUMBER: US/10/006,117A
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-117A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGGTCCCATCTACTCC 1064
Db      1 GGTGACCTGGTCCCATCTACTCC 24

RESULT 28
US-10-006-117A-294/C
; Sequence 294, Application US/10006117A
; Publication No. US20030082627A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
```

```

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C13
; CURRENT APPLICATION NUMBER: US/10/006,117A
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION removed - See File Wrapper or Palm
; PRIOR FILING DATE: 2001-07-09
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-117A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTCTATGGGTCTGTCTGGG 1486
DB      24  GGAGTGTCTATGGGTCTGTCTGGG 1

RESULT 29
US-10-017-527A-293
; Sequence 293, Application US/10017527A
; Publication No. US20030082628A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C63
; CURRENT APPLICATION NUMBER: US/10/017,527A
; PRIOR FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
```

```

; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
```

PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103338
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169

PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCATCTACTCC 24

RESULT 30
US-10-017-527A-294/C
Sequence 294, Application US/10017527A
Publication No. US20030082628A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guirney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PLC63
CURRENT APPLICATION NUMBER: US/10/017,527A
CURRENT FILING DATE: 2001-12-13
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09


```

; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTCATGGTCTGTCTGGG 1486
DB      24 GGAAGTCATGGTCTGTCTGGG 1

RESULT 31
US-10-013-913A-293
; Sequence 293, Application US/10013913A
; Publication No. US20030083462A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C40
; CURRENT APPLICATION NUMBER: US/10/013,913A
; CURRENT FILING DATE: 2002-07-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-913A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCTTACTCTCC 1064
DB      1 GCTGACCTGTTCCCTTACTCTCC 24

RESULT 32
US-10-013-913A-294/C
; Sequence 294, Application US/10013913A
; Publication No. US20030083462A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09

; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C6
; CURRENT APPLICATION NUMBER: US/10/013,913A
; CURRENT FILING DATE: 2002-07-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-913A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTCATGGTCTGTCTGGG 1486
DB      24 GGAAGTCATGGTCTGTCTGGG 1

RESULT 33
US-10-007-194A-293
; Sequence 293, Application US/10007194A
; Publication No. US20030092061A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09

; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C6
; CURRENT APPLICATION NUMBER: US/10/013,913A
; CURRENT FILING DATE: 2002-07-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-913A-294
```



```
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 34
US-10-007-194A-294/c
; Sequence 294, Application US/10007194A
; Publication No. US20030092061A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
```

```
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
```

; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103355
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807

; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGTGTGATGGGTCTGTGTGGG 1486
|||||
Db 24 GGAGTGTGATGGGTCTGTGTGGG 1

RESULT 35
US-10-013-430A-293
; Sequence 293, Application US/10013430A
; Publication No. US20030092883A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C31
; CURRENT APPLICATION NUMBER: US/10/013,430A
; PRIOR FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293

; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-430A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGCTCCATCTACCTCC 1064
|||||
Db 1 GGTGACCTGCTCCATCTACCTCC 24

RESULT 36
US-10-013-430A-294/C
; Sequence 294, Application US/10013430A
; Publication No. US20030092883A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey

```
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC31
/ CURRENT APPLICATION NUMBER: US/10/013,430A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-430A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAGGTGTCATGGGTCTGTGTGG 1486
Db      24  GGAGGTGTCATGGGTCTGTGTGG 1

RESULT 37
US-10-011-671A-293
/ Sequence 293 Application US/10011671A
/ Publication No. US2003006954A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC27
/ CURRENT APPLICATION NUMBER: US/10/011,671A
/ CURRENT FILING DATE: 2002-06-10
/ PRIOR APPLICATION NUMBER: 60/098716
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098723
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098749
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098750
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098803
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098821
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098843
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/099536
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099596
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099598
```

```
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099602
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099642
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099741
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099754
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099763
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099792
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099808
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099812
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099815
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099816
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/100385
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100388
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100390
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100584
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100627
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100661
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100662
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100664
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100683
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100684
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100710
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100711
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100848
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/100849
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/100919
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100930
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/101014
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101068
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101071
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101279
/ PRIOR FILING DATE: 1998-09-22
/ PRIOR APPLICATION NUMBER: 60/101471
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101472
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101474
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101475
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101476
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101477
/ PRIOR FILING DATE: 1998-09-23
```

PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266

PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGGTTCCTACTCTCC 1064
Db 1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 38
US-10-011-671A-294/c
Sequence 294, Application US/10011671A
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC27
CURRENT FILING DATE: US/10/011,671A
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099566
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10

1	PRIOR APPLICATION NUMBER: 60/099754
2	PRIOR FILING DATE: 1998-09-10
3	PRIOR APPLICATION NUMBER: 60/099763
4	PRIOR FILING DATE: 1998-09-10
5	PRIOR APPLICATION NUMBER: 60/099792
6	PRIOR FILING DATE: 1998-09-10
7	PRIOR APPLICATION NUMBER: 60/099808
8	PRIOR FILING DATE: 1998-09-10
9	PRIOR APPLICATION NUMBER: 60/099812
10	PRIOR FILING DATE: 1998-09-10
11	PRIOR APPLICATION NUMBER: 60/099815
12	PRIOR FILING DATE: 1998-09-10
13	PRIOR APPLICATION NUMBER: 60/099846
14	PRIOR FILING DATE: 1998-09-10
15	PRIOR APPLICATION NUMBER: 60/100385
16	PRIOR FILING DATE: 1998-09-15
17	PRIOR APPLICATION NUMBER: 60/100388
18	PRIOR FILING DATE: 1998-09-15
19	PRIOR APPLICATION NUMBER: 60/100390
20	PRIOR FILING DATE: 1998-09-15
21	PRIOR APPLICATION NUMBER: 60/100584
22	PRIOR FILING DATE: 1998-09-16
23	PRIOR APPLICATION NUMBER: 60/100627
24	PRIOR FILING DATE: 1998-09-16
25	PRIOR APPLICATION NUMBER: 60/100661
26	PRIOR FILING DATE: 1998-09-16
27	PRIOR APPLICATION NUMBER: 60/100662
28	PRIOR FILING DATE: 1998-09-16
29	PRIOR APPLICATION NUMBER: 60/100664
30	PRIOR FILING DATE: 1998-09-16
31	PRIOR APPLICATION NUMBER: 60/100683
32	PRIOR FILING DATE: 1998-09-17
33	PRIOR APPLICATION NUMBER: 60/100684
34	PRIOR FILING DATE: 1998-09-17
35	PRIOR APPLICATION NUMBER: 60/100710
36	PRIOR FILING DATE: 1998-09-17
37	PRIOR APPLICATION NUMBER: 60/100711
38	PRIOR FILING DATE: 1998-09-17
39	PRIOR APPLICATION NUMBER: 60/100848
40	PRIOR FILING DATE: 1998-09-18
41	PRIOR APPLICATION NUMBER: 60/100849
42	PRIOR FILING DATE: 1998-09-18
43	PRIOR APPLICATION NUMBER: 60/100919
44	PRIOR FILING DATE: 1998-09-17
45	PRIOR APPLICATION NUMBER: 60/100930
46	PRIOR FILING DATE: 1998-09-17
47	PRIOR APPLICATION NUMBER: 60/101014
48	PRIOR FILING DATE: 1998-09-18
49	PRIOR APPLICATION NUMBER: 60/101068
50	PRIOR FILING DATE: 1998-09-18
51	PRIOR APPLICATION NUMBER: 60/101071
52	PRIOR FILING DATE: 1998-09-18
53	PRIOR APPLICATION NUMBER: 60/101279
54	PRIOR FILING DATE: 1998-09-22
55	PRIOR APPLICATION NUMBER: 60/101475
56	PRIOR FILING DATE: 1998-09-23
57	PRIOR APPLICATION NUMBER: 60/101476
58	PRIOR FILING DATE: 1998-09-23
59	PRIOR APPLICATION NUMBER: 60/101477
60	PRIOR FILING DATE: 1998-09-23
61	PRIOR APPLICATION NUMBER: 60/101479
62	PRIOR FILING DATE: 1998-09-23
63	PRIOR APPLICATION NUMBER: 60/101738
64	PRIOR FILING DATE: 1998-09-24
65	PRIOR APPLICATION NUMBER: 60/101741
66	PRIOR FILING DATE: 1998-09-24
67	PRIOR APPLICATION NUMBER: 60/101743

1	PRIOR FILING DATE: 1998-09-24	60/101915
2	PRIOR APPLICATION NUMBER: 60/101915	
3	PRIOR FILING DATE: 1998-09-24	
4	PRIOR APPLICATION NUMBER: 60/101916	
5	PRIOR FILING DATE: 1998-09-24	
6	PRIOR APPLICATION NUMBER: 60/102070	
7	PRIOR FILING DATE: 1998-09-29	
8	PRIOR APPLICATION NUMBER: 60/102079	
9	PRIOR FILING DATE: 1998-09-29	
10	PRIOR APPLICATION NUMBER: 60/102240	
11	PRIOR FILING DATE: 1998-09-29	
12	PRIOR APPLICATION NUMBER: 60/102307	
13	PRIOR FILING DATE: 1998-09-29	
14	PRIOR APPLICATION NUMBER: 60/102330	
15	PRIOR FILING DATE: 1998-09-29	
16	PRIOR APPLICATION NUMBER: 60/102331	
17	PRIOR FILING DATE: 1998-09-29	
18	PRIOR APPLICATION NUMBER: 60/102484	
19	PRIOR FILING DATE: 1998-09-30	
20	PRIOR APPLICATION NUMBER: 60/102487	
21	PRIOR FILING DATE: 1998-09-30	
22	PRIOR APPLICATION NUMBER: 60/102570	
23	PRIOR FILING DATE: 1998-09-30	
24	PRIOR APPLICATION NUMBER: 60/102571	
25	PRIOR FILING DATE: 1998-09-30	
26	PRIOR APPLICATION NUMBER: 60/102684	
27	PRIOR FILING DATE: 1998-09-30	
28	PRIOR APPLICATION NUMBER: 60/102687	
29	PRIOR FILING DATE: 1998-10-01	
30	PRIOR APPLICATION NUMBER: 60/102655	
31	PRIOR FILING DATE: 1998-10-02	
32	PRIOR APPLICATION NUMBER: 60/103258	
33	PRIOR FILING DATE: 1998-10-06	
34	PRIOR APPLICATION NUMBER: 60/103314	
35	PRIOR FILING DATE: 1998-10-07	
36	PRIOR APPLICATION NUMBER: 60/103315	
37	PRIOR FILING DATE: 1998-10-07	
38	PRIOR APPLICATION NUMBER: 60/103328	
39	PRIOR FILING DATE: 1998-10-07	
40	PRIOR APPLICATION NUMBER: 60/103499	
41	PRIOR FILING DATE: 1998-10-07	
42	PRIOR APPLICATION NUMBER: 60/103395	
43	PRIOR FILING DATE: 1998-10-07	
44	PRIOR APPLICATION NUMBER: 60/103396	
45	PRIOR FILING DATE: 1998-10-07	
46	PRIOR APPLICATION NUMBER: 60/103401	
47	PRIOR FILING DATE: 1998-10-07	
48	PRIOR APPLICATION NUMBER: 60/103678	
49	PRIOR FILING DATE: 1998-10-08	
50	PRIOR APPLICATION NUMBER: 60/103679	
51	PRIOR FILING DATE: 1998-10-08	
52	PRIOR APPLICATION NUMBER: 60/103711	
53	PRIOR FILING DATE: 1998-10-08	
54	PRIOR APPLICATION NUMBER: 60/104257	
55	PRIOR FILING DATE: 1998-10-14	
56	PRIOR APPLICATION NUMBER: 60/104987	
57	PRIOR FILING DATE: 1998-10-20	
58	PRIOR APPLICATION NUMBER: 60/105000	
59	PRIOR FILING DATE: 1998-10-20	
60	PRIOR APPLICATION NUMBER: 60/105002	
61	PRIOR FILING DATE: 1998-10-20	
62	PRIOR APPLICATION NUMBER: 60/105104	
63	PRIOR FILING DATE: 1998-10-21	
64	PRIOR APPLICATION NUMBER: 60/105159	
65	PRIOR FILING DATE: 1998-10-22	
66	PRIOR APPLICATION NUMBER: 60/105266	
67	PRIOR FILING DATE: 1998-10-22	
68	PRIOR APPLICATION NUMBER: 60/105693	
69	PRIOR FILING DATE: 1998-10-26	
70	PRIOR APPLICATION NUMBER: 60/105694	
71	PRIOR FILING DATE: 1998-10-26	
72	PRIOR APPLICATION NUMBER: 60/105807	
73	PRIOR FILING DATE: 1998-10-27	

;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486
DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 39
US-10-012-755A-293

;; Sequence 293, Application US/10012755A
;; Publication No. US20030096955A1

;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.

;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same

;; FILE REFERENCE: P2830PIC28

;; CURRENT APPLICATION NUMBER: US/10/012.755A

;; CURRENT FILING DATE: 2002-06-10

;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 293

;; LENGTH: 24

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Synthetic oligonucleotide probe

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064
DB 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 40
US-10-012-755A-294/C

;; Sequence 294, Application US/10012755A
;; Publication No. US20030096955A1

;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.

;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same

;; FILE REFERENCE: P2830PIC28

;; CURRENT APPLICATION NUMBER: US/10/015.386A

;; CURRENT FILING DATE: 2001-12-12

;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 293

;; LENGTH: 24

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Synthetic oligonucleotide probe

;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same

;; FILE REFERENCE: P2830PIC28

;; CURRENT APPLICATION NUMBER: US/10/012.755A

;; CURRENT FILING DATE: 2002-06-10

;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 294

;; LENGTH: 24

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-012-755A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486
DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 41
US-10-015-386A-293

;; Sequence 293, Application US/10015386A
;; Publication No. US2003009625A1

;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same

;; FILE REFERENCE: P2830PIC28

;; CURRENT APPLICATION NUMBER: US/10/015.386A

;; CURRENT FILING DATE: 2001-12-12

;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 293

;; LENGTH: 24

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-015-386A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064
DB 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 42

```
US-10-015-386A-294/c
; Sequence 294, Application US/10015386A
; Publication No. US20030099625A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C55
; CURRENT APPLICATION NUMBER: US/10/015,386A
; PRIORITY FILING DATE: 2001-12-12
; Prior Application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-386A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTGATGGGTCTGTGTGGG 1486
DB      24  GGAGTGTGATGGGTCTGTGTGGG 1

RESULT 43
US-10-011-692A-293
; Sequence 293, Application US/10011692A
; Publication No. US20030109672A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C30
; CURRENT APPLICATION NUMBER: US/10/011,692A
; PRIORITY FILING DATE: 2001-12-07
; Prior Application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
```

```
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGGTTCCTACTCTCC 1064
DB      1  GGTGACCTGGTTCCTACTCTCC 24

RESULT 44
US-10-011-692A-294/c
; Sequence 294, Application US/10011692A
; Publication No. US20030109672A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C30
; CURRENT APPLICATION NUMBER: US/10/011,692A
; PRIORITY FILING DATE: 2001-12-07
; Prior Application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTGATGGGTCTGTGTGGG 1486
DB      24  GGAGTGTGATGGGTCTGTGTGGG 1

RESULT 45
US-10-006-768A-293
; Sequence 293, Application US/10006768A
; Publication No. US20030113793A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
```



```

; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C10
; CURRENT APPLICATION NUMBER: US/10/006,768A
; NUMBER OF SEQ ID NOS: 477
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-768A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTTCCTACTCTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 46
US-10-006-768A-294/C
; Sequence 294, Application US/10006768A
; Publication No. US20030113793A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C10
; CURRENT APPLICATION NUMBER: US/10/006,768A
; NUMBER OF SEQ ID NOS: 477
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-768A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTATGGGTCTGTGTGGG 1486
Db      24 GGAAGTGTATGGGTCTGTGTGGG 1

RESULT 47
US-10-017-610A-293
; Sequence 293, Application US/10017610A
; Publication No. US20030113795A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C64
; CURRENT APPLICATION NUMBER: US/10/017,610A
; NUMBER OF SEQ ID NOS: 60
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 295
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-610A-295

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTTCCTACTCTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 46
US-10-006-768A-294/C
; Sequence 294, Application US/10006768A
; Publication No. US20030113793A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C64
; CURRENT APPLICATION NUMBER: US/10/017,610A
; NUMBER OF SEQ ID NOS: 60
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 295
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-610A-295

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTATGGGTCTGTGTGGG 1486
Db      24 GGAAGTGTATGGGTCTGTGTGGG 1

RESULT 47
US-10-017-610A-293
; Sequence 293, Application US/10017610A
; Publication No. US20030113795A1
; GENERAL INFORMATION:
```

PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965

PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Fred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGATTCCCATCTACTCC 1064
DB 1 GCTGACCTGATTCCCATCTACTCC 24

RESULT 48
US-10-017-610A-294/c
Sequence 294, Application US/10017610A
Publication No. US20030113795A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2830PIC64
CURRENT APPLICATION NUMBER: US/10/017,610A
CURRENT FILING DATE: 2001-12-13
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100663
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710

PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07

```
/ PRIOR APPLICATION NUMBER: 60/103328
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103395
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103396
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103401
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103449
/ PRIOR FILING DATE: 1998-10-06
/ PRIOR APPLICATION NUMBER: 60/103633
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103678
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103679
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103711
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/104257
/ PRIOR FILING DATE: 1998-10-14
/ PRIOR APPLICATION NUMBER: 60/104987
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105000
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105002
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105104
/ PRIOR FILING DATE: 1998-10-21
/ PRIOR APPLICATION NUMBER: 60/105169
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105266
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105693
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105694
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105807
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105881
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105882
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/106023
/ PRIOR FILING DATE: 1998-10-28

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1463 GGAAGTGCATGGGTCTGTGGG 1486
Db      24  GGAAGTGCATGGGTCTGTGGG 1
```

```
RESULT 49
US-10-006-063A-293
/ Sequence 293, Application US/10006063A
/ Publication No. US20030114652A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
```

```
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC3
/ CURRENT APPLICATION NUMBER: US/10/006,063A
/ CURRENT FILING DATE: 2002-03-15
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-063A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1041 GGTGACCTGGTTCCCATCTACTCC 1064
Db      1  GGTGACCTGGTTCCCATCTACTCC 24
```

```
RESULT 50
US-10-006-063A-294/c
/ Sequence 294, Application US/10006063A
/ Publication No. US20030114652A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC3
/ CURRENT APPLICATION NUMBER: US/10/006,063A
/ CURRENT FILING DATE: 2002-03-15
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-063A-294
```

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1463 GGAAGTGCATGGGTCTGTGGG 1486
Db      24  GGAAGTGCATGGGTCTGTGGG 1
```

```
RESULT 51
US-10-020-063A-293
/ Sequence 293, Application US/10020063A
/ Publication No. US20030119097A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
```

```

; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C65
; CURRENT APPLICATION NUMBER: US/10/020,063A
; PRIOR FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-020-063A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 52
US-10-020-063A-294/c
; Sequence 294, Application US/10020063A
; Publication No. US20030119097A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
```

```

; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C65
; CURRENT APPLICATION NUMBER: US/10/020,063A
; PRIOR FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-020-063A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTGATGGGTCTGTGTGGG 1486
DB      24 GGAAGTGTGATGGGTCTGTGTGGG 1

RESULT 53
US-10-015-391A-293
; Sequence 293, Application US/10015391A
; Publication No. US20030120053A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C59
; CURRENT APPLICATION NUMBER: US/10/015,391A
; PRIOR FILING DATE: 2001-12-12
; Remaining Prior Application data removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
```

```
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-391A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1041 GCTGACCTGGTTCCTACTCTACTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTACTCC 24
```

```
RESULT 54
US-10-015-391A-294/c
/ Sequence 294, Application US/10015391A
/ Publication No. US20030120053A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C59
/ CURRENT APPLICATION NUMBER: US/10/015,391A
/ CURRENT FILING DATE: 2001-12-12
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-391A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTGTGATGGGTGTGTGTGGG 1486
Db      24 GGAAGTGTGATGGGTGTGTGTGGG 1

RESULT 55
US-10-017-407A-293
/ Sequence 293, Application US/10017407A
/ Publication No. US20030125535A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
```

```
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C61
/ CURRENT APPLICATION NUMBER: US/10/017,407A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-407A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1041 GCTGACCTGGTTCCTACTCTACTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTACTCC 24
```

```
RESULT 56
US-10-017-407A-294/c
/ Sequence 294, Application US/10017407A
/ Publication No. US20030125535A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C61
/ CURRENT APPLICATION NUMBER: US/10/017,407A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-407A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1463 GGAAGTGTGATGGGTGTGTGTGGG 1486
Db      24 GGAAGTGTGATGGGTGTGTGTGGG 1
```

```
RESULT 57
US-10-011-833A-293
; Sequence 293, Application US/10011833A
; Publication No. US20030129650A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Botstein, David
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C22
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION: 2002-06-25
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-833A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGGTTCCTACTCTCC 1064
DB      1 GGTGACCTGGTTCCTACTCTCC 24

RESULT 58
US-10-011-833A-294/C
; Sequence 294, Application US/10011833A
; Publication No. US20030129650A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C22
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION: 2002-06-25
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-833A-294
; Sequence 294, Application US/10006041A
; Publication No. US20030130490A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C8
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION: 2001-12-06
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-041A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGGTTCCTACTCTCC 1064
DB      1 GGTGACCTGGTTCCTACTCTCC 24

RESULT 59
US-10-006-041A-293
; Sequence 293, Application US/10006041A
; Publication No. US20030130490A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C8
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION: 2001-12-06
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-041A-294/C
; Sequence 294, Application US/10006041A
; Publication No. US20030130490A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C22
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION: 2002-06-25
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/006,041A
/ CURRENT FILING DATE: 2001-12-06
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-041A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTGTCTCATGGTCTGTGGG 1486
Db      24  GGAAGTGTCTCATGGTCTGTGGG 1

RESULT 61
US-10-015-822A-293
/ Sequence 293, Application US/10015822A
/ Publication No. US20030130491A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Baton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/015,822A
/ CURRENT FILING DATE: 2002-06-10
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-822A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTGTTCCCATCTACTCC 1064
Db      1  GCTGACCTGTGTTCCCATCTACTCC 24

RESULT 62
US-10-015-822A-294/C
/ Sequence 294, Application US/10015822A
/ Publication No. US20030130491A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Baton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/015,822A
/ CURRENT FILING DATE: 2002-06-10
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-822A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTGTCTCATGGTCTGTGGG 1486
Db      24  GGAAGTGTCTCATGGTCTGTGGG 1

RESULT 63
US-10-015-387A-293
/ Sequence 293, Application US/10015387A
/ Publication No. US20030135034A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Baton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/015,387A
/ CURRENT FILING DATE: 2001-12-12
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-387A-293
```


Query Match	1.0%;	Score 24;	DB 1;	Length 24;
Best Local Similarity	100.0%;	Pred. No. 82;		
Matches 24;	Conservative 0;	Mismatches 0;	Indels	

```

Oy      1041 GCTGACCTGGTTCCTACTCTACTCC 1064
          |||||
Db      1 GCTGACCTGGTTCCTACTCTACTCC 24

```

RESULT 64
US-10-015-387A-294/C

```

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Peoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2830P1C54
CURRENT APPLICATION NUMBER: US/10/015,387A
PRIOR FILING DATE: 2001-12-12
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-387A-294

```

Query Match	1.0%;	Score 24;	DB 1;	Length 24;
Best Local Similarity	100.0%;	Pred. No. 82;		
Matches 24;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Oy	1463	GGAAGTGTCAATGGGTCCTGTGGG	1486
Dd	24	GGAAGTGTCAATGGGTCCTGTGGG	1

RESULT 65
US-10-006-130A-293

APPLICANT:	Baker, Kevin P.
APPLICANT:	Botstein, David
APPLICANT:	Desnoyers, Luc
APPLICANT:	Eaton, Dan 1.
APPLICANT:	Ferrara, Napoleone
APPLICANT:	Fong, Sherman
APPLICANT:	Gao, Wei-Qiang
APPLICANT:	Goddard, Audrey
APPLICANT:	Godowski, Paul J.
APPLICANT:	Grimaldi, Christopher J.
APPLICANT:	Gurney, Austin L.
APPLICANT:	Hallan, Kenneth J.
APPLICANT:	Pan, James
APPLICANT:	Paoletti, Nicholas P.
TITLE OF INVENTION:	Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION:	Acids Encoding the Same

```

: FILE REFERENCE: P2830P1C7
:
: CURRENT APPLICATION NUMBER: US/10/006,130A
:
: CURRENT FILING DATE: 2002-03-19
:
: Prior Application removed - See File Wrapper or Palm
:
: NUMBER OF SEQ ID NOS: 477
:

```

```

Query Match Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 24; Conservative 0; Mismatches 0; Gaps 0

```

```

Oy      1041 GGTGACCTGGTTCCTACTACTCC 1064
          |||||
Db      1 GGTGACCTGGTTCCTACTACTCC 24

```

RESULT 66
US-10-006-130A-294/C
; Sequence 294, Application US/10006130A
; Publication No. US20030148375A1

```

/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C7
/ CURRENT APPLICATION NUMBER: US/10/006,130A
/ CURRENT FILING DATE: 2002-03-19
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
/ US-10-006-130A-294

```

Query Match	1.0%	Score 24;	DB 1;	length 24;
Similarity	100.0%	Pred. No. 82;		
Best Local	0;	Mismatches	0;	Gaps 0
Matches 24;	Conservative			

Oy	1463	GGAAGTGTCA	TGGGTGTCTG	TGGG	1486
Db	24	GGAA	TGTCA	TGGGTGTCTG	TGGG

RESULT 67
US-10-006-172A-293

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C11
CURRENT APPLICATION NUMBER: US/10/006,172A
CURRENT FILING DATE: 2002-03-19
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683

PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06

```
/ PRIOR APPLICATION NUMBER: 60/103314
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103315
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103328
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103395
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103396
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103401
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103449
/ PRIOR FILING DATE: 1998-10-06
/ PRIOR APPLICATION NUMBER: 60/103633
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103678
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103679
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103711
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/104257
/ PRIOR FILING DATE: 1998-10-14
/ PRIOR APPLICATION NUMBER: 60/104987
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105000
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105002
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105104
/ PRIOR FILING DATE: 1998-10-21
/ PRIOR APPLICATION NUMBER: 60/105169
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105266
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105693
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105694
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105807
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105881
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105882
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/106023
/ PRIOR FILING DATE: 1998-10-28

Query Match      1 0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No. 82;
Matches 24; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 68
US-10-006-172A-294/c
/ Sequence 294, Application US/10006172A
/ Publication No. US20030153000A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.

/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Peoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C11
/ CURRENT APPLICATION NUMBER: US/10/006,172A
/ CURRENT FILING DATE: 2002-03-19
/ PRIOR APPLICATION NUMBER: 60/098716
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098723
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098749
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098750
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098803
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098821
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098843
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/099536
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099596
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099598
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099602
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099642
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099741
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099754
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099763
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099792
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099808
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099812
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099815
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099816
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/100385
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100388
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100390
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100584
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100627
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100661
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100662
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100664
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100683
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100684
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100710
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100711
/ PRIOR FILING DATE: 1998-09-17
```

;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100849
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100930
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101014
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101068
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101071
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101279
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: 60/101471
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101472
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101474
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101475
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101476
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101479
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101738
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102330
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102570
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103328
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395

;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match Best Local Similarity 1.0%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGTGTATCGGTGTCTGTGGG 1486
DB 24 GGAGTGTATCGGTGTCTGTGGG 1

RESULT 69
US-10-017-253A-293
; Sequence 293, Application US/10017253A
; Publication No. US20030166055A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC62

```

; CURRENT APPLICATION NUMBER: US/10/017,253A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098726
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-253A-293

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
DB      1 GCTGACCTGTTCCCATCTACTCC 24

```

```

RESULT 70
US-10-017-253A-294/c
; Sequence 294, Application US/10017253A
; Publication No. US2003016055A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C62
; CURRENT APPLICATION NUMBER: US/10/017,253A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01

```

```

; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-253A-294

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTCTATGGTGTCTGTGGG 1486
DB      24 GGAGTGTCTATGGTGTCTGTGGG 1

```

```

RESULT 71
US-10-015-392A-293
; Sequence 293, Application US/10015392A
; Publication No. US2003016901A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C58
; CURRENT APPLICATION NUMBER: US/10/015,392A
; CURRENT FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09

```

```

; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-392A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 72
US-10-015-392A-294/C
; Sequence 294, Application US/10015392A
; Publication No. US2003016901A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C58
; CURRENT APPLICATION NUMBER: US/10/015,392A
; PRIOR FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
```

```

US-10-015-392A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTCATGAGGTGCTGTGAGG 1486
Db      24 GGAAGTCATGAGGTGCTGTGAGG 1

RESULT 73
US-10-017-306A-293
; Sequence 293, Application US/10017306A
; Publication No. US20030170718A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C66
; CURRENT APPLICATION NUMBER: US/10/017,306A
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-306A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 74
US-10-017-306A-294/C
; Sequence 294, Application US/10017306A
; Publication No. US20030170718A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
```

```

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C66
; CURRENT APPLICATION NUMBER: US/10/017,306A
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-306A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarly 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTGATGGTGTCTGTGGG 1486
DB      24  GGAAGTGTGATGGTGTCTGTGGG 1

RESULT 75
US-10-017-867A-293
; Sequence 293, Application US/10017867A
; Publication No. US20030180792A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C60
; CURRENT APPLICATION NUMBER: US/10/017,867A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
```

```

; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
```

; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807

; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105861
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTGCTCCATCTACTCC 1064
|||||
Db 1 GCTGACCTGTGCTCCATCTACTCC 24

RESULT 76
US-10-017-867A-294/c
; Sequence 294, Application US/10017867A
; Publication No. US20030180792A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC60
; CURRENT APPLICATION NUMBER: US/10/017,867A
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTATGGGTCTCTGTGGG 1486
DB 24 GGAAGTGTCTATGGGTCTCTGTGGG 1

RESULT 77
US-10-012-064A-293
; Sequence 293, Application US/10012064A
; Publication No. US20030180836A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC19
; CURRENT APPLICATION NUMBER: US/10/012,064A
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-064A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTTCCTACTCTCTCC 1064
DB 1 GCTGACCTGGTTCCTACTCTCTCC 24

RESULT 78
US-10-012-064A-294/C
; Sequence 294, Application US/10012064A
; Publication No. US20030180836A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC19
; CURRENT APPLICATION NUMBER: US/10/012,064A
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-064A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTATGGGTCTCTGTGGG 1486
DB 24 GGAAGTGTCTATGGGTCTCTGTGGG 1

RESULT 79
US-10-013-909A-293
; Sequence 293, Application US/10013909A
; Publication No. US20030186318A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone

QY 1041 GCTGACCTGGTTCCTACTCTCTCC 1064
DB 1 GCTGACCTGGTTCCTACTCTCTCC 24

```
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C35
; CURRENT APPLICATION NUMBER: US/10/013,909A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-909A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 80
US-10-013-909A-294/c
; Sequence 294, Application US/10013909A
; Publication No. US20030186318A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C35
; CURRENT APPLICATION NUMBER: US/10/013,909A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-909A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTCAATGGGTGTGTGGG 1486
DB      1 GGAAGTGTCAATGGGTGTGTGGG 1486
```

```
DB      24 GGAAGTGTCAATGGGTGTGTGGG 1
RESULT 81
US-10-015-671A-293
; Sequence 293, Application US/10015671A
; Publication No. US20030186319A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C47
; CURRENT APPLICATION NUMBER: US/10/015,671A
; CURRENT FILING DATE: 2001-12-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-671A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 82
US-10-015-671A-294/c
; Sequence 294, Application US/10015671A
; Publication No. US20030186319A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C47
; CURRENT APPLICATION NUMBER: US/10/015,671A
; CURRENT FILING DATE: 2001-12-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
```

```
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-671A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTGTGGG 1486
Db      24  GGAAGTGCATGGGTCTGTGGG 1

RESULT 83
US-10-015-610A-293
; Sequence 293, Application US/10015610A
; Publication No. US20030186361A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC52
; CURRENT APPLICATION NUMBER: US/10/015,610A
; CURRENT FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-610A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1041 GCTGACCTGGTTCGCATCTACTCC 1064
Db      1    GCTGACCTGGTTCGCATCTACTCC 24

RESULT 84
US-10-015-610A-294/C
; Sequence 294, Application US/10015610A
; Publication No. US20030186361A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC52
; CURRENT APPLICATION NUMBER: US/10/015,610A
; CURRENT FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-610A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTGTGGG 1486
Db      24  GGAAGTGCATGGGTCTGTGGG 1

RESULT 85
US-10-012-137A-293
; Sequence 293, Application US/10012137A
; Publication No. US20030187189A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC29
; CURRENT APPLICATION NUMBER: US/10/012,137A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-137A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGGTCCCATCTACTCC 1064
Db      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 86
US-10-012-137A-294/c
; Sequence 294, Application US/10012137A
; Publication No. US20030187189A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC29
; CURRENT APPLICATION NUMBER: US/10/012,137A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-137A-294
```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTGCATGGGTCTGTGGG 1486
Db      24 GGAAGTGCATGGGTCTGTGGG 1

RESULT 87
US-10-012-752A-293
; Sequence 293, Application US/10012752A
; Publication No. US20030187190A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC24
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-752A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGGTCCCATCTACTCC 1064
Db      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 88
US-10-012-752A-294/c
; Sequence 294, Application US/10012752A
; Publication No. US20030187190A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC29
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-752A-294
```

```

; FILE REFERENCE: P2830P1C24
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-752A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTGATGGGTGTGTGTGGG 1486
Db      24  GGAAGTGTGATGGGTGTGTGTGGG 1

RESULT 89
US-10-012-754A-293
; Sequence 293, Application US/10012754A
; Publication No. US20030187191A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C18
; CURRENT APPLICATION NUMBER: US/10/012,754A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-754A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGATGCCATCTACTTCC 1064
Db      1  GCTGACCTGATGCCATCTACTTCC 24

RESULT 90
US-10-012-754A-294/C
; Sequence 294, Application US/10012754A
; Publication No. US20030187191A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
```

```

; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C18
; CURRENT APPLICATION NUMBER: US/10/012,754A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-754A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTGATGGGTGTGTGTGGG 1486
Db      24  GGAAGTGTGATGGGTGTGTGTGGG 1

RESULT 91
US-10-013-910A-293
; Sequence 293, Application US/10013910A
; Publication No. US20030187192A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C13
; CURRENT APPLICATION NUMBER: US/10/013,910A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-910A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1041 GCTGACCTGGTTCCTCATCTACTCC 1064
|||||
Db 1 GCTGACCTGGTTCCTCATCTACTCC 24

RESULT 92
US-10-013-910A-294/c
; Sequence 294, Application US/10013910A
; Publication No. US20030187192A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C3
; CURRENT APPLICATION NUMBER: US/10/013,910A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-910A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGGTGCATGGGTCTGTCTGGG 1486
|||||
Db 24 GGAGGTGCATGGGTCTGTCTGGG 1

RESULT 93
US-10-013-911A-293
; Sequence 293, Application US/10013911A
; Publication No. US20030187193A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C3
; CURRENT APPLICATION NUMBER: US/10/013,911A
; CURRENT FILING DATE: 2001-12-10
; Prior Application Number: 60/098716

; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18

; PRIOR APPLICATION NUMBER: 60/101068
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101071
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101279
 ; PRIOR FILING DATE: 1998-09-22
 ; PRIOR APPLICATION NUMBER: 60/101471
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101472
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101474
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101475
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101476
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101477
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101479
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101738
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101741
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101743
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101915
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101916
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/102207
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102240
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102307
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102330
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102331
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102484
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102487
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102570
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102571
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102684
 ; PRIOR FILING DATE: 1998-10-01
 ; PRIOR APPLICATION NUMBER: 60/102687
 ; PRIOR FILING DATE: 1998-10-01
 ; PRIOR APPLICATION NUMBER: 60/102965
 ; PRIOR FILING DATE: 1998-10-02
 ; PRIOR APPLICATION NUMBER: 60/103258
 ; PRIOR FILING DATE: 1998-10-06
 ; PRIOR APPLICATION NUMBER: 60/103314
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103315
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103348
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103395
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103396
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103401
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103449
 ; PRIOR FILING DATE: 1998-10-06
 ; PRIOR APPLICATION NUMBER: 60/103633
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103678

; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103679
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103711
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/104257
 ; PRIOR FILING DATE: 1998-10-14
 ; PRIOR APPLICATION NUMBER: 60/104987
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105000
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105002
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105104
 ; PRIOR FILING DATE: 1998-10-21
 ; PRIOR APPLICATION NUMBER: 60/105169
 ; PRIOR FILING DATE: 1998-10-22
 ; PRIOR APPLICATION NUMBER: 60/105266
 ; PRIOR FILING DATE: 1998-10-22
 ; PRIOR APPLICATION NUMBER: 60/105693
 ; PRIOR FILING DATE: 1998-10-26
 ; PRIOR APPLICATION NUMBER: 60/105694
 ; PRIOR FILING DATE: 1998-10-26
 ; PRIOR APPLICATION NUMBER: 60/105807
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/105881
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/105882
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/106023
 ; PRIOR FILING DATE: 1998-10-28

Query Match Best Local Similarity 1.0%; Score 24; DB 1; Length 24;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
 Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 94
 US-10-013-911A-294/c
 ; Sequence 294, Application US/10013911A
 ; Publication No. US20030187193A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan I.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth J.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: P2830P1C39
 ; CURRENT APPLICATION NUMBER: US/10/013,911A
 ; CURRENT FILING DATE: 2001-12-10
 ; PRIOR APPLICATION NUMBER: 60/098716
 ; PRIOR FILING DATE: 1998-09-01
 ; PRIOR APPLICATION NUMBER: 60/098723
 ; PRIOR FILING DATE: 1998-09-01
 ; PRIOR APPLICATION NUMBER: 60/098749
 ; PRIOR FILING DATE: 1998-09-01
 ; PRIOR APPLICATION NUMBER: 60/098750
 ; PRIOR FILING DATE: 1998-09-01


```

; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAGGTGTCATGGGTCTGTGTGG 1486
Db      24  GGAGGTGTCATGGGTCTGTGTGG 1

RESULT 95
US-10-013-912A-293
; Sequence 293, Application US/10013912A
; Publication No. US20030187194A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C32
; CURRENT APPLICATION NUMBER: US/10/013,912A
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098536
```

```

; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA

US-10-013-912A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GGTGACCTGTTCCCATCTACTCC 1064
Db      1  GGTGACCTGTTCCCATCTACTCC 24

RESULT 96
US-10-013-912A-294/C
; Sequence 294, Application US/10013912A
; Publication No. US20030187194A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C32
; CURRENT APPLICATION NUMBER: US/10/013,912A
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-912A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1463 GGAAGTGTCTATGGGTCTGTGTGGG 1486
          |||||||
DB       24 GGAAGTGTCTATGGGTCTGTGTGGG 1
```

```
RESULT 97
US-10-015-653A-293
```

```
; Sequence 293, Application US/10015653A
; Publication No. US20030187195A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC43
; CURRENT APPLICATION NUMBER: US/10/015,653A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-653A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1041 GGTGACCTGGTCCCATCTACTCC 1064
          |||||||
DB       1 GGTGACCTGGTCCCATCTACTCC 24
```

```
RESULT 98
US-10-015-653A-294/C
```

```
; Sequence 294, Application US/10015653A
; Publication No. US20030187195A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
```

```

; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC43
; CURRENT APPLICATION NUMBER: US/10/015,653A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-653A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1463 GGAAGTGTCTATGGGTCTGTGTGGG 1486
          |||||||
DB       24 GGAAGTGTCTATGGGTCTGTGTGGG 1
```

```
RESULT 99
US-10-012-101B-293
```

```
; Sequence 293, Application US/10012101B
; Publication No. US20030187239A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/012,101B
; CURRENT FILING DATE: 2001-12-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-101B-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1041 GGTGACCTGGTCCCATCTACTCC 1064
          |||||||
DB       1 GGTGACCTGGTCCCATCTACTCC 24
```

```
RESULT 100
```

```
US-10-012-101B-294/C
; Sequence 294, Application US/10012101B
```

```
; Publication No. US20030187239A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/012,101B
; PRIORITY FILING DATE: 2001-12-06
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-012-101B-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTCTGTGGG 1486
DB      24  GGAAGTGCATGGGTCTCTGTGGG 1

RESULT 101
US-10-015-480A-293
; Sequence 293, Application US/10015480A
; Publication No. US20030190667A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC50
; CURRENT APPLICATION NUMBER: US/10/015,480A
; PRIORITY FILING DATE: 2002-06-25
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-015-480A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
DB      1  GCTGACCTGTTCCCATCTACTCC 24

RESULT 102
US-10-015-480A-294/c
; Sequence 294, Application US/10015480A
; Publication No. US20030190667A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC50
; CURRENT APPLICATION NUMBER: US/10/015,480A
; PRIORITY FILING DATE: 2002-06-25
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-015-480A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTCTGTGGG 1486
DB      24  GGAAGTGCATGGGTCTCTGTGGG 1

RESULT 103
US-10-015-715A-293
; Sequence 293, Application US/10015715A
; Publication No. US20030190668A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

```
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC56
; CURRENT APPLICATION NUMBER: US/10/015,715A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-715A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGGTCCCATCTACTCC 1064
DB      1 GGTGACCTGGTCCCATCTACTCC 24

RESULT 104
US-10-015-715A-294/c
; Sequence 294, Application US/10015715A
; Publication No. US20030190668A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC56
; CURRENT APPLICATION NUMBER: US/10/015,715A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-715A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGGTGTCATGGGTCTCTGTGGG 1486
DB      24 GGAGGTGTCATGGGTCTCTGTGGG 1

RESULT 105
US-10-012-237A-293
; Sequence 293, Application US/10012237A
; Publication No. US20030191281A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
```

```
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC21
; CURRENT APPLICATION NUMBER: US/10/012,237A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-237A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGGTCCCATCTACTCC 1064
DB      1 GGTGACCTGGTCCCATCTACTCC 24

RESULT 106
US-10-012-237A-294/c
; Sequence 294, Application US/10012237A
; Publication No. US20030191281A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC21
; CURRENT APPLICATION NUMBER: US/10/012,237A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-237A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

OY 1463 GGAAGTGTATGGGTGTGTGTGGG 1486
|||||
Db 24 GGAAGTGTATGGGTGTGTGTGGG 1

RESULT 107
US-10-013-906A-293
Sequence 293, Application US/10013906A
Publication No. US20030191282A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
Acids Encoding the Same

FILE REFERENCE: P2830PIC36
CURRENT APPLICATION NUMBER: US/10/013,906A
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388

PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30

PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103355
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105861
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCCATCTACTCC 24

RESULT 108

US-10-013-906A-294/c
Sequence 294, Application US/10013906A
Publication No. US20030191282A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C36
CURRENT FILING DATE: 2002-06-10
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16

; PRIOR APPLICATION NUMBER: 60/100661
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100662
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100664
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100683
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100684
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100710
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100711
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100848
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/100849
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/100919
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100930
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/101014
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101068
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101071
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101279
 ; PRIOR FILING DATE: 1998-09-22
 ; PRIOR APPLICATION NUMBER: 60/101471
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101472
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101474
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101475
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101476
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101477
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101479
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101738
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101741
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101743
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101915
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101916
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/102207
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102240
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102307
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102330
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102331
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102484
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102487
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102570
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102571
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102684

; PRIOR FILING DATE: 1998-10-01
 ; PRIOR APPLICATION NUMBER: 60/102687
 ; PRIOR FILING DATE: 1998-10-01
 ; PRIOR APPLICATION NUMBER: 60/102965
 ; PRIOR FILING DATE: 1998-10-02
 ; PRIOR APPLICATION NUMBER: 60/103258
 ; PRIOR FILING DATE: 1998-10-06
 ; PRIOR APPLICATION NUMBER: 60/103314
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103315
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103328
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103395
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103396
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103401
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103449
 ; PRIOR FILING DATE: 1998-10-06
 ; PRIOR APPLICATION NUMBER: 60/103633
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103678
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103679
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103711
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/104257
 ; PRIOR FILING DATE: 1998-10-14
 ; PRIOR APPLICATION NUMBER: 60/104987
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105000
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105002
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105104
 ; PRIOR FILING DATE: 1998-10-21
 ; PRIOR APPLICATION NUMBER: 60/105169
 ; PRIOR FILING DATE: 1998-10-22
 ; PRIOR APPLICATION NUMBER: 60/105266
 ; PRIOR FILING DATE: 1998-10-22
 ; PRIOR APPLICATION NUMBER: 60/105693
 ; PRIOR FILING DATE: 1998-10-26
 ; PRIOR APPLICATION NUMBER: 60/105694
 ; PRIOR FILING DATE: 1998-10-26
 ; PRIOR APPLICATION NUMBER: 60/105807
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/105881
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/105882
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/106023
 ; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 82;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAAGTGTATGAGGTGTCTGTGG 1486
 |||
 Db 24 GGAAGTGTATGAGGTGTCTGTGG 1

RESULT 109
 US-10-015-388A-293
 ; Sequence 293, Application US/10015388A
 ; Publication No. US20030191299A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc


```

; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C44
; CURRENT APPLICATION NUMBER: US/10/015,388A
; PRIOR APPLICATION: 2002-07-15
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-388A-293

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1041 GCTGACCTGCTCCCATCTACTCC 1064
DB      1 GCTGACCTGCTCCCATCTACTCC 24

```

```

RESULT 110
US-10-015-388A-294/c
; Sequence 294, Application US/10015388A
; Publication No. US20030191299A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C44
; CURRENT APPLICATION NUMBER: US/10/015,388A
; PRIOR APPLICATION: 2002-07-15
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-388A-294

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1463 GGAAGTGTATGGGTGTCTGTGGG 1486
DB      1424 GGAAGTGTATGGGTGTCTGTGGG 1

```

```

RESULT 111
US-10-012-753A-293
; Sequence 293, Application US/10012753A
; Publication No. US20030195334A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C17
; CURRENT APPLICATION NUMBER: US/10/012,753A
; PRIOR APPLICATION: 2001-12-07
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-753A-293

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1041 GCTGACCTGCTCCCATCTACTCC 1064
DB      1 GCTGACCTGCTCCCATCTACTCC 24

```

```

RESULT 112
US-10-012-753A-294/c
; Sequence 294, Application US/10012753A
; Publication No. US20030195334A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C17
; CURRENT APPLICATION NUMBER: US/10/012,753A
; PRIOR APPLICATION: 2001-12-07
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-753A-294

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-753A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1463 GGAAGTGCATGGGTCTGTCTGGG 1486

Db 24 GGAAGTGCATGGGTCTGTCTGGG 1

RESULT 113

```
US-10-015-385A-293
/ Sequence 293, Application US/10015385A
/ Publication No. US20030195347A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Baton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C51
/ CURRENT APPLICATION NUMBER: US/10/015,385A
/ CURRENT FILING DATE: 2002-07-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-385A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1041 GGTGACCTGTTCCCATCTACTCC 1064

Db 1 GGTGACCTGTTCCCATCTACTCC 24

RESULT 114

```
US-10-015-385A-294/c
/ Sequence 294, Application US/10015385A
/ Publication No. US20030195347A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
```

```
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C51
/ CURRENT APPLICATION NUMBER: US/10/015,385A
/ CURRENT FILING DATE: 2002-07-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-385A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1463 GGAAGTGCATGGGTCTGTCTGGG 1486

Db 24 GGAAGTGCATGGGTCTGTCTGGG 1

RESULT 115

```
US-10-007-236A-293
/ Sequence 293, Application US/10007236A
/ Publication No. US2003019893A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Baton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C12
/ CURRENT APPLICATION NUMBER: US/10/007,236A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-007-236A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1041 GGTGACCTGTTCCCATCTACTCC 1064

Db 1 GGTGACCTGTTCCCATCTACTCC 24

```
RESULT 116
US-10-007-236A-294/C
; Sequence 294, Application US/10007236A
; Publication No. US20030198993A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C12
; CURRENT APPLICATION NUMBER: US/10/007,236A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-007-236A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTCTATGGGTCTGTGTGGG 1486
DB      24  GGAGTGTCTATGGGTCTGTGTGGG 1

RESULT 117
US-10-015-389A-293
; Sequence 293, Application US/10015389A
; Publication No. US20030199675A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C48
; CURRENT APPLICATION NUMBER: US/10/015,389A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-389A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACCTCC 1064
DB      1  GCTGACCTGTTCCCATCTACCTCC 24

RESULT 118
US-10-015-389A-294/C
; Sequence 294, Application US/10015389A
; Publication No. US20030199675A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C48
; CURRENT APPLICATION NUMBER: US/10/015,389A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-389A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTCTATGGGTCTGTGTGGG 1486
DB      24  GGAGTGTCTATGGGTCTGTGTGGG 1

RESULT 119
US-10-015-519A-293
; Sequence 293, Application US/10015519A
; Publication No. US20030203401A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
```

```
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC49
/ CURRENT APPLICATION NUMBER: US/10/015,519A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-519A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 120
US-10-015-519A-294/c
/ Sequence 294, Application US/10015519A
/ Publication No. US20030203401A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC49
/ CURRENT APPLICATION NUMBER: US/10/015,519A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-519A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTGCATGGGTGTCGTGGG 1486
Db      24 GGAAGTGCATGGGTGTCGTGGG 1

RESULT 121
US-10-013-915A-293
/ Sequence 293, Application US/10013915A
```

```
/ Publication No. US20030204053A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC37
/ CURRENT APPLICATION NUMBER: US/10/013,915A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-915A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 122
US-10-013-915A-294/c
/ Sequence 294, Application US/10013915A
/ Publication No. US20030204053A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC37
/ CURRENT APPLICATION NUMBER: US/10/013,915A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-915A-294
```

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTATGGGTGTCTGTGGG 1486
DB 24 GGAAGTGTCTATGGGTGTCTGTGGG 1

RESULT 123
US-10-015-394A-293

; Sequence 293, Application US/10015394A
; Publication No. US20030204054A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan 1.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gueney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C41

; CURRENT APPLICATION NUMBER: US/10/015,394A

; CURRENT FILING DATE: 2001-12-11

; PRIOR APPLICATION NUMBER: 60/098716

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098723

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098749

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098750

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098803

; PRIOR FILING DATE: 1998-09-02

; PRIOR APPLICATION NUMBER: 60/098821

; PRIOR FILING DATE: 1998-09-02

; PRIOR APPLICATION NUMBER: 60/098843

; PRIOR FILING DATE: 1998-09-02

; PRIOR APPLICATION NUMBER: 60/099536

; PRIOR FILING DATE: 1998-09-09

; PRIOR APPLICATION NUMBER: 60/099596

; PRIOR FILING DATE: 1998-09-09

; PRIOR APPLICATION NUMBER: 60/099598

; PRIOR FILING DATE: 1998-09-09

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 293

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

; US-10-015-394A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTTCCTACTACTCC 1064
DB 1 GCTGACCTGGTTCCTACTACTCC 24

RESULT 124

US-10-015-394A-294/C

; Sequence 294, Application US/10015394A

; Publication No. US20030204054A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan 1.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gueney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C41

; CURRENT APPLICATION NUMBER: US/10/015,394A

; CURRENT FILING DATE: 2001-12-11

; PRIOR APPLICATION NUMBER: 60/098716

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098723

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098749

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098750

; PRIOR FILING DATE: 1998-09-01

; PRIOR APPLICATION NUMBER: 60/098803

; PRIOR FILING DATE: 1998-09-02

; PRIOR APPLICATION NUMBER: 60/098821

; PRIOR FILING DATE: 1998-09-02

; PRIOR APPLICATION NUMBER: 60/098843

; PRIOR FILING DATE: 1998-09-02

; PRIOR APPLICATION NUMBER: 60/099536

; PRIOR FILING DATE: 1998-09-09

; PRIOR APPLICATION NUMBER: 60/099596

; PRIOR FILING DATE: 1998-09-09

; PRIOR APPLICATION NUMBER: 60/099598

; PRIOR FILING DATE: 1998-09-09

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 294

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

; US-10-015-394A-294

RESULT 125

US-10-015-390A-293

; Sequence 293, Application US/10015390A

; Publication No. US20030216562A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan 1.

; APPLICANT: Ferrara, Napoleone

```

; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC53
; CURRENT APPLICATION NUMBER: US/10/015,390A
; CURRENT FILING DATE: 2002-07-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO: 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-390A-293

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1041 GCTGACCTGTTCCATCTACTCC 1064
DB      1 GCTGACCTGTTCCATCTACTCC 24

```

```

RESULT 126
US-10-015-390A-294/c
; Sequence 294, Application US/10015390A
; Publication No. US20030216562A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC53
; CURRENT APPLICATION NUMBER: US/10/015,390A
; CURRENT FILING DATE: 2002-07-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO: 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-390A-294

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1463 GGAAGTGTATGGGTCTGTGGG 1486

```

```

DB      24 GGAAGTGTATGGGTCTGTGGG 1
RESULT 127
US-10-006-746A-293
; Sequence 293, Application US/10006746A
; Publication No. US20030220471A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC5
; CURRENT APPLICATION NUMBER: US/10/006,746A
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15

```

; PRIOR APPLICATION NUMBER: 60/100584
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100627
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100661
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100662
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100664
 ; PRIOR FILING DATE: 1998-09-16
 ; PRIOR APPLICATION NUMBER: 60/100663
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100684
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100710
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100711
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100848
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/100849
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/100939
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/100930
 ; PRIOR FILING DATE: 1998-09-17
 ; PRIOR APPLICATION NUMBER: 60/101014
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101068
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101071
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/101279
 ; PRIOR FILING DATE: 1998-09-22
 ; PRIOR APPLICATION NUMBER: 60/101471
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101472
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101474
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101475
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101476
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101477
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101479
 ; PRIOR FILING DATE: 1998-09-23
 ; PRIOR APPLICATION NUMBER: 60/101738
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101741
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101743
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101915
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/101916
 ; PRIOR FILING DATE: 1998-09-24
 ; PRIOR APPLICATION NUMBER: 60/102207
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102240
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102307
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102330
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102331
 ; PRIOR FILING DATE: 1998-09-29
 ; PRIOR APPLICATION NUMBER: 60/102484
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102487
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102570

; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102571
 ; PRIOR FILING DATE: 1998-09-30
 ; PRIOR APPLICATION NUMBER: 60/102684
 ; PRIOR FILING DATE: 1998-10-01
 ; PRIOR APPLICATION NUMBER: 60/102687
 ; PRIOR FILING DATE: 1998-10-01
 ; PRIOR APPLICATION NUMBER: 60/102965
 ; PRIOR FILING DATE: 1998-10-02
 ; PRIOR APPLICATION NUMBER: 60/103258
 ; PRIOR FILING DATE: 1998-10-06
 ; PRIOR APPLICATION NUMBER: 60/103314
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103315
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103328
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103395
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103396
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103401
 ; PRIOR FILING DATE: 1998-10-07
 ; PRIOR APPLICATION NUMBER: 60/103449
 ; PRIOR FILING DATE: 1998-10-06
 ; PRIOR APPLICATION NUMBER: 60/103633
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103678
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103679
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/103711
 ; PRIOR FILING DATE: 1998-10-08
 ; PRIOR APPLICATION NUMBER: 60/104257
 ; PRIOR FILING DATE: 1998-10-14
 ; PRIOR APPLICATION NUMBER: 60/104987
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105000
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105002
 ; PRIOR FILING DATE: 1998-10-20
 ; PRIOR APPLICATION NUMBER: 60/105104
 ; PRIOR FILING DATE: 1998-10-21
 ; PRIOR APPLICATION NUMBER: 60/105169
 ; PRIOR FILING DATE: 1998-10-22
 ; PRIOR APPLICATION NUMBER: 60/105266
 ; PRIOR FILING DATE: 1998-10-22
 ; PRIOR APPLICATION NUMBER: 60/105693
 ; PRIOR FILING DATE: 1998-10-26
 ; PRIOR APPLICATION NUMBER: 60/105694
 ; PRIOR FILING DATE: 1998-10-26
 ; PRIOR APPLICATION NUMBER: 60/105807
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/105881
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/105882
 ; PRIOR FILING DATE: 1998-10-27
 ; PRIOR APPLICATION NUMBER: 60/106023
 ; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 82;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
 |||||
 Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 128
 US-10-006-746A-294/c
 ; Sequence 294, Application US/10006746A
 ; Publication No. US20030220471A1

GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan 1.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guirney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C5
CURRENT APPLICATION NUMBER: US/10/006,746A
CURRENT FILING DATE: 2001-12-06
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662

PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01


```
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28
```

```
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1463 GGAAGTGTCAATGGTGTCTGTGGG 1486
Db 24 GGAAGTGTCAATGGTGTCTGTGGG 1
```

```
RESULT 129
US-10-226-254A-293
; Sequence 293, Application US/10226254A
; Publication No. US20030224478A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
```

```
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PLC68
; TITLE OF INVENTION: Acids Encoding the Same
; CURRENT FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; REMAINING PRIOR APPLICATION DATA REMOVED - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-226-254A-293
```

```
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1041 GGTGACCTGTTCCCATCTACTCC 1064
Db 1 GGTGACCTGTTCCCATCTACTCC 24
```

```
RESULT 130
US-10-226-254A-294/C
; Sequence 294, Application US/10226254A
; Publication No. US20030224478A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
```

```
FILE REFERENCE: P2830PIC68
CURRENT APPLICATION NUMBER: US/10/226,254A
CURRENT FILING DATE: 2002-08-21
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
Remaining Prior Application data removed - See file Wrapper or PALM.
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-226-254A-294
```

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1463 GGAAGTGCATGGGTCGTCTGGG 1486

DB 24 GGAAGTGCATGGGTCGTCTGGG 1

```
RESULT 131
US-10-011-795A-293
Sequence 293, Application US/10011795A
Publication No. US20040005626A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, Nicholas F.
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC25
CURRENT APPLICATION NUMBER: US/10/011,795A
CURRENT FILING DATE: 2001-12-07
Prior application removed - See file Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 293
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
```

OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-011-795A-293

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064

DB 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 132
US-10-011-795A-294/C

```
Sequence 294, Application US/10011795A
Publication No. US20040005626A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, Nicholas F.
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC25
CURRENT APPLICATION NUMBER: US/10/011,795A
CURRENT FILING DATE: 2001-12-07
Prior application removed - See file Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-795A-294
```

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1463 GGAAGTGCATGGGTCGTCTGGG 1486

DB 24 GGAAGTGCATGGGTCGTCTGGG 1

```
RESULT 133
US-10-012-231A-293
Sequence 293, Application US/10012231A
Publication No. US20040014130A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, Nicholas F.
APPLICANT: Paoni, Nicholas F.
```

```

; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC23
; CURRENT APPLICATION NUMBER: US/10/012,231A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-231A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTTCCTACTCTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 134
US-10-012-231A-294/c
; Sequence 294, Application US/10012231A
; Publication No. US20040014130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC23
; CURRENT APPLICATION NUMBER: US/10/012,231A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-231A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTCTGGG 1486
Db      24 GGAAGTGCATGGGTCTCTGGG 1

RESULT 135
US-10-015-395A-293
; Sequence 293, Application US/10015395A
; Publication No. US20040073015A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC57
; CURRENT APPLICATION NUMBER: US/10/015,395A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-395A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTTCCTACTCTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 136
US-10-015-395A-294/c
; Sequence 294, Application US/10015395A
; Publication No. US20040073015A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC57
; CURRENT APPLICATION NUMBER: US/10/015,395A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-395A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
```

Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486
|||||

DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 137
US-10-012-149A-293

; Sequence 293, Application US/10012149A
; Publication No. US20050043520A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan I.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Guirney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Peoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830PIC26

; CURRENT APPLICATION NUMBER: US/10/012,149A

; CURRANT FILING DATE: 2002-06-25

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 293

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCATCTACTCC 1064
|||||

DB 1 GCTGACCTGTTCCATCTACTCC 24

RESULT 138
US-10-012-149A-294/C

; Sequence 294, Application US/10012149A
; Publication No. US20050043520A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan I.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Guirney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Peoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830PIC26

; CURRENT APPLICATION NUMBER: US/10/012,149A

; CURRANT FILING DATE: 2002-06-25

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 294

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486
|||||

DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 139
US-10-643-801-6/C

; Sequence 6, Application US/10643801
; Publication No. US20050043524A1

; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRANT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 6

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: PCR Primer

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 838 TGTGAGGAGTACTGATGCTG 861
|||||

DB 24 TGTGAGGAGTACTGATGCTG 1

RESULT 140
US-10-719-900-684231

; Sequence 684231, Application US/10719900
; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRANT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/4427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 684231

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

; US-10-719-900-684231

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1469 GTCATGGGTCTGTGGTATTATTA 1493
|||||
Db 1 GTCATGGGTCTGTGGTATTATTA 25

RESULT 141
US-10-719-900-761465
; Sequence 761465, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 761465
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-761465

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1314 TACATGAGGCGCTGTGAAGCTCT 1338
|||||
Db 1 TACATGAGGCGCTGTGAAGCTCT 25

RESULT 142
US-10-719-956-19410
; Sequence 19410, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 19410
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-19410

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1457 AAATTGGAAGTCTCATGGCTGCTCT 1481
|||||
Db 1 AAATTGGAAGTCTCATGGCTGCTCT 25

RESULT 143
US-10-719-956-102353
; Sequence 102353, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956

; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 102353
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-102353

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1285 AGCAAGACATCGACCTGTACACAC 1309
|||||
Db 1 AGCAAGACATCGACCTGTACACAC 25

RESULT 144
US-10-719-956-145295
; Sequence 145295, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 145295
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-145295

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1321 AGCCCTGTGAAGCTCTTGACAA 1345
|||||
Db 1 AGCCCTGTGTGAAGCTCTTGACAA 25

RESULT 145
US-10-719-956-323131
; Sequence 323131, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 323131
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-323131

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1296 GACCTGTACCAACACATGTATCATGG 1320
Db 1 GACCTGTACCACTTCATGTATCATGG 25

RESULT 146

US-10-278-733-22
; Sequence 22, Application US/10278733
; Publication No. US20030100480A1
; GENERAL INFORMATION:
; APPLICANT: Smith, Steven
; APPLICANT: Chen, Hubert
; APPLICANT: Farese, Robert V Jr
; TITLE OF INVENTION: Methods and compositions for modulating
; TITLE OF INVENTION: sebaceous glands
; FILE REFERENCE: UCAL-105CIP4
; CURRENT APPLICATION NUMBER: US/10/278,733
; CURRENT FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 10/040,315
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/339,472
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/107,771
; PRIOR FILING DATE: 1998-11-09
; PRIOR APPLICATION NUMBER: PCT/US98/17883
; PRIOR FILING DATE: 1998-08-28
; PRIOR APPLICATION NUMBER: 09/103,754
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide primer
US-10-278-733-22

Query Match 1.0%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 918 AGTGGCAATGCTATCATCATCGT 940
Db 1 AGTGGCAATGCTATCATCATCGT 23

RESULT 147

US-10-324-618-25
; Sequence 25, Application US/10324618
; Publication No. US20030170691A1
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Ruth
; APPLICANT: Wu, Zhidan
; APPLICANT: Kapeller-Libermann, Rosana
; APPLICANT: Hubbard, Brian K.
; TITLE OF INVENTION: HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2
; TITLE OF INVENTION: (DGAT2) FAMILY MEMBERS AND USES THEREFOR
; FILE REFERENCE: MP101-263P2RM
; CURRENT APPLICATION NUMBER: US/10/324,618
; CURRENT FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: 60/341,947
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: 60/411,859
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 86606 forward primer

US-10-324-618-25

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1777 CAAGCCCTTTATTCGCACTAC 1798
Db 1 CAAGCCCTTTATTCGCACTAC 22

RESULT 148

US-10-643-801-5
; Sequence 5, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 5
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-643-801-5

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 791 CATACGGCCTTACTGCGCTACA 812
Db 1 CATACGGCCTTACTGCGCTACA 22

RESULT 149

US-10-643-801-7
; Sequence 7, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-643-801-7

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 814 TGGCAGGCACTTCGGAATGCC 835
Db 1 TGGCAGGCACTTCGGAATGCC 22

RESULT 150

US-10-883-760-23
; Sequence 23, Application US/10883760
; Publication No. US20050035174A1

```

; GENERAL INFORMATION:
; APPLICANT: Yadav, Narendra
; TITLE OF INVENTION: ACYLTRANSFERASES FOR ALTERATION OF POLYUNSATURATED FATTY ACIDS
; FILE REFERENCE: CL2302 US NA
; CURRENT APPLICATION NUMBER: US/10/883,760
; CURRENT FILING DATE: 2004-07-06
; NUMBER OF SEQ ID NOS: 86
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer P7
; NAME/KEY: misc_feature
; LOCATION: (24)..(24)
; OTHER INFORMATION: n is a, c, g, or t
US-10-883-760-23

Query Match          0.9%; Score 22; DB 1; Length 29;
Best Local Similarity 75.9%; Pred. No. 1.5e+02;
Matches 22; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY      693 AACTATATCTTTGGATACACCCCATGG 721
Db      1 AACTACATCTTCGGCTAAYCNCACAG 29

RESULT 151
US-10-719-900-16467
; Sequence 16467, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 16467
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-16467

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1008 AAGGCTTTGTGAACCTGCGCCCTGC 1032
Db      1 AAGGCTTTGTGAAGCTGCGCCCTGC 25

RESULT 152
US-10-719-900-811306
; Sequence 811306, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
```

```

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 811306
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-811306

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1138 TCCGAAATACATGTTTCGCC 1162
Db      1 TCCGAAATATATTGTTTCGCC 25

RESULT 153
US-10-719-900-880907
; Sequence 880907, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 880907
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-880907

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1270 TGGAGCACCACCAACCCAGCAACAT 1294
Db      1 TGGAGCACCACCAACCCAGCAACAT 25

RESULT 154
US-10-719-956-19409
; Sequence 19409, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 19409
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-19409

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1457 AAATTGGAAGTGTATGGGTGCT 1481
Db      1 AAATTGGAAGCTATGGGTGCT 25
```

```
RESULT 155
US-10-719-956-102354
; Sequence 102354, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 102354
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-102354

Query Match
Best Local Similarity 0.9%; Score 21.8; DB 1; Length 25;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1285 AGCAAGACATCGACCTGTACCAACAC 1309
DB 1 AGAAAGACATCGTCTGTACCAACAC 25

RESULT 156
US-10-719-956-145296
; Sequence 145296, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 145296
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-145296

Query Match
Best Local Similarity 0.9%; Score 21.8; DB 1; Length 25;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1321 AGGCCTGTGAGGCTCTTGACAA 1345
DB 1 AGGCCTGTGAGGCTCTTGACAA 25

RESULT 157
US-10-719-956-630251
; Sequence 630251, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
```

```
; SEQ ID NO 630251
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-630251

Query Match
Best Local Similarity 0.9%; Score 21.8; DB 1; Length 25;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1270 TGGACACCCCAACCCAGCAAGCAT 1294
DB 1 TGGACACCCCAACCCAGCAAGCAT 25

RESULT 158
US-10-719-900-16468
; Sequence 16468, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 16468
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-16468

Query Match
Best Local Similarity 0.8%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1008 AAGGCTTTGTGAACGTGACCCTGC 1032
DB 1 AAAGCTTGTGTAGCTGACCCTGC 25

RESULT 159
US-10-719-900-263580
; Sequence 263580, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 263580
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-263580

Query Match
Best Local Similarity 0.8%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1036 ATGAGCTGACCTGGTCCCACTCA 1060
DB 1 ATGAGCTGATCTGTTCCCACTTA 25
```



```
RESULT 160
US-10-719-900-407646
; Sequence 407646, Application US/10719900
; Publication No. US20050026164A1
; ORGANISM: Mus musculus
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 407646
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-407646

Query Match
Best Local Similarity 88.0%; Score 20.2; DB 1; Length 25;
Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

1286 GCAAGACATGACCTGTACACACC 1310
DB 1 GAAAGACATGACCTGTACCATGCC 25

RESULT 161
US-10-719-900-539350
; Sequence 539350, Application US/10719900
; Publication No. US20050026164A1
; ORGANISM: Mus musculus
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 539350
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-539350

Query Match
Best Local Similarity 88.0%; Score 20.2; DB 1; Length 25;
Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

987 GCAGTACCCCTGCGAACCAGG 1011
DB 1 GCAGTACCCCTGAAGAACCCAAAG 25

RESULT 162
US-10-719-900-539351
; Sequence 539351, Application US/10719900
; Publication No. US20050026164A1
; ORGANISM: Mus musculus
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 539351
```

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-539351

Query Match
Best Local Similarity 88.0%; Score 20.2; DB 1; Length 25;
Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

987 GCAGTACCCCTGCGAACCAGG 1011
DB 1 GCAGTACCCCTGAAGAACCCAAAG 25

RESULT 163
US-10-719-900-811305
; Sequence 811305, Application US/10719900
; Publication No. US20050026164A1
; ORGANISM: Mus musculus
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 811305
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-811305

Query Match
Best Local Similarity 88.0%; Score 20.2; DB 1; Length 25;
Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

1138 TCCAGAAATACATTGTTTCGCCCC 1162
DB 1 TCCAGAAATATATGTTTCGCCCC 25

RESULT 164
US-10-719-900-832328
; Sequence 832328, Application US/10719900
; Publication No. US20050026164A1
; ORGANISM: Mus musculus
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 832328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-832328

Query Match
Best Local Similarity 88.0%; Score 20.2; DB 1; Length 25;
Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

2232 TCTGACGACGAGATTAGTCCAAAG 2256
DB 1 TCTGACGACGAGAGTTTCCAAATG 25

RESULT 165
```

```
US-10-719-900-880908
; Sequence 880908, Application US/10719950
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 880908
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-880908

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1270 TGGAGCACCACCAAGCCAGCAAGACAT 1294
DB      1 TGGAGCACCACCGAGCCAGAAAGACAT 25

RESULT 166
US-10-719-956-70482
; Sequence 70482, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 70482
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-70482

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1348 ACAAGACCAAGTTCGGCTTCCCGGA 1372
DB      1 ACAAGACCAAAATCGGCTTCCAGA 25

RESULT 167
US-10-719-956-630252
; Sequence 630252, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 630252
; LENGTH: 25
```

```
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-630252

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1270 TGGAGCACCACCAAGCCAGCAAGACAT 1294
DB      1 TGGAGCACCACCGAGCCAGAAAGACAT 25

RESULT 168
US-10-324-618-26/C
; Sequence 26, Application US/10324618
; Publication No. US20030170691A1
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Ruth
; APPLICANT: Wu, Zhidan
; APPLICANT: Kapeller-Libermann, Rosana
; APPLICANT: Hubbard, Brian K.
; TITLE OF INVENTION: HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2
; FILE REFERENCE: MP101-263P2RM
; CURRENT APPLICATION NUMBER: US/10/324,618
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: 60/341,947
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: 60/411,859
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 86606 reverse primer
US-10-324-618-26

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1831 CAGTTTCTGTGCCAAGGGGA 1850
DB      20 CAGTTTCTGTGCCAAGGGGA 1

RESULT 169
US-10-307-817-379/C
; Sequence 379, Application US/10307817
; Publication No. US20040058338A1
; GENERAL INFORMATION:
; APPLICANT: Agee et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-502C
; CURRENT APPLICATION NUMBER: US/10/307,817
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 682
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 379
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-307-817-379

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1218 TACTCAAGCCATCACCAC 1237
Db 20 TACTCAAGCCATCACCAC 1

RESULT 170
US-10-643-801-20/c
; Sequence 20, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-20

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 579 CCCAGAAAGGTGCGCAGAG 598
Db 20 CCCAGAAAGGTGCGCAGAG 1

RESULT 171
US-10-643-801-21/c
; Sequence 21, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-21

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 639 CGAGACTACTTCCCATCCA 658
Db 20 CGAGACTACTTCCCATCCA 1

RESULT 172
US-10-643-801-22/c
; Sequence 22, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-22

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 644 CTACTTCCCATCCAGCTGG 663
Db 20 CTACTTCCCATCCAGCTGG 1

RESULT 173
US-10-643-801-23/c
; Sequence 23, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-23

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 649 TTCCCATCCAGCTGCTGAAG 668
Db 20 TTCCCATCCAGCTGCTGAAG 1

RESULT 174
US-10-643-801-24/c
; Sequence 24, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-24

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 654 ATCCAGCTGTTGAAGACACA 673
|||||
DB 20 ATCCAGCTGTTGAAGACACA 1

RESULT 175
US-10-643-801-25/c
; Sequence 25, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-25

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 659 GCTGTGAAGACACACACC 678
|||||
DB 20 GCTGTGAAGACACACACC 1

RESULT 176
US-10-643-801-26/c
; Sequence 26, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-26

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 664 TGAAGACACCAACTGCTG 683
|||||
DB 20 TGAAGACACCAACTGCTG 1

RESULT 177
US-10-643-801-27/c
; Sequence 27, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-27

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 ACACACCAACTGTCACAC 688
|||||
DB 20 ACACACCAACTGTCACAC 1

RESULT 178
US-10-643-801-28/c
; Sequence 28, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-28

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 CAACCTGTCACACACAGA 693
|||||
DB 20 CAACCTGTCACACACAGA 1

RESULT 179
US-10-643-801-29/c
; Sequence 29, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-29

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 679 TGCTGACCAACGAACTAT 698

Db 20 TGCTGACCACGAGACTAT 1

RESULT 180
US-10-643-801-30/c
; Sequence 30, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-30

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 684 ACCACCGAAGTATATCTT 703
Db 20 ACCACCGAAGTATATCTT 1

RESULT 181
US-10-643-801-31/c
; Sequence 31, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-31

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 689 CAGGAAGTATATCTTTGGAT 708
Db 20 CAGGAAGTATATCTTTGGAT 1

RESULT 182
US-10-643-801-32/c
; Sequence 32, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-32

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 694 ACTATATCTTTGGATACAC 713
Db 20 ACTATATCTTTGGATACAC 1

RESULT 183
US-10-643-801-33/c
; Sequence 33, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-33

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 723 ATCATGGCCTGGGTCCTT 742
Db 20 ATCATGGCCTGGGTCCTT 1

RESULT 184
US-10-643-801-34/c
; Sequence 34, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-34

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 846 GAGTACCTGATGCTGAGG 865

```
Db      20 GAGTACCTGATGTCGGAG 1

RESULT 185
US-10-643-801-35/c
; Sequence 35, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-35

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      909 AAGATGGAGTGGCAATGC 928
Db      20 AAGATGGAGTGGCAATGC 1

RESULT 186
US-10-643-801-36/c
; Sequence 36, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-36

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      914 TGGAGTGGCAATGCTATCA 933
Db      20 TGGAGTGGCAATGCTATCA 1

RESULT 187
US-10-643-801-37/c
; Sequence 37, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-37

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      919 GTGGCAATGCTATCATCATC 938
Db      20 GTGGCAATGCTATCATCATC 1

RESULT 188
US-10-643-801-38/c
; Sequence 38, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-38

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      924 AATGCTATCATCATCGTGT 943
Db      20 AATGCTATCATCATCGTGT 1

RESULT 189
US-10-643-801-39/c
; Sequence 39, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-39

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      963 CTGAGCTCATTGCTGGCAA 982
Db      20 CTGAGCTCATTGCTGGCAA 1
```

```
RESULT 190
US-10-643-801-40/c
; Sequence 40, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-40

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1110 TCCTGGGGCGGATGGGTCCA 1129
DB 20 TCCTGGGGCGGATGGGTCCA 1

RESULT 191
US-10-643-801-41/c
; Sequence 41, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-41

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 GGGCCGATGGGTCCAGAGA 1134
DB 20 GGGCCGATGGGTCCAGAGA 1

RESULT 192
US-10-643-801-42/c
; Sequence 42, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 42
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-42

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1120 GATGGGTCCAGAGAGTTC 1139
DB 20 GATGGGTCCAGAGAGTTC 1

RESULT 193
US-10-643-801-43/c
; Sequence 43, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-43

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1125 GTCCAGAGAGAGTTCAGAA 1144
DB 20 GTCCAGAGAGAGTTCAGAA 1

RESULT 194
US-10-643-801-44/c
; Sequence 44, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-44

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1197 GACACCTGGGGGCTGTGCC 1216
DB 20 GACACCTGGGGGCTGTGCC 1
```

```
RESULT 195
US-10-643-801-45/C
; Sequence 45, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-45

Query Match
Best Local Similarity 0.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1202 CTGGGGGCTGTCCTACT 1221
Db 20 CTGGGGGCTGTCCTACT 1

RESULT 196
US-10-643-801-46/C
; Sequence 46, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-46

Query Match
Best Local Similarity 0.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1207 GGCTGTGCTTACTCCAG 1226
Db 20 GGCTGTGCTTACTCCAG 1

RESULT 197
US-10-643-801-47/C
; Sequence 47, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 47
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-47

Query Match
Best Local Similarity 0.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1309 CCATGTACATGAGGCCCTG 1328
Db 20 CCATGTACATGAGGCCCTG 1

RESULT 198
US-10-643-801-48/C
; Sequence 48, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-48

Query Match
Best Local Similarity 0.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1314 TACATGAGAGCCCTGTGAA 1333
Db 20 TACATGAGAGCCCTGTGAA 1

RESULT 199
US-10-643-801-49/C
; Sequence 49, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-49

Query Match
Best Local Similarity 0.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1319 GGAGGCTGTGTAAGCTCT 1338
Db 20 GGAGGCTGTGTAAGCTCT 1
```



```
RESULT 200
US-10-643-801-50/c
; Sequence 50, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-50

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1469 GTCATGGGTCCTCTGCGGTT 1488
DB      20 GTCATGGGTCCTCTGCGGTT 1

RESULT 201
US-10-643-801-51/c
; Sequence 51, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-51

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1474 GGGTGTCTGTGGTATTATTA 1493
DB      20 GGGTGTCTGTGGTATTATTA 1

RESULT 202
US-10-643-801-52/c
; Sequence 52, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-52

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1479 TCTGTGGGTTATTAAAGA 1498
DB      20 TCTGTGGGTTATTAAAGA 1

RESULT 203
US-10-643-801-62/c
; Sequence 62, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-62

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      46 GGCTGTTTCTTCGCGCCAC 65
DB      20 GGCTGTTTCTTCGCGCCAC 1

RESULT 204
US-10-643-801-63/c
; Sequence 63, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-63

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      134 GCTTGGCGGAAGCCCTGSC 153
DB      20 GCTTGGCGGAAGCCCTGSC 1

RESULT 205
```

```
US-10-643-801-64/c
; Sequence 64, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-64

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      222 GCTTCAGCCATGAAGACCTT 241
DB      20 GCTTCAGCCATGAAGACCTT 1

RESULT 206
US-10-643-801-65/c
; Sequence 65, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-65

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      246 GCCGCTACTCCGGGCTCTT 265
DB      20 GCCGCTACTCCGGGCTCTT 1

RESULT 207
US-10-643-801-66/c
; Sequence 66, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-66

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-66

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      441 ATCTCAGTCTCCAGTGGGT 460
DB      20 ATCTCAGTCTCCAGTGGGT 1

RESULT 208
US-10-643-801-67/c
; Sequence 67, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-67

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      855 ATGTCTGAGAGTATCTGCC 874
DB      20 ATGTCTGAGAGTATCTGCC 1

RESULT 209
US-10-643-801-68/c
; Sequence 68, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-68

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      987 GCAGTCACCTGCGGACCG 1006
DB      20 GCAGTCACCTGCGGACCG 1

RESULT 210
US-10-643-801-69/c
```

```
; Sequence 69, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-69

Query Match
0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1387 AGGTGAAGTGAAGCCAGCCTT 1406
DB 20 AGGTGAAGTGAAGCCAGCCTT 1

RESULT 211
US-10-643-801-70/c
; Sequence 70, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-70

Query Match
0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1401 AGCCTTCGGGGCCCACTCCC 1420
DB 20 AGCCTTCGGGGCCCACTCCC 1

RESULT 212
US-10-643-801-71/c
; Sequence 71, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-71

Query Match
0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1414 AACTCCCTGAGAGACCAGC 1433
DB 20 AACTCCCTGAGAGACCAGC 1

RESULT 213
US-10-643-801-72/c
; Sequence 72, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-72

Query Match
0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1449 TGCTCTGTAAATTGGAGT 1468
DB 20 TGCTCTGTAAATTGGAGT 1

RESULT 214
US-10-643-801-73/c
; Sequence 73, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-73

Query Match
0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1584 GCTTGCCCTGTCTAGTGG 1603
DB 20 GCTTGCCCTGTCTAGTGG 1

RESULT 215
US-10-643-801-74/c
; Sequence 74, Application US/10643801
```

```
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-74

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1635 AGCTAACCTCTCTCTCTCC 1654
DB      20 AGCTAACCTCTCTCTCTCC 1

RESULT 216
US-10-643-801-75/c
; Sequence 75, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-75

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1647 TTCTTCCCTCCGAGGTGA 1666
DB      20 TTCTTCCCTCCGAGGTGA 1

RESULT 217
US-10-643-801-76/c
; Sequence 76, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-643-801-76/c
; Sequence 77, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-77

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1679 AGCTTCTTGGGAGAGAG 1698
DB      20 AGCTTCTTGGGAGAGAG 1

RESULT 218
US-10-643-801-77/c
; Sequence 77, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-77

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1707 TAGTGACTTGACCAAGTTAG 1726
DB      20 TAGTGACTTGACCAAGTTAG 1

RESULT 219
US-10-643-801-78/c
; Sequence 78, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-78

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1724 TAGATGATTCACTTTTGCC 1743
DB      20 TAGATGATTCACTTTTGCC 1

RESULT 220
US-10-643-801-79/c
; Sequence 79, Application US/10643801
; Publication No. US20050043524A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-79

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1743 CCTAGGATGAGAGCGGAA 1762
Db      20 CCTAGGATGAGAGCGGAA 1

RESULT 221
US-10-643-801-80/c
; Sequence 80, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-80

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1763 AGCCACTTCTCATCAAGCC 1782
Db      20 AGCCACTTCTCATCAAGCC 1

RESULT 222
US-10-643-801-81/c
; Sequence 81, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-81

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1802 ACCCTGCTAGTCTGAAA 1821
Db      20 ACCCTGCTAGTCTGAAA 1

RESULT 223
US-10-643-801-82/c
; Sequence 82, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-82

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1946 CCTAGTCACTCATATCGAG 1965
Db      20 CCTAGTCACTCATATCGAG 1

RESULT 224
US-10-643-801-83/c
; Sequence 83, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-83

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1969 GGACTGGCTCCAGATGAG 1988
Db      20 GGACTGGCTCCAGATGAG 1

RESULT 225
US-10-643-801-84/c
; Sequence 84, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-84
```

```
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-84
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1974 GGCCTCAGGATGAGGATG 1993
Db      20 GGCCTCAGGATGAGGATG 1
```

```
RESULT 226
US-10-643-801-85/c
; Sequence 85, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-85
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1989 GATGGGGGTGGCAATGACAC 2008
Db      20 GATGGGGGTGGCAATGACAC 1
```

```
RESULT 227
US-10-643-801-86/c
; Sequence 86, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-86
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      2055 GCCGCCACCATGAGCTAGGT 2074
Db      20 GCCGCCACCATGAGCTAGGT 1
```

```
RESULT 228
US-10-643-801-87/c
; Sequence 87, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-87
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      2067 AGCTAGGTGAGTACTGCT 2086
Db      20 AGCTAGGTGAGTACTGCT 1
```

```
RESULT 229
US-10-643-801-88/c
; Sequence 88, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-88
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      2088 TTCTTGAGGTGCTGATGAC 2107
Db      20 TTCTTGAGGTGCTGATGAC 1
```

```
RESULT 230
US-10-643-801-89/c
; Sequence 89, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
```



```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18.
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 94
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-94

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2220 GGGGCGCTGGCCTTCTGAGCA 2239
Db      20 GGGGCGCTGGCCTTCTGAGCA 1

RESULT 236
US-10-643-801-95/c
/ Sequence 95, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 95
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-95

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2242 AGATTAGTTCCAAGCAGGT 2261
Db      20 AGATTAGTTCCAAGCAGGT 1

RESULT 237
US-10-643-801-96/c
/ Sequence 96, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 96
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-96

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2269 GAACCAAGCCCTCACTTTTC 2288
Db      20 GAACCAAGCCCTCACTTTTC 1

RESULT 238
US-10-643-801-97/c
/ Sequence 97, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 97
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-97

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2367 TTGCACCATGTCAGACTTTT 2386
Db      20 TTGCACCATGTCAGACTTTT 1

RESULT 239
US-10-643-801-143
/ Sequence 143, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 143
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-143

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      579 CCCAAGAAAGGTGGCAGAG 598
Db      1 CCCAAGAAAGGTGGCAGAG 20

RESULT 240
US-10-643-801-144
/ Sequence 144, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
```


;; CURRENT APPLICATION NUMBER: US/10/643,801
;; CURRENT FILING DATE: 2003-08-18
;; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-144

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 639 CGAGACTCTTCCCATCCA 658
DB 1 CGAGACTCTTCCCATCCA 20

RESULT 241
US-10-643-801-145
; Sequence 145, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-145

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 649 TTCCCATCCAGCTGTGAAG 668
DB 1 TTCCCATCCAGCTGTGAAG 20

RESULT 242
US-10-643-801-146
; Sequence 146, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 146
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-146

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 654 ATCCAGCTGTGAAGACACA 673
DB 1 ATCCAGCTGTGAAGACACA 20

RESULT 243
US-10-643-801-147
; Sequence 147, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-147

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 659 GCTGTGAAGACACACACC 678
DB 1 GCTGTGAAGACACACACC 20

RESULT 244
US-10-643-801-148
; Sequence 148, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 148
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-148

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 664 TGAAGACACACACCTGCTG 683
DB 1 TGAAGACACACACCTGCTG 20

RESULT 245
US-10-643-801-149
; Sequence 149, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 149
; LENGTH: 20
; TYPE: DNA

ORGANISM: H. sapiens
FEATURE:
US-10-643-801-149

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 ACACACCACTGCTGACAC 688
|||||
DB 1 ACACACCACTGCTGACAC 20

RESULT 246
US-10-643-801-150

Sequence 150, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot

APPLICANT: Kenneth W. Dobie

TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

FILE REFERENCE: RTS-0678US

CURRENT APPLICATION NUMBER: US/10/643,801

CURRENT FILING DATE: 2003-08-18

NUMBER OF SEQ ID NOS: 230

SEQ ID NO 150

LENGTH: 20

TYPE: DNA

ORGANISM: H. sapiens

FEATURE:

US-10-643-801-150

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 CAACCTGCTGACCAACGGA 693
|||||
DB 1 CAACCTGCTGACCAACGGA 20

RESULT 247
US-10-643-801-151

Sequence 151, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot

APPLICANT: Kenneth W. Dobie

TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

FILE REFERENCE: RTS-0678US

CURRENT APPLICATION NUMBER: US/10/643,801

CURRENT FILING DATE: 2003-08-18

NUMBER OF SEQ ID NOS: 230

SEQ ID NO 151

LENGTH: 20

TYPE: DNA

ORGANISM: H. sapiens

FEATURE:

US-10-643-801-151

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 679 TGCTGACCAACGGAACCTAT 698
|||||
DB 1 TGCTGACCAACGGAACCTAT 20

RESULT 248
US-10-643-801-152

Sequence 152, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie

TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

FILE REFERENCE: RTS-0678US

CURRENT APPLICATION NUMBER: US/10/643,801

CURRENT FILING DATE: 2003-08-18

NUMBER OF SEQ ID NOS: 230

SEQ ID NO 152

LENGTH: 20

TYPE: DNA

ORGANISM: H. sapiens

FEATURE:

US-10-643-801-152

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 684 ACCACCAAGAACTATATCTT 703
|||||
DB 1 ACCACCAAGAACTATATCTT 20

RESULT 249
US-10-643-801-153

Sequence 153, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot

APPLICANT: Kenneth W. Dobie

TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

FILE REFERENCE: RTS-0678US

CURRENT APPLICATION NUMBER: US/10/643,801

CURRENT FILING DATE: 2003-08-18

NUMBER OF SEQ ID NOS: 230

SEQ ID NO 153

LENGTH: 20

TYPE: DNA

ORGANISM: H. sapiens

FEATURE:

US-10-643-801-153

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 689 CAGGAAGTAATCTTGGAT 708
|||||
DB 1 CAGGAAGTAATCTTGGAT 20

RESULT 250
US-10-643-801-154

Sequence 154, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot

APPLICANT: Kenneth W. Dobie

TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

FILE REFERENCE: RTS-0678US

CURRENT APPLICATION NUMBER: US/10/643,801

CURRENT FILING DATE: 2003-08-18

NUMBER OF SEQ ID NOS: 230

SEQ ID NO 154

LENGTH: 20

TYPE: DNA

ORGANISM: H. sapiens

FEATURE:

US-10-643-801-154

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

	Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	694	ACTATATCTTGATACCAAC	713							
Db	1	ACTATATCTTGATACCAAC	20							

```

RESULT 251
US-10-643-801-155
: Sequence 155, Application US/10643801
: Publication No. US20050043524A1
: GENERAL INFORMATION:
: APPLICANT: Sanjay Bhanot
: APPLICANT: Kenneth W. Doble
: TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
: FILE REFERENCE: RTS-06780US
: CURRENT APPLICATION NUMBER: US/10/643,801
: CURRENT FILING DATE: 2003-08-18
: NUMBER OF SEQ ID NOS: 230
: SEQ ID NO 155
: LENGTH: 20
: TYPE: DNA
: ORGANISM: H. sapiens
: FEATURE:
: US-10-643-801-155

```

```

RESULT 252
US-10-643-801-156
; Sequence 156, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RFS-0678U5
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 156
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-156

Query Match                                0.8%; Score 20; DB 1; Length 20;
Best Local Similarity    100.0%; Pred No. 1,4e+02;
Matches      20; Conservative   0; Mismatches     0; Indels       0; Gaps      0;

OY          846 GAGTACCTGATGTCTGGAGC 865
             ||| ||||| ||||| |||||
Db           1 GAGTACTCATGTCTGGAGG 20

RESULT 253
US-10-643-801-157
; Sequence 157, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RFS-0678U5
CURRENT APPLICATION NUMBER: US/10/643,801
```

```

: CURRENT FILING DATE: 2003-08-18
:
: NUMBER OF SEQ ID NOS: 230
:
: SEQ ID NO:157
:
: LENGTH: 20
:
: TYPE: DNA
:
: ORGANISM: H. sapiens
:
: FEATURE:
:
: OS-10-643-801-157

```

```

RESULT 254
US-10-643-801-158
; Sequence 158, Application US/10643801
; Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 158
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-158

```

```

RESULT 255
US-10-643-801-159
; Sequence 159, Application US/10643801
; Publication NO. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 159
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-159

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      919 GTGGCAATGCTATCATCATC 938
|||||
db      1 GTGGCAATGCTATCATCATC 20

```

RESULT 256
US-10-643-801-160
; Sequence 160, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 160
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-160

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 924 AATGCTATCATCATCGTGGT 943
|||||
Db 1 AATGCTATCATCATCGTGGT 20

RESULT 257
US-10-643-801-161
; Sequence 161, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 161
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-161

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 963 CTGAGCTCCATGCTGGCAA 982
|||||
Db 1 CTGAGCTCCATGCTGGCAA 20

RESULT 258
US-10-643-801-162
; Sequence 162, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens

; FEATURE:
US-10-643-801-162

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1110 TCCTGGGGCCGATGGTCCA 1129
|||||
Db 1 TCCTGGGGCCGATGGTCCA 20

RESULT 259
US-10-643-801-163
; Sequence 163, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 163
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-163

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1115 GGGCCGATGGTCCAGAGA 1134
|||||
Db 1 GGGCCGATGGTCCAGAGA 20

RESULT 260
US-10-643-801-164
; Sequence 164, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 164
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-164

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1120 GATGGTCCAGAGAAGTTC 1139
|||||
Db 1 GATGGTCCAGAGAAGTTC 20

RESULT 261
US-10-643-801-165
; Sequence 165, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:

```

; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-165
```

```

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1125 GTCCAGAGAGTTCAGAA 1144
Db      1 GTCCAGAGAGTTCAGAA 20
```

```

RESULT 262
US-10-643-801-166
; Sequence 166, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-166
```

```

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1197 GACACCTGGGGCTGTGCC 1216
Db      1 GACACCTGGGGCTGTGCC 20
```

```

RESULT 263
US-10-643-801-167
; Sequence 167, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-167
```

```

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1202 CTGGGGGCTGTGCTTACT 1221
Db      1 CTGGGGGCTGTGCTTACT 20
```

```

RESULT 264
US-10-643-801-168
; Sequence 168, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-168
```

```

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1207 GGCTGGTCCCTACTCCAG 1226
Db      1 GGCTGGTCCCTACTCCAG 20
```

```

RESULT 265
US-10-643-801-169
; Sequence 169, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-169
```

```

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1309 CCATGTACATGAGGCCCTG 1328
Db      1 CCATGTACATGAGGCCCTG 20
```

```

RESULT 266
US-10-643-801-170
; Sequence 170, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
```

/ NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 170
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-170

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1314 TACATGAGGCGCTGTGAA 1333
|||||
Db 1 TACATGAGGCGCTGTGAA 20

RESULT 267
US-10-643-801-171

; Sequence 171, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 171

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-643-801-171

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1319 GGAGGCCCTGTGAGCTCT 1338
|||||
Db 1 GGAGGCCCTGTGAGCTCT 20

RESULT 268
US-10-643-801-172

; Sequence 172, Application US/10643801

; Publication No. US20050043524A1

; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 172

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-643-801-172

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1469 GTCATGGGTGTCTGTGGTT 1488
|||||
Db 1 GTCATGGGTGTCTGTGGTT 20

RESULT 269
US-10-643-801-173

; Sequence 173, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 173

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-643-801-173

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1474 GGGTGTCTGTGGTTATTTA 1493
|||||
Db 1 GGGTGTCTGTGGTTATTTA 20

RESULT 270
US-10-643-801-174

; Sequence 174, Application US/10643801

; Publication No. US20050043524A1

; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 174

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-643-801-174

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1479 TCTGTGGTTATTTAAGA 1498
|||||
Db 1 TCTGTGGTTATTTAAGA 20

RESULT 271
US-10-643-801-182

; Sequence 182, Application US/10643801

; Publication No. US20050043524A1

; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 182

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-643-801-182

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 GGCTGTTTCTCTCGCCGAC 65
DB 1 GGCTGTTTCTCTCGCCGAC 20

RESULT 272

US-10-643-801-183
; Sequence 183, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 183
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-183

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 134 GCTCTGCGGACGCTGCG 153
DB 1 GCTCTGCGGACGCTGCG 20

RESULT 273

US-10-643-801-184
; Sequence 184, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 184
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-184

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 222 GCTTCAGCCATGAACCT 241
DB 1 GCTTCAGCCATGAACCT 20

RESULT 274

US-10-643-801-185
; Sequence 185, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 185
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-185

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 246 GCGGCTACTCGGGGTCT 265
DB 1 GCGGCTACTCGGGGTCT 20

RESULT 275

US-10-643-801-186
; Sequence 186, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 186
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-186

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 441 ATCTAGTCTCAGTGGT 460
DB 1 ATCTAGTCTCAGTGGT 20

RESULT 276

US-10-643-801-187
; Sequence 187, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 187
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-187

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      987 GCAGTCACCCCTGCGGAACG 1006
          |||||
Db      1 GCAGTCACCCCTGCGGAACG 20

```

RESULT 277
US-10-643-801-188
; Sequence 188, Application US/10643801
; Publication No. US20050043524A1

Query Match	0.8%	Score 20	DB 1	Length 20
Best Local Similarity	100.0%	Pred. No.	1.4e+02	
Matches 20	Conservative 0	Mismatches 0	Indels 0	Gaps 0

```

RESULT 278
US-10-643-801-189
: Sequence 189: Application US//10643801
: Publication No. US20050043524A1
: GENERAL INFORMATION:
: APPLICANT: Sanjay Bhanot
: APPLICANT: Kenneth W. Dobie
: TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
: FILE REFERENCE: RTS-0678US
: CURRENT APPLICATION NUMBER: US//10/643,801
: CURRENT FILING DATE: 2003-08-18
: NUMBER OF SEQ ID NOS: 230
: SEQ ID NO 189
: LENGTH: 20
: TYPE: DNA
: ORGANISM: H. sapiens
: FEATURE:
US-10-643-801-189

```

Query Match	0.8%	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%	Pred. No. 1.4e+02;		
Matches 20; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0

```

RESULT 279
US-10-643-801-190
; Sequence 190, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RRS-067818
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230

```

```

; SEQ ID NO 190
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-190

```

Query Match	0.8;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 1.4e+02;		
Matches 20;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

```

RESULT 280
US-10-643-801-191
; Sequence 191, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RPS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 191
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-191

```

Query Match	0.8;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0;	Pred. No. 1.4e+02;		
Matches 20;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

```

RESULT 281
US-10-643-801-192
; Sequence 192: Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 192
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-192

```

Query Match	0.8%;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 1.4e+02;		
Matches 20;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0

RESULT 282


```
US-10-643-801-193
; Sequence 193, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-193

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1647 TTCTTCCCTTCTGAGTGA 1666
|||||
1 TTCTTCCCTTCTGAGTGA 20

Db

RESULT 283
US-10-643-801-194
; Sequence 194, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 194
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-194

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1679 AGTCTTCTTGGGAGAGG 1698
|||||
1 AGTCTTCTTGGGAGAGG 20

Db

RESULT 284
US-10-643-801-195
; Sequence 195, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 195
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-195

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1707 TAGTGACTTGACCACTTAG 1726
|||||
1 TAGTGACTTGACCACTTAG 20

Db

RESULT 285
US-10-643-801-196
; Sequence 196, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-196

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1724 TAGATGATTCACCTTTTGGC 1743
|||||
1 TAGATGATTCACCTTTTGGC 20

Db

RESULT 286
US-10-643-801-197
; Sequence 197, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 197
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-197

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1763 ACCCACTTCTCATACAGCC 1782
|||||
1 ACCCACTTCTCATACAGCC 20

Db

RESULT 287
US-10-643-801-198
; Sequence 198, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
```

```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 198
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
US-10-643-801-198

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1802 ACGCTGCTAGTCTGAAA 1821
DB      1 ACGCTGCTAGTCTGAAA 20

RESULT 288
US-10-643-801-199
/ Sequence 199, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 199
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
US-10-643-801-199

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1946 CCTAGTCACTCATATCGAG 1965
DB      1 CCTAGTCACTCATATCGAG 20

RESULT 289
US-10-643-801-200
/ Sequence 200, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 200
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
US-10-643-801-200

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1969 GGACTGGCTCCAGATGAG 1988
```

```
DB      1 GGACTGGCTCCAGATGAG 20

RESULT 290
US-10-643-801-201
/ Sequence 201, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 201
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
US-10-643-801-201

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1974 GGCTCCAGATGAGATGG 1993
DB      1 GGCTCCAGATGAGATGG 20

RESULT 291
US-10-643-801-202
/ Sequence 202, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 202
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
US-10-643-801-202

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1989 GATGGGGTGGCATGACAC 2008
DB      1 GATGGGGTGGCATGACAC 20

RESULT 292
US-10-643-801-203
/ Sequence 203, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 203
```

LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-203

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2055 GCCGCCCATGAGCTAGCT 2074
DB 1 GCCGCCCATGAGCTAGCT 20

RESULT 293
US-10-643-801-204

Sequence 204, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 204
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-204

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2067 AGCTAGGTGAGTAACTGCT 2086
DB 1 AGCTAGGTGAGTAACTGCT 20

RESULT 294

US-10-643-801-205

Sequence 205, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 205
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-205

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2088 TTCTTGGGTGGTGGATGAC 2107
DB 1 TTCTTGGGTGGTGGATGAC 20

RESULT 295
US-10-643-801-206

Sequence 206, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 206
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-206

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2125 TCAGCCTTGCCCTGAGCAC 2144
DB 1 TCAGCCTTGCCCTGAGCAC 20

RESULT 296
US-10-643-801-207

Sequence 207, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 207
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-207

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2137 TGGAGCAGTGGCTTACTGCT 2156
DB 1 TGGAGCAGTGGCTTACTGCT 20

RESULT 297
US-10-643-801-208

Sequence 208, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 208
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-208

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2143 ACATGCTTACTGTGGCCTC 2162
DB 1 ACATGCTTACTGTGGCCTC 20

RESULT 298
US-10-643-801-209

; Sequence 209, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-209

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2150 TACTGTGGCCTTACTTAC 2169
DB 1 TACTGTGGCCTTACTTAC 20

RESULT 299
US-10-643-801-210

; Sequence 210, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 210
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-210

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2220 GGAGCCTGGCCTTCTGAGCA 2239
DB 1 GGAGCCTGGCCTTCTGAGCA 20

RESULT 300
US-10-643-801-211

; Sequence 211, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 211
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-211

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2242 AGATTAGTTCAGACAGGT 2261
DB 1 AGATTAGTTCAGACAGGT 20

RESULT 301
US-10-643-801-212

; Sequence 212, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 212
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-212

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2269 GAACCCAGCCTCACTTTC 2288
DB 1 GAACCCAGCCTCACTTTC 20

RESULT 302
US-10-643-801-213

; Sequence 213, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 213
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-213

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2367 TTGACCATGTGAGACTTTT 2386
DB 1 TTGACCATGTGAGACTTTT 20

```
Db      1 TTGCACCATGTGCACTTTT 20

RESULT 303
US-10-719-956-301629/c
; Sequence 301629, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Method of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 301629
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-301629

Query Match      0.8%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      801 TACCTGCTACTGCGAGGC 821
Db      24 TACCTGCTACTGCGAGGC 4

RESULT 304
US-10-719-900-885846/c
; Sequence 885846, Application US/10719900
; Publication No. US2005026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Method of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 885846
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-885846

Query Match      0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      742 TCTGCACTTGACGACAGAGGCCA 765
Db      24 TCTGCACTTGACGACAGAGGCCA 1

RESULT 305
US-10-809-189-52073/c
; Sequence 52073, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189

; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for windows Version 4.0
; SEQ ID NO 52073
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-52073

Query Match      0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1311 ATGTACATGAGGCGCTGTGANG 1334
Db      25 ATGTAGTGGAGACCTGTGTGANG 2

RESULT 306
US-10-956-157-170437
; Sequence 170437, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 170437
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-170437

Query Match      0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1413 CAACTCCTGTGAGGAGAACAGCTGC 1436
Db      1 CAACTCCTGTGATGAAACAGCTCC 24

RESULT 307
US-10-719-956-226834
; Sequence 226834, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Method of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 226834
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-226834

Query Match      0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
```

```
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1235 CACTGTTGGGAGAGCCCTCACC 1258
Db 1 CACTGTTATGGGAGAGCCTTTCAC 24

RESULT 308
US-10-719-900-194173/c
; Sequence 194173, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 194173
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-194173

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2205 GATCCTCTTCAGAGGGGCTT 2226
Db 22 GATCCTCTTCAGAGGGGCTT 1

RESULT 309
US-10-719-900-903590
; Sequence 903590, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 903590
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-903590

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 544 TCTACTTCACTTGCGTGGTGT 565
Db 3 TCTACTTGACTTGGCTGAGATT 24

RESULT 310
US-10-719-956-30682
; Sequence 30682, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
```

```
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 30682
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-30682

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 213 ACTGGCGGGGCTTCAGCCATGA 234
Db 2 ACTGGCGGGGCTGCACCATGA 23

RESULT 311
US-10-719-956-451896
; Sequence 451896, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 451896
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-451896

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1474 GGGGTCTGTGGGTATTATAA 1495
Db 1 GGGAGTCTGTGGGTCTTTAAA 22

RESULT 312
US-10-643-801-108/c
; Sequence 108, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-108

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```


Db 1 TCCATGCGCGAGGCTCTTTC 20

RESULT 318
US-10-278-733-24
; Sequence 24, Application US/10278733
; Publication No. US20030100480A1
; GENERAL INFORMATION:
; APPLICANT: Smith, Steven
; APPLICANT: Chen, Hubert
; TITLE OF INVENTION: Farnese, Robert V Jr
; TITLE OF INVENTION: Method and compositions for modulating
; FILE REFERENCE: UCAL-105C1P4
; CURRENT APPLICATION NUMBER: US/10/278,733
; CURRENT FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 10/040,315
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/339,472
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/107,771
; PRIOR FILING DATE: 1998-11-09
; PRIOR APPLICATION NUMBER: PCT/US98/17883
; PRIOR FILING DATE: 1998-08-28
; PRIOR APPLICATION NUMBER: 09/103,754
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide primer
US-10-278-733-24

Query Match
Best Local Similarity 0.7%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 980 CAGAATGCAGTCACCTG 998
Db 1 CAAGACGCGAGTCACCTG 19

RESULT 319
US-10-643-801-141/c
; Sequence 141, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-141

Query Match
Best Local Similarity 0.7%; Score 17.4; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2372 CCATGTCAGACTTTGTAT 2390
Db 19 CCATGTCAGACTTTGTAT 1

RESULT 320
US-10-229-834A-11
; Sequence 11, Application US/10229834A
; Publication No. US20030150003A1
; GENERAL INFORMATION:
; APPLICANT: Lawrence Berkeley National Laboratory
; APPLICANT: Rubin, Edward
; APPLICANT: Pennacchio, Len
; TITLE OF INVENTION: A novel apolipoprotein gene involved in lipid metabolism
; FILE REFERENCE: IB-1709
; CURRENT APPLICATION NUMBER: US/10/229,834A
; CURRENT FILING DATE: 2002-08-27
; PRIOR APPLICATION NUMBER: US 60/318,219
; PRIOR FILING DATE: 2001-08-27
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-229-834A-11

Query Match
Best Local Similarity 0.7%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1173 CATGTCGAGGCTCTCTCT 1194
Db 1 CAGGTCGAGGCTCTCTCT 22

RESULT 321
US-10-806-782-20/c
; Sequence 20, Application US/10806782
; Publication No. US20040166061A1
; GENERAL INFORMATION:
; APPLICANT: Enerback, Sven
; APPLICANT: Carlsson, Peter
; TITLE OF INVENTION: Animal Model
; FILE REFERENCE: 10806-117A
; CURRENT APPLICATION NUMBER: US/10/806,782
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/587,945
; PRIOR FILING DATE: 2000-06-06
; PRIOR APPLICATION NUMBER: US 60/190,692
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/085,380
; PRIOR FILING DATE: 1998-05-26
; PRIOR APPLICATION NUMBER: SE 9701963-2
; PRIOR FILING DATE: 1997-05-26
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 3' primer
US-10-806-782-20

Query Match
Best Local Similarity 0.7%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 239 CCTATAGCGGCTACTCCGG 260
Db 22 CCTATAGCGGCTACTCCGG 1

RESULT 322
US-10-349-143-11680


```
; Sequence 11680, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marra
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020C01
; CURRENT APPLICATION NUMBER: US/10/349,143
; PRIOR FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11680
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-22404 for SEQ 3815, in complement
US-10-349-143-11680
```

```
Query Match          0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1643 TCTCTTCTTCCCTTCTCT 1659
DB      1 TCTCTTCTTCCCTTCTCT 17
```

```
RESULT 323
US-09-733-294A-40/c
; Sequence 40, Application US/09733294A
; Patent No. US20020045588A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Susan W. Freiler
; APPLICANT: Edward V. Wanciewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF TERT EXPRESSION
; FILE REFERENCE: ISPH-0527
; CURRENT APPLICATION NUMBER: US/09/733,294A
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: 09/572,423
; PRIOR FILING DATE: 2000-05-16
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-733-294A-40
```

```
Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      139 GCGGAGAGCCCTGGCCCCGG 158
DB      20 GTGGAGAGCCCTGGCCCCGG 1
```

```
RESULT 324
US-10-174-175-15/c
```

```
; Sequence 15, Application US/10174175
; Publication No. US20030232440A1
; GENERAL INFORMATION:
; APPLICANT: James Karraas
; APPLICANT: Sue Freiler
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STAT1 EXPRESSION
; FILE REFERENCE: PTS-0032
; CURRENT APPLICATION NUMBER: US/10/174,175
; PRIOR FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 73
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-175-15
```

```
Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      588 GGTGGCAGAGTGTCTCAGTG 607
DB      20 GGTGGCAGAGTGTCTCAGTG 1
```

```
RESULT 325
US-10-174-175-52
; Sequence 52, Application US/10174175
; Publication No. US20030232440A1
; GENERAL INFORMATION:
; APPLICANT: James Karraas
; APPLICANT: Sue Freiler
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STAT1 EXPRESSION
; FILE REFERENCE: PTS-0032
; CURRENT APPLICATION NUMBER: US/10/174,175
; PRIOR FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 73
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION:
US-10-174-175-52
```

```
Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      588 GGTGGCAGAGTGTCTCAGTG 607
DB      1 GGTGGCAGAGTGTCTCAGTG 20
```

```
RESULT 326
US-10-818-939-27
; Sequence 27, Application US/10818939
; Publication No. US20050020527A1
; GENERAL INFORMATION:
; APPLICANT: Peters, Thomas
; APPLICANT: Grosse, Johannes
; APPLICANT: Schuster, Volker
; APPLICANT: Schuette, Helke
; APPLICANT: Margardt, Andreas
; TITLE OF INVENTION: Splicer-like protein genes, expression
; TITLE OF INVENTION: products, non-human animal model: uses in human metabolic
; FILE REFERENCE: 14851-005001
; CURRENT APPLICATION NUMBER: US/10/818,939
; CURRENT FILING DATE: 2004-04-05
```

```
; PRIOR APPLICATION NUMBER: US 60/550,192
; PRIOR FILING DATE: 2004-03-04
; PRIOR APPLICATION NUMBER: US 60/460,110
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: US 60/550,800
; PRIOR FILING DATE: 2004-03-05
; PRIOR APPLICATION NUMBER: US 60/538,831
; PRIOR FILING DATE: 2004-01-23
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-818-939-27

Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1933 CCCCTACCTCACCCTAGTC 1952
DB      1 CCTCTACCCACCCCTAGTC 20

RESULT 327
US-10-643-801-106/c
; Sequence 106, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-106

Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      427 AACAGCTACAGCATCTCA 446
DB      20 AACAGCTGAGGATCTCA 1

RESULT 328
US-10-643-801-109/c
; Sequence 109, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-109

Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      610 TCCGAACCTGAGGCTGTGG 629
DB      20 TCCGAACCTGAGGCTGTGG 1

RESULT 329
US-10-643-801-113/c
; Sequence 113, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-113

Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1030 TCGGTCATGAGCTGACCTG 1049
DB      20 TCGGTCATGAGCTGACCTG 1

RESULT 330
US-10-643-801-114/c
; Sequence 114, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-114

Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1075 ATGAAGTGTACAGCAGGTG 1094
DB      20 ATGAAGTGTACAGCAGGTG 1

RESULT 331
US-10-643-801-122/c
; Sequence 122, Application US/10643801
```

```
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-122

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1542 TTTAGAGGAGGAGGAGTCTAGT 1561
DB 20 TTTAGAGGAGGAGGAGTCTAGT 1

RESULT 332
US-10-643-801-215
; Sequence 215, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 215
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
; OTHER INFORMATION:
US-10-643-801-215

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 610 TCCGAACCTGGCGCTGCTGG 629
DB 1 TCCGAACCTGGCGCTGCTGG 20

RESULT 333
US-10-643-801-216
; Sequence 216, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
; OTHER INFORMATION:
US-10-643-801-216
```

```
Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1075 ATGAGCTGTACAGCAGGTG 1094
DB 1 ATGAGCTGTACAGCAGGTG 20

RESULT 334
US-10-643-801-220
; Sequence 220, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhano
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 220
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
; OTHER INFORMATION:
US-10-643-801-220

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1542 TTTAGAGGAGGAGGAGTCTAGT 1561
DB 1 TTTAGAGGAGGAGGAGTCTAGT 20

RESULT 335
US-09-005-243-16
; Sequence 16, Application US/09005243
; Patent No. US20020018763A1
; GENERAL INFORMATION:
; APPLICANT: Zeebo, Kristina M.
; APPLICANT: Boeselman, Robert A.
; APPLICANT: Suggs, Sidney V.
; APPLICANT: Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Garstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/005,243
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/449,653
; FILING DATE: 24-MAY-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/589,701
```

```

; FILING DATE: 01-OCT-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/34465
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-09-005-243-16

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATCC 21

RESULT 336
US-09-224-683-16
; Sequence 16, Application US/09224683
; Patent No. US20020031491A1
; GENERAL INFORMATION:
; APPLICANT: Zeebo, Kristina M.
; APPLICANT: Bosseiman, Robert A.
; APPLICANT: Suggs, Sidney V.
; APPLICANT: Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor: Composition Claims
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/224,683
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/005,893
; FILING DATE: 12-JAN-1998
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/449,653
; FILING DATE: 24-MAY-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/982,255
```

```

; FILING DATE: 25-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/589,701
; FILING DATE: 01-OCT-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35136
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-09-224-683-16

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATCC 21

RESULT 337
US-10-113-916-13
; Sequence 13, Application US/10113916
; Publication No. US20030186251A1
; GENERAL INFORMATION:
; APPLICANT: Brookhaven Science Associates
; APPLICANT: Dunn, John J.
; TITLE OF INVENTION: Genome Sequence Tags
; FILE REFERENCE: BSA 02-03
; CURRENT APPLICATION NUMBER: US/10/113,916
; CURRENT FILING DATE: 2002-04-01
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Yersinia pestis
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Y. pestis-specific primer
; US-10-113-916-13

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 487 CCTGCAGTGCATCTCTCATG 506
DB 1 CATGCAGTGCATCTCTCATG 20

RESULT 338
US-10-175-608-16
; Sequence 16, Application US/10175608
```

Publication No. US20040181044A1
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristztina M.
Boseelman, Robert A.
Sugge, Sidney V.
Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/175,608
FILING DATE: 16-Oct-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/635,249
FILING DATE: 07-AUG-2000
APPLICATION NUMBER: 09/486,546
FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 10-APR-1991
APPLICATION NUMBER: 09/589,701
FILING DATE: 10-OCT-1991
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/35199
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-175-608-16
Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2402 ATTAATGAAGTGAATCC 2421
DB 2 ATTAATGCAAGTATATTC 21
RESULT 339
US-10-791-074-13
Sequence 13, Application US/10791074

Publication No. US20040219580A1
GENERAL INFORMATION:
APPLICANT: DUNN, JOHN J.
APPLICANT: LELIE, DANIEL VANDER
APPLICANT: KRAUSE, MAUREN K.
APPLICANT: MCCORKLE, SEAN R.
TITLE OF INVENTION: GENOME SEQUENCE TAGS
FILE REFERENCE: BSA 02-16
CURRENT APPLICATION NUMBER: US/10/791,074
CURRENT FILING DATE: 2004-03-02
PRIOR APPLICATION NUMBER: 10/113,916
PRIOR FILING DATE: 2002-04-01
NUMBER OF SEQ ID NOS: 95
SOFTWARE: Patentn Ver. 3.2
SEQ ID NO 13
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-791-074-13
Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 487 CCTGCAGTGCATCTCTCAGT 506
DB 1 CATGCAGTGCATCTCTCAGC 20
RESULT 340
US-10-620-642-16
Sequence 16, Application US/10620642
Publication No. US20050080250A1
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristztina M.
Boseelman, Robert A.
Sugge, Sidney V.
Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/620,642
FILING DATE: 16-Jul-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/10/175,608
FILING DATE: 16-Oct-2002
APPLICATION NUMBER: 09/635,249
FILING DATE: 07-AUG-2000
APPLICATION NUMBER: 09/486,546
FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 10-APR-1991
APPLICATION NUMBER: 09/589,701
FILING DATE: 10-OCT-1991

```

; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
;   NAME: Clough, David M.
;   REGISTRATION NUMBER: 36,107
;   REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 312/474-6300
;   TELEFAX: 312/474-0448
;   TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 21 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-620-642-16

Query Match
Best Local Similarity 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAGTGAATCC 2421
DB 2 ATTAATGAAGTGAATATCC 21

RESULT 341
US-10-491-758-41/c
; Sequence 41, Application US/10491758
; Publication No. US20050037494A1
; GENERAL INFORMATION:
; APPLICANT: HECKER, MARKUS
; APPLICANT: WAGNER, ANDREAS H.
; TITLE OF INVENTION: Inhibition of STAT-1
; FILE REFERENCE: DEBE:032US
; CURRENT APPLICATION NUMBER: US/10/491,758
; PRIOR FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: DE 101 48 886.6
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 41
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-491-758-41

Query Match
Best Local Similarity 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 589 GTGGCAGAGCTGACGATG 608
DB 22 GTGGCAGAGTCTCAGTGG 3

RESULT 342
US-10-223-598-39
; Sequence 39, Application US/10223598
; Publication No. US2003009639A1
; GENERAL INFORMATION:
; APPLICANT: Rikhiisa, Yasuko
; APPLICANT: Zhi, Ning
```

```

; APPLICANT: Chaahi, No. US2003009639A1io
; TITLE OF INVENTION: Nucleic Acid Encoding the Major Outer Membrane Protein of the Can
; TITLE OF INVENTION: Agent of Human Granulocytic Ehrlichiosis and Peptides Encoded Th
; FILE REFERENCE: 22727/0413
; CURRENT APPLICATION NUMBER: US/10/223,598
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: 09/288,339
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Human Granulocytic Ehrlichiosis Agent
US-10-223-598-39

Query Match
Best Local Similarity 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 GTTGACTGGAACACACC 580
DB 4 GTTGACTGGAACACTCC 21

RESULT 343
US-10-786-720-1409
; Sequence 1409, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1409
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-1409

Query Match
Best Local Similarity 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 61.1%; Pred. No. 2.8e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 2177 AGATCCTGATTCGTGAT 2194
DB 3 AGAUAUCUGAUCUGAUAU 20

RESULT 344
US-10-786-720-2516
; Sequence 2516, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2516
; LENGTH: 21
; TYPE: RNA
```

ORGANISM: RNAi-sense strand
US-10-786-720-2516

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 61.1%; Pred. No. 2.8e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 2177 AGATCTAGATCTGAT 2194
|||:|||||:|||||:
DB 3 AGAUAUAGAUUCUGAU 20

RESULT 345
US-10-751-736-41385
; Sequence 41385, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41385
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-41385

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1523 TTACATGTAGCTCTT 1540
::|||:|||||:|||||:
DB 2 UUAACAUGUAGGCCU 19

RESULT 346
US-10-751-736-42150
; Sequence 42150, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42150
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-42150

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1523 TTACATGTAGCTCTT 1540
::|||:|||||:|||||:
DB 2 UUAACAUGUAGGCCU 19

RESULT 347
US-10-799-369-36
; Sequence 36, Application US/10799369
; Publication No. US20050042629A1
; GENERAL INFORMATION:
; APPLICANT: Applied Biosystems
; APPLICANT: Bolchakova, Elena V.
; APPLICANT: Rozelle, James E.
; TITLE OF INVENTION: A Novel DNA Polymerase from the Thermophilic Thermus scotoductus
; FILE REFERENCE: 1560.002W01
; CURRENT APPLICATION NUMBER: US/10/799,369
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/34489
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 60/322218
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Thermus scotoductus
US-10-799-369-36

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1322 GGCCCTGGTGAAGCTCTT 1339
|||||:|||||:|||||:
DB 3 GGCCATGTGAAGCTCTT 20

RESULT 348
US-10-800-350-359
; Sequence 359, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parakash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 359
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-359

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 ACCCATGAAGACCTTCAT 244
|||||:|||||:|||||:

Db 4 AGCCATGAAGATCTCAT 21

RESULT 349

US-10-800-077-359
; Sequence 359, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 359
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-359

Query Match

Best Local Similarity 94.4%; Score 16.4; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 AGCCATGAAGATCTCAT 244

Db 4 AGCCATGAAGATCTCAT 21

RESULT 350

US-10-625-152-4
; Sequence 4, Application US/10625152
; Publication No. US20040132776A1
; GENERAL INFORMATION:
; APPLICANT: Agus, David B.
; TITLE OF INVENTION: Use of Benzothienones to Treat and Prevent Prostate Cancer
; FILE REFERENCE: 81476-294295
; CURRENT APPLICATION NUMBER: US/10/625,152
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: US 10/412,087
; PRIOR FILING DATE: 2002-05-09
; PRIOR APPLICATION NUMBER: US 60/290,307
; PRIOR FILING DATE: 2001-05-10
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-625-152-4

Query Match

Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1327 TGGTGAAGCTCTTCGACAGC 1347

Db 1 TGGTGAAGATCTTCGACATGC 21

RESULT 351

US-10-786-720-20417

; Sequence 20417, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20417
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-20417

Query Match

Best Local Similarity 61.9%; Score 16.2; DB 1; Length 21;
Matches 13; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1716 GGACCAAGTATGATGATCACT 1736

Db 1 GGAUCAGUGAGAUCAUUCANU 21

RESULT 352

US-10-751-736-14616/c
; Sequence 14616, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14616
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-14616

Query Match

Best Local Similarity 85.7%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1125 GTCGAGAGAGTTCAGAAA 1145

Db 21 GTCAGACGAGAGTTCAGAAA 1

RESULT 353

US-10-751-736-15119
; Sequence 15119, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)


```
; CURRENT APPLICATION NUMBER: US/10/751.736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15119
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-15119

Query Match
Best Local Similarity 71.4%; Pred. No. 2.9e+02;
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 995 CTTGCGGACCGCAGGCTT 1015
DB 1 CCUGCUGAACCCUACUGGCUU 21

RESULT 354
US-10-751-736-19221/c
; Sequence 19221, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19221
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-19221

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 768 GAAGTGAGCAAGATTCCCA 788
DB 21 GAAGTGAGCAAGAGGTCCA 1

RESULT 355
US-10-751-736-42616
; Sequence 42616, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42616
```

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-42616

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1130 GAAGAGTTCGGAATACAT 1150
DB 1 GAGGAAGCTTCGGAATACAT 21

RESULT 356
US-10-751-736-43132
; Sequence 43132, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43132
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-43132

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1692 AAGAGATTGCCATTAGTGA 1712
DB 1 AAGAAAGCTTGCAATTAGTGA 21

RESULT 357
US-10-751-736-43411
; Sequence 43411, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43411
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-43411

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1692 AAGAGATTGCCATTAGTGA 1712
DB 1 AAGAAAGCTTGCAATTAGTGA 21

RESULT 357
US-10-751-736-43411
; Sequence 43411, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43411
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-43411

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 GAAGAAGATTGCCTTAGTG 1711

DB 1 GAAGAAAGCTTGCAATTAGTG 21

RESULT 358

US-10-712-672-391

Sequence 391, Application US/10712672

Publication No. US20040102413A1

GENERAL INFORMATION:

APPLICANT: Ribozyne Pharmaceuticals, Inc.

APPLICANT: Chowrira, Bharat

APPLICANT: McSwiggan, Jim

APPLICANT: Stinchcomb, Dan

TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme

FILE REFERENCE: MBH00-882-C (400/019)

CURRENT APPLICATION NUMBER: US/10/712,672

PRIOR FILING DATE: 2003-11-13

PRIOR APPLICATION NUMBER: US/09/653,225

PRIOR FILING DATE: 2000-08-31

PRIOR APPLICATION NUMBER: 60/197,769

PRIOR FILING DATE: 2000-04-14

PRIOR APPLICATION NUMBER: 60/150,713

PRIOR FILING DATE: 1999-08-31

NUMBER OF SEQ ID NOS: 5586

SOFTWARE: PatentIn version 3.0

SEQ ID NO 391

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-712-672-391

Query Match 0.7%; Score 16; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 2.5e+02;

Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 143 GAAGCCCTGGCCCCGG 158

DB 2 GAAGCCCTGGCCCCGG 17

RESULT 359

US-10-483-289A-25/c

Sequence 25, Application US/10483289A

Publication No. US20050048466A1

GENERAL INFORMATION:

APPLICANT: Qian, Qijun

TITLE OF INVENTION: A specific proliferation in tumour cell which can express

TITLE OF INVENTION: anticogene with high efficiency and the use of it.

FILE REFERENCE: IEC020038PUS

CURRENT APPLICATION NUMBER: US/10/483,289A

PRIOR FILING DATE: 2004-01-09

NUMBER OF SEQ ID NOS: 27

SOFTWARE: PatentIn version 3.1

SEQ ID NO 25

LENGTH: 19

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide

US-10-483-289A-25

Query Match 0.7%; Score 16; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 2.8e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 143 GAAGCCCTGGCCCCGG 158

DB 19 GAAGCCCTGGCCCCGG 4

RESULT 360

US-10-180-781-80/c

Sequence 80, Application US/10180781

Publication No. US2003018080A1

GENERAL INFORMATION:

APPLICANT: Tanzi, Rudolph E.

APPLICANT: Schellenberg, Gerard D.

APPLICANT: Masco, Wilma

APPLICANT: Levy-lahad, Ephrat

APPLICANT: Bird, Thomas D.

APPLICANT: Galas, David J.

TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO

ALZHEIMER'S DISEASE

NUMBER OF SEQUENCES: 88

CORRESPONDENCE ADDRESS:

ADDRESSES: Seed Intellectual Property Law Group PLLC

STREET: 701 Fifth Ave, Suite 6300

CITY: Seattle

STATE: Washington

COUNTRY: USA

ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/180,781

FILING DATE: 24-Jun-2002

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Potler, Jane E. R.

REGISTRATION NUMBER: 33,332

REFERENCE/DOCKET NUMBER: 920010.571C2

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 80:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 80:

US-10-180-781-80

Query Match 0.7%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 2.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1842 CCAAGGGAGGAGCTGGAG 1860

DB 19 CCAAGGGAGGAGCTGGAG 1

RESULT 361

US-08-771-737-8/c

Sequence 8, Application US/08771737

Publication No. US20010006796A1

GENERAL INFORMATION:

APPLICANT: Briggs, Clark A.

APPLICANT: Gopalakrishnan, Murali

APPLICANT: McKenna, David G.

APPLICANT: Monteggia, Lisa M.

APPLICANT: Koch, Jean-Marie

APPLICANT: Sullivan, James P.

APPLICANT: Touma, Edward

APPLICANT: Abbott Laboratories

TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE

TITLE OF INVENTION: RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USES THEREOF

FILE REFERENCE: 6017.US.01

CURRENT APPLICATION NUMBER: US/08/771,737

CURRENT FILING DATE: 1996-12-20

NUMBER OF SEQ ID NOS: 8
SOFTWARE: FASTSEQ for Windows Version 3.0
SEQ ID NO 8
LENGTH: 20
TYPE: DNA
ORGANISM: Homo Sapien
US-08-771-737-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 GGCACTTCGAAATGCGCTG 837
DB 20 GGCAAGCTCGAATGCGCTG 2

RESULT 362
US-09-954-936-8/c
Sequence 8, Application US/09954936
Publication No. US20030073161A1
GENERAL INFORMATION:
APPLICANT: Briggs, Clark A.
APPLICANT: Gopalakrishnan, Murali
APPLICANT: McKenna, David G.
APPLICANT: Monteggia, Lisa M.
APPLICANT: Roch, Jean-Marc
APPLICANT: Sullivan, James P.
APPLICANT: Touma, Edward
APPLICANT: Abbott Laboratories
TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USES THEREOF
FILE REFERENCE: 6017 US. 01
CURRENT APPLICATION NUMBER: US/09/954,936
CURRENT FILING DATE: 2001-09-18
PRIOR APPLICATION NUMBER: 08/771,737
PRIOR FILING DATE: 1996-12-20
NUMBER OF SEQ ID NOS: 8
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 20
TYPE: DNA
ORGANISM: Homo Sapien
US-09-954-936-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 GGCACTTCGAAATGCGCTG 837
DB 20 GGCAAGCTCGAATGCGCTG 2

RESULT 363
US-09-972-607-12
Sequence 12, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Jacqueline Wycat
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 12
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-12

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2278 CCTGACTTCTGTGCGCTT 2296
DB 1 CCTGACTTCTGTGCGCTT 19

RESULT 364
US-10-376-566-63
Sequence 63, Application US/10376566
Publication No. US20030158144A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
APPLICANT: Mark P. Roach
APPLICANT: Erich Kolier
TITLE OF INVENTION: ANTISENSE MODULATION OF ESTROGEN RECEPTOR BETA EXPRESSION
FILE REFERENCE: RTS-0347
CURRENT APPLICATION NUMBER: US/10/376,566
CURRENT FILING DATE: 2003-02-27
PRIOR APPLICATION NUMBER: US/10/005,058
PRIOR FILING DATE: 2001-12-07
NUMBER OF SEQ ID NOS: 96
SEQ ID NO 63
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-376-566-63

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 CATGAGGCGCTGTGTAAG 1334
DB 1 CATGAGGCGCTGTGTAAG 19

RESULT 365
US-10-455-229-22
Sequence 22, Application US/10455229
Publication No. US20040016030A1
GENERAL INFORMATION:
APPLICANT: LOWE, BRENDA A.
APPLICANT: CHOMET, PAUL
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR PRODUCTION OF MAIZE LINES
WITH INCREASED TRANSFORMABILITY
FILE REFERENCE: DEM:195US
CURRENT APPLICATION NUMBER: US/10/455,229
CURRENT FILING DATE: 2003-06-05
PRIOR APPLICATION NUMBER: 60/386,522
PRIOR FILING DATE: 2002-06-06
NUMBER OF SEQ ID NOS: 32
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 22
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Primer
US-10-455-229-22

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 CCTCTCTCTCTCCCTTCCCT 1659
|||||

Db 1 CCTCTCTGCACCCCTTCCT 19

RESULT 366
US-10-628-841-12
; Sequence 12, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-12

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 2278 CCTCACTTCTCTGCGCCTT 2296

Db 1 CCTCACTTCTCTGCGCCTT 19

RESULT 367
US-10-749-075-8/c
; Sequence 8, Application US/10749075
; Publication No. US20040203033A1
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murail
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Sullivan, James P.
; APPLICANT: Touna, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; TITLE OF INVENTION: RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USES THEREOF
; FILE REFERENCE: 6017, US. 01
; CURRENT APPLICATION NUMBER: US/10/749,075
; PRIOR FILING DATE: 2003-12-30
; PRIOR APPLICATION NUMBER: US/08/771,737
; PRIOR FILING DATE: 1996-12-20
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-749-075-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 819 GGCACCTTCGAATGCTG 837

Db 20 GGCAGCTCCGAATGCTG 2

RESULT 368
US-10-643-801-111/c

; Sequence 111, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; PRIOR FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-111

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 865 GTATCTGCCCTGTCAACCG 883

Db 20 GCATCTGCCCTGTCAACCG 2

RESULT 369
US-10-257-158A-6237/c
; Sequence 6237, Application US/10257158A
; Publication No. US20050142543A1
; GENERAL INFORMATION:
; APPLICANT: Barany, Francis
; APPLICANT: Zilvi, Monib
; APPLICANT: Gerry, Norman P.
; APPLICANT: Favis, Reyna
; APPLICANT: Kliman, Richard
; TITLE OF INVENTION: METHOD OF DESIGNING ADDRESSABLE ARRAY FOR DETECTION OF NUCLEIC AC
; TITLE OF INVENTION: SEQUENCE DIFFERENCES USING LIGASE DETECTION REACTION
; FILE REFERENCE: 19603/2834
; CURRENT APPLICATION NUMBER: US/10/257,158A
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: PCT/US01/10958
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: US 60/197,271
; PRIOR FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 9544
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6237
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Hypothetical Probe Sequence
US-10-257-158A-6237

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 1113 TGGGGCGATGGTCCAGA 1131

Db 19 TGGGGCTGATGGTCCAGA 1

RESULT 370
US-10-432-422-20/c
; Sequence 20, Application US/10432422
; Publication No. US20040076981A1
; GENERAL INFORMATION:
; APPLICANT: Syngenta Participations AG
; APPLICANT: Corneil Research Foundation, Inc.
; APPLICANT: Yoder, Olen

```

; APPLICANT: Turgeon, Barbara G.
; APPLICANT: Lu, Shen-wen
; TITLE OF INVENTION: Fungal Iron Reductase Gene
; FILE REFERENCE: 1360.017W01
; CURRENT APPLICATION NUMBER: US/10/432,422
; CURRENT FILING DATE: 2003-05-21
; PRIOR APPLICATION NUMBER: US 60/252,732
; PRIOR FILING DATE: 2000-11-22
; PRIOR APPLICATION NUMBER: US 60/252,649
; PRIOR FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 210
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-432-422-20

Query Match      0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      510 ATATTCTGCACGTGATGCT 528
      |||||||||||||
Db      20 ATGTTCTGCACGTGATGCT 2

RESULT 371
US-10-786-720-12520
; Sequence 12520, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101311L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12520
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-12520

Query Match      0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      2343 TTCTGTATCTCTTGATGA 2361
      |||||||||
Db      3 TTCTGTAACTCTTGAAGA 21

RESULT 372
US-10-786-720-12521
; Sequence 12521, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101311L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135

```

```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12521
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI-sense strand
US-10-786-720-12521

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 3.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY      2343 TTCTGTATCTCTGATGA 2361
      ::||::|||
Db      1 UUCUGUUAACUCUGAGAGA 19

RESULT 373
US-10-786-720-12522/c
; Sequence 12522, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM1013311)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12522
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI-antisense strand
US-10-786-720-12522

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2343 TTCTGTATCTCTGATGA 2361
      |||||
Db      19 TTCTGTATCTCTGATGA 1

RESULT 374
US-10-786-720-20416
; Sequence 20416, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM1013311)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20416
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-20416

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1716 GGACCAAGTTAGTGATCA 1734
      |||

```

Db 3 GGATCAGTGAGATGATTCA 21

RESULT 375

US-10-786-720-20418/c
; Sequence 20418, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM1013311)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20418
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-20418

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1716 GGACCACTTAGATGATTCA 1734

Db 19 GGATCAGTGAGATGATTCA 1

RESULT 376

US-10-751-736-18485/c
; Sequence 18485, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18485
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-18485

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2127 AGCCTTGCCCTGGAGCACA 2145

Db 20 AGCCTTGCCCTGGATCACA 2

RESULT 377

US-10-751-736-40402
; Sequence 40402, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40402
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-40402

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1845 AGGGAGAGGTTGGAGAGC 1863

Db 2 AGAGGAGGAGTTGGAGAGAC 20

RESULT 378

US-10-751-736-42617
; Sequence 42617, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42617
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-42617

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 3.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1133 GAAGTCCGAAATACATT 1151

Db 2 GAAGCTCCGAAATACATU 20

RESULT 379

US-10-847-918-12719
; Sequence 12719, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19

PRIOR APPLICATION NUMBER: US 60/471,729
PRIOR FILING DATE: 2003-05-20
NUMBER OF SEQ ID NOS: 14937
SOFTWARE: PatentIn version 3.2
SEQ ID NO 12719
LENGTH: 21
TYPE: RNA
ORGANISM: RNAI-sense strand
US-10-847-918-12719

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 3.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1185 CTCTTCTCCGACACT 1203
Db 2 CUCUCUCUCUCUCACCU 20

RESULT 380

US-09-866-108-2021
Sequence 2021, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2021
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2021

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 CCGGCTGCTTCTGCA 747
Db 1 CCGGCTGCTTCTGCA 17

RESULT 381

US-09-866-108-2842
Sequence 2842, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2842
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2842

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1974 GGCCTCAGATAGGA 1990
Db 1 GGCCTCAGATAGGA 17

RESULT 382

```
US-10-238-700-2/c
; Sequence 2, Application US/10238700
; Publication No. US2003015352A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2
```

```
Query Match          0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      16 CGCGCGGCTGCGCGCT 32
      |||||
Db       17 CGCGCGGCTGCGCGCT 1
```

```
RESULT 383
US-10-712-672-390
; Sequence 390, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-390
```

```
Query Match          0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      141 GCGAGCCTGCGCCCG 157
      |||||
Db       1 GGGAGCCCGGCCCG 17
```

```
RESULT 384
US-10-723-361-2021
; Sequence 2021, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 2021
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2021
```

```
Query Match          0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      731 CCTGGTGCCTTCTGCA 747
      |||||
Db       1 CCTGGTGCCTTCTGCA 17
```

```
RESULT 385
US-10-723-361-2842
; Sequence 2842, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```



```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 2842
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2842
```

```
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1974 GGCCTCGAGTATGAGA 1990
Db 1 GGCCTCGAGTATGAGA 17
```

```
RESULT 386
US-10-498-462-1757
; Sequence 1757, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; PRIOR FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 1757
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-1757
```

```
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 725 CATGGCGCTGGTGCTT 741
Db 1 CTTGGCGCTGGTGCTT 17
```

```
RESULT 387
US-10-498-462-1759
; Sequence 1759, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; PRIOR FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
```

```
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 1759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-1759
```

```
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 727 TGGCGCTGGTGCTTTC 743
Db 1 TGGCGCTGGTGCTTTC 17
```

```
RESULT 388
US-10-724-270-2/c
; Sequence 2, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: MGSwigen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-2
```

```
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 16 CGCGCGGCTGCCGCTT 32
Db 17 CGCGCGGCTGCCGCTT 1
```

```
RESULT 389
US-10-353-461-2
; Sequence 2, Application US/10353461
; Publication No. US20030176682A1
; GENERAL INFORMATION:
```

```
/ APPLICANT: Vlaams Interniversitair Instituut voor Biotechnol
/ TITLE OF INVENTION: Molecular characterization of chromosome translocation
/ TITLE OF INVENTION: t(11;18) (q21;q21) and its correlation to
/ TITLE OF INVENTION: carcinogenesis
/ FILE REFERENCE: PMA/MALT/V043
/ CURRENT APPLICATION NUMBER: US/10/353,461
/ PRIOR FILING DATE: 2003-01-26
/ PRIOR APPLICATION NUMBER: US/09/579,692
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: 60/138,834
/ PRIOR FILING DATE: 1999-06-09
/ NUMBER OF SEQ ID NOS: 56
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 2
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: primer MLTxl
US-10-353-461-2

Query Match          0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      739 CCTTCGCACTTCAGC 755
DB      1 CCTTCGCACTTCATC 17

RESULT 390
US-10-303-266-15
/ Sequence 15, Application US/10303266
/ Publication No. US20040101848A1
/ GENERAL INFORMATION:
/ APPLICANT: Donna T. Ward
/ APPLICANT: Alexander H. Borchers
/ APPLICANT: Kenneth W. Doble
/ TITLE OF INVENTION: MODULATION OF GLUCOSE TRANSPORTER-4 EXPRESSION
/ FILE REFERENCE: RTS-0426
/ CURRENT APPLICATION NUMBER: US/10/303,266
/ CURRENT FILING DATE: 2002-11-23
/ NUMBER OF SEQ ID NOS: 157
/ SEQ ID NO 15
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-266-15

Query Match          0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1219 ACTCCAAGCCCATCACC 1235
DB      2 ACTCCAAGCCCATCACC 18

RESULT 391
US-10-874-242-13/c
/ Sequence 13, Application US/10874242
/ Publication No. US20050026252A1
/ GENERAL INFORMATION:
/ APPLICANT: ESTES, SCOTT
/ APPLICANT: ZHANG, WEIQION
/ TITLE OF INVENTION: NOVEL PROMOTERS AND USES THEREOF
/ FILE REFERENCE: 07680.0027-00000
/ CURRENT APPLICATION NUMBER: US/10/874,242
/ CURRENT FILING DATE: 2004-06-24
/ PRIOR APPLICATION NUMBER: 60/480,768
/ PRIOR FILING DATE: 2003-06-24
```

```
/ NUMBER OF SEQ ID NOS: 41
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 13
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: reverse primer for rps21
US-10-874-242-13

Query Match          0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 3.2e+02;
Matches 16; Conservative 1; Indels 0; Gaps 0;

QY      2402 ATTAATGAAGTGAGAA 2418
DB      17 ATTAATGAAGTGAGAA 1

RESULT 392
US-09-373-938-10
/ Sequence 10, Application US/09373938
/ Publication No. US20020115202A1
/ GENERAL INFORMATION:
/ APPLICANT: Hallenbeck, Paul
/ APPLICANT: Chen, Cheayun Theresa
/ TITLE OF INVENTION: ADENO VIRAL VECTORS INCLUDING DNA SEQUENCES ENCODING ANGIOGENIC IN
/ FILE REFERENCE: 4-30899P1
/ CURRENT APPLICATION NUMBER: US/09/373,938
/ CURRENT FILING DATE: 1999-08-13
/ NUMBER OF SEQ ID NOS: 17
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 10
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-09-373-938-10

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      518 CACTGATTGCTGGCTCATCG 537
DB      1 CACTGCTTACTGGCTTATCG 20

RESULT 393
US-09-784-552/c
/ Sequence 552, Application US/09784674
/ Publication No. US20030054346A1
/ GENERAL INFORMATION:
/ APPLICANT: Shannon, Karen W.
/ APPLICANT: Wolber, Paul K.
/ APPLICANT: Delenstarr, Glenda C.
/ APPLICANT: Webb, Peter G.
/ APPLICANT: Kincaid, Robert H.
/ TITLE OF INVENTION: Methods for evaluating oligonucleotide
/ probe sequences
/ NUMBER OF SEQUENCES: 1165
/ CORRESPONDENCE ADDRESS:
/ ADDRESSSEE: Records Manager, Legal Department, Hewlett-Packard
/ STREET: 3000 Hanover Street
/ CITY: Palo Alto
/ STATE: CA
/ COUNTRY: USA
/ ZIP: 94304
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
CLASSIFICATION: No. US20030054346A1 available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 552:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 552:
US-09-784-674-552

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAGTCACTA 1562
DB 20 TAAAAAGAAAAATCAGTA 1

RESULT 394
US-09-784-674-553/c
Sequence 553, Application US/09784674
Publication No. US20030054346A1
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
Delensstarr, Glenda C.
Webb, Peter G.
Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide probe sequences
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 2080
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
CLASSIFICATION: No. US20030054346A1 available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697

REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 553:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 553:
US-09-784-674-553

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1542 TTAAGAGAAAGTCACT 1561
DB 20 TAAAAAGAAAAATCAGT 1

RESULT 395
US-10-080-797-8
Sequence 8, Application US/10080797
Publication No. US20020183253A1
GENERAL INFORMATION:
APPLICANT: Dixon, Katherine H.
APPLICANT: Camochiaro, Peter A.
APPLICANT: Brazzell, Romulus K.
TITLE OF INVENTION: METHOD FOR TREATING OCULAR
FILE REFERENCE: 4-31881A
CURRENT APPLICATION NUMBER: US/10/080,797
CURRENT FILING DATE: 2002-02-21
NUMBER OF SEQ ID NOS: 21
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 8
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PCR Primer
US-10-080-797-8

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTCGTGCTCATCG 537
DB 1 CACTGCTTACTGCTTATCG 20

RESULT 396
US-10-057-550-80/c
Sequence 80, Application US/10057550
Publication No. US20030032607A1
GENERAL INFORMATION:
APPLICANT: Monla, Brett P.
TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
FILE REFERENCES:
CURRENT APPLICATION NUMBER: US/10/057,550
CURRENT FILING DATE: 2002-01-25
PRIOR APPLICATION NUMBER: 09/506,073
PRIOR FILING DATE: 2000-02-18
PRIOR APPLICATION NUMBER: US 09/143,214
PRIOR FILING DATE: 1998-08-28
PRIOR APPLICATION NUMBER: PCT/US98/13961
PRIOR FILING DATE: 1998-07-06

```
; PRIOR APPLICATION NUMBER: US 08/888,982
; PRIOR FILING DATE: 1997-07-07
; PRIOR APPLICATION NUMBER: US 08/756,806
; PRIOR FILING DATE: 1996-11-26
; PRIOR APPLICATION NUMBER: PCT/US95/07111
; PRIOR FILING DATE: 1995-05-31
; PRIOR APPLICATION NUMBER: US 08/250,856
; PRIOR FILING DATE: 1994-05-31
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-057-550-80

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1873 CCGTGTGTGAGGCGCAGTAG 1892
Db      20 CAGTGGTGTGAGGCGCAGCAG 1

RESULT 397
US-10-037-182-22/c
; Sequence 22, Application US/10037182
; Publication No. US20030044899A1
; GENERAL INFORMATION:
; APPLICANT: Trygsvason, Karl
; APPLICANT: Doi, Masayuki
; APPLICANT: Thyboll, Jili
; TITLE OF INVENTION: Recombinant Laminin 10
; FILE REFERENCE: 99-274-F
; CURRENT APPLICATION NUMBER: US/10/037,182
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/257,449
; PRIOR FILING DATE: 2000-12-21
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 60/279,282
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer Bact
US-10-037-182-22

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      450 CTCGAGTGGTCTCTGCTTC 469
Db      20 CCCGAGTGATCTCTGCCCTT 1

RESULT 398
US-10-045-360-16
; Sequence 16, Application US/10045360
; Publication No. US20030138781A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; TITLE OF INVENTION: METHODS FOR DETERMINING STEROID RESPONSIVENESS
; FILE REFERENCE: UPA-008
; CURRENT APPLICATION NUMBER: US/10/045,360
; CURRENT FILING DATE: 2002-01-22
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIF
US-10-045-360-16

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1634 CAGCTAACCCTCTCTCTCC 1653
Db      1 CAGCAAACTCTCTGTCTCC 20

RESULT 399
US-10-176-277-16/c
; Sequence 16, Application US/10176277
; Publication No. US2003023243A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-176-277-16

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1121 ATGGGTCGAGGAAGTTC 1140
Db      20 AGGCTCCAGGAAGAGTTC 1

RESULT 400
US-10-176-277-20/c
; Sequence 20, Application US/10176277
; Publication No. US2003023243A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-176-277-20

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      308 TCACGAGGACCTGCGCTGT 327
Db      20 TCACGAGGACCTGCACTTT 1
```

```
RESULT 401
US-10-176-277-53
; Sequence 53, Application US/10176277
; Publication No. US20030232443A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-176-277-53

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1121 ATGGGTCAGAGAGATTCC 1140
Db 1 AGGCTTCAGAGAGGTTCC 20

RESULT 402
US-10-176-277-56
; Sequence 56, Application US/10176277
; Publication No. US20030232443A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-176-277-56

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 308 TCACGAGAGACCTGCGCTGT 327
Db 1 TCACGAGAGCCCTGCACTTT 20

RESULT 403
US-10-186-157-76
; Sequence 76, Application US/10186157
; Publication No. US20040002151A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Walt
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF SILENPHOSPHATE SYNTHETASE 2 EXPRESSION
; FILE REFERENCE: RTS-0193
; CURRENT APPLICATION NUMBER: US/10/186,157
; CURRENT FILING DATE: 2002-06-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-186-157-76

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1548 AGGAAAGTCATATTTC 1567
Db 1 AGGAAAGCCACTACTTCA 20

RESULT 404
US-10-289-762-3356
; Sequence 3356, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragment thereof and uses thereof, in particular for the diagnosis, prev.
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3356
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3356

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 386 CCTCTCTCTGTCACCTGGC 405
Db 1 CCTCTCTCTATCAGCTTC 20

RESULT 405
US-10-210-838-36
; Sequence 36, Application US/10210838
; Publication No. US20040023905A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF LAR EXPRESSION
; FILE REFERENCE: PTS-0013
; CURRENT APPLICATION NUMBER: US/10/210,838
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 198
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-838-36

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1986 GAGATGGGCGTGCATATGA 2005
Db 1 GAGATGGCGCATGACATATGA 20
```

RESULT 406
US-10-210-838-141/c
; Sequence 141, Application US/10210838
; Publication No. US20040023905A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF LAR EXPRESSION
; FILE REFERENCE: PFS-0013
; CURRENT APPLICATION NUMBER: US/10/210,838
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 198
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-838-141

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1986 GAGGATGGGGTGCACATGA 2005
DB 20 GAGGATGGCGATGACATGA 1

RESULT 407
US-10-348-346-16
; Sequence 16, Application US/10348346
; Publication No. US20040072181A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; APPLICANT: Chailberg, Sharon S.
; APPLICANT: Lazar, James G.
; TITLE OF INVENTION: METHODS FOR DETERMINING DRUG RESPONSIVENESS
; FILE REFERENCE: UPA-009
; CURRENT APPLICATION NUMBER: US/10/348,346
; CURRENT FILING DATE: 2003-04-22
; PRIOR APPLICATION NUMBER: US 10/045,360
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: US 60/370,008
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIF
US-10-348-346-16

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1634 CAGCTNACTCTCTCTTCC 1653
DB 1 CAGCAAACTCTCTTGTCC 20

RESULT 408
US-10-273-826-24/c
; Sequence 24, Application US/10273826
; Publication No. US20040077083A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF HISTONE DEACETYLASE 4 EXPRESSION
; FILE REFERENCE: RTS-0161

; CURRENT APPLICATION NUMBER: US/10/273,826
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-273-826-24

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAGTGAGCAAGAGT 783
DB 20 CACAGAGTGGAAGATGAAGT 1

RESULT 409
US-10-274-347-24/c
; Sequence 24, Application US/10274347
; Publication No. US20040077084A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; APPLICANT: Steven Davidssen
; APPLICANT: Tunling Li
; APPLICANT: Keith Glaser
; TITLE OF INVENTION: ANTISENSE MODULATION OF HISTONE DEACETYLASE 4 EXPRESSION
; FILE REFERENCE: RTS-0264
; CURRENT APPLICATION NUMBER: US/10/274,347
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-274-347-24

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAGTGAGCAAGAGT 783
DB 20 CACAGAGTGGAAGATGAAGT 1

RESULT 410
US-10-280-183A-459/c
; Sequence 459, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Charterjee, Anubindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shantu
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G.
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; FILE REFERENCE: PC18306A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794

PRIOR FILING DATE: 2000-04-28
NUMBER OF SEQ ID NOS: 652
SOFTWARE: PatentIn Ver. 3.1
SEQ ID NO 459
LENGTH: 20
TYPE: DNA
ORGANISM: Mouse
US-10-280-183A-459

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1991 TGGGGTGGCAATGACACCC 2010
DB 20 TGGAGTGCATGATATCCC 1

RESULT 411
US-10-300-424-77/c
Sequence 77, Application US/10300424
Publication No. US20040096835A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF TNFSF14 EXPRESSION
FILE REFERENCE: RTS-0437
CURRENT APPLICATION NUMBER: US/10/300,424
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 129
SEQ ID NO 77
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-424-77

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 988 CAGTCACCTGCGGACCGC 1007
DB 20 CAGTCACCTGCGGACCGC 1

RESULT 412
US-10-300-424-124
Sequence 124, Application US/10300424
Publication No. US20040096835A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF TNFSF14 EXPRESSION
FILE REFERENCE: RTS-0437
CURRENT APPLICATION NUMBER: US/10/300,424
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 129
SEQ ID NO 124
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-300-424-124

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 988 CAGTCACCTGCGGACCGC 1007
DB 1 CAGTCACCTGCGGACCGC 20

RESULT 413
US-10-300-399-28
Sequence 28, Application US/10300399
Publication No. US20040097450A1
GENERAL INFORMATION:
APPLICANT: Andrew T. Wate
TITLE OF INVENTION: MODULATION OF TDP-1 EXPRESSION
FILE REFERENCE: RTS-0173
CURRENT APPLICATION NUMBER: US/10/300,399
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 158
SEQ ID NO 28
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-399-28

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 1 ATCACCATCCCAAGCTGA 20

RESULT 414
US-10-300-399-105/c
Sequence 105, Application US/10300399
Publication No. US20040097450A1
GENERAL INFORMATION:
APPLICANT: Andrew T. Wate
TITLE OF INVENTION: MODULATION OF TDP-1 EXPRESSION
FILE REFERENCE: RTS-0173
CURRENT APPLICATION NUMBER: US/10/300,399
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 158
SEQ ID NO 105
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-300-399-105

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 20 ATCACCATCCCAAGCTGA 1

RESULT 415
US-10-688-706-316/c
Sequence 316, Application US/10688706
Publication No. US20040102412A1
GENERAL INFORMATION:
APPLICANT: Broechar, Kay
TITLE OF INVENTION: ANTISENSE MODULATION OF GPAT EXPRESSION
FILE REFERENCE: 01393/1
CURRENT APPLICATION NUMBER: US/10/688,706
CURRENT FILING DATE: 2003-10-17
PRIOR APPLICATION NUMBER: 60/419,268
PRIOR FILING DATE: 2002-10-17
NUMBER OF SEQ ID NOS: 3071
SEQ ID NO 316
SOFTWARE: PatentIn version 3.2
LENGTH: 20
TYPE: DNA

```
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: human GFAT antisense
US-10-688-706-316

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 147 CCTGGCCCCGGGGCGCCGG 166
DB 20 CCTGGCCTGCGCGCCGTG 1

RESULT 416
US-10-688-706-2458
/ Sequence 2458, Application US/10688706
/ Publication No. US20040102412A1
/ GENERAL INFORMATION:
/ APPLICANT: Pharmacia Corp.
/ APPLICANT: Broscat, Kay
/ TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
/ FILE REFERENCE: 01393/1
/ CURRENT APPLICATION NUMBER: US/10/688,706
/ PRIOR FILING DATE: 2003-10-17
/ PRIOR APPLICATION NUMBER: 60/419,268
/ NUMBER OF SEQ ID NOS: 1071
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 2458
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: human GFAT antisense
US-10-688-706-2458

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 416 CAAGTGGAAGACGCTAC 435
DB 1 CAAGTGGAAGACGCTAC 20

RESULT 417
US-10-316-459-16/c
/ Sequence 16, Application US/10316459
/ Publication No. US20040110149A1
/ GENERAL INFORMATION:
/ APPLICANT: C. Frank Bennett
/ APPLICANT: Ravi Jain
/ TITLE OF INVENTION: MODULATION OF BUB1-BETA EXPRESSION
/ FILE REFERENCE: RTS-0461
/ CURRENT APPLICATION NUMBER: US/10/316,459
/ CURRENT FILING DATE: 2002-12-10
/ NUMBER OF SEQ ID NOS: 169
/ SEQ ID NO 16
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-459-16

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 132 GTGCTCTGCGGAGCCCTG 151
DB 20 GTGCTCTGAGTGAAGCCATG 1
```

```
RESULT 418
US-10-316-459-94
/ Sequence 94, Application US/10316459
/ Publication No. US20040110149A1
/ GENERAL INFORMATION:
/ APPLICANT: C. Frank Bennett
/ APPLICANT: Ravi Jain
/ TITLE OF INVENTION: MODULATION OF BUB1-BETA EXPRESSION
/ FILE REFERENCE: RTS-0461
/ CURRENT APPLICATION NUMBER: US/10/316,459
/ CURRENT FILING DATE: 2002-12-10
/ NUMBER OF SEQ ID NOS: 169
/ SEQ ID NO 94
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
US-10-316-459-94

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 132 GTGCTCTGCGGAGCCCTG 151
DB 1 GTGCTCTGAGTGAAGCCATG 20

RESULT 419
US-10-671-395-1546/c
/ Sequence 1546, Application US/10671395
/ Publication No. US20040132063A1
/ GENERAL INFORMATION:
/ APPLICANT: Pharmacia Corp.
/ APPLICANT: Gierse, James K
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOAM PROSTAGLANDIN E2 SYNTHASE
/ FILE REFERENCE: 1179/1/US
/ CURRENT APPLICATION NUMBER: US/10/671,395
/ CURRENT FILING DATE: 2003-09-25
/ PRIOR APPLICATION NUMBER: 60/413,549
/ PRIOR FILING DATE: 2002-09-25
/ NUMBER OF SEQ ID NOS: 1809
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 1546
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: Human pGR2 antisense
US-10-671-395-1546

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1667 CAAGGAAATCTCACTTCT 1686
DB 20 CACAGGAGCTCAGCCTTCT 1

RESULT 420
US-10-666-909-14/c
/ Sequence 14, Application US/10666909
/ Publication No. US20040137623A1
/ GENERAL INFORMATION:
/ APPLICANT: Brenda F. Baker
/ APPLICANT: Kathleen Myers
/ APPLICANT: Joshua Finger
/ TITLE OF INVENTION: DELIVERY OF OLIGONUCLEOTIDE COMPOUNDS INTO OSTEOCLASTS AND MODULA
/ TITLE OF INVENTION: OSTEOCLAST DIFFERENTIATION
```


FILE REFERENCE: 23546-07993/RTSP-0313US.P1
CURRENT APPLICATION NUMBER: US/10/666,909
CURRENT FILING DATE: 2003-09-17
PRIOR APPLICATION NUMBER: 10/111,868
PRIOR FILING DATE: 2002-08-06
PRIOR APPLICATION NUMBER: PCT/US00/29828
PRIOR FILING DATE: 2000-10-30
PRIOR APPLICATION NUMBER: 09/435,296
PRIOR FILING DATE: 1999-11-05
NUMBER OF SEQ ID NOS: 110
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 14
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: antisense oligonucleotide
US-10-666-909-14

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 GCCAGCGCGCGGCTGCGCG 30
DB 20 GCCCGCGCGCGCTGCGCG 1

RESULT 421
US-10-666-909-62
Sequence 62, Application US/10666909
Publication No. US20040137623A1
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker
APPLICANT: Kathleen Myers
APPLICANT: Joshua Finger
TITLE OF INVENTION: DELIVERY OF OLIGONUCLEOTIDE COMPOUNDS INTO OSTEOCLASTS AND MODULA
FILE REFERENCE: 23546-07993/RTSP-0313US.P1
CURRENT APPLICATION NUMBER: US/10/666,909
CURRENT FILING DATE: 2003-09-17
PRIOR APPLICATION NUMBER: 10/111,868
PRIOR FILING DATE: 2002-08-06
PRIOR APPLICATION NUMBER: PCT/US00/29828
PRIOR FILING DATE: 2000-10-30
PRIOR APPLICATION NUMBER: 09/435,296
PRIOR FILING DATE: 1999-11-05
NUMBER OF SEQ ID NOS: 110
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 62
LENGTH: 20
TYPE: DNA
ORGANISM: M. musculus
FEATURE:
US-10-666-909-62

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 GCCAGCGCGCGGCTGCGCG 30
DB 1 GCCCGCGCGCGCTGCGCG 20

RESULT 422
US-10-744-055-16
Sequence 16, Application US/10744055
Publication No. US20040203031A1
GENERAL INFORMATION:
APPLICANT: Whitehead, Alexander Steven
APPLICANT: Chailberg, Sharon S.
APPLICANT: Lazar, James G.

TITLE OF INVENTION: METHODS FOR DETERMINING DRUG RESPONSIVENESS
FILE REFERENCE: UPA-009
CURRENT APPLICATION NUMBER: US/10/744,055
CURRENT FILING DATE: 2003-12-22
PRIOR APPLICATION NUMBER: US/10/348,346
PRIOR FILING DATE: 2003-04-22
PRIOR APPLICATION NUMBER: US 10/045,360
PRIOR FILING DATE: 2002-01-22
PRIOR APPLICATION NUMBER: US 60/370,008
PRIOR FILING DATE: 2002-04-03
NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatentIn version 3.1
SEQ ID NO 16
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PCR mutagenesis primer GREIF
US-10-744-055-16

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1634 CAGCTAACCTCTCTCTCC 1653
DB 1 CAGCAACCTCTCTTCTCC 20

RESULT 423
US-10-877-231-552/c
Sequence 552, Application US/10877231
Publication No. US20050027461A1
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstar, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSER: Records Manager, Legal Department, Hewlett-Packard
COMPANY: M/S 2050
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/877,231
FILING DATE: 24-Jun-2004
CLASSIFICATION: Not available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 552:
SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 552:
US-10-877-231-552

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAAGTCAGTA 1562
DB 20 TAAAAAGAAAATCAGTA 1

RESULT 424

US-10-877-231-553/c
Sequence 553, Application US/10877231
Publication No. US20050027461A1

GENERAL INFORMATION:

APPLICANT: Shannon, Karen W.
Wolber, Paul K.
Delestaer, Glenda C.
Webb, Peter G.
Kincaid, Robert H.

TITLE OF INVENTION: Methods for evaluating oligonucleotide
probe sequences

NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:

ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
Company M/S 2050
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/877,231

FILING DATE: 24-Jun-2004

CLASSIFICATION: Not available

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/784,674

FILING DATE: 15-Feb-2001

APPLICATION NUMBER: 09/021,701

FILING DATE: 10-Feb-1998

ATTORNEY/AGENT INFORMATION:

NAME: Choi, Wendy A.

REGISTRATION NUMBER: 36,697

REFERENCE/DOCKET NUMBER: 10971464-1

TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386

TELEFAX: 650-852-8063

INFORMATION FOR SEQ ID NO: 553:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA

HYPOTHETICAL: NO

ANTI-SENSE: NO

SEQUENCE DESCRIPTION: SEQ ID NO: 553:
US-10-877-231-553

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1542 TTAAAGAGAAAAGTCAGT 1561
DB 20 TAAAAAGAAAATCAGT 1

RESULT 425

US-10-643-801-107/c
Sequence 107, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot
Kenneth W. Dobie

TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

FILE REFERENCE: RTS-0678US

CURRENT APPLICATION NUMBER: US/10/643,801

CURRENT FILING DATE: 2003-08-18

NUMBER OF SEQ ID NOS: 230

SEQ ID NO 107

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide

US-10-643-801-107
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 CTTGACTGGAGAGTGCCCTG 490
DB 20 CTGGGCTAGGAGTGCCCTG 1

RESULT 426

US-10-643-801-116/c
Sequence 116, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot
Kenneth W. Dobie

TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

FILE REFERENCE: RTS-0678US

CURRENT APPLICATION NUMBER: US/10/643,801

CURRENT FILING DATE: 2003-08-18

NUMBER OF SEQ ID NOS: 230

SEQ ID NO 116

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide

US-10-643-801-116
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1233 ACCACTGTGTGGAGAGCC 1252
DB 20 ACCACCGTGTGGGAGAGCC 1

RESULT 427

US-10-831-901A-1717/c
Sequence 1717, Application US/10831901A
Publication No. US20050100885A1

GENERAL INFORMATION:
APPLICANT: Crooke, Stanley T.

```

; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIO0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1717
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1717

```

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 3.3e+02; Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
QY 1775 TACAGGCCCTTATTGCCA 1794
Db 20 TACAGTGCCTTATTGACA 1

```

RESULT 428

```

US-10-831-901A-1718/C
; Sequence 1718, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIO0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06

```

```

; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1718
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1718

```

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 3.3e+02; Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
QY 1776 ACAGGCCCTTATTGCCAC 1795
Db 20 ACAGTGCCTTATTGACAC 1

```

RESULT 429

```

US-10-831-901A-1719/C
; Sequence 1719, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIO0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1719
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1719

```

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 3.3e+02; Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
QY 1777 CAAGCCCTTATTGCCACT 1796
Db 20 CAAGTGCCTTATTGACACT 1

```

```
RESULT 430
US-10-831-901A-1720/c
; Sequence 1720, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Rangarajan, Rangarajan
; APPLICANT: Freiler, Susan M.
; APPLICANT: Messire, Christian
; APPLICANT: Hostadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL00080US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1720
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1720

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1778 AAGCCCTTATGACACTA 1797
DB      20 AAGTGCCTTATTGACACTA 1

RESULT 431
US-10-018-320A-13
; Sequence 13, Application US/10018320A
; Publication No. US20050130116A1
; GENERAL INFORMATION:
; APPLICANT: Dohmer, Johannes
; APPLICANT: Krebsfanger, Niels
; APPLICANT: Bichelbaum, Michel
; APPLICANT: Zanger, Ulrich M.
; TITLE OF INVENTION: Stable Expression of Polymorphic Forms of Human Cytochrome
; FILE REFERENCE: 01-1637
; CURRENT APPLICATION NUMBER: US/10/018,320A
; CURRENT FILING DATE: 2001-11-12
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
```

```
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-018-320A-13

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      518 CACTGATTCGCGCTATCG 537
DB      1 CACTGCTTACTGCGCTTATCG 20

RESULT 432
US-09-961-077-153
; Sequence 153, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; Edington, Brent E.
; McSwiggan, James A.
; Merlo, Patricia Ann Owens
; Guo, Lining
; Skokut, Thomas A.
; Young, Scott A.
; Folkerts, Otto
; Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 153:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 153:
US-09-961-077-153

Query Match      0.6%; Score 15; DB 1; Length 17;
```

Best Local Similarity 86.7%; Pred. No. 3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 AGAAGTCCCGGCA 792
DB 3 AGAAGUCCCGGCA 17

RESULT 433

US-09-961-077-155
Sequence 155, Application US/09961077
Publication No. US20030014775A1

GENERAL INFORMATION:

APPLICANT: Zwick, Michael G.

Edington, Brent E.

McSwiggen, James A.

Merlo, Patricia Ann Owens

Guo, Lining

Skokut, Thomas A.

Young, Scott A.

Folkert, Otto

Merlo, Donald J.

TITLE OF INVENTION: COMPOSITION AND METHODS FOR
MODULATION OF GENE EXPRESSION
IN PLANTS

NUMBER OF SEQUENCES: 1263

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/961.077

FILING DATE: 21-Sep-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/679,645

FILING DATE: July 12, 1996

APPLICATION NUMBER: 60/001,135

FILING DATE: July 13, 1995

APPLICATION NUMBER: 08/300,726

FILING DATE: September 2, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Wardburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 219/247

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 155:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 155:

US-09-961-077-155

Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 AGAAGTCCCGGCA 792

DB 2 AGAAGUCCCGGCA 16

RESULT 434

US-10-156-306-6949/c

Sequence 6949, Application US/10156306

Publication No. US20030119017A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: McSwiggen, James

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat

FILE REFERENCE: MBH01-664-A (400/050)

CURRENT APPLICATION NUMBER: US/10/156,306

CURRENT FILING DATE: 2002-05-28

NUMBER OF SEQ ID NOS: 8013

SOFTWARE: PatentIn version 3.0

SEQ ID NO 6949

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-156-306-6949

Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1184 CCTCTTCTCCTCCGA 1198
DB 17 CCTCTTCTCCTCCGA 3

RESULT 435

US-10-156-306-6950/c

Sequence 6950, Application US/10156306

Publication No. US20030119017A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: McSwiggen, James

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat

FILE REFERENCE: MBH01-664-A (400/050)

CURRENT APPLICATION NUMBER: US/10/156,306

CURRENT FILING DATE: 2002-05-28

NUMBER OF SEQ ID NOS: 8013

SOFTWARE: PatentIn version 3.0

SEQ ID NO 6950

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-156-306-6950

Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1184 CCTCTTCTCCTCCGA 1198
DB 15 CCTCTTCTCCTCCGA 1

RESULT 436

US-10-238-700-2764

Sequence 2764, Application US/10238700

Publication No. US20030153521A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: McSwiggen, James

TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Leve

FILE REFERENCE: 400/057 (MBH01-1158-A)

CURRENT APPLICATION NUMBER: US/10/238,700

CURRENT FILING DATE: 2002-09-18

```
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2764
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2764

Query Match          0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      146 GCCCTGGCCCCGGGG 160
DB      3 GCCCTGGCCCCGGGG 17

RESULT 437
US-10-498-462-1758
; Sequence 1758, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 1758
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-1758

Query Match          0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      727 TGGGCTGGGTGCT 741
DB      2 TGGGCTGGGTGCT 16

RESULT 438
US-10-724-270-1443
; Sequence 1443, Application US/10724270
; Publication No. US2005008031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: MGSwigen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
```

```
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1443
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1443

Query Match          0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      146 GCCCTGGCCCCGGGG 160
DB      3 GCCCTGGCCCCGGGG 17

RESULT 439
US-09-938-689-14/c
; Sequence 14, Application US/09938689
; Publication No. US20030028911A1
; GENERAL INFORMATION:
; APPLICANT: Huang, Manley
; APPLICANT: Harding, Fiona
; TITLE OF INVENTION: TRANSGENIC MAMMAL CAPABLE OF FACILITATING PRODUCTION OF
; FILE REFERENCE: 9342-028
; CURRENT APPLICATION NUMBER: US/09/938,689
; CURRENT FILING DATE: 2001-08-23
; PRIOR APPLICATION NUMBER: 09/651,361
; PRIOR FILING DATE: 2000-08-30
; PRIOR APPLICATION NUMBER: 60/151,688
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-09-938-689-14

Query Match          0.6%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1423 GAGGACCAAGCTGCA 1437
DB      15 GAGGACCAAGCTGCA 1

RESULT 440
US-08-887-505-145/c
; Sequence 145, Application US/08887505
; Publication No. US20020081577A1
; GENERAL INFORMATION:
; APPLICANT: Kilukskje, Robert E.
; APPLICANT: Frank, Bruce L.
; APPLICANT: Goodchild, John
; APPLICANT: Wolfe, Jia L.
```

APPLICANT: Roberts, Peter C.
APPLICANT: Hamlin, Jr., Henry A.
APPLICANT: Roberts, No. US2002008157A11 A.
APPLICANT: Walther, Debra M.
TITLE OF INVENTION: OLIGONUCLEOTIDES SPECIFIC FOR
TITLE OF INVENTION: HEPATITIS C VIRUS
NUMBER OF SEQUENCES: 172
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Hale and Dorr LLP
STREET: 60 State Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/887,505
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/471,968
FILING DATE: 06-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Kerner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-040CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 526-6000
TELEFAX: (617) 526-5000
INFORMATION FOR SEQ ID NO: 145:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA/RNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
US-08-887-505-145

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2e+02;
Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 372 TCCGCGCTCCGAGACCTC 389
DB 18 TCAGCCTCCAGACCCC 1

RESULT 441
US-10-297-068-352
Sequence 352, Application US/10297068
Publication No. US20030228585A1
GENERAL INFORMATION:
APPLICANT: INOKO, Hidetoshi
APPLICANT: KAGIYA, Taeko
APPLICANT: ICHIHARA, Tatsuo
APPLICANT: Matsumura, Yoshiyuki
APPLICANT: MORIYA, Shogo
APPLICANT: NISHIDA, Michio
TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
FILE REFERENCE: 1314OP1174
CURRENT APPLICATION NUMBER: US/10/297,068
CURRENT FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: JP 2000-164798
PRIOR FILING DATE: 2000-06-01
NUMBER OF SEQ ID NOS: 1298
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 352

LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: capture
US-10-297-068-352

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1071 GAGATGAAGTGTACAG 1088
DB 1 GAGATTAAAGTGTACAG 18

RESULT 442
US-10-813-203-1
Sequence 1, Application US/10813203
Publication No. US20050037495A1
GENERAL INFORMATION:
APPLICANT: SIGNAL PHARMACEUTICALS LLC.
APPLICANT: SAH, Dinah W. Y.
APPLICANT: GAGE, Fred H.
APPLICANT: RAY, Jacobshara
TITLE OF INVENTION: HUMAN CNS CELL LINES AND METHODS OF USE THEREFOR
FILE REFERENCE: REGEN1610-1
CURRENT APPLICATION NUMBER: US/10/813,203
CURRENT FILING DATE: 2004-03-29
PRIOR APPLICATION NUMBER: US 08/711,628
PRIOR FILING DATE: 1996-09-03
NUMBER OF SEQ ID NOS: 16
SOFTWARE: Patent In version 3.1
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: PCR primer
US-10-813-203-1

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTCGGAGACCGCAG 1010
DB 1 AACCTGCAGACCGCAG 18

RESULT 443
US-08-983-605-55/c
Sequence 55, Application US/08983605A
Publication No. US2002006118A1
GENERAL INFORMATION:
APPLICANT: Roder, Marion
TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
TITLE OF INVENTION: Triticum aestivum and Triticum aestivum and the Use of
FILE REFERENCE: 2936.10400
CURRENT APPLICATION NUMBER: US/08/983,605A
CURRENT FILING DATE: 1998-05-01
EARLIER APPLICATION NUMBER: DE 195 25 284.5
EARLIER FILING DATE: 1995-06-28
NUMBER OF SEQ ID NOS: 466
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 55
LENGTH: 19
TYPE: DNA
ORGANISM: Triticum aestivum
US-08-983-605-55

Query Match 0.6%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCCCTTCTCCACCC 1935

Db 18 ATCTCCTTCTCCACCC 1

RESULT 444

US-09-901-484A-476
Sequence 476, Application US/09901484A
Patent No. US20020119460A1
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Bouguetelerc, Lydie
TITLE OF INVENTION: Prostate Cancer Gene
FILE REFERENCE: GEN-T11XC3D2
CURRENT APPLICATION NUMBER: US/09/901,484A
CURRENT FILING DATE: 2001-07-09
PRIOR APPLICATION NUMBER: US 08/996,306
PRIOR FILING DATE: 1997-12-22
PRIOR APPLICATION NUMBER: US 60/099,658
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: US 09/218,207
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: US 09/338,907
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: US 09/853,526
PRIOR FILING DATE: 2001-05-11
NUMBER OF SEQ ID NOS: 578
SOFTWARE: PatentIn version 3.1
SEQ ID NO 476
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)-(19)
OTHER INFORMATION: microsequencing oligo for 99-140-130.misl
US-09-901-484A-476

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 424 AAAAGCAGCTACGAGTCA 441

Db 2 AAAAGCAGCTACGAGTCA 19

RESULT 445

US-09-966-147-22/C
Sequence 22, Application US/09966147
Patent No. US20020146416A1
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
TITLE OF INVENTION: HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Knobbe, Martens, Olson & Bear, LLP
STREET: 620 Newport Center Drive, 16th Floor
CITY: Newport Beach
STATE: California
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/966,147

FILING DATE: 27-Sep-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/446172

FILING DATE: 19-MAY-1995

APPLICATION NUMBER: 08/286846

FILING DATE: 05-AUG-1994

APPLICATION NUMBER: 08/215139

FILING DATE: 18-MAR-1994

ATTORNEY/AGENT INFORMATION:

NAME: Dreger, Ginger

REGISTRATION NUMBER: 33,055

REFERENCE/DOCKET NUMBER: GENENT.33CPC4C

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 954-4114

TELEFAX: (415) 954-4111

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 22:

US-09-966-147-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 3,4e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCACCTTGCGCTGAG 2141

Db 19 CTCACCTTGCGCTGAG 2

RESULT 446

US-09-853-526-476
Sequence 476, Application US/09853526
Patent No. US20020165345A1
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bouguetelerc, Lydie
TITLE OF INVENTION: PROSTATE CANCER GENE
FILE REFERENCE: GENSET.18CPLCP
CURRENT APPLICATION NUMBER: US/09/853,526
CURRENT FILING DATE: 2001-05-11
PRIOR APPLICATION NUMBER: 09/338,907
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 08/996,306
PRIOR FILING DATE: 1997-12-22
PRIOR APPLICATION NUMBER: 60/099,658
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 09/218,207
PRIOR FILING DATE: 1998-12-22
NUMBER OF SEQ ID NOS: 578
SOFTWARE: Patent.pm
SEQ ID NO 476
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..19
OTHER INFORMATION: microsequencing oligo for 99-140-130.misl
US-09-853-526-476

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 424 AAAAGCAGTACAGTCA 441
|||||
Db 2 AAAAGCAGTACAGACCA 19

RESULT 447
US-09-864-954D-8/c
; Sequence 8, Application US/09864954D
; Publication No. US20030118993A1
; GENERAL INFORMATION:
; APPLICANT: Sepp Kaul
; APPLICANT: Josef Preiherr (Deceased)
; APPLICANT: Ulrich Weidle
; TITLE OF INVENTION: A nucleic acid which is upregulated in human tumor
; TITLE OF INVENTION: cells, a protein encoded thereby and a process for
; FILE OF INVENTION: tumor diagnosis
; FILE REFERENCE: Case 20678
; CURRENT APPLICATION NUMBER: US/09/864,954D
; PRIOR FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: EP00110953.7
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: EP00115369.1
; PRIOR FILING DATE: 2000-07-15
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer RTR-5
US-09-864-954D-8

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2395 CTGGAATTAATGAAG 2412
|||||
Db 19 CTGGAATGAATGAATG 2

RESULT 448
US-10-045-360-17/c
; Sequence 17, Application US/10045360
; Publication No. US20030138781A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; TITLE OF INVENTION: METHODS FOR DETERMINING STEROID RESPONSIVENESS
; FILE REFERENCE: UDA-008
; CURRENT APPLICATION NUMBER: US/10/045,360
; CURRENT FILING DATE: 2002-01-22
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIR
US-10-045-360-17

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1630 GGCTCAGCTAACCTCTCT 1647
|||||
Db 18 GGCACAGCAAACTCTCT 1

RESULT 449

US-10-374-469-22/c
; Sequence 22, Application US/10374469
; Publication No. US20030157099A1
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; APPLICANT: Ufer, Roman

TITLE OF INVENTION: HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson & Bear, LLP
STREET: 620 Newport Center Drive, 16th Floor
CITY: Newport Beach
STATE: California
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA: US/10/374,469
APPLICATION NUMBER: US/10/374,469
FILING DATE: 24-Feb-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/966,147
FILING DATE: 27-Sep-2000
APPLICATION NUMBER: 08/446172
FILING DATE: 19-MAY-1995
APPLICATION NUMBER: 08/286846
FILING DATE: 05-AUG-1994
APPLICATION NUMBER: 08/215139
FILING DATE: 18-MAR-1994

ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: GENENT-33CPC4C

TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 954-4114
TELEFAX: (415) 954-4111

INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-374-469-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2124 CTCAGCCTGGCCTGAG 2141
|||||
Db 19 CTCACCTTGGCCTGGCG 2

RESULT 450
US-10-698-597-22/c
; Sequence 22, Application US/10698597
; Publication No. US20040058416A1
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; APPLICANT: Ufer, Roman

TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson & Bear
STREET: 620 Newport Center Drive 16th Floor

RESULT 450

```

; CITY: Newport Beach
; STATE: California
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/698.597
; FILING DATE: 31-Oct-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/724.524
; FILING DATE: 27-No. US20040058416a1-2000
; APPLICATION NUMBER: 09/156.923
; FILING DATE: 18-SEP-1998
; APPLICATION NUMBER: 08/359.705
; FILING DATE: 20-DEC-1994
; APPLICATION NUMBER: 08/268846
; FILING DATE: 10-AUG-1994
; APPLICATION NUMBER: 08/215139
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Dreger, Ginger
; REGISTRATION NUMBER: 33,055
; REFERENCE/DOCKET NUMBER: GENENT.33CP2C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 949/760-0404
; TELEFAX: 949/760-9502
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-698-597-22

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2124 CTCAGCCTTGCTGAG 2141
DB      19 CTCACCTTGCTGCG 2

RESULT 451
US-10-348-346-17/c
; Sequence 17, Application US/10348346
; Publication No. US20040072181A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; APPLICANT: Chailberg, Sharon S.
; TITLE OF INVENTION: METHODS FOR DETERMINING DRUG RESPONSIVENESS
; FILE REFERENCE: UPA-009
; CURRENT APPLICATION NUMBER: US/10/348.346
; CURRENT FILING DATE: 2003-04-22
; PRIOR APPLICATION NUMBER: US 10/045.360
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: US 60/370.008
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIR
```

```

US-10-348-346-17

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1630 GGCTAGCTTACCTCTCT 1647
DB      18 GGCACAGCAACCTCTCT 1

RESULT 452
US-10-683-990-57/c
; Sequence 57, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683.990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358.580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363.124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386.782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393.796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399.348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406.784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408.378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409.293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440.129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r

US-10-683-990-57

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      451 TCCAGTGGTCTCTCTCT 468
DB      18 TCCGAGGGTCTCTCTCT 1

RESULT 453
US-10-683-990-154
; Sequence 154, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
```



```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of FOS Gene Expression
; FILE REFERENCE: 400/193 (MHB03-194-A)
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05162
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-923-115-119

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 3.4e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      15 GCGCCGCGGCTGCGGCT 32
      |||||
Db      2 GCGCCGCGGCGGCGGCU 19

RESULT 457
US-10-888-226-288/c
; Sequence 288, Application US/10888226
; Publication No. US20050124568A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MGSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase
; FILE REFERENCE: 400-199 (MHB03-710-A)
; CURRENT APPLICATION NUMBER: US/10/888,226
; PRIOR FILING DATE: 2004-07-09
; PRIOR APPLICATION NUMBER: US 60/486,729
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 955
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 288
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-888-226-288

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2133 GGCCTGAGCAGATCCTT 2150
      |||||
Db      19 GGCCTGAGCAGATCCTT 2

RESULT 458
US-10-888-226-702
; Sequence 702, Application US/10888226
; Publication No. US20050124568A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MGSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase
; FILE REFERENCE: 400-199 (MHB03-710-A)
; CURRENT APPLICATION NUMBER: US/10/888,226
; PRIOR FILING DATE: 2004-07-09
; PRIOR APPLICATION NUMBER: US 60/486,729
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 955
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 702
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-888-226-702

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

QY 2133 GGCCTGAGCAGATGCTT 2150
|||||
Db 1 GGCCTGAGCAGATGCTT 18

RESULT 459
US-10-505-030-4/c
; Sequence 4, Application US/10505030
; Publication No. US20050142128A1
; GENERAL INFORMATION:
; APPLICANT: SCHRAEMER, ULRICH
; TITLE OF INVENTION: THERAPY OF DISEASES OF THE EYE, THE INNER EAR AND THE
; FILE REFERENCE: DEBE:041US
; CURRENT APPLICATION NUMBER: US/10/505,030
; CURRENT FILING DATE: 2004-08-16 PCT/DE 03/00415
; PRIOR FILING DATE: 2003-02-12
; PRIOR APPLICATION NUMBER: 102 06 723.6
; PRIOR FILING DATE: 2002-02-18
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-10-505-030-4

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1273 AGCACCACCCAGCAAG 1290
|||||
Db 19 ACCACCACCCAGCAAG 2

RESULT 460
US-10-697-527-55/c
; Sequence 55, Application US/10697527
; Publication No. US20040146898A1
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: MICROSATELLITE MARKERS FOR PLANTS OF THE SPECIES TRITICUM AESTIVUM
; FILE REFERENCE: US 08/983,605
; CURRENT APPLICATION NUMBER: US/10/697,527
; CURRENT FILING DATE: 2003-10-30
; PRIOR APPLICATION NUMBER: PCT/DE96/01185
; PRIOR FILING DATE: 1996-06-27
; PRIOR APPLICATION NUMBER: DE 195 25 284.5
; PRIOR FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 55
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Triticum sp.
US-10-697-527-55

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCTTCTGCGACCC 1935
|||||
Db 18 ATCTCTTCTGCGACCC 1

RESULT 461
US-10-923-522-6/c

; Sequence 6, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Chowitra, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MBH03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-923-522-6

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 16 CGCGCGGCTGCGGCTC 33
|||||
Db 18 CGCGCGGCTGCGGCTC 1

RESULT 462
US-10-923-522-269
; Sequence 269, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Chowitra, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MBH03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390

```

; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 269
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-923-522-269

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 3.4e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      16 CGCGCGCGCTGCCGCTC 33
Db      2 CGCGCGCGCGCGCGCTC 19

RESULT 463
US-10-923-522-568
; Sequence 568, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Chowrira, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MBH03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; PRIOR FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 568
; LENGTH: 19
; TYPE: RNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-923-522-568

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      717 CATGATATCATGGGCTG 734
Db      1 CCUGGUACCAUGGCTUG 18

RESULT 464
US-10-923-522-887/c
; Sequence 887, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Chowrira, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MBH03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; PRIOR FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 887
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-923-522-887

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      717 CATGATATCATGGGCTG 734
Db      19 CCTGGTACCATGGGCTTG 2
```

Search completed: August 8, 2005, 10:01:30
Job time : 15 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 8, 2005, 09:56:45 ; Search time 8 Seconds
(without alignments)
3.700 Million cell updates/sec

Title: US-10-643-801-4
Perfect score: 2421
Sequence: 1 ccccggaagccagcgccg.....ataatgaagtgagatcc 2421

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 287 seqs, 6113 residues

Total number of hits satisfying chosen parameters: 574

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 287 summaries

Database : fetch4rng.seq:*

Prod. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	60	2.5	60	1	ABN43866 Human spliced tcrn
C 2	60	2.5	65	1	ADD27789 Human psoriasis re
C 3	57	2.4	65	1	AAT20778 Human gene signatu
C 4	40.5	1.7	51	1	AAI32434 Human SNP oligonuc
C 5	28	1.2	28	1	AAD56898 Human 86606 DGAT2
C 6	27.6	1.1	31	1	AAK06395 Human biallelic po
C 7	27	1.1	27	1	ADO42529 Human NOVX probe #
C 8	24	1.0	24	1	AAA37275 Human PRO1433 reve
C 9	24	1.0	24	1	AAA37274 Human PRO1433 forw
C 10	24	1.0	24	1	AAFS4410 Probe #43 used in
C 11	24	1.0	24	1	AAFS4411 DNA encoding prote
C 12	24	1.0	24	1	ACD68450 Novel human secret
C 13	24	1.0	24	1	ACD68449 Novel human secret
C 14	24	1.0	24	1	ACH04551 Human secreted/tra
C 15	24	1.0	24	1	ACH04552 Human secreted/tra
C 16	24	1.0	24	1	ACD68095 Novel human secret
C 17	24	1.0	24	1	ACD68095 Novel human secret
C 18	24	1.0	24	1	ADC18163 Human PRO PCR prim
C 19	24	1.0	24	1	ADC18162 Human secreted/tra
C 20	24	1.0	24	1	ADD70809 Human secreted/tra
C 21	24	1.0	24	1	ADD70808 Human secreted/tra
C 22	24	1.0	24	1	ADD39886 Human secreted/tra
C 23	24	1.0	24	1	ADD39885 Human secreted/tra
C 24	24	1.0	24	1	ADD70331 Human secreted/tra
C 25	24	1.0	24	1	ADD70332 Human secreted/tra
C 26	24	1.0	24	1	ADD38452 Human secreted/tra
C 27	24	1.0	24	1	ADD38453 Human secreted/tra
C 28	24	1.0	24	1	ADD39408 Human secreted/tra
C 29	24	1.0	24	1	ADD39409 Human secreted/tra
C 30	24	1.0	24	1	ADD38931 Human secreted/tra
C 31	24	1.0	24	1	ADD38932 Human secreted/tra
C 32	24	1.0	24	1	ADD40362 Human secreted/tra
C 33	24	1.0	24	1	ADD40363 Human secreted/tra
C 34	24	1.0	24	1	ADE50584 Human secreted/tra
C 35	24	1.0	24	1	ADE50583 Human secreted/tra
C 36	24	1.0	24	1	ADE20196 Human secreted/tra
C 37	24	1.0	24	1	ADE20195 Human secreted/tra
C 38	24	1.0	24	1	ADE50106 Human secreted/tra
C 39	24	1.0	24	1	ADE50107 Human secreted/tra
C 40	24	1.0	24	1	ADE21665 Human secreted/tra
C 41	24	1.0	24	1	ADE21664 Human secreted/tra
C 42	24	1.0	24	1	ADE30089 Human secreted/tra
C 43	24	1.0	24	1	ADE30089 Human secreted/tra
C 44	24	1.0	24	1	ADF55982 Human secreted/tra
C 45	24	1.0	24	1	ADF55983 Human secreted/tra
C 46	24	1.0	24	1	ADH99486 Human secreted/tra
C 47	24	1.0	24	1	ADH99487 Human secreted/tra
C 48	24	1.0	24	1	ADH99487 Human secreted/tra
C 49	24	1.0	24	1	ADH99487 Human secreted/tra
C 50	24	1.0	24	1	ADH99487 Human secreted/tra
C 51	24	1.0	24	1	ADH99487 Human secreted/tra
C 52	24	1.0	24	1	ADH99487 Human secreted/tra
C 53	24	1.0	24	1	ADH99487 Human secreted/tra
C 54	24	1.0	24	1	ADH99487 Human secreted/tra
C 55	24	1.0	24	1	ADH99487 Human secreted/tra
C 56	24	1.0	24	1	ADH99487 Human secreted/tra
C 57	24	1.0	24	1	ADH99487 Human secreted/tra
C 58	24	1.0	24	1	ADH99487 Human secreted/tra
C 59	24	1.0	24	1	ADH99487 Human secreted/tra
C 60	24	1.0	24	1	ADH99487 Human secreted/tra
C 61	24	1.0	24	1	ADH99487 Human secreted/tra
C 62	24	1.0	24	1	ADH99487 Human secreted/tra
C 63	24	1.0	24	1	ADH99487 Human secreted/tra
C 64	24	1.0	24	1	ADH99487 Human secreted/tra
C 65	24	1.0	24	1	ADH99487 Human secreted/tra
C 66	24	1.0	24	1	ADH99487 Human secreted/tra
C 67	24	1.0	24	1	ADH99487 Human secreted/tra
C 68	24	1.0	24	1	ADH99487 Human secreted/tra
C 69	24	1.0	24	1	ADH99487 Human secreted/tra
C 70	24	1.0	24	1	ADH99487 Human secreted/tra
C 71	24	1.0	24	1	ADH99487 Human secreted/tra
C 72	24	1.0	24	1	ADH99487 Human secreted/tra
C 73	24	1.0	24	1	ADH99487 Human secreted/tra
C 74	24	1.0	24	1	ADH99487 Human secreted/tra
C 75	24	1.0	24	1	ADH99487 Human secreted/tra
C 76	24	1.0	24	1	ADH99487 Human secreted/tra
C 77	24	1.0	24	1	ADH99487 Human secreted/tra
C 78	24	1.0	24	1	ADH99487 Human secreted/tra
C 79	24	1.0	24	1	ADH99487 Human secreted/tra
C 80	24	1.0	24	1	ADH99487 Human secreted/tra
C 81	24	1.0	24	1	ADH99487 Human secreted/tra
C 82	24	1.0	24	1	ADH99487 Human secreted/tra
C 83	24	1.0	24	1	ADH99487 Human secreted/tra
C 84	24	1.0	24	1	ADH99487 Human secreted/tra
C 85	24	1.0	24	1	ADH99487 Human secreted/tra
C 86	24	1.0	24	1	ADH99487 Human secreted/tra
C 87	24	1.0	24	1	ADH99487 Human secreted/tra
C 88	24	1.0	24	1	ADH99487 Human secreted/tra
C 89	24	1.0	24	1	ADH99487 Human secreted/tra
C 90	24	1.0	24	1	ADH99487 Human secreted/tra
C 91	24	1.0	24	1	ADH99487 Human secreted/tra
C 92	24	1.0	24	1	ADH99487 Human secreted/tra
C 93	24	1.0	24	1	ADH99487 Human secreted/tra
C 94	24	1.0	24	1	ADH99487 Human secreted/tra
C 95	24	1.0	24	1	ADH99487 Human secreted/tra
C 96	24	1.0	24	1	ADH99487 Human secreted/tra
C 97	24	1.0	24	1	ADH99487 Human secreted/tra
C 98	24	1.0	24	1	ADH99487 Human secreted/tra
C 99	24	1.0	24	1	ADH99487 Human secreted/tra
C 100	24	1.0	24	1	ADH99487 Human secreted/tra
C 101	24	1.0	24	1	ADH99487 Human secreted/tra
C 102	24	1.0	24	1	ADH99487 Human secreted/tra
C 103	24	1.0	24	1	ADH99487 Human secreted/tra
C 104	24	1.0	24	1	ADH99487 Human secreted/tra
C 105	24	1.0	24	1	ADH99487 Human secreted/tra
C 106	24	1.0	24	1	ADH99487 Human secreted/tra

107	16.4	0.7	21	1	AAZ30148	PCR primer pnf12 u
108	16.4	0.7	21	1	ADA50411	Thermus scotoductu
109	16.4	0.7	21	1	ADR87061	Human Egr1b2 sho
110	16.4	0.7	21	1	AAO63503	Human EphrinB2 ant
111	16.2	0.7	21	1	AAZ26556	NANBV primer 77R,
112	16.2	0.7	21	1	AAZ26556	Human polymorphic
113	16.2	0.7	21	1	AAZ26556	Human gene single
114	16.2	0.7	21	1	ADQ93958	Human oestrogen re
115	16.2	0.7	21	1	AAZ54545	Specific tumour ce
116	16	0.7	19	1	ABQ76085	Anticancer gene-as
117	16	0.7	20	1	AAZ03129	PCR primer used to
118	16	0.7	20	1	ABZ88088	Human oligonucleot
119	16	0.7	21	1	ABD24318	AI095013-derived o
120	16	0.7	21	1	ADQ90611	Mouse Sca-2 target
121	16	0.7	21	1	ADQ90612	Sca-2 siRNA duplex
122	16	0.7	21	1	ADQ90612	Sca-2 siRNA duplex
123	15.8	0.7	19	1	AAZ85565	APC mutant gene ev
124	15.8	0.7	19	1	AAZ85565	HIV-1 related bind
125	15.8	0.7	19	1	ABL89068	Real-time PCR forw
126	15.8	0.7	19	1	ABL89073	V274T variant huma
127	15.8	0.7	19	1	ACH66843	E. coli SecA antis
128	15.8	0.7	20	1	AAZ44694	Human jun N-term
129	15.8	0.7	20	1	AAZ38463	Human jun N-term
130	15.8	0.7	20	1	AAZ29835	Capture oligonucle
131	15.8	0.7	20	1	AAZ29835	Antisense oligonuc
132	15.8	0.7	20	1	ABT44412	Chimeric antisense
133	15.8	0.7	20	1	ADN61692	Novel mutant prote
134	15.8	0.7	20	1	ADN61692	Human CCR-2 promot
135	15.8	0.7	20	1	AAZ29695	Human gene single
136	15.8	0.7	21	1	AAZ29695	CPS1/TRS1 genomic
137	15.8	0.7	21	1	AAZ29695	Sequencing primer
138	15.8	0.7	21	1	ABZ68426	Human GMPLP-1 17-m
139	15.8	0.7	21	1	ABZ68426	Human GMPLP-1 17-m
140	15.8	0.7	21	1	ABZ68426	Human ERG DNzyme
141	15.4	0.6	17	1	ABN02850	Human MD23 scanlin
142	15.4	0.6	17	1	ABK18894	Human K-Ras DNzyme
143	15.4	0.6	17	1	ABZ59890	Human PCP1 DNA fr
144	15.4	0.6	17	1	ABZ59890	Human PCP1 DNA fr
145	15.4	0.6	17	1	ADZ63855	Human GMPLP-1 prob
146	15.4	0.6	17	1	ADZ63855	Human GMPLP-1 prob
147	15.4	0.6	17	1	ADZ63855	Human GMPLP-1 prob
148	15.4	0.6	17	1	ADZ63855	Human GMPLP-1 prob
149	15.4	0.6	17	1	ADZ63855	Human GMPLP-1 prob
150	15.4	0.6	18	1	ADZ63855	Human GMPLP-1 prob
151	15.4	0.6	19	1	ADZ63855	Human GMPLP-1 prob
152	15.4	0.6	19	1	ADZ63855	Human GMPLP-1 prob
153	15.4	0.6	19	1	ADZ63855	Human GMPLP-1 prob
154	15.4	0.6	19	1	ADZ63855	Human GMPLP-1 prob
155	15.4	0.6	19	1	ADZ63855	Human GMPLP-1 prob
156	15.4	0.6	19	1	ADZ63855	Human GMPLP-1 prob
157	15.4	0.6	20	1	AAZ05177	Human ADR78942
158	15.4	0.6	20	1	AAZ05177	Human ADR78942
159	15.4	0.6	20	1	AAZ05177	Human ADR78942
160	15.4	0.6	20	1	AAZ05177	Human ADR78942
161	15.4	0.6	20	1	AAZ05177	Human ADR78942
162	15.4	0.6	20	1	AAZ05177	Human ADR78942
163	15.4	0.6	20	1	AAZ05177	Human ADR78942
164	15.4	0.6	20	1	AAZ05177	Human ADR78942
165	15.4	0.6	20	1	AAZ05177	Human ADR78942
166	15.4	0.6	20	1	AAZ05177	Human ADR78942
167	15.4	0.6	20	1	AAZ05177	Human ADR78942
168	15.4	0.6	20	1	AAZ05177	Human ADR78942
169	15.4	0.6	20	1	AAZ05177	Human ADR78942
170	15.2	0.6	20	1	AAZ05177	Human ADR78942
171	15.2	0.6	20	1	AAZ05177	Human ADR78942
172	15.2	0.6	20	1	AAZ05177	Human ADR78942
173	15.2	0.6	20	1	AAZ05177	Human ADR78942
174	15.2	0.6	20	1	AAZ05177	Human ADR78942
175	15.2	0.6	20	1	AAZ05177	Human ADR78942
176	15.2	0.6	20	1	AAZ05177	Human ADR78942
177	15.2	0.6	20	1	AAZ05177	Human ADR78942
178	15.2	0.6	20	1	AAZ05177	Human ADR78942
179	15.2	0.6	20	1	AAZ05177	Human ADR78942

180	15.2	0.6	20	1	AAZ05177	Human ADR78942
181	15.2	0.6	20	1	AAZ05177	Human ADR78942
182	15.2	0.6	20	1	AAZ05177	Human ADR78942
183	15.2	0.6	20	1	AAZ05177	Human ADR78942
184	15.2	0.6	20	1	AAZ05177	Human ADR78942
185	15.2	0.6	20	1	AAZ05177	Human ADR78942
186	15.2	0.6	20	1	AAZ05177	Human ADR78942
187	15.2	0.6	20	1	AAZ05177	Human ADR78942
188	15.2	0.6	20	1	AAZ05177	Human ADR78942
189	15.2	0.6	20	1	AAZ05177	Human ADR78942
190	15.2	0.6	20	1	AAZ05177	Human ADR78942
191	15.2	0.6	20	1	AAZ05177	Human ADR78942
192	15.2	0.6	20	1	AAZ05177	Human ADR78942
193	15.2	0.6	20	1	AAZ05177	Human ADR78942
194	15.2	0.6	20	1	AAZ05177	Human ADR78942
195	15.2	0.6	20	1	AAZ05177	Human ADR78942
196	15.2	0.6	20	1	AAZ05177	Human ADR78942
197	15.2	0.6	20	1	AAZ05177	Human ADR78942
198	15.2	0.6	20	1	AAZ05177	Human ADR78942
199	15.2	0.6	20	1	AAZ05177	Human ADR78942
200	15.2	0.6	20	1	AAZ05177	Human ADR78942
201	15.2	0.6	20	1	AAZ05177	Human ADR78942
202	15.2	0.6	20	1	AAZ05177	Human ADR78942
203	15.2	0.6	20	1	AAZ05177	Human ADR78942
204	15.2	0.6	20	1	AAZ05177	Human ADR78942
205	15.2	0.6	20	1	AAZ05177	Human ADR78942
206	15.2	0.6	20	1	AAZ05177	Human ADR78942
207	15.2	0.6	20	1	AAZ05177	Human ADR78942
208	15.2	0.6	20	1	AAZ05177	Human ADR78942
209	15.2	0.6	20	1	AAZ05177	Human ADR78942
210	15.2	0.6	20	1	AAZ05177	Human ADR78942
211	15.2	0.6	20	1	AAZ05177	Human ADR78942
212	15.2	0.6	20	1	AAZ05177	Human ADR78942
213	15.2	0.6	20	1	AAZ05177	Human ADR78942
214	15.2	0.6	20	1	AAZ05177	Human ADR78942
215	15.2	0.6	20	1	AAZ05177	Human ADR78942
216	15.2	0.6	20	1	AAZ05177	Human ADR78942
217	15.2	0.6	20	1	AAZ05177	Human ADR78942
218	15.2	0.6	20	1	AAZ05177	Human ADR78942
219	15.2	0.6	20	1	AAZ05177	Human ADR78942
220	15.2	0.6	20	1	AAZ05177	Human ADR78942
221	15.2	0.6	20	1	AAZ05177	Human ADR78942
222	15.2	0.6	20	1	AAZ05177	Human ADR78942
223	15.2	0.6	20	1	AAZ05177	Human ADR78942
224	15.2	0.6	20	1	AAZ05177	Human ADR78942
225	15.2	0.6	20	1	AAZ05177	Human ADR78942
226	15.2	0.6	20	1	AAZ05177	Human ADR78942
227	15.2	0.6	20	1	AAZ05177	Human ADR78942
228	15.2	0.6	20	1	AAZ05177	Human ADR78942
229	15.2	0.6	20	1	AAZ05177	Human ADR78942
230	15.2	0.6	20	1	AAZ05177	Human ADR78942
231	15.2	0.6	20	1	AAZ05177	Human ADR78942
232	15.2	0.6	20	1	AAZ05177	Human ADR78942
233	15.2	0.6	20	1	AAZ05177	Human ADR78942
234	15.2	0.6	20	1	AAZ05177	Human ADR78942
235	15.2	0.6	20	1	AAZ05177	Human ADR78942
236	15.2	0.6	20	1	AAZ05177	Human ADR78942
237	15.2	0.6	20	1	AAZ05177	Human ADR78942
238	15.2	0.6	20	1	AAZ05177	Human ADR78942
239	15.2	0.6	20	1	AAZ05177	Human ADR78942
240	15.2	0.6	20	1	AAZ05177	Human ADR78942
241	15.2	0.6	20	1	AAZ05177	Human ADR78942
242	15.2	0.6	20	1	AAZ05177	Human ADR78942
243	15.2	0.6	20	1	AAZ05177	Human ADR78942
244	15.2	0.6	20	1	AAZ05177	Human ADR78942
245	15.2	0.6	20	1	AAZ05177	Human ADR78942
246	15.2	0.6	20	1	AAZ05177	Human ADR78942
247	15.2	0.6	20	1	AAZ05177	Human ADR78942
248	15.2	0.6	20	1	AAZ05177	Human ADR78942
249	15.2	0.6	20	1	AAZ05177	Human ADR78942
250	15.2	0.6	20	1	AAZ05177	Human ADR78942
251	15.2	0.6	20	1	AAZ05177	Human ADR78942
252	15.2	0.6	20	1	AAZ05177	Human ADR78942

Mouse Ig-kappa Ica
Oligonucleotide hy
Oligonucleotide hy
VEGF receptor Flt-
Mouse immunoglobul
Murine SACL gene-8
Human lysophosphol
Laminin 5 express
Human TSP1 domain
Human hbeta4BP an
Human raf kinase r
Human C/EBP beta p
Human ADAMTS prote
PCR primer 3 relat
Serrum amyloid A1 m
HIV PRT antisense
Human oligonucleot
Human oligonucleot
Human oligonucleot
Human rat-associat
AA156940-derived o
AA164211-derived o
PCR primer used in
Primer of the inve
Human Centromere p
Human Centromere p
Human Centromere p
Human Centromere p
Antisense DNA olig
Human endothelial
Human Sp2 specific
Mouse Ig kappa Ica
Human mPGES-1 chlm
Human HDAC4 specif
PCR primer used to
Murine SACL DNA PC
Chimeric phosphoro
Human TDP-1 antis
Human TDP-1 target
Human BUB1-beta ta
Human BUB1-beta an
Human oestrogen re
Human oestrogen re
Mouse RANK antisen
Mouse RANK antisen
Human LAR chimeric
Human LAR target o
Human TNFSF14 DNA
Human TNFSF14 DNA
Granule bound star
Human H-Ras DNzyme
Human PCP1 DNA fr
Human IKK-gamma su
Human inter-leukin-
Human oligonucleot
AA1095013-derived o
5' primer for huma
Oligo HCV-213, tar
NMDA receptor 1 pr
Multiple antisense
PCR primer HVESTR
Human adenosine re
Primer 4L for a hu
Human CD4 antisen
Human multiple tar

253	14.8	0.6	18	1	AAF21465	Human multiple tar
C 254	14.8	0.6	18	1	AAS05704	Polypyrimidine reg
C 255	14.8	0.6	18	1	ABL30663	Human HLA genotypi
C 256	14.8	0.6	18	1	ABSG5939	Inhibitory oligonu
C 257	14.8	0.6	18	1	ABSG6456	Human nucleic acid
C 258	14.8	0.6	18	1	ABSG7159	Human MTA oligonuc
C 259	14.8	0.6	18	1	ABD20418	Human pulmonary ar
C 260	14.8	0.6	18	1	ABD32442	Human MTA oligo SE
C 261	14.8	0.6	18	1	ADH08326	Mutant gene fragme
C 262	14.8	0.6	18	1	ADM69504	Plant gene polymor
C 263	14.8	0.6	18	1	ADM76423	Human myeloid leuk
C 264	14.8	0.6	18	1	ADR27622	Monoclonal antibod
C 265	14.8	0.6	19	1	AAR07055	Human trkC recepto
C 266	14.8	0.6	19	1	AAT77561	Wheat microsomal l
C 267	14.8	0.6	19	1	AAZ01319	PCR primer for PGI
C 268	14.8	0.6	19	1	AAZ88855	Human trkC recepto
C 269	14.8	0.6	19	1	AAA46217	Primer IPM14F for
C 270	14.8	0.6	19	1	AAA84585	Cyclin E ribozyme
C 271	14.8	0.6	19	1	AAH59747	Cyclin E ribozyme
C 272	14.8	0.6	19	1	ABL57139	Human PKM gene spe
C 273	14.8	0.6	19	1	ADB25800	Human CYP2D6-relat
C 274	14.8	0.6	19	1	ACR79453	Serum amyloid A1 m
C 275	14.8	0.6	19	1	ADB65548	Human c-fos transc
C 276	14.8	0.6	19	1	ADB65664	Human c-fos siNA 1
C 277	14.8	0.6	19	1	ADB29461	Mitogen activated
C 278	14.8	0.6	19	1	ADB29624	Mitogen activated
C 279	14.8	0.6	19	1	ADB29711	Mitogen activated
C 280	14.8	0.6	19	1	ADB29816	Mitogen activated
C 281	14.8	0.6	19	1	ACH00745	Albino and pigment
C 282	14.8	0.6	19	1	ADP83712	Human breakpoint c
C 283	14.8	0.6	19	1	ADP84593	Human ABL1-targele
C 284	14.8	0.6	19	1	ADP84274	Human ABL1-targele
C 285	14.8	0.6	19	1	ADP83575	Human breakpoint c
C 286	14.8	0.6	19	1	ADG34885	Human TNF receptor
C 287	14.8	0.6	19	1	ADG35008	Human TNF receptor

ALIGNMENTS

```
RESULT 1
ABN43866/C
ID ABN43866 standard; DNA; 60 BP.
XX
AC ABN43866;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human spliced transcript detection oligonucleotide SEQ ID NO:16614.
XX
KW Human; mouse; rat; splice transcript; detection; RNA transcript;
KM splice variant; transcriptome; oligonucleotide library; ss.
XX
OS Homo sapiens.
XX
PN WO200210449-A2.
XX
PD 07-FEB-2002.
XX
PF 20-JUL-2001; 2001WO-IB001903.
XX
PR 28-JUL-2000; 2000US-0221607P.
XX
RR 02-MAY-2001; 2001US-0287724P.
XX
PA (COMP-) COMPUGEN INC.
XX
PI Shoshan A, Wasserman A, Mintz E, Mintz L, Feigler S;
XX
DR WPI, 2002-257383/30.
XX
PT New oligonucleotide libraries comprising oligonucleotides which
selectively hybridize to mRNAs transcribed from a transcription unit of a
genome, useful for detecting tissue-, pathology-, and developmental-
```

```
PT specific genes.
XX
BS Example 1; SEQ ID NO 16614; 47bp; English.
XX
CC The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-)
CC transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridising selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterising the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialised mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition: to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular
CC disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from
CC rats, humans and mice, which are used in the exemplification of the
CC present invention. N.B. The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 BP; 16 A; 7 C; 23 G; 14 T; 0 U; 0 Other;
XX
Query Match 2.5%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 6.3e-05;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1767 ACTTCTATACAGCCCTTATTCGACATACCCACGCTGTAGTCTGAAACTGCA 1826
DB 60 ACTTCTATACAGCCCTTATTCGACATACCCACGCTGTAGTCTGAAACTGCA 1
XX
RESULT 2
ADD27789
ID ADD27789 standard; cDNA; 65 BP.
XX
AC ADD27789;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human psoriasis related genes EST #1.
XX
KW Human; ss; psoriasis; Psoriasis-related gene; body map; EST;
KM expressed sequence tag.
XX
OS Homo sapiens.
XX
PN JP2002330770-A.
XX
PD 19-NOV-2002.
XX
PF 25-MAY-2001; 2001JP-00156529.
XX
PR 30-AUG-2000; 2000JP-00260818.
XX
RR 01-NOV-2000; 2000JP-00334042.
XX
XX (TANA ) TANABE SEIYAKU CO.
XX
PA WPI, 2003-460750/44.
XX
DR Gene of which expression changes in Psoriasis and examination directed to
XX PT said gene, a recombinant vector, a host cell.
XX PS Claim 7; SEQ ID NO 4; 27bp; Japanese.
XX
XX The invention relates to detection of psoriasis by determining the
```

expression level of a Psoriasis-related gene in a biosample collected from a human or nonhuman animal individual. The gene consisting of one of 5 538-2713 nucleotide sequences, given in the specification, or a DNA hybridizing with it under stringent conditions are disclosed. The method is used for the detection of Psoriasis. The Psoriasis-related gene was detected by the body map method. The present sequence is an EST (expressed sequence tag) from one of the psoriasis-related genes.

XX Sequence 65 BP; 24 A; 11 C; 11 G; 19 T; 0 U; 0 Other;

XX Query Match 2.5%; Score 60; DB 1; Length 65;
Best Local Similarity 100.0%; Pred. No. 6e-05;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2362 GATCATTTGACACATGTCAGACTTTGTATATGCTTGAATAATGAAGTGAGATCC 2421
DB 1 GATCATTTGACACATGTCAGACTTTGTATATGCTTGAATAATGAAGTGAGATCC 60

RESULT 3

AA20778
ID AA20778 standard; cDNA to mRNA; 65 BP.

AC AA20778;

DT 26-JUL-1996 (first entry)

XX Human gene signature HUMGS01999.

XX Gene signature; messenger RNA; mRNA; relative abundance; frequency;
KW human; cloning; mapping; non-biased library; diagnosis; detection;
KM cell typing; abnormal cell function; ss.

XX Homo sapiens.

OS W09514772-A1.

PN 01-JUN-1995.

PD 11-NOV-1994; 94MO-JP001916.

PF 12-NOV-1993; 93JP-00355504.

PR (MATS/) MATSUBARA K.

PA (OKUB/) OKUBO K.

PI Matsubara K, Okubo K;

XX WPI; 1995-206931/27.

XX Single-stranded DNA for identifying gene signatures - isolated from 3'-
PT directed human cDNA library that reflects relative abundance of corresp.
PT mRNA in specific human tissues.

PS Claim 1; Page 721; 2245pp; Japanese.

XX A single-stranded DNA (or its complementary strand or the corresp. double
CC -stranded DNA) which comprises one of the 7837 "GS" sequences given in
CC AAT19001-126637 and which is able to hybridize to part of human genomic
CC DNA, cDNA or mRNA is claimed. The GS (Gene Signature) sequences were
CC obtained from 3'-directed cDNA libraries prepared from various human
CC tissues; synthesis of cDNA was initiated from the 3'-end of mRNA by using
CC poly(I) as the sole primer. Since the 3'-untranslated sequence is unique
CC to a particular mRNA species, almost all the 3'-oriented cDNAs hybridize
CC with specific mRNAs. Each library is constructed so as to reflect
CC accurately the relative abundance of different mRNAs in the particular
CC tissue from which it was derived. The appearance frequency of a given GS
CC in a cDNA library can be determined (esp. using primers and probes
CC derived from the GS sequences) as a means of diagnosing abnormal cell
CC function or for recognizing different cell types

XX Sequence 65 BP; 24 A; 10 C; 9 G; 19 T; 0 U; 3 Other;

XX Query Match 2.4%; Score 57; DB 1; Length 65;
Best Local Similarity 96.6%; Pred. No. 0.00015;
Matches 57; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2362 GATCATTTGACACATGTCAGACTTTGTATATGCTTGAATAATGAAGTGAGATCC 2420
DB 1 GATCATTTGACACATGTCAGACTTTGTATATGCTTGAATAATGAAGTGAGATCC 59

RESULT 4

AA132434/c
ID AA132434 standard; DNA; 51 BP.

AC AA132434;

DT 24-JAN-2002 (first entry)

XX Human SNP oligonucleotide #5642.

XX Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;
KW neuroprotective; antimicrobial; gene therapy; vaccine; amylose; cancer;
KW amyloid protein; angiotensin; apoptosis related protein; cadherin;
KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
KW complement related protein; cytochrome; kinesin; cytokine; interferon;
KW interleukin; G-protein coupled receptor; thioesterase; inflammation;
KW multifactorial disease; autoimmune disease; infection;
KW nervous system disease; ss.

XX Homo sapiens.

OS W0200147944-A2.

PN 05-JUL-2001.

PD 28-DEC-2000; 2000MO-US035498.

PF 28-DEC-1999; 99US-0173419P.

PR 27-DEC-2000; 2000US-00173419.

PA (CURA-) CURAGEN CORP.

PI Shinketsu RA, Leach M;

XX WPI; 2001-465210/50.

XX Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,
PT oncogenes and histones, useful for diagnosing and treating, e.g. cancer,
PT autoimmune diseases and infections.

PS Claim 1; Page 3012; 4143pp; English.

XX The present invention relates to oligonucleotides encoding polymorphic
CC variants of proteins related to amylases, amyloid proteins, angiotensin,
CC apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,
CC histones, kinases, colony stimulating factors, complement related
CC proteins, cytochromes, kinesins, cytokines, interferons, interleukins, G-
CC protein coupled receptors and thioesterases. The present sequence is one
CC such oligonucleotide. The oligonucleotides and the peptides encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate expression of the proteins listed above.
CC Disorders that may be prevented, diagnosed and/or treated include
CC multifactorial diseases with a genetic component, such as autoimmune
CC diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes,
CC systemic lupus erythematosus and Grave's disease), inflammation, cancer
CC (e.g. cancers of the bladder, brain, breast, colon and kidney,
CC leukemia), diseases of the nervous system and an infection of pathogenic
CC organisms

XX Sequence 51 BP; 8 A; 14 C; 16 G; 13 T; 0 U; 0 Other;

XX Query Match 1.7%; Score 40.5; DB 1; Length 51;
Best Local Similarity 98.1%; Pred. No. 0.031;
Matches 51; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1390 TGAAGTGGAGCCCTTGGGGCCCACTCCCTGGAGAACGAGCTCAATC 1441
|||||
DB 51 TGAAGTGGAGCCAG-CTTGGGGCCCACTCCCTGGAGAACGAGCTCAATC 1

RESULT 5
AAS56898
ID AAS56898 standard; DNA; 28 BP.

AC AAS56898;
XX
DT 06-NOV-2003 (first entry)

DE Human 86606 DGAT2 gene specific PCR probe.

XX Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;
KW coronary artery disease; hypertension; heart failure; tissue typing;
KW aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;
KW atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;
KW diabetes; chromosome mapping; forensic biology; PCR; probe; ss.

OS Homo sapiens.

PN WO2003053363-A2.

XX 03-JUL-2003.

PF 19-DEC-2002; 2002WO-US040974.

XX 19-DEC-2001; 2001US-0341947P.

PR 19-SEP-2002; 2002US-0411859P.

XX (MILL-) MILLENNIUM PHARM INC.

PI Gimeno RE, Wu Z, Kapeller-Libermann R, Hubbard BK;

XX WPI; 2003-559092/52.

PT New human diacylglycerol acyltransferase 2 (DGAT2) family member
PT polypeptide and nucleic acid molecules, useful for diagnosing and
PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or
PT triglyceride synthesis.

XX Example 3; Page 100; 154pp; English.

XX The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)
CC family members and their uses. DGAT2 family member sequences or their
CC modulators are useful for diagnosing and treating a subject with a
CC disorder associated with the aberrant DGAT family member polypeptide
CC activity or nucleic acid expression, such as a disorder associated with
CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or
CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,
CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated
CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is
CC also useful in screening assays (e.g. tissue typing, chromosome mapping,
CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,
CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as
CC surrogate markers (e.g. markers of disease states or markers of drug
CC activity). The present sequence is human DGAT2 gene specific PCR probe.
CC This sequence is used in the exemplification of the invention

XX Sequence 28 BP; 6 A; 10 C; 6 G; 6 T; 0 U; 0 Other;

QY Query Match 1.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1800 CCACGCTGCTTCTAGTCTGAACTGACG 1827
|||||
DB 1 CCACGCTGCTTCTAGTCTGAACTGACG 28

RESULT 6
AAX06395/cf
ID AAX06395 standard; DNA; 31 BP.

XX AAX06395;

DT 31-MAR-1999 (first entry)

DE Human diallelic polymorphic DNA fragment SGC33608.

XX Polymorphism; diallelic; paternity testing; forensic; genetic mapping;
KW phenotypic typing; medicament; disease; marker; human; ss.

OS Homo sapiens.

PN WO9858529-A2.

XX 30-DEC-1998.

PF 22-JUN-1998; 98WO-US012930.

XX 24-JUN-1997; 97US-0050594P.

XX (AFFY-) AFFYMETRIX INC.

PI Lipshutz RJ, Chee M, Fan J, Berno A;

XX WPI; 1999-080963/07.

PT New nucleic acid segments containing polymorphic sites - used for, e.g.
PT detecting a disease phenotype, in forensics, paternity testing or genetic
PT mapping of phenotypic traits.

XX Claim 1; Page 25; 61pp; English.

XX Sequences AAX06101-X06558 represent human DNA fragments which contain
CC diallelic polymorphic markers. The base occupying the polymorphic site is
CC indicated by the appropriate IUPAC-IUB ambiguity code. These fragments
CC can be used in a method for determining polymorphic forms in an
CC individual. The invention further provides computer-readable storage
CC medium for storing data for access by an application programme being
CC executed on a data processing system. Such a method comprises a data
CC structure stored in the computer-readable storage medium, the data
CC structure including information resident in a database used by the
CC application programme and including records, each record comprising
CC information identifying a polymorphism shown in the above sequences. The
CC products and methods can be used for analysing polymorphic sites in
CC individuals for testing for the presence of a disease phenotype or in
CC forensics, paternity testing or genetic mapping of phenotypic traits.
CC They can also be used for the production of polypeptides expressed by
CC variant genes and for the production of transgenic animals. The nucleic
CC acid segments can also be used in the manufacture of medicaments for the
CC treatment or prophylaxis of diseases

XX Sequence 31 BP; 4 A; 9 C; 10 G; 7 T; 0 U; 1 Other;

QY Query Match 1.1%; Score 27.6; DB 1; Length 31;
Best Local Similarity 96.4%; Pred. No. 2.4;
Matches 27; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1404 CTTGGGGCCCACTCCCTGGAGAACCA 1431
|||||
DB 28 CTTGGGGCCCACTCCCTGGAGAACCA 1

RESULT 7
ADO42529
ID ADO42529 standard; DNA; 27 BP.

XX ADO42529;

DT 15-JUL-2004 (first entry)

DE Human NOVX probe #1.
XX
KW Human; NOVX; ss; cancer; atherosclerosis; diabetes; Alzheimer's disease;
KW Parkinson's disease; graft-versus-host disease; scleroderma;
KW hypertension; haemophilia; idiopathic thrombocytopenic purpura;
KW immunodeficiency; AIDS; dyslipidemia; obesity; Crohn's disease;
KW bronchial asthma; anorexia; cancer-associated cachexia;
KW multiple sclerosis; fertility; probe.
OS Homo sapiens.
XX
PN US2004058338-A1.
PD
25-MAR-2004.
PF
02-DEC-2002; 2002US-00307817.
XX
03-DEC-2001; 2001US-0336881P.
PR 05-DEC-2001; 2001US-0336820P.
PR 07-DEC-2001; 2001US-0338285P.
PR 10-DEC-2001; 2001US-0338318P.
PR 10-DEC-2001; 2001US-0338989P.
PR 11-DEC-2001; 2001US-0339022P.
PR 11-DEC-2001; 2001US-0339314P.
PR 11-DEC-2001; 2001US-0339516P.
PR 11-DEC-2001; 2001US-0339517P.
PR 12-DEC-2001; 2001US-0339611P.
PR 12-DEC-2001; 2001US-0340981P.
PR 12-DEC-2001; 2001US-0341346P.
PR 14-DEC-2001; 2001US-0340390P.
PR 14-DEC-2001; 2001US-0340440P.
PR 14-DEC-2001; 2001US-0340565P.
PR 14-DEC-2001; 2001US-0340608P.
PR 14-DEC-2001; 2001US-0341144P.
PR 17-DEC-2001; 2001US-0341477P.
PR 17-DEC-2001; 2001US-0341540P.
PR 18-DEC-2001; 2001US-0341768P.
PR 20-DEC-2001; 2001US-0344592P.
PR 31-DEC-2001; 2001US-0344903P.
PR 01-FEB-2002; 2002US-0353286P.
PR 01-FEB-2002; 2002US-0353288P.
PR 06-FEB-2002; 2002US-0355999P.
PR 26-FEB-2002; 2002US-0359626P.
PR 26-FEB-2002; 2002US-0359671P.
PR 27-FEB-2002; 2002US-0359914P.
PR 27-FEB-2002; 2002US-0359956P.
PR 28-FEB-2002; 2002US-0360924P.
PR 28-FEB-2002; 2002US-0360964P.
PR 28-FEB-2002; 2002US-0361028P.
PR 28-FEB-2002; 2002US-0361256P.
PR 28-FEB-2002; 2002US-0361264P.
PR 05-MAR-2002; 2002US-0361770P.
PR 05-MAR-2002; 2002US-0362230P.
PR 13-MAR-2002; 2002US-0364181P.
PR 13-MAR-2002; 2002US-0364238P.
PR 15-MAR-2002; 2002US-0364978P.
PR 15-MAR-2002; 2002US-0365025P.
PR 17-APR-2002; 2002US-0372889P.
PR 15-MAY-2002; 2002US-0380981P.
PR 16-MAY-2002; 2002US-0381004P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.
PR 29-MAY-2002; 2002US-0384024P.
PR 02-JUL-2002; 2002US-0393332P.
PR 06-AUG-2002; 2002US-0401315P.
PR 07-AUG-2002; 2002US-0401788P.
PR 20-AUG-2002; 2002US-0404675P.
PR 23-AUG-2002; 2002US-0405400P.
PR 23-AUG-2002; 2002US-0405684P.
PR 23-AUG-2002; 2002US-0405687P.
PR 23-AUG-2002; 2002US-0405698P.

PR 26-AUG-2002; 2002US-0406353P.
XX
XX (AGEE/) AGEE M. L.
PA (AUSO/) ALSOBROOK J P.
PA (ANDE/) ANDERSON D W.
PA (BERG/) BERGHS C.
PA (BOLD/) BOLDG F L.
PA (BURG/) BURGESS C E.
PA (CATT/) CATTERTON E.
PA (DIPT/) DIPIPO V A.
PA (EDIN/) EDINGER S R.
PA (EISE/) EISEN A.
PA (ELLE/) ELLERMAN K.
PA (GANG/) GANGOLLI E A.
PA (GERL/) GERLACH V.
PA (GORM/) GORMAN L.
PA (ROTH/) ROTHBERG B G.
PA (GUOX/) GUO X S.
PA (HERR/) HERRMANN J L.
PA (HALV/) HALVORSEN Y.
PA (JTWI/) JI W.
PA (KERU/) KERUDA R.
PA (KHRA/) KHRAMTSOV N V.
PA (LARO/) LAROCHELLE W J.
PA (LEPL/) LEPLLEY D M.
PA (LILL/) LI L.
PA (MACD/) MACDOUGALL J R.
PA (MILL/) MILLER C E.
PA (ORTT/) ORT T.
PA (PADI/) PADIGARU M.
PA (PATT/) PATTURAJAN M.
PA (PENNA/) PENNA C E A.
PA (PEYM/) PEYMAN J A.
PA (RIEG/) RIEGER D K.
PA (ROTH/) ROTHENBERG M E.
PA (SHEN/) SHENOY S G.
PA (SMIT/) SMITHSON G.
PA (SPAD/) SPADERNA S K.
PA (SPYD/) SPYTEK K A.
PA (STON/) STONE D J.
PA (TAUP/) TAUPIER R J.
PA (VERN/) VERNET C A M.
PA (VOSS/) VOSS E Z.
PA (ZHON/) ZHONG M.
XX
PI Agee ML, Alsobrook JP, Anderson DM, Berghs C, Boldog FL;
PI Buggess CE, Catterton E, Dipippo VA, Edinger SR, Eisen A;
PI Ellerman K, Gangolli EA, Gerlach V, Gorman L, Rothberg BG, Guo XS;
PI Herrmann JL, Halvorsen Y, Ji W, Kekuda R, Khrantsov NV;
PI Larochelele WJ, Lepley DM, Li L, Macdougall JR, Miller CE, Ort T;
PI Padigaru M, Paturajan M, Penna CE, Peyman JA, Rieger DK;
PI Rothenberg ME, Shenoy SG, Smithson G, Spaderna SK, Spytek KA;
PI Stone DJ, Taupier RJ, Vernet CM, Voss EZ, Zhong M;
XX
XX WPI; 2004-268786/25.
XX
XX New human NOVX polypeptides and nucleic acid molecules, useful for
PT diagnosing, preventing or treating NOVX-associated disorder, e.g. cancer,
PT atherosclerosis, diabetes, Alzheimer's disease, Parkinson's disease or
PT scleroderma.
XX
XX
XX Example D; SEQ ID NO 378; 610bp; English.
XX
XX The invention relates to human NOVX polypeptides and the polynucleotides
XX encoding them. The invention also relates to antibodies specific to the
XX NOVX polypeptides. The polypeptides, polynucleotides and antibodies are
XX useful for manufacturing a medicament for treating a syndrome associated
XX with a human disease, such as a pathology associated with the NOVX
XX polypeptide. The sequences are useful for diagnosing, treating or
XX preventing a NOVX-associated disorder, e.g., cancer, atherosclerosis,
XX diabetes, Alzheimer's disease, Parkinson's disease, graft-versus-host
XX disease, scleroderma, hypertension, haemophilia, idiopathic
XX thrombocytopenic purpura, immunodeficiencies, AIDS, dyslipidemia,

CC obesity, Crohn's disease, bronchial asthma, anorexia, cancer-associated
CC cachexia, multiple sclerosis or fertility. The nucleic acids may be used
CC as hybridisation probes, in chromosome mapping, in tissue typing, in
CC preventive medicine or in pharmacogenomics. This sequence represents a
CC probe used in analysis of expression of a human NOVX polynucleotide of
CC the invention.

SO Sequence 27 BP; 3 A; 10 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 1.1%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 3.2;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1167 ATCTTCATGTCGAGGCTCTCTCC 1193
Db 1 ATCTTCATGTCGAGGCTCTCTCC 27

RESULT 8
AAA37275/C
ID AAA37275 standard; DNA; 24 BP.

XX AAA37275;

DT 08-AUG-2000 (first entry)

XX Human PRO1433 reverse PCR primer SEQ ID NO:294.

XX Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
KW PCR primer; hybridisation; probe; ss.

XX Homo sapiens.

PN WQ200012708-A2.

PD 09-MAR-2000.

PF 01-SEP-1999; 99WO-US020111.

XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 15-SEP-1998; 98US-0100642P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100651P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.

PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102966P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106033P.
PR 27-OCT-1998; 98US-0106034P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106034P.
PR 29-OCT-1998; 98US-0106348P.
PR 29-OCT-1998; 98US-0106349P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-OCT-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106934P.
PR 03-NOV-1998; 98US-0106935P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.

PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108825P.
PR 17-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
XX (GETH) GENENTECH INC.
XX
XX Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
XX WPI; 2000-237871/20.
XX
XX
XX WPI; 2000-237871/20.
XX
XX
XX New mammalian DNA sequences encoding transmembrane, receptor or secreted
XX PRO polypeptides, useful for screening of potential peptide or small
XX molecule inhibitors of the relevant receptor/ligand interactions.
XX
XX Example 85; Page 445; 773pp; English.
XX
XX AAA37022 to AAA37144 encode the new isolated human transmembrane,
XX receptor or secreted PRO polypeptides given in AAY9340 to AAY9462. The
XX transmembrane and receptor PRO proteins can be used for screening of
XX potential peptide or small molecule inhibitors of the relevant
XX receptor/ligand interactions. The polypeptides and nucleotide sequences
XX encoding then have various industrial applications, including uses as
XX pharmaceutical and diagnostic agents. AAA37145 to AAA37350 represent PCR
XX primers and hybridisation probes used in the isolation of the PRO
XX polypeptides from the present invention
XX
XX
XX Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1463 GGAGTGTATGGGTCTGTCTGG 1486
DB 24 GGAGTGTATGGGTCTGTCTGG 1
RESULT 9
ID AAA37274 standard; DNA; 24 BP.
XX AAA37274;
AC
XX
XX
XX 08-AUG-2000 (first entry)
XX DT
XX
XX Human PRO1433 forward PCR primer SEQ ID NO:293.
XX DE
XX Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
XX transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
XX PCR primer; hybridisation; probe; ss.
XX
XX Homo sapiens.
XX OS
XX
XX WO200012708-A2.
XX
XX 09-MAR-2000.
XX PD
XX 01-SEP-1999; 99WO-US020111.
XX PF
XX 01-SEP-1998; 98US-0098716P.
XX PR

PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102076P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103335P.
PR 07-OCT-1998; 98US-0103336P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.

PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102330P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102484P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103358P.
 PR 06-OCT-1998; 98US-0103349P.
 PR 07-OCT-1998; 98US-0103314P.
 PR 07-OCT-1998; 98US-0103315P.
 PR 07-OCT-1998; 98US-0103328P.
 PR 07-OCT-1998; 98US-0103395P.
 PR 07-OCT-1998; 98US-0103396P.
 PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104387P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.
 PR 27-OCT-1998; 98US-0105881P.
 PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0108500P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106802P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.

PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 16-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US020119.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.

XX PA
 XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski FJ, Grimaldi JC, Gunney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PW, Wood WI;
 XX
 DR WPI; 2003-585293/55.
 XX
 PT Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,
 PT PRO1787 that modulate glucose or free fatty acid uptake by skeletal
 PT muscle cells, and are useful for treating diabetes, hyper- or hypo-
 PT insulinemia.

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGTGCATGCGTGTCTGCGG 1486
 |||||
 Db 24 GGAGTGCATGCGTGTCTGCGG 1

RESULT 13
 ACDB68449
 ID ACDB68449 strand: DNA; 24 BP.
 XX
 AC ACDB68449;
 XX
 DT 17-SEP-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein related primer #85.
 XX
 KW Human; secreted and transmembrane protein; PRO; angiogenesis;
 KW endothelial cell proliferation; wound healing; immune response;
 KW T-lymphocytes proliferation; neonatal heart hypertrophy; tumour;
 KW cardiac insufficiency disorder; calcium flux; inflammation;

KW vascular endothelial growth factor-stimulated proliferation;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW nephropathy; Schnaefel-Henoch purpura; celiac disease; Crohn's disease;
KW dermatitis herpetiformis; diabetes; hemoglobin electrophoresis;
KW pancreatic beta-cell precursor cell differentiation; thalassemias;
KW obesity; auditory hair cell regeneration; hearing loss; bone disorder;
KW cartilage disorder; sports injury; arthritis; PCR; primer; ss.
XX Homo sapiens.
OS
PN US2003073130-A1.
XX
PD 17-APR-2003.
XX
PF 11-DEC-2001; 2001US-00015869.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099566P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-010216P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102309P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.

PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105002P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0106033P.
PR 27-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0108464P.
PR 30-NOV-1998; 98US-0108856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0108787P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108846P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144738P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.

PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US019941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-0096374.
XX
XX (GENTH) GENENTECH INC.
PI Baker KP, Boretstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-585293/55.
XX
PT Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 that modulate glucose or free fatty acid uptake by skeletal
PT muscle cells, and are useful for treating diabetes, hyper- or hypo-
PT insulinemia.
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No.8.7; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1041 GCTGACCTGTTCCCATCTACTCC 1064
DB 1 GCTGACCTGTTCCCATCTACTCC 24
RESULT 14
ACH04551
ID ACH04551 standard; DNA; 24 BP.
XX
XX ACH04551;
DT 01-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; vulnery;
KW cardiant; antidiabetic; anorectic; antiarthritic; angiogenesis; cancer;
KW adrenal cortical capillary; endothelial cell growth; wound healing;
KW stimulated T-lymphocyte proliferation; immune response suppression;
KW neonatal heart hypertrophy; cardiac insufficiency disorder;
KW vascular endothelial growth factor; inflammation; mononuclear cell;
KW eosinophil; diabetes; obesity; or hyper-insulinemia; hypo-insulinaemia;
KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
KW sports injury; arthritis; primer.
XX
OS Homo sapiens.

XX
PN US2003044841-A1.
XX
PD 06-MAR-2003.
XX
PF 06-DEC-2001; 2001US-00006856.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098536P.
PR 09-SEP-1998; 98US-0098596P.
PR 09-SEP-1998; 98US-0098598P.
PR 09-SEP-1998; 98US-0098602P.
PR 09-SEP-1998; 98US-0098642P.
PR 10-SEP-1998; 98US-0098741P.
PR 10-SEP-1998; 98US-0098754P.
PR 10-SEP-1998; 98US-0098763P.
PR 10-SEP-1998; 98US-0098792P.
PR 10-SEP-1998; 98US-0098808P.
PR 10-SEP-1998; 98US-0098812P.
PR 10-SEP-1998; 98US-0098815P.
PR 10-SEP-1998; 98US-0098816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 21-OCT-1998; 98US-0105002P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106565P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

PA (GENE) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-492259/46.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating various cardiac insufficiency
PT disorders, bone and/or cartilage disorders such as sports injuries and
PT arthritis.
XX

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24
|||||
|||

RESULT 15
ACH04552/c
ID ACH04552 standard; DNA; 24 BP.
XX
AC ACH04552;
XX
DT 01-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; vulnery;
KW cardiact; antidiabetic; anorectic; antiarthritic; angiogenesis; cancer;
KW adrenal cortical capillary; endothelial cell growth; wound healing;
KW stimulated T-lymphocyte proliferation; immune response suppression;
KW neonatal heart hypertrophy; cardiac insufficiency disorder;
KW vascular endothelial growth factor; inflammation; mononuclear cell;
KW endothelial; diabetes; obesity; or hyper-insulinaemia; hypo-insulinaemia;
KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
KW sports injury; arthritis; primer.
XX
OS Homo sapiens.
XX
PN US2003044841-A1.
XX
PD 06-MAR-2003.
XX
PF 06-DEC-2001; 2001US-00006856.
XX

PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102655P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.

PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106037P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106249P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0108500P.
PR 03-NOV-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106465P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107782P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-0109674P.
PR 05-JAN-1999; 99US-0109674P.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99US-0145698P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 16-DEC-1999; 99US-0162506P.
PR 05-JAN-2000; 2000US-05000219.
PR 06-JAN-2000; 2000US-05000376.
PR 11-FEB-2000; 2000US-05003565.
PR 18-FEB-2000; 2000US-05004342.
PR 24-FEB-2000; 2000US-05005004.
PR 02-MAR-2000; 2000US-05005841.
PR 15-MAR-2000; 2000US-05006884.
PR 17-MAY-2000; 2000US-05013705.
PR 22-MAY-2000; 2000US-05014042.
PR 30-MAY-2000; 2000US-05014941.

```
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GENTH ) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2003-492259/46.
XX
XX Novel secreted and transmembrane polypeptides and polynucleotides
XX encoding them useful for treating various cardiac insufficiency
XX disorders, bone and/or cartilage disorders such as sports injuries and
XX arthritis.
XX
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1463 GGAAGTGCATGGCTGCTGTCGG 1466
DB 24 GGAAGTGCATGGCTGCTGTCGG 1
XX
XX RESULT 16
XX ACD68096/C
XX ID ACD68096 standard; DNA; 24 BP.
XX AC ACD68096;
XX XX
XX DT 17-SEP-2003 (first entry)
XX DE
XX Novel human secreted and transmembrane protein related primer #86.
XX KW Human; secreted and transmembrane protein; PRO; gene therapy; vaccine;
XX KW tissue typing; chromosome identification; vaccine; PCR; primer; ss.
XX OS Homo sapiens.
XX XX
XX EN US2003073129-A1.
XX PD 17-APR-2003.
XX XX
XX PF 04-SEP-2001; 2001US-00946374.
XX XX
XX PR 01-SEP-1998; 98US-0098716P.
XX PR 01-SEP-1998; 98US-0098723P.
XX PR 01-SEP-1998; 98US-0098749P.
XX PR 01-SEP-1998; 98US-0098750P.
XX PR 02-SEP-1998; 98US-0098803P.
XX PR 02-SEP-1998; 98US-0098821P.
XX PR 02-SEP-1998; 98US-0098843P.
XX PR 09-SEP-1998; 98US-0099536P.
XX PR 09-SEP-1998; 98US-0099596P.
XX PR 09-SEP-1998; 98US-0099598P.
XX PR 09-SEP-1998; 98US-0099603P.
XX PR 09-SEP-1998; 98US-0099643P.
XX PR 10-SEP-1998; 98US-0099741P.
XX PR 10-SEP-1998; 98US-0099754P.
```

```
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-010385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100399P.
PR 16-SEP-1998; 98US-0100384P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 24-SEP-1998; 98US-0101917P.
PR 24-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105861P.
```

PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000356.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001US-0087035.
PR 01-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019692.

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
XX
PA (GENTH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-585292/55.
XX
XX
PT Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Example 85; Page 260; 561pp; English.
XX
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I), having at least 80% sequence identity to a sequence
CC selected from any one of the 123 amino acid sequences given in
XX
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAAGTGTCAAGCGGTCTGTGGG 1486
DB 24 GGAAGTGTCAAGCGGTCTGTGGG 1
|||||
RESULT 17
ACD68095
ID ACD68095 standard; DNA; 24 BP.
XX
AC ACD68095;
XX
DT 17-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein related primer #85.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy; vaccine;
XX tissue typing; chromosome identification; vaccine; PCR; primer; ss.
OS Homo sapiens.
XX
PN US2003073129-A1.
XX
PD 17-APR-2003.
XX
PF 04-SEP-2001; 2001US-00946374.
XX
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.

PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100663P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101915P.
PR 29-SEP-1998; 98US-0102071P.
PR 29-SEP-1998; 98US-0102072P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105633P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105883P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.

PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108847P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0145638P.
PR 01-SEP-1999; 99US-0145638P.
PR 15-SEP-1999; 99WO-US021194.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006684.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.

(GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnovers L, Eaton DI, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KO,

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI: 2003-585292/55.
XX Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX Example 85; Page 260; 561pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (1), having at least 80% sequence identity to a sequence
CC selected from any one of the 123 amino acid sequences given in

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCATCTACTCC 24

RESULT 18
ADCl8163/C
ID ADCl8163 standard; DNA; 24 BP.
XX ADCl8163;
AC ADCl8163;
XX 18-DEC-2003 (first entry)
DT 18-DEC-2003 (first entry)
XX Human PRO PCR primer #86.
DE Human PRO; PCR; ss; protein electrophoresis; chromosome mapping;
KW Human; PRO; PCR; ss; protein electrophoresis; chromosome mapping;
XX gene mapping; genetic disorder; primer.
XX Homo sapiens.
OS US2003064925-A1.
FN US2003064925-A1.
XX 03-APR-2003.
PD 03-APR-2003.
XX 10-DEC-2001; 2001US-00013907.
PF 10-DEC-2001; 2001US-00013907.
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.

PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100702P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101744P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 07-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 20-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0106082P.
PR 27-OCT-1998; 98US-0106083P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106024P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106346P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.

PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102655P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-010379P.
PR 08-OCT-1998; 98US-0104371P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-010633P.
PR 28-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106502P.
PR 03-NOV-1998; 98US-0106566P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.

PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114232P.
PR 05-JAN-1999; 99US-05000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-05020111.
PR 15-SEP-1999; 99US-05021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-05028313.
PR 02-DEC-1999; 99US-05028551.
PR 16-DEC-1999; 99US-05030095.
PR 05-JAN-2000; 2000US-05000219.
PR 06-JAN-2000; 2000US-05000376.
PR 11-FEB-2000; 2000US-05003565.
PR 18-FEB-2000; 2000US-05004342.
PR 24-FEB-2000; 2000US-05005004.
PR 02-MAR-2000; 2000US-05005841.
PR 15-MAR-2000; 2000US-05006884.
PR 17-MAY-2000; 2000US-05013705.
PR 22-MAY-2000; 2000US-05014042.
PR 30-MAY-2000; 2000US-05014941.
PR 02-JUN-2000; 2000US-05015264.
PR 23-JUN-2000; 2000US-05023522.
PR 24-AUG-2000; 2000US-05023328.
PR 08-NOV-2000; 2000US-05030952.
PR 10-NOV-2000; 2000US-05030873.
PR 01-DEC-2000; 2000US-05032678.
PR 28-FEB-2001; 2001US-05006520.
PR 01-MAR-2001; 2001US-05006666.
PR 01-JUN-2001; 2001US-05017800.
PR 20-JUN-2001; 2001US-05019692.
PR 29-JUN-2001; 2001US-05021066.
PR 09-JUL-2001; 2001US-05021735.
PR 04-SEP-2001; 2001US-00946374.

(GENTH) GENENTECH INC.
BAKER KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
Pan U, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK,
Williams PM, Wood WI;
WPI; 2003-555602/52.

XX Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
XX
XX Example 85; SEQ ID NO 293; 555pp; English.

XX The invention relates to human PRO polypeptides and the polynucleotides
XX encoding them. The sequences are useful in the preparation of a
CC medicament for treating a condition responsive to a PRO polypeptide. The
CC polypeptides are useful in a number of functional biological assays, as
CC molecular weight markers for protein electrophoresis and as therapeutic
CC agents. The polynucleotides are useful as hybridisation probes for a cDNA

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
      |||||
      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 20
ADD70809/c
ID      ADD70809 standard; DNA; 24 BP.
XX
XX      ADD70809;
AC
XX      15-JAN-2004 (first entry)
XX
XX      Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX      Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX      immune response; cardiac insufficiency disorder; calcium flux;
XX      umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX      arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX      Berger disease; neuropathy; Schonlein-Henoch purpura; coeliac disease;
XX      dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
OS      Homo sapiens.
XX
XX      US2003099625-A1.
XX
XX      29-MAY-2003.
PD
XX      12-DEC-2001; 2001US-00015386.
PF
XX      01-SEP-1998; 98US-0098716P.
PR      01-SEP-1998; 98US-0098723P.
XX
XX      01-SEP-1998; 98US-0098749P.
PR      01-SEP-1998; 98US-0098750P.
XX
XX      02-SEP-1998; 98US-0098803P.
PR      02-SEP-1998; 98US-0098821P.
XX
XX      02-SEP-1998; 98US-0098843P.
PR      02-SEP-1998; 98US-0099366P.
XX
XX      09-SEP-1998; 98US-0099596P.
PR      09-SEP-1998; 98US-0099598P.
XX
XX      09-SEP-1998; 98US-0099602P.
PR      09-SEP-1998; 98US-0099642P.
XX
XX      10-SEP-1998; 98US-0099741P.
PR      10-SEP-1998; 98US-0099754P.
XX
XX      10-SEP-1998; 98US-0099763P.
PR      10-SEP-1998; 98US-0099792P.
XX
XX      10-SEP-1998; 98US-0099808P.
PR      10-SEP-1998; 98US-0099812P.
XX
XX      10-SEP-1998; 98US-0099815P.
PR      10-SEP-1998; 98US-0099816P.
XX
XX      15-SEP-1998; 98US-0100385P.
PR      15-SEP-1998; 98US-0100388P.
XX
XX      15-SEP-1998; 98US-0100390P.
PR      15-SEP-1998; 98US-0100584P.
XX
XX      16-SEP-1998; 98US-0100627P.
PR      16-SEP-1998; 98US-0100661P.
XX
XX      16-SEP-1998; 98US-0100662P.
PR      16-SEP-1998; 98US-0100664P.
XX
XX      17-SEP-1998; 98US-0100683P.
PR      17-SEP-1998; 98US-0100684P.
XX
XX      17-SEP-1998; 98US-0100710P.
PR      17-SEP-1998; 98US-0100711P.
XX
XX      17-SEP-1998; 98US-0100919P.
PR      17-SEP-1998; 98US-0100930P.
XX
XX      18-SEP-1998; 98US-0100848P.
PR      18-SEP-1998; 98US-0100849P.
XX
XX      18-SEP-1998; 98US-0101014P.
PR      18-SEP-1998; 98US-0101068P.
XX
```

```
PR      18-SEP-1998; 98US-0101071P.
PR      22-SEP-1998; 98US-0101279P.
XX
XX      23-SEP-1998; 98US-0101471P.
PR      23-SEP-1998; 98US-0101472P.
XX
XX      23-SEP-1998; 98US-0101474P.
PR      23-SEP-1998; 98US-0101475P.
XX
XX      23-SEP-1998; 98US-0101476P.
PR      23-SEP-1998; 98US-0101477P.
XX
XX      23-SEP-1998; 98US-0101479P.
PR      24-SEP-1998; 98US-0101738P.
XX
XX      24-SEP-1998; 98US-0101741P.
PR      24-SEP-1998; 98US-0101743P.
XX
XX      24-SEP-1998; 98US-0101915P.
PR      24-SEP-1998; 98US-0101916P.
XX
XX      29-SEP-1998; 98US-0102207P.
PR      29-SEP-1998; 98US-0102240P.
XX
XX      29-SEP-1998; 98US-0102307P.
PR      29-SEP-1998; 98US-0102330P.
XX
XX      29-SEP-1998; 98US-0102331P.
PR      30-SEP-1998; 98US-0102484P.
XX
XX      30-SEP-1998; 98US-0102487P.
PR      30-SEP-1998; 98US-0102570P.
XX
XX      30-SEP-1998; 98US-0102571P.
PR      01-OCT-1998; 98US-0102684P.
XX
XX      02-OCT-1998; 98US-0102687P.
PR      06-OCT-1998; 98US-0102965P.
XX
XX      06-OCT-1998; 98US-0103258P.
PR      06-OCT-1998; 98US-0103449P.
XX
XX      07-OCT-1998; 98US-0103314P.
PR      07-OCT-1998; 98US-0103315P.
XX
XX      07-OCT-1998; 98US-0103328P.
PR      07-OCT-1998; 98US-0103352P.
XX
XX      07-OCT-1998; 98US-0103395P.
PR      07-OCT-1998; 98US-0103401P.
XX
XX      08-OCT-1998; 98US-0103633P.
PR      08-OCT-1998; 98US-0103678P.
XX
XX      08-OCT-1998; 98US-0103679P.
PR      08-OCT-1998; 98US-0103711P.
XX
XX      14-OCT-1998; 98US-0104257P.
PR      20-OCT-1998; 98US-0104987P.
XX
XX      20-OCT-1998; 98US-0105000P.
PR      20-OCT-1998; 98US-0105002P.
XX
XX      21-OCT-1998; 98US-0105104P.
PR      21-OCT-1998; 98US-0105169P.
XX
XX      22-OCT-1998; 98US-0105266P.
PR      26-OCT-1998; 98US-0105693P.
XX
XX      26-OCT-1998; 98US-0105694P.
PR      27-OCT-1998; 98US-0105807P.
XX
XX      27-OCT-1998; 98US-0105881P.
PR      27-OCT-1998; 98US-0105882P.
XX
XX      28-OCT-1998; 98US-0106023P.
PR      28-OCT-1998; 98US-0106029P.
XX
XX      28-OCT-1998; 98US-0106030P.
PR      28-OCT-1998; 98US-0106032P.
XX
XX      28-OCT-1998; 98US-0106178P.
PR      29-OCT-1998; 98US-0106248P.
XX
XX      29-OCT-1998; 98US-0106384P.
PR      29-OCT-1998; 98US-0108500P.
XX
XX      30-OCT-1998; 98US-0106464P.
PR      03-NOV-1998; 98US-0106856P.
XX
XX      03-NOV-1998; 98US-0106902P.
PR      03-NOV-1998; 98US-0106905P.
XX
XX      03-NOV-1998; 98US-0106919P.
PR      03-NOV-1998; 98US-0106932P.
XX
XX      03-NOV-1998; 98US-0106934P.
PR      10-NOV-1998; 98US-0107783P.
XX
XX      17-NOV-1998; 98US-0108775P.
PR      17-NOV-1998; 98US-0108779P.
XX
XX      17-NOV-1998; 98US-0108787P.
PR      17-NOV-1998; 98US-0108788P.
XX
XX      17-NOV-1998; 98US-0108801P.
```

PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-01000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-01502011.
PR 15-SEP-1999; 99US-01502119.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-01628313.
PR 02-DEC-1999; 99US-01628551.
PR 16-DEC-1999; 99US-01630095.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-0003565.
PR 18-FEB-2000; 2000US-0004342.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 15-MAR-2000; 2000US-0006884.
PR 17-MAY-2000; 2000US-0013705.
PR 22-MAY-2000; 2000US-0014042.
PR 30-MAY-2000; 2000US-0014941.
PR 02-JUN-2000; 2000US-0015264.
PR 23-AUG-2000; 2000US-0023522.
PR 24-AUG-2000; 2000US-0023528.
PR 08-NOV-2000; 2000US-0030952.
PR 10-NOV-2000; 2000US-0030873.
PR 01-DEC-2000; 2000US-0035678.
PR 28-FEB-2001; 2001US-0006520.
PR 01-MAR-2001; 2001US-0006666.
PR 01-JUN-2001; 2001US-0017800.
PR 20-JUN-2001; 2001US-0019692.
PR 29-JUN-2001; 2001US-0021066.
PR 09-JUL-2001; 2001US-0021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurey AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX
XX WPI, 2003-874602/81.
XX
XX Novel isolated PRO polypeptides e.g., PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
PT cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
XX
XX Example 85; SEQ ID NO 294; 553bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC

Query Match 1.0%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred.No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTATGGGTGTGTGGG 1486
|||||

DB 24 GGAAGTGTATGGGTGTGTGGG 1
1463
RESULT 21
ADD70808
ID ADD70808 standard; DNA; 24 BP.
XX
AC ADD70808;
XX
DT 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
DE
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003099625-A1.
XX
PD 29-MAY-2003.
XX
XX 12-DEC-2001; 2001US-00015386.
PF
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099603P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099793P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.

PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102310P.
PR 29-SEP-1998; 98US-0102311P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103439P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104357P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 22-OCT-1998; 98US-0105593P.
PR 26-OCT-1998; 98US-0105694P.
PR 26-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.

PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 98US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-014458P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX PA (GETH) GENENTECH INC.
XX Baker KP, Borstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godswest RJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX MPI; 2003-874602/81.
XX DR
XX PT Novel isolated PRO polypeptides e.g., PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
PT cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
XX
XX Example 85; SEQ ID NO 293; 553bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTTCCTACTCTCC 1064
Db 1 GCTGACCTGGTTCCTACTCTCC 24
RESULT 22
ADD39886/C
ID ADD39886 standard; DNA; 24 BP.
XX

AC	ADD39886;	
XX		
DT	15-JAN-2004	(first entry)
XX		
DE	Human secreted/transmembrane protein PRO1433 PCR primer #2.	
XX		
KW	Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour	
KW	immune response; cardiac insufficiency disorder; calcium flux;	
KW	umbilical vein endothelial cell; bone disorder; cartilage disorder;	
KW	arthritis; wound healing; diabetes; skeletal muscle cells; obesity;	
KW	Berger disease; neuropathy; Schonlein-Henoch purpura; colliac disease;	
KW	dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003083462-A1.	
XX		
PD	01-MAY-2003.	
XX		
PF	10-DEC-2001; 2001US-00013913.	
XX		
PR	05-JAN-1999;	99WO-US000106.
PR	01-SEP-1999;	99WO-US020111.
PR	15-SEP-1999;	99WO-US021194.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	16-DEC-1999;	99WO-US030095.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004342.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032878.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	04-SEP-2001;	2001US-00946374.
XX		
PA	(GENTH) GENENTECH INC.	
XX		
PI	Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;	
PI	Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;	
PI	Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;	
PI	Williams PM, Wood WI;	
XX		
DR	WPI: 2003-755122/71.	
XX		
PT	New secreted and transmembrane PRO polypeptides useful for treating	
PT	cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper-	
PT	hypo-insulinemia, sports injuries and arthritis.	
XX		
PS	Example 85; SEQ ID NO 294, 557pp: English.	
XX		
CC	The invention relates to an isolated PRO polypeptide (secreted or	
CC	transmembrane protein) having at least 80% amino acid sequence identity	
CC	to an amino acid sequence chosen from 123 fully defined sequences as	
CC	given in the specification (including their extracellular domains either	
CC	or without their associated signal peptides. Also include are the	
CC	nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a	
CC	host cell comprising the vector, producing PRO, a chimeric molecule	

CC		comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC		pro antibody. Pro is useful as molecular weight markers for protein
CC		electrophoresis and also for chromosome identification. PRO is also
CC		useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC		probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC		useful for generating transgenic animals or knock-out animals which are
CC		useful in development and screening useful reagents. PRO NA is also
CC		useful in gene therapy. PRO1244, PRO1266 and PRO1303 polypeptides are
CC		useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC		polypeptides are useful for suppressing immune response. PRO1246
CC		polypeptide is useful for treating cardiac insufficiency disorders.
CC		PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC		PRO1561 polypeptide are useful for stimulating calcium flux in human
CC		umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC		polypeptides are useful for treating bone and/or cartilage disorders
CC		(e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC		polypeptides are useful for treating diabetes in skeletal muscle cells
CC		and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC		treating Berger disease or other nephropathies associated with Schonlein-
CC		Hemoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC		disease. PRO1478, PRO1465, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC		PRO1410 and PRO1575 are useful in treating thalassaemias. The present
CC		sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC		the invention.
XX		
SO		Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
OY		
DB		
Query Match		1.0%; Score 24; DB 1; Length 24;
Best Local Similarity		100.0%; Pred. No. 8.7;
Matches	24; Conservative	0; Mismatches 0; Indels 0; Gaps 0
1463	GGAAGTGTCAATGGTGCTGTCGGC	1486
24	GGAAGTGTCAATGGTGCTGTCGGC	1
RESULT 23		
ADD39885		
ID	ADD39885 standard; DNA; 24 BP.	
XX		
AC	ADD39885;	
DT		
XX		
DE	15-JAN-2004 (first entry)	
XX		
DE	Human secreted/transmembrane protein PRO1433 PCR primer #1.	
XX		
KW	Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;	
KW	immune response; cardiac insufficiency disorder; calcium flux;	
KW	umbilical vein endothelial cell; bone disorder; cartilage disorder;	
KW	arthritis; wound healing; diabetes; skeletal muscle cells; obesity;	
KW	Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;	
XX	dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.	
OS	Homo sapiens.	
XX		
PN	US2003083462-A1.	
PD		
XX		
PF	01-MAY-2003.	
XX		
PF	10-DEC-2001; 2001US-00013913.	
XX		
PR	05-JAN-1999; 99WO-US000106.	
PR	01-SEP-1999; 99WO-US020111.	
PR	15-SEP-1999; 99WO-US021194.	
PR	30-NOV-1999; 99WO-US028313.	
PR	02-DEC-1999; 99WO-US028551.	
PR	16-DEC-1999; 99WO-US030095.	
PR	05-JAN-2000; 2000WO-US000219.	
PR	06-JAN-2000; 2000WO-US000376.	
PR	11-FEB-2000; 2000WO-US000565.	
PR	18-FEB-2000; 2000WO-US004342.	
PR	24-FEB-2000; 2000WO-US005004.	
PR	02-MAR-2000; 2000WO-US005841.	

PR 15-MAR-2000; 2000MO-US006884.
PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014042.
PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US015264.
PR 23-AUG-2000; 2000MO-US023522.
PR 24-AUG-2000; 2000MO-US023328.
PR 08-NOV-2000; 2000MO-US030952.
PR 10-NOV-2000; 2000MO-US030873.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
XX (GENTH) GENENTECH INC.

PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski FJ, Grimaldi JC, Gunney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX

DR MPI; 2003-755122/71.

PT New secreted and transmembrane PRO polypeptides useful for treating
PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
PT hypo-insulinemia, sports injuries and arthritis.

XX Example 85; SEQ ID NO 293; 557bp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the PRO
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. PRO is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, colliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

XX Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
|||||

DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 24
ADD70331

ID ADD70331 standard; DNA; 24 BP.

XX ADD70331;

XX 15-JAN-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #1.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX

OS Homo sapiens.

XX US2003054406-A1.

XX 20-MAR-2003.

PF 06-DEC-2001; 2001US-00006818.

XX 01-SEP-1998; 98US-0098716P.

PR 01-SEP-1998; 98US-0098723P.

PR 01-SEP-1998; 98US-0098749P.

PR 02-SEP-1998; 98US-0098803P.

PR 02-SEP-1998; 98US-0098821P.

PR 02-SEP-1998; 98US-0098843P.

PR 09-SEP-1998; 98US-0099536P.

PR 09-SEP-1998; 98US-0099596P.

PR 09-SEP-1998; 98US-0099602P.

PR 09-SEP-1998; 98US-0099642P.

PR 10-SEP-1998; 98US-0099741P.

PR 10-SEP-1998; 98US-0099754P.

PR 10-SEP-1998; 98US-0099792P.

PR 10-SEP-1998; 98US-0099793P.

PR 10-SEP-1998; 98US-0099808P.

PR 15-SEP-1998; 98US-0100388P.

PR 15-SEP-1998; 98US-0100390P.

PR 16-SEP-1998; 98US-0100584P.

PR 16-SEP-1998; 98US-0100627P.

PR 16-SEP-1998; 98US-0100661P.

PR 16-SEP-1998; 98US-0100662P.

PR 16-SEP-1998; 98US-0100664P.

PR 17-SEP-1998; 98US-0100683P.

PR 17-SEP-1998; 98US-0100684P.

PR 17-SEP-1998; 98US-0100710P.

PR 17-SEP-1998; 98US-0100711P.

PR 17-SEP-1998; 98US-0100911P.

PR 17-SEP-1998; 98US-0100930P.

PR 18-SEP-1998; 98US-0100848P.

PR 18-SEP-1998; 98US-0100849P.

PR 18-SEP-1998; 98US-0101014P.

PR 18-SEP-1998; 98US-0101068P.

PR 18-SEP-1998; 98US-0101071P.

PR 22-SEP-1998; 98US-0101279P.

PR 23-SEP-1998; 98US-0101471P.

PR 23-SEP-1998; 98US-0101472P.

PR 23-SEP-1998; 98US-0101474P.

PR 23-SEP-1998; 98US-0101475P.

PR 23-SEP-1998; 98US-0101476P.

PR	23-SEP-1998	98US-01014777
PR	23-SEP-1998	98US-01014792
PR	24-SEP-1998	98US-0101738P
PR	24-SEP-1998	98US-0101741P
PR	24-SEP-1998	98US-0101743P
PR	24-SEP-1998	98US-0101915P
PR	24-SEP-1998	98US-0101916P
PR	24-SEP-1998	98US-0102026P
PR	24-SEP-1998	98US-0102240P
PR	24-SEP-1998	98US-0102307P
PR	24-SEP-1998	98US-0102330P
PR	24-SEP-1998	98US-0102331P
PR	24-SEP-1998	98US-0102484P
PR	30-SEP-1998	98US-0102487P
PR	30-SEP-1998	98US-0102570P
PR	30-SEP-1998	98US-0102571P
PR	30-SEP-1998	98US-0102571P
PR	01-OCT-1998	98US-0102684P
PR	01-OCT-1998	98US-0102687P
PR	02-OCT-1998	98US-0102965P
PR	06-OCT-1998	98US-0103288P
PR	06-OCT-1998	98US-0103449P
PR	07-OCT-1998	98US-0103314P
PR	07-OCT-1998	98US-0103315P
PR	07-OCT-1998	98US-0103328P
PR	07-OCT-1998	98US-0103358P
PR	07-OCT-1998	98US-0103396P
PR	07-OCT-1998	98US-0103401P
PR	08-OCT-1998	98US-0103633P
PR	08-OCT-1998	98US-0103678P
PR	08-OCT-1998	98US-0103679P
PR	14-OCT-1998	98US-0103711P
PR	14-OCT-1998	98US-0104257P
PR	20-OCT-1998	98US-0104987P
PR	20-OCT-1998	98US-0105000P
PR	20-OCT-1998	98US-0105002P
PR	21-OCT-1998	98US-0105104P
PR	22-OCT-1998	98US-0105169P
PR	22-OCT-1998	98US-0105266P
PR	26-OCT-1998	98US-0105632P
PR	26-OCT-1998	98US-0105674P
PR	27-OCT-1998	98US-0105807P
PR	27-OCT-1998	98US-0105881P
PR	27-OCT-1998	98US-0105882P
PR	27-OCT-1998	98US-0106062P
PR	28-OCT-1998	98US-0106023P
PR	28-OCT-1998	98US-0106029P
PR	28-OCT-1998	98US-0106030P
PR	28-OCT-1998	98US-0106032P
PR	28-OCT-1998	98US-0106033P
PR	28-OCT-1998	98US-0106178P
PR	28-OCT-1998	98US-0106248P
PR	29-OCT-1998	98US-0106384P
PR	29-OCT-1998	98US-0106500P
PR	30-OCT-1998	98US-0106504P
PR	30-NOV-1998	98US-0106686P
PR	03-NOV-1998	98US-0106686P
PR	03-NOV-1998	98US-0106687P
PR	03-NOV-1998	98US-0106905P
PR	03-NOV-1998	98US-0106932P
PR	03-NOV-1998	98US-0106934P
PR	10-NOV-1998	98US-0107783P
PR	17-NOV-1998	98US-0108775P
PR	17-NOV-1998	98US-0108779P
PR	17-NOV-1998	98US-0108867P
PR	17-NOV-1998	98US-0108878P
PR	17-NOV-1998	98US-0108781P
PR	17-NOV-1998	98US-0108800P
PR	17-NOV-1998	98US-0108802P
PR	17-NOV-1998	98US-0108806P
PR	17-NOV-1998	98US-0108867P
PR	17-NOV-1998	98US-0108925P
PR	18-NOV-1998	98US-0108844P
PR	18-NOV-1998	98US-0108849P
PR	18-NOV-1998	98US-0108849P

```

PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-012674P.
PR 23-JUN-1999; 99US-014037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US015494.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botsstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;
XX Pi Gao W, Goddard A, Godowski RJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Pi Pan J, Peoni NF, Roy MA, Smith V, Stewart RA, Tumas D, Watanabe CK;
XX Pi Williams PM, Wood WI;
XX
XX WPI, 2003-708344/67.
XX
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
XX PT biological activity of cell, as molecular weight markers in protein
XX PT electrophoresis, for treating arthritis, tumor.
XX
XX PS Example 65; SEQ ID NO 293; 549pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0
OY 1041 GCTGACCTGGTTCCTACTACTCC
DB 1 GCTGACCTGGTTCCTACTACTCC 24
RESULT 25
ADD70332/c
ID ADD70332 standard; DNA; 24 BP.
XX

```

AC ADD70332;
XX 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR: primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003054406-A1.
XX
PD 20-MAR-2003.
XX
PF 06-DEC-2001; 2001US-0006818.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.

PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105841P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.

```
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0140137P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003555.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015254.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GERTH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-708344/67.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
XX Example 85; SEQ ID NO 294; 549pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAAGTGTATGGGTGTCTGTGGG 1486
DB 24 GGAAGTGTATGGGTGTCTGTGGG 1
XX
XX RESULT 26
XX ADD38452
XX ID ADD38452 standard; DNA; 24 BP.
XX
XX AC ADD38452;
XX
XX DT 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
```

```
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003096955-A1.
XX
XX 22-MAY-2003.
XX
XX 07-DEC-2001; 2001US-00012755.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100564P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100661P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100664P.
XX 17-SEP-1998; 98US-0100683P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100919P.
XX 17-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.
XX 18-SEP-1998; 98US-0100849P.
XX 18-SEP-1998; 98US-0101014P.
XX 18-SEP-1998; 98US-0101068P.
XX 18-SEP-1998; 98US-0101071P.
XX 22-SEP-1998; 98US-0101279P.
XX 23-SEP-1998; 98US-0101471P.
XX 23-SEP-1998; 98US-0101472P.
XX 23-SEP-1998; 98US-0101474P.
XX 23-SEP-1998; 98US-0101475P.
XX 23-SEP-1998; 98US-0101476P.
XX 23-SEP-1998; 98US-0101477P.
XX 23-SEP-1998; 98US-0101479P.
XX 24-SEP-1998; 98US-0101738P.
XX 24-SEP-1998; 98US-0101741P.
XX 24-SEP-1998; 98US-0101741P.
XX 24-SEP-1998; 98US-0101915P.
XX 24-SEP-1998; 98US-0101916P.
XX 29-SEP-1998; 98US-0102207P.
XX 29-SEP-1998; 98US-0102240P.
XX 29-SEP-1998; 98US-0102307P.
XX 29-SEP-1998; 98US-0102330P.
XX 29-SEP-1998; 98US-0102331P.
XX 30-SEP-1998; 98US-0102484P.
XX 30-SEP-1998; 98US-0102487P.
XX 30-SEP-1998; 98US-0102570P.
```

```
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106912P.
PR 03-NOV-1998; 98US-0106934P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108755P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108854P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0112266P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-US020111.
PR 15-SEP-1999; 99US-US021194.
PR 29-OCT-1999; 99US-0162506P.

PR 30-NOV-1999; 99US-US028313.
PR 02-DEC-1999; 99US-US028551.
PR 16-DEC-1999; 99US-US030095.
PR 05-JAN-2000; 2000US-US000219.
PR 06-JAN-2000; 2000US-US000376.
PR 11-FEB-2000; 2000US-US003565.
PR 18-FEB-2000; 2000US-US004342.
PR 24-FEB-2000; 2000US-US005004.
PR 02-MAR-2000; 2000US-US005841.
PR 15-MAR-2000; 2000US-US006884.
PR 17-MAR-2000; 2000US-US013705.
PR 22-MAY-2000; 2000US-US014042.
PR 30-MAY-2000; 2000US-US014941.
PR 02-JUN-2000; 2000US-US015264.
PR 23-AUG-2000; 2000US-US023522.
PR 24-AUG-2000; 2000US-US023328.
PR 08-NOV-2000; 2000US-US030952.
PR 10-NOV-2000; 2000US-US030873.
PR 01-DEC-2000; 2000US-US032678.
PR 28-FEB-2001; 2001US-US006520.
PR 01-MAR-2001; 2001US-US006666.
PR 01-JUN-2001; 2001US-US017800.
PR 20-JUN-2001; 2001US-US019692.
PR 29-JUN-2001; 2001US-US021066.
PR 09-JUL-2001; 2001US-US021735.
PR 04-SEP-2001; 2001US-00946374.

PA (GETH ) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX Williams PM, Wood WI;
XX WPI; 2003-787000/74.
XX
XX Novel isolated PRO polypeptide, useful for treating cancerous tumors,
XX cardiac insufficiency disorders, wound healing, diabetes mellitus,
XX thalassemias.
XX
XX Example 85; SEQ ID NO 293; 556bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 123 fully defined sequences as
XX CC

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCATCTACTCC 1064
DB 1 GCTGACCTGGTCCATCTACTCC 24

RESULT 27
ADD38453/C
ID ADD38453 standard; DNA; 24 BP.
XX
XX ADD38453;
AC
XX
XX ADD38453;
DT 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
XX dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
```

XX US2003096955-A1.
PN 22-MAY-2003.
XX
XX 07-DEC-2001; 2001US-00012755.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100948P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102584P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103458P.
PR 06-OCT-1998; 98US-0103499P.
PR 07-OCT-1998; 98US-0103314P.

PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105694P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106024P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106544P.
PR 03-NOV-1998; 98US-0106555P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106912P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108825P.
PR 17-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108845P.
PR 18-NOV-1998; 98US-0108845P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000MO-US005004.
PR 02-MAR-2000; 2000MO-US005841.
PR 15-MAR-2000; 2000MO-US006884.
PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014042.
PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US015264.
PR 23-AUG-2000; 2000MO-US023522.
PR 24-AUG-2000; 2000MO-US023328.
PR 08-NOV-2000; 2000MO-US030952.
PR 10-NOV-2000; 2000MO-US030873.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2003-787000/74.
XX
XX Novel isolated PRO polypeptide, useful for treating cancerous tumors,
PT cardiac insufficiency disorders, wound healing, diabetes mellitus,
PT thalassemias.
XX
XX Example 85; SEQ ID NO 294; 556pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAGTGTATGGTGTGTGTGCG 1486
Db 24 GGAAGTGTATGGTGTGTGTGCG 1

RESULT 28
ADD39408
ID ADD39408 standard; DNA; 24 BP.
XX
XX ADD39408;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
DE
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003096954-A1.
XX
XX 22-MAY-2003.
XX
XX 07-DEC-2001; 2001US-00011671.
XX

PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098951P.
PR 09-SEP-1998; 98US-0098956P.
PR 09-SEP-1998; 98US-0098986P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100386P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101067P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-010207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102448P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103335P.
PR 07-OCT-1998; 98US-0103336P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.

```
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106646P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US004342.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US030873.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX
XX (GENTECH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PM, Wood WI,
XX
XX WPI, 2003-786999/74.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
XX biological activity of cell, as molecular weight markers in protein
XX electrophoresis, for treating arthritis, tumor.
XX
XX Example 85; SEQ ID NO 293; 550pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1041 GCTGACCTGTTCCCATCTACTCC 1064
DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 29
ADD39409/C
ID ADD39409 standard; DNA; 24 BP.
XX
XX ADD39409;
AC
XX
XX 15-JAN-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; celliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003096954-A1.
PN
XX
XX 22-MAY-2003.
PD
XX
XX
XX
XX 07-DEC-2001; 2001US-00011671.
XX
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
```

PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-010179P.
PR 23-SEP-1998; 98US-010171P.
PR 23-SEP-1998; 98US-010172P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102955P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103388P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.

PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105159P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.

PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106062P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 30-OCT-1998; 98US-0106500P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106565P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99MO-US000106.
 PR 16-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99MO-US020111.
 PR 15-SEP-1999; 99MO-US021194.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99MO-US028313.
 PR 02-DEC-1999; 99MO-US028551.
 PR 16-DEC-1999; 99MO-US030095.
 PR 05-JAN-2000; 2000MO-US000219.
 PR 06-JAN-2000; 2000MO-US000376.
 PR 11-FEB-2000; 2000MO-US000365.
 PR 18-FEB-2000; 2000MO-US004342.
 PR 24-FEB-2000; 2000MO-US005004.
 PR 02-MAR-2000; 2000MO-US005841.
 PR 15-MAR-2000; 2000MO-US006884.
 PR 17-MAY-2000; 2000MO-US013705.
 PR 22-MAY-2000; 2000MO-US014941.
 PR 30-MAY-2000; 2000MO-US015264.
 PR 02-JUN-2000; 2000MO-US023522.
 PR 23-AUG-2000; 2000MO-US023528.
 PR 24-AUG-2000; 2000MO-US023128.
 PR 08-NOV-2000; 2000MO-US030552.
 PR 10-NOV-2000; 2000MO-US030873.
 PR 01-DEC-2000; 2000MO-US032678.
 PR 28-FEB-2001; 2001MO-US006520.
 PR 01-MAR-2001; 2001MO-US006666.
 PR 01-JUN-2001; 2001MO-US017800.
 PR 20-JUN-2001; 2001MO-US019992.
 PR 29-JUN-2001; 2001MO-US021066.
 PR 09-JUL-2001; 2001MO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX

PA (GETH) GENENTECH INC.
 XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski FU, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PM, Wood WI;
 XX WPI, 2003-765477/72.
 DR
 XX
 XX
 PT New isolated PRO polypeptide such as PRO1560, PRO444, PRO1018, PRO1773,
 PT PRO1244, PRO1246, useful for treating cancerous tumors, cardiac
 PT insufficiency disorders, wound healing, Crohn's disease, celiac disease.
 XX
 PS Example 85; SEQ ID NO 293; 555bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8,7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
 Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 31
 ADD38932/C
 ID ADD38932 standard; DNA; 24 BP.
 XX
 AC ADD38932;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; celiac disease;
 KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003092061-A1.
 PD 15-MAY-2003.
 XX
 PF 06-DEC-2001; 2001US-00007194.
 XX
 PR 01-SEP-1998; 98US-0098716P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.
 PR 02-SEP-1998; 98US-0098803P.
 PR 02-SEP-1998; 98US-0098821P.
 PR 02-SEP-1998; 98US-0098843P.
 PR 02-SEP-1998; 98US-0099536P.
 PR 09-SEP-1998; 98US-0099598P.
 PR 09-SEP-1998; 98US-0099602P.
 PR 09-SEP-1998; 98US-0099642P.
 PR 09-SEP-1998; 98US-0099741P.
 PR 10-SEP-1998; 98US-0099754P.
 PR 10-SEP-1998; 98US-0099763P.
 PR 10-SEP-1998; 98US-0099792P.
 PR 10-SEP-1998; 98US-0099808P.
 PR 10-SEP-1998; 98US-0099812P.
 PR 10-SEP-1998; 98US-0099815P.
 PR 10-SEP-1998; 98US-0099816P.
 PR 15-SEP-1998; 98US-0100385P.
 PR

```

PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 22-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101389P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103459P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106033P.

PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106565P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108852P.
PR 17-NOV-1998; 98US-0108853P.
PR 17-NOV-1998; 98US-0108854P.
PR 17-NOV-1998; 98US-0108855P.
PR 17-NOV-1998; 98US-0108856P.
PR 18-NOV-1998; 98US-0108857P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0112965P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004332.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PM, Wood WI,
XX

```

DR WPI: 2003-765477/72.
XX New isolated PRO polypeptide such as PRO1560, PRO444, PRO1018, PRO1773,
PT PRO1244, PRO1246, useful for treating cancerous tumors, cardiac disease,
PT insufficiency disorders, wound healing, Crohn's disease, celiac disease.
XX
XX Example 85; SEQ ID NO 294; 555pp; English.
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAGTGTGATGGTCTGTGCGG 1486
DB 24 GGAGTGTGATGGTCTGTGCGG 1
RESULT 32
ADD40362
ID ADD40362 standard; DNA; 24 BP.
XX
XX ADD40362;
AC
XX
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schomlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
XX
OS Homo sapiens.
XX
XX US2003082627-A1.
PD
XX 01-MAY-2003.
XX
PF 06-DEC-2001; 2001US-00006117.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.

PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102076P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-OCT-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.

XX 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107763P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108944P.
PR 22-DEC-1998; 98US-0113286P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99MO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145688P.
PR 01-SEP-1999; 99MO-US020111.
PR 15-SEP-1999; 99MO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99MO-US028313.
PR 02-DEC-1999; 99MO-US028551.
PR 16-DEC-1999; 99MO-US030095.
PR 05-JAN-2000; 2000MO-US000219.
PR 06-JAN-2000; 2000MO-US000376.
PR 11-FEB-2000; 2000MO-US003565.
PR 18-FEB-2000; 2000MO-US004342.
PR 24-FEB-2000; 2000MO-US005004.
PR 02-MAR-2000; 2000MO-US005841.
PR 15-MAR-2000; 2000MO-US006884.
PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014042.
PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US015264.
PR 23-AUG-2000; 2000MO-US023522.
PR 24-AUG-2000; 2000MO-US023328.
PR 08-NOV-2000; 2000MO-US030952.
PR 10-NOV-2000; 2000MO-US030873.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX WPI; 2003-755104/71.
XX

PT New isolated PRO polypeptides such as PRO1560, PRO444, PRO1018, PRO1773,
PT PRO1244, PRO1246 are useful for treating cancerous tumors and cardiac
PT insufficiency disorders.
XX

XX Example 85; SEQ ID NO 293; 550pp; English.

XX	CC	The invention relates to an isolated PRO polypeptide (secreted or
CC	transmembrane protein) having at least 80% amino acid sequence identity	
XX	10	
Query Match	1.0%; Score 24; DB 1; Length 24;	
Best Local Similarity	100.0%; Pred. No. 8.7;	
Matches	24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
OY	1041 GCTGACCTGGTTCCTACTCTCC 1064	
Db	1 GCTGACCTGGTTCCTACTCTCC 24	
RESULT 33		
ADD40363/c		
ID	ADD40363 standard; DNA; 24 BP.	
XX		
AC	ADD40363;	
XX		
DT	15-JAN-2004 (first entry)	
XX		
DE	Human secreted/transmembrane protein PRO1433 PCR primer #2.	
XX		
KW	Human; PC; primer; secreted protein; transmembrane protein; PRO; tumour;	
KW	immune response; cardiac insufficiency disorder; calcium flux;	
KW	umbilical vein endothelial cell; bone disorder; cartilage disorder;	
KW	arthritis; wound healing; diabetes; skeletal muscle cells; obesity;	
KW	Berger disease; nephropathy; Schönlein-Henoch purpura; colliac disease;	
KW	dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003082627-A1.	
XX		
PD	01-MAY-2003.	
XX		
PF	06-DEC-2001; 2001US-00006117.	
XX		
PR	01-SEP-1998; 98US-0098716P.	
PR	01-SEP-1998; 98US-0098723P.	
PR	01-SEP-1998; 98US-0098749P.	
PR	01-SEP-1998; 98US-0098750P.	
PR	02-SEP-1998; 98US-0098803P.	
PR	02-SEP-1998; 98US-0098821P.	
PR	02-SEP-1998; 98US-0098843P.	
PR	09-SEP-1998; 98US-0099536P.	
PR	09-SEP-1998; 98US-0099596P.	
PR	09-SEP-1998; 98US-0099598P.	
PR	09-SEP-1998; 98US-0099602P.	
PR	09-SEP-1998; 98US-0099642P.	
PR	10-SEP-1998; 98US-0099741P.	
PR	10-SEP-1998; 98US-0099754P.	
PR	10-SEP-1998; 98US-0099763P.	
PR	10-SEP-1998; 98US-0099792P.	
PR	10-SEP-1998; 98US-0099808P.	
PR	10-SEP-1998; 98US-0099812P.	
PR	10-SEP-1998; 98US-0099815P.	
PR	10-SEP-1998; 98US-0099816P.	
PR	15-SEP-1998; 98US-0100385P.	
PR	15-SEP-1998; 98US-0100388P.	
PR	15-SEP-1998; 98US-0100390P.	
PR	16-SEP-1998; 98US-0100544P.	
PR	16-SEP-1998; 98US-0100627P.	
PR	16-SEP-1998; 98US-0100661P.	
PR	16-SEP-1998; 98US-0100662P.	
PR	16-SEP-1998; 98US-0100664P.	
PR	17-SEP-1998; 98US-0100683P.	
PR	17-SEP-1998; 98US-0100684P.	
PR	17-SEP-1998; 98US-0100710P.	
PR	17-SEP-1998; 98US-0100711P.	
PR	17-SEP-1998; 98US-0100919P.	
PR	17-SEP-1998; 98US-0100930P.	
PR	18-SEP-1998; 98US-0100848P.	

PR	14-SEP-1998	98UTS-0100649P
PR	14-SEP-1998	98UTS-0100141P
PR	18-SEP-1998	98UTS-0101066P
PR	18-SEP-1998	98UTS-0101071P
PR	22-SEP-1998	98UTS-0101279P
PR	23-SEP-1998	98UTS-0101471P
PR	23-SEP-1998	98UTS-0101472P
PR	23-SEP-1998	98UTS-0101475P
PR	23-SEP-1998	98UTS-0101476P
PR	23-SEP-1998	98UTS-0101477P
PR	24-SEP-1998	98UTS-0101738P
PR	24-SEP-1998	98UTS-0101741P
PR	24-SEP-1998	98UTS-0101743P
PR	24-SEP-1998	98UTS-0101915P
PR	24-SEP-1998	98UTS-0101916P
PR	29-SEP-1998	98UTS-0102207P
PR	29-SEP-1998	98UTS-0102240P
PR	29-SEP-1998	98UTS-0102307P
PR	29-SEP-1998	98UTS-0102330P
PR	29-SEP-1998	98UTS-0102331P
PR	30-SEP-1998	98UTS-0102484P
PR	30-SEP-1998	98UTS-0102487P
PR	30-SEP-1998	98UTS-0102570P
PR	30-SEP-1998	98UTS-0102571P
PR	01-OCT-1998	98UTS-0102684P
PR	01-OCT-1998	98UTS-0102687P
PR	01-OCT-1998	98UTS-0102955P
PR	06-OCT-1998	98UTS-0103256P
PR	06-OCT-1998	98UTS-0103449P
PR	07-OCT-1998	98UTS-0103314P
PR	07-OCT-1998	98UTS-0103315P
PR	07-OCT-1998	98UTS-0103328P
PR	07-OCT-1998	98UTS-0103395P
PR	07-OCT-1998	98UTS-0103396P
PR	07-OCT-1998	98UTS-0103401P
PR	08-OCT-1998	98UTS-0103633P
PR	08-OCT-1998	98UTS-0103678P
PR	08-OCT-1998	98UTS-0103679P
PR	08-OCT-1998	98UTS-0103711P
PR	14-OCT-1998	98UTS-0104557P
PR	20-OCT-1998	98UTS-0104987P
PR	20-OCT-1998	98UTS-0105000P
PR	20-OCT-1998	98UTS-0105002P
PR	21-OCT-1998	98UTS-0105104P
PR	21-OCT-1998	98UTS-0105169P
PR	22-OCT-1998	98UTS-0105566P
PR	26-OCT-1998	98UTS-0105693P
PR	26-OCT-1998	98UTS-0105694P
PR	26-OCT-1998	98UTS-0105807P
PR	27-OCT-1998	98UTS-0105881P
PR	27-OCT-1998	98UTS-0105882P
PR	27-OCT-1998	98UTS-0106023P
PR	28-OCT-1998	98UTS-0106023P
PR	28-OCT-1998	98UTS-0106030P
PR	28-OCT-1998	98UTS-0106033P
PR	28-OCT-1998	98UTS-0106033P
PR	28-OCT-1998	98UTS-0106178P
PR	28-OCT-1998	98UTS-0106248P
PR	29-OCT-1998	98UTS-0106384P
PR	29-OCT-1998	98UTS-0106500P
PR	30-OCT-1998	98UTS-0106546P
PR	03-NOV-1998	98UTS-0106956P
PR	03-NOV-1998	98UTS-0106958P
PR	03-NOV-1998	98UTS-0106959P
PR	03-NOV-1998	98UTS-0106919P
PR	03-NOV-1998	98UTS-0106932P
PR	10-NOV-1998	98UTS-0106934P
PR	10-NOV-1998	98UTS-0107783P
PR	17-NOV-1998	98UTS-0108779P
PR	17-NOV-1998	98UTS-0108779P

PR	17-NOV-1998;	98US-0108787P.
PR	17-NOV-1998;	98US-0108788P.
PR	17-NOV-1998;	98US-0108801P.
PR	17-NOV-1998;	98US-0108802P.
PR	17-NOV-1998;	98US-0108806P.
PR	17-NOV-1998;	98US-0108807P.
PR	17-NOV-1998;	98US-0108857P.
PR	17-NOV-1998;	98US-0108925P.
PR	18-NOV-1998;	98US-0108848P.
PR	18-NOV-1998;	98US-0108849P.
PR	18-NOV-1998;	98US-0108850P.
PR	18-NOV-1998;	98US-0108851P.
PR	18-NOV-1998;	98US-0108852P.
PR	18-NOV-1998;	98US-0108858P.
PR	18-NOV-1998;	98US-0108904P.
PR	22-DEC-1998;	98US-0113296P.
PR	30-DEC-1998;	98US-0114223P.
PR	05-JAN-1999;	99WO-US000106.
PR	16-APR-1999;	99US-0129674P.
PR	20-JUL-1999;	99US-0141037P.
PR	26-JUL-1999;	99US-0144758P.
PR	01-SEP-1999;	99WO-US020111.
PR	15-SEP-1999;	99WO-US021194.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	16-DEC-1999;	99WO-US030095.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004342.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	04-SEP-2001;	2001US-00946374.
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;	
PI	Gao W, Goddard A, Godowski PJ, Girmaldi JC, Gunney AL, Hillan KJ,	
PI	Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;	
PI	Williams PM, Wood WJ;	
XX		
DX	WPI, 2003-755104/71.	
XX		
PT	New isolated PRO polypeptides such as PRO1560, PRO444, PRO1018, PRO1773,	
PT	PRO1444, PRO1246, are useful for treating cancerous tumors and cardiac	
PT	insufficiency disorders.	
XX		
PS	Example 85; SEQ ID NO 294; 550pp; English.	
XX		
CC	The invention relates to an isolated PRO polypeptide (secreted or	
CC	transmembrane protein) having at least 80% amino acid sequence identity	
Query Match	1.0%; Score 24; DB 1; Length 24;	
Best Local Similarity	100.0%; Pred. No. 8.7;	
Matches	24; Conservative 0; Mismatches 0; Indels 0; Gaps 0	

Qy 1463 GGAGGTCATGGTCTCTGGG 1486
Db 24 GGAGGTCATGGTCTCTGGG 1
RESULT 34
ADE50584/C
ID ADE50584 standard; DNA; 24 BP.
XX
XX ADE50584;
AC
XX
DT 29-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003069179-A1.
XX
XX 10-APR-2003.
XX
XX 11-DEC-2001; 2001US-00015393.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0098936P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 09-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.

PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105933P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105883P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.

```
PR 17-NOV-1998; 98US-0108925P.  
PR 18-NOV-1998; 98US-0108848P.  
PR 18-NOV-1998; 98US-0108849P.  
PR 18-NOV-1998; 98US-0108850P.  
PR 18-NOV-1998; 98US-0108851P.  
PR 18-NOV-1998; 98US-0108852P.  
PR 18-NOV-1998; 98US-0108858P.  
PR 18-NOV-1998; 98US-0108904P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 30-DEC-1998; 98US-0114223P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 16-APR-1999; 99US-0129674P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 15-SEP-1999; 99WO-US021194.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US030095.  
PR 16-DEC-1999; 99WO-US030095.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023528.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 04-SEP-2001; 2001US-00946374.  
XX  
PA (GENTH ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,  
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,  
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK,  
PI Williams PM, Wood WI;  
XX  
DR WPI; 2003-708395/67.  
XX  
PT Novel secreted and transmembrane PRO polypeptides useful in the  
PT preparation of a medicament for treating a condition responsive to PRO  
PT polypeptide and as therapeutic agents e.g. vaccines.  
XX  
PS Example 85; SEQ ID NO 294; 555bp; English.  
XX  
CC The invention relates to an isolated PRO polypeptide (secreted or  
CC transmembrane protein) having at least 80% amino acid sequence identity  
CC  
Query Match 1.0%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 8.7;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1463 GGAAGTGCATGGGTCTGTGGG 1486  
DB 24 GGAAGTGCATGGGTCTGTGGG 1  
RESULT 35
```

```
AD50583  
ID ADE50583 standard; DNA; 24 BP.  
XX  
AC ADE50583;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.  
XX  
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;  
KW immune response; cardiac insufficiency disorder; calcium flux;  
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;  
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;  
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;  
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2003069179-A1.  
XX  
PD 10-APR-2003.  
XX  
PF 11-DEC-2001; 2001US-00015393.  
XX  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 01-SEP-1998; 98US-0098749P.  
PR 01-SEP-1998; 98US-0098750P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 02-SEP-1998; 98US-0098936P.  
PR 09-SEP-1998; 98US-0098956P.  
PR 09-SEP-1998; 98US-0098959P.  
PR 09-SEP-1998; 98US-0098960P.  
PR 09-SEP-1998; 98US-0098964P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099792P.  
PR 10-SEP-1998; 98US-0099808P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 10-SEP-1998; 98US-0099815P.  
PR 10-SEP-1998; 98US-0099816P.  
PR 15-SEP-1998; 98US-0100385P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 15-SEP-1998; 98US-0100390P.  
PR 16-SEP-1998; 98US-0100584P.  
PR 16-SEP-1998; 98US-0100627P.  
PR 16-SEP-1998; 98US-0100661P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100710P.  
PR 17-SEP-1998; 98US-0100711P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100848P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 18-SEP-1998; 98US-0101071P.  
PR 22-SEP-1998; 98US-0101279P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101474P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101476P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 23-SEP-1998; 98US-0101479P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101741P.
```



```

PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108755P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.

```

```

PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US02678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US017800.
PR 01-JUN-2001; 2001WO-US019692.
PR 20-JUN-2001; 2001WO-US021066.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GENTH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2003-708395/67.
XX
XX Novel secreted and transmembrane PRO polypeptides useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide and as therapeutic agents e.g. vaccines.
XX
XX Example 85; SEQ ID NO 293; 555pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTTCCATCATCTACC 1064
Db 1 GCTGACCTGGTTCCATCTACTCC 24
RESULT 36
ADE20196/c
ID ADE20196 standard; DNA; 24 BP.
XX
XX ADE20196;
AC
XX
XX 29-JAN-2004 (first entry)
DT
XX

```

DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthralgia; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
XX
OS Homo sapiens.
XX
PN US2003092883-A1.
XX
PD 15-MAY-2003.
XX
PF 10-DEC-2001; 2001US-00013430.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098936P.
PR 09-SEP-1998; 98US-0098958P.
PR 09-SEP-1998; 98US-0098958P.
PR 09-SEP-1998; 98US-0098960P.
PR 09-SEP-1998; 98US-0098962P.
PR 10-SEP-1998; 98US-0098974P.
PR 10-SEP-1998; 98US-0098975P.
PR 10-SEP-1998; 98US-0098976P.
PR 10-SEP-1998; 98US-0098979P.
PR 10-SEP-1998; 98US-0098980P.
PR 10-SEP-1998; 98US-0098981P.
PR 10-SEP-1998; 98US-0098981P.
PR 15-SEP-1998; 98US-0100085P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101297P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.

PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 28-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106912P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.

PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028310.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Boretstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2003-765493/72.
XX
XX New isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.
XX
PS Example 85; SEQ ID NO 294; 555pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1 0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1463 GGAAGTGCATGCGTCTGTGCGG 1486
Db 24 GGAAGTGCATGCGTCTGTGCGG 1
RESULT 37
ADE20195
ID ADE20195 standard; DNA; 24 BP.
XX
AC ADE20195;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;

KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003092883-A1.
XX
PD 15-MAY-2003.
XX
PF 10-DEC-2001; 2001US-00013430.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099793P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0100627P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100392P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 01-OCT-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

```

PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103799P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105004P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106466P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141073P.
PR 23-JUN-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.

```

```

PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US030952.
PR 08-NOV-2000; 2000WO-US030973.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

```

(GETH) GENENTECH INC.

```

XX PA Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX PI Gao W, Goddard A, Goddard BJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Thomas D, Watanabe CK;
XX PI Williams PW, Wood WI;
XX MPI; 2003-765493/72.

```

```

PT New isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.

```

Example 85; SEQ ID NO 293; 555pp; English.

```

CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity

```

```

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064

```

```

Db 1 GCTGACCTGGTCCCATCTACTCC 24

```

RESULT 38

```

ID ADE50106 standard; DNA; 24 BP.

```

```

AC ADE50106;

```

```

DT 29-JAN-2004 (first entry)

```

```

DE Human secreted/transmembrane protein PRO1433 PCR primer #1.

```

```

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

```

```

OS Homo sapiens.

```

```

XX US2003082626-A1.

```

```

PN 01-MAY-2003.

```

XX 06-DEC-2001; 2001US-00006116.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100949P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101071P.
PR 23-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-010138P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-010349P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.

PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 26-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108804P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99MO-US000106.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0144037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99MO-US020111.
PR 15-SEP-1999; 99MO-US021194.
PR 18-OCT-1999; 99US-00403297.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99MO-US028313.
PR 02-DEC-1999; 99MO-US028551.
PR 16-DEC-1999; 99MO-US030095.
PR 05-JAN-2000; 2000MO-US000219.
PR 06-JAN-2000; 2000MO-US000376.
PR 11-FEB-2000; 2000MO-US003565.
PR 18-FEB-2000; 2000MO-US004342.

PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-765413/72.
XX
XX Novel isolated PRO polypeptides useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1041 GCTGACCTGGTTCCTACTCTCC 1064
Db 1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 39
ADE50107/C
ID ADE50107 standard; DNA; 24 BP.
XX
AC ADE50107;
XX
DT 29-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassaemia; ss.
XX
OS Homo sapiens.
XX
XX US2003082626-A1.
PN
XX
XX 01-MAY-2003.
PD
XX
PF 06-DEC-2001; 2001US-00006116.
XX
XX 01-SEP-1998; 98US-0098718P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.

PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098833P.
PR 09-SEP-1998; 98US-0099556P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100641P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 30-SEP-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.

```
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0108464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 30-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0114223P.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99US-0145698P.
PR 18-OCT-1999; 99US-00403297.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 16-DEC-1999; 99US-0162506P.
PR 05-JAN-2000; 2000US-0000212P.
PR 06-JAN-2000; 2000US-0000376P.
PR 11-FEB-2000; 2000US-00003565.
PR 18-FEB-2000; 2000US-0000342P.
PR 24-FEB-2000; 2000US-00005004.
PR 02-MAR-2000; 2000US-00005841.
PR 15-MAR-2000; 2000US-00005884.
PR 17-MAY-2000; 2000US-00014705.
PR 22-MAY-2000; 2000US-00014042.
PR 30-MAY-2000; 2000US-00014941.
PR 02-JUN-2000; 2000US-00015264.

PR 23-AUG-2000; 2000US-00023522.
PR 24-AUG-2000; 2000US-00023328.
PR 08-NOV-2000; 2000US-00030952.
PR 10-NOV-2000; 2000US-00030873.
PR 01-DEC-2000; 2000US-00032678.
PR 28-FEB-2001; 2001US-00006520.
PR 01-MAR-2001; 2001US-00006666.
PR 01-JUN-2001; 2001US-00072035.
PR 01-JUN-2001; 2001US-00072800.
PR 14-JUN-2001; 2001US-00082636.
PR 20-JUN-2001; 2001US-00082636.
PR 29-JUN-2001; 2001US-00082636.
PR 09-JUL-2001; 2001US-00082636.
PR 04-SEP-2001; 2001US-00082636.

PR (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK,
PI Williams PM, Wood WI;
XX WPI; 2003-765413/72.
XX
XX Novel isolated PRO polypeptides useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTATGCGGTCTCTGTCGCG 1486
DB 24 GGAAGTGTCTATGCGGTCTCTGTCGCG 1

RESULT 40
ID ADE21665 standard; DNA; 24 BP.
AC ADE21665;
XX
XX 29-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; celliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003082628-A1.
XX
XX 01-MAY-2003.
XX
XX 13-DEC-2001; 2001US-00017527.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099602P.
```

```

PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100390P.
PR 15-SEP-1998; 98US-0100398P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103799P.
PR 08-OCT-1998; 98US-0103799P.
PR 14-OCT-1998; 98US-0104571P.
PR 14-OCT-1998; 98US-0104577P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.

PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 28-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 29-OCT-1998; 98US-0106464P.
PR 30-OCT-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.
PR 05-JAN-1999; 98US-0129674P.
PR 16-APR-1999; 98US-0141037P.
PR 23-JUN-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 01-SEP-1999; 98US-0145698P.
PR 15-SEP-1999; 98US-0145698P.
PR 29-OCT-1999; 98US-0145698P.
PR 30-NOV-1999; 98US-0145698P.
PR 02-DEC-1999; 98US-0145698P.
PR 16-DEC-1999; 98US-0145698P.
PR 05-JAN-2000; 98US-0145698P.
PR 06-JAN-2000; 98US-0145698P.
PR 11-FEB-2000; 98US-0145698P.
PR 18-FEB-2000; 98US-0145698P.
PR 24-FEB-2000; 98US-0145698P.
PR 02-MAR-2000; 98US-0145698P.
PR 15-MAR-2000; 98US-0145698P.
PR 17-MAY-2000; 98US-0145698P.
PR 22-MAY-2000; 98US-0145698P.
PR 30-MAY-2000; 98US-0145698P.
PR 02-JUN-2000; 98US-0145698P.
PR 23-AUG-2000; 98US-0145698P.
PR 24-AUG-2000; 98US-0145698P.
PR 08-NOV-2000; 98US-0145698P.
PR 10-NOV-2000; 98US-0145698P.
PR 01-DEC-2000; 98US-0145698P.
PR 28-FEB-2001; 98US-0145698P.
PR 01-MAR-2001; 98US-0145698P.
PR 20-JUN-2001; 98US-0145698P.
PR 29-JUN-2001; 98US-0145698P.

```


PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2003-755105/71.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for treating
PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
PT hypo-inulinemia, sports injuries and arthritis.
XX
PS Example 85; SEQ ID NO 294; 548bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGGTCATGGGTCGTGTGGG 1486
DB 24 GGAGGTCATGGGTCGTGTGGG 1

RESULT 41
ADE21664
ID ADE21664 standard; DNA; 24 BP.
XX
XX ADE21664;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003082628-A1.
XX
PD 01-MAY-2003.
XX
PF 13-DEC-2001; 2001US-00017527.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0098836P.
PR 02-SEP-1998; 98US-0098956P.
PR 02-SEP-1998; 98US-0098962P.
PR 02-SEP-1998; 98US-00989642P.
PR 02-SEP-1998; 98US-00989741P.
PR 02-SEP-1998; 98US-00989754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.

PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105044P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.

PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0106500P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99US-00000106.
 PR 16-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99US-0145698P.
 PR 15-SEP-1999; 99US-0145698P.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99US-0162506P.
 PR 02-DEC-1999; 99US-0162506P.
 PR 16-DEC-1999; 99US-0162506P.
 PR 05-JAN-2000; 2000US-00000195.
 PR 06-JAN-2000; 2000US-00000376.
 PR 11-FEB-2000; 2000US-00000356.
 PR 18-FEB-2000; 2000US-00000342.
 PR 24-FEB-2000; 2000US-00000342.
 PR 02-MAR-2000; 2000US-00000341.
 PR 15-MAR-2000; 2000US-00000341.
 PR 17-MAR-2000; 2000US-00000341.
 PR 22-MAY-2000; 2000US-00000341.
 PR 30-MAY-2000; 2000US-00000341.
 PR 02-JUN-2000; 2000US-00000341.
 PR 23-AUG-2000; 2000US-00000341.
 PR 24-AUG-2000; 2000US-00000341.
 PR 08-NOV-2000; 2000US-00000341.
 PR 10-NOV-2000; 2000US-00000341.
 PR 01-DEC-2000; 2000US-00000341.
 PR 28-FEB-2001; 2001US-00000341.
 PR 01-MAR-2001; 2001US-00000341.
 PR 01-JUN-2001; 2001US-00000341.
 PR 20-JUN-2001; 2001US-00000341.
 PR 29-JUN-2001; 2001US-00000341.
 PR 09-JUL-2001; 2001US-00000341.
 PR 04-SEP-2001; 2001US-00000341.

(GETH) GENENTECH INC.
 Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PM, Wood WI;
 XX WPI; 2003-755105/71.
 DR WPI; 2003-755105/71.
 XX WPI; 2003-755105/71.
 PT Novel secreted and transmembrane PRO polypeptides useful for treating
 PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
 PT hypo-insulinemia, sports injuries and arthritis.
 XX
 PS Example 85; SEQ ID NO 293; 548bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGGTTCCCATCTACTCC 1064
 Db 1 GCTGACCTGGTTCCCATCTACTCC 24

RESULT 42
 ADF30089
 ID ADF30089 standard; DNA; 24 BP.
 XX
 AC ADF30089;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
 KW dermatitis; herpeticiformis; Cronn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003204053-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 10-DEC-2001; 2001US-00013915.
 XX
 XX 01-SEP-1998; 98US-0098716P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.
 PR 02-SEP-1998; 98US-0098803P.
 PR 02-SEP-1998; 98US-0098821P.
 PR 02-SEP-1998; 98US-0098843P.
 PR 09-SEP-1998; 98US-0098953P.
 PR 09-SEP-1998; 98US-0098956P.
 PR 09-SEP-1998; 98US-0098958P.
 PR 09-SEP-1998; 98US-0098960P.
 PR 09-SEP-1998; 98US-0098962P.
 PR 09-SEP-1998; 98US-0098964P.
 PR 10-SEP-1998; 98US-0098974P.
 PR 10-SEP-1998; 98US-0098975P.
 PR 10-SEP-1998; 98US-0098976P.
 PR 10-SEP-1998; 98US-0098979P.
 PR 10-SEP-1998; 98US-0098980P.
 PR 10-SEP-1998; 98US-0098982P.
 PR 10-SEP-1998; 98US-0098981P.
 PR 10-SEP-1998; 98US-0098981P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 16-SEP-1998; 98US-0100584P.
 PR 16-SEP-1998; 98US-0100627P.

PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 02-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103458P.
PR 06-OCT-1998; 98US-0103459P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106622P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.

PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108853P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.
XX Baker KP, Botstein D, Deameyers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski FV, Grimaldi JC, Gurney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PW, Wood WI;
XX MPI; 2003-900674/82.
XX New PRO nucleic acid, useful for the manufacture of a medicament for
XX diagnosing or treating tumor or for tissue typing.
XX Example 85; SEQ ID NO 293; 558pp; English.
PS

XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred No. 8.7; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 43
ADFF30090/c
ID ADFF30090 standard; DNA; 24 BP.

XX AC ADFF30090;

XX DT 12-FEB-2004 (first entry)

XX DE Human secreted/transmembrane protein PRO1433 PCR primer #2.

XX KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

XX OS Homo sapiens.

XX PN US2003204053-A1.

XX PD 30-OCT-2003.

XX PF 10-DEC-2001; 2001US-00013915.

XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.

PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105164P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106850P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.

PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-US020111.
PR 15-SEP-1999; 99US-US021194.
PR 30-NOV-1999; 99US-US028311.
PR 02-DEC-1999; 99US-US028551.
PR 16-DEC-1999; 99US-US030095.
PR 05-JAN-2000; 2000US-US000219.
PR 06-JAN-2000; 2000US-US000376.
PR 11-FEB-2000; 2000US-US003565.
PR 18-FEB-2000; 2000US-US004342.
PR 24-FEB-2000; 2000US-US005004.
PR 02-MAR-2000; 2000US-US005841.
PR 15-MAR-2000; 2000US-US006884.
PR 17-MAY-2000; 2000US-US013705.
PR 22-MAY-2000; 2000US-US014042.
PR 30-MAY-2000; 2000US-US014941.
PR 02-JUN-2000; 2000US-US015264.
PR 23-AUG-2000; 2000US-US023522.
PR 24-AUG-2000; 2000US-US023328.
PR 08-NOV-2000; 2000US-US030952.
PR 10-NOV-2000; 2000US-US030873.
PR 01-DEC-2000; 2000US-US032678.
PR 28-FEB-2001; 2001US-US006520.
PR 01-MAR-2001; 2001US-US006666.
PR 20-JUN-2001; 2001US-US017800.
PR 29-JUN-2001; 2001US-US019692.
PR 09-JUL-2001; 2001US-US021735.
PR 04-SEP-2001; 2001US-US0246374.
XX
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski P, Grimaldi JC, Gurney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PM, Wood WI;
XX
XX MPI; 2003-900674/82.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
XX diagnosing or treating tumor or for tissue typing.
XX
XX
XX Example 85; SEQ ID NO 294; 558bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 123 fully defined sequences as
XX given in the specification (including their extracellular domains either
XX or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches: 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAGTGTGATGGGTGTCTGTGGG 1486
DB 24 GGAGTGTGATGGGTGTCTGTGGG 1
RESULT 44
ADFS5982
ID ADFS5982 standard; DNA; 24 BP.
XX
XX ADFS5982;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; neuropathy; Schönlein-Henoch purpura; colliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003204054-A1.
XX
XX 30-OCT-2003.
XX
XX 11-DEC-2001; 2001US-00015394.
XX
XX
XX 17-NOV-1998; 98US-0108787P.
XX 01-SEP-1999; 99US-US020111.
XX 18-OCT-1999; 99US-US0403297.
XX 18-FEB-2000; 2000US-US004342.
XX 04-SEP-2001; 2001US-US0946374.
XX
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski P, Grimaldi JC, Gurney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PM, Wood WI;
XX
XX MPI; 2003-900675/82.
XX
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
XX diagnosing or treating tumor or for tissue typing.
XX
XX
XX Example 85; SEQ ID NO 293; 558bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 123 fully defined sequences as
XX given in the specification (including their extracellular domains either
XX or without their associated signal peptides. Also include are the
XX nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
XX host cell comprising the vector, producing PRO, a chimaeric molecule
XX comprising PRO fused to a heterologous amino acid sequence, and an anti-
XX PRO antibody. PRO is useful as molecular weight markers for protein
XX electrophoresis and also for chromosome identification. PRO is also
XX useful for tissue typing. PRO and PRO NA are useful as hybridisation
XX probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
XX useful for generating transgenic animals or knock-out animals which are
XX useful in development and screening useful reagents. PRO NA is also
XX useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
XX useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
XX polypeptides are useful for suppressing immune response. PRO1246
XX polypeptide is useful for treating cardiac insufficiency disorders.
XX PRO1246 polypeptide is also useful for treating tumours. PRO1246 and

CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1375 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1178, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

CC SQ Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCCATCTACTCC 1064
Db 1 GGTGACCTGGTCCCATCTACTCC 24

RESULT 45
ADFS5983/C
ID ADFS5983 standard; DNA; 24 BP.

AC ADFS5983;
XX
XX
XX
DT 12-FEB-2004 (first entry)
XX
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

XX
OS Homo sapiens.
XX
XX
PN US2003204054-A1.
XX
PD 30-OCT-2003.
XX
XX
PF 11-DEC-2001; 2001US-00015394.
XX
XX
PR 17-NOV-1998; 98US-0108787P.
PR 01-SEP-1998; 98WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
PA (GENTH) GENENTECH INC.
XX
XX
PI Baker KP, Bostein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX
DR WPI; 2003-900675/82.

XX New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.

XX
XX
PS Example 85; SEQ ID NO 294; 558bp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either

CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1265, and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

CC SQ Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTATGGTGTGTGTGGG 1486
Db 24 GGAAGTGTATGGTGTGTGTGGG 1

RESULT 46
ADH99486
ID ADH99486 standard; DNA; 24 BP.

AC ADH99486;
XX
XX
XX
DT 15-APR-2004 (first entry)
XX
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

XX
XX
OS Homo sapiens.
XX
XX
PN US2003065142-A1.
XX
PD 03-APR-2003.
XX
XX
PF 11-DEC-2001; 2001US-00015499.
XX
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.

```

PR 09-SEP-1998; 98US-0099538P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 17-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100930P.
PR 17-SEP-1998; 98US-0100931P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103388P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.

PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105633P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105822P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000105.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99WO-US020111.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000375.
PR 11-FEB-2000; 2000WO-US003365.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.

```

PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Baton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
DR WPI; 2003-567191/53.
XX
XX PT Novel secreted and transmembrane polypeptide useful identifying agonists
PT or antagonists of polypeptide, as molecular weight markers, and in tissue
PT typing.
XX
XX PS Example 85; SEQ ID NO 293; 553pp; English.
XX
XX CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTTCCTACTCTCC 1064
DB 1 GCTGACCTGGTTCCTACTCTCC 24
RESULT 47
ADH99487/c
ID ADH99487 standard; DNA; 24 BP.
XX
AC ADH99487;
XX
DT 15-APR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; Coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX PN US2003065142-A1.
XX
XX PD 03-APR-2003.
XX
XX PF 11-DEC-2001; 2001US-00015499.
XX
XX PR 01-SEP-1998; 98US-0098716P.
XX PR 01-SEP-1998; 98US-0098723P.
XX PR 01-SEP-1998; 98US-0098749P.
XX PR 01-SEP-1998; 98US-0098750P.
XX PR 02-SEP-1998; 98US-0098803P.
XX PR 02-SEP-1998; 98US-0098821P.
XX PR 02-SEP-1998; 98US-0098843P.
XX PR 02-SEP-1998; 98US-0099536P.
XX PR 02-SEP-1998; 98US-0099566P.
XX PR 02-SEP-1998; 98US-0099598P.
XX PR 02-SEP-1998; 98US-0099602P.
XX PR 02-SEP-1998; 98US-0099642P.
XX PR 02-SEP-1998; 98US-0099741P.
XX PR 02-SEP-1998; 98US-0099754P.
XX PR 02-SEP-1998; 98US-0099763P.
XX PR 10-SEP-1998; 98US-0099792P.
XX
XX PR 10-SEP-1998; 98US-0099808P.
XX PR 10-SEP-1998; 98US-0099812P.
XX PR 10-SEP-1998; 98US-0099815P.
XX PR 10-SEP-1998; 98US-0099816P.
XX PR 15-SEP-1998; 98US-0100385P.
XX PR 15-SEP-1998; 98US-0100388P.
XX PR 15-SEP-1998; 98US-0100390P.
XX PR 15-SEP-1998; 98US-0100584P.
XX PR 16-SEP-1998; 98US-0100627P.
XX PR 16-SEP-1998; 98US-0100661P.
XX PR 16-SEP-1998; 98US-0100662P.
XX PR 16-SEP-1998; 98US-0100663P.
XX PR 16-SEP-1998; 98US-0100684P.
XX PR 17-SEP-1998; 98US-0100684P.
XX PR 17-SEP-1998; 98US-0100710P.
XX PR 17-SEP-1998; 98US-0100711P.
XX PR 17-SEP-1998; 98US-0100919P.
XX PR 17-SEP-1998; 98US-0100930P.
XX PR 17-SEP-1998; 98US-0100848P.
XX PR 18-SEP-1998; 98US-0100849P.
XX PR 18-SEP-1998; 98US-0101014P.
XX PR 18-SEP-1998; 98US-0101068P.
XX PR 18-SEP-1998; 98US-0101071P.
XX PR 22-SEP-1998; 98US-0101279P.
XX PR 23-SEP-1998; 98US-0101471P.
XX PR 23-SEP-1998; 98US-0101472P.
XX PR 23-SEP-1998; 98US-0101474P.
XX PR 23-SEP-1998; 98US-0101475P.
XX PR 23-SEP-1998; 98US-0101476P.
XX PR 23-SEP-1998; 98US-0101477P.
XX PR 23-SEP-1998; 98US-0101479P.
XX PR 24-SEP-1998; 98US-0101738P.
XX PR 24-SEP-1998; 98US-0101741P.
XX PR 24-SEP-1998; 98US-0101743P.
XX PR 24-SEP-1998; 98US-0101915P.
XX PR 24-SEP-1998; 98US-0101916P.
XX PR 29-SEP-1998; 98US-0102207P.
XX PR 29-SEP-1998; 98US-0102240P.
XX PR 29-SEP-1998; 98US-0102307P.
XX PR 29-SEP-1998; 98US-0102330P.
XX PR 29-SEP-1998; 98US-0102331P.
XX PR 30-SEP-1998; 98US-0102484P.
XX PR 30-SEP-1998; 98US-0102487P.
XX PR 30-SEP-1998; 98US-0102570P.
XX PR 30-SEP-1998; 98US-0102571P.
XX PR 01-OCT-1998; 98US-0102684P.
XX PR 01-OCT-1998; 98US-0102687P.
XX PR 02-OCT-1998; 98US-0102965P.
XX PR 06-OCT-1998; 98US-0103258P.
XX PR 06-OCT-1998; 98US-0103449P.
XX PR 07-OCT-1998; 98US-0103314P.
XX PR 07-OCT-1998; 98US-0103315P.
XX PR 07-OCT-1998; 98US-0103328P.
XX PR 07-OCT-1998; 98US-0103395P.
XX PR 07-OCT-1998; 98US-0103396P.
XX PR 07-OCT-1998; 98US-0103401P.
XX PR 08-OCT-1998; 98US-0103633P.
XX PR 08-OCT-1998; 98US-0103679P.
XX PR 08-OCT-1998; 98US-0103711P.
XX PR 08-OCT-1998; 98US-0104257P.
XX PR 14-OCT-1998; 98US-0104987P.
XX PR 20-OCT-1998; 98US-0105000P.
XX PR 20-OCT-1998; 98US-0105002P.
XX PR 20-OCT-1998; 98US-0105003P.
XX PR 21-OCT-1998; 98US-0105104P.
XX PR 22-OCT-1998; 98US-0105169P.
XX PR 22-OCT-1998; 98US-0105266P.
XX PR 26-OCT-1998; 98US-0105693P.
XX PR 26-OCT-1998; 98US-0105694P.
XX PR 27-OCT-1998; 98US-0105807P.
XX PR 27-OCT-1998; 98US-0105811P.
XX PR 27-OCT-1998; 98US-0105822P.
XX PR 27-OCT-1998; 98US-0106062P.


```
PR 16-SEP-1998; 98US-0100584P.  
PR 16-SEP-1998; 98US-0100627P.  
PR 16-SEP-1998; 98US-0100661P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100710P.  
PR 17-SEP-1998; 98US-0100711P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100848P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 18-SEP-1998; 98US-0101071P.  
PR 22-SEP-1998; 98US-0101279P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101474P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101476P.  
PR 23-SEP-1998; 98US-0101479P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101741P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101915P.  
PR 24-SEP-1998; 98US-0101916P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102307P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102484P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.  
PR 07-OCT-1998; 98US-0103114P.  
PR 07-OCT-1998; 98US-0103315P.  
PR 07-OCT-1998; 98US-0103328P.  
PR 07-OCT-1998; 98US-0103395P.  
PR 07-OCT-1998; 98US-0103396P.  
PR 08-OCT-1998; 98US-0103401P.  
PR 08-OCT-1998; 98US-0103633P.  
PR 08-OCT-1998; 98US-0103678P.  
PR 08-OCT-1998; 98US-0103679P.  
PR 08-OCT-1998; 98US-0103711P.  
PR 14-OCT-1998; 98US-0104257P.  
PR 20-OCT-1998; 98US-0104987P.  
PR 20-OCT-1998; 98US-0105000P.  
PR 20-OCT-1998; 98US-0105002P.  
PR 21-OCT-1998; 98US-0105104P.  
PR 22-OCT-1998; 98US-0105169P.  
PR 22-OCT-1998; 98US-0105266P.  
PR 26-OCT-1998; 98US-0105693P.  
PR 26-OCT-1998; 98US-0105694P.  
PR 27-OCT-1998; 98US-0105807P.  
PR 27-OCT-1998; 98US-0105881P.  
PR 27-OCT-1998; 98US-0105882P.  
PR 28-OCT-1998; 98US-0106023P.  
PR 28-OCT-1998; 98US-0106029P.  
PR 28-OCT-1998; 98US-0106030P.  
PR 28-OCT-1998; 98US-0106032P.  
PR 28-OCT-1998; 98US-0106033P.  
PR 29-OCT-1998; 98US-0106178P.  
PR 29-OCT-1998; 98US-0106248P.  
PR 29-OCT-1998; 98US-0106384P.  
  
PR 29-OCT-1998; 98US-0108500P.  
PR 30-OCT-1998; 98US-0106464P.  
PR 03-NOV-1998; 98US-0106855P.  
PR 03-NOV-1998; 98US-0106902P.  
PR 03-NOV-1998; 98US-0106905P.  
PR 03-NOV-1998; 98US-0106919P.  
PR 03-NOV-1998; 98US-0106934P.  
PR 10-NOV-1998; 98US-0107783P.  
PR 17-NOV-1998; 98US-0108775P.  
PR 17-NOV-1998; 98US-0108779P.  
PR 17-NOV-1998; 98US-0108787P.  
PR 17-NOV-1998; 98US-0108788P.  
PR 17-NOV-1998; 98US-0108801P.  
PR 17-NOV-1998; 98US-0108802P.  
PR 17-NOV-1998; 98US-0108806P.  
PR 17-NOV-1998; 98US-0108807P.  
PR 17-NOV-1998; 98US-0108867P.  
PR 18-NOV-1998; 98US-0108925P.  
PR 18-NOV-1998; 98US-0108848P.  
PR 18-NOV-1998; 98US-0108849P.  
PR 18-NOV-1998; 98US-0108850P.  
PR 18-NOV-1998; 98US-0108851P.  
PR 18-NOV-1998; 98US-0108852P.  
PR 18-NOV-1998; 98US-0108858P.  
PR 18-NOV-1998; 98US-0108904P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 30-DEC-1998; 98US-0114223P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 16-APR-1999; 99US-0129674P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 15-SEP-1999; 99WO-US021194.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 16-DEC-1999; 99WO-US030095.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 04-SEP-2001; 2001US-00946374.  
  
(GETH ) GENENTECH INC.  
XX  
XX  
PI Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;  
PI Gao W, Goddard A, Godowsky PJ, Grimaldi JC, Gurney AB, Hillan KJ;  
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;  
PI Williams PM, Wood WI;  
XX  
XX WPI, 2004-021098/02.  
PT New secreted and transmembrane PRO nucleic acid, for use in molecular  
PT biology, chromosome and gene mapping, in generating antisense RNA and
```

PT DNA, in various diagnostic assays and in gene therapy.
XX
PS Example 85; SEQ ID NO 294; 552bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAGGTCATGCGTCTGTGGG 1486
DB 24 GGAGGTCATGCGTCTGTGGG 1
RESULT 49
ADE96666
ID ADE96666 standard; DNA; 24 BP.
XX
AC ADE96666;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
immune response; cardiac insufficiency disorder; calcium flux;
umbilical vein endothelial cell; bone disorder; cartilage disorder;
arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003195347-A1.
XX
PD 16-OCT-2003.
XX
PF 12-DEC-2001; 2001US-00015385.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100389P.
PR 15-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.

PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101272P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105812P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106063P.
PR 28-OCT-1998; 98US-0106069P.
PR 28-OCT-1998; 98US-0106073P.
PR 28-OCT-1998; 98US-0106074P.
PR 28-OCT-1998; 98US-0106075P.
PR 28-OCT-1998; 98US-0106076P.
PR 28-OCT-1998; 98US-0106077P.
PR 28-OCT-1998; 98US-0106078P.
PR 28-OCT-1998; 98US-0106079P.
PR 28-OCT-1998; 98US-0106080P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.

PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-US020111.
PR 15-SEP-1999; 99US-US021194.
PR 30-NOV-1999; 99US-US028313.
PR 02-DEC-1999; 99US-US028551.
PR 16-DEC-1999; 99US-US030095.
PR 05-JAN-2000; 2000US-US000219.
PR 06-JAN-2000; 2000US-US003376.
PR 11-FEB-2000; 2000US-US003565.
PR 18-FEB-2000; 2000US-US004342.
PR 24-FEB-2000; 2000US-US005004.
PR 02-MAR-2000; 2000US-US005841.
PR 15-MAR-2000; 2000US-US006884.
PR 17-MAY-2000; 2000US-US013705.
PR 22-MAY-2000; 2000US-US014042.
PR 30-MAY-2000; 2000US-US014941.
PR 02-JUN-2000; 2000US-US015264.
PR 23-AUG-2000; 2000US-US023522.
PR 24-AUG-2000; 2000US-US023528.
PR 08-NOV-2000; 2000US-US030952.
PR 10-NOV-2000; 2000US-US030873.
PR 01-DEC-2000; 2000US-US032678.
PR 28-FEB-2001; 2001US-US006520.
PR 01-MAR-2001; 2001US-US006666.
PR 01-JUN-2001; 2001US-US017800.
PR 20-JUN-2001; 2001US-US017800.
PR 29-JUN-2001; 2001US-US021066.
PR 09-JUL-2001; 2001US-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski P, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart RA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-021098/02.
XX
XX New secreted and transmembrane PRO nucleic acid, for use in molecular
PT biology, chromosome and gene mapping, in generating antisense RNA and
PT DNA, in various diagnostic assays and in gene therapy.
XX
XX Example 85; SEQ ID NO 293; 552pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as

CC given in the specification (including their extracellular domains either
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GGTGACCTGGTTCATCTACTCC 1064
DB 1 GGTGACCTGGTTCATCTACTCC 24
RESULT 50
ADP25977
ID ADP25977 standard; DNA; 24 BP.
XX
XX ADP25977;
XX
XX 12-FEB-2004 (first entry)
XX
XX DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human, PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthralgia; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
XX dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003199675-A1.
XX
XX 23-OCT-2003.
XX
XX PF 11-DEC-2001; 2001US-00015389.
XX
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100661P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100664P.
XX 17-SEP-1998; 98US-0100683P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100919P.
XX 17-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.
XX 18-SEP-1998; 98US-0100849P.
XX 18-SEP-1998; 98US-0101014P.

PR 18-SEP-1998; 98US-0101068P.
 PR 18-SEP-1998; 98US-0101071P.
 PR 22-SEP-1998; 98US-0101279P.
 PR 23-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101738P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102310P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102484P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0103314P.
 PR 07-OCT-1998; 98US-0103315P.
 PR 07-OCT-1998; 98US-0103328P.
 PR 07-OCT-1998; 98US-0103395P.
 PR 07-OCT-1998; 98US-0103966P.
 PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.
 PR 27-OCT-1998; 98US-0105881P.
 PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106062P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0106500P.
 PR 30-OCT-1998; 98US-0106644P.
 PR 03-NOV-1998; 98US-0106656P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.

PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 16-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 26-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021134.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023525.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 PA (GETH) GENENTECH INC.
 XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Pan Y, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PM, Wood WI;
 XX WPI, 2004-041394/04.
 DR Novel isolated PRO polypeptide useful for tissue typing, modulating
 PT biological activity of cell, as molecular weight markers in protein
 PT electrophoresis, for treating arthritis, tumor.
 XX Example 85; SEQ ID NO 293; 552bp; English.
 PS The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC
 Query Match 1.0%; Score 24; DB 1; Length 24;
 Beet Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1041 GGTGACCTGCTCCATCTACTCC 1064

```

Db          1  |||||
              GCTGACCTGATTCCTACTCTCC 24

RESULT 51
ADF25978/c
ID          ADF25978 standard; DNA; 24 BP.
XX
XX          ADF25978;
AC
XX
DT          12-FEB-2004 (first entry)
DE
XX          Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX          Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW          immune response; cardiac insufficiency disorder; calcium flux;
KW          umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW          arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW          Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW          dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX          Homo sapiens.
OS
XX          US200319675-A1.
PN
XX
XX          23-OCT-2003.
PD
XX          11-DEC-2001; 2001US-00015389.
PF
XX          01-SEP-1998; 98US-0098716P.
PR          01-SEP-1998; 98US-0098723P.
PR          01-SEP-1998; 98US-0098749P.
PR          01-SEP-1998; 98US-0098750P.
PR          02-SEP-1998; 98US-0098803P.
PR          02-SEP-1998; 98US-0098821P.
PR          02-SEP-1998; 98US-0098843P.
PR          09-SEP-1998; 98US-0099536P.
PR          09-SEP-1998; 98US-0099596P.
PR          09-SEP-1998; 98US-0099598P.
PR          09-SEP-1998; 98US-0099602P.
PR          09-SEP-1998; 98US-0099642P.
PR          10-SEP-1998; 98US-0099741P.
PR          10-SEP-1998; 98US-0099754P.
PR          10-SEP-1998; 98US-0099763P.
PR          10-SEP-1998; 98US-0099792P.
PR          10-SEP-1998; 98US-0099808P.
PR          10-SEP-1998; 98US-0099812P.
PR          10-SEP-1998; 98US-0099815P.
PR          10-SEP-1998; 98US-0099816P.
PR          15-SEP-1998; 98US-0100385P.
PR          15-SEP-1998; 98US-0100388P.
PR          15-SEP-1998; 98US-0100390P.
PR          16-SEP-1998; 98US-0100584P.
PR          16-SEP-1998; 98US-0100627P.
PR          16-SEP-1998; 98US-0100661P.
PR          16-SEP-1998; 98US-0100662P.
PR          16-SEP-1998; 98US-0100664P.
PR          17-SEP-1998; 98US-0100683P.
PR          17-SEP-1998; 98US-0100684P.
PR          17-SEP-1998; 98US-0100710P.
PR          17-SEP-1998; 98US-0100711P.
PR          17-SEP-1998; 98US-0100919P.
PR          17-SEP-1998; 98US-0100930P.
PR          18-SEP-1998; 98US-0100848P.
PR          18-SEP-1998; 98US-0100849P.
PR          18-SEP-1998; 98US-0101014P.
PR          18-SEP-1998; 98US-0101068P.
PR          18-SEP-1998; 98US-0101071P.
PR          22-SEP-1998; 98US-0101279P.
PR          23-SEP-1998; 98US-0101471P.
PR          23-SEP-1998; 98US-0101472P.
PR          23-SEP-1998; 98US-0101474P.
PR          23-SEP-1998; 98US-0101475P.

```

```

PR          23-SEP-1998; 98US-0101476P.
PR          23-SEP-1998; 98US-0101477P.
PR          23-SEP-1998; 98US-0101479P.
PR          24-SEP-1998; 98US-0101738P.
PR          24-SEP-1998; 98US-0101741P.
PR          24-SEP-1998; 98US-0101743P.
PR          24-SEP-1998; 98US-0101915P.
PR          24-SEP-1998; 98US-0101916P.
PR          29-SEP-1998; 98US-0102207P.
PR          29-SEP-1998; 98US-0102240P.
PR          29-SEP-1998; 98US-0102307P.
PR          29-SEP-1998; 98US-0102330P.
PR          29-SEP-1998; 98US-0102331P.
PR          30-SEP-1998; 98US-0102484P.
PR          30-SEP-1998; 98US-0102487P.
PR          30-SEP-1998; 98US-0102570P.
PR          30-SEP-1998; 98US-0102571P.
PR          01-OCT-1998; 98US-0102684P.
PR          01-OCT-1998; 98US-0102687P.
PR          02-OCT-1998; 98US-0102965P.
PR          06-OCT-1998; 98US-0103258P.
PR          06-OCT-1998; 98US-0103449P.
PR          07-OCT-1998; 98US-0103314P.
PR          07-OCT-1998; 98US-0103315P.
PR          07-OCT-1998; 98US-0103328P.
PR          07-OCT-1998; 98US-0103395P.
PR          07-OCT-1998; 98US-0103396P.
PR          07-OCT-1998; 98US-0103401P.
PR          08-OCT-1998; 98US-0103633P.
PR          08-OCT-1998; 98US-0103678P.
PR          08-OCT-1998; 98US-0103679P.
PR          08-OCT-1998; 98US-0103711P.
PR          14-OCT-1998; 98US-0104257P.
PR          20-OCT-1998; 98US-0104987P.
PR          20-OCT-1998; 98US-0105000P.
PR          20-OCT-1998; 98US-0105002P.
PR          21-OCT-1998; 98US-0105104P.
PR          22-OCT-1998; 98US-0105169P.
PR          22-OCT-1998; 98US-0105266P.
PR          26-OCT-1998; 98US-0105639P.
PR          26-OCT-1998; 98US-0105694P.
PR          27-OCT-1998; 98US-0105807P.
PR          27-OCT-1998; 98US-0105881P.
PR          27-OCT-1998; 98US-0105882P.
PR          27-OCT-1998; 98US-0106062P.
PR          28-OCT-1998; 98US-0106023P.
PR          28-OCT-1998; 98US-0106029P.
PR          28-OCT-1998; 98US-0106032P.
PR          28-OCT-1998; 98US-0106032P.
PR          28-OCT-1998; 98US-0106032P.
PR          28-OCT-1998; 98US-0106033P.
PR          28-OCT-1998; 98US-0106178P.
PR          29-OCT-1998; 98US-0106248P.
PR          29-OCT-1998; 98US-0106384P.
PR          29-OCT-1998; 98US-0108500P.
PR          30-OCT-1998; 98US-0106464P.
PR          03-NOV-1998; 98US-0106856P.
PR          03-NOV-1998; 98US-0106902P.
PR          03-NOV-1998; 98US-0106905P.
PR          03-NOV-1998; 98US-0106919P.
PR          03-NOV-1998; 98US-0106932P.
PR          10-NOV-1998; 98US-0106934P.
PR          17-NOV-1998; 98US-0108775P.
PR          17-NOV-1998; 98US-0108779P.
PR          17-NOV-1998; 98US-0108787P.
PR          17-NOV-1998; 98US-0108788P.
PR          17-NOV-1998; 98US-0108801P.
PR          17-NOV-1998; 98US-0108802P.
PR          17-NOV-1998; 98US-0108806P.
PR          17-NOV-1998; 98US-0108807P.
PR          17-NOV-1998; 98US-0108867P.
PR          17-NOV-1998; 98US-0108925P.
PR          18-NOV-1998; 98US-0108848P.

```


PR	24-SEP-1998;	98US-0101915P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102307P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102484P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	01-OCT-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103444P.
PR	07-OCT-1998;	98US-0103314P.
PR	07-OCT-1998;	98US-0103315P.
PR	07-OCT-1998;	98US-0103328P.
PR	07-OCT-1998;	98US-0103395P.
PR	07-OCT-1998;	98US-0103396P.
PR	08-OCT-1998;	98US-0103401P.
PR	08-OCT-1998;	98US-0103633P.
PR	08-OCT-1998;	98US-0103678P.
PR	08-OCT-1998;	98US-0103679P.
PR	14-OCT-1998;	98US-0103711P.
PR	14-OCT-1998;	98US-0104257P.
PR	20-OCT-1998;	98US-0104987P.
PR	20-OCT-1998;	98US-0105000P.
PR	20-OCT-1998;	98US-0105002P.
PR	21-OCT-1998;	98US-0105104P.
PR	22-OCT-1998;	98US-0105169P.
PR	22-OCT-1998;	98US-0105266P.
PR	26-OCT-1998;	98US-0105693P.
PR	26-OCT-1998;	98US-0105694P.
PR	27-OCT-1998;	98US-0105807P.
PR	27-OCT-1998;	98US-0105811P.
PR	27-OCT-1998;	98US-0105882P.
PR	28-OCT-1998;	98US-0106023P.
PR	28-OCT-1998;	98US-0106029P.
PR	28-OCT-1998;	98US-0106030P.
PR	28-OCT-1998;	98US-0106032P.
PR	28-OCT-1998;	98US-0106033P.
PR	28-OCT-1998;	98US-0106178P.
PR	29-OCT-1998;	98US-0106248P.
PR	29-OCT-1998;	98US-0106384P.
PR	29-OCT-1998;	98US-0108500P.
PR	30-OCT-1998;	98US-0106464P.
PR	03-NOV-1998;	98US-0106856P.
PR	03-NOV-1998;	98US-0106902P.
PR	03-NOV-1998;	98US-0106905P.
PR	03-NOV-1998;	98US-0106919P.
PR	03-NOV-1998;	98US-0106932P.
PR	10-NOV-1998;	98US-0106934P.
PR	10-NOV-1998;	98US-0107783P.
PR	17-NOV-1998;	98US-0108775P.
PR	17-NOV-1998;	98US-0108779P.
PR	17-NOV-1998;	98US-0108787P.
PR	17-NOV-1998;	98US-0108788P.
PR	17-NOV-1998;	98US-0108801P.
PR	17-NOV-1998;	98US-0108802P.
PR	17-NOV-1998;	98US-0108806P.
PR	17-NOV-1998;	98US-0108807P.
PR	17-NOV-1998;	98US-0108867P.
PR	17-NOV-1998;	98US-0108925P.
PR	18-NOV-1998;	98US-0108848P.
PR	18-NOV-1998;	98US-0108849P.
PR	18-NOV-1998;	98US-0108850P.
PR	18-NOV-1998;	98US-0108851P.
PR	18-NOV-1998;	98US-0108852P.
PR	18-NOV-1998;	98US-0108858P.
PR	18-NOV-1998;	98US-0108904P.
PR	22-DEC-1998;	98US-0113296P.
PR	22-DEC-1998;	98US-0113296P.
PR	30-DEC-1998;	98US-0114223P.
PR	05-JAN-1999;	99WO-US000106.
PR	16-APR-1999;	99US-0129674P.
PR	23-JUN-1999;	99US-0141037P.
PR	20-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	98US-0145698P.
PR	01-SEP-1999;	99WO-US020111.
PR	15-SEP-1999;	99WO-US021194.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	16-DEC-1999;	99WO-US030095.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004342.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015

KW	Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;	PR	30-SEP-1998;	98US-0102487P.
KW	immune response; cardiac insufficiency disorder; calcium flux;	PR	30-SEP-1998;	98US-0102570P.
KW	umbilical vein endothelial cell; bone disorder; cartilage disorder;	PR	30-SEP-1998;	98US-0102571P.
KW	arthritis; wound healing; diabetes; skeletal muscle cells; obesity;	PR	01-OCT-1998;	98US-0102684P.
KW	Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;	PR	01-OCT-1998;	98US-0102687P.
KW	dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.	PR	02-OCT-1998;	98US-0102965P.
OS		PR	06-OCT-1998;	98US-0103258P.
XX	Homo sapiens.	PR	06-OCT-1998;	98US-0103449P.
XX		PR	07-OCT-1998;	98US-0103314P.
XX	US2003198993-A1.	PR	07-OCT-1998;	98US-0103315P.
XX		PR	07-OCT-1998;	98US-0103328P.
XX		PR	07-OCT-1998;	98US-0103395P.
XX		PR	07-OCT-1998;	98US-0103396P.
XX		PR	07-OCT-1998;	98US-0103401P.
XX		PR	07-OCT-1998;	98US-0103633P.
XX		PR	08-OCT-1998;	98US-0103678P.
XX		PR	08-OCT-1998;	98US-0103679P.
XX		PR	08-OCT-1998;	98US-0103711P.
XX		PR	14-OCT-1998;	98US-0104257P.
XX		PR	20-OCT-1998;	98US-0104987P.
XX		PR	20-OCT-1998;	98US-0105000P.
XX		PR	20-OCT-1998;	98US-0105002P.
XX		PR	21-OCT-1998;	98US-0105104P.
XX		PR	22-OCT-1998;	98US-0105169P.
XX		PR	22-OCT-1998;	98US-0105266P.
XX		PR	26-OCT-1998;	98US-0105693P.
XX		PR	26-OCT-1998;	98US-0105694P.
XX		PR	27-OCT-1998;	98US-0105807P.
XX		PR	27-OCT-1998;	98US-0105811P.
XX		PR	27-OCT-1998;	98US-0105882P.
XX		PR	27-OCT-1998;	98US-0106023P.
XX		PR	28-OCT-1998;	98US-0106023P.
XX		PR	28-OCT-1998;	98US-0106029P.
XX		PR	28-OCT-1998;	98US-0106030P.
XX		PR	28-OCT-1998;	98US-0106032P.
XX		PR	28-OCT-1998;	98US-0106033P.
XX		PR	28-OCT-1998;	98US-0106178P.
XX		PR	29-OCT-1998;	98US-0106348P.
XX		PR	29-OCT-1998;	98US-0106384P.
XX		PR	29-OCT-1998;	98US-0108500P.
XX		PR	30-OCT-1998;	98US-0106464P.
XX		PR	30-NOV-1998;	98US-0106856P.
XX		PR	03-NOV-1998;	98US-0106902P.
XX		PR	03-NOV-1998;	98US-0106905P.
XX		PR	03-NOV-1998;	98US-0106919P.
XX		PR	03-NOV-1998;	98US-0106932P.
XX		PR	10-NOV-1998;	98US-0107783P.
XX		PR	17-NOV-1998;	98US-0108775P.
XX		PR	17-NOV-1998;	98US-0108779P.
XX		PR	17-NOV-1998;	98US-0108787P.
XX		PR	17-NOV-1998;	98US-0108788P.
XX		PR	17-NOV-1998;	98US-0108801P.
XX		PR	17-NOV-1998;	98US-0108802P.
XX		PR	17-NOV-1998;	98US-0108806P.
XX		PR	17-NOV-1998;	98US-0108807P.
XX		PR	17-NOV-1998;	98US-0108867P.
XX		PR	17-NOV-1998;	98US-0108925P.
XX		PR	18-NOV-1998;	98US-0108848P.
XX		PR	18-NOV-1998;	98US-0108849P.
XX		PR	18-NOV-1998;	98US-0108850P.
XX		PR	18-NOV-1998;	98US-0108851P.
XX		PR	18-NOV-1998;	98US-0108852P.
XX		PR	18-NOV-1998;	98US-0108856P.
XX		PR	18-NOV-1998;	98US-0108904P.
XX		PR	22-DEC-1998;	98US-0113296P.
XX		PR	30-DEC-1998;	98US-0114223P.
XX		PR	05-JAN-1999;	99WO-US000106.
XX		PR	16-APR-1999;	99US-0128674P.
XX		PR	23-JUN-1999;	99US-0141037P.
XX		PR	20-JUL-1999;	99US-0144758P.
XX		PR	26-JUL-1999;	99US-0145698P.
XX		PR	01-SEP-1999;	99WO-US020111.

PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
XX PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX PI Williams PM, Wood WT;
XX
XX WPI; 2004-041347/04.
XX
XX
XX Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,
XX PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
XX PT cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
XX
XX
XX Example 85; SEQ ID NO 293; 553pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX CC transmembrane protein) having at least 80% amino acid sequence identity
XX
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1041 GCTGACCTGTTCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCATCTACTCC 24
RESULT 54
ADP29612
ID ADF29612 standard; DNA; 24 BP.
XX
XX ADF29612;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX

OS Homo sapiens.
XX
XX US2003203401-A1.
XX
XX 30-OCT-2003.
PD
XX
PF 11-DEC-2001; 2001US-00015519.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0100381P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100662P.
XX 17-SEP-1998; 98US-0100664P.
XX 17-SEP-1998; 98US-0100683P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100919P.
XX 17-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.
XX 18-SEP-1998; 98US-0100849P.
XX 18-SEP-1998; 98US-0101014P.
XX 18-SEP-1998; 98US-0101014P.
XX 18-SEP-1998; 98US-0101068P.
XX 18-SEP-1998; 98US-0101071P.
XX 22-SEP-1998; 98US-0101271P.
XX 23-SEP-1998; 98US-0101471P.
XX 23-SEP-1998; 98US-0101472P.
XX 23-SEP-1998; 98US-0101472P.
XX 23-SEP-1998; 98US-0101474P.
XX 23-SEP-1998; 98US-0101475P.
XX 23-SEP-1998; 98US-0101476P.
XX 23-SEP-1998; 98US-0101477P.
XX 23-SEP-1998; 98US-0101477P.
XX 24-SEP-1998; 98US-0101738P.
XX 24-SEP-1998; 98US-0101741P.
XX 24-SEP-1998; 98US-0101743P.
XX 24-SEP-1998; 98US-0101915P.
XX 24-SEP-1998; 98US-0101916P.
XX 29-SEP-1998; 98US-0102207P.
XX 29-SEP-1998; 98US-0102240P.
XX 29-SEP-1998; 98US-0102307P.
XX 29-SEP-1998; 98US-0102330P.
XX 29-SEP-1998; 98US-0102331P.
XX 30-SEP-1998; 98US-0102484P.
XX 30-SEP-1998; 98US-0102487P.
XX 30-SEP-1998; 98US-0102570P.
XX 30-SEP-1998; 98US-0102571P.
XX 01-OCT-1998; 98US-0102584P.
XX 01-OCT-1998; 98US-0102687P.
XX 02-OCT-1998; 98US-0102965P.
XX 06-OCT-1998; 98US-0103258P.


```

XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.

PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103719P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99WO-US020111.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

```

PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US015264.
PR 23-AUG-2000; 2000MO-US023522.
PR 24-AUG-2000; 2000MO-US023528.
PR 08-NOV-2000; 2000MO-US030952.
PR 10-NOV-2000; 2000MO-US030973.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WJ;
XX
DR WPI; 2004-041478/04.
XX
XX
PT New isolated PRO polypeptide useful for tissue typing, modulating the
PT biological activity of a cell, as molecular weight markers in protein
PT electrophoresis, and for treating e.g. arthritis, or tumor.
XX
PS Example 85; SEQ ID NO 294; 551bp; English.
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAAGTCTATGGCTGCTCTGGG 1486
DB 24 GGAAGTCTATGGCTGCTCTGGG 1
RESULT 56
ADE97143
ID ADE97143 standard; DNA; 24 BP.
XX
AC ADE97143;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KM immune response; cardiac insufficiency disorder; calcium flux;
KM umbilical vein endothelial cell; bone disorder; cartilage disorder;
KM arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KM Berger disease; neuropathy; Schonlein-Henoch purpura; coeliac disease;
KM dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003195334-A1.
PD 16-OCT-2003.
XX
PF 07-DEC-2001; 2001US-00012753.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.

PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 15-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-010179P.
PR 22-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102310P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.

PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105663P.
PR 26-OCT-1998; 98US-0105684P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.

PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WJ;
XX
DR WPI; 2004-041280/04.
XX
PT New isolated PRO polypeptides useful for treating diseases such as cancer
PT and diabetes.
XX
PS Example 85; SEQ ID NO 293; 551bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24
|||||

RESULT 57
ADE97144/C
ID ADE97144 standard; DNA; 24 BP.
XX
XX ADE97144;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW Immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003195334-A1.
XX
PD 16-OCT-2003.
XX
PF 07-DEC-2001; 2001US-00012753.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.

PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101388P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102309P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102344P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 01-OCT-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103459P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.

PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 01-SEP-1999; 99WO-US020111.
PR 01-SEP-1999; 99WO-US021119.
PR 15-SEP-1999; 99WO-US021199.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030099.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030878.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PM, Wood WI;
 XX WPI; 2004-041280/04.
 XX
 PT New isolated PRO polypeptides useful for treating diseases such as cancer
 PT and diabetes.
 XX
 PS Example 85; SEQ ID NO 294; 551bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred.No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGGTCTCATGGGTCTCTGGG 1486
 DB 24 GGAGGTCTCATGGGTCTCTGGG 1

RESULT 58
 ADH03181
 ID ADH03181 standard; DNA; 24 BP.
 AC
 XX ADH03181;
 AC
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW Immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
 KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 OS
 XX
 PN US2003216562-A1.
 XX
 PD 20-NOV-2003.
 PF
 XX 12-DEC-2001; 2001US-00015390.
 XX
 PR 01-SEP-1998; 98US-0098716P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.
 PR 02-SEP-1998; 98US-0098803P.
 PR 02-SEP-1998; 98US-0098821P.
 PR 02-SEP-1998; 98US-0098843P.
 PR 02-SEP-1998; 98US-0098536P.
 PR 02-SEP-1998; 98US-0098566P.
 PR 02-SEP-1998; 98US-0098588P.
 PR 02-SEP-1998; 98US-0098602P.
 PR 02-SEP-1998; 98US-0098622P.
 PR 02-SEP-1998; 98US-0098741P.
 PR 02-SEP-1998; 98US-0098754P.
 PR 02-SEP-1998; 98US-0098763P.
 PR 02-SEP-1998; 98US-0098782P.
 PR 02-SEP-1998; 98US-0098808P.
 PR 02-SEP-1998; 98US-0098812P.
 PR 02-SEP-1998; 98US-0098815P.
 PR 02-SEP-1998; 98US-0098816P.

PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100388P.
 PR 15-SEP-1998; 98US-0100390P.
 PR 16-SEP-1998; 98US-0100584P.
 PR 16-SEP-1998; 98US-0100627P.
 PR 16-SEP-1998; 98US-0100641P.
 PR 16-SEP-1998; 98US-0100662P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 17-SEP-1998; 98US-0100683P.
 PR 17-SEP-1998; 98US-0100684P.
 PR 17-SEP-1998; 98US-0100710P.
 PR 17-SEP-1998; 98US-0100711P.
 PR 17-SEP-1998; 98US-0100911P.
 PR 17-SEP-1998; 98US-0100930P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0101014P.
 PR 18-SEP-1998; 98US-0101068P.
 PR 18-SEP-1998; 98US-0101071P.
 PR 22-SEP-1998; 98US-0101279P.
 PR 23-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101738P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102330P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102484P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0103314P.
 PR 07-OCT-1998; 98US-0103315P.
 PR 07-OCT-1998; 98US-0103328P.
 PR 07-OCT-1998; 98US-0103395P.
 PR 07-OCT-1998; 98US-0103396P.
 PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.
 PR 27-OCT-1998; 98US-0105881P.
 PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106062P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.

PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108948P.
PR 18-NOV-1998; 98US-0108949P.
PR 18-NOV-1998; 98US-0108950P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114232P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 22-MAY-2000; 2000WO-US01705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US039952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US016992.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurrey AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX
XX WPI, 2004-021867/02.

XX
PT Novel isolated PRO polypeptide useful for treating tumor, kidney
PT disorders, diabetes mellitus, thalassemias.
XX
XX Example 85; SEQ ID NO 293; 552pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGGTTCCTACTCTCC 1064
1 GCTGACCTGGTTCCTACTCTCC 24

Db
RESULT 59
ADH03182/c
ID ADH03182 standard; DNA; 24 BP.
XX
XX ADH03182;
AC
XX
XX 11-MAR-2004 (first entry)
DT
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR, primer; secreted protein; transmembrane protein; PRO; tumour;
XX Immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003216562-A1.
PN
XX
XX 20-NOV-2003.
PD
XX
XX 12-DEC-2001; 2001US-00015390.
PF
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100661P.
XX 16-SEP-1998; 98US-0100662P.

PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101747P.
PR 23-SEP-1998; 98US-0101755P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102077P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102584P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102655P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106454P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.

PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 98US-0129674P.
PR 23-JUN-1999; 98US-014037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX Pan J, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Gao W, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX Williams PM, Wood WI;
XX WPI; 2004-021867/02.
XX Novel isolated PRO polypeptide useful for treating tumor, kidney
XX disorders, diabetes mellitus, thalassemias.
XX Example 85; SEQ ID NO 294; 552pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
XX CC

CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTATGGGTCTCTGTGGG 1486

DB 24 GGAAGTGTATGGGTCTCTGTGGG 1

RESULT 60

ADH04135

ID ADH04135 standard; DNA; 24 BP.

AC ADH04135;

XX 11-MAR-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #1.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;

KW immune response; cardiac insufficiency disorder; calcium flux;

KW umbilical vein endothelial cell; bone disorder; cartilage disorder;

KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;

KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;

XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.

XX US2003220471-A1.

XX 27-NOV-2003.

PD 06-DEC-2001; 2001US-0006746.

XX 04-SEP-2001; 2001US-00946374.

PR (GENTH) GENENTECH INC.

XX Baker KP, Boretstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;

PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;

PI Williams PM, Wood WI;

XX WPI; 2004-010888/01.

XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful

PT in gene therapy, chromosome identification, tissue typing, or as

PT hybridization probes in chromosome and gene mapping.

XX Example 85; SEQ ID NO 293; 554bp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or

CC transmembrane protein) having at least 80% amino acid sequence identity

CC to an amino acid sequence chosen from 123 fully defined sequences as

CC given in the specification (including their extracellular domains either

CC or without their associated signal peptides. Also include are the

CC polypeptide is useful for treating cardiac insufficiency disorders.

CC PRO1246 polypeptide are also useful for treating tumours. PRO1246 and

CC PRO1561 polypeptides are useful for stimulating calcium flux in human

CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474

CC polypeptides are useful for treating bone and/or cartilage disorders

CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418

CC polypeptides are useful for treating diabetes in skeletal muscle cells

CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for

CC treating Berger disease or other nephropathies associated with Schönlein-

CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's

CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,

CC PRO1410 and PRO1575 are useful in treating thalassemias. The present

CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of

CC the invention.

XX Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064

DB 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 61

ADH04136/C

ID ADH04136 standard; DNA; 24 BP.

XX ADH04136;

XX 11-MAR-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #2.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;

KW immune response; cardiac insufficiency disorder; calcium flux;

KW umbilical vein endothelial cell; bone disorder; cartilage disorder;

KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;

KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;

XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.

XX US2003220471-A1.

XX 27-NOV-2003.

PD 06-DEC-2001; 2001US-0006746.

XX 04-SEP-2001; 2001US-00946374.

PR (GENTH) GENENTECH INC.

XX Baker KP, Boretstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;

PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;

CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancersous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassaemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.
XX
SQ Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAAGTGCATGCGGTCTGTGGG 1486
|||
24 GGAAGTGCATGCGGTCTGTGGG 1
Db
RESULT 62
ADH03659/C
ID ADH03659 standard; DNA; 24 BP.
XX
AC ADH03659;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
XX
OS Homo sapiens.
XX
ID US2003224478-A1.
XX
PN 04-DEC-2003.
XX
PD 21-AUG-2002; 2002US-00226254.
XX
PE 29-OCT-1999; 99US-0162506P.
XX
PR 18-FEB-2000; 2000MO-US004342.
XX
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart RA, Tumas D, Watanabe CK,
PI Williams FM, Wood WI;

XX
DR WPI; 2004-022072/02.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acid
PT molecules, useful in gene therapy, or preparing a medicament for treating
PT a condition that is responsive to the PRO polypeptide or anti-PRO
PT antibody, e.g. cancer.
XX
PS Example 85; SEQ ID NO 294; 557bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancersous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassaemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.
XX
SQ Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAAGTGCATGCGGTCTGTGGG 1486
|||
24 GGAAGTGCATGCGGTCTGTGGG 1
Db
RESULT 63
ADH03658
ID ADH03658 standard; DNA; 24 BP.
XX
AC ADH03658;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.
XX
XX Homo sapiens.
XX
OS US2003224478-A1.
XX
XX

XX 04-DEC-2003.
PD
XX
PF 21-AUG-2002; 2002US-00226254.
XX
PR 29-OCT-1999; 99US-0162506P.
PR 18-FEB-2000; 2000WO-US004342.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Goddard PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumes D, Watanabe CK;
PI Williams PM, Wood WT;
XX
DR MPI; 2004-022072/02.
XX
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acid
PT molecules, useful in gene therapy, or preparing a medicament for treating
PT a condition that is responsive to the PRO polypeptide or anti-PRO
PT antibody, e.g. cancer.
XX
XX
PS Example 85; SEQ ID NO 293; 557bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. PRO is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1312, PRO1279, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.
XX
XX
SQ Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 8; 7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1041 GGTGACCTGGTTCCTACTCTCC 1064
DB 1 GGTGACCTGGTTCCTACTCTCC 24
XX
XX
XX RESULT 64
XX ADH04613/C
XX ID ADH04613 standard; DNA; 24 BP.
XX
XX
XX ADH04613;
AC

XX
DT 25-MAR-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2004005626-A1.
XX
XX
XX 08-JAN-2004.
XX
XX
XX 07-DEC-2001; 2001US-00011795.
XX
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100628P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101016P.
PR 18-SEP-1998; 98US-0101068P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101736P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101745P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
XX

PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102307P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102484P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
PR	07-OCT-1998;	98US-0103314P.
PR	07-OCT-1998;	98US-0103315P.
PR	07-OCT-1998;	98US-0103328P.
PR	07-OCT-1998;	98US-0103395P.
PR	07-OCT-1998;	98US-0103401P.
PR	08-OCT-1998;	98US-0103633P.
PR	08-OCT-1998;	98US-0103678P.
PR	08-OCT-1998;	98US-0103679P.
PR	14-OCT-1998;	98US-0103711P.
PR	14-OCT-1998;	98US-0104257P.
PR	20-OCT-1998;	98US-0104987P.
PR	20-OCT-1998;	98US-0105000P.
PR	20-OCT-1998;	98US-0105002P.
PR	21-OCT-1998;	98US-0105104P.
PR	22-OCT-1998;	98US-0105169P.
PR	22-OCT-1998;	98US-0105266P.
PR	26-OCT-1998;	98US-0105693P.
PR	26-OCT-1998;	98US-0105694P.
PR	27-OCT-1998;	98US-0105807P.
PR	27-OCT-1998;	98US-0105881P.
PR	27-OCT-1998;	98US-0105882P.
PR	27-OCT-1998;	98US-0106062P.
PR	28-OCT-1998;	98US-0106023P.
PR	28-OCT-1998;	98US-0106029P.
PR	28-OCT-1998;	98US-0106030P.
PR	28-OCT-1998;	98US-0106032P.
PR	28-OCT-1998;	98US-0106033P.
PR	29-OCT-1998;	98US-0106178P.
PR	29-OCT-1998;	98US-0106248P.
PR	29-OCT-1998;	98US-0106384P.
PR	29-OCT-1998;	98US-0108500P.
PR	30-OCT-1998;	98US-0106464P.
PR	03-NOV-1998;	98US-0106856P.
PR	03-NOV-1998;	98US-0106902P.
PR	03-NOV-1998;	98US-0106905P.
PR	03-NOV-1998;	98US-0106919P.
PR	03-NOV-1998;	98US-0106932P.
PR	03-NOV-1998;	98US-0106934P.
PR	10-NOV-1998;	98US-0107783P.
PR	17-NOV-1998;	98US-0108775P.
PR	17-NOV-1998;	98US-0108779P.
PR	17-NOV-1998;	98US-0108787P.
PR	17-NOV-1998;	98US-0108788P.
PR	17-NOV-1998;	98US-0108801P.
PR	17-NOV-1998;	98US-0108802P.
PR	17-NOV-1998;	98US-0108806P.
PR	17-NOV-1998;	98US-0108807P.
PR	17-NOV-1998;	98US-0108867P.
PR	17-NOV-1998;	98US-0108925P.
PR	18-NOV-1998;	98US-0108848P.
PR	18-NOV-1998;	98US-0108849P.
PR	18-NOV-1998;	98US-0108850P.
PR	18-NOV-1998;	98US-0108851P.
PR	18-NOV-1998;	98US-0108852P.
PR	18-NOV-1998;	98US-0108858P.
PR	18-NOV-1998;	98US-0108904P.
PR	22-DEC-1998;	98US-0113296P.
PR	30-DEC-1998;	98US-0114423P.
PR	05-JAN-1999;	99WO-US000106.

PR	16-APR-1999;	99US-0129674P.
PR	23-JUN-1999;	99US-0141037P.
PR	20-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	99US-0145698P.
PR	01-SEP-1999;	99WO-US020111.
PR	15-SEP-1999;	99WO-US021194.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	16-DEC-1999;	99WO-US030095.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004342.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-JUN-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR		

KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX Homo sapiens.
OS
PN US2004005626-A1.
XX
PD 08-JAN-2004.
XX
PF 07-DEC-2001; 2001US-00011795.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.

PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103711P.
PR 08-OCT-1998; 98US-0104257P.
PR 14-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108853P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0111296P.
PR 30-DEC-1998; 98US-0114233P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.

PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KF, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PM, Wood WI;
 XX
 DR WPI; 2004-081719/08.
 XX
 PT Novel isolated PRO polypeptide, useful for treating diabetes mellitus,
 PT cancerous tumors, cardiac insufficiency disorders, thalassemia,
 PT arthritis.
 XX
 PS Example 85; SEQ ID NO 293; 563bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC
 Query Match 1 0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1041 GCTGACCTGGTCCATCTACTCC 1064
 DB 1 GCTGACCTGGTCCATCTACTCC 24
 RESULT 66
 ADH61613
 ID ADH61613 standard; DNA; 24 BP.
 XX
 AC ADH61613;
 XX
 DT 22-APR-2004 (first entry)
 XX
 XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
 KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX

PN US2004014130-A1.
 XX
 PD 22-JAN-2004.
 XX
 XX 07-DEC-2001; 2001US-00012231.
 XX
 PR 01-SEP-1998; 98US-0098715P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.
 PR 02-SEP-1998; 98US-0098803P.
 PR 02-SEP-1998; 98US-0098821P.
 PR 09-SEP-1998; 98US-0098843P.
 PR 09-SEP-1998; 98US-0098935P.
 PR 09-SEP-1998; 98US-0099596P.
 PR 09-SEP-1998; 98US-0099598P.
 PR 09-SEP-1998; 98US-0099602P.
 PR 09-SEP-1998; 98US-0099642P.
 PR 10-SEP-1998; 98US-0099741P.
 PR 10-SEP-1998; 98US-0099754P.
 PR 10-SEP-1998; 98US-0099763P.
 PR 10-SEP-1998; 98US-0099792P.
 PR 10-SEP-1998; 98US-0099808P.
 PR 10-SEP-1998; 98US-0099812P.
 PR 10-SEP-1998; 98US-0099815P.
 PR 15-SEP-1998; 98US-0099815P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100388P.
 PR 15-SEP-1998; 98US-0100390P.
 PR 16-SEP-1998; 98US-0100584P.
 PR 16-SEP-1998; 98US-0100627P.
 PR 16-SEP-1998; 98US-0100661P.
 PR 16-SEP-1998; 98US-0100662P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 17-SEP-1998; 98US-0100683P.
 PR 17-SEP-1998; 98US-0100684P.
 PR 17-SEP-1998; 98US-0100710P.
 PR 17-SEP-1998; 98US-0100711P.
 PR 17-SEP-1998; 98US-0100931P.
 PR 17-SEP-1998; 98US-0100930P.
 PR 18-SEP-1998; 98US-0100848P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0101014P.
 PR 18-SEP-1998; 98US-0101068P.
 PR 18-SEP-1998; 98US-0101071P.
 PR 22-SEP-1998; 98US-0101279P.
 PR 23-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101473P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101738P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102330P.
 PR 30-SEP-1998; 98US-0102344P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0103314P.
 PR 07-OCT-1998; 98US-0103315P.

PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105593P.
PR 26-OCT-1998; 98US-0105594P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114232P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAR-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
PA (GENTECH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX
XX WPI; 2004-108212/11.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
XX
PS Example 85; SEQ ID NO 293; 562pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
Query Match 100%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGTTCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCATCTACTCC 24
RESULT 67
ADH61614/C
ID ADH61614 standard; DNA; 24 BP.
XX
AC ADH61614;
XX
XX
DT 22-APR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Cronin's disease; thalassemia; ss.
XX
XX Homo sapiens.
OS
XX
PN US2004014130-A1.
XX
PD 22-JAN-2004.
XX
XX
XX 07-DEC-2001; 2001US-00012231.
XX
XX 01-SEP-1998; 98US-0098716P.

PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 22-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102076P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103679P.

PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0108500P.
PR 03-NOV-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.

PR	24-AUG-2000;	2000WO-US023238.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	04-SEP-2001;	2001US-00946374.
XX		
PA	(GETH)	GENENTECH INC.
XX		
PI	Baker KP, Botstein D, Deaneoyers L, Eaton DL, Ferrara N, Fong S,	
PI	Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,	
PI	Pan J, Peon NF, Roy MA, Smith V, Stewart TA, Tunes D, Watanabe CK;	
PI	Williams PM, Wood WI;	
DR	WPI; 2004-108212/11.	
XX		
PT	Novel isolated PRO polypeptide useful for tissue typing, modulating	
PT	biological activity of cell, as molecular weight markers in protein	
PT	electrophoresis, for treating arthritis, tumor.	
XX		
PS	Example 85; SEQ ID NO 294; 562bp; English.	
XX		
CC	The invention relates to an isolated PRO polypeptide (secreted or	
CC	transmembrane protein) having at least 80% amino acid sequence identity	
CC	to an amino acid sequence chosen from 123 fully defined sequences as	
XX		
Query Match	1.0%; Score 24; DB 1; Length 24;	
Best Local Similarity	100.0%; Pred. No. 8.7;	
Matches	24; Conservative	0; Mismatches
		0; Indels
		0; Gaps
		0;
QY	1463 GGAAGTCATCGCGTCTGTGCGG 1486	
Db	24 GGAAGTCATCGCGTGTGCGG 1	
RESULT 68		
ID	ADL94813/c	
ID	ADL94813 standard; DNA; 24 BP.	
XX		
AC	ADL94813;	
XX		
DT	01-JUL-2004 (first entry)	
XX		
DE	Human secreted/transmembrane protein PRO1433 PCR primer #2.	
XX		
KW	Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;	
KW	immune response; cardiac insufficiency disorder; calcium flux;	
KW	umbilical vein endothelial cell; bone disorder; cartilage disorder;	
KW	arthritis; wound healing; diabetes; skeletal muscle cells; obesity;	
KW	Berger disease; nephropathy; Schönlein-Henoch purpura; colliac disease;	
KW	dermatitis; herpiformis; Crohn's disease; thalassemia; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	US2004073015-A1.	
XX		
PD	15-APR-2004.	
XX		
PE	12-DEC-2001; 2001US-00015395.	
XX		
PR	23-SEP-1998; 98US-0101477P.	
PR	20-JUL-1999; 99US-0144758P.	
PR	01-SEP-1999; 99WO-US020111.	
PR	18-OCT-1999; 99US-00403297.	
PR	18-FEB-2000; 2000WO-US004342.	
PR	04-SEP-2001; 2001US-00946374.	
XX		
PA	(GETH)	GENENTECH INC.

P1	Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
P1	Gao W, Goddard A, Godowski P, Grimaldi JC, Gunney AL, Hillan KJ,
P1	Pant J, Peoni NP, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
P1	Williams PM, Wood WI;
XX	
DR	WPI, 2004-315422/29.
XX	
PT	New PRO polynucleotides and polypeptides, useful in promoting wound
PT	healing and in diagnosing and treating cancer, neurodegenerative
PT	diseases, stroke, hypertension or diabetes mellitus.
XX	
PS	Example 85; SEQ ID NO 294; 550pp; English.
XX	
CC	The invention relates to an isolated PRO polypeptide (secreted or
CC	transmembrane protein) having at least 80% amino acid sequence identity
CC	to an amino acid sequence chosen from 123 fully defined sequences as
CC	given in the specification (including their extracellular domains either
CC	or without their associated signal peptides. Also include are the
CC	nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC	host cell comprising the vector, producing PRO, a chimeric molecule
CC	comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC	PRO antibody. Pro is useful as molecular weight markers for protein
CC	electrophoresis and also for chromosome identification. PRO is also
CC	useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC	probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC	useful for generating transgenic animals or knock-out animals which are
CC	useful in development and screening useful reagents. PRO NA is also
CC	useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC	useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC	polypeptides are useful for suppressing immune response. PRO1246
CC	polypeptide is useful for treating cardiac insufficiency disorders.
CC	PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC	PRO1561 polypeptide are useful for stimulating calcium flux in human
CC	umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC	polypeptides are useful for treating bone and/or cartilage disorders
CC	(e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC	polypeptides are useful for treating diabetes in skeletal muscle cells
CC	and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC	treating Berger disease or other nephropathies associated with Schonlein-
CC	Hemoch purpura, coeliac disease, dermatitis, herpetiformis or Crohn's
CC	disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC	PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC	sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC	the invention.
SQ	
SQ	Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
Query Match	1.0%; Score 24; DB 1; Length 24;
Best Local Similarity	100.0%; Pred. No. 8.7;
Matches 24; Conservative	0; Mismatches 0; Indels 0; Gaps 0
CY	1463 GGAAGTCATGCGGTCTGTGGG 1466
DB	24 GGAAGTCATGCGGTCTGTGGG 1
ADL94812	
ID	ADL94812 standard; DNA; 24 BP.
AC	ADL94812;
XX	
DT	01-UU-2004 (first entry)
XX	
DE	Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX	
KW	Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW	immune response; cardiac insufficiency disorder; calcium flux;
KW	umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW	arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW	Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW	dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.

XX Homo sapiens.
OS
XX US2004073015-A1.
XX
XX
XX 15-APR-2004.
XX
XX 12-DEC-2001; 2001US-00015395.
XX
XX 23-SEP-1998; 98US-0101477P.
PR 20-JUL-1999; 99US-0144758P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Baton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WT;
XX
XX WPI; 2004-315422/29.
XX
XX New PRO polynucleotides and polypeptides, useful in promoting wound
PT healing and in diagnosing and treating cancer, neurodegenerative
PT diseases, stroke, hypertension or diabetes mellitus.
XX
XX Example 85; SEQ ID NO 293; 550pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schöten-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.
XX
XX Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;
SQ

Query Match 1 0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. NO. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCATCTACTCC 1064
|||
Db 1 GCTGACCTGTTCCATCTACTCC 24

RESULT 70
AD042528
ID AD042528 standard; DNA; 23 BP.
XX
XX
XX AD042528;
AC
XX
XX 15-JUL-2004 (first entry)
DT
XX
XX Human NOVX PCR primer #1.
DE
XX
XX Human; NOVX; PCR; ss; cancer; atherosclerosis; diabetes;
KW Alzheimer's disease; Parkinson's disease; graft-versus-host disease;
KW scleroderma; hypertension; haemophilia;
KW idiopathic thrombocytopenic purpura; immunodeficiency; AIDS;
KW dyslipidemia; obesity; Crohn's disease; bronchial asthma; anorexia;
KW cancer-associated cachexia; multiple sclerosis; fertility; primer.
XX
XX Homo sapiens.
OS
XX
XX US2004058338-A1.
XX
XX 25-MAR-2004.
XX
XX 02-DEC-2002; 2002US-00307817.
XX
XX
XX 03-DEC-2001; 2001US-0336881P.
PR 05-DEC-2001; 2001US-0336820P.
PR 07-DEC-2001; 2001US-0338285P.
PR 10-DEC-2001; 2001US-0338318P.
PR 10-DEC-2001; 2001US-0338989P.
PR 11-DEC-2001; 2001US-0339022P.
PR 11-DEC-2001; 2001US-0339314P.
PR 11-DEC-2001; 2001US-0339517P.
PR 11-DEC-2001; 2001US-0339517P.
PR 12-DEC-2001; 2001US-0340981P.
PR 12-DEC-2001; 2001US-0340981P.
PR 14-DEC-2001; 2001US-0340396P.
PR 14-DEC-2001; 2001US-0340440P.
PR 14-DEC-2001; 2001US-0340565P.
PR 14-DEC-2001; 2001US-0340608P.
PR 14-DEC-2001; 2001US-0341144P.
PR 17-DEC-2001; 2001US-0341477P.
PR 17-DEC-2001; 2001US-0341540P.
PR 18-DEC-2001; 2001US-0341768P.
PR 20-DEC-2001; 2001US-0342592P.
PR 31-DEC-2001; 2001US-0344903P.
PR 01-FEB-2002; 2002US-0353286P.
PR 01-FEB-2002; 2002US-0353286P.
PR 26-FEB-2002; 2002US-0359599P.
PR 26-FEB-2002; 2002US-0359626P.
PR 26-FEB-2002; 2002US-0359671P.
PR 27-FEB-2002; 2002US-0359914P.
PR 27-FEB-2002; 2002US-0359956P.
PR 28-FEB-2002; 2002US-0360924P.
PR 28-FEB-2002; 2002US-0360964P.
PR 28-FEB-2002; 2002US-0361028P.
PR 28-FEB-2002; 2002US-0361255P.
PR 28-FEB-2002; 2002US-0361264P.
PR 05-MAR-2002; 2002US-0361770P.
PR 05-MAR-2002; 2002US-0362230P.
PR 13-MAR-2002; 2002US-0364181P.
PR 13-MAR-2002; 2002US-0364238P.
PR 15-MAR-2002; 2002US-0364978P.
PR 15-MAR-2002; 2002US-0365025P.
PR 17-APR-2002; 2002US-0373288P.
PR 15-MAY-2002; 2002US-0380981P.
PR 16-MAY-2002; 2002US-0381004P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.

29-MAY-2002; 2002US-0384024P.
PR 02-JUL-2002; 2002US-0393332P.
PR 06-AUG-2002; 2002US-0401315P.
PR 07-AUG-2002; 2002US-0401788P.
PR 20-AUG-2002; 2002US-0404676P.
PR 23-AUG-2002; 2002US-0405400P.
PR 23-AUG-2002; 2002US-0405684P.
PR 23-AUG-2002; 2002US-0405687P.
PR 23-AUG-2002; 2002US-0405688P.
PR 26-AUG-2002; 2002US-0406353P.
XX
PA (AGEE/) AGEE M L.
PA (ALSO/) ALSOBROOK J P.
PA (ANDE/) ANDERSON D W.
PA (BERG/) BERGHS C.
PA (BOLD/) BOLDOG F L.
PA (BURG/) BURGESS C E.
PA (CATT/) CATTERTON E.
PA (DIP1/) DIPIPPO V A.
PA (EDIN/) EDINGER S R.
PA (EISE/) EISEN A.
PA (ELLE/) ELLERMAN K.
PA (GANG/) GANGOLLI E A.
PA (GERL/) GERLACH V.
PA (GORM/) GORMAN L.
PA (ROTH/) ROTHBERG B G.
PA (GUOX/) GUO X S.
PA (HERR/) HERRMANN J L.
PA (HALV/) HALVORSEN Y.
PA (JIMW/) JI W.
PA (KEKU/) KERAMTSOV N V.
PA (KHRA/) KHRAMTSOV N V.
PA (LARO/) LAROCHELLE W J.
PA (LEPL/) LEPELEY D M.
PA (LILL/) LI L.
PA (MACD/) MACDOUGALL J R.
PA (MILL/) MILLER C E.
PA (ORTT/) ORT T.
PA (PAD1/) PADIGARU M.
PA (PATT/) PATTURAJAN M.
PA (PENNA/) PENNA C E A.
PA (PEYM/) PEYMAN J A.
PA (RIEG/) RIEGER D K.
PA (ROTH/) ROTHENBERG M E.
PA (SHEN/) SHENOY S G.
PA (SMIT/) SMITHSON G.
PA (SPAD/) SPADERNA S K.
PA (SPYT/) SPYTEK K A.
PA (STON/) STONE D J.
PA (TAUP/) TAUPIER R J.
PA (VERN/) VERNET C A M.
PA (VOSS/) VOSS E Z.
PA (ZHON/) ZHONG M.
XX
PI Agee ML, Alsobrook JP, Anderson DW, Berghs C, Boldog FL,
PI Burgess CE, Catterton E, Dipippo VA, Edinger SR, Eisen A,
PI Ellerman K, Gangolli EA, Gerlach V, Gorman L, Rothberg BG, Guo XS,
PI Hermann JL, Halvorsen Y, Ji W, Kekuda R, Khrantsov NV,
PI Larochele WJ, Lepeley DM, Li L, MacDougall JR, Miller CE, Ort T,
PI Padigaru M, Paturajan M, Penna CE, Peyman JA, Rieger DK,
PI Rothberg ME, Shenoys SG, Smithson G, Spaderna SK, Spytek KA,
PI Stone DJ, Taupier RJ, Vernet CM, Voss EZ, Zhong M;
XX
DR WPI; 2004-268786/25.
XX
XX New human NOVX polypeptides and nucleic acid molecules, useful for
PT diagnosing, preventing or treating NOVX-associated disorder, e.g. cancer,
PT atherosclerosis, diabetes, Alzheimer's disease, Parkinson's disease or
PT scleroderma.
XX
XX Example D; SEQ ID NO 377; 610bp; English.
XX
XX The invention relates to human NOVX polypeptides and the polynucleotides

CC encoding them. The invention also relates to antibodies specific to the
CC NOVX polypeptides. The polypeptides, polynucleotides and antibodies are
CC useful for manufacturing a medicament for treating a syndrome associated
CC with a human disease, such as a pathology associated with the NOVX
CC polypeptide. The sequences are useful for diagnosing, treating or
CC preventing a NOVX-associated disorder, e.g., cancer, atherosclerosis,
CC diabetes, Alzheimer's disease, Parkinson's disease, graft-versus-host
CC disease, scleroderma, hypertension, haemophilia, idiopathic
CC thrombocytopenic purpura, immunodeficiencies, AIDS, dyslipidemia,
CC obesity, Crohn's disease, bronchial asthma, anorexia, cancer-associated
CC cachexia, multiple sclerosis or fertility. The nucleic acids may be used
CC as hybridisation probes, in chromosome mapping, in tissue typing, in
CC preventive medicine or in pharmacogenomics. This sequence represents a
CC PCR primer used in analysis of expression of a human NOVX polynucleotide
CC of the invention.
XX
SQ Sequence 23 BP; 11 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 1.0%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1127 CCAGAGAGAGTTCCAGAAATACA 1149
Db 1 CCAGAGAGAGTTCCAGAAATACA 23
XX
RESULT 71
AAD56896
ID AAD56896 standard; DNA; 22 BP.
XX
AC AAD56896;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human 86606 DGAT2 gene specific forward PCR primer.
XX
KW Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;
KW coronary artery disease; hypertension; heart failure; tissue typing;
KW aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;
KW atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;
KW diabetes; chromosome mapping; forensic biology; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200305363-A2.
XX
PD 03-JUL-2003.
XX
PF 19-DEC-2002; 2002WO-US040974.
XX
PR 19-DEC-2001; 2001US-0341947P.
PR 19-SEP-2002; 2002US-0411859P.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Gimeno RE, Wu Z, Kapeller-Libermann R, Hubbard BK;
XX
DR WPI; 2003-559092/52.
XX
XX New human diacylglycerol acyltransferase 2 (DGAT2) family member
PT polypeptide and nucleic acid molecules, useful for diagnosing and
PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or
PT triglyceride synthesis.
XX
XX Example 3; Page 100; 154bp; English.
XX
XX The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)
CC family members and their uses. DGAT2 family member sequences or their
CC modulators are useful for diagnosing and treating a subject with a
CC disorder associated with the aberrant DGAT family member polypeptide
CC activity or nucleic acid expression, such as a disorder associated with
CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or

CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,
CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated
CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is
CC also useful in screening assays (e.g. tissue typing, chromosome mapping,
CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,
CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as
CC surrogate markers (e.g. markers of disease states or markers of drug
CC activity). The present sequence is human DGAT2 gene specific PCR primer.
CC This sequence is used in the exemplification of the invention
XX

Sequence 22 BP; 5 A; 9 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1777 CAAAGCCCTTATTGCCACTAC 1798
DB 1 CAAAGCCCTTATTGCCACTAC 22

RESULT 72
ADD27798/C

ID ADD27798 standard; DNA; 22 BP.

AC ADD27798;

DT 15-JAN-2004 (first entry)

DE Human psoriasis related genes PCR primer #7.

KW ss; psoriasis; Psoriasis-related gene; body map; PCR; primer; human.

OS Homo sapiens.

PN JP2002330770-A.

PD 19-NOV-2002.

PF 25-MAY-2001; 2001JP-00156529.

PR 30-AUG-2000; 2000JP-00260818.

PR 01-NOV-2000; 2000JP-00334042.

PA (TANA) TANABE SEIYAKU CO.

DR WPI; 2003-460750/44.

PT Gene of which expression changes in Psoriasis and examination directed to
PT said gene, a recombinant vector, a host cell.

PS Example 3; SEQ ID NO 13; 27pp; Japanese.

CC The invention relates to detection of psoriasis by determining the
CC expression level of a Psoriasis-related gene in a biosample collected
CC from a human or nonhuman animal individual. The gene consisting of one of
CC 5 538-2713 nucleotide sequences, given in the specification, or a DNA
CC hybridising with it under stringent conditions are disclosed. The method
CC is used for the detection of Psoriasis. The Psoriasis-related gene was
CC detected by the body map method. The present sequence is a PCR primer
CC used in the isolation of the psoriasis-related genes.
XX

Sequence 22 BP; 6 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 17;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2357 GATGAGATCATTCACCATGTC 2378
DB 22 GATGAGATCATTCACCATGTC 1

RESULT 73
ADD27797
ID ADD27797 standard; DNA; 22 BP.

AC ADD27797;

DT 15-JAN-2004 (first entry)

DE Human psoriasis related genes PCR primer #6.

KW ss; psoriasis; Psoriasis-related gene; body map; PCR; primer; human.

OS Homo sapiens.

PN JP2002330770-A.

PD 19-NOV-2002.

PF 25-MAY-2001; 2001JP-00156529.

PR 30-AUG-2000; 2000JP-00260818.

PR 01-NOV-2000; 2000JP-00334042.

PA (TANA) TANABE SEIYAKU CO.

DR WPI; 2003-460750/44.

PT Gene of which expression changes in Psoriasis and examination directed to
PT said gene, a recombinant vector, a host cell.

PS Example 3; SEQ ID NO 12; 27pp; Japanese.

CC The invention relates to detection of psoriasis by determining the
CC expression level of a Psoriasis-related gene in a biosample collected
CC from a human or nonhuman animal individual. The gene consisting of one of
CC 5 538-2713 nucleotide sequences, given in the specification, or a DNA
CC hybridising with it under stringent conditions are disclosed. The method
CC is used for the detection of Psoriasis. The Psoriasis-related gene was
CC detected by the body map method. The present sequence is a PCR primer
CC used in the isolation of the psoriasis-related genes.
XX

Sequence 22 BP; 5 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 17;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2057 CGCCACCATGAGCTAGGTGAG 2078
DB 1 CGCCACCATGAGCTAGGTGAG 22

RESULT 74
AAD56897/C

ID AAD56897 standard; DNA; 20 BP.

AC AAD56897;

DT 06-NOV-2003 (first entry)

DE Human 86606 DGAT2 gene specific reverse PCR primer.

XX Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;

XX coronary artery disease; hypertension; heart failure; tissue typing;

XX aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;

XX atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;

XX diabetes; chromosome mapping; forensic biology; PCR; primer; ss.

OS Homo sapiens.

PN WO2003053363-A2.

PR 03-JUL-2003.

XX 19-DEC-2002; 2002MO-US040974.
XX 19-DEC-2001; 2001US-0341947P.
PR 19-SEP-2002; 2002US-0411859P.
XX (MILL-) MILLENNIUM PHARM INC.
XX
PI GImeno RE, Wu Z, Kapeller-Libermann R, Hubbard BK;
XX WPI; 2003-559092/52.
XX
XX New human diacylglycerol acyltransferase 2 (DGAT2) family member
PT polypeptide and nucleic acid molecules, useful for diagnosing and
PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or
PT triglyceride synthesis.
XX
XX Example 3; Page 100; 154pp; English.
XX
XX The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)
CC family members and their uses. DGAT2 family member sequences or their
CC modulators are useful for diagnosing and treating a subject with a
CC disorder associated with the aberrant DGAT family member polypeptide
CC activity or nucleic acid expression, such as a disorder associated with
CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or
CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,
CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated
CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is
CC also useful in screening assays (e.g. tissue typing, chromosome mapping,
CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,
CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as
CC surrogate markers (e.g. markers of disease states or markers of drug
CC activity). The present sequence is human DGAT2 gene specific PCR primer.
XX This sequence is used in the exemplification of the invention
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.84; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1831 CAGTTTCTGTGCAAGGGA 1850
Db 20 CAGTTTCTGTGCAAGGGA 1
XX
RESULT 75
ADO42530/c
ID ADO42530 standard; DNA; 20 BP.
XX
AC ADO42530;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human NOVX PCR primer #2.
XX
KW Human; NOVX; PCR; ss; cancer; atherosclerosis; diabetes;
KW Alzheimer's disease; Parkinson's disease; gratic-verus-host disease;
KW scleroderma; hypertension; haemophilia;
KW idiopathic thrombocytopenic purpura; immunodeficiency; AIDS;
KW dyslipidemia; obesity; Crohn's disease; bronchial asthma; anorexia;
KW cancer-associated cachexia; multiple sclerosis; fertility; primer.
XX
OS Homo sapiens.
XX
PN US2004058338-A1.
XX
PD 25-MAR-2004.
XX
XX 02-DEC-2002; 2002US-00307817.
XX
XX 03-DEC-2001; 2001US-0336881P.
XX
XX 05-DEC-2001; 2001US-0336820P.

PR 07-DEC-2001; 2001US-0338285P.
PR 07-DEC-2001; 2001US-0338318P.
PR 10-DEC-2001; 2001US-0338989P.
PR 10-DEC-2001; 2001US-0339022P.
PR 11-DEC-2001; 2001US-0339314P.
PR 11-DEC-2001; 2001US-0339516P.
PR 11-DEC-2001; 2001US-0339517P.
PR 11-DEC-2001; 2001US-0339611P.
PR 12-DEC-2001; 2001US-0340981P.
PR 12-DEC-2001; 2001US-0341346P.
PR 14-DEC-2001; 2001US-0340390P.
PR 14-DEC-2001; 2001US-0340440P.
PR 14-DEC-2001; 2001US-0340565P.
PR 14-DEC-2001; 2001US-0340608P.
PR 14-DEC-2001; 2001US-0341144P.
PR 17-DEC-2001; 2001US-0341777P.
PR 17-DEC-2001; 2001US-0341540P.
PR 18-DEC-2001; 2001US-0341768P.
PR 20-DEC-2001; 2001US-0342592P.
PR 31-DEC-2001; 2001US-0344903P.
PR 01-FEB-2002; 2002US-0353286P.
PR 01-FEB-2002; 2002US-0353288P.
PR 26-FEB-2002; 2002US-0353599P.
PR 26-FEB-2002; 2002US-0353626P.
PR 26-FEB-2002; 2002US-0359671P.
PR 27-FEB-2002; 2002US-0359914P.
PR 27-FEB-2002; 2002US-0359956P.
PR 28-FEB-2002; 2002US-0360924P.
PR 28-FEB-2002; 2002US-0360964P.
PR 28-FEB-2002; 2002US-0361028P.
PR 28-FEB-2002; 2002US-0361256P.
PR 28-FEB-2002; 2002US-0361264P.
PR 05-MAR-2002; 2002US-0361770P.
PR 05-MAR-2002; 2002US-036230P.
PR 13-MAR-2002; 2002US-0364181P.
PR 13-MAR-2002; 2002US-0364238P.
PR 15-MAR-2002; 2002US-0364978P.
PR 15-MAR-2002; 2002US-0365025P.
PR 17-APR-2002; 2002US-0373288P.
PR 15-MAY-2002; 2002US-0380981P.
PR 16-MAY-2002; 2002US-0381004P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.
PR 29-MAY-2002; 2002US-0384024P.
PR 02-JUL-2002; 2002US-0393332P.
PR 06-AUG-2002; 2002US-0401315P.
PR 07-AUG-2002; 2002US-0401788P.
PR 20-AUG-2002; 2002US-0404565P.
PR 23-AUG-2002; 2002US-0405400P.
PR 23-AUG-2002; 2002US-0405684P.
PR 23-AUG-2002; 2002US-0405687P.
PR 23-AUG-2002; 2002US-0405698P.
PR 26-AUG-2002; 2002US-0406553P.
XX
XX (AGEE/) AGEE M. L.
XX (ALSO/) ALSOON D. J. P.
XX (ANDE/) ANDERSON D. W.
XX (BERG/) BERGS C.
XX (BOLD/) BOLDOG F. L.
XX (BURG/) BURGESS C. E.
XX (CATT/) CATTERTON E.
XX (DIP/) DIPIPPO V. A.
XX (EDIN/) EDINGER S. R.
XX (EISE/) EISEN A.
XX (ELLE/) ELLERMAN K.
XX (GANG/) GANGOLI E. A.
XX (GERL/) GERLACH V.
XX (GORM/) GORMAN L.
XX (ROTH/) ROTHBERG B. G.
XX (GUOX/) GUO X. S.
XX (HERR/) HERRMANN J. L.


```
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
XX Example 2; Page 348; 418bp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX CC invention has cytostatic activity. The nucleotide may have a use in gene
XX CC therapy. The KTOM1 nucleic acid may be used to diagnose, treat or
XX CC monitor a disease caused by altered expression of human KTOM1.
XX CC Compositions comprising the nucleic acids, proteins or antibodies may be
XX CC used to treat subjects having defects in KTOM1 which can manifest as
XX CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX CC function. The sequence represents a probe used in the invention to scan
XX CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
XX SQ Sequence 25 BP; 5 A; 7 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 19.2; DB 1; Length 25;
XX Best Local Similarity 87.5%; Pred. No. 37;
XX Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 1419 CCTGGAGAACCGCTGCAATCA 1442
XX ||||| ||||| ||||| |||||
XX Db 25 CCTGGAGGCTCTGCTGCAATCA 2
XX
XX RESULT 78
XX ABO64741/c
XX ID ABO64741 standard; DNA; 25 BP.
XX
XX AC ABO64741;
XX
XX DT 20-AUG-2002 (first entry)
XX
XX DE Human KTOM1a portion (AB063232) probe # 1454.
XX
XX KW Human; KTOM1a; kidney tumour overexpressed membrane; cytostatic;
XX gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
XX kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200224750-A2.
XX
XX PD 28-MAR-2002.
XX
XX PF 21-SEP-2001; 2001WO-US029656.
```

```
XX
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 23-MAY-2001; 2001US-00864761.
XX 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
XX Example 2; Page 348; 418bp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX CC invention has cytostatic activity. The nucleotide may have a use in gene
XX CC therapy. The KTOM1 nucleic acid may be used to diagnose, treat or
XX CC monitor a disease caused by altered expression of human KTOM1.
XX CC Compositions comprising the nucleic acids, proteins or antibodies may be
XX CC used to treat subjects having defects in KTOM1 which can manifest as
XX CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX CC function. The sequence represents a probe used in the invention to scan
XX CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
XX SQ Sequence 25 BP; 5 A; 7 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 19.2; DB 1; Length 25;
XX Best Local Similarity 87.5%; Pred. No. 37;
XX Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 1419 CCTGGAGAACCGCTGCAATCA 1442
XX ||||| ||||| ||||| |||||
XX Db 24 CCTGGAGGCTCTGCTGCAATCA 1
XX
XX RESULT 79
XX AAH48071/c
XX ID AAH48071 standard; DNA; 24 BP.
XX
XX AC AAH48071;
XX
XX DT 19-SEP-2001 (first entry)
XX
XX DE Dihydropyrimidinase synthase 9 PCR primer #2.
XX
XX KW Dihydropyrimidinase synthase 9; cytostatic; haemostatic; virucide;
XX immunomodulatory; antiinflammatory; gene therapy; malignant tumour;
XX haemopathy; HIV infection; immunological disease; inflammation;
XX PCR primer; ss.
XX
XX OS Unidentified.
XX
XX PN WO200147980-A1.
XX
XX PD 05-JUL-2001.
```

XX 25-DEC-2000; 2000MO-CN000715.
 XX PF
 XX 27-DEC-1999; 99CN-00125792.
 XX PR
 XX (SHAN-) SHANGHAI BIOWINDOM GENE DEV INC.
 XX PA
 XX Mao Y, Xie Y;
 XX PI
 XX WPI, 2001-418229/44.
 XX DR
 XX Dihydrodipicolinate synthase 9 and encoded polynucleotide, used in
 XX PT diagnosis and treatment of malignant tumors, hemopathy, human
 XX PT immunodeficiency virus infection, immunological diseases and
 XX PT inflammation.
 XX PS
 XX Example 3; Page 16; 39pp; Chinese.
 XX CC The present invention relates to dihydrodipicolinate synthase 9 and its
 XX CC coding sequence (see AAH48069 and AAG64225). Dihydrodipicolinate synthase
 XX CC 9 and its coding sequence are useful in the diagnosis and treatment of
 XX CC malignant tumor, haemopathy, human immunodeficiency virus (HIV)
 XX CC infection, immunological diseases and various inflammations. The present
 XX CC sequence is a PCR primer, which was used in an example from the present
 XX CC invention
 XX SQ Sequence 24 BP; 9 A; 2 C; 1 G; 12 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 18.8; DB 1; Length 24;
 XX Best Local Similarity 90.9%; Pred. No. 43;
 XX Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1498 AAATTATACAAATTTGCTTAA 1519
 Db 23 AAATTATACAAATTTGTTTAA 2
 RESULT 80
 ADF72789
 ID ADF72789 standard; DNA; 23 BP.
 XX AC
 XX ADF72789;
 XX DT
 XX 26-FEB-2004 (first entry)
 XX DE
 XX Detection probe #1.
 XX KW detection; triplet expansion disease; fragile X syndrome;
 XX KW Huntington's disease; bulbar muscular dystrophy;
 XX KW spinocerebral ataxia type I; myotonic dystrophy; Friedrich ataxia; ss;
 XX KW probe.
 XX OS Synthetic.
 XX PN WO2003076654-A2.
 XX PD
 XX 18-SEP-2003.
 XX PF
 XX 04-MAR-2003; 2003WO-EP002202.
 XX PR
 XX 08-MAR-2002; 2002DE-01010100.
 XX PR 17-JUN-2002; 2002DE-01027042.
 XX PA
 XX (NOVE-) NOVEMBER GES MOLEKULARE MED AG.
 XX PI
 XX Palecek E, Kosak H;
 XX DR
 XX WPI; 2003-756830/71.
 XX PT Detection, quantification and characterization of analyte, useful for
 XX PT diagnosing diseases associated with triplet extensions, using probes with
 XX PT electrochemical labels.

PS Disclosure; SEQ ID NO 3; 50pp; German.
 XX
 XX This invention describes a novel method for detection, quantification
 XX CC and/or characterisation of an analyte using two affinity probes, each
 XX CC having an electrochemically detectable marker. The analyte is bound,
 XX CC preferably specifically to a capture molecule which may be immobilised on
 XX CC a surface. Especially the capture molecule is a nucleic acid or its
 XX CC analogue, particularly peptide nucleic acid (PNA), antibody or receptor,
 XX CC and may also include an affinity molecule, particularly (strept)avidin,
 XX CC biotin or a biotinylated oligonucleotide. One of the probes or analyte
 XX CC contains an affinity component, especially streptavidin or biotin.
 XX CC Particularly the analyte is a nucleic acid having a polyT or polyA tail,
 XX CC most particularly a DNA fragment associated with a triplet-expansion
 XX CC disease. Both probes are nucleic acid or analogues, particularly PNA and
 XX CC especially have a linear primary structure with the marker attached at
 XX CC one end. The markers are reversibly oxidisable or reducible, e.g. osmium
 XX CC complexes, nanogold particles, ferrocenyl, anthraquinone groups or dyes,
 XX CC particularly of the indophenol, thiazine or phenazine types. The method
 XX CC is specifically used to detect DNA fragments that include repetitive
 XX CC sequences, particularly triplet expansions associated with fragile X
 XX CC syndrome, Huntington's disease, bulbar muscular dystrophy,
 XX CC spinocerebral ataxia type I, myotonic dystrophy, or Friedrich ataxia, but
 XX CC may also be used to detect proteins or other biomolecules. The method is
 XX CC simple, rapid (particularly when compared with the known PCR/Southern
 XX CC blotting method for diagnosis of triplet-expansion diseases) and very
 XX CC sensitive.
 XX SQ Sequence 23 BP; 8 A; 0 C; 5 G; 10 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 17.8; DB 1; Length 23;
 XX Best Local Similarity 90.5%; Pred. No. 59;
 XX Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1536 TCTTTTAAAGAGGAAAAG 1556
 Db 3 TTTTAAAGAGGAAAAG 23
 RESULT 81
 AAH26588/c
 ID AAH26588 standard; DNA; 22 BP.
 XX AC
 XX AAH26588;
 XX DT
 XX 12-NOV-2001 (first entry)
 XX DE
 XX Mouse GLUT4 3' PCR primer.
 XX KW Glucose transporter-4; GLUT4; FOXC2; adipose tissue; mouse;
 XX KW transgenic animal; obesity; malnutrition; hyperlipidaemia; diabetes;
 XX KW hypertension; antidiabetic; anorectic; hypolipemic; hypotensive;
 XX KW gene therapy; insulin; PCR primer; ss.
 XX OS Mus sp.
 XX PN WO200160853-A1.
 XX PD
 XX 23-AUG-2001.
 XX PF
 XX 16-FEB-2001; 2001WO-SE000339.
 XX PR
 XX 18-FEB-2000; 2000SE-00000531.
 XX PR 26-MAY-2000; 2000SE-00001982.
 XX PR 06-JUN-2000; 2000US-00587945.
 XX PR 14-DEC-2000; 2000SE-00004629.
 XX PA
 XX (PHAA) PHARMACIA AB.
 XX PI
 XX Enerbaeck S, Carlsson P;
 XX DR
 XX WPI; 2001-557641/62.
 XX PT New construct comprising a human FOXC2 gene, useful in gene therapy for

PT treating obesity- or malnutrition-related diseases (e.g. obesity or
PT hyperlipidemia), as well as for identifying compounds useful in treating
PT these diseases.
XX
XX Example 1; Page 32; 92pp; English.
XX
CC The present sequence is that of a 3' primer, used with the 5' primer
CC given in AAH26567, for the PCR amplification of mouse insulin-responsive
CC glucose transporter-4 (GLUT-4) cDNA. cDNA probes for mouse FOXO2, ap2,
CC ADL1/SREBP1, cytochrome c-oxidase subunit II, adiponin, beta-1-3
CC adrenergic receptors, GLUT4, insulin receptor and insulin receptor
CC substrate IRS1 and IRS2 were prepared by RT-PCR using mouse epididymal
CC fat poly(A) + RNA and the primers given in AAH26571-94. The probes were
CC used in Northern blots to examine gene expression in the brown and white
CC adipose tissue (WAT) of wild-type mice and 3 transgenic mice expressing
CC the human FOXO2 gene (see AAH26570). Upregulation of GLUT4 was observed
CC in transgenic mice. This was most evident in WAT. FOXO2 is expressed
CC exclusively in adult adipose tissue and plays a major role in regulating
CC energy balance and adiposity. The invention provides methods for
CC identifying compounds capable of increasing or decreasing FOXO2 protein
CC activity or gene expression, and for using such compounds to treat
CC medical conditions related to obesity, such as obesity, non-insulin
CC dependent diabetes mellitus, hypertension and hyperlipidaemia (claimed),
CC or medical conditions related to malnutrition, such as anorexia (claimed)
XX
XX
SQ Sequence 22 BP; 5 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 73;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 239 CCTCATAGCGCGCTACTCGGG 260
DB 22 CCTCATAGCGCGCTACTCGGG 1
RESULT 82
ADF08228
ID ADF08228 standard; DNA; 22 BP.
XX
AC ADF08228;
XX
XX 12-FEB-2004 (first entry)
XX
DE Transgenic APOAV mouse genotyping primer #2.
XX
XX ss; PCR; primer; mouse; apolipoprotein A-V; APOAV; triglyceride;
XX lipid-related; diabetic disease; cardiovascular disease;
XX plasma triglyceride; diabetes; obesity; metabolic disease; gene therapy;
XX single nucleotide polymorphism; apoA5; human.
OS Mus musculus.
OS Homo sapiens.
XX
XX US2003150003-A1.
XX
XX 07-AUG-2003.
XX
XX 27-AUG-2002; 2002US-00229834.
XX
XX 07-SEP-2001; 2001US-0318219P.
XX
XX (RUBI/) RUBIN E.
XX (PENN/) PENNACCHIO L A.
XX
XX Rubin E, Pennacchio LA;
XX
XX MPI; 2003-897618/82.
XX
XX New human apolipoprotein A-V (APOAV) polynucleotides and polypeptides,
XX useful for identifying or screening of drugs that treat lipid-related or
XX diabetic diseases, for lowering plasma triglycerides, or in gene therapy.
XX

PS Disclosure; SEQ ID NO 11; 192pp; English.
XX
XX The invention relates to an isolated polynucleotide homologous to the
CC cDNA apolipoprotein A-V (APOAV) sequence. The human apolipoprotein A-V
CC (APOAV) gene, polynucleotides and polypeptides are useful for determining
CC predisposition towards elevated triglyceride levels, for identifying or
CC screening of drugs that treat lipid-related or diabetic diseases, or in
CC genetic analysis of cardiovascular diseases. The APOAV polypeptide is
CC useful for lowering plasma triglycerides or treating diabetes, obesity or
CC other metabolic diseases. The APOAV gene and vector are useful in gene
CC therapy. The single nucleotide polymorphisms are useful for determining
CC the genetic status of individuals or for studying individual risk
CC factors. The transgenic non-human animals are useful for further animal
CC studies of human or mouse apoA5. The present sequence represents a
CC transgenic APOAV mouse genotyping primer.
XX
XX
SQ Sequence 22 BP; 2 A; 6 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 73;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1173 CATGTCGAGCGCTTCTCTCT 1194
DB 1 CAGGTCGAGCGCTTCTCTCT 22
RESULT 83
AAZ77324
ID AAZ77324 standard; DNA; 21 BP.
XX
XX AAZ77324;
XX
XX 10-SEP-2001 (first entry)
XX
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:11680.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation;
XX amplification; single nucleotide polymorphism; SNP; PCR primer;
XX diagnosis; ss.
OS Homo sapiens.
XX
XX WO954500-A2.
XX
XX 28-OCT-1999.
XX
XX 21-APR-1999; 99WO-1B000822.
XX
XX 21-APR-1998; 98US-0082614P.
XX 23-NOV-1998; 98US-0109732P.
XX
XX (GEST) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX
XX MPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 9; Page 2720; 2745pp; English.
XX
XX AAZ6564 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ65579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the

CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID Nos 2852, 2913, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 21 BP; 0 A; 11 C; 0 G; 10 T; 0 U; 0 Other;
Query Match 0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1643 TCTCTTCTTCCCTTCTTCT 1659
DB 1 TCTCTTCTTCCCTTCTTCT 17
RESULT 84
AAS96617/c
ID AAS96617 standard; DNA; 20 BP.
XX
AC AAS96617;
XX
DT 09-APR-2002 (first entry)
XX
DE Telomerase reverse transcriptase, antisense oligonucleotide #27.
XX
XX Telomerase reverse transcriptase; TERT; cytosolic; apoptosis;
KW cell growth inhibitor; antisense oligonucleotide; antisense technology;
KW ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX MO200188198-A1.
XX
XX 22-NOV-2001.
XX
XX 15-MAY-2001; 2001MO-US015774.
XX
XX 16-MAY-2000; 2000US-00572423.
PR 07-DEC-2000; 2000US-00733294.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Gaarde WA, Freier SM, Wanciewicz E;
PI
XX WPI; 2002-075321/10.
DR
XX New compound targeted to nucleic acid molecule encoding telomerase
PT transcriptase (TERT), which specifically hybridizes with and inhibits
PT expression of TERT, useful for modulating apoptosis and inhibiting cell
PT growth.
XX
PS Claim 26; Page 90; 154pp; English.
XX
XX The invention describes a compound, 8-50 nucleobases in length targeted
CC to a nucleic acid molecule encoding human TERT (telomerase reverse
CC transcriptase), where the compound specifically hybridizes with and
CC inhibits the expression of TERT. A series of oligonucleotides were
CC designed to target different regions of the human TERT RNA. These were 20
CC nucleotides in length and composed of a central gap region consisting of
CC ten 2'-deoxynucleotides, flanked on both sides (5' and 3' directions) by
CC five-nucleotide wings. The wings were composed of 2'-methoxyethyl (2'-
CC MOE) nucleotides. The compounds were analysed for their effect on human
CC TERT mRNA levels by reverse transcriptase (RT)-polymerase chain reaction
CC (PCR). The compound is useful for inhibiting the expression of TERT in
CC cells or tissues, for treating a human having disease or condition
CC associated with TERT, for modulating apoptosis, for inhibiting cell
CC growth (preferably, cancer cell growth), in antisense therapy and for
CC diagnostics and therapeutics. This sequence is an antisense

CC oligonucleotide used to modulate the activity of nucleic acid molecules
CC encoding TERT, described in the method of the invention
XX
SQ Sequence 20 BP; 2 A; 9 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 139 GCGGAGACCCCTGGCCCGG 158
DB 20 GTGGGAGACCCCTGGCCCGG 1
RESULT 85
ADJ32329
ID ADJ32329 standard; DNA; 20 BP.
XX
AC ADJ32329;
XX
DT 22-APR-2004 (first entry)
XX
DE Human STAT1 target DNA fragment #3.
XX
XX Human; signal transducer and activator of transcription; STAT1;
KW hyperproliferative disorder; cancer; infection; immune response;
KW gene therapy; ds.
XX
XX Homo sapiens.
OS
XX US2003232440-A1.
XX
XX 18-DEC-2003.
XX
XX 17-JUN-2002; 2002US-00174175.
XX
XX 17-JUN-2002; 2002US-00174175.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Karras J, Freier SM, Dobie KW;
PI
XX WPI; 2004-052173/05.
DR
XX New antisense oligonucleotide targeted to a nucleic acid encoding signal
PT transducers and activators of transcription 1, useful for treating
PT cancer, or viral or bacterial infections.
XX
XX Example 15; SEQ ID NO 52; 72pp; English.
XX
XX The invention relates to novel antisense compounds targeted to a nucleic
CC acid molecule encoding signal transducers and activators of transcription
CC 1 (STAT1) to inhibit its expression. Compounds, compositions and methods
CC of the invention are useful for treating diseases or conditions
CC associated with STAT1 such as hyperproliferative disorders e.g. cancer,
CC viral or bacterial infections and diseases or conditions involving
CC hyperactivation of immune response. They are also useful in research and
CC diagnostics for modulating the expression of STAT1. The invention is also
CC useful in gene therapy. The present sequence is human STAT1 target DNA
CC fragment used in the exemplification of the invention.
XX
SQ Sequence 20 BP; 3 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 588 GGTGCGAGAGGTACAGTG 607
DB 1 GGTGCGAGAGGTACAGTG 20
RESULT 86

ADJ32292/c
ID ADJ32292 standard; DNA; 20 BP.
XX
AC ADJ32292;
XX
DT 22-APR-2004 (first entry)
XX
DE Human STAT1 antisense oligonucleotide, ISIS 204461.
XX
KW Human; signal transducer and activator of transcription; STAT1;
KW antisense; hyperproliferative disorder; cancer; infection;
KW immune response; gene therapy; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT 1..20
FT modified_base /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone where all cytidine
FT residues are 5-methylcytidines"
FT 1..5
FT modified_base /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT modified_base /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN US2003232440-A1.
XX
PD 18-DEC-2003.
XX
PF 17-JUN-2002; 2002US-00174175.
XX
PR 17-JUN-2002; 2002US-00174175.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Karras J, Freier SM, Dobie KW;
XX WPI; 2004-052173/05.
XX
DR WPI; 2004-052173/05.
XX
XX
PT New antisense oligonucleotide targeted to a nucleic acid encoding signal
PT transducers and activators of transcription 1, useful for treating
PT cancer, or viral or bacterial infections.
XX
XX
PS Example 15; SEQ ID NO 15; 72bp; English.
XX
XX
CC The invention relates to novel antisense compounds targeted to a nucleic
CC acid molecule encoding signal transducers and activators of transcription
CC 1 (STAT1) to inhibit its expression. Compounds, compositions and methods
CC of the invention are useful for treating diseases or conditions
CC associated with STAT1 such as hyperproliferative disorders e.g. cancer,
CC viral or bacterial infections and diseases or conditions involving
CC hyperactivation of immune response. They are also useful in research and
CC diagnostics for modulating the expression of STAT1. The invention is also
CC useful in gene therapy. The present sequence is an antisense
CC oligonucleotide targeted to human STAT1 DNA. This sequence is used in
CC the exemplification of the invention.
XX
XX
SQ Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 588 GGTGGCAGAGGTCTCAGTG 607
DB 20 GGTGGCAGAGGTCTCAGTG 1

RESULT 87
ADK98410 standard; DNA; 20 BP.
ID ADK98410
XX
AC ADK98410;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #4130.
XX
KW human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
OS JP2003259875-A.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.
XX
PF 08-MAR-2002; 2002JP-00064373.
XX
PR 08-MAR-2002; 2002JP-00064373.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI; 2004-093977/10.
XX
PT Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX
XX
PS Claim 2; SEQ ID NO 7439; 2627bp; Japanese.
XX
XX
CC The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX
XX
SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 757 CAGAGCCACAGACTGAGC 776
DB 1 CAGAGCCCTCAGAGGTGAGC 20
XX
XX
RESULT 88
AAQ11523
ID AAQ11523 standard; DNA; 21 BP.
XX
AC AAQ11523;
XX
DT 20-JUN-1991 (first entry)
XX
DE Rat Stem Cell Factor probe/primer 228-30.
XX
KW Stem cell factor; SCF; leukopenia; AIDS; haematopoiesis; primer; probe;
KW 88.
XX
XX
OS Synthetic.
OS EP423980-A.
XX
PN EP423980-A.
XX
PD 24-APR-1991.
XX
PF 04-OCT-1990; 90EP-00310899.
XX
PR 16-OCT-1989; 89US-00422383.
XX
PR 11-JUN-1990; 90US-00537198.

PR 24-AUG-1990; 90US-00573616.
 PR 28-SEP-1990; 90MO-US005548.
 PR 01-OCT-1990; 90US-00589701.
 XX
 PA (AMGE-) AMGEN.
 XX
 PI Zeebo KM, Suggs SV, Bosselman RA, Martin FH;
 XX
 DR WPI, 1991-119233/17.
 XX
 PT New naturally-occurring polypeptide stem cell factor analogues - have
 XX haematopoietic biological activity of stem cell factor and are used to
 PT treat e.g. leucopenia, AIDS, nerve damage and infertility.
 XX
 PS Disclosure; Fig 12A; 127pp; English.
 XX
 CC Determination of the amino acid sequence of fragments of the rat SCF
 CC protein (see AAK11708) made it possible to design mixed sequence
 CC oligonucleotides (see AAQ1509-526) specific for rat SCF (see AAQ1538
 CC for the genomic and AAQ11539 for the cDNA sequence). The location of this
 CC sequence is 45-65. The SCF has the ability to stimulate growth of
 CC primitive progenitors including early hematopoietic progenitor cells and
 CC non-hematopoietic stem cells such as neural stem cells and primordial
 CC germ stem cells. The product may be used in a pharmaceutical compen. for
 CC treating, in a mammal, leucopenia, thrombocytopenia, anaemia, AIDS,
 CC neoplasia, nerve damage, infertility and intestinal damage
 CC
 SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2402 ATAAATGAAGTGAATCC 2421
 Db 2 ATAAATGCAGTATATCC 21
 RESULT 89
 AAT04911
 ID AAT04911 standard; cDNA; 21 BP.
 XX
 AC AAT04911;
 XX
 DT 25-MAR-2003 (revised)
 DT 15-MAY-1996 (first entry)
 XX
 DE Rat stem cell factor (SCF) cDNA oligonucleotide primer 228-30.
 XX
 KW Stem cell factor; progenitor; haematopoiesis; SCF; anaemia;
 KW thrombocytopenia; leucopenia; AIDS; immunodeficiency; bone graft;
 KW transplant; neoplasia; myelosuppression; bone marrow; ss.
 XX
 OS Synthetic.
 XX
 PN EP676470-A1.
 XX
 PD 11-OCT-1995.
 XX
 PF 04-OCT-1990; 95EP-00105391.
 XX
 PR 16-OCT-1989; 89US-00422383.
 PR 11-JUN-1990; 90US-00537198.
 PR 24-AUG-1990; 90US-00573616.
 PR 28-SEP-1990; 90MO-US005548.
 PR 01-OCT-1990; 90US-00589701.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Zeebo KM, Suggs SV, Bosselman RA, Martin FH;
 XX
 DR WPI, 1995-346090/45.
 XX

PT New stem cell factor polypeptide(s) - for stimulating the growth of
 PT primitive progenitor cells, esp. for treating disorders involving blood
 PT cells.
 XX
 PS Example 3; Fig 12A; 127pp; English.
 XX
 CC AAT04897-T04914 are oligonucleotide primers and probes used for the
 CC amplification and sequencing of rat stem cell factor (SCF). Non-naturally
 CC occurring SCF and C-terminally truncated polypeptides, having amino acid
 CC sequences sufficiently duplicative of naturally occurring SCF, stimulate
 CC growth of primitive progenitors such as haematopoietic progenitor cells,
 CC neural stem cells and primordial germ stem cells. The peptides can be
 CC used in a composition for treating leucopenia, anaemia or
 CC thrombocytopenia, for enhancing engraftment of bone marrow during
 CC transplantation or for bone marrow recovery after chemotherapy or
 CC radiation-induced bone marrow aplasia or myelosuppression. They can also
 CC be used for treating neoplasia, nerve damage, infertility, intestinal
 CC damage or myeloproliferative disorders. Antibodies may be raised against
 CC the peptides for use in detection or neutralisation of SCF in serum. SCF
 CC may be useful for the treatment of AIDS and severe combined
 CC immunodeficiency (SCID) states alone or in combination with other factors
 CC such as IL-7. (Updated on 25-MAR-2003 to correct PF field.)
 XX
 SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2402 ATAAATGAAGTGAATCC 2421
 Db 2 ATAAATGCAGTATATCC 21
 RESULT 90
 AAA13736
 ID AAA13736 standard; DNA; 21 BP.
 XX
 AC AAA13736;
 XX
 DT 27-JUN-2000 (first entry)
 DT
 XX
 DE Rat stem cell factor oligonucleotide 228-30.
 XX
 KW Stem cell factor; SCF; haematopoietic progenitor cell; blood forming;
 KW primitive progenitor cell; haematopoietic disorder; syngeneic;
 KW allogeneic; autologous bone marrow transplant; gene therapy;
 KW transfection; haematopoietic stem cell; acute blood loss; neoplasia;
 KW cancer; ss.
 XX
 OS Rattus sp.
 XX
 PN EP992579-A1.
 XX
 PD 12-APR-2000.
 XX
 PF 04-OCT-1990; 99EP-00122861.
 XX
 PR 16-OCT-1989; 89US-00422383.
 PR 11-JUN-1990; 90US-00537198.
 PR 24-AUG-1990; 90US-00573616.
 PR 28-SEP-1990; 90MO-US005548.
 PR 01-OCT-1990; 90US-00589701.
 PR 04-OCT-1990; 90EP-00310899.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Zeebo KM, Suggs SV, Bosselmann RA, Martin FH;
 XX
 DR WPI, 2000-259135/23.
 XX
 PT Production of hematopoietic cells suitable for administration to a
 PT subject using progenitor cells and expanding the cells using stem cell

PT factor.
 XX
 PS Example 3; Fig 12A, 123pp; English.
 XX
 CC A method has been developed of making haematopoietic cells suitable for
 CC administration to a subject. The method comprises: (a) obtaining
 CC haematopoietic progenitor cells from a donor; and (b) expanding the cells
 CC by adding to the cells a haematopoietically effective dose of a
 CC polypeptide product having at least part of the primary structural
 CC confirmation and one or more of the biological properties of naturally
 CC occurring stem cell factor (SCF). The method is useful for stimulating
 CC primitive progenitor cells including early haematopoietic progenitor
 CC cells which are capable of maturing to erythroid, megakaryocyte,
 CC granulocyte, lymphocyte and macrophage cells. SCF results in absolute
 CC increases in haematopoietic cells of both myeloid and lymphoid lineages.
 CC SCF is useful for treating haematopoietic disorders. The method is useful
 CC for expanding early haematopoietic progenitors in syngeneic, allogeneic
 CC or autologous bone marrow transplant. SCF is useful for enhancing the
 CC efficiency of gene therapy based on transfecting haematopoietic stem
 CC cells. SCF is also useful for combating the myelosuppressive effects of
 CC anti-HIV drugs such as AZT and for enhancing haematopoietic recovery
 CC after acute blood loss and as a boost to the immune system for fighting
 CC neoplasia (cancer). The present sequence represents an oligonucleotide
 CC for rat SCF cDNA which is used in an example from the present invention
 XX
 SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2402 ATTAATGCAAGTGAGATCC 2421
 DB 2 ATTAATGCAAGTGATATATCC 21
 ID AAH41315 standard; DNA; 21 BP.
 AC AAH41315;
 XX
 DT 21-AUG-2001 (first entry)
 XX
 DE Rat stem cell factor (SCF) related oligonucleotide SEQ ID NO:16.
 XX
 KM Stem cell factor; SCF; stem cell factor receptor; blood cell disorder;
 KM Gene therapy; PCR primer; mutagenesis; probe; ss.
 XX
 OS Rattus sp.
 XX
 PN US6207454-B1.
 PD 27-MAR-2001.
 XX
 PF 31-DEC-1998; 98US-00224681.
 XX
 PR 16-OCT-1989; 89US-00422383.
 PR 11-JUN-1990; 90US-00537198.
 PR 24-AUG-1990; 90US-00573616.
 PR 01-OCT-1990; 90US-00589701.
 PR 25-NOV-1992; 92US-00982255.
 PR 21-DEC-1993; 93US-00172329.
 PR 24-MAY-1995; 95US-00449653.
 PR 12-JAN-1998; 98US-00058993.
 XX
 PA (AMGEN-) AMGEN INC.
 XX
 PI Zeebo KM, Bosseelman RA, Suggs SV, Martin FH;
 DR WPI; 2001-366062/38.
 XX
 PT Enhancing efficiency of transfer of polynucleotide into a target

PT mammalian cell in vitro, involves exposing cell that expresses a stem
 PT cell factor receptor to stem cell factor, and introducing polynucleotide
 PT into cell in vitro.
 XX
 PS Example 3; Fig 12A; 210pp; English.
 XX
 CC The present invention describes a method for enhancing (E) the efficiency
 CC of transfer of a polynucleotide (I) into a target mammalian cell (II) in
 CC vitro, comprising exposing (II) that expresses a stem cell factor (SCF)
 CC receptor to a biologically active SCF, its analogue or fragment, which
 CC induces cell proliferation, and introducing (I) to (II) in vitro.
 CC Exposure of SCF to (II) results in increased uptake of (I) into the cell.
 CC The method is useful for enhancing the efficiency of the transfer of a
 CC polynucleotide into a target mammalian cell in vitro. The method is
 CC useful in gene therapy techniques. AAH41301 to AAH41364 and AAB98351 to
 CC AAB98390 represent sequences used in the exemplification of the present
 CC invention
 XX
 SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2402 ATTAATGCAAGTGAGATCC 2421
 DB 2 ATTAATGCAAGTGATATATCC 21
 ID AAS04095 standard; DNA; 21 BP.
 AC AAS04095;
 XX
 DT 29-AUG-2001 (first entry)
 XX
 DE Rat SCF (stem cell factor) cDNA PCR primer 228-30.
 XX
 KM Rat; stem cell factor; SCF; early haematopoietic progenitor cell;
 KM blood disorder; leukaemia; Hodgkin's disease; lymphoma; splenomegaly;
 KM anaemia; Kala azar; septicemia; malaria; hypoplasmatation disorder;
 KM PCR primer; ss.
 XX
 OS Rattus sp.
 XX
 PN US6207417-B1.
 PD 27-MAR-2001.
 XX
 PF 07-JUN-1995; 95US-00482918.
 XX
 PR 16-OCT-1989; 89US-00422383.
 PR 11-JUN-1990; 90US-00537198.
 PR 24-AUG-1990; 90US-00573616.
 PR 01-OCT-1990; 90US-00589701.
 PR 21-DEC-1993; 93US-00172329.
 XX
 PA (ZSEB/) ZSEBO K M.
 PA (BOSS/) BOSSELMAN R A.
 PA (SUGS/) SUGS S V.
 PA (MART/) MARTIN F H.
 XX
 PI Zeebo KM, Bosseelman RA, Suggs SV, Martin FH;
 DR WPI; 2001-298941/31.
 XX
 PT Novel nucleic acids encoding stem cell factor useful for treating
 PT disorders involving blood cells, e.g. leukemia, splenomegaly, Hodgkin's
 PT disease, Kala azar, anemia and septicemia.
 XX
 PS Example 3; Fig 12A; 209pp; English.

CC The present sequence for PCR primer 228-30 is 1 of 18 oligonucleotides
CC (AA504081-AA504098) used to isolate the rat SCF (stem cell factor) cDNA
CC sequence. The present invention relates to novel stem cell factors
CC (AAU02453-AAU02458, AAU02460, AAU02461) and the polynucleotides encoding
CC them. SCF stimulate primitive progenitor cells including early
CC haematopoietic progenitor cells. The invention also describes SCF
CC peptides (AAU02462-AAU02481) and the oligonucleotides (AA504099-AA504117)
CC used in the isolation of human SCF sequences. The polynucleotide encoding
CC SCF is useful for producing SCF and useful in gene therapy. It is useful
CC for treating disorders involving blood cells such as myelofibrosis,
CC metastatic carcinoma, acute leukaemia, multiple myeloma, Hodgkin's
CC disease, lymphoma, Gaucher's disease, anaemia, congestive splenomegaly,
CC Kala azar, sarcoidosis, military tuberculosis, disseminated fungus
CC disease, fulminating septicemia, malaria, vitamin B12 and folic acid
CC deficiency, pyridoxine deficiency, and hypopigmentation disorders such as
CC piebaldism and vitiligo

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

XX SQ

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
|||||
2 ATTAATGCAAGTGATATCC 21

DB

RESULT 93
AAF89075
ID AAF89075 standard; DNA; 21 BP.
XX AAF89075;
XX AC

DT 13-JUN-2001 (first entry)

DE Rat stem cell factor PCR primer SEQ ID NO: 16.

XX Human; rat; mammal; stem cell factor; SCF; cell growth stimulation;
XX gene therapy; haematopoietic disorder; aplastic anaemia; leukaemia;
XX neurological damage; intestinal damage; infertility; AIDS; SCID;
XX severe combined immunodeficiency; PCR primer; ss.

OS Rattus sp.
XX
XX US6207802-B1.
XX PN

PD 27-MAR-2001.
XX PF

XX 09-NOV-1994; 94US-00336728.
XX PR

XX 16-OCT-1989; 89US-00422383.
XX PR 11-JUN-1990; 90US-00537198.
XX PR 24-AUG-1990; 90US-00573616.
XX PR 01-OCT-1990; 90US-00589701.
XX PR 25-NOV-1992; 92US-00982255.
XX PA

XX (AMGE-) AMGEN INC.
XX PI

XX Zsebo KM, Bosselman RA, Suggs SV, Martin FH;
XX DR WPI; 2001-353108/37.
XX PT

XX Novel isolated non-human mammalian stem cell factor polypeptide
XX stimulating growth of early hematopoietic progenitor cells, useful for
XX treating aplastic anemia, lymphoma, Letterer-Siwe disease, Kala azar,
XX sarcoïdosis.
XX PT

XX Example 3; Fig 12A; 209pp; English.
XX PS

XX The present invention provides the protein and coding sequences of
XX mammalian stem cell factors (SCFs). These are capable of stimulating the
XX growth of early haematopoietic progenitor cells, neural stem cells and

CC primordial germ stem cells. The sequences are useful in the treatment of
CC leukaemias, haematopoietic disorders, aplastic anaemia, paroxysmal
CC nocturnal haemoglobinuria, malaria, pigmentation disorders, neurological
CC and intestinal damage, infertility, AIDS and severe combined
CC immunodeficiency (SCID). The present sequence is primer used to amplify
XX an SCF in the exemplification of the invention

XX SQ

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

XX SQ

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
|||||
2 ATTAATGCAAGTGATATCC 21

DB

RESULT 94
AAH23873
ID AAH23873 standard; DNA; 21 BP.
XX AAH23873;
XX AC

DT 07-AUG-2001 (first entry)

DE Rat SCF (stem cell factor) cDNA PCR primer 228-30.

XX Rat; stem cell factor; SCF; early haematopoietic progenitor cell;
XX blood disorder; leukaemia; Hodgkin's disease; lymphoma; splenomegaly;
XX anaemia; Kala azar; septicemia; malaria; hypopigmentation disorder;
XX PCR primer; ss.

OS Rattus sp.
XX
XX US6204363-B1.
XX PN

PD 20-MAR-2001.
XX PF

XX 25-NOV-1992; 92US-00982255.
XX PR

XX 16-OCT-1989; 89US-00422383.
XX PR 11-JUN-1990; 90US-00537198.
XX PR 24-AUG-1990; 90US-00573616.
XX PR 01-OCT-1990; 90US-00589701.
XX PR 10-APR-1991; 91US-00684535.
XX PA

XX (AMGE-) AMGEN INC.
XX PI

XX Zsebo KM, Bosselman RA, Suggs SV, Martin FH;
XX DR WPI; 2001-256683/26.
XX PT

XX New stem cell factor polypeptides and their analogs which stimulate
XX growth of early hematopoietic progenitors, useful for treating aplastic
XX anemia, carcinoma, multiple myeloma, vitiligo, kala azar, Hodgkin's
XX disease.
XX PT

XX Example 3; Fig 12A; 166pp; English.
XX PS

XX The present sequence for PCR primer 228-30 is 1 of 18 oligonucleotides
XX (AAH23859-AAH23876) used to isolate the rat SCF (stem cell factor) cDNA
XX sequence. The present invention relates to novel stem cell factors
XX (AAH73561-AAH73568, AAH73571-AAH73576) and the polynucleotides encoding
XX them. SCF stimulate primitive progenitor cells including early
XX haematopoietic progenitor cells. The invention also describes SCF
XX peptides (AAH73578-AAH73597) and the oligonucleotides (AAH23877-AAH23895)
XX used in the isolation of human SCF sequences. The polynucleotide encoding
XX SCF is useful for producing SCF and useful in gene therapy. It is useful
XX for treating disorders involving blood cells such as myelofibrosis,
XX metastatic carcinoma, acute leukaemia, multiple myeloma, Hodgkin's
XX disease, lymphoma, Gaucher's disease, anaemia, congestive splenomegaly,
XX Kala azar, sarcoidosis, military tuberculosis, disseminated fungus

CC disease, fulminating septicemia, malaria, vitamin B12 and folic acid
CC deficiency, pyridoxine deficiency, and hypopigmentation disorders such as
CC piebaldism and vitiligo

Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATAAATGAAGTGAATCC 2421

Db 2 ATAAATGAAGTGAATCC 21

RESULT 95
AAS04196 standard; DNA; 21 BP.

XX AAS04196;

XX 29-AUG-2001 (first entry)

DE Rat SCF (stem cell factor) cDNA PCR primer 228-30.

XX Rat; stem cell factor; SCF; early haematopoietic progenitor cell;

KW blood disorder; leukaemia; Hodgkin's disease; lymphoma; splenomegaly;

KW anaemia; Kala azar; septicemia; malaria; hypopigmentation disorder;

KW PCR primer; ss.

OS Rattus sp.

XX US6218148-B1.

XX 17-APR-2001.

XX 21-DEC-1993; 93US-00172329.

XX 16-OCT-1989; 89US-00422383.

XX 11-JUN-1990; 90US-00537198.

XX 24-AUG-1990; 90US-00573616.

XX 01-OCT-1990; 90US-00589701.

XX 25-NOV-1992; 92US-00982255.

XX (AMGE-) AMGEN INC.

XX Zeebo KM, Bosselman RA, Suggs SV, Martin FH;

XX WPI; 2001-281051/29.

XX Isolated DNA sequence, encoding polypeptide product useful for

XX stimulating growth of early hematopoietic progenitor cells.

XX Example 3; Fig 12A; 167pp; English.

XX The present sequence for PCR primer 228-30 is 1 of 18 oligonucleotides
CC (AAS04192-AAS04199) used to isolate the rat SCF (stem cell factor) cDNA
CC sequence. The present invention relates to novel stem cell factors
CC (AAU02761-AAU02767, AAU02770-AAU02775, AAU02797) and the polynucleotides
CC encoding them. SCF stimulate primitive progenitor cells including early
CC haematopoietic progenitor cells. The invention also describes SCF
CC peptides (AAU02777-AAU02794) and the oligonucleotides (AAS04200-AAS04218)
CC used in the isolation of human SCF sequences. The polynucleotide encoding
CC SCF is useful for producing SCF and useful in gene therapy. It is useful
CC for treating disorders involving blood cells such as myelofibrosis,
CC metastatic carcinoma, acute leukaemia, multiple myeloma, Hodgkin's
CC disease, lymphoma, Gaucher's disease, anaemia, congestive splenomegaly,
CC Kala azar, sarcoidosis, military tuberculosis, disseminated fungus
CC disease, fulminating septicemia, malaria, vitamin B12 and folic acid
CC deficiency, pyridoxine deficiency, and hypopigmentation disorders such as
CC piebaldism and vitiligo

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATAAATGAAGTGAATCC 2421

Db 2 ATAAATGAAGTGAATCC 21

RESULT 96
AAS10431 standard; DNA; 21 BP.

XX AAS10431;

XX 24-OCT-2001 (first entry)

DE Rat stem cell factor (SCF) cDNA PCR primer 228-30.

XX Rat; stem cell factor; SCF; haematopoietic progenitor cell;

KW blood disorder; Hodgkin's disease; vitamin B12; folic acid deficiency;

KW hypopigmentation disorder; viral disorder; AIDS; PCR primer; ss.

OS Rattus sp.

XX US6248319-B1.

XX 19-JUN-2001.

XX 24-MAY-1995; 95US-00449653.

XX 16-OCT-1989; 89US-00422383.

XX 11-JUN-1990; 90US-00537198.

XX 24-AUG-1990; 90US-00573616.

XX 01-OCT-1990; 90US-00589701.

XX 10-APR-1991; 91US-00684535.

XX 25-NOV-1992; 92US-00982255.

XX 21-DEC-1993; 93US-00172329.

XX (ZSEB/) ZSEBO K M.

XX (BOSS/) BOSSSELMAN R A.

XX (SUGS/) SUGGS S V.

XX (MART/) MARTIN F H.

XX Zeebo KM, Bosselman RA, Suggs SV, Martin FH;

XX WPI; 2001-407312/43.

XX Increasing the number of early hematopoietic progenitor cells in the

XX peripheral blood useful for the treatment of blood disorders including

XX Hodgkin's disease comprises the administration of human stem cell factor.

XX Example 3; Fig 12A; 210pp; English.

XX The present sequence for rat stem cell factor (SCF) cDNA PCR primer 228-
CC 30 is 1 of 18 primers (AAS10417-AAS10434) used to amplify various
CC portions of the rat SCF cDNA sequence. The sequence is described in an
CC invention relating to novel stem cell factors, the polynucleotides
CC encoding them and methods for producing the stem cell factors. The
CC methods involve increasing the number of early haematopoietic progenitor
CC cells in human peripheral blood by administering a haematopoietically
CC effective human stem cell factor polypeptide. The methods are useful for
CC the treatment of blood disorders, including myelofibrosis,
CC myeloid leukaemia, osteopetrosis, metastatic carcinoma, acute leukaemia,
CC multiple myeloma, Hodgkin's disease, lymphoma, Gaucher's disease, Niemann
CC Pick disease, refractory anaemia, malaria, vitamin B12 and folic acid
CC deficiency, hypopigmentation disorders i.e. piebaldism and viral induced
CC disorders, including AIDS

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
|||||
DB 2 ATTAATGCAAGTATATCC 21

RESULT 97

AAD35448
ID AAD35448 standard; DNA, 21 BP.

AC AAD35448;

DT 25-JUL-2002 (first entry)

DE Rat SCF cDNA amplifying PCR primer, 228-30.

KM Rat; stem cell factor; SCF protein; leucopaenia; thrombocytopenia;
KM anaemia; myelosuppression; nerve damage; myeloproliferative disorder;
KM infertility; neoplasia; myelofibrosis; myelosclerosis; osteopetrosis;
KM metastatic carcinoma; acute leukaemia; multiple myeloma; sarcoidosis;
KM Hodgkin's disease; lymphoma; Gaucher's disease; Niemann-Pick disease;
KM Letterer-Siwe disease; refractory erythroblastic anaemia; Kala azar;
KM Di Guglielmo syndrome; congestive splenomegaly; splenic pancytopenia;
KM disseminated fungus disease; fulminating septicaemia; plebaldism; AIDS;
KM acquired immune deficiency syndrome; malaria; military tuberculosis;
KM pyridoxine deficiency; vitamin B12 deficiency; folic acid deficiency;
KM Diamond Blackfan anaemia; hypopigmentation disorder; vitiligo; PCR;
KM primer; ss.

OS Rattus sp.

PN US2002018763-A1.

PD 14-FEB-2002.

PF 12-JUN-1998; 98US-00005243.

PR 24-MAY-1995; 95US-00449653.

PA (ZSEB/) ZSEBO K M.

PA (BOSS/) BOSSELMAN R A.

PA (SUGS/) SUGGS S V.

PA (MART/) MARTIN F H.

PA Zsebo KM, Bosseلمان RA, Suggs SV, Martin FH;

DR WPI; 2002-350789/38.

PT Novel non-naturally-occurring stem cell factor polypeptide, useful for

PT treating leucopenia, thrombocytopenia, anemia and for enhancing

PT engraftment of bone marrow during transplantation in a mammal.

PT Example 3; Fig 12A; 217pp; English.

PS The present invention relates to novel non-naturally-occurring stem cell
CC factor (SCF) polypeptides having an amino acid sequence sufficiently
CC duplicative of that of naturally-occurring SCF to allow possession of
CC haematopoietic biological activity of naturally occurring SCF. Sequences
CC of the invention are useful for treating leucopenia, thrombocytopenia,
CC anaemia and for enhancing bone marrow recovery in treatment of radiation,
CC engraftment of bone marrow during transplantation in mammals and chemical
CC or chemotherapeutic induced bone marrow aplasia or myelosuppression. They
CC are also useful for treating acquired immune deficiency in a human, nerve
CC damage, neoplasia, infertility, myeloproliferative disorder, intestinal
CC damage in a mammal. SCF sequences are useful for preparing biologically
CC active polymer polypeptide adduct, for enhancing transfection of early
CC haematopoietic progenitor cells with a gene, and transfer of a gene into
CC a mammal. They are useful for treating myelofibrosis, myelosclerosis,
CC osteopetrosis, metastatic carcinoma, acute leukaemia, multiple myeloma,
CC Hodgkin's disease, lymphoma, Gaucher's disease, Niemann-Pick disease,
CC Letterer-Siwe disease, refractory erythroblastic anaemia, Di Guglielmo

CC syndrome, congestive splenomegaly, Kala azar, sarcoidosis, primary
CC splenic pancytopenia, disseminated fungus disease, malaria, military
CC tuberculosis, fulminating septicaemia, pyridoxine deficiency, vitamin B12
CC and folic acid deficiency, Diamond Blackfan anaemia, hypopigmentation
CC disorders such as plebaldism, AIDS (acquired immune deficiency syndrome)
CC and vitiligo. The present sequence is a PCR primer which is used for
CC amplifying rat SCF cDNA. This sequence is also used as a probe

SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 84;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
|||||
DB 2 ATTAATGCAAGTATATCC 21

RESULT 98

AB573832
ID AB573832 standard; DNA, 21 BP.

AC AB573832;

DT 05-DEC-2002 (first entry)

DE Rat SCF cDNA oligonucleotide 228-30.

KM Stem cell factor; SCF; blood-forming system; blood cell disorder;
KM haematopoietic system; metastatic carcinoma; acute leukaemia;
KM multiple myeloma; Hodgkin's disease; lymphoma; malaria; vitiligo;
KM refractory erythroblastic anaemia; military tuberculosis; cytostatic;
KM disseminated fungus disease; haematopoietic; tuberculosis;
KM antianaemic; antifungal; antimalarial; dermatological; rat; ss.

OS Rattus norvegicus.

PN EP1241258-A2.

PD 18-SEP-2002.

PF 04-OCT-1990; 2002EP-00008587.

PR 16-OCT-1989; 89US-00422383.

PR 11-JUN-1990; 90US-00537198.

PR 24-AUG-1990; 90US-00573616.

PR 28-SEP-1990; 90WO-US005548.

PR 01-OCT-1990; 90US-00589701.

PR 04-OCT-1990; 90EP-00310899.

PR 04-OCT-1990; 95EP-00105391.

PA (AMGE-) AMGEN INC.

PA Zsebo KM, Suggs SV, Bosseلمان RA, Martin FH;

DR WPI; 2002-684093/74.

PT Production of a human stem cell factor (SCF) polypeptide for treating

PT disorders involving blood cells, such as leukemia, compriess culturing

PT mammalian cells comprising non-human SCF promoter DNA linked to DNA

PT encoding the human SCF.

PT Example 3; Fig 12A; 120pp; English.

PS The present invention relates to novel stem cell factors (SCFs),
CC polynucleotide sequences encoding the SCFs, and methods of producing
CC them. SCFs are involved in the blood-forming (haematopoietic) system in
CC mammals, particularly humans. The method of the invention is useful for
CC the production of human SCF. The stem cell factors are useful to treat
CC disorders involving blood cells e.g. metastatic carcinoma, acute
CC leukaemia, multiple myeloma, Hodgkin's disease, lymphoma, refractory
CC erythroblastic anaemia, military tuberculosis, disseminated fungus

CC disease, malaria, and vitiligo. The present sequence representing an
CC oligonucleotide for rat SCF cDNA is used in the examples of the present
CC invention

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2402 ATAAATGAAAGTGAGATCC 2421

DB 2 ATAAATGCAAGTGATATCC 21

RESULT 99

ADE35984 ADE35984 standard; DNA; 21 BP.

XX ADE35984;

DT 29-JAN-2004 (first entry)

XX Y. pestis specific PCR primer #5.

KW PCR; primer; ss; genome signature tag; library;

KW genome signature tag library.

OS Yersinia pestis.

XX US2003186251-A1.

PD 02-OCT-2003.

PF 01-APR-2002; 2002US-0013916.

PR 01-APR-2002; 2002US-0013916.

PA (BROCO-) BROOKHAVEN SCI ASSOC LLC.

PI Dunn JF, Van Der Lelje D, Krause MK;

DR WPI; 2003-844149/78.

XX Generating a genome signature tag library useful for genetic analysis.

PS Example; Page 7; 12pp; English.

CC The invention relates to a method of generating a genome signature tag
CC library. The method is used for generating a genome signature tag
CC library. The present sequence represents a Y. pestis specific PCR primer.

XX Sequence 21 BP; 4 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 487 CCTGCAGTGCCTCTCANG 506

DB 1 CATGCAGTGCCTCTCANG 20

RESULT 100
ADE52444 ADE52444 standard; DNA; 21 BP.

XX ADE52444;

DT 29-JAN-2004 (first entry)

XX Stem cell factor (SCF) related DNA #15.

KW Stem cell factor; SCF; hematopoietic activity; infertility;
KW intestinal damage; myeloproliferative disorder; leucopenia;
KW thrombocytopenia; anaemia; bone marrow transplant; immune deficiency;
KW neoplasia; nerve damage; osteoporosis; metastatic carcinoma; leukaemia;
KW military tuberculosis; hematopoietic progenitor cell; ss.

OS Synthetic.

XX US2002031491-A1.

PD 14-MAR-2002.

PF 31-DEC-1998; 98US-00224683.

PR 16-OCT-1998; 89US-00422383.

PR 11-JUN-1990; 90US-00537198.

PR 24-AUG-1990; 90US-00573616.

PR 01-OCT-1990; 90US-00589701.

PR 10-APR-1991; 91US-00684535.

PR 25-NOV-1992; 92US-00982255.

PR 21-DEC-1993; 93US-00172329.

PR 24-MAY-1995; 95US-00449653.

PR 12-JAN-1998; 98US-00005893.

PA (ZSEB/) ZSEBO K M.

PA (BOSS/) BOSSSELMAN R A.

PA (SUGG/) SUGGS S V.

PA (MART/) MARTIN F H.

PI Zsebo KM, Bosselman RA, Suggs SV, Martin FH;

DR WPI; 2003-851459/79.

XX New non-natural stem cell factor, useful for treating e.g. leucopenia or

PT immune deficiency, also related nucleic acid and antibodies.

PS Disclosure; SEQ ID NO 16; 217pp; English.

CC The invention relates to stem cell factor (SCF) polypeptides with
CC hematopoietic activity and the polynucleotides encoding them. The
CC polypeptides are used for treating infertility, intestinal damage,
CC myeloproliferative disorders, leucopenia, thrombocytopenia or anaemia,
CC for improving engraftment of bone marrow transplants, for enhancing bone
CC marrow recovery after radiotherapy or chemotherapy and in treatment of
CC immune deficiency, neoplasia, nerve damage, osteoporosis, metastatic
CC carcinoma, leukaemia and military tuberculosis. The SCF polypeptides are
CC also used to expand hematopoietic progenitor cells for transplantation
CC and to prepare such cells for transfection with a gene. The SCF
CC polynucleotides can be used for recombinant expression of the
CC polypeptides and also as probes for mapping of the SCF gene, for
CC identifying SCF-related diseases and as a marker for neighbouring genes.
CC Antibodies raised against the polypeptides are useful in diagnosis and to
CC remove SCF from blood. This sequence represents SCF related DNA of the
CC invention.

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2402 ATAAATGAAAGTGAGATCC 2421

DB 2 ATAAATGCAAGTGATATCC 21

RESULT 101

ADP99286 ADP99286 standard; DNA; 21 BP.

XX ADP99286;

DT 23-SEP-2004 (first entry)

XX Rat stem cell factor, SCF, PCR primer #15.
 DE Rat; SCF; stem cell factor; gene therapy; hematopoietic progenitor cell;
 XX aplastic anaemia; paroxysmal nocturnal haemoglobinuria; myelofibrosis;
 KM myelocystic leukaemia; osteopetrosis; metastatic carcinoma; acute leukaemia;
 KM multiple myeloma; Hodgkin's disease; lymphoma; Gaucher's disease;
 KM Niemann-Pick disease; Letterer-Siwe disease;
 KM refractory erythroidlastic anaemia; Di Guglielmo syndrome;
 KM congestive splenomegaly; Kala awar; sarcoidosis;
 KM primary splenic pancytopenia; miliary tuberculosis;
 KM disseminated fungus disease; Fulminating septicemia; malaria;
 KM vitamin B12 deficiency; folic acid deficiency; pyridoxine deficiency;
 KM Diamond Blackfan anaemia; hypopigmentation disorder; piebaldism;
 KM vitiligo; neurological damage; infertility; intestinal damage;
 KM irradiation; chemotherapy; AIDS; hematopoietic recovery;
 KM acute blood loss; neoplasm; cancer; ss; PCR; primer.
 XX Rattus norvegicus.
 OS Synthetic.
 XX US6759215-B1.
 PN 06-JUL-2004.
 PD 07-AUG-2000; 2000US-00635251.
 XX 16-OCT-1989; 89US-00422383.
 PR 11-JUN-1990; 90US-00537198.
 PR 24-AUG-1990; 90US-00573616.
 PR 01-OCT-1990; 90US-00589701.
 PR 10-APR-1991; 91US-00684535.
 PR 25-NOV-1992; 92US-00982255.
 PR 21-DEC-1993; 93US-00117329.
 PR 24-MAY-1995; 95US-00449182.
 XX (AMGE-) AMGEN INC.
 PA Zeebo KM, Bosselman RA, Suggs SV, Martin FH;
 PI WPI; 2004-497128/47.
 DR Preparing a human stem cell factor (SCF) polypeptide, useful for treating
 PT hematopoietic disorders, e.g., aplastic anemia, comprises growing host
 PT cells transformed or transfected with DNA encoding a human SCF.
 XX Example 3; SEQ ID NO 16; 210pp; English.
 PS The invention relates to preparing a (vertebrate) human stem cell factor
 CC (SCF) polypeptide comprising growing host cells transformed or
 CC transfected with DNA encoding a human SCF that stimulates growth of
 CC hematopoietic progenitor cells under nutrient conditions, the DNA being
 CC operatively linked to an expression control sequence, and isolating the
 CC polypeptide produced. Also included is a recombinant host cell
 CC transformed or transfected with an expression construct comprising a
 CC vertebrate SCF polypeptide-encoding DNA operatively linked to a
 CC heterologous expression regulatory sequence, permitting the expression of
 CC the vertebrate SCF polypeptide in the host cell. Disclosed as new are rat
 CC and human nucleic acids encoding SCF, SCF protein fragments. The DNA
 CC sequences are useful for effecting the large scale synthesis of SCF by a
 CC variety of recombinant techniques or for generating new and useful viral
 CC and circular plasmid DNA vectors, new and useful transformed and
 CC transfected prokaryotic and eukaryotic host cells, and new and useful
 CC methods for cultured growth of such host cells capable of expression of
 CC SCF and its related products. The DNA sequences are also useful as
 CC labeled probes in isolating human genomic DNA encoding SCF, in methods
 CC of protein synthesis, in genetic therapy in humans and other mammals, and
 CC in developing transgenic mammalian species which may serve as eukaryotic
 CC hosts for production of SCF and SCF products in quantity. The SCF is
 CC useful for treating hematopoietic disorders, e.g., aplastic anaemia,
 CC paroxysmal nocturnal haemoglobinuria, myelofibrosis, myelocystic leukaemia,
 CC osteopetrosis, metastatic carcinoma, acute leukaemia, multiple myeloma,

CC Hodgkin's disease, lymphoma, Gaucher's disease, Niemann-Pick disease,
 CC Letterer-Siwe disease, refractory erythroidlastic anaemia, Di Guglielmo
 CC syndrome, congestive splenomegaly, Kala awar, sarcoidosis, primary
 CC splenic pancytopenia, miliary tuberculosis, disseminated fungus disease,
 CC fulminating septicemia, malaria, vitamin B 12 and folic acid deficiency,
 CC pyridoxine deficiency, Diamond Blackfan anaemia, and hypopigmentation
 CC disorders such as piebaldism and vitiligo. The SCF are also useful for
 CC treating neurological damage, infertility states, intestinal damage
 CC resulting from irradiation or chemotherapy, and AIDS. SCF is also useful
 CC for enhancing hematopoietic recovery after acute blood loss and as a
 CC boost to the immune system for fighting neoplasia (cancer). The present
 CC sequence is a rat SCF PCR primer used in the isolation of SCF DNA.
 XX
 SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2402 ATTAATGAAGTGAATCC 2421
 DB 2 ATTAATGCAAGTGAATCC 21
 RESULT 102
 ADD01326/C
 ID ADD01326 standard; DNA; 22 BP.
 XX
 AC ADD01326;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human STAT-1 inhibitor oligonucleotide SEQ ID 41.
 XX
 XX ss; inhibitor; STAT-1; signal transducer and activator of transcription;
 XX cardiovascular; restenosis; percutaneous angioplasty; stenosis;
 XX graft versus host reaction; ischaemic injury; reperfusion injury;
 XX organ transplantation; immunological hypersensitivity; allergic rhinitis;
 XX food; urticaria; celiac disease; contact dermatitis;
 XX immune complex disease; alveolitis; arthritis; bone disease;
 XX glomerulonephritis; allergic vasculitis; gout; osteitis; osteomyelitis;
 XX polyneuritis; bronchitis; endocarditis; hepatitis; myocarditis;
 XX nephritis; pericarditis; peritonitis; pancreatitis; septic shock;
 XX vasculitic; immunosuppressive; antiallergic; antiinflammatory;
 XX dermatological; antiarthritic; nephrotropic; antitumor; osteopathic;
 XX hepatotropic; virucide; cardiac; antibacterial; human.
 XX
 XX Homo sapiens.
 OS
 XX WO2003030944-A2.
 PN 17-APR-2003.
 XX
 PD 02-OCT-2002; 2002WO-DE003748.
 XX
 PF 04-OCT-2001; 2001DE-01048886.
 XX
 PR (AVON-) AVONTEC GMBH.
 PA Hecker M, Wagner AH;
 PI WPI; 2003-381684/36.
 DR Use of inhibitor of STAT-1 activity, for treating or preventing e.g.
 CC cardiovascular complications, graft versus host reactions or
 CC immunological hypersensitivity.
 PT
 PT Disclosure; SEQ ID NO 41; 53pp; German.
 PS This invention describes the novel use of an inhibitor of STAT-1 (signal
 CC transducer and activator of transcription) for prevention or treatment of
 CC cardiovascular complications and other diseases e.g. restenosis after
 CC percutaneous angioplasty or stenosis in venous by-passes; graft versus

CC host reactions; ischemic/reperfusion injury in surgical operations or
CC organ transplantation; immunological hypersensitivity reactions;
CC especially allergic rhinitis, food and medicine allergies (particularly
CC urticaria and celiac disease), contact dermatitis, immune complex
CC diseases, especially alveolitis, arthritis, glomerulonephritis and
CC allergic vasculitis, inflammatory cartilage and bone diseases (especially
CC arthritis, gout, osteitis and osteomyelitis), polynneuritis, also
CC (sub)acute infection-related, particularly post-infection, inflammatory
CC conditions, particularly bronchitis, endocarditis, hepatitis,
CC myocarditis, nephritis, pericarditis, peritonitis and pancreatitis,
CC including septic shock. The inhibitor is a double-stranded (ds) DNA
CC oligonucleotide which acts as a decoy, a single-stranded antisense
CC oligonucleotide, an antisense expression vector or ds RNA-interference
CC (RNAi) oligonucleotide. The products of the invention have vasotropic,
CC immunosuppressive, anti-allergic, anti-inflammatory, dermatological,
CC anti-arthritic, nephroprotective, anti-gout, osteopathic, hepatotropic,
CC virocidic, cardiant and antibacterial activity. ADD01286-ADD01346
CC represent the STAT-1 decoy oligonucleotides used in the method of the
CC invention.

SO Sequence 22 BP; 6 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 589 GTGGCAGAGTCTCAGTGG 608
DB 22 GTGGCAGAGTCTCAGTGG 3

RESULT 103
ADC79529/c
ID ADC79529 standard; DNA; 22 BP.

AC ADC79529;

DT 01-JAN-2004 (first entry)

DE Human STAT-1 decoy oligonucleotide #41.

XX vasotropic; anti-allergic; neuroprotective; immunosuppressive;
XX anti-rheumatic; anti-inflammatory; dermatological; anti-arthritic;
XX anti-asthmatic; anti-diabetic; antiparasitic; antibacterial; STAT-1;
XX proinflammatory; leucocyte; endothelial cell; smooth muscle cell; CD40;
XX E-selectin; inducible nitric oxide synthase; iNOS; interleukin-12;
XX interferon-gamma; cardiovascular; restenosis; percutaneous angioplasty;
XX transplant rejection; graft versus host disease; diabetes mellitus;
XX hypersensitivity reaction; autoimmune disease; diabetes mellitus;
XX multiple sclerosis; rheumatoid arthritis; chronic inflammatory disease;
XX arthritis; asthma; bronchitis; psoriasis; neurodermatitis;
XX ulcerative colitis; Crohn's disease; psoriasis; neurodermatitis;

XX Homo sapiens.

XX WO2003031459-A2.

XX PD 17-APR-2003.

XX PF 02-OCT-2002; 2002WO-DE003747.

XX PR 04-OCT-2001; 2001DE-01048828.

XX PA (AVON-) AVONTEC GMBH.

XX PI Hecker M, Wagner AH;

XX DR WPI; 2003-363361/34.

XX PT New decoy oligonucleotides, useful for treating and preventing e.g.
XX PT cardiovascular complications or transplant rejection, by neutralization
XX PT of STAT-1.

PS Claim 3, SEQ ID NO 41; 52pp; German.

XX This invention describes novel decoy oligonucleotides which have
XX vasotropic, anti-allergic, neuroprotective, immunosuppressive,
XX anti-rheumatic, anti-inflammatory, dermatological, anti-arthritic,
XX anti-asthmatic, anti-diabetic, antiparasitic and antibacterial activity.
XX The oligonucleotides neutralise or inhibit expression of STAT-1 and thus
XX of a range of potentially proinflammatory gene products in leucocytes,
XX endothelial and smooth muscle cells. Genes that have a STAT-1 binding
XX site in their promoters include those for CD40, E-selectin, inducible
XX nitric oxide synthase (NOS), interleukin-12 and interferon-gamma. Also
XX the oligonucleotides of the invention may lift inhibition of gene
XX expression where this is blocked by transcription factors, e.g. the gene
XX for endothelial NOS which is down regulated by interferon-gamma. The
XX decoy oligonucleotide and new antisense oligonucleotides, are used to
XX treat or prevent cardiovascular complications, especially restenosis
XX after percutaneous angioplasty and stenosis in venous by-passes,
XX transplant rejection, graft versus host disease, ischemic/reperfusion
XX injuries of surgery, immunological hypersensitivity reactions (types I-
XX V), autoimmune diseases (especially diabetes mellitus, multiple sclerosis
XX and rheumatoid arthritis), all forms of (sub)acute or chronic
XX inflammatory diseases, especially of the joints (arthritis), respiratory
XX organs (bronchial asthma and chronic bronchitis), skin (psoriasis and
XX neurodermatitis) or gastrointestinal tract (ulcerative colitis or Crohn's
XX disease). ADC79489-ADC79549 represent the decoy oligonucleotides
XX described in the disclosure of the invention.

SO Sequence 22 BP; 6 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 589 GTGGCAGAGTCTCAGTGG 608
DB 22 GTGGCAGAGTCTCAGTGG 3

RESULT 104

ADR77478
ID ADR77478 standard; DNA; 19 BP.

AC ADR77478;

DT 16-DEC-2004 (first entry)

DE Human apolipoprotein B (ApoB) oligonucleotide seqid 1963.

XX anti-lipemic; cardiant; vasotropic; anti-arteriosclerotic; anti-diabetic;
XX cytoprotic; anticonvulsant; nootropic; muscular; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX colon cancer; lung cancer; neurological disease; Huntington disease;
XX spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; se.

XX Homo sapiens.

XX WO2004080406-A2.

XX PD 23-SEP-2004.

XX PF 08-MAR-2004; 2004WO-US007070.

XX PR 07-MAR-2003; 2003US-0452682P.

XX PR 12-MAR-2003; 2003US-0454265P.

XX PR 13-MAR-2003; 2003US-0454962P.

XX PR 13-MAR-2003; 2003US-0455050P.

XX PR 14-APR-2003; 2003US-0462894P.

XX PR 17-APR-2003; 2003US-0463772P.

XX PR 25-APR-2003; 2003US-0465665P.


```

SQ Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 215 TCGGCGCGGCTTCAGCCAT 232
DB 1 TCGGCGCGGCTTCAGCCAT 18

RESULT 106
AAD09637/C
ID AAD09637 standard; DNA; 20 BP.
XX
AC AAD09637;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human PKA C-alpha chimeric antisense oligonucleotide (ISIS# 102594).
XX
KW Human; protein kinase A; PKA catalytic subunit C-alpha inhibitor;
KM therapy; infection; inflammation; tumour; prophylaxis; antisense;
XX phosphorothioate backbone; chimeric; ss.
OS Homo sapiens.
OS Synthetic.
OS Chimeric.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "Methoxyethyl residues"
FT modified_base 4
FT /tag= c
FT /mod_base= m5c
FT misc_feature 6..15
FT /tag= d
FT /note= "Central gap region"
FT modified_base 16..20
FT /tag= e
FT /mod_base= OTHER
FT /note= "Methoxyethyl residues"
FT modified_base 17..19
FT /tag= f
FT /mod_base= m5c
XX
XX US6248586-B1.
XX
XX 19-JUN-2001.
XX
XX 17-DEC-1999; 99US-00467082.
XX
XX 17-DEC-1999; 99US-00467082.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Montia BP, Cowseert LM;
XX
XX WPI; 2001-407321/43.
XX
XX Antisense oligonucleotides for inhibiting the expression of the human
XX protein kinase A catalytic subunit C-alpha, particularly useful for
XX preventing, delaying or treating infection, inflammation or tumor
XX formation.
XX
XX Claim 1; Col 44; 35pp; English.
XX
```

```

CC The invention is directed to antisense compounds, particularly
CC oligonucleotides which are targeted to a DNA encoding human protein
CC kinase A (PKA) catalytic subunit C-alpha to modulate (inhibit) its
CC expression. The antisense compounds are useful for diagnostics,
CC therapeutics, prophylaxis and as research reagents or kits. The antisense
CC oligonucleotides are useful for treating human, suspected of having or
CC being prone to a disease or condition associated with the expression of
CC PKA catalytic subunit C-alpha. In particular, the antisense
CC oligonucleotides are useful for preventing, delaying or treating
CC infection, inflammation and tumour formation. They are also useful in
CC antisense therapy. The present sequence is a chimeric antisense
CC oligonucleotide with a phosphorothioate backbone. This oligo is targeted
CC to the 5' untranslated region (UTR) of human PKA catalytic subunit C-
CC alpha to inhibit its expression
XX
SQ Sequence 20 BP; 0 A; 8 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 68 CTGCGCGCGCGCGCGCAGC 85
DB 20 CGGCGCGCGCGCGCGCAGC 3

RESULT 107
AAZ30148
ID AAZ30148 standard; DNA; 21 BP.
XX
AC AAZ30148;
XX
DT 26-JAN-2000 (first entry)
XX
DE PCR primer pnf12 used to amplify DNA encoding 3' end of P44-12 protein.
XX
KW Human granulocytic ehrlichiosis; HGE; HGE agent; P44 protein; P44-12;
KM outer membrane protein; hypervariable region; HVR; CR1; CR2; vaccine;
XX Ehrlichia chaffeensis; Borrelia burgdorferi; PCR primer; ss.
XX
OS Synthetic.
OS Ehrlichia sp.
XX
XX W09952370-A1.
XX
XX 21-OCT-1999.
XX
XX 08-APR-1999; 99WO-US007759.
XX
XX 09-APR-1998; 98US-0081192P.
XX
XX 07-APR-1999; 99US-0128087P.
XX
XX (OHIS ) OHIO STATE RES FOUND.
XX
XX Rikhsa Y, Zhi N, Ohashi N;
XX
XX WPI; 1999-620249/53.
XX
XX New outer membrane proteins from the agent that causes human granulocytic
XX ehrlichiosis, used for diagnosis, treatment and prevention.
XX
XX Example 2; Page 24; 52pp; English.
XX
XX PCR primers AAZ30148-49 were used to amplify DNA encoding P44-12 protein
XX of the agent that causes human granulocytic ehrlichiosis (HGE). P44
XX proteins are outer membrane proteins, which comprise a hypervariable
XX region (HVR), and two conserved regions (CR1 and CR2), linked, directly
XX or indirectly through a linker to the N-terminus and C-terminus,
XX respectively, of HVR. The proteins are used to diagnose HGE, by binding to
XX antibodies present in infected subjects and as immunogens or vaccines for
XX treatment/prevention of HGE. Antibodies against Ab are used for
XX immunolabeling of isolates of the HGE agent, for detecting HGE in
XX biological samples, for affinity purification of P44 proteins and for
```

CC identifying P44-expressing cells. P44 nucleic acids are used for
CC recombinant production of the protein, and as a source of primers or
CC probes (for isolating and identifying cDNA or genomic clones, their
CC allelic variants or transcripts, or for amplification) or as antisense
CC reagents. The P44 proteins can be used to differentiate between infection
CC by the HGE agent and infection by *Escherichia chaffeensis* or *Borrelia*
CC *burgdorferi*.
XX
SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 GTTTGACTGGAAACACACC 580
Db 4 GTTTGACTGGAAACACTCC 21

RESULT 108
ADA50411
ID ADA50411 standard; DNA; 21 BP.
AC ADA50411;
XX
XX
DT 20-NOV-2003 (first entry)
XX
DE Thermus scotoductus nucleic acid polymerase PCR primer SEQ ID NO:36.
XX
XX nucleic acid polymerase; enzyme; Thermus scotoductus; DNA polymerase;
KM salt tolerance; thermostability; PCR primer; ss.
XX
OS Synthetic.
XX Thermus scotoductus.
XX
XX WO2003066804-A2.
XX
XX 14-AUG-2003.
XX
XX 13-SEP-2002; 2002WO-US029102.
XX
XX 14-SEP-2001; 2001US-0322218P.
XX
XX 30-NOV-2001; 2001US-0334489P.
XX
XX (APPL-) APPLERA CORP.
XX (BOLC/) BOLCHAKOVA E V.
XX (ROZZ/) ROZZELLE J E.
XX
XX Bolchakova EV, Rozzelle JE;
PI
XX
XX WPI; 2003-663590/62.
XX
XX
XX New nucleic acid encoding a Thermus scotoductus strain X-1, ATCC Deposit
PT No. 27978 nucleic acid polymerase, useful for producing nucleic acid
PT polymerases having e.g., improved sequence discrimination or better salt
PT tolerance.
XX
XX Example 1; Page 81; 179pp; English.
XX
XX The present invention describes isolated nucleic acids encoding nucleic
XX acid polymerases from Thermus scotoductus. Also described: (1) an
XX isolated nucleic acid (I) encoding a nucleic acid polymerase from Thermus
XX scotoductus strain X-1, ATCC Deposit No. 27978; (2) an isolated DNA
XX polymerase polypeptide from Thermus scotoductus strain X-1, ATCC Deposit
XX No. 27978; (3) an isolated nucleic acid (II) comprising any of a set of
XX 12 nucleic acid sequences (S1, see ADA50425 to ADA50436) which encodes a
XX nucleic acid polymerase; (4) an isolated nucleic acid (III) encoding a
XX nucleic acid polymerase comprising any of a set of 16 amino acid
XX sequences (S2, see ADA50389 to ADA50404); (5) isolated nucleic acid
XX polymerases comprising any of amino acid sequences S2; (6) vectors
XX comprising (I), (II), or (III), and especially expression vectors in
XX which the nucleic acid polymerase gene is operably linked to a promoter;
XX (7) a host cell comprising an isolated nucleic acid molecule encoding a

CC nucleic acid polymerase from Thermus scotoductus strain X-1, ATCC Deposit
CC No. 27978; (8) a host cell comprising (I) or (II); (9) a kit comprising a
CC container containing a nucleic acid polymerase comprising any of amino
CC acid sequences S2; (10) preparing (M1) a nucleic acid polymerase
CC comprising any of amino acid sequences S2 by incubating a host cell
CC comprising an encoding nucleic acid under conditions sufficient for RNA
CC transcription and translation; (11) a nucleic acid polymerase prepared by
CC M1; (12) synthesizing DNA (M2) comprising contacting a polypeptide
CC comprising any of amino acid sequences S2 with a DNA under conditions
CC sufficient to permit DNA polymerisation; (13) a method (M3) for
CC chemocyclic amplification of nucleic acid; and (14) a method (M4) of
CC primer extension. The nucleic acid is useful for producing nucleic acid
CC polymerases having improved sequence discrimination, better salt
CC tolerance or varying degrees of thermostability with applications e.g. in
CC PCR and DNA sequencing. The present sequence represents a PCR primer for
CC Thermus scotoductus nucleic acid polymerase, which is used in an example
XX from the present invention.
XX
SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1322 GACCCTGGTGAAGCTCTT 1339
Db 3 GACCATGCTGAAGCTCTT 20

RESULT 109
ADR87061
ID ADR87061 standard; DNA; 21 BP.
XX
XX ADR87061;
XX
XX 16-DEC-2004 (first entry)
XX
XX
XX Human ephrinB2 short interference RNA seqid 366.
XX
XX
XX
XX Cytostatic; antiinflammatory; antirheumatic; antipneumatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmacological; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; human; ephrin B2; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
XX
XX
XX Homo sapiens.
XX
XX
XX WO2004080425-A2.
XX
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Kerebesz N, Reddy R, Gail P;
XX WPI; 2004-668883/65.
XX
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
XX Example 9; Page 98; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B2 siRNA that can be used to control EphB2
CC expression.

SO Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 AGCCATGAAGACCTCAT 244
DB 4 AGCCATGAAGATCCTCAT 21
|||||
|||||

RESULT 110

ID ADR82616 standard; DNA; 21 BP.

XX ADR82616;

DT 16-DEC-2004 (first entry)

DE Human EphrinB2 antisense RNAi probe #18.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antineoplastic; antiproliferative;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX Homo sapiens.
XX WO2004080418-A2.
XX 23-SEP-2004.

PD 12-MAR-2004; 2004WO-US007491.

PF 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

PA Reddy R, Gill P;

PI WPI; 2004-668879/65.

DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX Example 9; Page 105; 206BP; English.

PS The invention relates to an isolated nucleic acid compound comprising at
XX

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphrinB2
CC antisense RNAi probe.

SO Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 AGCCATGAAGACCTCAT 244
DB 4 AGCCATGAAGATCCTCAT 21
|||||
|||||

RESULT 111

ID AA063503 standard; DNA; 21 BP.

XX AA063503;

DT 17-JAN-1995 (first entry)

DE NANBH primer 77R, binding position 2535-2554.

XX Polymerase chain reaction; PCR; amplify; primer; non-A, non-B hepatitis;
XX NANBH; virus; blood transmissible; detection; hepatitis virus; RT-PCR;
XX C100 antibody; HCV RNA; NS5 region; ss.
XX Synthetic.

OS JP06105690-A.

PN 19-APR-1994.

PD 10-MAR-1992; 92JP-00051885.

PF 10-MAR-1992; 92JP-00051885.

PR (KAEN)/ KAENNO K.

XX WPI; 1994-163130/20.

DR Blood-transmissible non-A non-B hepatitis virus DNA - used for detection
XX of hepatitis virus.
XX Example 1; Page 3; 22pp; Japanese.

CC The sequences given in AA063500-35 are primers which were used in the
CC amplification of regions of the non-A, non-B hepatitis (NANBH) virus
CC genome. The pref. virus is blood transmissible and the amplified
CC fragments are used in the detection of hepatitis virus. The target DNA
CC was isolated from serum of chronically infected NANBH patients who were
CC C100 antibody-positive and HCV RNA (NS5 region) positive. Reverse
CC transcription-PCR and PCR were performed on cDNA and the total human
CC NANBH DNA was constructed from 23 clones (see also AA063499)

XX Sequence 21 BP; 8 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1256 CACCATCCCAAGCTGAGCA 1276
DB 1 CATCATCCCAAGCAGAGCA 21
|||||
|||||

```
RESULT 112
AAZ26556
ID AAZ26556 standard; DNA; 21 BP.
XX
AC AAZ26556;
XX
DT 30-NOV-1999 (first entry)
XX
DE Human polymorphic region 745.
XX
KW Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
KW cell viability; loss of heterozygosity; precancerous condition; ASI;
KW allele specific inhibitor; somatic cell; diagnosis; prevention;
KW atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
KW graft versus host disease; malignant cell removal; bone marrow; ss.
XX
OS Homo sapiens.
XX
PN WO9841648-A2.
XX
PD 24-SEP-1998.
XX
PF 19-MAR-1998; 98WO-US005419.
XX
PR 20-MAR-1997; 97US-0041057P.
XX
PA (VARI-) VARIAGENICS INC.
XX
PI Housman D, Ledley FD, Stanton VP;
XX
DR WPI; 1998-521232/44.
XX
PT Identifying target genes for allele-specific drugs - used for diagnosis,
PT prevention and treatment of, e.g. cancers, atherosclerotic plaque,
PT dysplastic lesions, endometriosis or graft versus host disease.
XX
PS Disclosure; Fig 7; 605pp; English.
XX
CC This invention describes a novel method for identifying an inhibitor
CC potentially useful for treatment of cancer, where the inhibitor is active
CC on a gene vital for cell growth or viability, and where the gene is
CC subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is
CC used for preventing the development of cancer in a patient having a
CC precancerous condition, by administering to the patient a first allele
CC specific inhibitor (ASI) targeted to an allele of a first essential gene
CC present in cells of the precancerous condition, where the normal somatic
CC cells of the patient are heterozygous for the first gene, the inhibitor
CC is active on at least one but less than all allelic forms of the gene
CC present in a population and targets only one allelic form present in the
CC normal somatic cells, and the first gene. The products and methods can be
CC used in the diagnosis, prevention and treatment of LOH disorders, e.g.
CC cancers, atherosclerotic plaques, premalignant metaplastic or dysplastic
CC lesions, benign tumours, endometriosis, polycystic kidney disease, and
CC graft versus host disease. The method can also be used to remove
CC malignant cells from bone marrow transplants. AAZ25812-226825 represent
CC human polymorphic sites described in the method of the invention
XX
SQ Sequence 21 BP; 6 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 822 AACTTCGAAATGCGTGTGTTG 842
DB 1 AACTTCAGAAAGCCAGTGTG 21
```

```
RESULT 113
AAF96288
ID AAF96288 standard; DNA; 21 BP.
```

```
XX
AC AAF96288;
XX
DT 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
DE Human gene single nucleotide polymorphism #1049.
XX
KW Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
OS Homo sapiens.
XX
PN WO200118250-A2.
XX
PD 15-MAR-2001.
XX
PF 07-SEP-2000; 2000WO-US024503.
XX
PR 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX
DR WPI; 2001-226749/23.
XX
PT Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
PS Example; Page 123; 242pp; English.
XX
CC The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
CC Revised record issued on 18-NOV-2004 : The variation feature was
CC incorrectly given a capital V
XX
SQ Sequence 21 BP; 8 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 745 GCAACTTCAGCAGAGGCCA 765
DB 1 GTAACCTCAGCAAAAGGCCA 21
```

```
RESULT 114
ADQ93958
```

```

ID ADQ93958 standard; DNA; 21 BP.
XX
XX ADQ93958;
AC
XX
DT 23-SEP-2004 (first entry)
XX
DE Human oestrogen receptor (ER)-alpha DNA amplifying forward RT-PCR primer.
XX
XX Androgen-independent prostate cancer; hormone refractory prostate cancer;
XX benzothiphene; therapy; human; ER; oestrogen receptor; RT;
XX reverse transcription; PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX US2004132776-A1.
XX
XX 08-JUL-2004.
XX
XX 23-JUL-2003; 2003US-00625152.
XX
XX 09-MAY-2002; 2002US-00142087.
XX
XX (CEDA-) CEDARS SINAI MEDICAL CENT.
XX
XX Agus DB;
XX
XX WPI; 2004-517037/49.
XX
XX Use of benzothiphene derivatives for preventing and/or treating androgen
XX -independent prostate cancer in mammals.
XX
XX Example 6; SEQ ID NO 4; 21bp; English.
XX
XX The present invention relates to a method for treating and preventing
XX androgen-independent prostate cancer (also called hormone refractory
XX prostate cancer) in mammal. The method involves administration of a
XX benzothiphene derivative to a mammal. The present sequence is human
XX oestrogen receptor (ER)-alpha DNA amplifying reverse transcription (RT)-
XX PCR primer. This sequence is used to illustrate the method of the
XX invention.
XX
XX Sequence 21 BP; 4 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX
XX Query Match
XX Best Local Similarity 0.7%; Score 16.2; DB 1; Length 21;
XX Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 1327 TGGTGAAGCTCTTCGACAAGC 1347
XX |||||
XX 1 TGGTGAAGCTCTTCGACAATGC 21
XX
XX
XX RESULT 115
XX AAL55455/c
XX ID AAL55455 standard; DNA; 19 BP.
XX
XX AAL55455;
XX
XX 22-MAY-2003 (first entry)
XX
XX Specific tumour cell proliferation related PCR primer, SEQ ID No 25.
XX
XX Recombination virus; proliferating; tumour cell; anti-oncogene;
XX proliferation; telomerase promoter; therapy; tumour; PCR; primer; ss.
XX
XX Unidentified.
XX
XX OS
XX PN WO2003006640-A1.
XX
XX 23-JAN-2003.
XX
XX 12-JUL-2002; 2002WO-CN000493.
XX
XX

```

```

PR 12-JUL-2001; 2001CN-00126113.
XX
XX (QIAN/) QIAN Q.
XX
XX Qian Q, Wu M, Shan S;
XX
XX WPI; 2002-464081/22.
XX
XX Telomerase promoter-controlled recombinant viruses proliferating
XX specifically in tumor cells to highly express antioncogene to kill tumor
XX cells by synergism, applicable in treating tumor.
XX
XX Example 6; Page 30; 56pp; Chinese.
XX
XX The invention relates to a recombination virus proliferating in a tumour
XX cell, which can express an anti-oncogene with high efficiency. The
XX invention also relates to the method of its proliferation. A telomerase
XX promoter controlling the transcription of at least one necessary gene for
XX a recombination virus proliferating, can make the virus optionally
XX proliferate in a tumour cell, which has the activity of telomerase and
XX basically does not proliferate in a normal cell without the activity of a
XX telomerase. The recombination virus can be used in therapy of many kinds
XX of tumours. This polynucleotide sequence represents a PCR primer relating
XX to the specific proliferation in a tumour cell of the invention
XX
XX Sequence 19 BP; 1 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match
XX Best Local Similarity 0.7%; Score 16; DB 1; Length 19;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 143 GAAGCCCTGGCCCCGG 158
XX |||||
XX 19 GAAGCCCTGGCCCCGG 4
XX
XX
XX RESULT 116
XX ABQ76085/c
XX ID ABQ76085 standard; DNA; 19 BP.
XX
XX ABQ76085;
XX
XX 30-SEP-2002 (first entry)
XX
XX Anticancer gene-associated PCR primer #16.
XX
XX Proliferation; anticancer gene; tumour cell; telomerase; promoter;
XX early virus gene; PCR; primer; ss.
XX
XX Unidentified.
XX
XX OS
XX PN CN1339584-A.
XX
XX 13-MAR-2002.
XX
XX 12-JUL-2001; 2001CN-00126113.
XX
XX 12-JUL-2001; 2001CN-00126113.
XX
XX (QIAN/) QIAN Q.
XX
XX Qian Q, Wu M, Cen X;
XX
XX WPI; 2002-464081/50.
XX
XX Telomerase promoter-controlled recombinant viruses proliferating
XX specifically in tumor cells to highly express antioncogene to kill tumor
XX cells by synergism, applicable in treating tumor.
XX
XX Example 5; Page 16; 25pp; Chinese.
XX
XX This invention describes a novel recombined virus for specific
XX proliferation and efficient expression of an anticancer gene in tumour
XX

```

CC cells. By inserting a telomerase promoter in the upstream area of an
 CC early virus gene, the recombinant virus is made to proliferate
 CC selectively in tumor cells with telomerase activity rather than in
 CC normal cells without telomerase activity. This recombinant virus may be
 CC used to treat several kinds of tumors. This sequence represents a PCR
 CC primer used to illustrate the method described in the disclosure of the
 CC invention

SO Sequence 19 BP; 1 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 16; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 143 GAAGCCTGGCCCGG 158
 DB 19 GAAGCCTGGCCCGG 4

RESULT 117
 AA203129/c
 ID AA203129 standard; DNA; 20 BP.
 AC AA203129;
 XX
 XX 07-OCT-1999 (first entry)
 DT
 DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
 XX
 XX Vaccine; eye disease; conventional trachoma; nongonococcal trachoma;
 KW paratrachoma; inclusion conjunctivitis; genital disease; perlepatitis;
 KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
 KW bartolinitis; pneumopathy; venereal lymphogranulomatosis; ss.
 XX
 XX Synthetic.
 OS Chlamydia trachomatis.
 XX
 XX WO928475-A2.
 PN
 XX 10-JUN-1999.
 PD
 XX 27-NOV-1998; 98WO-IB001939.
 PF
 XX 28-NOV-1997; 97FR-00015041.
 PR 17-DEC-1997; 97FR-00016034.
 PR 04-NOV-1998; 98US-0107077P.
 XX
 XX (GENSET) GENSET.
 PA
 XX Griffais R;
 PI
 XX WPI; 1999-371125/31.
 DR
 XX Genome sequence of Chlamydia trachomatis.
 PT
 XX Disclosure; Page 1581; 1755pp; English.
 PS
 XX PCR primers AA201426-206209 were used to amplify open reading frames
 CC (ORFs) of the genome of Chlamydia trachomatis (see AA201425). These ORFs
 CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
 CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
 CC be used to control growth of the microorganism. Chlamydia trachomatis is
 CC responsible for a large number of diseases, e.g. eye diseases such as
 CC conjunctivitis; genital disease; nongonococcal trachoma, paratrachoma, and inclusion
 CC conjunctivitis; genital diseases such as nongonococcal urethritis;
 CC epididymitis, cervicitis, salpingitis, perlepatitis, bartolinitis;
 CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
 CC The polypeptides of the invention may be of use in treating these
 CC diseases
 CC
 SO Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 16; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2206 ATCCCTCTTCAGAGG 2221
 DB 19 ATCCCTCTTCAGAGG 4

RESULT 118
 AB28088/c
 ID AB28088 standard; DNA; 20 BP.
 XX
 XX AB28088;
 AC
 XX 17-OCT-2003 (first entry)
 DT
 DE Human oligonucleotide sequence.
 XX
 XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; anti-allergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 XX Homo sapiens.
 OS
 XX WO200285308-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013135.
 PF
 XX 24-APR-2001; 2001US-0286137P.
 PR
 XX (EPIC-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.
 DR
 XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 XX Disclosure; SEQ ID NO 3330; 872pp; English.
 PS
 XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, anti-allergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 CC
 SO Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 16; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 TCAGTCTTCTGGCGA 1692
DB 20 TCAGTCTTCTGGCGA 5
RESULT 119
ABD24318/C
ID ABD24318 standard; DNA; 20 BP.
XX
AC ABD24318;
XX
DT 29-JUL-2004 (first entry)
XX
DE A1095013-derived oligonucleotide DNA SEQ ID 3330.
XX
KM Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KM surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KM analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KM respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KM emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KM pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
XX 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR MPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 3330; 763bp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, of the anti-sense oligos corresponding to
CC The reduced adenosine content of the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 TCAGTCTTCTGGCGA 1692
DB 20 TCAGTCTTCTGGCGA 5
RESULT 120
ADQ90647
ID ADQ90647 standard; mRNA; 21 BP.
XX
AC ADQ90647;
XX
DT 21-OCT-2004 (first entry)
XX
XX Mouse Sca-2 target oligonucleotide SEQ ID NO:44.
DE
KM Lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
KM gene therapy; Sca-2; ss.
XX
OS Mus musculus.
OS Synthetic.
OS
PN WO2004065549-A2.
XX
PD 05-AUG-2004.
XX
PF 15-JAN-2004; 2004WO-US001320.
XX
PR 17-JAN-2003; 2003US-0440987P.
XX
PA (UYFL) UNIV FLORIDA.
XX
PI Chang L, He J;
PI
XX
DR MPI; 2004-562155/54.
XX
PT New lentiviral vector comprising a nucleotide sequence encoding a small
PT interference RNA, useful for reducing expression of a target gene in a
PT cell.
XX
PS Example 1; SEQ ID NO 44; 51bp; English.
XX
CC The present invention describes a lentiviral vector comprising a
CC nucleotide sequence encoding a small interference RNA (siRNA). Also
CC described is a method of reducing expression of a target gene in a cell
CC comprising: (a) introducing into the cell a lentiviral vector encoding a
CC siRNA specific for the gene; and (b) placing the cell under conditions,
CC where the siRNA specific for the gene is expressed to cause a detectable
CC decrease in expression of the gene. The siRNA has cytostatic and virucide
CC activities, and can be used in gene therapy. The vector is useful for
CC reducing expression of a target gene in a cell. The present sequence
CC represents a mouse Sca-2 target oligonucleotide, which is used in an
CC example from the present invention.
XX
SQ Sequence 21 BP; 5 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
XX
Query Match 0.7%; Score 16; DB 1; Length 21;
Best Local Similarity 68.8%; Pred. No. 1.1e+02;
Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
QY      739 CCTTCTGCACTTCAG 754
      ||:::||:::||::||
DB      6 CCUUCUCGACACUUCAG 21

RESULT 121
ADQ90611
ID      ADQ90611 standard; DNA; 21 BP.
XX
AC      ADQ90611;
XX
DT      21-OCT-2004 (first entry)
XX
DE      Sca-2 siRNA duplex sense oligonucleotide SEQ ID NO:8.
XX
KM      lentiviral vector; small interference RNA; siRNA; cytosstatic; virucide;
KW      gene therapy; Sca-2; ss.
XX
OS      Mus musculus.
OS      Synthetic.
XX
PN      MO2004065549-A2.
XX
PD      05-AUG-2004.
XX
PF      15-JAN-2004; 2004MO-US001320.
XX
PR      17-JAN-2003; 2003US-0440987P.
XX
      (UYFL ) UNIV FLORIDA.
XX
PI      Chang L, He J;
XX
DR      WPI; 2004-562155/54.
XX
PT      New lentiviral vector comprising a nucleotide sequence encoding a small
PT      interference RNA, useful for reducing expression of a target gene in a
PT      cell.
XX
PS      Example 1; SEQ ID NO 8; 51pp; English.
XX
CC      The present invention describes a lentiviral vector comprising a
CC      nucleotide sequence encoding a small interference RNA (siRNA). Also
CC      described is a method of reducing expression of a target gene in a cell
CC      comprising: (a) introducing into the cell a lentiviral vector encoding a
CC      siRNA specific for the gene; and (b) placing the cell under conditions
CC      where the siRNA specific for the gene is expressed to cause a detectable
CC      decrease in expression of the gene. The siRNA has cytosstatic and virucide
CC      activities, and can be used in gene therapy. The vector is useful for
CC      reducing expression of a target gene in a cell. The present sequence
CC      represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
CC      example from the present invention.
XX
SQ      Sequence 21 BP; 3 A; 7 C; 3 G; 8 T; 0 U; 0 Other;
      Query Match      0.7%; Score 16; DB 1; Length 21;
      Best Local Similarity 100.0%; Pred.No. 1.1e+02;
      Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      739 CCTTCTGCACTTCAG 754
      ||:::||:::||::||
DB      4 CCTTCTGCACTTCAG 19

RESULT 122
ADQ90612/C
ID      ADQ90612 standard; DNA; 21 BP.
XX
AC      ADQ90612;
XX
DT      21-OCT-2004 (first entry)
XX
```

```
DE      Sca-2 siRNA duplex antisense oligonucleotide SEQ ID NO:9.
XX
KM      lentiviral vector; small interference RNA; siRNA; cytosstatic; virucide;
KW      gene therapy; Sca-2; ss.
XX
OS      Mus musculus.
OS      Synthetic.
XX
PN      MO2004065549-A2.
XX
PD      05-AUG-2004.
XX
PF      15-JAN-2004; 2004MO-US001320.
XX
PR      17-JAN-2003; 2003US-0440987P.
XX
      (UYFL ) UNIV FLORIDA.
XX
PI      Chang L, He J;
XX
DR      WPI; 2004-562155/54.
XX
PT      New lentiviral vector comprising a nucleotide sequence encoding a small
PT      interference RNA, useful for reducing expression of a target gene in a
PT      cell.
XX
PS      Example 1; SEQ ID NO 9; 51pp; English.
XX
CC      The present invention describes a lentiviral vector comprising a
CC      nucleotide sequence encoding a small interference RNA (siRNA). Also
CC      described is a method of reducing expression of a target gene in a cell
CC      comprising: (a) introducing into the cell a lentiviral vector encoding a
CC      siRNA specific for the gene; and (b) placing the cell under conditions
CC      where the siRNA specific for the gene is expressed to cause a detectable
CC      decrease in expression of the gene. The siRNA has cytosstatic and virucide
CC      activities, and can be used in gene therapy. The vector is useful for
CC      reducing expression of a target gene in a cell. The present sequence
CC      represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
CC      example from the present invention.
XX
SQ      Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
      Query Match      0.7%; Score 16; DB 1; Length 21;
      Best Local Similarity 100.0%; Pred.No. 1.1e+02;
      Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      739 CCTTCTGCACTTCAG 754
      ||:::||:::||::||
DB      16 CCTTCTGCACTTCAG 1

RESULT 123
AAT85565/C
ID      AAT85565 standard; DNA; 19 BP.
XX
AC      AAT85565;
XX
DT      11-NOV-1997 (first entry)
XX
DE      Human STM2 exon 10 RT-PCR primer EX102R.
XX
KM      Autosomal dominant early-onset Alzheimer's Disease; AD4 gene; STM2;
KW      neurodegeneration; senile dementia; human chromosome 1;
KW      Voilga German kindred; VG; reverse transcription; PCR primer;
KW      polymerase chain reaction; Homo sapiens; diagnosis; detection;
KW      polymorphism; alternative splicing; ss.
XX
OS      Synthetic.
XX
PN      MO9703192-A2.
XX
DT      30-JAN-1997.
XX
```

PF 05-JUL-1996; 96WO-US011386.
 XX
 PR 07-JUL-1995; 95US-0000956P.
 PR 28-JUL-1995; 95US-0001675P.
 PR 11-AUG-1995; 95US-0002174P.
 PR 14-AUG-1995; 95US-0002328P.
 XX
 PA (DARW-) DARWIN MOLECULAR CORP.
 PA (VAME-) VA MEDICAL CENT.
 PA (GEHO) GEN HOSPITAL CORP.
 XX
 PI Levy-Lehah E, Tanzi RE, Schellenberg GD, Wasco W, Bird TD;
 PI Mulligan J, Galae DJ;
 XX WPI; 1997-119048/11.
 DR
 XX New Alzheimer's disease related gene, AD4 - used to develop prode. for
 PT detecting pre-disposition to or for diagnosis, prevention or treatment of
 PT Alzheimer's disease.
 XX
 PS Example 9; Page 55; 83pp; English.
 XX
 CC A genetically isolated group of families with autosomal dominant early-
 CC onset Alzheimer's Disease (AD) has been studied and initial mapping
 CC analyses have predicted the AD4 locus (also known as STM2) resides on
 CC chromosome 1. The group of families has been designated the Volga German
 CC (VG) kindreds. The entire gene has been amplified from VG individuals and
 CC unaffected individuals (from VG and unrelated lineages). Sequence
 CC analysis has shown that affected individuals have a nucleotide change at
 CC codon 141 resulting in an amino acid alteration from Asn to Ile. In a
 CC study of the expression pattern of STM2, two alternative sequences were
 CC identified which resulted from alternative splicing of exon 10. Both
 CC transcripts were present in RT-PCR products from a lymphoblastoid cell
 CC line using primers EX10JL and EX102R (see AAT85564 and AAT85565) from
 CC exon 9 and 10, respectively. Both transcripts were also found in
 CC leukocytes and skeletal muscle. One foetal brain library contained both
 CC transcripts with the longer being the more abundant, while a second
 CC library contained only the longer transcript. A foreskin fibroblast
 CC library contained only the shorter transcript
 XX
 SQ Sequence 19 BP; 1 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1842 CCAAGCGAGAGAGTGGAG 1860
 DB 19 CCCAGCGAGAGAGCTGGAG 1
 XX
 RESULT 124
 ID AAV43852
 AC AAV43852 standard; DNA; 19 BP.
 XX AAV43852;
 DT 26-OCT-1998 (first entry)
 XX
 DE APC mutant gene evaluating primer 1.
 XX
 KW APC; human; colorectal cancer; CRC; missense mutation; Ashkenazi Jew;
 XX PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN MO9833940-A1.
 XX
 PD 06-AUG-1998.
 XX
 PF 21-JAN-1998; 98WO-US000961.
 XX

PR 31-JAN-1997; 97US-00791883.
 XX
 PA (UXJO) UNIV JOHNS HOPKINS.
 XX
 PI Laken S, Gruber S, Petersen G, Kinzler K, Vogelstein B;
 PI WPI; 1998-437490/37.
 DR
 XX
 PT Detection of mutation in APC gene - comprising T to A transversion at
 PT nucleotide 3920, useful for predicting predisposition to colorectal
 PT cancer.
 XX
 PS Example 2; Page 8; 23pp; English.
 XX
 CC This primer is used for evaluating the stability of the (A)8 repeat
 CC embodying the R1307K mutation of the APC gene by PCR amplification. This
 CC is used for exemplifying the method of the invention of detecting a
 CC mutation in APC gene. The method uses an allele-specific nucleic acid
 CC probe which comprises a nucleic acid sequence of a region of a human
 CC mutant APC or its ribonucleotide equivalent, where the region contains a
 CC T to A transversion at nucleotide 3920. The method is used for
 CC determining the presence in a proband of a mutation in APC which is
 CC associated with a family history of colorectal cancer (CRC) especially
 CC among Ashkenazi Jews
 XX
 SQ Sequence 19 BP; 5 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1040 AGCTGACCGGTCCATC 1058
 DB 1 AGCTGACCTGATCCATC 19
 XX
 RESULT 125
 ID ABL89068
 AC ABL89068 standard; DNA; 19 BP.
 XX ABL89068;
 DT 22-MAY-2002 (first entry)
 XX
 DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:290.
 XX
 KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
 KW reverse transcriptase; binding group; ss.
 XX
 OS Human immunodeficiency virus 1.
 OS Synthetic.
 XX
 PN EP1174518-A1.
 XX
 PD 23-JAN-2002.
 XX
 PF 20-JUL-2000; 2000EP-00202611.
 XX
 PR 20-JUL-2000; 2000EP-00202611.
 XX
 PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
 XX
 PI Loukachov VV, Van Gemen B, Goudamit J;
 XX
 DR WPI; 2002-156696/21.
 XX
 PT Collection of binding groups for determining or typing samples,
 PT especially clinical samples, has groups capable to identify essentially
 PT all members of the family of nucleic acids of relatively high
 PT significance.
 XX
 PS Disclosure; Page 77; 166pp; English.
 XX

CC The present invention describes a collection of binding groups for a
CC family of nucleic acids comprising members of relative high and relative
CC low significance, where the binding groups are selected to be capable to
CC identify, alone or in combination, essentially all members of the family
CC of nucleic acids of relatively high significance. The collection of
CC binding groups is useful for typing of nucleic acid in a clinical sample,
CC by contacting the nucleic acid with the collection and determining
CC whether one or more binding groups bound to the nucleic acid of the
CC sample. This method is useful for determining whether the sample
CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention

CC SQ Sequence 19 BP; 12 A; 1 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1543 TAAGAGGAAAAAGTCAGT 1561
DB 1 TAAAAAGAAAAAGTCAGT 19
|||||
|||||

RESULT 126
ABL89073
ID ABL89073 standard; DNA; 19 BP.
XX
AC ABL89073;
XX
XX 22-MAY-2002 (first entry)
XX
XX
XX HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:295.
DE
XX
XX Binding molecule; HIV-1; human immunodeficiency virus type 1;
KW
XX reverse transcriptase; binding group; ss.
OS
XX Human immunodeficiency virus 1.
OS
XX Synthetic.
OS
XX
XX EPI174518-A1.
PN
XX
XX 23-JAN-2002.
PD
XX
XX 20-JUL-2000; 2000EP-00202611.
PF
XX
XX 20-JUL-2000; 2000EP-00202611.
PR
XX
XX 20-JUL-2000; 2000EP-00202611.
PR
XX
XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
PA
XX
XX Loukachov VV, Van Gemen B, Goudemilt J;
PI
XX
XX WPI; 2002-156696/21.
DR
XX
XX
XX Collection of binding groups for determining or typing samples,
PT especially clinical samples, has groups capable to identify essentially
PT all members of the family of nucleic acids of relatively high
PT significance.
PT
XX
XX
XX Disclosure; Page 78; 166pp; English.
XX
XX The present invention describes a collection of binding groups for a
CC family of nucleic acids comprising members of relative high and relative
CC low significance, where the binding groups are selected to be capable to
CC identify, alone or in combination, essentially all members of the family
CC of nucleic acids of relatively high significance. The collection of
CC binding groups is useful for typing of nucleic acid in a clinical sample,
CC by contacting the nucleic acid with the collection and determining
CC whether one or more binding groups bound to the nucleic acid of the
CC sample. This method is useful for determining whether the sample

CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention

CC SQ Sequence 19 BP; 12 A; 1 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1543 TAAGAGGAAAAAGTCAGT 1561
DB 1 TAAAAAGAAAAAGTCAGT 19
|||||
|||||

RESULT 127
ACH66643/C
ID ACH66643 standard; DNA; 19 BP.
XX
XX ACH66643;
AC
XX
XX 06-NOV-2003 (first entry)
XX
XX
XX Real-time PCR forward primer used to detect mouse CD40 expression.
DE
XX
XX Mouse; ss; PCR; primer; real-time PCR; costimulatory molecule; CD40;
KW major histocompatibility complex; MHC; class II; antigen;
KW tumour; deacetylase inhibitor; DAI; tumourigenesis; immune system;
KW T lymphocyte; T cell activation; immunogenicity; antigen presentation;
KW cell lysis; trichostatin A; TSA; sodium butyrate; cyclostatic; CD40.
XX
XX
XX Mus sp.
OS
XX
XX US6518012-B1.
PN
XX
XX 11-FEB-2003.
PD
XX
XX 31-MAR-2000; 2000US-00540257.
PF
XX
XX 02-APR-1999; 99US-0127591P.
PR
XX
XX 29-JUL-1999; 99US-0146275P.
PR
XX
XX (HEAL-) HEALTH RES INC.
PA
XX
XX Tomasi TB;
PI
XX
XX WPI; 2003-575859/54.
DR
XX
XX
XX Increasing expression of gene in tumor cells in vitro comprises
PT contacting tumor cells with deacetylase inhibitor.
PT
XX
XX Example 1; Fig 9; 20pp; English.
XX
XX The invention discloses a method for increasing the expression of
CC costimulatory molecules, such as CD40, and major histocompatibility
CC complex (MHC) class I and class II antigens in tumour cells in vitro. The
CC method comprises contacting the tumour cells with deacetylase inhibitor
CC (DAI). Tumourigenesis is related, in part, to the failure of the immune
CC system to reject spontaneously arising tumours by responding
CC appropriately to tumour antigens. Induction of T lymphocytes is
CC considered to be a critical initial step and T cell activation requires
CC an antigen specific signal, which involves the antigenic peptide and the
CC MHC class I and II proteins. The increased expression of these molecules
CC increases the immunogenicity of tumours and their susceptibility to
CC lysis. The inhibitors of deacetylation, at low concentrations, produce
CC little or no apoptosis and maintain a normal cell cycle. The expression
CC of MHC genes, and other molecules of immunologic importance, in antigen
CC presentation and cell lysis is induced. The DAI are preferably
CC trichostatin A (TSA) or sodium butyrate. The sequence presented is a real
CC time PCR primer used to detect expression levels of the mouse CD40 gene

XX Sequence 19 BP; 1 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1999 GCAATGACACCTCGCAGG 2017
DB 19 GCAAGACACCATGACAGG 1
RESULT 128
AAV44694/C
ID AAV44694 standard; DNA; 20 BP.
XX AAV44694;
AC
XX
XX 09-OCT-1998 (first entry)
DT
XX
XX V274T variant human alpha7 nAChR antisense sequence.
DE
XX Alpha7 nAChR; alpha7 nicotinic acetylcholine receptor subunit; cancer;
KW neurodegeneration; enzyme dysfunction; affective disorder; therapy;
KW immune dysfunction; diabetic neuropathy; Alzheimer's disease;
KW schizophrenia; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX WO9828331-A2.
XX
XX 02-JUL-1998.
XX
XX 22-DEC-1997; 97WO-US023405.
XX
XX 20-DEC-1996; 96US-00771737.
XX
XX (ABBO) ABBOTT LAB.
XX
XX Briggs CA, Gopalakrishnan M, McKenna DG, Monteggia LM, Roch J;
PI Sullivan JF, Tounsa E;
XX
XX MPI; 1998-377593/32.
XX
XX Nucleic acid encoding variant of human alpha 7 nicotinic acetylcholine
PT receptor sub-unit - used to identify modulators of the receptor,
PT potentially useful for treating neuro-degeneration, cancer etc.
XX
XX
XX Example 7; Page 30; 44pp; English.
XX
XX This sequence is an antisense inhibitor of the DNA encoding the V247T
CC variant of human alpha7 nicotinic acetylcholine receptor (nAChR) subunit
CC of the invention. Cells containing the DNA are used to express the
CC protein and to identify modulators of alpha7 nAChR activity or
CC cytoprotective agents, e.g. antisense compounds or antagonists that are
CC potentially useful for treating neurodegeneration, enzyme dysfunction,
CC affective disorders and immune dysfunction, such as cancer, post-herpetic
CC neuralgia, diabetic neuropathy, osteoarthritis, Alzheimer's or
CC Parkinson's diseases, kuru, psychosis and schizophrenia. Probes based on
CC the DNA are used to detect the DNA in usual hybridisation or
CC amplification tests, while monoclonal antibodies are used to detect the
CC protein for diagnosis (in vitro or by in situ immuno-fluorescent assay).
CC Compared with wild-type alpha7 nAChR, the protein has about 100-fold
CC greater sensitivity to cholinergic receptor agonists (nicotine or
CC acetylcholine) and response to these agonists decays more slowly, but the
CC wild-type inward rectification is retained
XX
XX
XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 819 GGCACTTCGAATGCTG 837
DB 20 GGCAAGCTCGAATGCTG 2
RESULT 129
AAK38483
ID AAK38483 standard; DNA; 20 BP.
XX
XX AAK38483;
AC
XX
XX 16-JUN-1999 (first entry)
DT
XX
XX E. coli SecA antisense oligonucleotide 39.
DE
XX Microorganism inhibitor; antisense; nuclease resistant; treatment;
KW ribonucleotide reductase; secA gene; pathological condition; R1 subunit;
KW antimicrobial agent; crop protection; primer; R2 subunit; ss.
XX
XX Synthetic.
OS
XX Escherichia coli.
XX
XX WO9902673-A2.
XX
XX 21-JAN-1999.
XX
XX 10-JUL-1998; 98WO-CA000666.
XX
XX 10-JUL-1997; 97US-0052160P.
XX
XX (GENE-) GENESENSE TECHNOLOGIES INC.
XX
XX Wright JA, Young AH, Dugourd D;
PI
XX MPI; 1999-120874/10.
XX
XX
XX New oligonucleotides complementary to RR or SecA genes - useful to
PT inhibit growth of microorganisms.
PT
XX
XX Disclosure; Page 24; 103pp; English.
XX
XX
XX This invention describes novel antisense oligonucleotides (AAK38301-
CC X38552) which are nuclease resistant, and comprises about 3-50
CC nucleotides complementary to the ribonucleotide reductase gene or the
CC secA gene of a microorganism. The antisense oligonucleotides are used to
CC treat mammalian pathological conditions mediated by microorganisms. The
CC oligonucleotides are particularly useful as antimicrobial agents in crop
CC protection
XX
XX
XX Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1345 AGCACAAGCACAAGTTCG 1363
DB 2 AGCACCAGACCAAGTTCG 20
RESULT 130
AAA29835
ID AAA29835 standard; DNA; 20 BP.
XX
XX AAA29835;
AC
XX
XX 25-AUG-2000 (first entry)
DT
XX
XX Human jun N-terminal kinase kinase-2 antisense oligonucleotide #20.
DE
XX Human jun N-terminal kinase kinase-2; JNK-2; modulation; tumour;
KW antiinflammatory; cytosstatic; antiinfectious; infection; inflammation;

```
KM detection; antisense therapy; phosphorothioate; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /note= "Phosphorothioate linkages"
XX
XX US6054440-A.
XX
XX 25-APR-2000.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowser LM;
XX
XX WPI; 2000-338506/29.
XX
XX Antisense compound specifically hybridizing and inhibiting the expression
PT of human Jun N-terminal Kinase Kinase-2 is useful for treating infection,
XX inflammation and tumor.
XX
XX Claim 3; Col 40; 31pp; English.
XX
XX The present invention describes an antisense compound (I) of 8-30
CC nucleobases, specifically hybridizing to, and inhibiting expression of,
CC human Jun N-terminal Kinase Kinase-2 (JNK-2). Also described is a method
CC of inhibiting the expression of human JNK-2 in human cells or tissues,
CC comprising contacting the cells or tissues, with (I), in vitro. (I) has
CC antiinflammatory, cytostatic and antiinfectious activities. (I) is useful
CC for inhibiting the expression of JNK-2 in human cells or tissues and
CC prevents or delays infection, inflammation or tumor formation associated
CC with altered expression of JNK-2. (I) is also useful for detecting the
CC levels of JNK-2 in a sample. The present sequence represents a
CC phosphorothioate antisense oligonucleotide for human JNK-2, from the
CC present invention
XX
XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2043 TGCAGGAGGATGCCGCCA 2061
DB 1 TCCAGGAGGAGCGCCGCCA 19
XX
XX RESULT 131
XX AAA29834
XX ID AAA29834 standard; DNA; 20 BP.
XX
XX AAA29834;
XX
XX 25-AUG-2000 (first entry)
XX
XX Human Jun N-terminal Kinase Kinase-2 antisense oligonucleotide #19.
XX
XX Human; Jun N-terminal Kinase Kinase-2; JNK-2; modulation; tumour;
XX antiinflammatory; cytosaratic; antiinfectious; infection; inflammation;
XX detection; antisense therapy; phosphorothioate; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /note= "Phosphorothioate linkages"
```

```
XX
XX US6054440-A.
XX
XX 25-APR-2000.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowser LM;
XX
XX WPI; 2000-338506/29.
XX
XX Antisense compound specifically hybridizing and inhibiting the expression
PT of human Jun N-terminal Kinase Kinase-2 is useful for treating infection,
XX inflammation and tumor.
XX
XX Claim 3; Col 40; 31pp; English.
XX
XX The present invention describes an antisense compound (I) of 8-30
CC nucleobases, specifically hybridizing to, and inhibiting expression of,
CC human Jun N-terminal Kinase Kinase-2 (JNK-2). Also described is a method
CC of inhibiting the expression of human JNK-2 in human cells or tissues,
CC comprising contacting the cells or tissues, with (I), in vitro. (I) has
CC antiinflammatory, cytostatic and antiinfectious activities. (I) is useful
CC for inhibiting the expression of JNK-2 in human cells or tissues and
CC prevents or delays infection, inflammation or tumor formation associated
CC with altered expression of JNK-2. (I) is also useful for detecting the
CC levels of JNK-2 in a sample. The present sequence represents a
CC phosphorothioate antisense oligonucleotide for human JNK-2, from the
CC present invention
XX
XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2045 CAGGAGGATGCCGCCAC 2063
DB 1 CAGGAGGAGCGCCGCCATC 19
XX
XX RESULT 132
XX AB194517/C
XX ID AB194517 standard; DNA; 20 BP.
XX
XX AB194517;
XX
XX 16-FEB-2002 (first entry)
XX
XX Capture oligonucleotide zip ID#1604 oligo #9.
XX
XX Human; K-ras; PCR primer; probe; capture probe; mutation detection;
XX ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
XX infection; 21 hydroxylase deficiency; Turner Syndrome; Obesity; cancer;
XX oncogene; tumour suppressor; human papillomavirus; forensic;
XX environmental monitoring; food industry; feed industry; ss.
XX
XX Synthetic.
XX
XX WO200179548-A2.
XX
XX 25-OCT-2001.
XX
XX 04-APR-2001; 2001WO-US010958.
XX
XX 14-APR-2000; 2000US-0197271P.
XX
XX (CORR ) CORNELL RES FOUND INC.
XX
```

PI Barany F, Zivvi M, Gerry NP, Favis R, Kliman R;
XX WPI; 2002-034366/04.
XX
XX Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch.
XX
XX Example 5; Fig 29; 300pp; English.
XX
XX The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridize with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Hemophilus influenzae, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents
CC selected from Onchocerca volvulus, Batamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting DNA amplification involving oncogenes, tumour suppressor genes, or genes
CC involved in cancer amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying if ligation of the oligonucleotide probe
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. AB182074 to
CC AB197546 represent oligonucleotide sequences used in the exemplification
XX of the present invention
XX
SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1113 TGGGGCCGATGGTCCAGA 1131
Db 19 TGGGGCTGATTGTCACGA 1
XX
RESULT 133
ADA44714
ID ADA44714 standard; DNA; 20 BP.
XX
XX ADA44714;
AC
XX
XX 20-NOV-2003 (first entry)
DT
XX
XX Antisense oligonucleotide #ISIS 115386 #SEQ ID 12.
DE
XX
XX Antisense oligonucleotide; cytoskeletal; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylycytosine"
FT 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT modified_base

FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX
XX WO2003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/3.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX
XX Example 15; Page 76; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2278 CCTCACTTCTCTGGGCTT 2296
Db 1 CCTCACTTCTCTGGGCTT 19
XX
RESULT 134
ABT44412
ID ABT44412 standard; DNA; 20 BP.
XX
XX ABT44412;
AC
XX
XX 06-NOV-2003 (first entry)
DT
XX
XX Chimeric antisense oligonucleotide ISIS 192387 to inhibit human ESRB.
DE
XX
XX Oestrogen receptor beta; ESRB; steroid hormone; female sexual maturation;
KW bone maintenance; cardiovascular system; ER beta; oestrogen receptor 2;
KW ERS2; Alzheimer's; uterine leiomyomata; cytoskeletal; kidney neoplasm; ss;
KW cellular proliferation; cancer; human; antisense; chimeric.
XX
XX Chimeric - Homo sapiens.
XX
XX WO2003050133-A1.
XX
XX 19-JUN-2003.
XX

```
XX 06-DEC-2002; 2002WO-US039200.
PF 07-DEC-2001; 2001US-00005058.
XX
PR (ISIS-) ISIS PHARM INC.
XX
PI Double KW, Roach MP, Koller E;
XX WPI; 2003-577284/54.
DR
XX
PT New antisense oligonucleotides for modulating estrogen receptor beta gene
PT expression, particularly useful for treating cancers, specifically
PT leiomyoma, pancreatic cancer, prostate cancer, breast cancer, bone cancer
PT or lymphoma.
XX
XX Claim 3; Page 81; 160pp; English.
XX
CC This invention relates to a novel antisense compounds that modulate the
CC expression of oestrogen receptor beta (ERSB). Oestrogen is a steroid
CC hormone that exerts a wide range of effects throughout the human body
CC being primarily involved in female sexual maturation. Additionally,
CC however, oestrogen targets male reproductive tissues, is known to be
CC important in bone maintenance and plays a protective role in the
CC cardiovascular system. This hormone receptor, ERB (also known as ER
CC beta, oestrogen receptor 2 and ER2) has been mapped to chromosome 14q22-
CC q24, a region known to be associated with early onset of Alzheimer's
CC disease, uterine leiomyoma and neoplasms of the kidney. Furthermore,
CC ERB has been localised to metastatic cells indicating an involvement in
CC cellular proliferation. Accordingly, the selective inhibition of ERB by
CC the cytostatic antisense oligonucleotides of this invention could provide
CC a therapeutic target for the treatment of cancer, as well as other ERB-
CC related disorders. This oligonucleotide sequence is the chimeric human
CC antisense oligo used to inhibit expression of human ERB, the aim of the
CC invention. Note that it has two terminal five nucleotide 2'-methoxyethyl
CC (2'-MOE) wings separated by a ten deoxynucleotide gap. The
CC oligonucleotide backbone is phosphorothioate throughout
CC
XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
SQ
XX
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY
1316 CATGAGGCCCTGTGAG 1334
DB 1 CATGAGGCCCTGTGAG 19
XX
RESULT 135
ADN61692
ID ADN61692 standard; DNA; 20 BP.
XX
AC ADN61692;
XX
DT 01-JUN-2004 (first entry)
XX
DE Corn chromosome 6 SSR marker nc009 6.03 PCR primer 2 SEQ ID:22.
XX
XX Corn: plant; transformable; introgression; chromosomal locus;
XX bin 6.02-6.04; bin 10.04-10.06; bin 1.03-1.06; bin 1.08-1.11;
XX bin 3.05-3.07; corn seed; plant breeding; transgenic plant; chromosome 6;
XX SSR marker; marker assisted breeding; PCR; primer; ss.
XX
OS Zea mays.
XX
XX WO2003103377-A2.
XX
XX 18-DEC-2003.
XX
XX 05-JUN-2003; 2003WO-US017626.
XX
XX 06-JUN-2002; 2002US-0386522P.
XX
```

```
XX (MONS ) MONSANTO TECHNOLOGY LLC.
PA Lowe BA, Chomet P;
XX
PI WPI; 2004-062179/06.
XX
DR
XX
PT Producing a transformable corn line comprises introgressing at least one
PT chromosomal locus mapping to bin 6.02-6.04 or 10.04-10.06, where the
PT locus is introgressed from a more transformable corn line into a less
PT transformable corn line.
XX
XX Example 3; SEQ ID NO 22; 77bp; English.
XX
CC The invention relates to a method of producing a transformable corn line
CC by introgressing at least one chromosomal locus mapping to bin 6.02-6.04
CC or bin 10.04-10.06, where the locus is introgressed from a more
CC transformable corn line into a less transformable corn line. The
CC invention also relates to corn variety 178-187-20 seed (ATCC accession
CC no. PTA-5183) and corn variety 178-74-25 seed (ATCC accession no. PTA-
CC 5182); progeny of a plant grown from the seed cited above, where the
CC progeny comprises loci mapping to chromosomal bins 1.03-1.06, 1.08-1.11,
CC 3.05-3.07, and 6.02-6.04; a transgenic corn plant produced by
CC transforming the progeny cited above; and hybrid corn seed and plants
CC produced by crossing a corn line with the progeny cited above. Because
CC more transformable lines are typically agronomically poor, while lines
CC with superior or desired agronomic traits tend to be less transformable,
CC the methods of the invention provide a means of testing for the effects
CC of an introduced gene on traits such as yield, kernel quality and plant
CC phenotype in earlier plant generations in a breeding programme. Sequences
CC ADN61671-ADN61702 represent PCR primers used in an example of the
CC invention to amplify corn SSR markers useful in marker assisted breeding.
XX
SQ Sequence 20 BP; 1 A; 11 C; 0 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY
1641 CCTCTCTTCTCCCTCTCT 1659
DB 1 CCTCTCTTCTCCCTCTCT 19
XX
RESULT 136
ADT00517
ID ADT00517 standard; DNA; 20 BP.
XX
AC ADT00517;
XX
DT 16-DEC-2004 (first entry)
XX
DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID505.
XX
XX tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
XX tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
XX GUCY2F; MCKK; MLK4; kinase domain; cytoskeletal; tyrosine kinase inhibitor;
XX guanlylate cyclase stimulator; ss.
XX
OS Homo sapiens.
XX
XX WO2004082458-A2.
XX
XX 30-SEP-2004.
XX
XX 18-FEB-2004; 2004WO-US004452.
XX
XX 21-FEB-2003; 2003US-0448537P.
XX
XX 29-MAY-2003; 2003US-0473895P.
XX
XX (UJJO ) UNIV JOHNS HOPKINS.
XX
XX Bardeili A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
XX
```

XX DR WPI; 2004-718702/70.
XX PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
XX agents.
XX PS Disclosure; SEQ ID NO 505; 363pp; English.
XX CC This invention relates to a novel activated mutant protein tyrosine
CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alterations in 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytoskeletal activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.
XX SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
XX Query Match 0.7%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 221 GGCTTGCAGCATTAAGACC 239
Db 2 GGCTTGCAGCATTAAGACC 20
RESULT 137
ID AAF92695/C
XX AA92695 standard; DNA; 21 BP.
XX AC AA92695;
XX DT 05-JUN-2000 (first entry)
XX DE Human CCR-2 promoter SNP (position 41768) constant PCR primer.
XX KW CCR2; C-C chemokine receptor-2; human; promoter; SNP;
KW single nucleotide polymorphism; detection; diagnostic;
KW disease susceptibility; cardiovascular disease; inflammatory disease;
KW rheumatoid arthritis; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200006769-A2.
XX PD 10-FEB-2000.
XX PF 20-JUL-1999; 99WO-GB002341.
XX PR 25-JUL-1998; 98GB-00016193.
XX PR 28-JAN-1999; 99GB-00001844.
XX PA (ZENE) ZENECA LTD.
XX PI Smith JC, Anand R, Morten JEN;
XX DR WPI; 2000-205470/18.
XX PT Diagnosing chemokine receptor allele-2 polymorphisms for diagnosing
PT rheumatoid arthritis and cardiovascular disease comprises determining the
XX sequence of the allele or its promoter at specified positions.
XX PS Example 2; Page 24; 35pp; English.
XX CC The invention relates to a novel method of diagnosing a single nucleotide

CC polymorphism (SNP) in the human C-C chemokine receptor-2 gene (CCR-2).
CC The method of the invention comprises determining the nucleic acid
CC sequence at at least 1 of 13 specific positions in the coding region of
CC the CCR-2 gene and/or its promoter sequence. In the coding region of the
CC CCR-2 gene (EMBL U80924) polymorphisms at positions 2385 and 2649 are
CC detected, while in the CCR-2 promoter sequence (EMBL U95626) the
CC polymorphisms that can be detected are at positions 40915, 41047, 41058,
CC 41507, 41768, 42401, 42598, 42673, 42874 and 43018. The invention
CC also relates to allele-specific primers and probes for detecting these
CC SNPs, diagnostic kits comprising the diagnostic primers and probes, and
CC methods of treating a patient by administering a CCR-2 ligand antagonist
CC drug after diagnosing a SNP in the CCR-2 gene. The method is useful for
CC diagnosing SNPs in the CCR-2 gene and is therefore useful in assessing
CC the predisposition and/or susceptibility of an individual to conditions
CC such as rheumatoid arthritis and cardiovascular diseases which are
CC mediated by CCR-2 ligands. CCR-2 ligand antagonist drugs are useful for
CC treating CCR-2 ligand mediated diseases in humans such as rheumatoid
CC arthritis and other inflammatory diseases. The SNP identification method
CC is also useful for assessing the efficacy of therapeutic compounds in the
CC treatment of CCR-2 ligand mediator diseases and developing new drugs
CC therapies targeting allelic variants of the CCR-2 gene. Computer readable
CC mediums comprising polymorphism-containing nucleic acids are useful in
CC homology searching, mapping, haplotyping, genotyping, pharmacogenetic
CC analysis and other bioinformatic analysis. Polymorphism-containing
CC nucleic acids are useful in characterising individuals in terms of
CC haplotype and other sub-groupings; this information may be used to
CC determine the patient's susceptibility to treatment with particular
CC drugs. SNPs of the CCR-2 gene are useful as genetic markers in linkage
CC studies. Processes such as characterising individuals in terms of
CC haplotype and other sub-groupings are made easier by storing the sequence
CC information in a computer readable medium. Sequences 292694-292695
CC represent a set of PCR primers for detecting an SNP (A to T mutation) at
CC position 41768 of the CCR-2 promoter (EMBL U95626). Primer 292694 is the
CC diagnostic allele-specific primer, while primer 292695 is a constant
CC primer
XX SQ Sequence 21 BP; 7 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
XX Query Match 0.7%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1208 GCTGGGCCCTACTCCAG 1226
Db 20 GCTGGTCTCTCTCCAG 2
RESULT 138
ID AAF95623/C
XX AAF95623 standard; DNA; 21 BP.
XX AC AAF95623;
XX DT 18-NOV-2004 (revised)
XX DT 06-JUN-2001 (first entry)
XX DE Human gene single nucleotide polymorphism #384.
XX KW Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; fornses;is;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX OS Homo sapiens.
XX OS Unidentified.
XX FH Key location/Qualifiers
XX FT variation 11
XX FT /*tag= a
XX PN /standard_name= "single nucleotide polymorphism"
XX WO200118250-A2.

PD 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (MHED) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JU,
PI WPI; 2001-226749/23.
XX
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
XX atherosclerosis.
XX
XX Example; Page 75; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC
CC Revised record issued on 18-NOV-2004 : The variation feature was
CC incorrectly given a capital V
XX
XX Sequence 21 BP; 5 A; 5 C; 9 G; 2 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1187 CTTCTCTCCGACACCTGG 1205
Db |||||
19 CTTCTCTCGGGACCTCG 1

RESULT 139
AAS07302/C
ID AAS07302 standard; DNA; 21 BP.
XX
XX AAS07302;
AC
XX 12-SEP-2001 (first entry)
DT
XX
XX CPS1/TES1 genomic DNA sequencing primer FPS.
DE
XX CPS1; peptide synthetase; peptide toxin; fungal pathogen;
KW corn crop infection; ss; sequencing primer; FPS.
XX
XX Cochliobolus heterostrophus.
OS
XX WO200138489-A2.
PN
XX 31-MAY-2001.
PD
XX 22-NOV-2000; 2000WO-US032227.
PF
XX 23-NOV-1999; 99US-00448215.
PR
XX (CORR) CORNELL RES FOUND INC.
PA
XX

PI Yoder OC, Turgeon BC, Lu S;
XX
XX WPI; 2001-367672/38.
XX
XX
XX New isolated nucleic acid molecule from a plant pathogen useful in
PT preventing plant pathogenic infections.
PT
XX
XX Example 1; Page 54; 132pp; English.
XX
XX The sequence represents a sequencing primer used to sequence a genomic
CC clone from Cochliobolus heterostrophus which contains the CPS1 and TES1
CC peptide synthetase genes. CPS1 is an enzyme thought to be involved in the
CC production of peptide toxins, which are involved in the pathogenic
CC infection of corn crops. The nucleic acids and proteins can be used as
CC targets for anti-fungal compounds to prevent fungal corn infection and
CC the nucleic acids can be used in gene therapy to alter the biosynthetic
CC pathway for the peptide toxins to lower the pathogenicity of the fungi
XX
XX Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 510 ATATCTGCACCTGATTGCT 528
Db |||||
20 ATGTTCTGCACCTGATGCT 2

RESULT 140
ABS68426/C
ID ABS68426 standard; DNA; 21 BP.
XX
XX ABS68426;
AC
XX 19-NOV-2002 (first entry)
DT
XX
XX Sequencing primer #17 for fungal DNA flanking REM1 insertion site.
DE
XX
XX Fungal pathogen; peptide synthetase gene cluster; iron reductase;
KW permenase; major facilitator superfamily transporter; MFS transporter;
KW anti-fungal agent; fungicide; pathogenic fungi; plant pathogen; CPS1;
KW animal pathogen; fungal infection; wild grass; cereal; corn; mycoidae;
KW leaf spot maize; immunocompromised vertebrate; pneumonia; arthritis;
KW military disease; bone infection; joint infection; skin disease;
KW aesophagitis; vaginitis; onychomycosis; inflammation; urinary tract;
KW kidney; liver; brain; gastrointestinal tract; lung; fungicidal;
KW mycoidae; antiarthritic; antiinflammatory; dermatological; CoA ligase;
KW sequencing; primer; ss.
XX
XX Cochliobolus heterostrophus.
OS
XX Synthetic.
OS
XX WO200242444-A2.
PN
XX 30-MAY-2002.
PD
XX 21-NOV-2001; 2001WO-US043381.
PF
XX 22-NOV-2000; 2000US-0252649P.
PR
XX 22-NOV-2000; 2000US-0252732P.
PR
XX (SYGN) SYNGENTA PARTICIPATIONS AG.
PA (CORR) CORNELL RES FOUND INC.
PA (YODE/) YODER O.
PA (TURG/) TURGEON B G.
PA (LUS/) LU S.
XX
XX Yoder O, Turgeon BG, Lu S;
PI
XX WPI; 2002-666824/71.
DR
XX Nucleic acid molecules comprising fungal, e.g. Cochliobolus
PT

PT heterostrophus, genes from a peptide synthetase gene cluster, useful for
PT identifying anti-fungal agents for treating fungal infections such as
PT pneumonia and arthritis.
XX
XX Example 1; Page 187; 315pp; English.
XX
CC The present invention relates to nucleic acid molecules comprising
CC fungal, e.g. Cochliobolus heterostrophus, genes from a peptide synthetase
CC gene cluster, encoding e.g. an iron reductase and/or a permease, or a
CC major facilitator superfamily (MFS) transporter protein. The
CC polynucleotides and polypeptides are useful for identifying a novel
CC fungicidal or mycotoxic mode of action which permits rapid discovery of
CC novel inhibitors of gene products that are useful as fungicides or
CC mycotoxins. Anti-fungal agents identified using the polynucleotide and
CC polypeptide sequences of the invention, and antisense DNA are useful as
CC fungicides to suppress the growth of pathogenic fungi. The fungal
CC pathogens include plant pathogens such as Septoria tritici, or Cochliobolus
CC heterostrophus, or animal pathogens such as Candida albicans. The anti-
CC fungal agents are useful for treating fungal infections in plants such as
CC wild grasses or cereals (e.g. corn). For example they can be used to
CC treat a disease called leaf spot maize caused by the pathogen C.
CC heterostrophus. The anti-fungal agents are particularly useful for
CC treating fungal infections of vertebrates, including immunocompromised
CC vertebrates, for e.g. pneumonia, arthritis, military disease, bone and
CC joint infection, skin disease, asophagitis, vaginitis, onychomycosis,
CC and inflammation of the urinary tract, kidney, liver, brain,
CC gastrointestinal tract and lung. ABS68410-ABS68443 represent sequencing
CC primers used to sequence C. heterostrophus DNA flanking the RMI vector
CC insertion site in the examples of the present invention
XX
XX SQ Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 510 ATATTCGACGATGCT 528
XX |||||
XX 20 ATCTTCGACGATGCT 2
XX
XX Db
XX
XX RESULT 141
XX ABN02029
XX ID ABN02029 standard; DNA; 17 BP.
XX AC ABN02029;
XX XX
XX DT 29-MAY-2002 (first entry)
XX XX
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2021.
XX
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX XX
XX PF 25-MAY-2001; 2001WO-US016981.
XX
XX XX
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PF

PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX PA
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR
XX XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 2021; 214pp; English.
XX
XX CC The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionization, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX SQ Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 1.5e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 731 CCTGGGCTCTGCA 747
XX |||||
XX 1 CCTGGGCTCTGCA 17
XX
XX Db
XX
XX RESULT 142
XX ABN02850
XX ID ABN02850 standard; DNA; 17 BP.
XX AC ABN02850;
XX XX
XX DT 29-MAY-2002 (first entry)
XX XX
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2842.
XX
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX XX
XX PF 25-MAY-2001; 2001WO-US016981.
XX

XX ADB00305;
AC
XX
XX 20-NOV-2003 (first entry)
DT
XX
XX Human MD23 scanning oligonucleotide SEQ ID 1291.
DE
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX
XX EPI281758-A2.
PN
XX
XX 05-FEB-2003.
PD
XX
XX 30-JUL-2002; 2002EP-00016874.
PF
XX
XX 02-AUG-2001; 2001US-00922181.
PR
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Shannon M, Gu Y, Nguyen C;
PI
XX
XX WPI; 2003-423107/40.
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
PS
XX
XX Example 8; SEQ ID NO 1291; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder,
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 5 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX
XX Homo sapiens.
OS
XX
XX WO200297114-A2.
PN
XX
XX 05-DEC-2002.
PD
XX
XX 29-MAY-2002; 2002WO-US016840.
PF
XX
XX 29-MAY-2001; 2001US-0294140P.
PR
XX
XX 06-JUN-2001; 2001US-0296249P.
PR
XX
XX 10-SEP-2001; 2001US-0318471P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcsw1gen J;
PI
XX
XX WPI; 2003-140484/13.
DR
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
PS
XX
XX Claim 58; Page 85; 185pp; English.
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB266524,
CC AB266530 - AB266585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 1 A; 6 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CGCCGCGGCTGCGGCT 32
DB 17 CGCCGCGGCTGCGGCT 1

RESULT 146
ADF63855
ID ADF63855 standard; DNA; 17 BP.
AC ADF63855;
XX
XX 12-FEB-2004 (first entry)
DT
XX
XX Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1759.
DE
XX
XX chromatin organization modifier; CHROMO domain; cytosolic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
XX Homo sapiens.
OS
XX
XX WO2003050284-A1.
PN
XX
XX 19-JUN-2003.
PD
XX
XX 22-NOV-2002; 2002WO-US037506.
PF
XX

XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX
PS Disclosure; SEQ ID NO 2021; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPL-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPL-1, or as an inhibitor of hGDMPL-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SO Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 731 CCTGGGTCCTTCTGCA 747
DB 1 CCTGGGTCCTTCTGCA 17
RESULT 149
ACN65940
ID ACN65940 standard; DNA; 17 BP.
XX
XX ACN65940;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPL-1 probe SEQ ID NO:2842.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPL-1;
KM hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;
KM skeletal muscle function.
XX
OS Homo sapiens.
XX
XX US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0265680P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GVYV/) GU Y.
PA (JIVY/) JI Y.
PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-53378/51.
XX
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 2842; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPL-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPL-1, or as an inhibitor of hGDMPL-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SO Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1974 GGCTTCAGATGAGCA 1990
DB 1 GGCTTCAGATGAGCA 17
RESULT 150
ADA19158/c
ID ADA19158 standard; DNA; 18 BP.
XX
XX ADA19158;
XX
XX 20-NOV-2003 (first entry)
XX
XX Rat astrocyte konjirin 5' RACE primer SEQ ID NO:4.
XX
XX rat; astrocyte; konjirin; osteogenic protein binding region; neurotropic;
KM neuroprotective; antiparkinsonian; cerebroprotective;
KM bone morphogenic protein antagonist; BMP antagonist; gene therapy;
KM brain disorder; Alzheimer's disease; Parkinson's disease;
KM cerebral ischaemia; external brain trauma; primer; ss.
XX
OS Synthetic.
OS Rattus sp.
XX
XX WO2003070937-A1.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-JP001850.
XX
XX 20-FEB-2002; 2002JP-00042984.
XX
XX (TAIS/) TAISHO PHARM CO LTD.
PA (SATO/) SATO K.
XX
XX Sato K, Ueki T;
PI
XX
DR WPI; 2003-671811/63.
XX

PT Protein kohjirin comprising an osteogenic protein binding region and gene
PT encoding it for prevention and treatment of brain disorders, e.g.
PT Alzheimer's disease.
XX
XX
PS Example 2; Page 26; 69pp; Japanese.
CC The present invention describes a protein designated kohjirin (I), which
CC comprises an osteogenic protein binding region. Kohjirin has neurotropic,
CC neuroprotective, antiparkinsonian and cerebroprotective activities, and
CC can be used as a bone morphogenic protein (BMP) antagonist, and in gene
CC therapy. The kohjirin protein comprises an osteogenic binding region and
CC is useful in drugs or for developing drugs for the treatment and
CC prevention of brain disorders, e.g. Alzheimer's disease, Parkinson's
CC disease, cerebral ischaemia and external brain trauma. The present
CC sequence represents a 5' RACE primer for rat kohjirin, which is used in
CC an example from the present invention.
SQ Sequence 18 BP; 5 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.6%; Score 15.4; DB 1; Length 18;
XX Best Local Similarity 94.1%; Pred. No. 1.4e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 957 GAGTCTCTGAGCTCCAT 973
DB 17 GAGTCTCTGAGCTGCAT 1
RESULT 151
ID ADF88173 standard; DNA; 19 BP.
XX
XX ADF88173;
XX
XX 26-FEB-2004 (first entry)
XX
DE Single nucleotide polymorphism detection primer, SEQ ID NO 1756.
XX
XX human; single nucleotide polymorphism; microarray; side effect; ss;
XX primer; PCR.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX JP2003235571-A.
XX
XX 26-AUG-2003.
XX
XX 12-FEB-2002; 2002JP-00034717.
XX
XX 12-FEB-2002; 2002JP-00034717.
XX
XX (KAGA-) KAGAKU GIUTTSU SHINKO JIGYODAN.
XX
XX WPI; 2003-820454/77.
XX
XX Novel polynucleotide useful for detecting single nucleotide polymorphisms
XX in human gene.
XX
XX Claim 2; SEQ ID NO 1756; 704pp; Japanese.
XX
XX The invention relates to a novel polynucleotide isolated and purified
XX from a human gene having any one of 935 fully defined sequences as given
XX in specification, or a sequence having a base substitution. The invention
XX further relates to: an oligonucleotide containing single nucleotide
XX polymorphisms; a PCR primer set chosen from the combination of two DNA
XX fragments from any one of 1220 fully defined sequences as given in
XX specification; a labelling probe containing the SNP containing oligo; and
XX a microarray equipped with the SNP containing oligo. The isolated human
XX gene of the invention is useful for detecting the single nucleotide
XX polymorphisms in human gene. The isolated human gene is also useful for
XX diagnosis of disease and determination of side effect to a medical agent.
XX The isolated human gene is also effective in detecting single nucleotide

CC polymorphisms in a human gene. This polynucleotide sequence represents
CC one of the PCR primers used in the single nucleotide polymorphism
CC detection method of the invention.
XX
XX
SQ Sequence 19 BP; 3 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.6%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 1.3e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1034 TCATGAGCTGACCTGG 1050
DB 2 TCATGAGCTGACCTGG 18
RESULT 152
ID ADO60774
XX ADO60774 standard; RNA; 19 BP.
XX
XX ADO60774;
XX
XX 09-SEP-2004 (first entry)
XX
XX
XX Anti-AKT3 siRNA related DNA sequence SEQ ID NO:476.
XX
XX ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
XX RNA interference.
XX
XX Synthetic.
XX
XX WO2004045543-A2.
XX
XX 03-JUN-2004.
XX
XX 14-NOV-2003; 2003WO-US036787.
XX
XX 14-NOV-2002; 2002US-0426137P.
XX
XX 10-SEP-2003; 2003US-0502050P.
XX
XX (DHAR-) DHARMACON INC.
XX
XX Anastasia K, Angela R, Devin L, William M, Stephen S;
XX WPI; 2004-420527/39.
XX
XX Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
XX by selecting a target gene and measuring the functionality of the
XX nucleotide sequences that are complementary to a stretch of nucleotides
XX of the target sequence.
XX
XX Example 12; SEQ ID NO 476; 199pp; English.
XX
XX The invention relates to a novel method for selecting siRNA (short
XX interfering RNA) comprising selecting an siRNA molecule of 19-25
XX nucleoside bases by selecting a target gene and measuring the
XX functionality of sequences of 19-25 nucleotides in length that are
XX substantially complementary to a stretch of nucleotides of the target
XX sequence, where the functionality is dependent upon non-target specific
XX criteria. Also claimed are methods for gene-silencing, developing an
XX siRNA algorithm for selecting siRNA, selecting an siRNA molecule
XX with improved functionality, selecting hyperfunctional siRNA, an siRNA molecule
XX effective at silencing Bcl-2, and a kit for gene silencing comprising the
XX siRNA. The siRNA molecule comprises a sequence substantially similar to a
XX sequence consisting of GGAGAGUGUGUGAGAGUA; GAACUACUCCAUUUAAG;
XX GAACGACACCGGAGAU; AGAUGAGUACAGUACAU; UGAAGACUCUGUCAGUUU;
XX CAGGCGCCUCUGUTUGA; UCGGCGCUCUGUGAUUU; GAGUAGUGUAGUAGUA;
XX GGAGAGUGUAGUAGUAGUAC; and GAAGACUCUCUGUAGUUG. The siRNA molecule
XX comprises a sense strand and an anti-sense strand. The siRNA molecule
XX comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
XX pairs. The kit comprises at least two siRNA comprising a first optimised
XX siRNA and a second optimised siRNA. The method is useful in selecting
XX siRNA for generating a gene silencing reagent. The present sequence is
XX used in the exemplification of the invention. The sequence is shown in

CC		are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100 levels; or glucose-6-phosphatase levels in a subject; producing (I);
CC		stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instructions for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1) The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apob-100, elevated or otherwise unwanted levels of cholesterol, and/or deregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance,
CC		dyslipidaemias, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human apolipoprotein B (ApoB) antisense oligonucleotide that can be used to control ApoB gene expression.
CC		
XX	SQ	Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
YY		
Query Match		0.6%; Score 15.4; DB 1; Length 19;
Best Local Similarity		94.1%; Pred. No. 1.3e+02;
Matches	16; Conservative	1; Indels 0; Gaps 0
DY		507 TACATATTCTGCAGTGA 523
DB	19 TTCAATTCTGCACTGA 3	
RESULT 154		
ID	ADR75724	
AD	ADR75724 standard; DNA; 19 BP.	
XX		
AC	ADR75724:	
XX		
DT	16-DEC-2004 (first entry)	
XX		
DE	Human apolipoprotein B (ApoB) oligonucleotide seqd 209.	
XX		
KW	antilipemic; cardiant; vasootropic; antiarteriosclerotic; antidiabetic; cytoprotic; anticovulsant; nootropic; muscular; anti-HIV; RNA interference; tRNA; antisense technology; lipid metabolism; cholesteral imbalance; dyslipidaemia hypercholesterolaemia; coronary artery disease; CAD; coronary heart disease; CHD; atherosclerosis; hepatic glucose production; glucose-metabolism-related disorder; diabetes; cancer; breast cancer; colon cancer; lung cancer; neurological disease; Huntington disease; spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apob, ss.	
XX	Homo sapiens.	
OS		
PN	WO2004080406-A2.	
XX		
PD	23-SEP-2004.	
XX		
PF	08-MAR-2004; 2004WO-US007070.	
XX		
PR	07-MAR-2003; 2003US-0452682P.	
PR	12-MAR-2003; 2003US-0454265P.	
PR	13-MAR-2003; 2003US-0454962P.	
PR	13-MAR-2003; 2003US-0455050P.	
PR	14-APR-2003; 2003US-0462894P.	
PR	17-APR-2003; 2003US-0463772P.	
PR	25-APR-2003; 2003US-0465665P.	
PR	25-APR-2003; 2003US-0465802P.	
PR	09-MAY-2003; 2003US-0469612P.	

08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.

(ALMY-) ALMYLAM PHARM.

Manoharan M, Bumcrot D;
WPI; 2004-677362/66.

Interference RNA agent useful for treating dyslipidemias, coronary artery disease, diabetes, cancer or neurological diseases, comprises sense PT sequence and antisense sequence which has specific modifications.

Example 5; SEQ ID NO 209; 378bp; English.

The invention describes a RNA interference (RNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O-alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are: a pharmaceutical preparation comprising (II); reducing (MI) apob-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. (MI) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apob-100, elevated or otherwise unwanted levels of cholesterol, and/or disregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human apolipoprotein B (apob) antisense oligonucleotide that can be used to control Apob gene expression.

Sequence 19 BP; 0 A; 6 C; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0

2330 CCTTCCTGGTGTCT 2346
|||||
3 CCTTCCTGGTGTCT 19

RESULT 155
ADR77893/C
ID ADR77893 standard; DNA; 19 BP.

ADR77893;
16-DEC-2004 (first entry)

Human apolipoprotein B (Apob) oligonucleotide seqid 2378.

antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
cytostatic; anticovulant; nootropic; muscula; anti-HIV;
RNA interference; iRNA; antisense technology; lipid metabolism;
cholesterol imbalance; dyslipidaemia hypercholesterolaemia;

coronary artery disease; CAD; coronary heart disease; CHD; atherosclerosis; hepatic glucose production; glucose-metabolism-related disorder; diabetes; cancer; breast cancer; colon cancer; lung cancer; neurological disease; Huntington disease; spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apob; ss.

Homo sapiens.

WO2004080406-A2.

23-SEP-2004.

08-MAR-2004; 2004WO-US007070.

07-MAR-2003; 2003US-0452682P.
12-MAR-2003; 2003US-0454265P.
13-MAR-2003; 2003US-0454962P.
13-MAR-2003; 2003US-0455050P.
14-APR-2003; 2003US-0462894P.
17-APR-2003; 2003US-0463772P.
25-APR-2003; 2003US-0465655P.
25-APR-2003; 2003US-0465802P.
09-MAY-2003; 2003US-0469612P.
08-AUG-2003; 2003US-0493986P.
11-AUG-2003; 2003US-0494597P.
26-SEP-2003; 2003US-0506341P.
09-OCT-2003; 2003US-0510246P.
10-OCT-2003; 2003US-0510318P.
07-NOV-2003; 2003US-0518453P.

(ALANY-) ALNYLAM PHARM.

Manoharan M, Bumcrot D;
WPI: 2004-677362/66.

Interference RNA agent useful for treating dyslipidemiae, coronary artery disease, diabetes, cancer or neurological disease, comprises sense sequence and antisense sequence which has specific modifications.

Example 5; SEQ ID NO 2378; 378bp; English.

The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O-alkyl modifications, the antisense sequences have one or more asymmetrical phosphorochioloate modifications and the antisense sequence targets a human gene sequence. Also described are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I); involve selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apob-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidemiae, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human apolipoprotein B (ApoB) antisense oligonucleotide that can be used to control ApoB gene expression.

Sequence 19 BP; 3 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 507 TACATATTCGACTGA 523
 |||||
 Db 19 TTCATATTCGACTGA 3

RESULT 156
 ADR78342
 ID ADR78342 standard; DNA: 19 BP.
 XX ADR78342;
 AC ADR78342;
 DT 16-DEC-2004 (first entry)
 XX
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 2827.
 XX
 KM antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KM cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KM RNA interference; IRNA; antisense technology; lipid metabolism;
 KM cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KM coronary artery disease; CAD; coronary heart disease; CHD;
 KM atherosclerosis; hepatic glucose production;
 KM glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KM colon cancer; lung cancer; neurological disease; Huntington disease;
 KM spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; ApoB; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454285P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 PA
 XX (ALANY-) ALNYLAM PHARM.
 XX
 PI Manoharan M, Bumcrot D;
 XX
 DR WPI; 2004-677362/66.
 XX
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 PS Example 5; SEQ ID NO 2827; 378bp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) ApoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and

CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing ApoB-100 levels or glucose-6-phosphatase levels. (MI)
 CC is useful for reducing ApoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of ApoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.

QY 2330 CCTCTCTGTGTGTCT 2346
 |||||
 Db 3 CCTCTCTGTGTGTCT 19

RESULT 157
 AA205177/c
 ID AA205177 standard; DNA: 20 BP.
 XX
 AC AA205177;
 XX
 DT 07-OCT-1999 (first entry)
 XX
 DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
 XX
 KM Vaccine; eye disease; conventional trachoma; nongonococcal trachoma;
 KM paratrachoma; inclusion conjunctivitis; genital disease; peritrichitis;
 KM nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
 KM bartolinitis; pneumopathy; venereal lymphogranulomatosis; ss.
 OS Synthetic.
 OS Chlamydia trachomatis.
 XX
 PN WO928475-A2.
 XX
 PD 10-JUN-1999.
 XX
 PF 27-NOV-1998; 98WO-IB001939.
 XX
 PR 28-NOV-1997; 97FR-00015041.
 PR 17-DEC-1997; 97FR-00016034.
 PR 04-NOV-1998; 98US-0107077P.
 XX
 PA (GSEST) GENSET.
 XX
 PI Griffiths R;
 XX
 DR WPI; 1999-371125/31.
 XX
 PT Genome sequence of Chlamydia trachomatis.
 XX
 PS Disclosure, Page 1749; 1755pp; English.
 XX
 CC PCR primers AA201426-206209 were used to amplify open reading frames
 CC (ORFs) of the genome of Chlamydia trachomatis (see AA201425). These ORFs
 CC encode polypeptides (see AA36754-Y37949) which can be used as vaccines

CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as
CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis,
CC epididymitis, cervicitis, salpingitis, perihepatitis, bartolinitis;
CC pneumonia in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
CC
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1123 GGGTCCAGAGAGTTC 1139
DB 20 GAGTCCAGAGAGTTC 4
RESULT 158
AAC90974
ID AAC90974 standard; DNA; 20 BP.
XX
AC AAC90974;
XX
DT 19-MAR-2001 (first entry)
XX
DE Human AP12-MLT chimeric cDNA construction PCR primer #2.
XX
KW Human; AP12-MLT chimera; chimeric; apoptosis inhibitor 2; MLT; AP12;
KW mucosa-associated lymphoid tissue lymphoma associated translocation;
KW chromosome 11 region q21-q22.3; chromosome 18 region q21.1-q22;
KW molecular characterisation; chromosome translocation; carcinogenesis;
KW fusion protein; malignancy; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
OS Chimeric.
XX
PN WC200073500-A1.
XX
PD 07-DEC-2000.
XX
PF 26-MAY-2000; 2000MO-EP004796.
XX
PR 27-MAY-1999; 99EP-00201683.
XX
PA (VLA-A-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI Baens M, Marynen P, Dierlamm J;
XX
DR WPI; 2001-061556/07.
XX
PT Determining if a tissue sample has a chromosome (11:18) translocation
PT associated with malignancies by amplifying a nucleic acid sample using
PT primers complementary to chromosome 11 region q21-q22.3 and chromosome 18
PT region q21.1-q22.
XX
XX
XX Example 1; Page 11; 47pp; English.
XX
PS The present invention describes a method for determining if a tissue
CC sample comprises a cell with a chromosome (11:18) translocation
CC associated with malignancies such as mucosa-associated lymphoid tissue
CC (MALT) lymphomas. The method comprises subjecting a sample nucleic acid
CC to amplification using primers complementary to sequences which are on
CC chromosome 11 region q21-q22.3 and on chromosome 18 region q21.1-q22. The
CC method can be used for determining if a tissue sample or analogue
CC comprises a chromosome (11:18) translocation associated with malignancies
CC such as mucosa-associated lymphoid tissue lymphomas. The nucleic acid or
CC the antibody may be used as a probe for detection, for hybridisation to
CC southern blot cell DNAs or for in situ hybridisation of cells, or for

CC determining the presence of complementary DNA. The present sequence
CC represents a PCR primer used in the construction of the specifically
CC claimed chimeric human apoptosis inhibitor 2 (AP12)/MALT-lymphoma
CC associated translocation (MLT) protein
XX
SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 739 CCTTCGCACTTCACG 755
DB 1 CCTTCGCACTTCATC 17
RESULT 159
AAC92562
ID AAC92562 standard; DNA; 20 BP.
XX
AC AAC92562;
XX
DT 27-MAR-2001 (first entry)
XX
DE Human nucleolin phosphorothioate antisense oligonucleotide, SEQ ID NO:12.
XX
KW Human nucleolin; P92; C23; phosphoprotein; ribosome biogenesis;
KW ribosome transport; cytokinesis; nucleogenesis; cell proliferation;
KW cell growth; transcriptional repression; replication;
KW signal transduction; chromatin decondensation; Ag-NOR family;
KW nucleolin antibody; systemic connective tissue disease; SLE;
KW systemic lupus erythematosus;
KW scleroderma-like chronic graft versus host disease;
KW expression inhibition; tumour formation; cancer; inflammation;
KW immune disorder; phosphorothioate; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN US6165786-A.
XX
PD 26-DEC-2000.
XX
PF 03-NOV-1999; 99US-00433699.
XX
PR 03-NOV-1999; 99US-00433699.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowseart LM;
XX
DR WPI; 2001-079846/09.
XX
PT Novel antisense compound targeted to human nucleolin which specifically
PT hybridizes with and inhibits the expression of human nucleolin, useful
PT for modulating the expression of nucleolin in cells.
XX
XX
XX Claim 14; Col 41-42; 41pp; English.
XX
PS Sequences AAC92560-C92639 represent antisense oligonucleotides targeted
CC to the human nucleolin gene, which inhibit its expression. The antisense
CC oligonucleotides were designed to target different regions of the human
CC nucleolin mRNA, and were analysed for their effect on nucleolin mRNA
CC levels by quantitative real-time PCR. Nucleolin (also known as P92 or
CC C23) is the most abundant nucleolar phosphoprotein in actively growing
CC cells. Nucleolin primarily participates in ribosome biogenesis and
CC transport of ribosomal components, being able to transiently bind to pre-
CC ribosomes in the nucleolus via a ribonucleoprotein consensus sequence.
CC However, it has also been shown to be involved in cytokinesis,
CC nucleogenesis, cell proliferation and growth, transcriptional repression,
CC replication, signal transduction, and chromatin decondensation. Nucleolin
CC is a member of the Ag-NOR (active ribosomal gene located in the nucleolar
CC organiser region) family of proteins which are markers of active
CC ribosomal genes, and whose expression is associated with the prediction

CC of tumour growth rate. The presence of antibodies against nucleolin are
CC associated with systemic connective tissue diseases such as systemic
CC lupus erythematosus (SLE) and scleroderma-like chronic graft versus host
CC disease. The oligonucleotides of the invention are useful for diagnosis,
CC prevention and treatment of conditions associated with nucleolin
CC expression, such as tumour formation, immune disorders and inflammation
XX
SQ Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1120 GATGGTCGAGAGAG 1136
Db 2 GATGAGTCGAGAGAG 18
RESULT 160
ABZ88613
ID ABZ88613 standard; DNA; 20 BP.
XX
AC ABZ88613;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; de.
XX
OS Homo sapiens.
XX
PN MO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002MO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPICGENESIS PHARM INC.
XX
PI Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahbuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 3855; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1106 GGGCTCCTGGGGCCGAT 1122
Db 4 GGGCTCCTGGGGCCGAT 20
RESULT 161
ADL93361
ID ADL93361 standard; DNA; 20 BP.
XX
AC ADL93361;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human API2-MLT primer #2.
XX
KW chromosome (11:18) translocation; cancer;
KW mucosa-associated lymphoid tissue; MALT lymphoma; API2-MLT; human; ss;
KW primer.
XX
OS Homo sapiens.
XX
PN US2003176682-A1.
XX
PD 18-SEP-2003.
XX
PF 28-JAN-2003; 2003US-00353461.
XX
PR 09-JUN-1999; 99US-0138834P.
XX
PR 26-MAY-2000; 2000US-00579692.
XX
PA (DIER/) DIERLAWM J.
PA (BAEN/) BAENS M.
PA (MARI/) MARIJEN P.
XX
PI Dierlamm J, Baens M, Marijen P;
XX
DR WPI; 2003-852143/79.
XX
PT Nucleic acids derived from a chromosome (11:18) translocation associated
PT with malignancies such as mucosa-associated lymphoid tissue (MALT)
PT lymphomas, useful for diagnosing low grade lymphomas.
XX
PS Example; SEQ ID NO 2; 39pp; English.
XX
CC The invention relates to nucleic acids derived from a chromosome (11:18)
CC translocation associated with malignancies such as mucosa-associated
CC lymphoid tissue (MALT) lymphomas. The nucleic acids are useful in the
CC diagnosis of low grade lymphomas. The present sequence represents a human
CC API2-MLT primer.
XX
SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 739 CCTTGCACACTTCAGC 755
Db 1 CCTTGCACACTTCATC 17

```
RESULT 162
ADM35952
ID ADM35952 standard; DNA; 20 BP.
XX
AC ADM35952;
XX
DT 03-JUN-2004 (first entry)
XX
DE Phosphorothioate Cpdl/du DNA oligo #3 useful for induction of NK LU.
XX
KW phosphorothioate; natural killer lytic activity; NK LU; ss;
KW immunostimulatory; deoxyinosine; deoxyuridine; antigenic;
KW immune system deficiency; autoimmune disorder;
KW systemic lupus erythematosus; SLE; myasthenia gravis;
KW immunodeficiency disorder; AIDS; malignant tumour; gastric cancer;
KW skin cancer; leukaemia; lymphoma; infectious disease; dermatological;
KW immunosuppressive; antineoplastic; antineoplastic; virucide;
KW antiparasitic; cytostatic; antineoplastic; antineoplastic; neuroprotective;
KW antimicrobial; antiallergic; immunopharmacological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= Any n represents deoxyuridine or
FT deoxyinosine"
XX
PN WO2003047602-A1.
XX
PD 12-JUN-2003.
XX
PF 05-DEC-2002; 2002WO-EP013791.
XX
PR 07-DEC-2001; 2001AT-00001924.
XX
PA (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX
PI Schmidt W, Schellack C, Egyed A, Lingnau K;
XX
DR WPI; 2003-569024/53.
XX
PT Use of an immunostimulatory oligodeoxynucleic acid molecule in the
PT preparation of pharmaceutical composition for treating e.g. systemic
PT lupus erythematosus, sepsis or viral infections.
XX
PS Example 14; Page 107; 139pp; English.
XX
XX This invention relates to a novel use of immunostimulatory
XX oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
XX deoxyuridine (du). Specifically, it refers to ODN molecules that encode
XX antigenic proteins, yet do not induce the systemic production of pro-
XX inflammatory cytokines such as TNF-alpha and interleukin-6 (IL-6), thus
XX reducing the induction of potential harmful side effects. The present
XX invention describes compositions that are useful for preparing a
XX pharmaceutical composition that can activate dendritic cells, B cells,
XX natural killer cells and hence treat an immune system deficiency.
XX Furthermore, they can be used to treat various diseases including
XX autoimmune disorders such as systemic lupus erythematosus (SLE) and
XX myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
XX tumours that cause gastric and skin cancer as well as leukaemia and
XX lymphoma, and various infectious diseases for example from bacteria,
XX viruses and protozoa. Accordingly, such compositions exhibit
XX dermatological, immunosuppressive, antineoplastic, antineoplastic,
XX virucide, antiparasitic, cytostatic, antineoplastic, antineoplastic,
XX neuroprotective, antineoplastic, antineoplastic, antineoplastic. These
XX oligodeoxynucleotides have immunopharmacological activity and induce a
XX synergistic antigen specific immune response of an immunopotentiating
XX cytokine. This oligonucleotide sequence is an immunostimulatory di/du
XX containing ODN with a phosphorothioate backbone of the invention.
```

```
SQL Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 460 TCGTCCTCTCTGTACT 478
DB 1 TCGTCCTCTCTGTCT 19
RESULT 163
ADM35976
ID ADM35976 standard; DNA; 20 BP.
XX
AC ADM35976;
XX
DT 03-JUN-2004 (first entry)
XX
DE Cpdl/du ODN 1962 useful for B cell proliferation & IL-12 secretion.
XX
KW phosphorothioate; IL-12; B cell proliferation; ss; immunostimulatory;
KW deoxyinosine; deoxyuridine; antigenic; immune system deficiency;
KW autoimmune disorder; systemic lupus erythematosus; SLE;
KW myasthenia gravis; immunodeficiency disorder; AIDS; malignant tumour;
KW gastric cancer; skin cancer; leukaemia; lymphoma; infectious disease;
KW dermatological; immunosuppressive; antineoplastic; antineoplastic;
KW virucide; antiparasitic; cytostatic; antineoplastic; antineoplastic;
KW neuroprotective; antimicrobial; antiallergic; immunopharmacological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= Any n represents deoxyuridine or
FT deoxyinosine"
XX
PN WO2003047602-A1.
XX
PD 12-JUN-2003.
XX
PF 05-DEC-2002; 2002WO-EP013791.
XX
PR 07-DEC-2001; 2001AT-00001924.
XX
PA (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX
PI Schmidt W, Schellack C, Egyed A, Lingnau K;
XX
DR WPI; 2003-569024/53.
XX
PT Use of an immunostimulatory oligodeoxynucleic acid molecule in the
PT preparation of pharmaceutical composition for treating e.g. systemic
PT lupus erythematosus, sepsis or viral infections.
XX
PS Example 14; Page 108; 139pp; English.
XX
XX This invention relates to a novel use of immunostimulatory
XX oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
XX deoxyuridine (du). Specifically, it refers to ODN molecules that encode
XX antigenic proteins, yet do not induce the systemic production of pro-
XX inflammatory cytokines such as TNF-alpha and interleukin-6 (IL-6), thus
XX reducing the induction of potential harmful side effects. The present
XX invention describes compositions that are useful for preparing a
XX pharmaceutical composition that can activate dendritic cells, B cells,
XX natural killer cells and hence treat an immune system deficiency.
XX Furthermore, they can be used to treat various diseases including
XX autoimmune disorders such as systemic lupus erythematosus (SLE) and
XX myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
XX tumours that cause gastric and skin cancer as well as leukaemia and
XX lymphoma, and various infectious diseases for example from bacteria,
```

CC viruses and protozoa. Accordingly, such compositions exhibit
CC dermatological, immunosuppressive, antiinflammatory, antibacterial,
CC virucide, antiparasitic, cytostatic, antineoplastic, antiallergic,
CC neuroprotective, antimicrobial and antiallergic activities. These
CC oligodeoxynucleotides have immunopharmacological activity and induce a
CC synergistic antigen specific immune response of an immunopotentiating
CC cytokine. This oligonucleotide sequence is an immunostimulatory di/dU
CC containing ODN with a phosphorothioate backbone of the invention.
XX
SQ Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 460 TCCTGTCCTTCCTTGACT 478
Db 1 TCCTGTCCTTCCTTGACT 19
RESULT 164
ADM36056
ID ADM36056 standard; DNA; 20 BP.
XX
AC ADM36056;
XX
DT 03-JUN-2004 (first entry)
XX
DE Immunostimulatory Cpdi/dU DNA oligonucleotide #59.
XX
KM ss; immunostimulatory; deoxyinosine; deoxyuridine; antigenic;
KM immune system deficiency; autoimmune disorder;
KM systemic lupus erythematosus; SLE; myasthenia gravis;
KM immunodeficiency disorder; AIDS; malignant tumour; gastric cancer;
KM skin cancer; leukaemia; lymphoma; infectious disease; dermatological;
KM immunosuppressive; antineoplastic; antineoplastic; virucide;
KM antiparasitic; cytostatic; antineoplastic; antiallergic; neuroprotective;
KM antimicrobial; antiallergic; immunopharmacological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= Any n represents deoxyuridine or
FT deoxyinosine"
XX
PN WO2003047602-A1.
XX
PD 12-JUN-2003.
XX
PF 05-DEC-2002; 2002WO-EP013791.
XX
PR 07-DEC-2001; 2001AT-00001924.
XX
PA (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX
PI Schmidt W, Schellack C, Eyed A, Lingnau K;
XX
DR WPI; 2003-569024/53.
XX
PT Use of an immunostimulatory oligodeoxynucleic acid molecule in the
PT preparation of pharmaceutical composition for treating e.g. systemic
PT lupus erythematosus, sepsis or viral infections.
XX
PS Example 14; Page 112; 139pp; English.
XX
CC This invention relates to a novel use of immunostimulatory
CC oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
CC deoxyuridine (du). Specifically, it refers to ODN molecules that encode
CC antigenic proteins, yet do not induce the systemic production of pro-
CC inflammatory cytokines such as TNF-alpha and interleukin-6 (Il-6), thus

CC reducing the induction of potential harmful side effects. The present
CC invention describes compositions that are useful for preparing a
CC pharmaceutical composition that can activate dendritic cells, B cells,
CC natural killer cells and hence treat an immune system deficiency.
CC Furthermore, they can be used to treat various diseases including
CC autoimmune disorders such as systemic lupus erythematosus (SLE) and
CC myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
CC tumours that cause gastric and skin cancer as well as leukaemia and
CC lymphoma, and various infectious diseases for example from bacteria,
CC viruses and protozoa. Accordingly, such compositions exhibit
CC dermatological, immunosuppressive, antiinflammatory, antibacterial,
CC virucide, antiparasitic, cytostatic, antineoplastic, antiallergic,
CC neuroprotective, antimicrobial and antiallergic activities. These
CC oligodeoxynucleotides have immunopharmacological activity and induce a
CC synergistic antigen specific immune response of an immunopotentiating
CC cytokine. This oligonucleotide sequence is an immunostimulatory di/dU
CC containing ODN taken from table 1 of the invention.
XX
SQ Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 460 TCCTGTCCTTCCTTGACT 478
Db 1 TCCTGTCCTTCCTTGACT 19
RESULT 165
ADM35921
ID ADM35921 standard; DNA; 20 BP.
XX
AC ADM35921;
XX
DT 03-JUN-2004 (first entry)
XX
DE DNA oligo #1 useful for stimulating B cell proliferation in humans.
XX
KM ss; immunostimulatory; deoxyinosine; deoxyuridine; antigenic;
KM immune system deficiency; autoimmune disorder;
KM systemic lupus erythematosus; SLE; myasthenia gravis;
KM immunodeficiency disorder; AIDS; malignant tumour; gastric cancer;
KM skin cancer; leukaemia; lymphoma; infectious disease; dermatological;
KM immunosuppressive; antineoplastic; antineoplastic; virucide;
KM antiparasitic; cytostatic; antineoplastic; antiallergic; neuroprotective;
KM antimicrobial; antiallergic; immunopharmacological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= Any n represents deoxyuridine or
FT deoxyinosine"
XX
PN WO2003047602-A1.
XX
PD 12-JUN-2003.
XX
PF 05-DEC-2002; 2002WO-EP013791.
XX
PR 07-DEC-2001; 2001AT-00001924.
XX
PA (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX
PI Schmidt W, Schellack C, Eyed A, Lingnau K;
XX
DR WPI; 2003-569024/53.
XX
PT Use of an immunostimulatory oligodeoxynucleic acid molecule in the
PT preparation of pharmaceutical composition for treating e.g. systemic

PT lupus erythematosus, sepsis or viral infections.
XX
PS Example 14; Page 106; 139pp; English.
XX
CC This invention relates to a novel use of immunostimulatory
CC oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
CC deoxyuridine (du). Specifically, it refers to ODN molecules that encode
CC antigenic proteins, yet do not induce the systemic production of pro-
CC inflammatory cytokines such as TNF-alpha and interleukin-6 (IL-6), thus
CC reducing the induction of potential harmful side effects. The present
CC invention describes compositions that are useful for preparing a
CC pharmaceutical composition that can activate dendritic cells, B cells,
CC natural killer cells and hence treat an immune system deficiency.
CC Furthermore, they can be used to treat various diseases including
CC autoimmune disorders such as systemic lupus erythematosus (SLE) and
CC myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
CC tumours that cause gastric and skin cancer as well as leukaemia and
CC lymphoma, and various infectious diseases for example from bacteria,
CC viruses and protozoa. Accordingly, such compositions exhibit
CC dermatological, immunosuppressive, anti-inflammatory, antibacterial,
CC virologic, antiparasitic, cytostatic, antineoplastic, antiarthritic,
CC neuroprotective, antimicrobial and antiallergic activities. These
CC oligodeoxynucleotides have immunopharmacological activity and induce a
CC synergistic antigen specific immune response of an immunopotentiating
CC cytokine. This oligonucleotide sequence is an immunostimulatory di/du
CC containing ODN of the invention.
XX
SQ Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 460 TCCGTCCTCTGCTACT 478
Db 1 TCCGTCCTCTGCTACT 19
RESULT 166
ABD24843
ID ABD24843 standard; DNA; 20 BP.
XX
AC ABD24843;
XX
DT 29-JUL-2004 (first entry)
XX
DE A1092623-derived oligonucleotide SEQ ID 3855.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN MO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.

XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 3855; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity. Levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1106 GGCTCTCTGGGCGCAT 1122
Db 4 GGCTCTCTGGGCGCAT 20
RESULT 167
ADO26536
ID ADO26536 standard; DNA; 20 BP.
XX
AC ADO26536;
XX
DT 01-JUL-2004 (first entry)
XX
DE PCR primer MLT1 for human MLT cDNA.
XX
KW Chromosome translocation; malignancy;
KW mucosa-associated lymphoid tissue-lymphoma associated translocation;
KW MLT1; MLT; primary cell transformation; apoptosis inhibitor 2; APl2;
KW tumour; cytostatic; human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US6689875-B1.
XX
PD 10-FEB-2004.
XX
PF 26-MAY-2000; 2000US-00579692.
XX

```
PR 09-JUN-1999; 99US-0138834P.
XX
XX (VLA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
XX Dierlamm J, Baens M, Marijnen P;
XX
XX WPI; 2004-141430/14.
XX
PT New mucosa-associated lymphoid tissue-lymphoma associated translocation
PT protein, useful in diagnosing and treating tumors.
XX
XX Example; SEQ ID NO 2; 88bp; English.
XX
CC The present invention relates to a method for characterisation of
CC chromosome translocation T (11;18) (q21;q21) and its association with
CC malignancies such as mucosa-associated lymphoid tissue (MALT)-lymphomas.
CC Also disclosed are: the polynucleotide and polypeptide sequences for
CC human mucosa-associated lymphoid tissue (MALT)-lymphoma associated
CC translocation (MLT), and a novel mechanism of primary cell transformation
CC by expression of a fusion protein comprising at least apoptosis inhibitor
CC 2 (API2) fused to another protein such as MLT. The MLT polynucleotide and
CC polypeptide sequences, and the method of the invention are useful in
CC diagnosing and treating tumors. The present sequence represents a PCR
CC primer used in the examples of the present invention.
XX
XX
SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 739 CCTTGCACACTTCAGC 755
Db 1 CCTTGCACACTTCATC 17
RESULT 168
ADN71962
ID ADN71962 standard; DNA; 20 BP.
XX
XX ADN71962;
XX
XX 12-AUG-2004 (first entry)
XX
XX Human glucose transporter-4 antisense oligonucleotide #3.
XX
XX ss; human; antisense therapy; glucose transporter-4;
XX hyperproliferative disorder; probe.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= Other
XX /note= "phosphorothioate backbone. All cytidines are 5-
XX methylcytidines"
XX modified_base 1..5
XX /*tag= a
XX /mod_base= Other
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= Other
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004101848-A1.
XX
XX 27-MAY-2004.
XX
XX 23-NOV-2002; 2002US-00303266.
XX
XX 23-NOV-2002; 2002US-00303266.
XX
```

```
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Ward DT; Borchers AH, Dobie KW;
XX
XX WPI; 2004-399677/37.
XX
XX
PT New antisense oligonucleotides for modulating glucose transporter-4
PT expression, useful for diagnosing, preventing or treating conditions
PT associated with the transporter's expression e.g. hyperproliferative
PT disorders.
XX
XX Example 15; SEQ ID NO 15; 54bp; English.
XX
XX
CC The invention relates to antisense oligonucleotides targeted to a nucleic
CC acid molecule encoding glucose transporter-4. The oligonucleotides
CC specifically hybridise with the nucleic acid molecule encoding glucose
CC transporter-4 and inhibit the expression of glucose transporter-4. The
CC antisense oligonucleotide is useful for inhibiting the expression of
CC glucose transporter-4 in cells or tissues to prevent or treat diseases
CC associated with their expression, such as a hyperproliferative disorder.
CC In addition, the compound is used for diagnostics, prophylaxis, or as
CC research reagents or kits. The present sequence represents a human
CC glucose transporter-4 antisense oligonucleotide of the invention.
XX
XX
SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1219 ACTCCAGCCGATCACC 1235
Db 2 ACTCCAGCCGACGACC 18
RESULT 169
AAQ31923
ID AAQ31923 standard; DNA; 20 BP.
XX
XX AAQ31923;
XX
XX 25-MAR-2003 (revised)
XX
XX 20-APR-1993 (first entry)
XX
XX Beta-S globin gene primer 3.
XX
XX primer; polymerase chain reaction; PCR; human; beta-S; globin; gene;
XX target cell; linear DNA; indigenous region; target locus; marker; omega;
XX replacement; O; insertional; targeting vector; ss.
XX
XX Synthetic.
XX
XX WO9220808-A1.
XX
XX 26-NOV-1992.
XX
XX 13-MAY-1992; 92WO-US004054.
XX
XX 15-MAY-1991; 91US-00700501.
XX
XX (CELL-) CELL GENESYS INC.
XX
XX Smithlee O;
XX
XX WPI; 1992-415786/50.
XX
XX Genomic modification using DNA targeting for treating genetic disorder
XX etc. - by using vector contg. DNA with homology but different to a target
XX locus and a marker gene.
XX
XX Disclosure; Page 13; 42pp; English.
XX
```

CC The sequences given in AAQ91921-26 are primers which were used in an
CC example to illustrate the method of the invention. These primers were
CC used in the correction of the human beta-S globin gene. The method
CC comprises transforming the target cell with a linear DNA construct
CC containing a sequence with at least 50 bp homology with an indigenous
CC region (IR) of the target locus (TL), but different from the TL, and a
CC marker gene. The construct is an omega-(replacement) or O-(insertional)
CC targeting vector, where a non-homologous sequence forms an internal or
CC external loop, respectively. The cells are then grown and selected for
CC marker-containing cells. Cells containing the change in the IR were
CC isolated by identifying the presence of the construct sequence at the
CC locus. (Updated on 25-MAR-2003 to correct PN field.)
XX

SO Sequence 20 BP; 5 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 870 TGCCCTGTGACGGGACAC 889
1 TGGCGTGCACGCCGAAACAC 20

RESULT 170
AAQ82543/c
ID AAQ82543 standard; DNA; 20 BP.
XX
AC AAQ82543;
XX
DT 25-MAR-2003 (revised)
DT 13-SEP-1995 (first entry)
XX
DE Chromosome 11 (locus CD44) STS primer CD44-A.
XX
KM sequence sampled mapping; genomic analysis; complex genome mapping;
KM cosmid library; chromosome 11; sequence tagged site; STS analysis; ss.
XX
OS Synthetic.
XX
PN WO9429486-A1.
XX
PD 22-DEC-1994.
XX
PF 15-JUN-1994; 94MO-US006810.
XX
PR 15-JUN-1993; 93US-00078471.
PR 07-SEP-1993; 93US-00117952.
XX
PA (SALK) SALK INST BIOLOGICAL STUDIES.
XX
PI Evans GA, Smith MW;
PI
XX
DR WPI; 1995-036508/05.
XX
PT Sequencing complex genomes, present as fragments in a cosmid library - by
PT sequencing end-specific nucleotides of each clone then correlating with
PT spatial relationship of cosmid, esp. for mammalian chromosomes.
XX
PS Example 4; Page 86; 128bp; English.
XX
CC Sequences were determined from the ends of chromosome 11-specific cosmids
CC by automated sequencing without intermediate subcloning. A sample of 371
CC DNA sequence fragments were determined and of these, 277 were suitable
CC for STS primer prediction by computer analysis (using the "primer"
CC program available from E.Lander, MIT). The STSs and cosmids were mapped
CC by in situ hybridisation, somatic cell hybrid analysis or both. Using
CC this method, 370 STSs specific for human chromosome 11 were generated and
CC most of them were regionally mapped. This procedure illustrates a novel
CC method for sequencing complex genomes, designated "sequence sampled
CC mapping". The sequence sampled mapping method is useful for the
CC completion of high density sequence-based maps, and ultimately, for the
CC complete sequencing of genomic DNA directly from cosmid clones. See

CC AAQ82001-Q82706 for STS primers. (Also see AAQ91325-58). (Updated on 25-
CC MAR-2003 to correct PN field.)
XX
SQ Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 499 TCCCTATGTACATATTCGC 518
20 TCTTCATGTCCACATTTCGC 1

RESULT 171
AAT37932/c
ID AAT37932 standard; cDNA; 20 BP.
XX
AC AAT37932;
XX
DT 30-APR-1997 (first entry)
XX
DE VEGF-B167 exon 6B1 boundary 2.
XX
KM Endothelial cell; proliferation; vascular endothelial growth factor; VPF;
KM VEGF; endothelium; mesodermal cell; cationic dimer; tissue regeneration;
KM vascular permeability factor; cell mitogen; angiogenesis; cell growth;
KM embryonic development; wound healing; tissue reorganisation; antibody;
KM cancer; metastatic risk; tumour cell; mouse; ss.
XX
OS Mus musculus.
XX
PN WO9626736-A1.
XX
PD 06-SEP-1996.
XX
PF 01-MAR-1996; 96MO-US002957.
XX
PR 01-MAR-1995; 95US-00397651.
PR 06-JUN-1995; 95US-00469427.
PR 06-DEC-1995; 95US-00569063.
XX
PA (LUDWIG INST CANCER RES.
PA (UYHE-) UNIV HELSINKI LICENSING LTD OY.
XX
PI Eriksson U, Olofsson B, Alitalo K, Pajusola K;
PI
XX
DR WPI; 1996-412582/41.
XX
PT Vascular endothelial growth factor VEGF-B proteins - useful to accelerate
PT angiogenesis in wound healing, also related nucleic acid and antibodies
PT for cancer diagnosis.
XX
PS Example 7; Page 28; 107bp; English.
XX
CC AAT37919-737932 represent the intron/exon boundaries for the murine
CC vascular endothelial growth factor (VEGF) proteins of the invention (see
CC AAQ824-W04828, and AAQ824-W04830), which promote endothelial or mesodermal
CC cell proliferation. VEGF is also a glycosylated cationic dimer, and is
CC sometimes referred to as vascular permeability factor (VPF). VEGF has
CC diverse effects, depending on the specific biological context in which it
CC is found. VEGF is a potent endothelial cell mitogen, and directly
CC contributes to induction of angiogenesis in vivo by promoting endothelial
CC cell growth during normal embryonic development, wound healing, and
CC tissue regeneration/reorganisation. The VEGF proteins of the invention
CC share the angiogenic and other properties of VEGF, but are distributed
CC and expressed in tissues differently to VEGF. The proteins can therefore
CC be used to accelerate angiogenesis in wound healing. Antibodies against
CC the proteins can be used for inhibiting angiogenesis. The antibodies can
CC also be used diagnostically to quantitatively detect VEGF-B. Primers
CC complementary to the coding sequences for the proteins of the invention
CC can also be used to detect VEGF-B coding sequences. Quantification of
CC VEGF-B in cancer biopsy specimens may be useful as an indicator of

CC metastatic risk. VEGF-B expression in a cell can be retarded using
 CC antisense sequences direct against the VEGF coding sequences, this is
 CC especially useful in retarding VEGF expression in tumour cells
 XX

Sequence 20 BP, 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1192 CCTCCGACACCTGGGAGTG 1211
 DB 20 CCTCCGACACCTGGGAGTG 1

RESULT 172
 AAT65908
 ID AAT65908 standard; DNA; 20 BP.

AC AAT65908;
 XX
 DT 25-MAR-2003 (revised)
 DT 18-JUN-1997 (first entry)
 DE Primer #1 to amplify repeat sequence marker Mfd56.

XX Polymorphism; repeat sequence; genetic marker; primer; amplification;
 KM PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 KM linkage analysis; genetic disease; animal; plant; breeding; locus;
 KM hybridisation; chromosome; ds.

OS Synthetic.

PN US5582979-A.

PD 10-DEC-1996.

PF 04-APR-1994; 94US-00222177.

PR 21-APR-1989; 89US-00341562.

PR 05-SEP-1991; 91US-00754351.

PA (MARS-) MARSHFIELD CLINIC.

PI Weber JL;

DR WPI; 1997-042299/04.

PT Detection of polymorphic genetic markers of the form (dc-da)n(dg-dt)n -
 using novel nucleic acid mole. as primers.

PS Disclosure; Col 11-12; 186pp; English.

XX The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dc-da)n.(dg-dt)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g. paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. Clones containing the
 CC repeat sequences were isolated by hybridisation of chromosome-specific
 CC phage libraries with a synthetic poly(dc-da).(dg-dt) probe. Over 100
 CC repeat blocks were isolated. The primers AAT65798-T66047 were used to PCR
 CC amplify the inserts from the isolated clones containing the repeat
 CC sequences. The primers AAT65908-9 were used to amplify the repeat
 CC sequence marker clone Mfd56. (Updated on 25-MAR-2003 to correct PF
 CC field.)

XX Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 660 CTGCTGAGACACACACCT 679
 DB 1 CTGCTGATTCACACACCT 20

RESULT 173

AAK94030
 ID AAK94030 standard; DNA; 20 BP.

AC AAK94030;

DT 13-SEP-1999 (first entry)

DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KM sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KM neutralising epitope; PCR primer; ss.

OS Synthetic.

OS Chlamydia pneumoniae.

PN WO927105-A2.

PD 03-JUN-1999.

PF 20-NOV-1998; 98WO-1B001890.

PR 21-NOV-1997; 97FR-00014673.

PR 04-NOV-1998; 98US-0107078P.

PA (GEST) GENSET.

PI Griffiths R;

DR WPI; 1999-357842/30.

PT Genome sequence of Chlamydia pneumoniae.

PS Page 1638; Disclosure; 1912pp; English.

XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAY4584-AAY5879) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotide sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae

XX Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 386 CCTCTCTCTGACCTGGC 405
 DB 1 CCTCTCTCTACAGTGC 20

RESULT 174

AAA60404/C
 ID AAA60404 standard; DNA; 20 BP.

AC AAA60404;

DT 06-OCT-2000 (first entry)

DE Human telomerase antisense oligonucleotide hEST23 SEQ ID NO.5.

```
XX Human; telomerase; antisense oligonucleotide; inhibition; hEST2;
KW malignant tumour; cytosolic; telomerase inhibitor; liver cancer;
KM lung cancer; breast cancer; brain glioma; ss.
XX
XX Homo sapiens.
XX
XX WO200027858-A1.
XX
XX 18-MAY-2000.
XX
XX 29-OCT-1999; 99WO-CN000173.
XX
XX 09-NOV-1998; 98CN-00124461.
XX
XX (RADI-) INST RADIATION MEDICINE ACAD MILITARY ME.
XX
XX Wang S, Zheng X, Zhu B, Xing R, Guan W, Sun Z;
XX
XX WPI; 2000-376478/32.
XX
XX Antisense oligonucleotides which inhibit human telomerase activity useful
XX in the inhibition of malignant tumor growth, used to treat e.g. liver,
XX lung and breast cancers and brain glioma.
XX
XX Claim 2; Page 4; 32pp; Chinese.
XX
XX AAA60400 to AAA60428 represent specifically claimed antisense
XX oligonucleotides (1) complementary to a part of the gene encoding a
XX protein subunit hEST2 of human telomerase that has reverse transcriptase
XX activity, or its transcriptional mRNA. Also described are: (1) a
XX pharmaceutical composition comprising (1); (2) a reagent kit for
XX detecting telomerase hEST2 RNA component or DNA encoding telomerase hEST2
XX containing (1); and (3) preparing a drug for treating a tumour,
XX comprising the use of (1). The antisense oligonucleotides can inhibit
XX telomerase activity, applicable in inhibiting the growth of malignant
XX tumours e.g. for treatment of liver, lung and breast cancers and brain
XX glioma
XX
XX Sequence 20 BP; 1 A; 5 C; 11 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 144 AAGCCCTGGCCCCGGCGGC 163
XX |||||||||||||
XX 20 AAGCCCTGGCCCCGGCGCAC 1
XX
XX RESULT 175
XX AA261526
XX ID AA261526 standard; DNA; 20 BP.
XX
XX AA261526;
XX
XX 19-JUN-2000 (first entry)
XX
XX Primer 2L for a human 5'-OT EST (oxytloxin expressed sequence tag).
XX
XX Oxytloxin expressed sequence tag; 5'-OT EST; obesity; fertility; male;
XX transgenic animal; human late onset obesity; late onset visceral obesity;
XX male infertility; wasting; anorexia; cachexia; malabsorptive state;
XX catabolic state; inflammatory condition; Crohn's disease; AIDS wasting;
XX burn; cancer; bone disease; PCR primer; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200009686-A1.
XX
XX 24-FEB-2000.
XX
XX 12-AUG-1999; 99WO-GB002658.
```

```
XX
XX 12-AUG-1999; 98GB-00017566.
XX PR 06-MAY-1999; 99GB-00010522.
XX
XX (MEDI-) MEDICAL RES COUNCIL.
XX
XX Robinson ICAF, Stoye JP, Flavell D, Welle SE, Le Tissier P;
XX
XX WPI; 2000-224331/19.
XX
XX New anti-obesity polypeptide useful for treating obesity or infertility
XX in mammals.
XX
XX PS Disclosure; Page 26; 162pp; English.
XX
XX PCR primers and probes AA261525-26 are used to amplify and identify human
XX 5'-OT-EST (oxytloxin expressed sequence tag) cDNA sequences. The 5'-OT EST
XX gene is involved in the control of obesity and fertility in males. 5'-OT
XX EST nucleic acids are useful for producing transgenic animals. The
XX transgenic animals created serve as a model for human late onset obesity
XX and other related disorders and are also used for identifying the genetic
XX cause of obesity. Compounds which modulate 5'-OT EST expression or
XX activity are useful in the treatment or modulation of late onset visceral
XX obesity or male infertility particularly in the disorders related to
XX these conditions such as wasting, or anorexia, or cachexia associated
XX with prolonged illness, or malabsorptive states or catabolic states
XX associated with other diseases such as inflammatory conditions, Crohn's
XX disease or AIDS wasting, or burns, or cancer, or bone disease
XX
XX Sequence 20 BP; 4 A; 10 C; 3 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 358 GATCCAGCATCCTCTCCGCC 377
XX |||||||||||||
XX 1 GAATCAGCACCTCTCCGCC 20
XX
XX RESULT 176
XX AAA55723
XX ID AAA55723 standard; DNA; 20 BP.
XX
XX AAA55723;
XX
XX 30-AUG-2000 (first entry)
XX
XX TRAF1 antisense oligonucleotide ISIS# 101874.
XX
XX Tumour necrosis factor receptor-associated factor; TRAF; human;
XX antisense oligonucleotide; phosphorothioate; antiproliferative;
XX anti-inflammatory; E-selectin; jun kinase; ss.
XX
XX Synthetic.
XX
XX WO2000020435-A1.
XX
XX 13-APR-2000.
XX
XX 05-OCT-1999; 99WO-US023171.
XX PF
XX 06-OCT-1998; 98US-00167109.
XX PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Baker BF, Cowser LM, Monia BP, Xu XS;
XX
XX WPI; 2000-303732/26.
XX
XX Antisense oligonucleotides targeted to nucleic acids encoding human tumor
XX necrosis factor receptor-associated factor (TRAF), useful for treating
XX diseases associated with TRAF expression such as inflammatory diseases.
```


XX Example 33; Page 99; 170pp; English.
XX
CC The present invention relates to antisense oligonucleotides (see AA55496
CC -A55757) which are targeted to nucleic acids encoding a human tumour
CC necrosis factor receptor-associated factor (TRAF). The antisense
CC sequences comprise at least one modified internucleotide linkage, which
CC is a phosphorothioate linkage. The oligonucleotides also include at least
CC one modified sugar moiety such as a 2'-O-methoxyethyl sugar moiety.
CC Sequence AA55490-A55495 represent nucleotide sequences encoding human
CC TRAF-6. Included in the invention is a method for treating a human
CC having a disease associated with the expression of TRAF comprising
CC administering an antisense oligonucleotide. The reduction of Jun kinase
CC activation in cells comprises contacting the cells with an antisense
CC oligonucleotide targeted to TRAF-6. A method for the reduction of E-
CC selectin expression in cells or tissues comprises contacting the cells or
CC tissues with an antisense oligonucleotide targeted to TRAF-2 or TRAF-6.
CC The antisense oligonucleotides have antiproliferative and anti-
CC inflammatory activity and are useful for treating disorders associated
CC with cell proliferation and inflammation. The antisense oligonucleotides
CC may also be used as a diagnostic probe for studying gene function
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 436 AGGTCATCTCAGTCTCCAG 455
|||||
1 AGGCCATCTCAGGTTCCAG 20
Db
RESULT 177
AAH56532/C
ID AAH56532 standard; DNA; 20 BP.
XX
AC AAH56532;
DT 06-SEP-2001 (first entry)
DE S. pneumoniae groE operon antisense oligonucleotide SEQ ID NO:180.
XX
XX Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
XX microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
XX Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
XX antimicrobial; antiviral; antiproliferative; antisense therapy;
XX microbial infection; ss.
XX
OS Streptococcus pneumoniae.
XX
PN WO200136625-A2.
XX
PD 25-MAY-2001.
XX
PF 20-NOV-2000; 2000WO-CN001347.
XX
PR 18-NOV-1999; 99US-0166249P.
XX
PA (GENE-) GENESENSE TECHNOLOGIES INC.
XX
XX Wright JA, Young AH, Dugourd D;
PI Wright JA, Young AH, Dugourd D;
DR WPI; 2001-355633/37.
XX
XX Novel antisense compounds targeting nucleic acid encoding groEL or groES
XX PT gene of microorganism, which hybridize with and inhibit expression of the
XX PT gene, useful to inhibit growth of microorganism having the genes.
XX
XX Claim 3; Page 45; 110pp; English.
XX
XX The present invention specifically claims AAH56368 to AAH56832 which are
XX CC antisense oligonucleotides to nucleotide sequences encoding groE. More

CC generally, antisense compounds (I) comprising antisense oligonucleotides
CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC microorganism, where the antisense compound is complementary to GL or GS
CC of a microorganism and specifically hybridizes with and inhibits the
CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC antiproliferative activities, and can be used in antisense therapy and
CC for inhibition of expression of groES or groEL. (I) are useful for
CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC also useful for inhibiting the growth of a microorganism, or inhibiting
CC the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC virus) having a GL or GS gene which involves administering to the
CC microorganism or to a cell infected with the microorganism, (I). (I) are
CC also useful for treating a mammalian pathological condition mediated by
CC the microorganisms which involves identifying a eukaryotic organism
CC having a pathological condition mediated by microorganisms having a GL or
CC GS gene and administering (I) such that the growth of microorganism is
CC inhibited. The antisense compounds are utilised for diagnostics,
CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC prevent or delay microbial infections in humans. They are also useful as
CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC represent PCR primers for groE sequences which are used in the
CC exemplification of the present invention. AAH56855 to AAH56870 represent
CC groE nucleotide sequence given in the present invention
XX
SQ Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1548 AGGAAAAGTCACTATTCA 1567
|||||
20 AGGAGAAAGTAACTATGTC A 1
Db
RESULT 178
AAH47273
ID AAH47273 standard; DNA; 20 BP.
XX
AC AAH47273;
DT 30-NOV-2001 (first entry)
DE Nucleotide sequence of PCR primer pCDNA-S1.
XX
XX Serine protease-like protein; C-PLACB100992; Alzheimer's disease;
XX KW pharmaceutical; nootropic; neuroprotective; gene therapy; PCR primer; ss.
XX
XX Synthetic.
XX
OS
XX
PN WO200109349-A1.
XX
PD 08-FEB-2001.
XX
PF 28-JUL-2000; 2000WO-JP005062.
XX
PR 29-JUL-1999; 99JP-00248036.
XX
PR 27-AUG-1999; 99JP-00300253.
XX
PR 18-OCT-1999; 99US-0159590P.
XX
PR 11-JAN-2000; 2000JP-00118776.
XX
PR 17-FEB-2000; 2000US-0183322P.
XX
PR 02-MAY-2000; 2000JP-00183767.
XX
XX (HELI-) HELIX RES INST.
XX
XX Ota T, Isegaki T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
XX PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T, Yano K;
XX PI Murakami K, Kanazaki K, Inoue Y, Hashimoto E, Kashiwa A;
XX
XX WPI; 2001-564738/63.
XX
XX New genes encoding serine protease-like protein, useful for diagnosis and

PT treatment of Alzheimer's disease.
 XX
 PS Example 12; Page 33; 110pp; Japanese.
 XX
 CC The invention relates to genes encoding serine protease-like proteins.
 CC The genes are human and murine C-PLACE100992. The proteins can be
 CC expressed by standard recombinant methodology. The genes and proteins are
 CC useful in the diagnosis of Alzheimer's disease, or developing
 CC pharmaceuticals for treating the disease, and gene therapy. The present
 CC sequence represents a PCR primer used during the course of the invention
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
 QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 518 CACTGATTGCTGCTCATCG 537
 DB 1 CACTGCTTACTGGCTTATCG 20
 RESULT 179
 AA168544
 ID AA168544 standard; DNA; 20 BP.
 XX
 AC AA168544;
 XX
 DT 21-DEC-2001 (first entry)
 XX
 DE Human cytochrome p4502D6 associated primer SEQ ID 13.
 XX
 KW Cytochrome P450; human; metabolite toxicity; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN DE10012220-A1.
 XX
 PD 20-SEP-2001.
 XX
 PF 14-MAR-2000; 2000DE-01012220.
 XX
 PR 14-MAR-2000; 2000DE-01012220.
 XX
 PA (DOEH/) DOEHMER J.
 XX
 PI DoeHmer J, Krebsfaenger N, Eichelbaum M, Zanger UM;
 XX
 DR WPI; 2001-626902/73.
 XX
 PT Test system comprising cells expressing different cytochrome P450 2D6
 PT alleles used to investigate genetically caused metabolite toxicity and to
 PT determine toxic, mutagenic or carcinogenic effect of compounds.
 XX
 PS Example 1; Page 45; 72pp; German.
 XX
 CC This invention describes a novel test system comprising cells expressing
 CC a cytochrome P450 2D6 (MCP2D6) allele heterologous, and at least three P450
 CC 2D6 alleles are expressed in the system. The test system is used to
 CC investigate genetically caused toxicity of metabolites, particularly
 CC medicaments and to determine the toxic, mutagenic or carcinogenic effect of
 CC compounds. This sequence represents a primer used to illustrate the
 CC method of the invention
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
 QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 518 CACTGATTGCTGCTCATCG 537
 DB 1 CACTGCTTACTGGCTTATCG 20

RESULT 180
 AAFe0328
 ID AAFe0328 standard; DNA; 20 BP.
 XX
 AC AAFe0328;
 XX
 DT 10-MAY-2001 (first entry)
 XX
 DE Mouse Ig-kappa leader PCR primer #1.
 XX
 KW Mouse; endostatin; antitumour; cytostatic; antiarthritic; antipsoriatic;
 KW antidiabetic; ophthalmological; gene therapy; angiogenic inhibitor;
 KW adenoviral vector; diabetic retinopathy; cardiovascular disease;
 KW arthritis; psoriasis; cerebral oedema; intravascular coagulopathy;
 KW lymphoma; leukaemia; immunoglobulin; Ig; Ig-kappa; PCR primer; ss.
 XX
 OS Mus sp.
 XX
 PN WO200112830-A1.
 XX
 PD 22-FEB-2001.
 XX
 PF 11-AUG-2000; 2000MO-EP007865.
 XX
 PR 13-AUG-1999; 99US-00373938.
 XX
 PA (NOVS) NOVARTIS AG.
 PA (NOVS) NOVARTIS-ERFINDUNGEN VERN GES MBH.
 XX
 PI Hallenbeck PL, Chen CT;
 XX
 DR WPI; 2001-202871/20.
 XX
 PT Adenoviral vector for treating tumors and disorders associated with
 PT angiogenesis, such as cancer, arthritis, and psoriasis, comprises a DNA
 PT sequence encoding an angiogenic inhibitor, particularly endostatin.
 XX
 PS Example 1; Page 17; 59pp; English.
 XX
 CC The present sequence was used in the construction of an adenoviral vector
 CC which includes a DNA sequence encoding endostatin. The adenoviral vector
 CC is useful for expressing endostatin in a mammalian cell such as an A549
 CC or Hep3B cell. It is useful for treating other diseases and disorders
 CC associated with angiogenesis, such as neovascular diseases of the eye,
 CC including diabetic retinopathy, cardiovascular disease, arthritis,
 CC psoriasis, cerebral oedema and intravascular coagulopathy (Kasabach-
 CC Merritt syndrome). The vector inhibits, prevents or destroys the growth
 CC of tumours by preventing the formation of blood vessels in tumours, such
 CC as lymphoma and leukaemia
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
 QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 518 CACTGATTGCTGCTCATCG 537
 DB 1 CACTGCTTACTGGCTTATCG 20
 RESULT 181
 AAH80588/c
 ID AAH80588 standard; cDNA; 20 BP.
 XX
 AC AAH80588;
 XX
 DT 11-SEP-2003 (revised)
 DT 19-SEP-2001 (first entry)
 XX
 DE Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 552.

```

XX Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KM disease diagnosis; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN US6251588-B1.
XX
PD 26-JUN-2001.
XX
PF 10-FEB-1998; 98US-00021701.
XX
PR 10-FEB-1998; 98US-00021701.
XX
PA (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI Shannon KM, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
XX
DR WPI; 2001-424456/45.
XX
PT Predicting the potential of an oligonucleotide to hybridize to a target
PT nucleotide sequence, useful for evaluating oligonucleotide probe
PT sequences, by identifying a oligonucleotides based on the evaluation of
PT parameters.
XX
PS Example 2; Col 65; 342pp; English.
XX
CC The present invention describes a method for predicting the potential of
CC an oligonucleotide to hybridize to a (complementary) target nucleotide
CC sequence, involving identifying a subset of oligonucleotides within the
CC predetermined number of unique oligonucleotides based on the evaluation
CC of the parameter. Oligonucleotides in the subset are identified that are
CC clustered along a region of the nucleotide sequence that is hybridisable
CC to the target nucleotide sequence. This is useful for evaluating
CC oligonucleotide probe sequences. The present sequence is an
CC oligonucleotide described in the exemplification of the invention.
CC (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ Sequence 20 BP; 3 A; 2 C; 1 G; 14 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1543 TTAAGAGGAAAAAGTCAGTA 1562
DB 20 TTAAGAGGAAAAAGTCAGTA 1
XX
RESULT 182
AAH80589/C
ID AAH80589 standard; cDNA; 20 BP.
XX
AC AAH80589;
XX
DT 11-SEP-2003 (revised)
DT 19-SEP-2001 (first entry)
XX
DE Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 553.
XX
KM Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KM disease diagnosis; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN US6251588-B1.
XX
PD 26-JUN-2001.
XX
PF 10-FEB-1998; 98US-00021701.
XX
PR 10-FEB-1998; 98US-00021701.
XX

```

```

PA (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI Shannon KM, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
XX
DR WPI; 2001-424456/45.
XX
PT Predicting the potential of an oligonucleotide to hybridize to a target
PT nucleotide sequence, useful for evaluating oligonucleotide probe
PT sequences, by identifying a oligonucleotides based on the evaluation of
PT parameters.
XX
PS Example 2; Col 65; 342pp; English.
XX
CC The present invention describes a method for predicting the potential of
CC an oligonucleotide to hybridize to a (complementary) target nucleotide
CC sequence, involving identifying a subset of oligonucleotides within the
CC predetermined number of unique oligonucleotides based on the evaluation
CC of the parameter. Oligonucleotides in the subset are identified that are
CC clustered along a region of the nucleotide sequence that is hybridisable
CC to the target nucleotide sequence. This is useful for evaluating
CC oligonucleotide probe sequences. The present sequence is an
CC oligonucleotide described in the exemplification of the invention.
CC (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ Sequence 20 BP; 4 A; 2 C; 1 G; 13 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1542 TTAAGAGGAAAAAGTCAGT 1561
DB 20 TTAAGAGGAAAAAGTCAGT 1
XX
RESULT 183
AAH26100/C
ID AAH26100 standard; DNA; 20 BP.
XX
AC AAH26100;
XX
DT 17-SEP-2001 (first entry)
XX
DE VEGF receptor Flt-1 internal reverse PCR primer.
XX
KM Flt-1; vascular endothelial growth factor; VEGF; receptor; VEGF148;
KM human; cancer; tumour; antitumour; vascular disease; kidney disease;
KM arthritis; antiarthritic; therapy; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200153345-A1.
XX
PD 26-JUL-2001.
XX
PF 20-JAN-2000; 2000WO-GB000134.
XX
PR 20-JAN-2000; 2000WO-GB000134.
XX
PA (NBRI-) NORTH BRISTOL NHS TRUST.
XX
PI Harper SJ;
XX
DR WPI; 2001-465370/50.
XX
PT Treating or preventing e.g. tumor growth and metastasis, arthritis,
PT psoriasis, comprising inducing vascular endothelial growth factor (VEGF)
PT heterodimer formation in vivo, or administering a pre-formed VEGF
PT heterodimer.
XX
PS Example 1; Page 22; 37pp; English.
XX
CC The present sequence is that of an internal reverse PCR primer for human

```


CC which is then detected. The sequences represent cDNA encoding human and
CC mouse SACL polypeptides and PCR primers specific for the SACL genes
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1991 TGGGGGTGGCATGACACCC 2010
DB 20 TGGAGGTGACATGATACCC 1

RESULT 186
ABK37128/c
ID ABK37128 standard; DNA; 20 BP.

XX
AC ABK37128;

XX 08-MAY-2002 (first entry)

XX Human lysophospholipase I gene, antisense oligonucleotide #80.

XX Human; mouse; antiinflammatory; antiarteriosclerotic; vasotropic;

KM antilipemic; cardiant; lysophospholipase I; inflammation; ischaemia;

KM hyperlipidaemia; cardiovascular disorder; atherosclerosis;

KM antisense gene therapy; primer; ss.

XX Homo sapiens.

OS Synthetic.

XX WO200210185-A1.

XX 07-FEB-2002.

XX 20-JUL-2001; 2001WO-US022975.

XX 31-JUL-2000; 2000US-00629645.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Wyatt JR;

XX WPI; 2002-188720/24.

XX Novel antisense compound useful for treating inflammation,

XX hyperlipidemia, and cardiovascular disorders such as atherosclerosis and

XX myocardial ischemia, inhibits lysophospholipase I.

XX Claim 3; Page 82; 131pp; English.

XX The invention relates to an antisense compound (I) 8-30 nucleobases in

XX length targeted to a nucleic acid molecule encoding lysophospholipase I

XX (II), where (I) specifically hybridizes with and inhibits the expression

XX of (II). (I) is useful for inhibiting the expression of (II) in cells or

XX tissues, and for treating a human having a disease or condition

XX associated with lysophospholipase I e.g. inflammation, hyperlipidaemia,

XX and cardiovascular disorders such as atherosclerosis and myocardial

XX ischemia. (I) is useful as research reagent and diagnostics. (I) is also

XX useful for distinguishing functions of various members of a biological

XX pathway. (I) is useful in antisense gene therapy. ABK37028-ABK37191

XX represent lysophospholipase I coding sequences, antisense

XX oligonucleotides and related PCR primers of the invention. Note:

XX CC Antisense oligonucleotides are modified such that bases 1-5 and 16-20 are

XX 2'-methoxyethyl (2'-MOE) nucleotides, all bases have phosphorothioate

XX linkages, and all cytidines are 5-methyl cytidines

XX
SQ Sequence 20 BP; 0 A; 8 C; 9 G; 3 T; 0 U; 0 Other;

QY 4 CCGGAACGCCAGCGCCGCG 23
DB 20 CCGGAAGCCACCGCCGCG 1

RESULT 187
ABQ72917/c
ID ABQ72917 standard; DNA; 20 BP.

XX
AC ABQ72917;

XX 19-SEP-2002 (first entry)

XX Laminin 5 expression construct preparation primer SEQ ID NO:22.

XX Laminin alpha 5; laminin 10; vulnery; cell growth; differentiation;

KM tissue repair development; laminin; healing; vascular tissue;

KM re-endothelialisation; vascular injury; cell attachment; cell stasis;

KM proliferation; migration; primer; ss.

XX Homo sapiens.

OS Synthetic.

XX WO200250111-A2.

XX 27-JUN-2002.

XX 21-DEC-2001; 2001WO-US051035.

XX 21-DEC-2000; 2000US-0257449P.

XX 28-MAR-2001; 2001US-0279282P.

XX 13-NOV-2001; 2001US-00279282.

XX (BIOS-) BIOSTRATUM INC.

XX Trygvasson K, Doi M, Thyboll J;

XX WPI; 2002-557650/59.

XX The present invention describes human laminin alpha 5. Also described is

XX an isolated laminin 10. Laminin 10 has vulnery activity. Laminins are

XX useful in maintaining cell/tissue phenotype as well as promoting cell

XX growth and differentiation in tissue repair development. Specifically,

XX laminin 10 can be used for accelerating the healing injuries of vascular

XX tissue, improving the biocompatibility of grafts useful for treating such

XX injuries, for promoting re-endothelialisation at the site of vascular

XX CC injuries, and promoting cell attachment and subsequent cell stasis,

XX proliferation, differentiation, and/or migration. The present sequence

XX represents a primer used in the preparation of a laminin 5 expression

XX construct, which is used in the exemplification of the present invention

XX
SQ Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

RESULT 188

ABK70817

ID ABK70817 standard; DNA; 20 BP.

XX

```
AC ABK70817;
XX
XX 15-JUL-2002 (first entry)
XX
XX Human TSPI domain containing gene PCR primer pCDNA-S1.
DE
XX TSPI, thrombospondin domain; PCR; primer; ss; FG06969; FG01896;
KM angiogenesis; vasculogenesis.
XX
XX Homo sapiens.
OS
XX JF2002085059-A.
PN
XX
XX 26-MAR-2002.
PD
XX
XX 08-SEP-2000; 2000JP-00273778.
PF
XX
XX 08-SEP-2000; 2000JP-00273778.
PR
XX
XX (KAZU-) 2H KAZUSA DNA KENKYUSHO.
PA (YOSH ) YOSHITOMI PHARM IND KK.
XX
XX WPI; 2002-378268/41.
DR
XX
XX TSPI domain-containing polypeptide useful for drug compositions.
PT
XX
XX Example 6; Page 20; 51pp; Japanese.
PS
XX
XX The invention relates to a TSPI (thrombospondin 1) domain-containing
CC polypeptide comprising the proteins appearing as AA080188 and AA080189,
CC encoded by cDNAs designated FG06969 and FG01896. Also included are
CC proteins that are 50% homologous to the proteins and a polypeptide having
CC at least one deletion, replacement, addition or insertion of amino acid
CC in the proteins and having at least 8 repetitions of the TSPI domain. The
CC polypeptide can be used in drug compositions particularly for disorders
CC associated with angiogenesis and vasculogenesis. The present sequence is
CC a PCR primer for the TSPI domain containing DNA sequences
XX
XX Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY
XX 518 CACTGATGCTGCATCG 537
XX ||||| ||||| |||||
DB 1 CACTGCTACTGCTTATCG 20
XX
XX RESULT 189
XX AAD35752/c
XX ID AAD35752 standard; DNA; 20 BP.
XX
XX AAD35752;
AC
XX
XX 26-JUL-2002 (first entry)
DT
XX
XX Human h1beta4BP antisense oligonucleotide, ISIS #129477.
DE
XX
XX Antisense; human Integrin beta 4 binding protein; h1beta4BP; cytostatic;
KM cell proliferation; cancer; gene therapy; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
```

```
FT modified_base 14
FT /tag= d
FT /mod_base= m5c
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 17
FT /tag= e
FT /mod_base= m5c
FT modified_base 19
FT /tag= f
FT /mod_base= m5c
XX
XX US6355482-B1.
PN
XX
XX 12-MAR-2002.
PD
XX
XX 17-NOV-2000; 2000US-00716161.
PF
XX
XX 17-NOV-2000; 2000US-00716161.
PR
XX
XX 17-NOV-2000; 2000US-00716161.
PA (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freiler SM;
XX
XX WPI; 2002-370579/40.
DR
XX
XX Claim 3; Col 45-46; 40pp; English.
PS
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC encoding human integrin beta 4 binding protein (h1beta4BP), which
CC specifically hybridizes with the nucleic acid and inhibits its
CC expression. The antisense compounds are useful to prevent or treat
CC diseases associated with h1beta4BP expression, particularly conditions
CC involving aberrant or deregulated cell proliferation (e.g. cancer). The
CC h1beta4BP polynucleotide is used in gene therapy. The present sequence is
CC an antisense oligonucleotide targeted to h1beta4BP
XX
XX Sequence 20 BP; 9 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY
XX 1633 TCAGCTAACCTCTCTTTC 1652
XX ||||| ||||| |||||
DB 20 TCAGCTGTCCTCTCTTTC 1
XX
XX RESULT 190
XX AAD44835/c
XX ID AAD44835 standard; DNA; 20 BP.
XX
XX AAD44835;
AC
XX
XX 13-DEC-2002 (first entry)
DT
XX
XX Human raf kinase related antisense oligonucleotide #14.
DE
XX
XX Raf kinase; hyperproliferation; neovascularisation; ocular angiogenesis;
KM therapy; cancer; cytostatic; anti-angiogenic; vascular; ophthalmological;
XX antisense; ss.
OS
XX
XX Unidentified.
PN
XX
XX US6410518-B1.
XX
XX 25-JUN-2002.
PD
```

XX 18-FEB-2000; 2000US-00506073.
PF 31-MAY-1994; 94US-00250856.
XX 31-MAY-1995; 95WO-US007111.
PR 26-NOV-1996; 96US-00756806.
XX 07-JUL-1997; 97US-00888982.
PR 06-JUL-1998; 98WO-US013961.
XX 28-AUG-1998; 98US-00143214.
PA (ISIS-) ISIS PHARM INC.
XX Monta BP;
XX MPI; 2002-597918/64.
DR Treating cancer, angiogenesis or neovascularization by administering
XX antisense oligonucleotides targeted to human raf sequences.
XX
XX Disclosure; Col 59; 41pp; English.
XX The present invention relates to novel antisense oligonucleotides which
XX are targeted to nucleic acids encoding human raf proteins and capable of
XX inhibiting raf expression. The invention also relates to methods of
XX inhibiting hyperproliferation of cells which involves contacting the
XX hyperproliferating cells with a therapeutically effective amount of an
XX oligonucleotide of the invention. The method is useful for treating
XX cancer, angiogenesis or neovascularisation, especially ocular
XX angiogenesis or neovascularisation. The present DNA sequence is human raf
XX kinase related antisense oligonucleotide
SQ Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Db 1873 CGGTGTCGAGGGCAGTAG 1892
20 CAGTGTGTGAGGCGCAGCAG 1
RESULT 191
ABL94252
ID ABL94252 standard; DNA; 20 BP.
XX
XX ABL94252;
AC
XX
XX 29-JUL-2002 (first entry)
DT
XX
XX Human C/EBP beta phosphorothioate antisense oligonucleotide, SEQ ID:18.
XX
XX Human; C/EBP beta; CCAAT/enhancer-binding protein beta; C/EBP2; LAP;
XX TCF5; CRP2; NFIL6; IL6DB; NF-M; AGP/EBP; Apc/EBP; transcription factor;
XX tissue development; cellular function; proliferation; differentiation;
XX hormone responsiveness; oxidative stress response; IL-6 signalling
XX IL-6 signalling mediator; interleukin-6; carbohydrate metabolism;
XX immunity; Th1 response; female fertility; gluconeogenesis; ovarian;
XX cancer; tumour formation; type II; diabetes; infection; inflammation;
XX expression inhibition; phosphorothioate; antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT cytosines are 5-methylcytosine"

FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT cytosines are 5-methylcytosine"
US6271030-B1.
XX 07-AUG-2001.
PD
XX 14-JUN-2000; 2000US-00593711.
PF 14-JUN-2000; 2000US-00593711.
XX 14-JUN-2000; 2000US-00593711.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monta BP, Butler MM, Wyatt J;
XX MPI; 2002-214451/27.
DR
XX
XX Novel antisense compound targeted to nucleic acids encoding human or
XX mouse CCAAT/enhancer binding protein (C/EBP) beta, useful in vitro for
XX inhibiting expression of human or mouse C/EBP beta in cells/tissues.
XX
XX Claim 1; Col 42; 69pp; English.
PS
XX
XX Sequences ABL94252-ABL94476 represent antisense oligonucleotides targeted
XX to the human or mouse CCAAT/enhancer-binding protein alpha (C/EBP alpha)
XX gene, which inhibit its expression. The antisense oligonucleotides were
XX designed to target different regions of the human and/or mouse C/EBP
XX alpha RNA, and were analysed for their effect on C/EBP alpha mRNA levels
XX by quantitative real-time PCR. The C/EBP family of proteins are a family
XX of transcription factors which regulate the expression of a wide range of
XX genes that control normal tissue development, cellular function, cellular
XX proliferation and functional differentiation. C/EBP beta (also known as
XX C/EBP2, LAP, TCF5, CRP2, NFIL6, IL6DB, NF-M, AGP/EBP and Apc/EBP)
XX primarily regulates hormone responsiveness and oxidative stress responses
XX and is a mediator of IL-6 (interleukin-6) signalling. C/EBP beta is
XX thought to be involved in carbohydrate metabolism, immunity, the Th1
XX response, female fertility and gluconeogenic pathways. C/EBP beta is
XX expressed in the liver, lung, spleen, kidney, brain, and testis, with the
XX highest expression found in the lung. It is also expressed at a higher
XX level in malignant ovarian tissue compared with normal ovarian tissue,
XX and its expression in pancreas is upregulated in response to chronically
XX elevated levels of glucose, indicating that it is involved in the
XX impairment of insulin secretion in type II diabetes. The oligonucleotides
XX of the invention are useful for diagnosis, prevention and treatment of
XX conditions associated with C/EBP beta expression, such as cancer
XX (particularly ovarian cancer), tumour formation, diabetes (particularly
XX type II diabetes), infection, or inflammation
XX
XX Sequence 20 BP; 0 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
SQ
QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Db 21 CGGTGCGCGCTCTGCTGCG 40
1 CTGTGCGCGCGCTGCGCGG 20
RESULT 192
ABK49833
ID ABK49833 standard; DNA; 20 BP.
XX
XX ABK49833;
AC
XX
XX 15-JUL-2002 (first entry)
DT
XX
XX Human ADAMTS protein sequencing primer pCDNA-S1.
XX
XX Human; ss; ADAMTS; cytostatic; antidiabetic; antirheumatic;

KW antiarthritic; antiulcer; vulnery; neovascularisation; angioma;
 KW diabetic omentopathy; chronic rheumatoid arthritis; gene therapy;
 KW refractory skin ulcer; gastric ulcer; post-operative healing failure;
 KW repolymerin-type 2N-metalloproteinase domain; disintegrin-like domain; TSP1;
 KW thrombospondin type 1 domain; sexual cycle; tumour; 5P-syndrome deletion;
 KW chromosome 5p15.2-15.3; Cri-du-chat syndrome; primer.

XX Homo sapiens.

XX MO200231163-A1.

XX 18-APR-2002.

XX 11-OCT-2001; 2001WO-JP008913.

XX 11-OCT-2000; 2000JP-00311309.

XX 02-APR-2001; 2001JP-00102905.

XX (KAZU-) KAZUSA DNA RES INST FOUND.

XX (MITS-) MITSUBISHI PHARMA CORP.

XX Ohara O, Nagase T, Nomura N, Yano K, Murakami K, Yasuda S;
 PI Kanzaki K;

XX WPI; 2002-372277/40.

PT Human brain-originated ADAMTS family polypeptide and encoded gene,
 PT applicable in diagnosis and screening compounds for drug compositions in
 PT treating diseases due to e.g. neovascularization.

XX Example 3; Page 46; 172pp; Japanese.

XX The invention relates to a polypeptide belonging to the ADAMTS family is
 CC selected from sequences appearing as AAU79496, AAU79497 and AAU79499, a
 CC protein that contains the polypeptide, a protein having not less than 50%
 CC homology with the amino acid sequence of the polypeptides or a
 CC polypeptide modified from any of the polypeptides but with some amino
 CC acids deleted, substituted, added or inserted. Also included are the
 CC polynucleotides encoding the polypeptides (or their complementary strands
 CC or variants), a recombinant vector containing any of the polynucleotides,
 CC a transformant which is transformed with the recombinant vector,
 CC producing the polypeptide, protein or peptide by culturing the
 CC transformant, an antibody that can recognize the polypeptide, protein or
 CC peptide and screening compounds to promote or inhibit expression of the
 CC polynucleotide by using the polypeptide, protein, peptide, the
 CC polynucleotide, vector, transformant or/and antibody, particularly in the
 CC presence of a test compound for contact before evaluating the activity by
 CC measuring signal changes. The polypeptide and encoded gene are applicable
 CC in diagnosis and screening compounds for drug compositions in treating
 CC diseases due to neovascularisation, diabetic omentopathy, chronic
 CC rheumatoid arthritis, angioma, refractory skin and gastric ulcers and
 CC post-operative healing failure, including gene therapy. The gene encoding
 CC such polypeptide has conserved repolymerin-type 2N- metalloproteinase
 CC domain, disintegrin-like domain and TSP1 (thrombospondin type 1) domain.
 CC Its encoded protein is characterised by high expression in ovaries,
 CC changes in expression dose depending on the sexual cycle, a decrease in
 CC tumour cell and location of the gene on the 5P-syndrome deletion site on
 CC chromosome 5p15.2-15.3 (associated with Cri-du-chat syndrome). The
 CC present sequence is a sequencing primer for a ADAMTS cDNA sequence

XX Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

XX Query Match 0.6%; Score 15.2; DB 1; Length 20;

XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;

XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTGCTGCTATCG 537

DB 1 CACTGCTTACTGCTTATCG 20

RESULT 193

AD56714
 ID AD56714 standard; DNA; 20 BP.

XX AC AD56714;

XX 18-DEC-2003 (first entry)

XX PCR primer 3 related to human vitamin-D3 hydroxylase.

XX vitamin-D3 hydroxylase; VDDH; antipruritic; osteopathic; hypercalcaemia;
 KW gene therapy; antisense; hypoparathyroidism; rickets; psoriasis;
 KW osteoporosis; renal insufficiency; ss; primer; PCR.

XX Unidentified.

XX JP2003047479-A.

XX 18-FEB-2003.

XX 08-AUG-2001; 2001JP-00241396.

XX 08-AUG-2001; 2001JP-00241396.

XX (MOCH) MOCHIDA PHARM CO LTD.

XX (HERI-) HERIKUSU KENKUSHO KK.

XX WPI; 2003-508705/48.

PT Novel vitamin-D3 hydroxylase protein, useful for identifying modulators
 PT of the vitamin-D3 hydroxylation activity of the enzyme.

XX Example 1; Page 10; 18pp; Japanese.

XX The invention relates to a novel vitamin-D3 hydroxylase (VDDH) protein.
 CC The polypeptide of the invention demonstrates antipruritic and
 CC osteopathic activities and may be useful for identifying compounds which
 CC modulate the activity or inhibit the expression of vitamin-D3 hydroxylase
 CC and thus for treating or preventing hypercalcaemia. Furthermore, the
 CC polypeptide may be utilised during gene and antisense therapy, as well as
 CC for treating activated vitamin-D3 deficiency disorders such as
 CC hypoparathyroidism, rickets, psoriasis, osteoporosis and renal
 CC insufficiency. The current sequence is that of the PCR primer 3 of the
 CC invention which is related to human vitamin-D3 hydroxylase.

XX Sequence 20 BP; 2 A; 9 C; 7 G; 2 T; 0 U; 0 Other;

XX Query Match 0.6%; Score 15.2; DB 1; Length 20;

XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;

XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 106 AGCCTGACGCCGTCGCCGG 125

DB 1 AGCCTGACGCCGTCGCCGG 20

RESULT 194

ACF79452
 ID ACF79452 standard; DNA; 20 BP.

XX ACF79452;

XX 18-DEC-2003 (first entry)

XX Serum amyloid A1 modified promoter GREI primer GREIF.

XX Glucocorticoid responsive element; GRB; serum amyloid A1; SAA1; promoter;
 KW human; steroid responsiveness; PCR; primer; ss.

XX Homo sapiens.

XX Synthetic.

XX WO2003062792-A2.

PD 31-JUL-2003.
XX
PF 22-JAN-2003; 2003WC-US001651.
XX
PR 22-JAN-2003; 2002US-00045360.
XX
PR 03-APR-2002; 2002US-0370008P.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Whitehead AS, Challberg SS, Lazar JG;
XX
DR WPI; 2003-748014/70.
XX
PT Determining steroid responsiveness, useful e.g. for monitoring, or
XX assessing likely success of therapy, comprises measuring relative
PT expression of responsive and non-responsive genes.
XX
XX Example 1; Page 29; 0pp; English.
XX
CC The present sequence is that of primer GREIF, which was used in the PCR
CC mutagenesis of the human serum amyloid A1 (SAA1) gene promoter to produce
CC construct GREI (see ACF79439). GREI was used to confirm that a putative
CC glucocorticoid responsive element of SAA1 is functional. A method for
CC determining steroid responsiveness involves determining, in a tissue, the
CC body fluid or cell sample from a subject being treated with steroids, the
CC RNA expression levels of genes that are known to be, or suspected of
CC being, respectively, responsive and non-responsive to steroids. The first
CC gene is preferably the SAA1 gene controlled by a GRE, and the second gene
CC is the SAA2 gene; the responses of only the SAA1 gene are augmented by
CC glucocorticoid administration. The method is applied to subjects being
CC treated with steroids for a very wide range of diseases (e.g.
CC inflammation, cancer, autoimmune disease, arthritic diseases, coronary
CC artery disease, endocrine disease, stroke etc.), e.g. for monitoring to
CC detect loss of responsiveness, to detect response when a combination of
CC stimuli or drugs is administered and to assess side effects, to evaluate
CC subjects for transplantation or steroid therapy, and to determine
CC suitable doses of steroids
XX
SQ Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1634 CAGCTAACCTCTTCTCTCC 1653
DB 1 CAGCAAACTCTTGTCTCC 20
XX
RESULT 195
ADD81480/C
ID ADD81480 standard; DNA; 20 BP.
XX
AC ADD81480;
XX
DT 29-JAN-2004 (first entry)
XX
DE HIV PRT antisense derived probe #409.
XX
KW ss; oligonucleotide hybridisation potential; efficient hybridisation;
KM large array; minimum oligonucleotide synthesis; probe.
XX
OS Human immunodeficiency virus.
XX
PN US2003054346-A1.
XX
PD 20-MAR-2003.
XX
PF 15-FEB-2001; 2001US-00784674.
XX
PR 10-FEB-1998; 98US-00021701.
XX
PA (SHAN/) SHANNON K W.

PA (WOLB/) WOLBER P K.
PA (DELE/) DELENSTARR G C.
PA (WEBB/) WEBB P G.
PA (KINC/) KINCAID R H.
XX
PI Shannon KW, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
XX
DR WPI; 2003-743746/70.
XX
PT Predicting potential of oligonucleotides to hybridize to target
PT nucleotide sequence comprises determining and evaluating for each
PT oligonucleotide a parameter predictive of the oligonucleotides ability to
PT hybridize with target.
XX
PS Example 2; SEQ ID NO 553; 423pp; English.
XX
XX The invention relates to a method of predicting the potential of
CC oligonucleotides to hybridise to target nucleotide sequences. The method
CC is useful for predicting the potential of an oligonucleotide to hybridise
CC to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC contains chemically modified nucleotides. The method is also useful for
CC predicting the potential of the oligonucleotides to hybridise to a
CC complementary target nucleotide sequence. The method is useful to predict
CC efficient hybridisation oligonucleotides for each of multiple target
CC sequences therefore very large arrays may be constructed and tested with
CC minimum synthesis of oligonucleotides. The present sequence represents a
CC HIV PRT antisense derived probe.
XX
SQ Sequence 20 BP; 4 A; 2 C; 1 G; 13 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1542 TTAAGACGAAAGTCACT 1561
DB 20 TTAAGAAAGAAAAATCACT 1
XX
RESULT 196
ADD81479/C
ID ADD81479 standard; DNA; 20 BP.
XX
AC ADD81479;
XX
DT 29-JAN-2004 (first entry)
XX
DE HIV PRT antisense derived probe #408.
XX
KW ss; oligonucleotide hybridisation potential; efficient hybridisation;
KM large array; minimum oligonucleotide synthesis; probe.
XX
OS Human immunodeficiency virus.
XX
PN US2003054346-A1.
XX
PD 20-MAR-2003.
XX
PF 15-FEB-2001; 2001US-00784674.
XX
PR 10-FEB-1998; 98US-00021701.
XX
PA (SHAN/) SHANNON K W.
PA (WOLB/) WOLBER P K.
PA (DELE/) DELENSTARR G C.
PA (WEBB/) WEBB P G.
PA (KINC/) KINCAID R H.
XX
PI Shannon KW, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
XX
DR WPI; 2003-743746/70.
XX
PT Predicting potential of oligonucleotides to hybridize to target

PT nucleotide sequence comprises determining and evaluating for each
PT oligonucleotide a parameter predictive of the oligonucleotide's ability to
PT hybridize with target.

PS Example 2; SEQ ID NO 552; 423pp; English.

XX The invention relates to a method of predicting the potential of
CC oligonucleotides to hybridize to target nucleotide sequences. The method
CC is useful for predicting the potential of an oligonucleotide to hybridize
CC to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC contains chemically modified nucleotides. The method is also useful for
CC predicting the potential of the oligonucleotides to hybridize to a
CC complementary target nucleotide sequence. The method is useful to predict
CC efficient hybridization oligonucleotides for each of multiple target
CC sequences therefore very large arrays may be constructed and tested with
CC minimum synthesis of oligonucleotides. The present sequence represents a
CC HIV PRT antisense derived probe.

SQ Sequence 20 BP; 3 A; 2 C; 1 G; 14 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAGAGGAAAAAGTCAGTA 1562

Db 20 TAAAGAAAGAAATATCAGTA 1

RESULT 197
ABZ93072

ID ABZ93072 standard; DNA; 20 BP.

XX ABZ93072;

DT 17-OCT-2003 (first entry)

XX Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antilasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

PD 31-OCT-2002.

PF 23-APR-2002; 2002MO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIC-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-229219/22.

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.

PS Disclosure; SEQ ID NO 8314; 872pp; English.

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiqunone. A composition of the invention
CC has antiinflammatory, antiallergic, antilasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiqunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 20 BP; 12 A; 1 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAGAGGAAAAAGTCAGTA 1562

Db 1 TAAAGAAAGAAATATGCAATTA 20

RESULT 198
ABZ91914

ID ABZ91914 standard; DNA; 20 BP.

XX ABZ91914;

DT 17-OCT-2003 (first entry)

XX Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antilasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

PD 31-OCT-2002.

PF 23-APR-2002; 2002MO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIC-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-229219/22.

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.

PS Disclosure; SEQ ID NO 7156; 872pp; English.

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytoskeletal activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 9 A; 2 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.64; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2388 TATATGCTTGAATAATAT 2407
Db 1 TATATGCTTTAAAAAAT 20
|||||
|

RESULT 199
AB293016
ID AB293016 standard; DNA; 20 BP.
XX
AC AB293016;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KM Human; antisense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antiasthmatic; hypotensive; immunosuppressive; cytoskeletal; gene therapy;
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; de.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR MPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 8258; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytoskeletal activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.64; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1554 AAGTCAGTATTCAAGTCT 1573
Db 1 AGTCAGATTTCAGCTCT 20
|||||
|

RESULT 200
ACD42151/c
ID ACD42151 standard; DNA; 20 BP.
XX
AC ACD42151;
XX
DT 05-SEP-2003 (first entry)
XX
DE Human raf-associated antisense oligonucleotide #13.
XX
KM Antisense; c-raf; a-raf; b-raf; protein kinase; cancer; ss;
KM signal transduction; cell proliferation; lung carcinoma; cytostatic;
KM antisense gene therapy; chemotherapeutic agent; angiogenesis;
KM hyperproliferative condition; neovascularisation; ocular angiogenesis.
XX
OS Unidentified.
XX
PN US2003032607-A1.
XX
PD 13-FEB-2003.
XX
PF 25-JAN-2002; 2002US-00057550.
XX
PR 31-MAY-1994; 94US-00250856.
PR 31-MAY-1995; 95WO-US007111.
PR 26-NOV-1996; 96US-00756806.
PR 07-JUL-1997; 97US-00889892.
PR 06-JUL-1998; 98WO-US013961.
PR 28-AUG-1998; 98US-00143214.
PR 18-FEB-2000; 2000US-00506073.
XX
PA (MONT/) MONIA B P.
XX
PI Monia BP;
XX
DR MPI; 2003-503332/47.
XX
PT Novel antisense oligonucleotide which is targeted to mRNA encoding human
PT raf and which is capable of inhibiting raf expression, useful for
PT treating or preventing hyperproliferative conditions such as cancer.
XX
PS Disclosure; Page 31; 42pp; English.
XX
CC The invention relates to an oligonucleotide 8-50 nucleotides in length

CC which is targeted to mRNA encoding human c-raf, a-raf or b-raf (raf is a
CC protein kinase playing a regulatory role in signal transduction,
CC regulating cell proliferation and has been implicated in lung carcinoma),
CC and which is capable of inhibiting raf expression. Also included is a
CC composition comprising the oligonucleotide and a pharmaceutically
CC acceptable carrier. The antisense oligonucleotide is useful for
CC inhibiting the expression of human raf in human cells or tissues, by
CC contacting the human cells or tissues with the oligo. The oligo. is also
CC is useful for treating or preventing a disease or condition associated
CC with the expression of raf by administering it in combination with a
CC chemotherapeutic agent to a human or cells of the human, where the
CC expression of raf is abnormal expression, and the condition is a
CC hyperproliferative condition such as cancer, angiogenesis or
CC neovascularisation (preferably ocular angiogenesis or
CC neovascularisation). The oligo. is also useful for inhibiting
CC hyperproliferation of cells. The oligos. are also useful as tools, for
CC example for detecting and determining the role of raf expression in
CC various cell functions and physiological processes and conditions and for
CC diagnosing conditions associated with raf expression and for research
CC purposes. The present sequence is an antisense oligonucleotide included
CC in the sequence listing but not mentioned elsewhere in the specification
CX

SEQ Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1873 CCCTTGTGAGGCGAGTAG 1892
DB 20 CAGTGGTGTGAGGCGAGCAG 1

RESULT 201

ID ABD28144
ABD28144 standard; DNA; 20 BP.

AC ABD28144;
XX
XX
DT 29-JUL-2004 (first entry)
XX

DE AA156940-derived oligonucleotide SEQ ID 7156.

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

PN WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandraaagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15; SEQ ID NO 7156; 763bp; English.

PS This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiinflammatory, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or surfactant hypoproduction and/or lung
CC inflammation, allergies and/or chronic hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it

SEQ Sequence 20 BP; 9 A; 2 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2388 TATATGCTTGAATAAAT 2407
DB 1 TATATGCTTGAATAAAT 20

RESULT 202

ID ABD29246
ABD29246 standard; DNA; 20 BP.

AC ABD29246;

XX 29-JUL-2004 (first entry)

DE H16833-derived oligonucleotide SEQ ID 8258.

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

PN WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPiG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 8258; 763bp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
 XX
 QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 DB 1554 AAGTCAGTATTTCAAGTCT 1573
 1 AGGTCAGAAATTTCAAGCTCT 20
 RESULT 203
 ABD29302
 ID ABD29302 standard; DNA; 20 BP.
 XX
 AC ABD29302;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE AA644211-derived oligonucleotide SEQ ID 8314.
 XX
 KM Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KM surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KM analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KM respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KM emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KM pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 XX
 PN MO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002MO-US011143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPiG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 8314; 763bp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 12 A; 1 C; 3 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 DB 1543 TAAGAAGGAAAGTCACTA 1562
 1 TAAGAAAGAAATGTCATTA 20
 RESULT 204
 ADK71763/c
 ID ADK71763 standard; DNA; 20 BP.
 XX

```

AC ADX71763;
XX
DT 06-MAY-2004 (first entry)
XX
DE PCR primer used in a three prime end amplification.
XX
KM AKIP1; RNA-binding protein; ABA; abscisic acid;
XX ABA-activated protein kinase; AAPK; plant protectant; plant; transgenic;
XX PCR; primer; ss.
XX
OS Synthetic.
XX
PN WO2004013295-A2.
XX
PD 12-FEB-2004.
XX
PF 01-AUG-2003; 2003WO-US024197.
XX
PR 01-AUG-2002; 2002US-0400549P.
XX
PA (PENN-) PENN STATE RES FOUND.
XX
PI Asmann SM, Mansfield JL, Kinoshita T, Shimazaki K, Ng CKY;
XX WPI; 2004-157117/15.
XX
DR New AKIP1 nucleic acids and proteins, useful in producing plants with
XX improved response to stresses including cold, heat, salinity, synthetic
XX and natural chemical agents, viral, fungal and bacterial pathogens and
XX drought.
XX
PS Example; Page 38; 106pp; English.
XX
CC The invention relates to plant RNA-binding proteins and encoding
XX polynucleotides. The polynucleotide encodes an ABA (abscisic acid) -
XX mediated phosphorylation-regulated RNA binding protein, AKIP1. The
XX encoded protein is a substrate for phosphorylation by an ABA-activated
XX protein kinase or AAPK. The protein's ability to interact with RNA is
XX altered upon phosphorylation. The binding affinity for RNA increases upon
XX phosphorylation. The nucleic acid molecule and the encoded protein is
XX useful in producing plants with improved response to stresses including
XX cold, heat, salinity, synthetic and natural chemical agents, viral,
XX fungal and bacterial pathogens and drought. The present sequence
XX represents a PCR primer used in a three prime end amplification method.
XX
SQ Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1576 CACTTCGAGCTGCGCTGTT 1595
DB 20 CACTTCGAGCTGCGCTGTT 1
RESULT 205
ADK97267
ID ADK97267 standard; DNA; 20 BP.
XX
AC ADK97267;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #2987.
XX
KM human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.

```

```

XX
XX 08-MAR-2002; 2002JP-00064373.
XX
XX 08-MAR-2002; 2002JP-00064373.
XX
XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
XX
XX WPI; 2004-093977/10.
XX
XX Novel polynucleotide useful for PCR amplification along with two DNA
XX fragment from another set of sequences, or for detecting single
XX nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 6296; 2627pp; Japanese.
XX
CC The present invention relates to a polynucleotide isolated from a human
XX gene and is useful for detecting a single nucleotide polymorphism in a
XX human gene or for diagnosing of disease. The invention enables the
XX detection of a single nucleotide polymorphism in a human gene. The
XX present sequence represents a primer of the invention.
XX
SQ Sequence 20 BP; 6 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 754 GCACGAGGCCACAGAGTG 773
DB 1 GCACGAGTGCCACAGAGAGTG 20
RESULT 206
ADK95115
ID ADK95115 standard; DNA; 20 BP.
XX
AC ADK95115;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #835.
XX
KM human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.
XX
PF 08-MAR-2002; 2002JP-00064373.
XX
PR 08-MAR-2002; 2002JP-00064373.
XX
PA (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
XX
XX WPI; 2004-093977/10.
XX
XX Novel polynucleotide useful for PCR amplification along with two DNA
XX fragment from another set of sequences, or for detecting single
XX nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 4144; 2627pp; Japanese.
XX
CC The present invention relates to a polynucleotide isolated from a human
XX gene and is useful for detecting a single nucleotide polymorphism in a
XX human gene or for diagnosing of disease. The invention enables the
XX detection of a single nucleotide polymorphism in a human gene. The
XX present sequence represents a primer of the invention.
XX
SQ Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;

```



```

ID ADJ26884 standard; DNA; 20 BP.
XX
AC ADJ26884;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human Centromere protein B target DNA fragment #6.
XX
KW Centromere protein B; hyperproliferative disorder; cancer;
KW autoimmune disorder; rheumatoid arthritis; scleroderma;
KW Raynaud's syndrome; systemic lupus erythematosus; gene therapy;
KW cytostatic; immunosuppressive; dermatological; antiinflammatory; human;
KW ds.
XX
OS Homo sapiens.
XX
PN US2003232443-A1.
XX
PD 18-DEC-2003.
XX
PF 18-JUN-2002; 2002US-00176277.
XX
PR 18-JUN-2002; 2002US-00176277.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Dobie KW;
XX
DR WPI; 2004-052175/05.
XX
PT New antisense oligonucleotide targeted to a nucleic acid encoding
PT Centromere protein B, useful for treating a disease, e.g. cancer;
PT Rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
PT erythematosus.
XX
PS Example 15; SEQ ID NO 53; 47pp; English.
XX
CC The present invention relates to antisense compounds, compositions and
CC methods for modulating the expression of Centromere protein B. The
CC compound, composition and methods are useful for treating diseases or
CC conditions associated with Centromere protein B, such as
CC hyperproliferative disorders (e.g. cancer), autoimmune disorders e.g.
CC rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
CC erythematosus. The invention is also useful in gene therapy. The present
CC sequence is human Centromere protein B target DNA fragment used in the
CC exemplification of the invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1121 ATGGGTCGAGAGAGATTCC 1140
1 |||||
1 AGGGCTCCAGAGAGGTCC 20
Db
RESULT 210
ADJ26851/c
ID ADJ26851 standard; DNA; 20 BP.
XX
AC ADJ26851;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human Centromere protein B antisense oligonucleotide, ISIS #156872.
XX
KW Centromere protein B; hyperproliferative disorder; cancer;
KW autoimmune disorder; rheumatoid arthritis; scleroderma;
KW Raynaud's syndrome; systemic lupus erythematosus; gene therapy;
KW cytostatic; immunosuppressive; dermatological; antiinflammatory; human;
KW antisense; phosphorothioate backbone; ss.

```

```

XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone where all cytidines are
FT 5-methylcytidines"
FT 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /tag= C
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN US2003232443-A1.
XX
PD 18-DEC-2003.
XX
PF 18-JUN-2002; 2002US-00176277.
XX
PR 18-JUN-2002; 2002US-00176277.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Dobie KW;
XX
DR WPI; 2004-052175/05.
XX
PT New antisense oligonucleotide targeted to a nucleic acid encoding
PT Centromere protein B, useful for treating a disease, e.g. cancer;
PT Rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
PT erythematosus.
XX
PS Example 15; SEQ ID NO 20; 47pp; English.
XX
CC The present invention relates to antisense compounds, compositions and
CC methods for modulating the expression of Centromere protein B. The
CC compound, composition and methods are useful for treating diseases or
CC conditions associated with Centromere protein B, such as
CC hyperproliferative disorders (e.g. cancer), autoimmune disorders e.g.
CC rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
CC erythematosus. The invention is also useful in gene therapy. The present
CC sequence is human Centromere protein B antisense oligonucleotide used in
CC the exemplification of the invention.
XX
SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 308 TCACGAGGACCTGCCTGT 327
20 TCACGAGGACCTGCACATT 1
Db
RESULT 211
ADJ18833
ID ADJ18833 standard; DNA; 20 BP.
XX
AC ADJ18833;
XX
DT 20-MAY-2004 (first entry)
XX
DE Antisense DNA oligo used to modulate human LRH1 expression SegID 3383.
XX
KW human; ss; liver related homologue-1, LRH1, NR5A2; antisense;
KW phosphorothioate; 2' MOE; breast cancer; dyallipidaemia; atherosclerosis;

```


KW	low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KM	gall stone; triglyceridaemia; obesity; hepatitis; antiipaeamic;
KV	hepatocellular carcinoma; aromatase; cytotatic; antiipaeamic;
KW	antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW	antiinflammatory; virucidal.
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	Location/Qualifiers
FT	1..20
FT	/tag= b
FT	/mod_base= OTHER
FT	/label= OTHER= phosphorothioate backbone
FT	1..5
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT	cytidine nucleobases are 5-methylcytidine."
FT	16..20
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT	cytidine nucleobases are 5-methylcytidine."
XX	
PN	WO2004003201-A2.
PD	08-JAN-2004.
PP	01-JUL-2003; 2003WO-US020865.
PR	01-JUL-2002; 2002US-0392813P.
PA	(PRNA) PHARMACIA CORP.
PI	Kane CD;
DZ	WPI; 2004-083058/08.
XX	
PT	New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT	related homologue-1 (LRH1), useful for treating breast cancer,
PT	dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
PS	Example 15; SEQ ID NO 3383; 909pp; English.
XX	
CC	This invention relates to novel antisense compounds useful for modulating
CC	the expression of liver related homologue-1 (LRH1) and splice variants
CC	thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC	length that target a portion of an active site on the nucleic acid
CC	molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC	nuclear receptor protein that functions as a tissue specific
CC	transcription factor. The present invention describes antisense
CC	oligonucleotides that comprise at least one modified internucleoside
CC	linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC	a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC	methyluridine. These antisense compounds are useful for treating or
CC	diagnosing a disease associated with LRH1, such as breast cancer,
CC	dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC	LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC	triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC	hepatitis, as well as hepatocellular carcinoma or a condition associated
CC	with aromatase activity. Accordingly, these compositions exhibit
CC	cytostatic, antiipaeamic, antiarteriosclerotic, anorectic, hepatotropic,
CC	litholytic, antiinflammatory and antiviral activities. This
CC	oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC	expression of the human LRH1 protein of the invention.
XX	
SQ	Sequence 20 BP; 4 A; 4 C; 4 G; 8 T; 0 U; 0 Other;
Query Match	0 %; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pwd. No. 1.4e+02;
Matches 17; Conservative	0; Mismatches 3; Indels 0; Gaps 0

RESULT 212
 ADJ24083
 ID ADJ24083 standard; DNA; 20 BP.
 AC ADJ24083;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human endothelial lipase antisense oligonucleotide, SEQ ID 2481.
 XX
 KW Antihypertensive; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
 KW Human; Endothelial lipase; dyslipidaemia; high density lipoprotein; HDL;
 KW cardiovascular disorder; metabolic syndrome X; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FT Key
 FT modified_base 1..20
 FT Location/Qualifiers
 FT 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
 FT and 3' ends, which are 4 nucleotides in length. Also all
 FT cytidine residues are 5-methylcytidines"
 XX
 PN WO2004009541-A2.
 XX
 PD 29-JAN-2004.
 XX
 PE 18-JUL-2003; 2003WO-US022410.
 XX
 PR 19-JUL-2002; 2002US-0397106P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Bhat BG;
 XX
 WP; 2004-132912/13.
 XX
 PT New antisense oligonucleotide for modulating endothelial lipase
 XX expression, for diagnosing, preventing or treating e.g. dyslipidaemia, low
 XX high density lipoprotein or cardiovascular disorders.
 PT
 FT
 XX
 PS Claim 3; SEQ ID NO 2481; 1007bp; English.
 XX
 SQ
 The present invention relates to antisense oligonucleotides (ADJ21603-
 ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
 CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
 CC with and inhibits the expression of EL. The antisense oligonucleotides
 CC are useful for modulating the expression of endothelial lipase in cells
 CC or tissues to treat diseases associated with EL expression, such as
 CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
 CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
 CC used for diagnostics, prophylaxis, or as research reagents or kits.
 CC
 Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2242 AGATTAGTCCAAAGCAGCT 2261
 DB 1 AGATTGCTCCAAAGCAGTT 20

```
ADN06232
ID ADN06232 standard; DNA; 20 BP.
XX
AC ADN06232;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human SPS2 specific antisense oligonucleotide, ISIS 138303.
XX
KM Selenophosphate synthetase 2; SPS2; rheumatoid arthritis; infection;
KW inflammation; tumour; antisense therapy; human; antisense;
XX phosphorothioate backbone; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone in which all cytidines
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
XX
PN US2004002151-A1.
XX
PD 01-JAN-2004.
XX
PF 28-JUN-2002; 2002US-00186157.
XX
PR 28-JUN-2002; 2002US-00186157.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Watt AT, Freier SM;
XX
DR WPI; 2004-070740/07.
XX
PT New antisense oligonucleotides for modulating selenophosphate synthetase
PT 2 (SPS2) expression, useful for diagnosing, preventing or treating
PT conditions associated with SPS2, e.g. rheumatoid arthritis, inflammation
PT or tumors.
XX
PS Claim 1; SEQ ID NO 76; 47bp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of selenophosphate synthetase 2 (SPS2). The
CC composition comprises antisense oligonucleotides targeted to SPS2 gene.
CC The antisense oligonucleotide is useful for modulating the expression of
CC SPS2 in cells or tissues to treat diseases associated with their
CC expression, e.g. rheumatoid arthritis, infections, inflammation or
CC tumours. It is also used for diagnostics, prophylaxis, or as research
CC reagents or kits. The antisense oligonucleotide is useful in antisense
CC therapy. The present sequence is an antisense oligonucleotide targeted to
CC human SPS2 DNA. This sequence is used in the exemplification of the
CC invention.
XX
SQ Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1548 AGGAAAAGTCAGTATTCA 1567
DB 1 AGGAAAAGCCAGTACTTCA 20
```

```
RESULT 214
ADN060607
ID ADN060607 standard; DNA; 20 BP.
XX
AC ADN060607;
XX
DT 17-JUN-2004 (first entry)
XX
DE Mouse Ig kappa leader sequence PCR primer, SEQ ID 8.
XX
KM Retinal detachment; retinal edema; endostatin; ocular tissue;
KW ophthalmological; gene therapy; murine; PCR; primer; ss;
KW Ig kappa leader sequence.
XX
OS Mus sp.
OS WO2004020469-A2.
XX
PD 11-MAR-2004.
XX
PF 27-AUG-2003; 2003WO-EP009497.
XX
PR 28-AUG-2002; 2002US-0406470P.
XX
PA (NOVS ) NOVARTIS AG.
XX PA (NOVS ) NOVARTIS PHARMA GMBH.
XX
PI Campochiaro PA, Kaleko M;
XX
DR WPI; 2004-239158/22.
XX
PT Treating retinal detachment or retinal edema in an individual comprises
PT increasing the amount of an endostatin in the ocular tissues of the
PT individual to a retinal detachment- or retinal edema-inhibiting amount.
XX
PS Example 1; SEQ ID NO 8; 48bp; English.
XX
CC The present invention relates to a method for treating retinal detachment
CC or retinal edema in an individual. The method comprises effecting an
CC increase in the amount of an endostatin (ADN060600 or ADN060602) in ocular
CC tissues of the individual to a retinal detachment- or retinal edema-
CC inhibiting amount. The endostatin is used in manufacturing a medicament
CC for the treatment of retinal detachment or retinal edema in an
CC individual. The present sequence is a PCR primer, used in an example from
CC the invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTCGCTGCATCG 537
DB 1 CACTGCTTACTGCTTATCG 20

RESULT 215
ADN15359/C
ID ADN15359 standard; DNA; 20 BP.
XX
AC ADN15359;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1546.
XX
KM chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cycostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
```

KM neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KM immunomodulatory; cardiovascular; gene therapy; inflammation;
KM Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KM reperfusion injury; ophthalmic disorder; immunological disorder;
KM cardiovascular disorder; neurological disorder; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /+tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /+tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /+tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
PD 08-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
XX
PT New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 1546; 132bp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compound,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibit its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosratic,
CC antiinflammatory, immunomodulatory, cardiac, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory, and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1667 CAAGGAAACTGCTTCT 1686
DB 20 CACAGGAGCTCAGCTCT 1

RESULT 216.44
ADN49263/C
ID ADN49263 standard; DNA; 20 BP.
XX
XX ADN49263;
AC
XX
DT 15-JUL-2004 (first entry)
XX
DE Human HDAC4 specific antisense oligo, ISIS 130854.
XX
XX Histone deacetylase 4; HDAC4; hyperproliferative disorder; cancer;
KM antisense therapy; human; myeloid leukaemia; phosphorothioate backbone;
KM antisense, ss; HDAC-A.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /+tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone in which all cytidines
FT are 5-methylcytidines"
FT modified_base 1..5
FT /+tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl bases"
FT modified_base 16..20
FT /+tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl bases"
XX
PN US2004077083-A1.
XX
PD 22-APR-2004.
XX
PF 17-OCT-2002; 2002US-00273826.
XX
PR 17-OCT-2002; 2002US-00273826.
XX
XX (ISIS-) ISIS PHARM INC.
XX
PA
XX
PI Watt AT;
XX
DR WPI; 2004-340008/31.
XX
XX
PT New antisense oligonucleotides for modulating Histone deacetylase 4
PT expression, useful for diagnosing, preventing or treating diseases or
PT conditions associated with Histone deacetylase 4, such as cancer (i.e.
PT myeloid leukemia).
XX
PS Example 15; SEQ ID NO 24; 45bp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of histone deacetylase 4 (HDAC4). HDAC4 is
CC also known as HDAC-A. The composition comprises antisense compounds that
CC can be targeted towards HDAC4. The antisense oligonucleotide is useful
CC for inhibiting the expression of HDAC4 in cells or tissues. It is also
CC useful for treating an animal having a disease or condition associated
CC with HDAC4, such as a hyperproliferative disorder, particularly cancer
CC (i.e. myeloid leukaemia). The compound is used for diagnostics, in
CC prophylaxis, or as research reagents or kits. It is also useful in
CC antisense therapy. The present sequence is an antisense oligonucleotide
CC targeted towards human HDAC4 DNA.
XX
SQ Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAGTGCACAGAGT 783
|||||
DB 20 CACAGAGTGAAGTGAAGT 1

RESULT 217
ADM10436/C
ID ADM10436 standard; DNA; 20 BP.
XX
XX ADM10436;
AC
XX
XX
DT 15-JUL-2004 (first entry)
DE Human histone deacetylase 4 antisense oligonucleotide seqid 24.
XX
XX cytosolic; antimicrobial; antiinflammatory; antisense therapy;
XX antisense compound; histone deacetylase 4; cancer; infection;
XX inflammation; diagnostic; prophylaxis; human; antisense oligonucleotide;
XX 58.
XX Homo sapiens.
OS
XX
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone. All cytidines
FT are 5-methylcytidines"
FT 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX
XX US2004077084-A1.
XX
XX
XX 22-APR-2004.
XX
XX 17-OCT-2002; 2002US-00274347.
XX
XX 17-OCT-2002; 2002US-00274347.
XX
XX (ISIS-) ISIS PHARM INC.
XX (ABBO) ABBOTT LAB.
XX
XX Walt AT, Davidsen S, Li J, Glaser K;
XX
XX WPI; 2004-340009/31.
XX
XX
XX New antisense oligonucleotides for modulating human Histone deacetylase 4
XX expression, useful for diagnosing, preventing or treating diseases
XX associated with Histone deacetylase 4, e.g. cancer, infection or
XX inflammation.
XX
XX Example 15; SEQ ID NO 24; 46pp; English.
XX
XX The invention describes an antisense compound that is 8-50 nucleobases in
XX length targeted to a nucleic acid molecule encoding human Histone
XX deacetylase 4 (which comprises a sequence of 8459 bp fully defined in the
XX specification). The compound specifically hybridizes with and inhibits
XX the expression of human Histone deacetylase 4. Also described are: a
XX composition comprising the new antisense compound and a pharmaceutical
XX carrier or diluent; and a method of inhibiting the expression of Histone
XX deacetylase 4 in human cells or tissues, comprising contacting the cells
XX or tissues with the new compound so that the expression of Histone
XX deacetylase 4 is inhibited. The antisense oligonucleotide is useful for
XX modulating the expression of Histone deacetylase 4 in cells or tissues.
XX It is also useful for treating humans having a disease or condition
XX associated with Histone deacetylase 4, such as cancer, infection or
XX inflammation. In addition, the compound is used for diagnostics,

CC prophylaxis, or as research reagents or kits. This sequence represents a
CC human histone deacetylase 4 antisense oligonucleotide.
XX
XX
SQ Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAGTGCACAGAGT 783
|||||
DB 20 CACAGAGTGAAGTGAAGT 1

RESULT 218
ADO43909
ID ADO43909 standard; DNA; 20 BP.
XX
XX ADO43909;
AC
XX
XX
DT 15-JUL-2004 (first entry)
DE PCR primer used to amplify murine Ig kappa leader sequence DNA.
XX
XX
XX retina; endostatin; vascular endothelial growth factor receptor;
XX pigment epithelium-derived factor; angiotatin; plasminogen fragment;
XX rod-derived cone viability factor; antiangiogenic antithrombin;
XX cartilage-derived inhibitor; CD59 complement fragment;
XX fibronectin fragment; Gro-beta; heparinase; chorionic gonadotropin;
XX interferon; interferon inducible protein; IP-10; interleukin-12;
XX kringle 5; metalloproteinase inhibitor; placental ribonuclease inhibitor;
XX plasminogen activator inhibitor; platelet factor-4; PF4; prolactin;
XX transforming growth factor-beta; TGF-b; vasculostatin; vasostatin;
XX calreticulin; retinal disorder; retinal detachment; diabetic retinopathy;
XX retinal neovascularization; choroidal neovascularization; retinal edema;
XX PCR; ss; primer.
XX
XX
XX Mus sp.
OS
XX Synthetic.
XX
XX WO2004028635-A1.
XX
XX
XX 08-APR-2004.
XX
XX 26-SEP-2003; 2003WO-BP010725.
XX
XX 27-SEP-2002; 2002US-0414048P.
XX
XX (NOVS) NOVARTIS AG.
XX (NOVS) NOVARTIS PHARMA GMBH.
XX
XX Campochiaro PA, Kaleko M;
XX
XX WPI; 2004-305131/28.
XX
XX
XX Delivering a protein to the retina of a subject for treating retinal
XX disorders, e.g., retinal detachment, retinal edema or diabetic
XX retinopathy by periorcularly injecting a viral vector comprising a protein
XX -encoding nucleic acid.
XX
XX Example 1; Page 10; 47pp; English.
XX
XX The specification describes a method for delivering a protein to the
XX retina of a subject. The method comprises periorcularly injecting a viral
XX vector comprising a nucleic acid encoding endostatin. Alternatively, the
XX viral vector may encode soluble vascular endothelial growth factor
XX receptor, pigment epithelium-derived factor, angiotatin (plasminogen
XX fragment), rod-derived cone viability factor, antiangiogenic antithrombin
XX HI, cartilage-derived inhibitor (GDI), CD59 complement fragment,
XX fibronectin fragment, Gro-beta, a heparinase, human chorionic
XX gonadotropin (hCG), an interferon, interferon inducible protein (IP-10),
XX interleukin-12, kringle 5 (plasminogen fragment), metalloproteinase

CC inhibitors (TBVIPS), placental ribonuclease inhibitor, plasminogen
CC activator-inhibitor, platelet factor-4 (PF4), prolactin 16KD fragment,
CC proliferin-related protein (PRP), thrombospondin-1 (TSP-1), transforming
CC growth factor-beta (TGF-beta), vasculostatin or vasostatin (calreticulin
CC fragment). The method is useful in delivering a protein to the retina of
CC a subject for treatment of retinal disorders, e.g., retinal detachment,
CC diabetic retinopathy, retinal neovascularization, choroidal
CC neovascularization or retinal edema. PCR primers AD043909-AD043910 were
CC used to amplify DNA encoding murine Ig kappa leader sequence. The
CC amplified fragment was used to construct viral vectors for use in the
CC method of the invention.
CC
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 518 CACTGATTGCTGCGTCATCG 537
DB 1 CACTGCTTACTGCGTTATCG 20
RESULT 219
ADM16189/c
ID ADM16189 standard; DNA; 20 BP.
XX
AC ADM16189;
XX
DT 15-JUL-2004 (first entry)
XX
DE Murine SACL DNA PCR primer #416.
XX
KM Mouse; SACL; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
XX diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
XX primer.
XX
OS Mus musculus.
XX
PN US2004081964-A1.
XX
PD 29-APR-2004.
XX
PF 25-OCT-2002; 2002US-00280183.
XX
PR 25-OCT-2002; 2002US-00280183.
XX
PA (BACH/) BACHMANOV A A.
XX (BEAU/) BEAUCHAMP G K.
XX (LISG/) LI S.
XX (LIXX/) LI X.
XX (REED/) REED D R.
XX (TORD/) TORDOFF M G.
XX (ROSS/) ROSS D A.
XX (OHMA/) OHMAN J D.
XX (CHAT/) CHATTERJEE A.
XX (DJON/) DE JONG P J.
XX
PI Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;
PI Rose DA, Ohman JD, Chatterjee A, De Jong PJ;
XX
DR WPI; 2004-340133/31.
XX
PT New isolated polynucleotides for sensing carbohydrates, other sweeteners,
PT or ethanol, useful for screening drugs for inhibition or restoration of
PT gene function as antidiabetic, antioesity or antialcohol consumption
PT therapies.
XX
PS Example 12; SEQ ID NO 459; 148bp; English.
XX
CC The invention relates to SACL polypeptides and the polynucleotides
CC encoding them. The polynucleotides contain a variation associated with
CC sensing carbohydrates, other sweeteners or ethanol. The invention also

CC relates to a method for analysing a biomolecule in a biological sample,
CC comprising altering SACL activity in the sample and measuring the
CC activity, a method for analysing a polynucleotide in a biological sample,
CC comprising contacting a polynucleotide in a biological sample with a
CC probe where the probe hybridises to a SACL polynucleotide to form a
CC hybridisation complex and detecting the hybridisation complex, a method
CC of identifying susceptibility to obesity or diabetes comprising comparing
CC the nucleotide sequence of the suspected SACL allele with a wild type
CC nucleotide sequence, where the difference between the suspected allele
CC and the wild-type sequence identifies a sequence variation of the SACL
CC nucleotide sequence, and a method of treating or preventing obesity,
CC diabetes or alcoholism associated with expression of SACL, comprising
CC administering to a subject a pharmaceutical composition and a transgenic
CC animal that carries an altered SACL allele. The methods and compositions
CC of the invention are useful for screening drugs for inhibition or
CC restoration of gene function as antidiabetic, antioesity or antialcohol
CC consumption therapies and for identifying sweeteners and alcohols. This
CC sequence represents a PCR primer used to amplify murine SACL DNA of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1991 TGGGGGTGGCATGACACCC 2010
DB 20 TGGAGGTGCAATGATACCC 1
RESULT 220
ADP76517/c
ID ADP76517 standard; DNA; 20 BP.
XX
AC ADP76517;
XX
DT 12-AUG-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide #316.
XX
KM GFAT; Antidiabetic; Cardiant;
XX Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
XX reperfusion; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..4
FT /*tag= a
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
FT modified_base 17..20
FT /*tag= b
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
XX
PN WO2004035763-A2.
XX
PD 29-APR-2004.
XX
PF 02-OCT-2003; 2003WO-US033332.
XX
PR 17-OCT-2002; 2002US-0419268P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Broecheat KO, Crosby SD;
XX
DR WPI; 2004-348453/32.
XX
PT New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase

PT (GPAR), for treating diabetes, a cardiovascular or neurologic disorder,
XX ischemia/reperfusion injury.
PS Claim 4; SEQ ID NO 316; 175pp; English.
XX
CC The present invention relates to a compound which specifically hybridizes
CC with a nucleic acid molecule encoding GPAR, and inhibits the expression
CC of GPAR. Specifically claimed are antisense oligonucleotides capable of
CC modulating the expression of GPAR, and which comprise any of the 3063
CC sequences of 20 base pairs, given in the specification. The compound,
CC composition and methods are useful for treating a disease or condition
CC associated with GPAR, such as a disease or condition, e.g. diabetes, a
CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC They are also useful in research and diagnostics for modulating the
CC expression of GPAR. The present sequence represents a chimeric
CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC oligonucleotides inhibit human GPAR expression.
SQ Sequence 20 BP; 3 A; 8 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 147 CCTGCGCCCGCGCGCGG 166
DB 20 CCTGCGCCTCGCGCGCGCTG 1
RESULT 221
ADP78659
ID ADP78659 standard; DNA; 20 BP.
XX
AC ADP78659;
XX
DT 12-AUG-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide #2458.
XX
KW GPAR; Antidiabetic; Cardiant;
KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW reperfusion; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..4
FT /*tag= a
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
FT modified_base 17..20
FT /*tag= b
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
XX
XX WO2004035763-A2.
XX
XX 29-APR-2004.
XX
XX 02-OCT-2003; 2003WO-US033332.
XX
XX 17-OCT-2002; 2002US-0419268P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Broschat KO, Crosby SD;
XX
XX WPI; 2004-348453/32.
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
XX nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
XX (GPAR), for treating diabetes, a cardiovascular or neurologic disorder,
XX ischemia/reperfusion injury.

XX
PS Claim 4; SEQ ID NO 2458; 175pp; English.
XX
CC The present invention relates to a compound which specifically hybridizes
CC with a nucleic acid molecule encoding GPAR, and inhibits the expression
CC of GPAR. Specifically claimed are antisense oligonucleotides capable of
CC modulating the expression of GPAR, and which comprise any of the 3063
CC sequences of 20 base pairs, given in the specification. The compound,
CC composition and methods are useful for treating a disease or condition
CC associated with GPAR, such as a disease or condition, e.g. diabetes, a
CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC They are also useful in research and diagnostics for modulating the
CC expression of GPAR. The present sequence represents a chimeric
CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC oligonucleotides inhibit human GPAR expression.
SQ Sequence 20 BP; 8 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 416 CAAGGTGGAAGCAGCTAC 435
DB 1 CAAGGTGGAAGCAGCAAC 20
RESULT 222
ADN49541
ID ADN49541 standard; DNA; 20 BP.
XX
AC ADN49541;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human TDP-1 antisense oligonucleotide ISIS 133400.
XX
KW ss; human; antisense; tyrosyl-DNA phosphodiesterase-1; TDP-1;
KW hyperproliferative disorder.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN US2004097450-A1.
XX
XX 20-MAY-2004.
XX
XX 19-NOV-2002; 2002US-00300399.
XX
XX 19-NOV-2002; 2002US-00300399.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX PI Watt AT;
XX
XX WPI; 2004-389191/36.
XX
XX New compounds, particularly oligonucleotides targeted to a nucleic acid
XX encoding tyrosyl-DNA phosphodiesterase-1 (TDP-1), useful for treating
XX diseases associated with TDP-1, e.g. hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 28; 51pp; English.
XX
XX The invention relates to a compound targeted to and which specifically
XX hybridizes with a nucleic acid molecule encoding tyrosyl-DNA
XX phosphodiesterase-1 (TDP-1), and inhibits the expression of TDP-1. The
XX compound, composition and methods are useful for treating a disease or
XX condition associated with TDP-1, such as a hyperproliferative disorder.
XX They are also useful in research and diagnostics for modulating the
XX expression of TDP-1. The present sequence represents a human TDP-1
XX antisense oligonucleotide.
SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 1 ATCACCATGCCAAGCAGCA 20

RESULT 223
ADN9618/c
ID ADN9618 standard; DNA; 20 BP.

XX AC ADN9618;

XX DT 12-AUG-2004 (first entry)

XX DE Human TDP-1 target sequence ISIS 44337.

XX KM ss; human; tyrosyl-DNA phosphodiesterase-1; TDP-1;
hyperproliferative disorder.

XX OS Homo sapiens.

XX PN US2004097450-A1.

XX PD 20-MAY-2004.

XX PF 19-NOV-2002; 2002US-00300399.

XX PR 19-NOV-2002; 2002US-00300399.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Watt AT;

XX DR WPI; 2004-389191/36.

PT New compounds, particularly oligonucleotides targeted to a nucleic acid
encoding tyrosyl-DNA phosphodiesterase-1 (TDP-1), useful for treating
PT diseases associated with TDP-1, e.g. hyperproliferative disorders.

XX PS Example 15; SEQ ID NO 105; 51pp; English.

XX CC The invention relates to a compound targeted to and which specifically
hybridizes with a nucleic acid molecule encoding tyrosyl-DNA

XX CC phosphodiesterase-1 (TDP-1), and inhibits the expression of TDP-1. The
CC compound, composition and methods are useful for treating a disease or

XX CC condition associated with TDP-1, such as a hyperproliferative disorder.

XX CC They are also useful in research and diagnostics for modulating the
expression of TDP-1. The present sequence represents a human TDP-1 target
CC sequence.

XX SQ Sequence 20 BP; 2 A; 4 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 20 ATCACCATGCCAAGCAGCA 1

RESULT 224

ADP22828

ID ADP22828 standard; DNA; 20 BP.

XX AC ADP22828;

XX DT 26-AUG-2004 (first entry)

XX

DE Human BUB1-beta target sequence ISIS 196150.

XX KM ss; BUB1-beta; hyperproliferative disorder; cancer; human.

XX OS Homo sapiens.

XX PN US2004110149-A1.

XX PD 10-JUN-2004.

XX PF 10-DEC-2002; 2002US-00316459.

XX PR 10-DEC-2002; 2002US-00316459.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Jain R;

XX DR WPI; 2004-440338/41.

PT New oligonucleotide compound that inhibits expression of BUB1-beta,
PT useful for preparing a composition for treating hyperproliferative
PT disorder, e.g. cancer.

XX PS Example 15; SEQ ID NO 94; 92pp; English.

XX CC The invention relates to a new compound, having a sequence targeted to a
CC nucleic acid encoding BUB1-beta, which specifically hybridizes with the
CC nucleic acid encoding BUB1-beta and inhibits expression of BUB1-beta. The
CC oligonucleotide compound is useful for preparing a composition for
CC treating a hyperproliferative disorder, e.g. cancer. The present sequence
CC represents a human BUB1-beta target sequence.

XX SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 132 GTGCTCTGCGGAGCCCTG 151
DB 1 GTGCTCTGAGTGAGCCATG 20

RESULT 225

ADP22750/c

ID ADP22750 standard; DNA; 20 BP.

XX AC ADP22750;

XX DT 26-AUG-2004 (first entry)

XX DE Human BUB1-beta antisense oligonucleotide ISIS 280005.

XX KM ss; BUB1-beta; hyperproliferative disorder; cancer; human; antisense.

XX OS Homo sapiens.

XX PN Synthetic.

XX PD US2004110149-A1.

XX PF 10-JUN-2004.

XX PR 10-DEC-2002; 2002US-00316459.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Jain R;

XX DR WPI; 2004-440338/41.

XX

```
PT New oligonucleotide compound that inhibits expression of BUB1-beta,
PT useful for preparing a composition for treating hyperproliferative
PT disorder, e.g. cancer.
XX
XX
PS Example 15; SEQ ID NO 16; 92bp; English.
XX
CC The invention relates to a new compound, having a sequence targeted to a
CC nucleic acid encoding BUB1-beta, which specifically hybridises with the
CC nucleic acid encoding BUB1-beta and inhibits expression of BUB1-beta. The
CC oligonucleotide compound is useful for preparing a composition for
CC treating a hyperproliferative disorder, e.g. cancer. The present sequence
CC represents a human BUB1-beta antisense oligonucleotide.
XX
SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      132  GTGCTCTGCGGAGGCGCTG 151
Db      20  GTGCTCTGAGTGAAGCCATG 1

RESULT 226
ADO42827
ID ADO42827 standard; DNA; 20 BP.
XX
AC ADO42827;
XX
DT 26-AUG-2004 (first entry)
XX
DE Human oestrogen receptor-alpha (ER)-related oligonucleotide probe #11.
XX
KW human; oestrogen receptor-alpha; ER; ER activity regulator substance;
XX anti-oestrogen substance; oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO2004046352-A1.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-JP014494.
XX
PR 15-NOV-2002; 2002JP-00331994.
PR 15-NOV-2002; 2002JP-00331995.
PR 15-NOV-2002; 2002JP-00331996.
XX
PA (SUMO ) SUMITOMO CHEM CO LTD.
XX
PI Fujimori K;
XX
DR WPI; 2004-431978/40.
XX
PT New mutant estrogen receptor-alpha useful for determining effectiveness
PT of treatment by estrogen receptor activity regulator substance and
PT antiestrogen substance.
XX
PS Example 25; SEQ ID NO 40; 111bp; Japanese.
XX
CC The invention comprises the amino acid sequences of mutant human
CC oestrogen receptor-alpha (ER) proteins. The mutant ER proteins of the
CC invention are useful for determining the effectiveness of a treatment by
CC an ER activity regulator substance, and for determining the effectiveness
CC of a treatment by an anti-oestrogen substance. The present DNA sequence
CC represents an oligonucleotide probe that was used in an example of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1325 CCTGGTGAAGCTCTTCGACA 1344
Db      1  CATGGTGAGATCTTCGACA 20

RESULT 227
ADO42828
ID ADO42828 standard; DNA; 20 BP.
XX
AC ADO42828;
XX
DT 26-AUG-2004 (first entry)
XX
DE Human oestrogen receptor-alpha (ER)-related oligonucleotide probe #12.
XX
KW human; oestrogen receptor-alpha; ER; ER activity regulator substance;
XX anti-oestrogen substance; oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO2004046352-A1.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-JP014494.
XX
PR 15-NOV-2002; 2002JP-00331994.
PR 15-NOV-2002; 2002JP-00331995.
PR 15-NOV-2002; 2002JP-00331996.
XX
PA (SUMO ) SUMITOMO CHEM CO LTD.
XX
PI Fujimori K;
XX
DR WPI; 2004-431978/40.
XX
PT New mutant estrogen receptor-alpha useful for determining effectiveness
PT of treatment by estrogen receptor activity regulator substance and
PT antiestrogen substance.
XX
PS Example 25; SEQ ID NO 41; 111bp; Japanese.
XX
CC The invention comprises the amino acid sequences of mutant human
CC oestrogen receptor-alpha (ER) proteins. The mutant ER proteins of the
CC invention are useful for determining the effectiveness of a treatment by
CC an ER activity regulator substance, and for determining the effectiveness
CC of a treatment by an anti-oestrogen substance. The present DNA sequence
CC represents an oligonucleotide probe that was used in an example of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1328 GGTGAAGCTCTTCGACAAAGC 1347
Db      1  GGTGAAGATCTTCGACATGC 20

RESULT 228
ADQ14779/C
ID ADQ14779 standard; DNA; 20 BP.
XX
AC ADQ14779;
XX
DT 07-OCT-2004 (first entry)
XX
DE Mouse RANK antisense oligonucleotide ISIS181051.
XX
XX
```



```
RESULT 230
ADJ33507
ID ADJ33507 standard; DNA; 20 BP.
AC ADJ33507;
XX
XX 18-NOV-2004 (first entry)
XX
DE Human LAR chimeric phosphorothioate oligonucleotide SEQ ID NO:36.
XX
XX LAR; leukocyte antigen related protein; LAR inhibitor;
XX antisense oligonucleotide; cytostatic; gene therapy; metabolic disorder;
XX hyperproliferative disorder; cancer; human; phosphorothioate;
XX 2'-O-methoxyethyl; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX FT 1..20
XX FT /tag= b
XX FT modified_base
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate linkages"
XX FT 1..5
XX FT /tag= a
XX FT /mod_base= OTHER
XX FT /note= "2'-O-methoxyethyls"
XX FT 16..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "2'-O-methoxyethyls"
XX
XX WO2004010956-A2.
XX
XX 05-FEB-2004.
XX
XX 31-JUL-2003; 2003WO-US023994.
XX
XX 31-JUL-2002; 2002US-00210838.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Bhanot S, Dobie KM, Freier SM,
XX
XX WPI; 2004-143728/14.
XX
XX New compound comprises a sequence targeted to a nucleic acid encoding
XX Leukocyte Antigen Related protein (LAR), useful for preparing a
XX composition for treating metabolic or hyperproliferative disorders, e.g.
XX cancer.
XX
XX Example 15; SEQ ID NO 36; 197bp; English.
XX
XX The present invention describes a compound (I) comprising a sequence
XX comprising 8-80 base pairs (bp) targeted to a nucleic acid encoding LAR
XX (leukocyte antigen related protein), where (I) specifically hybridises
XX with the nucleic acid and inhibits expression of LAR. Also described: (1)
XX a composition comprising the compound (I) and a carrier or diluent; (2)
XX inhibiting the expression of LAR in cells or tissues; (3) treating an
XX animal having or suspected of having a disease or condition associated
XX with LAR; and (4) screening for an antisense compound. (I) has cytostatic
XX activity, and can be used in gene therapy. The antisense oligonucleotide
XX compound (I) can be used for preparing a composition for treating
XX metabolic or hyperproliferative disorders, particularly cancer. The
XX present sequence represents a human LAR chimeric phosphorothioate
XX antisense oligonucleotide, which is used in an example from the present
XX invention.
XX
XX Sequence 20 BP; 7 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1986 GAGGATGGGGTGCATGA 2005
Db 1 GAGGATGGGGTGCATGA 20
|||||
|||||

RESULT 231
ADJ33612/c
ID ADJ33612 standard; DNA; 20 BP.
XX
XX ADJ33612;
XX
AC ADJ33612;
XX
XX 18-NOV-2004 (first entry)
XX
XX Human LAR target oligonucleotide SEQ ID NO:141.
XX
XX LAR; leukocyte antigen related protein; LAR inhibitor;
XX antisense oligonucleotide; cytostatic; gene therapy; metabolic disorder;
XX hyperproliferative disorder; cancer; human; target; ss.
XX
XX Homo sapiens.
XX
XX WO2004010956-A2.
XX
XX 05-FEB-2004.
XX
XX 31-JUL-2003; 2003WO-US023994.
XX
XX 31-JUL-2002; 2002US-00210838.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Bhanot S, Dobie KM, Freier SM,
XX
XX WPI; 2004-143728/14.
XX
XX New compound comprises a sequence targeted to a nucleic acid encoding
XX Leukocyte Antigen Related protein (LAR), useful for preparing a
XX composition for treating metabolic or hyperproliferative disorders, e.g.
XX cancer.
XX
XX Example 16; SEQ ID NO 141; 197bp; English.
XX
XX The present invention describes a compound (I) comprising a sequence
XX comprising 8-80 base pairs (bp) targeted to a nucleic acid encoding LAR
XX (leukocyte antigen related protein), where (I) specifically hybridises
XX with the nucleic acid and inhibits expression of LAR. Also described: (1)
XX a composition comprising the compound (I) and a carrier or diluent; (2)
XX inhibiting the expression of LAR in cells or tissues; (3) treating an
XX animal having or suspected of having a disease or condition associated
XX with LAR; and (4) screening for an antisense compound. (I) has cytostatic
XX activity, and can be used in gene therapy. The antisense oligonucleotide
XX compound (I) can be used for preparing a composition for treating
XX metabolic or hyperproliferative disorders, particularly cancer. The
XX present sequence represents a human LAR target oligonucleotide, which is
XX used in an example from the present invention.
XX
XX Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1986 GAGGATGGGGTGCATGA 2005
Db 20 GAGGATGGGGTGCATGA 1
|||||
|||||

RESULT 232
ADS92384/c
ID ADS92384 standard; DNA; 20 BP.
XX
XX ADS92384;
```


KW fruit ripening; flower pigmentation; lignin production; ss.
XX
OS Zea mays.
XX
PN WO9710328-A2.
XX
PD 20-MAR-1997.
XX
PF 12-JUL-1996; 96WO-US011689.
XX
PR 13-JUL-1995; 95US-0001135P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX (DOWC) DOWELANCO.
XX
PI Zwick MG, Edington BE, Mcswigen JA, Merlo PAO, Guo L, Skokut TA,
XX Young SA, Folkerts O, Merlo DJ;
XX WPI; 1997-202224/18.
XX
DR Ribozyyme which modulates plant gene expression - preferably modulates
XX expression of DELTA-9 desaturase or granule bound starch synthase in
XX maize or canola.
XX
PS Claim 41; Page 74; 155pp; English.
XX
CC The present invention describes an enzymatic nucleic acid molecule (I)
CC with RNA cleaving activity, which modulates the expression of a plant
CC gene. Also described is a gene comprising a cDNA sequence encoding maize
CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
CC gene, in a plant (preferably a maize or canola plant). (I) can be used to
CC modulate caffeine synthesis in a coffee plant, nicotine production in a
CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
CC marigold plant or lignin production in a tobacco, aspen, poplar or pine
XX plant
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX
Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. NO. 1.6e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
QY 778 AGAAGTTCACGCA 792
|||:::|||||
3 AGAAGTTCACGCA 17
XX
Db
XX
RESULT 235
AAK62280
ID AAX62280 standard; RNA; 17 BP.
XX
XX AAX62280;
XX
DT 16-JUL-1999 (first entry)
XX
DE Granule bound starch synthase hammerhead substrate SEQ ID NO:155.
XX
XX
XX Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW modulation; gene expression; transgenic plant; cleavage; canola plant;
KW caffeine synthesis; coffee plant; nicotine production; tobacco;
KW fruit ripening; flower pigmentation; lignin production; ss.
XX
XX Zea mays.
XX
XX WO9710328-A2.
XX
XX PD 20-MAR-1997.
XX
XX PF 12-JUL-1996; 96WO-US011689.
XX

PR 13-JUL-1995; 95US-0001135P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA (DOWC) DOWELANCO.
XX
XX Zwick MG, Edington BE, Mcswigen JA, Merlo PAO, Guo L, Skokut TA;
XX Young SA, Folkerts O, Merlo DJ;
XX WPI; 1997-202224/18.
XX
XX Ribozyyme which modulates plant gene expression - preferably modulates
XX expression of DELTA-9 desaturase or granule bound starch synthase in
XX maize or canola.
XX
PS Claim 41; Page 74; 155pp; English.
XX
XX
CC The present invention describes an enzymatic nucleic acid molecule (I)
CC with RNA cleaving activity, which modulates the expression of a plant
CC gene. Also described is a gene comprising a cDNA sequence encoding maize
CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
CC gene, in a plant (preferably a maize or canola plant). (I) can be used to
CC modulate caffeine synthesis in a coffee plant, nicotine production in a
CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
CC marigold plant or lignin production in a tobacco, aspen, poplar or pine
XX plant
XX
SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
XX
XX
Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. NO. 1.6e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
QY 778 AGAAGTTCACGCA 792
|||:::|||||
2 AGAAGTTCACGCA 16
XX
Db
XX
RESULT 236
ABZ61331
ID ABZ61331 standard; RNA; 17 BP.
XX
XX ABZ61331;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #122.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytoskeletal; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX Homo sapiens.
XX
XX WO200297114-A2.
XX
XX PD 05-DEC-2002.
XX
XX PF 29-MAY-2002; 2002WO-US016840.
XX
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswigen J;
XX
XX WPI; 2003-140484/13.
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
XX creating cancer, modulates the expression of a nucleic acid encoding
XX
XX

PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX
PS Claim 58; Page 113; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosine, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265531, AB266520 - AB266524,
CC AB266530 - AB266595 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 0 A; 8 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 146 GCCCTGGCCCCGGCG 160
|||||
3 GCCCGGCCCGGGG 17
Db
RESULT 237
ADF63854
ID ADF63854 standard; DNA; 17 BP.
XX
XX ADF63854;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1758.
XX
KM Chromatin organisation modifier; CHROMO domain; cytosolic; PCCP1;
KM prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KM human; ss; probe.
XX
OS Homo sapiens.
XX
XX MO2003050284-A1.
PN
XX 19-JUN-2003.
PD
XX 22-NOV-2002; 2002WO-US037506.
PF
XX 10-DEC-2001; 2001US-0339764P.
PR
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
PA
XX Guo J;
PI
XX WPI; 2003-532916/50.
DR
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 1758; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytosolic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8 -
CC directed probe of the invention. Note: The current sequence is not shown

CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
XX
SQ Sequence 17 BP; 0 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
QY 727 TGGGCTGGGTGCT 741
|||||
2 TGGGCTGGGTGCT 16
Db
RESULT 238
ADL48694/c
ID ADL48694 standard; RNA; 17 BP.
XX
XX ADL48694;
XX
AC
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1204.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KM prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
KM protein kinase PKR; cerebrovascular accident;
KM central nervous system injury; CNS injury; spinal cord injury; cancer;
KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KM restenosis; asthma; Crohn's disease; diabetes; obesity;
KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KM graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KM allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KM substrate; ds.
XX
XX Unidentified.
OS
XX
XX MO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Chowrira B, Haeblerl P, Mcswiggen J, Forsnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2227; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 CC
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 0.6%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1184 CCTCTTCTCTCCGA 1198
 DB 17 CCTCTTCTCTCCGA 3
 RESULT 239
 ADL48695/c
 ID ADL48695 standard; RNA; 17 BP.
 XX
 AC ADL48695;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human IKK-gamma substrate sequence #1205.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeblerli P, Meswigen J, Fossnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2228; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 CC
 XX
 SQ Sequence 17 BP; 7 A; 1 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 0.6%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1184 CCTCTTCTCTCCGA 1198
 DB 15 CCTCTTCTCTCCGA 1
 RESULT 240
 AAF76146/c
 ID AAF76146 standard; DNA; 20 BP.
 XX
 AC AAF76146;
 XX
 DT 05-JUN-2001 (first entry)
 XX
 DE Human interleukin-7 (IL-7) PCR primer, SEQ ID NO:14.
 XX
 KW Transgenic mouse; immunodeficient; tissue recipient;
 KW lymphocyte deficient; human cytokine; interleukin; IL-7; IL-6; SCF; LIF;
 KW stem cell factor; leukemia inhibitory factor; GM-CSF; M-CSF;
 KW granulocyte macrophage-colony stimulating factor;
 KW macrophage-colony stimulating factor; human MHC class II; DR3;
 KW major histocompatibility complex; allergenicity determination;
 KW human monoclonal antibody generation; haematopoietic cell development;
 KW human immune system animal model; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200115521-A1.
 XX
 PD 08-MAR-2001.
 XX
 PF 30-AUG-2000; 2000WO-US023971.
 XX
 PR 31-AUG-1999; 99US-0151688P.
 XX
 PA (GENV) GENENCOR INT INC.
 XX
 PI Huang MA, Harding FA;
 XX
 DR WPI; 2001-169001/17.
 XX
 PT New transgenic mice, useful as non-human mammalian models of human
 PT disease, comprise recombination activation gene mutations and donor
 PT specific transgenes encoding cytokines.
 XX
 PS Example 2; Page 33; 68pp; English.
 XX
 CC The invention relates to a transgenic immunodeficient recipient mouse
 CC which is capable of supporting the growth of donor cells. In the mouse,
 CC both alleles of a gene activated in early lymphocyte development are
 CC disrupted, causing it to lack mature B and T cells. In particular, both
 CC alleles of the recombination activation gene-2 (RAG-2) gene are
 CC disrupted, which in turn prevents VDJ recombination. The mouse also
 CC comprises donor (e.g., human) specific transgenes encoding the cytokines
 CC interleukin-7 (IL-7), stem cell factor (SCF), leukemia inhibitory factor
 CC (LIF), granulocyte macrophage-colony stimulating factor (GM-CSF),
 CC macrophage-colony stimulating factor (M-CSF), and IL-6, which enable it
 CC to support the growth of transplanted donor cells. In another embodiment
 CC of the invention, the mouse comprises DNA encoding the human major
 CC histocompatibility complex (MHC) class II DR3 molecule, where the
 CC transgene has naturally linked Drab and Dab alleles. The transgenic
 CC mouse may be used as a model for determining the allergenicity of non-
 CC donor, e.g., non-human, macromolecules, to determine the effect compounds
 CC have on a human immune system; to generate fully human polyclonal or
 CC monoclonal antibodies to specific antigens; to determine whether

CC humanised or other monoclonal antibodies will raise a response in a human
CC immune system; to investigate the human cell mediated response to
CC pathogens and other immunomodulatory compounds; and to determine the
CC factors involved in regulating the development and function of human
CC haematopoietic cells. The transgenic mouse supports the functional
CC properties of human haematopoietic cells, unlike previous animal models
CC which produce functionally impaired haematopoietic cells or are
CC immunologically dysfunctional. In addition the transgenic mouse provides
CC a unique model system which supports T cell development in a manner which
CC more closely resembles normal ontogeny, as they possess CD4+ T cells in
CC the periphery that exhibit MHC-restricted antigen-specific responses.
CC Sequences AAF76133-AAF76192 represent human cytokine PCR primers used in
CC the development of human cytokine-expressing transgenic mice
XX
XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. NO. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1423	GAGGAACCAAGCTGCA	1437
Db	15	GAGGAACCAAGCTGCA	1

RESULT 241

ACC42584/C
ID ACC42584 standard; DNA; 20 BP

DT 26-AUG-2003 (First entry)

Human interleukin-7, IL-7, PCR primer 51-IL7R.

KM Human, PER; primer; transgenic mouse; lymphocyte maturation; IL-3; IL-7;
KM cytokine; interleukin-3; interleukin-6; interleukin-7; M-CSF; SCF;
KM macrophage-colony stimulating factor; stem cell factor; oncostatin M; OM
KM granulocyte-colony stimulating factor; GM-CSF; LIF;
KM leukemia inhibitory factor; BS.

OS Homo sapiens.

PN WO2003018744-A2.

PD 06-MAR-2003 .

PF 05-AUG-2002; 2002WO-US024807.

PR 23-AUG-2001; 2001US-00938689.

PA (GEMV) GENENCOR INT INC.

PI Harding FA, Huang M;

DR WPI; 2003-278650/27.

PT New recipient mammal, preferably a mouse, useful as a model of human disease to assess efficacy of therapeutic or prophylactic treatments, or for facilitating production of donor-specific functional immunity.

PS Example; Page 31; 70pp; English.

The present invention relates to a new transgenic mouse, which comprises a disruption in both alleles of a gene such that lymphocyte maturation does not occur and exogenous cytokines. The cytokines are selected from: interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-7 (IL-7), macrophage-colony stimulating factor (M-CSF), granulocyte-colony stimulating factor (GM-CSF), stem cell factor (SCF), leukemia inhibitory factor (LIF) and oncostatin M (OM). The gene disruption is in a gene that modulated VDJ recombination e.g. a RAG gene. The gene is disrupted by insertion of a transgene comprising major histocompatibility complex (MHC) Class II DR3 and Dd2 genes. The transgenic mouse is useful as a

CC model of human disease to assess efficacy of therapeutic or prophylactic
CC treatments, or to assess the antigenic potential of compounds. The
CC transgenic mouse is also useful for supporting donor haematopoietic stem
CC cells or facilitating production of donor-specific functional immunity.
CC PCR primers ACC42571-ACC42639 were used to generate the transgenic mouse
XX
XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0.

QY	1423	GAGGAACCAAGCTGCA	1437
Db	15	GAGGAACCAAGCTGCA	1

RESULT 242

ID ABZ88089 standard; DNA; 20 BP.

AC ABZ88089;

DT 17-OCT-2003 (first entry)

DE Human oligonucleotide sequence.
 XX Human, antiense; lung dysfunction; nasal airway dysfunction;
 KW antihistaminic; steroid; ubiquinone; antiinflammatory; anti-allergic;
 KW antihistaminic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antiense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.

OS Homo sapiens.

PN W0200285308-A2

PD 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013135.

PR 24-APR-2001; 2001US-0286137P.

PA (EPIC-) EPIGENESIS PHARM IN

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D,

XX

PT Pharmaceutical composition for treating ailments associated with impaired
Pharmacological composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubinone.

PS Disclosure; SEQ ID NO 3331; 872pp; English.

The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiaesthetic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine or receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1676 CTCAGTCTTCTTGGG 1690
DB 15 CTCAGTCTTCTTGGG 1
RESULT 243
ABD24319/c
ID ABD24319 standard; DNA; 20 BP.
XX
AC ABD24319;
XX
DT 29-JUL-2004 (first entry)
XX
DE A1095013-derived oligonucleotide DNA SEQ ID 3331.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiasthmatic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytoskeletal; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN W0200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI NYCE JW, Li Y, Sandrasagra A, Katz B, Pabalan J, Aguilar D,
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 3331; 763bp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating, allergies and
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiasthmatic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1676 CTCAGTCTTCTTGGG 1690
DB 15 CTCAGTCTTCTTGGG 1
RESULT 244
AAQ98499
ID AAQ98499 standard; DNA; 18 BP.
XX
AC AAQ98499;
XX
DT 17-APR-1996 (first entry)
XX
DE 5' primer for human NT2-N receptor coding sequence fragment.
XX
KW Polymerase chain reaction; PCR; primer; amplify; NT2-N; receptor;
KW NT2 cell; cholinergic neuronal cell; N-methyl-D-aspartate receptor;
KW NMDA; human; neurological disorder; central nervous system;
KW excitotoxicity; ss.
XX
OS Synthetic.
XX
PN US5449609-A.
XX
PD 12-SEP-1995.
XX
PF 31-JAN-1994; 94US-00189199.
XX
PR 31-JAN-1994; 94US-00189199.
XX
PA (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI Pleasure D, Younkin DP;
XX
DR WPI; 1995-327693/42.
XX
PT NT2-N functional glutamate receptor producing clonal neuronal cells -
PT used to screen agents for excitotoxic effects on the neurons of the
PT central nervous system useful in the study of neurological disorders.
XX
PS Example 2; Col 6; 14pp; English.
XX
CC The sequences represented by AAQ98499 and AAQ98500 are primers for a
CC fragment of human NT2-N receptor DNA. The sequence represented by
CC AAQ98501 is a probe for the amplified fragment. NT2-N cells are
CC cholinergic neuronal cells. NT2-N cells are produced by treating NT2
CC cells with retinoic acid. The amplified sequence was found to be a N-
CC methyl-D-aspartate (NMDA) receptor. By comparison with the rat NMDA
CC receptor (NMDAR1). NMDA is a glutamate receptor channel and is expressed

CC in neuronal cells. The NT2-N cells can be used to study agents in
CC relation to human neurological disorders. The agents that are to be
CC studied are compounds that are thought to exhibit excitotoxic effects on
CC the neurons of the central nervous system. A change in cellular response
CC in the presence of the agent as compared to cellular response in the
CC absence of the agent represents a positive screening result
XX
S0 Sequence 18 BP; 7 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match	0.6%	Score 14.8	DB 1	length 16
Best Local Similarity	88.9%	Pred No. 1.6e+02		
Matches 16	Conservative 0	Mismatches 2	Indels 0	Gaps 0

Db 1 AACCTGAGAACCGCAAG 18

Qy 993 ACCCTGGGAACCGCAAG 1010
| | | | | | | | | |
Db 1 AACCTGCAGAACCGCAAG 18

RESULT 245
AAT80355/C
ID AAT80355 standard; DNA; 18 BP
vv

DT 16-OCT-1997 (first entry)

DE Oligo HCV-213, targetted to HCV mRNA position +230 to +235.

KW Complementary; 5' untranslated region; UTR; hepatitis C virus; HCV
KW inhibition; replication; expression; detection; chronic hepatitis;
KW acute hepatitis; hepatocarcinoma; SB.

Synthetic

	Key	Location/Qualifiers
FH	modified_base	1. .12
FT		

FT	modified_base	/note= "2'-OMe RNA"
FT	13.	.18

PN WO9639500-A2

PD 12-DEC-1996.

PF 04-JUN-1996; 96WO-EP002427.

PR 06-JUN-1995; 95US-00471968.

PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
PA (HYBR-) HYBRIDON INC.

PI	Frank BL,	Goodchild J,	Hamlin HA,	Kilkuskie RE,	Roberts NA,
PI	Roberts PC,	Walthers DM,	Wolfe JL,		

DR WPI; 1997-043122/04.

PT Oligo:nucleotide(s) complementary to HCV 5' untranslated region - used in
PT the treatment and detection of HCV infection, esp. hepatitis and hepato-
PT carcinoma.

PS Claim 20; Page 20; 100pp; English.

CC The sequences given in A780211-382 represent synthetic oligonucleotides
CC which are complementary to a portion of the 5' untranslated region (UTR)
CC of hepatitis C virus (HCV). These sequences may be used in a
CC pharmaceutical composition for the control or prevention of HCV
CC infection. They may be used to inhibit replication or expression of HCV
CC or for detecting the presence of HCV in a sample. They may be used to
CC inhibit HCV replication in a cell and are therefore useful in the
CC treatment of HCV infections such as chronic and acute hepatitis and
CC hepatocarcinoma. This sequence binds to two non-contiguous regions of

CC HCV genome. This sequence is anchored at position -219 to -230 and is
CC targeted to position +230 to +235

SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 Other;

Query Match	0.6%	Score	14.8	DB 1	Length	18			
Best Local Similarity	88.9%	Pred. No.	1.6e+02						
Matches	16	Conservative	0	Mismatches	2	Indels	0	Gaps	0

OY		372	TCCGCCCTCCAGGACCTC	389
Db	.	18	TCAGCCCTCCAGGACCCC	1

RESULT 246
AAV18052
ID AAV18052 standard; DNA; 18 BP.

DT 30-JUL-1998 (first entry)

NMDA receptor 1 primer (1063-1080)

KM Primer; PCR, amplification; CNS, proliferation; astrocyte; ss, differentiation; glutamate receptor; neuron; Alzheimer's disease.

Synthetic.

XX
XX

XX 1000
XX 1000

XX 03 SEP 1967

XX 03 SEP 1966 000711Z

XX
XX

(STORY) STORY FURNISH TWO

[illegible]

XX
XX
WBT: 1000 103200/117

XX
X

PT Production of conditionally-immortalised human central nervous system
PT progenitor cells - useful for treatment of CNS-related diseases and in
PT assays for study of CNS cell development, death and abnormalities.
XX
SS Example 3; Page 35; 75pp; English.

PS Example 3; Page 35; 75pp; English.

The invention provides for a method for producing conditionally immortalized human CNS progenitor cell lines. One such cell line B4 was tested for the type of native channels and receptors it expressed during proliferating conditions and during differentiating conditions. This involved analysing PCR products from PCR reactions using primers for various channels and receptors. The primer pairs (AAV18052-1/18067) used were for detecting NMDAR1, glutamate receptor (GluR) 1, GluR2, GluR3, GluR4, GluR5, GluR6 and GluR7. The present forward primer corresponding to nucleotides 1053-1080 of NMDAR1 cDNA was used with the NMDAR1 reverse primer (AAV18053). Cell line B4 was shown to express GluR1, GluR2, GluR3, GluR4 and GluR7. GluR7 was expressed only under differentiating conditions. The method is claimed to be useful for producing astrocytes and/or neurons by culturing the immortalized human CNS progenitor cells under conditions where the growth-promoting gene expression is inhibited. Cells produced by the method are also claimed to be useful for treating patients where the patient is afflicted with a pathological condition involving degenerated neurons e.g. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and traumatic head injury. These cells may also be useful for screening agents that modulate activity of proteins produced by a CNS cell, for detecting the presence or absence of a protein in a sample and for screening for agents that affect CNS cell death or proteins that regulate CNS cell death.

SQ Sequence 18 BP; 7 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 993 ACCCTGCGAAGCGCAAG 1010
| | | | | | | | | | | | | | | | | |
Db 1 AACCTGCAAGACCGCAAG 18

RESULT 247
AAK55193
ID AAK55193 standard; DNA; 18 BP.
XX
AC AAK55193;
XX
DT 05-JUL-1999 (first entry)
XX
DE Multiple antisense oligonucleotide 14.
XX
KW Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW prostate cancer; ss.
XX
XX
OS Synthetic.
XX
PN MO9913886-A1.
XX
PD 25-MAR-1999.
XX
PF 17-SEP-1998; 98MO-US019419.
XX
PR 17-SEP-1997; 97US-0059160P.
XX
PR 09-JUN-1998; 98US-00093972.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 1999-229400/19.
XX
PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
XX vasoconstriction.
XX
PS Disclosure; Page 74; 120pp; English.
XX
XX The specification describes antisense oligonucleotides (AAK52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
CC end and the juxta-section between coding and non-coding regions and all
CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AAK55180-271. These multiple target oligonucleotides
CC (specifically AAK55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized

CC to the lungs, including breast and prostate cancer
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 158 GGGGCCGGGCGATGGGCC 175
| | | | | | | | | | | | | | | | | |
Db 1 GGGGCTGGGCGCTGGGCC 18

RESULT 248
AAK04573/C
ID AAK04573 standard; DNA; 18 BP.
XX
AC AAK04573;
XX
DT 15-APR-1999 (first entry)
XX
DE PCR primer HVESTP used to amplify mcg18 cDNA.
XX
DE MCG4 protein; gene regulatory function; heat shock protein;
KW guanine nucleotide exchange factor protein; MCG7 protein;
KW heat shock-binding protein; MCG18 protein; zinc finger protein; cancer;
KW PCR primer; ss.
XX
XX
OS Synthetic.
OS Homo sapiens.
XX
PN MO9853061-A1.
XX
PD 26-NOV-1998.
XX
PF 22-MAY-1998; 98MO-AU000380.
XX
PR 23-MAY-1997; 97AU-00006972.
XX
PR 23-MAY-1997; 97AU-00006973.
XX
PR 23-MAY-1997; 97AU-00006974.
XX
PR 22-JAN-1998; 98AU-00001458.
XX
PR 22-JAN-1998; 98AU-00001459.
XX
PR 22-JAN-1998; 98AU-00001460.
XX
PA (CONN-) COUNCIL QUEENSLAND INST MEDICAL RES.
XX
XX
PI Hayward N, Sillins G, Grimmond S, Gartside M, Hancock J;
XX
DR WPI; 1999-070146/06.
XX
PT New gene-expression regulatory genes, mcg4, mcg7, and mcg18 - encode a
XX zinc finger protein, a GEF, and a heat shock or heat shock binding
XX protein, useful to detect and treat cancer.
XX
XX Example 25; Page 54; 80pp; English.
XX
XX PCR primers AAK04573-81 were used to amplify cDNA encoding MCG18. The
CC MCG7 protein has gene regulatory functions, and has homology to a zinc
CC finger protein. The specification also describes MCG4, which is
CC homologous to guanine nucleotide exchange factor protein, and MCG7, which
CC is homologous to a heat shock protein or heat shock-binding protein.
CC Detection of mutations in the MCG genes can be used to identify the
CC propensity for various types of cancer, and to treat, arrest, or
CC otherwise ameliorate, the effects of a cancer in an animal or bird
XX
SQ Sequence 18 BP; 2 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2217 GAAGGGCGCTGGCTTCT 2234
| | | | | | | | | | | | | | | | | |

Db 18 GAAGGGCTGCGCCGCT 1
RESULT 249
AAA34640
ID AAA34640 standard; DNA; 18 BP.
XX
AC AAA34640;
XX
DT 28-JUL-2000 (first entry)
XX
DE Human adenosine receptor related polynucleotide SEQ ID NO:2329.
XX
KW Human: adenosine receptor; low adenosine antisense oligonucleotide;
XX phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; analgesic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US017712.
XX
PR 03-AUG-1998; 98US-0095212P.
XX
XX (UYEC-) UNIV EAST CAROLINA.
XX
XX Nyce JW;
XX
XX WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX
PS Disclosure; Page 556; 1343pp; English.
XX
CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiaesthetic, cyrostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA2313 to AAA3312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:1 to 1680 (AAA3223 to
CC AAA3399) are specifically claimed ONs from the present invention. N.B.
CC Sequences given in the disclosure of the present invention do not match
CC up with their corresponding SEQ ID NO: sequences given in the sequence
CC listing
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 158 GGCGCGGCGCATGGGCC 175
Db 1 GGCGCTGGGCGCTGGGCC 18

RESULT 250
AAZ61530
ID AAZ61530 standard; DNA; 18 BP.
XX
AC AAZ61530;
XX
DT 19-JUN-2000 (first entry)
XX
DE Primer 4L for a human 5'-OT EST (oxytocin expressed sequence tag).
XX
KW Oxytocin expressed sequence tag; 5'-OT EST; obesity; fertility; male;
KW transgenic animal; human late onset obesity; late onset visceral obesity;
KW male infertility; wasting; anorexia; cachexia; malabsorptive state;
KW catabolic state; inflammatory condition; Crohn's disease; AIDS wasting;
KW burn; cancer; bone disease; PCR primer; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200009686-A1.
XX
PD 24-FEB-2000.
XX
PF 12-AUG-1999; 99WO-GB002658.
XX
PR 12-AUG-1998; 98GB-00017566.
XX
PR 06-MAY-1999; 99GB-00010522.
XX
XX (MED1-) MEDICAL RES COUNCIL.
XX
XX Robinson ICAF, Stoye JP, Flavell D, Wells SE, Le Tissier P;
XX
XX WPI; 2000-224331/19.
XX
PT New anti-obesity polypeptide useful for treating obesity or infertility
PT in mammals.
XX
PS Disclosure; Page 26; 162pp; English.
XX
XX PCR primers and probes AAZ61529-30 are used to amplify and identify human
XX 5'-OT-EST (oxytocin expressed sequence tag) cDNA sequences. The 5'-OT EST
XX gene is involved in the control of obesity and fertility in males. 5'-OT
XX EST nucleic acids are useful for producing transgenic animals. The
XX transgenic animals created serve as a model for human late onset obesity
XX and other related disorders and are also used for identifying the genetic
XX cause of obesity. Compounds which modulate 5'-OT EST expression or
XX activity are useful in the treatment or modulation of late onset visceral
XX obesity or male infertility particularly in the disorders related to
XX these conditions such as wasting, or anorexia, or cachexia associated
XX with prolonged illness, or malabsorptive states or catabolic states
XX associated with other diseases such as inflammatory conditions, Crohn's
XX disease or AIDS wasting, or burns, or cancer, or bone disease
XX
SQ Sequence 18 BP; 2 A; 4 C; 11 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 281 GGCGGAGCTGACCGGAG 298
Db 1 GGCGGAGCTGACCGGAG 18

RESULT 251

AA52875
ID AA52875 standard; DNA; 18 BP.
AC AA52875;
XX
XX
XX 15-SEP-2000 (first entry)
DE Human CD44 antisense oligonucleotide ISIS# 18764.
XX
XX Human; CD44; cell surface adhesion receptor; cytosolic; antirheumatic;
KM antiinflammatory; antiarthritic; CD44 antisense inhibition;
KM hyperproliferative disorder; cancer; inflammatory disorder;
KM rheumatoid arthritis; ss.
XX
XX Homo sapiens.
OS
XX WO200035935-A1.
PN
XX 22-JUN-2000.
PD
XX 14-DEC-1999; 99WO-US029576.
PF
XX 17-DEC-1998; 98US-00213719.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Bennett CF, Cowser LM;
PI
XX WPI; 2000-431564/37.
DR
XX
XX New antiense compound, that inhibits the expression of human cell
PT surface adhesion receptor CD44, for treating hyperproliferative disorders
PT and inflammatory conditions, such as cancer and rheumatoid arthritis.
XX
XX Claim 3; Page 77; 105pp; English.
PS
XX The present sequence is one of a large number of antisense
CC oligonucleotides designed to target different regions of the human CD44
CC mRNA. CD44 is a multifunctional human cell surface adhesion receptor. The
CC oligonucleotides were analysed for effect on CD44 mRNA levels by
CC quantitative real-time PCR analysis. Antisense oligonucleotides that
CC inhibit CD44 expression can be used to treat CD44-associated conditions
CC including hyperproliferative disorders, such as cancer, and inflammatory
CC conditions, such as rheumatoid arthritis. The antisense compounds
CC hybridize to CD44 nucleic acids, thus allowing sandwich and other assays
CC to be easily constructed. Note: The sequence has a phosphorothioate
CC backbone and may be either an oligodeoxynucleotide or a chimeric
CC oligonucleotide containing 2'-methoxyethyl (2'-MOE) wings and a deoxy
CC gap. The ISIS number given above corresponds to the oligodeoxynucleotide
CC sequence
CC
SQ Sequence 18 BP; 4 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 502 TCATGTACATTTCTGCA 519
Db 1 TCATGTCCACATTCGCA 18
RESULT 252
AAF20762
ID AAF20762 standard; DNA; 18 BP.
XX
XX AAF20762;
AC
XX
XX 14-MAR-2001 (first entry)
DT
XX
XX Human multiple target antisense (MTA) oligonucleotide #2329.
DE
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KM

KM human; airway disorder; bronchoconstriction; lung inflammation;
KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KM immunosuppressive; antiasthmatic; analgesic; hypotensive; cytosolic;
KM respiratory obstruction; pulmonary obstruction; impeded respiration;
KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KM cancer; ss.
XX
XX Homo sapiens.
OS
XX WO200062736-A2.
PN
XX 26-OCT-2000.
PD
XX 24-MAR-2000; 2000WO-US008020.
PF
XX 06-APR-1999; 99US-0127958P.
PR
XX (UYEC-) UNIV EAST CAROLINA.
PA
XX (NYCE/) NYCE J W.
PI
XX Nyce JW;
PI
XX WPI; 2000-679539/66.
DR
XX
XX Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
XX Claim 14; Page 624; 1592pp; English.
PS
XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytosolic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and/or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system
CC transmitters, defensive, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins and
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention
CC
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 158 GGGGCGGGGCGGCGGCGC 175
Db 1 GGGGCTGGGGCTGGGGCC 18

RESULT 253
AAFP1465
ID AAFP1465 standard; DNA; 18 BP.
AC AAFP1465;
XX
XX 14-MAR-2001 (first entry)
DT
XX Human multiple target antisense (MTA) oligonucleotide #3032.
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KM human; airway disorder; bronchoconstriction; lung inflammation;
KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KM immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KM respiratory obstruction; pulmonary obstruction; impeded respiration;
KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KM cancer; ss.
XX
XX Homo sapiens.
OS
XX
XX MO200062736-A2.
PN
XX 26-OCT-2000.
PD
XX 24-MAR-2000; 2000MO-US008020.
PF
XX 06-APR-1999; 99US-0127958P.
PR
XX (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
XX NYCE JW;
PI
XX WPI; 2000-679539/66.
DR
XX Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
XX
PS Disclosure; Page 297; 1592pp; English.
XX
XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulin and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAFP18434 to AAFP21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of

CC the present invention
XX
XX Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
SO
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 158 GGGGCGGGGCGATCGGCC 175
DB 1 GGGGCTGGGCGCTGGGCC 18
RESULT 254
ID AAS05704 standard; DNA; 18 BP.
AC AAS05704;
XX
XX AAS05704;
AC
XX 07-SEP-2001 (first entry)
DT
XX Polypyrimidine region of SNP DYS271 target sequence.
XX
XX Triplex forming oligonucleotide; TFO; protected nucleic acid sequence;
KM PNAS; single nucleotide polymorphism; SNP; short tandem repeat; cancer;
KM SNP DYS271; ss.
XX
XX Synthetic.
OS
XX
XX MO200132929-A1.
PN
XX 10-MAY-2001.
PD
XX 03-NOV-2000; 2000MO-US030534.
PF
XX
XX 03-NOV-1999; 99US-0163356P.
PR 03-NOV-1999; 99US-0163356P.
PR 21-DEC-1999; 99US-0173348P.
PR 07-UTL-2000; 2000US-0216579P.
XX
XX (CYGE-) CYGENE INC.
PA (OSTE-) OSTE C C.
PA
XX Oste CC, Ramberg ER;
PI
XX
XX WPI; 2001-343488/36.
DR
XX Analyzing target nucleic acid sequences, useful for population genetics,
PT drug development and diagnosing cancer, comprises hybridizing triplex
PT forming oligonucleotide and probe to target sequence.
XX
XX Example 1; Page 64; 141pp; English.
PS
XX The sequence is the polypyrimidine region of SBNP DYS271 on the Crick
XX strand, 3' to the SNP score site used in the method of the invention. The
XX invention relates to analysing target nucleic acid sequences comprising
XX restricting isolated DNA, hybridizing at least one triplex forming
XX oligonucleotide (TFO), adding a 3' to 5' exonuclease to form a protected
XX nucleic acid sequence (PNAS) tail structure, hybridizing the captured
XX structure with a single nucleotide polymorphisms (SNP) identification
XX probe and determining the SNP score. The methods can be used for
XX analysing target nucleic acid sequences, especially genomic DNA
XX sequences, to determine if they contain SNPs or short tandem repeats
XX (STRs). The methods can be used to detect SNPs for use in population
XX genetic, drug development, forensics, cancer, genetic disease research,
XX genomic analysis, diagnostics and therapeutics in humans, plants and
XX animals
XX
XX Sequence 18 BP; 8 A; 1 C; 9 G; 0 T; 0 U; 0 Other;
SO
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1642 CTCCTCTCTCCCTCT 1659
 DB 18 CCCCTCTCTGCTCTCT 1
 RESULT 255
 ID ABL30863
 AC ABL30863 standard; DNA; 18 BP.
 XX ABL30863;
 XX 21-MAR-2002 (first entry)
 XX
 DE Human HLA genotyping oligonucleotide SEQ ID NO 352.
 XX
 KW Human, human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 OS Homo sapiens.
 XX
 PN WO200192572-A1.
 XX
 PD 06-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-JP004662.
 XX
 PR 01-JUN-2000; 2000JP-00164798.
 XX
 PA (NINON) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M,
 XX
 DR WPI; 2002-122074/16.
 XX
 PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
 PT individuals e.g. by determining immunogenetic differences when
 XX transplanting them.
 XX
 PS Claim 10; Page 160; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridizing a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals
 XX
 SQ Sequence 18 BP; 7 A; 2 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1071 GAGANTGAGTGTACAG 1088
 DB 1 GAGAAATGATGTACCAG 18
 RESULT 256
 ID ABS65939/C
 XX ABS65939 standard; DNA; 18 BP.
 AC ABS65939;
 XX
 DT 15-NOV-2002 (first entry)

XX
 DE Inhibitory oligonucleotide specific for hepatitis C virus #145.
 XX
 KW Hepatitis C virus; HCV; hepatocyte infection; non-A hepatitis;
 KW non-B hepatitis; acute hepatitis; chronic hepatitis;
 KW hepatocellular carcinoma; virucide; cytostatic; antisense therapy;
 KW gene therapy; ss; DNA-RNA hybrid.
 XX
 OS Synthetic.
 XX
 PN US2002081577-A1.
 XX
 PD 27-JUN-2002.
 XX
 PF 02-JUL-1997; 97US-00887505.
 XX
 PR 06-JUN-1995; 95US-00471968.
 PR 02-JUL-1996; 96US-0021104P.
 XX
 PA (KILK/) KILKUSKIE R L.
 PA (FRAN/) FRANK B L.
 PA (GOOD/) GOODCHILD J.
 PA (WOLF/) WOLFE J L.
 PA (ROBE/) ROBERTS P C.
 PA (HAML/) HAMLIN H A.
 PA (ROBE/) ROBERTS N A.
 PA (WALT/) WALTHER D M.
 XX
 PI Kilkuskie RL, Frank BL, Goodchild J, Wolfe JL, Roberts PC;
 PI Hamlin HA, Roberts NA, Walther DM;
 XX
 DR WPI; 2002-537132/57.
 XX
 PT Synthetic oligonucleotides complementary to a portion of the 5'
 PT untranslated region of hepatitis C virus (HCV), useful for diagnosing and
 PT treating HCV infections and hepatocellular carcinoma.
 XX
 PS Claim 23; Page 7; 74pp; English.
 XX
 CC The invention describes synthetic oligonucleotides complementary to a
 CC portion of the 5' untranslated region of hepatitis C virus. The
 CC oligonucleotides may be used in methods for controlling, preventing, and
 CC treating hepatitis C virus infection, in antisense technology and gene
 CC therapy, and of detecting the presence of hepatitis C virus in a sample.
 CC Hepatitis C virus (HCV) is an enveloped, positive sense, single-stranded
 CC RNA virus which infects hepatocytes. HCV is the major cause of non-A, non
 CC -B, acute and chronic hepatitis, and has been associated with
 CC hepatocellular carcinoma. The invention describes methods and kits for
 CC inhibiting replication of HCV, inhibiting the expression of HCV nucleic
 CC acid and protein, and for treating HCV infections. This sequence
 CC represents a synthetic DNA-RNA hybrid oligonucleotide used for inhibiting
 CC HCV replication and expression of HCV
 XX
 SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 Other;
 Query Match 0.6%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 372 TCCGCTCTCCAGACCTC 389
 DB 18 TCAGCCTCTCCAGACCCC 1
 RESULT 257
 ID AB296456
 XX AB296456 standard; DNA; 18 BP.
 AC AB296456;
 XX
 DT 17-OCT-2003 (first entry)
 DE Human nucleic acid sequence.

XX Human; antiense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antiseptic; respiratory; lung; adenine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US011135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antiseptic to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 11698; 872bp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antiseptic to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antiseptic gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenine, reducing levels of adenine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 158 GGGGCGGGGCGATGGGCC 175
Db 1 GGGGCTGGGGCTGGGCC 18
XX
RESULT 258
AB297159
ID AB297159 standard; DNA; 18 BP.
XX
AC AB297159;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human MTA oligonucleotide.

XX Human; antiense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antiseptic; respiratory; lung; adenine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US011135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antiseptic to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 12401; 872bp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antiseptic to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antiseptic gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenine, reducing levels of adenine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 158 GGGGCGGGGCGATGGGCC 175
Db 1 GGGGCTGGGGCTGGGCC 18
XX
RESULT 259
ABD20418
ID ABD20418 standard; DNA; 18 BP.
XX
AC ABD20418;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human pulmonary and inflammatory target DNA #29.

Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ds.

Homo sapiens.

WO200285309-A2.

31-OCT-2002.

23-APR-2002; 2002WO-US013143.

24-APR-2001; 2001US-0286036P.

(EPIG-) EPIGENESIS PHARM INC.

Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S; WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

Claim 15; SEQ ID NO 11699; 763bp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies and/or bronchoconstriction and/or lung inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.64; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.94; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

158 GGGGCGGGGCGATGGGCC 175

||||| ||||| |||||

Db 1 GGGGCTGGGCGCTGGGCC 18

RESULT 260

ABD32442

ABD32442 standard; DNA; 18 BP.

ABD32442;

29-JUL-2004 (first entry)

Human MTA oligo SEQ ID 12401.

Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

Homo sapiens.

WO200285309-A2.

31-OCT-2002.

23-APR-2002; 2002WO-US013143.

24-APR-2001; 2001US-0286036P.

(EPIG-) EPIGENESIS PHARM INC.

Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S;

WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

Claim 15; SEQ ID NO 12401; 763bp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 158 GGGGCGGGGCGATGGCC 175

DB 1 GGGGCTGGGGCTGGGCC 18

RESULT 261

ID ADH08326/c

ADH08326 standard; DNA; 18 BP.

XX AC ADH08326;

DT 11-MAR-2004 (first entry)

XX DE Mutant gene fragment designated 175AS1.

XX KM Biochip; target; ligand; analysis; molecular biology; ds.

XX OS Homo sapiens.

XX PN WO2003100423-A2.

XX PD 04-DEC-2003.

XX PF 23-MAY-2003; 2003WO-FR001574.

XX PR 24-MAY-2002; 2002FR-00007039.

XX PS (APIB-) APIBIO.

XX PI Cuzin M, Mandrand B, Cleuziat P, Abaibou H;

XX DR WPI; 2004-042856/04.

XX PT Biochip, useful in molecular biology, comprises a central array of sites

XX carrying analytical ligands and a peripheral region containing control

XX PT sites.

XX PS Example 2; Page 17; 28pp; French.

XX CC The invention relates to a biochip (1) that comprises a support (2) the

XX CC functional side of which has a working surface (3) with a network of

XX CC elementary sites (Xn), with many ligands, different for each Xn, attached

XX CC to them. The new feature is that Xn are distributed between: a central

XX CC zone (4), designed for detection of at least one target species, with

XX CC each site containing ligands for a particular target; and a peripheral

XX CC zone (5), surrounding (4) and containing control sites, which optionally

XX CC carry control ligands. The biochip is used for analysis in molecular

XX CC biology. The specified arrangement of sites allows not only determination

XX CC of many targets but also monitoring of the determination and of the

XX CC operating conditions. The signals emitted from the chip are not affected

XX CC by the geometrical environment of the chip, for any of the elementary

XX CC sites. The current sequence represents a fragment of a mutant gene that

XX CC is related to cancer.

XX CC Sequence 18 BP; 2 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2052 GATGCCGCCACCATGAGC 2069

DB 18 GCTGCCGCCACCATGAGC 1

RESULT 262

ID ADM69504/c

ADM69504 standard; DNA; 18 BP.

XX AC ADM69504;

XX DT 03-JUN-2004 (first entry)

XX DE Plant gene polymorphism marker related primer, SEQ ID 383.

XX XX Primer; variation mapping; mutation mapping; plant;

XX KM gene polymorphism marker; ss.

XX OS Synthetic.

XX PN JP2003289885-A.

XX PD 14-OCT-2003.

XX PF 31-JUN-2003; 2003JP-00024620.

XX PR 01-FEB-2002; 2002JP-00025338.

XX PA (RIKA) RIKAGAKU KENKYUSHO.

XX PA (SAIM-) SAI MEDIA KK.

XX PA (MATSU) MATSUT M.

XX PA (NAKA/) NAKAZAWA M.

XX DR WPI; 2004-126231/13.

XX PT A primer set and method useful for mapping at least the

XX PT variation/mutation part of a plant gene using a gene polymorphism marker.

XX PS Claim 7; SEQ ID NO 383; 120bp; Japanese.

XX CC The present invention relates to a primer set and method for mapping at

XX CC least the variation/mutation part of a plant gene using a gene

XX CC polymorphism marker. A mutation site of the plant gene is mapped by

XX CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is

XX CC prepared from a plant homozygously having a mutation to be an object of

XX CC the mapping; (b) A forward primer 1 containing a base corresponding to

XX CC the gene polymorphic marker of one ecotype plant, a forward primer 2

XX CC containing a base corresponding to the genetic polymorphism of the other

XX CC ecotype plant and a reverse primer 3 based on the base sequence common

XX CC with both the ecotype plants are prepared; (c) two kinds of

XX CC oligonucleotides emitting fluorescence of different colors when the

XX CC genetic polymorphism marker is detected are prepared; (d) an

XX CC amplification reaction of the genomic DNA is carried out in the presence

XX CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)

XX CC the fluorescence intensely emitted from the resultant reaction product

XX CC is detected and (f) the position on the genome of the mutation site is

XX CC determined from the results of detection. The present sequence is a

XX CC primer, used to illustrate the invention.

XX CC Sequence 18 BP; 7 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 547 ACTTCACTTGGCTGGTGT 564

DB 18 ACTTCACTTGGCTGGTGT 1

RESULT 263

ID ADM76423/c

ADM76423 standard; DNA; 18 BP.

XX AC ADM76423;

XX XX

```

DT 01-JUL-2004 (first entry)
XX Human myeloid leukemia related gene RHBDF1 oligonucleotide #12.
XX DE
XX ss; primer: cytosstatic; gene therapy; myeloid leukemia gene; RHBDF1;
XX KM cell proliferative disease; cancer; diagnosis.
XX OS
XX Homo sapiens.
XX PN WO2004031237-A1.
XX PD 15-APR-2004.
XX PF 29-JUL-2003; 2003WO-JP009589.
XX PR 30-SEP-2002; 2002US-0414867P.
XX PA (ONCO-) ONCOTHERAPY SCI INC.
XX PA (UYTY ) UNIV TOKYO.
XX PI Nakamura Y, Katagiri T;
XX DR MPI; 2004-347962/32.
XX PT New RHBDF1 polypeptide useful for diagnosing, treating or preventing a
XX cell proliferative disease, e.g. cancer or as a target molecule for a
XX PT developing drugs against the disease.
XX PS Disclosure; SEQ ID NO 12; 90pp; English.
XX CC The invention elates to a novel myeloid leukemia related gene RHBDF1. The
XX CC polypeptides, polynucleotides and antibodies are useful for treating or
XX CC preventing a cell proliferative disease, preferably cancer. They can also
XX CC be used for diagnosing cell proliferative disease and as target molecules
XX CC for developing drugs against the disease. The genes may also serve as a
XX CC diagnostic marker of cancer and the proteins encoded may be used in
XX CC diagnostic assays of cancer. This sequence corresponds to the human
XX CC RHBDF1 gene.
XX SQ Sequence 18 BP; 2 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 668 GACACACACCTGCTGAC 685
DB 18 GACACACTACCTGCAGAC 1
RESULT 264
ADR72762
XX ID ADR72762 standard; DNA; 18 BP.
XX AC ADR72762;
XX DT 02-DEC-2004 (first entry)
XX DE Monoclonal antibody-related HOAKs-1 PCR primer - SEQ ID 128.
XX KM monoclional antibody; cytosstatic; immunotherapy;
XX KM non-small cell lung cancer; pancreatic carcinoma; stomach cancer; PCR;
XX KM primer; ss.
XX OS
XX Unidentified.
XX OS
XX WO2004076658-A1.
XX PD 10-SEP-2004.
XX PF 27-FEB-2004; 2004WO-JP002402.
XX PR 28-FEB-2003; 2003JP-00054670.

```

```

PR 09-JUL-2003; 2003JP-00194643.
XX (MITS-) MITSUBISHI PHARMA CORP.
XX PA (UYKE-) UNIV KEIO.
XX PI Hosokawa S, Aoki M, Hirakawa Y, Itami S, Umeki H, Saikawa Y;
XX PI Kumai K, Fukuda K;
XX DR MPI; 2004-662011/64.
XX PT Novel monoclonal antibody useful as drug for treating cancer such as non-
XX PT small cell lung cancer, pancreatic carcinoma and stomach cancer.
XX PS Example 13; SEQ ID NO 128; 133pp; Japanese.
XX CC The invention relates to a novel monoclonal antibody which is produced by
XX CC hybridomas that are obtained by fusing lymphocytes originating in a
XX CC cancer tissue of a cancer patient with mouse myeloma cells. The antibody
XX CC of the invention demonstrates cytosstatic activity and may be useful
XX CC during immunotherapy for treating cancer, such as non-small cell lung
XX CC cancer, pancreatic carcinoma and stomach cancer. The antibody may be used
XX CC alone or may be bound to the surface of a liposome encapsulating a toxin
XX CC or anticancer drug. The current sequence is that of a monoclonal antibody
XX CC -related HOAKs-1 PCR primer of the invention.
XX SQ Sequence 18 BP; 2 A; 2 C; 10 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1091 GGTGATCTTCGACGAGGG 1108
DB 1 GGTGCTCTTCGACGAGGG 18
RESULT 265
AAT00705/C
XX ID AAT00705 standard; DNA; 19 BP.
XX AC AAT00705;
XX DT 08-JUL-1996 (first entry)
XX DE Human trkC receptor TK insert sense DNA primer.
XX KM trkC receptor; tyrosine-kinase; enzyme; procease; inflammation; pain;
XX KM diagnosis; neurotrophic factor; kidney; lung; psychiatric disorder;
XX KM DNA primer; PCR; polymerase chain reaction; ss.
XX OS
XX Synthetic.
XX PN WO9525795-A1.
XX PD 28-SEP-1995.
XX PF 17-MAR-1995; 95WO-US003426.
XX PR 18-MAR-1994; 94US-00215139.
XX PR 05-AUG-1994; 94US-00286846.
XX PR 20-DEC-1994; 94US-00359705.
XX PA (GETH ) GENENTECH INC.
XX PT Presta LG, Shelton DL, Ufer R;
XX DR MPI; 1995-344616/44.
XX PT New human trkB and trkC poly:peptide(s) and fusion proteins contg. them -
XX PT also DNA, vectors and transformed cells useful in treatment and diagnosis
XX PT of abnormal neurotrophic factor expression, e.g. inflammatory pain.
XX PS Disclosure; Page 70; 117pp; English.

```

XX This TK insert sense DNA primer was used in a Northern blot analysis to
 CC examine expression patterns of the trkC receptor in human tissue
 XX
 SQ Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCTGAG 2141
 DB 19 CTCACCTTGCTGCG 2

RESULT 266
 AAT7561/c
 ID AAT7561 standard; DNA; 19 BP.

XX AAT77561;
 XX
 DT 11-SEP-1997 (first entry)

XX Wheat microsatellite WMS122 left primer.

XX Microsatellite marker; hypervariable genomic fragment; Triticum aestivum;
 KM wheat; Triticeae; sequence tagged site; STS; primer; PCR; amplify;
 KM polymorphism; genetic analysis; hexaploid; tetraploid; mapping; ss.
 XX Synthetic.

XX DE19525284-A1.

XX 02-JUN-1997.

XX 28-JUN-1995; 95DE-01025284.

XX 28-JUN-1995; 95DE-01025284.

XX (PFLA-) INST PFLANZENGENETIK & KULTURPFLANZENFOR.

XX Roeder M, Plaschke J, Ganal M;

XX WPI; 1997-053731/06.

XX Primers for STS microsatellite markers for wheat and related species -
 PT useful for genetic mapping, analysis and labelling etc. of wheat.

XX Claim 5; Page 7; 8pp; German.

XX Microsatellite markers based on hypervariable genomic fragments, from
 CC Triticum aestivum (wheat) or the tribe Triticeae, consist of a sequence
 CC tagged site (STS), defined by 2 specific primers (of mean size 17-23
 CC bases) that flank a microsatellite sequence at both ends, which can be
 CC amplified to polymorphisms (PCR products of different sizes). The
 CC microsatellites are n-fold tandem repeats (n = 10 or more) of di-, tri-
 CC or tetra-nucleotide sequences, combination microsatellite sequences or an
 CC imperfect sequence in which individual bases are mutated. The
 CC microsatellite markers can be used for genetic analysis of hexaploid and
 CC tetraploid forms of wheat and for genetic mapping or labelling of
 CC monogenic and polygenic properties, and for their selection; for
 CC analyzing relationships and identifying varieties; and for evaluating
 CC varietal purity, hybrid identification and plant growth. The markers can
 CC differentiate between almost all European wheat lines and show a higher
 CC degree of DNA polymorphism than known probes for the wheat genome. They
 CC can be detected by PCR, so large numbers of samples can be analysed
 CC easily (e.g. several hundred per day). Microsatellite marker-related
 CC polymorphisms are stably inherited so can also serve as genetic markers.
 CC AAT77003-22 and AAT77535-716 are primer pairs that define the
 CC microsatellite markers. WMS122 has CT and CA type repeats
 XX
 SQ Sequence 19 BP; 6 A; 0 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCCCTTGCTGACCC 1935
 DB 18 ATCTCCCTTGCTGACCC 1

RESULT 267
 AA201319
 ID AA201319 standard; DNA; 19 BP.

XX AA201319;

XX 27-SEP-1999 (first entry)

XX PCR primer for PGI biallelic marker 99-140-130.

XX PGI gene; biallelic marker; PCR primer; PGI-related biallelic marker;
 KM cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
 KM PSA; human; ss.

XX Synthetic.

XX Homo sapiens.

XX WO9922644-A2.

XX 01-JUL-1999.

XX 22-DEC-1998; 98WO-1B002133.

XX 22-DEC-1997; 97US-00996306.

XX 09-SEP-1998; 98US-0099658P.

XX (GENT) GENSET.

XX Cohen D, Blumenfeld M, Chumakov I, Bougueteloret L;

XX WPI; 1999-405178/34.

XX Use of a prostate cancer associated gene and biallelic markers derived
 PT from it.

XX Claim 4; Page 368; 385pp; English.

XX The invention relates to a mammalian PGI gene and protein, and a set of
 CC PGI biallelic markers. The PGI polymorphic and biallelic markers are
 CC used in a hybridization assay, a sequencing assay, or in an allele-
 CC specific amplification assay for determining the identity of a nucleotide
 CC at a PGI-related biallelic marker. The methods can be used to detect and
 CC to assess the risk of developing cancer or prostate cancer. Early-stage
 CC diagnosis of prostate cancer relies on prostate specific antigen (PSA)
 CC dosage. However, the effectiveness of this is limited due to its
 CC inability to discriminate between malignant and non-malignant affections
 CC of the organ. A need exists for both a reliable diagnostic procedure
 CC which would enable early-stage diagnosis, and for preventative and
 CC curative treatments of the disease. The PGI gene can be used for
 CC detection of prostate cancer, and the risk of developing it in the
 CC future, and can also be used to determine therapies for the disease
 XX

SQ Sequence 19 BP; 9 A; 6 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 424 AAAAGCACTACAGTCA 441
 DB 2 AAAAGCACTACAGCA 19

RESULT 268

```

AAZ8855/c
ID AAZ8855 standard; DNA; 19 BP.
XX
AC AAZ8855;
XX
DT 30-MAY-2000 (first entry)
XX
DE Human trkB receptor TK insert sense primer.
XX
KW trkB; human; receptor tyrosine kinase; trkB; diagnosis; neurotrophin;
KW neurotrophic factor; primer; trkA; ss.
XX
OS Homo sapiens.
XX
PN US6027927-A.
XX
PD 22-FEB-2000.
XX
PF 01-OCT-1997; 97US-00942562.
XX
PR 18-MAR-1994; 94US-00215139.
PR 05-AUG-1994; 94US-00286846.
PR 19-MAY-1995; 95US-00444597.
XX
PA (GETH ) GENENTECH INC.
XX
PI Uffer R, Shelton DL, Presta LG;
XX
DR WPI; 2000-194832/17.
XX
PT New human trk receptors useful in the diagnosis of various human
PT pathological conditions associated with elevated or reduced levels of
PT neurotrophins capable of binding trkB and/or trkC.
XX
PS Disclosure; Col 93-94; 79pp; English.
XX
CC This invention describes a novel isolated and purified polypeptide (I),
CC belonging to the trk family of receptor tyrosine kinases, trkB and trkC.
CC (I) are useful in the purification of human neurotrophic factors and in
CC the diagnosis of various human pathological conditions associated with
CC elevated or reduced levels of neurotrophins capable of binding trkB
CC and/or trkC. AAZ8855-288868 represent primers used in the isolation of
CC the trkA, trkB and trkC receptor proteins described in the method of the
CC invention
XX
SQ Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2124 CTCAGCCTTGCGCTGGAG 2141
DB 19 CTCACCCTTGCGCTGGCG 2
XX
RESULT 269
AA46217/c
ID AAA46217 standard; DNA; 19 BP.
XX
AC AAA46217;
XX
DT 04-SEP-2000 (first entry)
XX
DE Primer IPM14F for interphotoreceptor matrix proteoglycan IPM150 cDNA.
XX
KW interphotoreceptor matrix; IPM; proteoglycan; IPM150; IPMC; IPM200;
KW chromosome 6q13-q15; ocular disease; retinal detachment;
KW choriorretinal degeneration; retinal degeneration; cone degeneration;
KW age related macular degeneration; photoreceptor degeneration;
KW retinal pigment epithelium degeneration; mucopolysaccharidosis;
KW rod-cone dystrophy; cone-rod dystrophy; PCR primer; ss.
XX

```

```

OS Unidentified.
XX
XX WO200026367-A2.
XX
XX 11-MAY-2000.
XX
PD 29-OCT-1999; 99WO-US025440.
XX
PF 29-OCT-1999; 98US-00183972.
XX
PR 29-OCT-1998; 98US-00183972.
XX
PA (IOWA ) UNIV IOWA RES FOUND.
XX
PI Hageman GS, Kuehn MH;
XX
XX WPI; 2000-365616/31.
XX
DR
XX
PT Nucleic acids encoding interphotoreceptor matrix proteoglycans useful for
PT preventing, diagnosing and treating ocular disorders such as retinal
PT detachment and choriorretinal degeneration.
XX
XX Claim 43; Page 44; 183pp; English.
XX
PS PCR primers AAA46209-42 were used to amplify cDNA encoding an
XX
XX interphotoreceptor matrix (IPM) proteoglycan, designated IPM150. The
XX protein is an IPM component (IPMC). Two subfamilies of IPMCs, IPM150 and
XX IPM200, exist. The human IPM150 gene is located on chromosome 6q13-q15,
XX between markers CHLC.GAVAL1F10 and D6S284. The IPM proteins may be used
XX to supplement a patient's own production of the protein or to rectify
XX alterations in their nucleic acids that result in expression of an
XX inactive protein. The IPM nucleic acids may be used in this way to treat
XX ocular diseases such as retinal detachment, choriorretinal degeneration,
XX retinal degeneration, age related macular degeneration, photoreceptor
XX degeneration, RPE (retinal pigment epithelium) degeneration, cone
XX degeneration, mucopolysaccharidosis, rod-cone dystrophy and cone-rod
XX dystrophy. The nucleic acids and proteins may also be used to assay for
XX other modulators of IPM proteoglycan expression and activity that may be
XX used to treat ocular diseases. The nucleic acids and proteins may also be
XX used as diagnostic reagents to detect the presence of IPM nucleic acids
XX and their products in samples from patients according to standard
XX methodologies
XX
SQ Sequence 19 BP; 4 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1184 CCTCTTCTCGGACAC 1201
DB 19 CCTCTGCTCTCAACAC 2
XX
RESULT 270
AA4585/c
ID AAA4585 standard; DNA; 19 BP.
XX
AC AAA4585;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin E ribozyme binding site #118.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotrophic; restenosis; ss.
XX
OS Mammalia.
XX
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
PD 06-DEC-1999; 99WO-US028772.
XX
PF 04-DEC-1998; 98US-0110954P.
XX
PR

```

XX	(IMMU-) IMMUSOL INC.
PA	
XX	
PI	Trletz R, Welch PJ, Barber JR, Robbins JM;
XX	
DR	WPI; 2000-412314/35.
XX	
PT	New hairpin and hammerhead ribozyme for inhibiting reescensiois, cleaves
PT	RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PCNA and Cyclin B1.	
PS	
XX	Disclosure; Page 79; 109pp; English.
CC	
CC	The present invention relates to a hairpin or hammerhead ribozyme,
CC	designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC	other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC	Representative examples of ribozyme recognition sites are given in
CC	AAAB2415 to AAAB6787. The ribozyme of the invention is useful for
CC	inhibiting .reescensiois by introduction of the ribozyme into cells. The
CC	ribozyme is resistant to endonuclease activity and hence is efficient in
CC	reescensiois treatment
SQ	
	Sequence 19 BP; 3 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
Query Match	0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity	88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative	0; Mismatches 2; Indels 0; Gaps 0
Oy	
	877 TCAGCGGGACACCATAG 894
Db	18 TCAGCCAGGACACCAATAG 1
RESULT 271	
AAH59747/C	
ID	AAH59747 standard; DNA; 19 BP.
XX	
AC	AAH59747;
XX	
DT	10-SEP-2001 (first entry)
XX	
DE	Cyclin E ribozyme binding site SEQ ID NO:2171.
XX	
KW	Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW	recognition site; target; ribozyme binding site; eye disease; vulnery;
KW	proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW	cyclokinase; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW	matrix metalloproteinase; growth factor; redutcase; scarring; cytostatic;
KW	antiproliferic; dermatological; antiseborrheic; antidiabetic; vitucide;
KW	antisclerling; ophthalmological; keratolytic; gene therapy; viral wart;
KW	atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW	basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW	sickle cell retinopathy; ss.
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	WO200130362-A2.
XX	
PD	03-MAY-2001.
XX	
PF	26-OCT-2000; 2000WO-US029500.
XX	
PR	26-OCT-1999; 99US-0161532P.
PA	(IMMU-) IMMUSOL INC.
XX	
PI	Robbins JM, Trletz R;
XX	
DR	WPI; 2001-300427/31.
XX	
PT	Treating proliferative skin or eye diseases and scarring, using ribozymes
PT	that cleave RNA encoding cyclokinases involved in inflammation, matrix

```

PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 229; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiproliferative,
CC dermatological, cytostatic, antileukemic, antidiabetic, antisticking,
CC ophthalmological, vulnerary, keratolytic and virulicide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seboreic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH6209 represent sequences used in the
CC exemplification of the present invention
SQ
SQ Sequence 19 BP; 3 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0
OY 877 TCAGCGCGGACACCATAG 894
DB 18 TCAGCCAGGACACCATAG 1
RESULT 272
ABLS7139/C
ID 1 ABL57139 standard; DNA; 19 BP.
XX
XX ABL57139;
AC
XX
XX 05-AUG-2002 (first entry)
DE
XX Human PKW gene specific PCR primer RTR-5.
XX
XX PKW: human; breast cancer; mammary carcinoma; metastasis; tumour;
XX diagnosis; gene therapy; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX
XX EPI158001-A1.
XX
XX -- 28-NOV-2001.
XX
XX 23-MAY-2001; 2001EP-00112004.
XX
XX 26-MAY-2000; 2000EP-00110953.
XX
XX 15-JUL-2000; 2000EP-00115369.
XX
XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.
XX
XX Kaul S, Preiherr J, Weidle U;
XX
XX WPI: 2002-418496/45.
XX
XX New nucleic acid, designated PKW, upregulated in mammary tumor cells,
XX useful as marker in diagnosis and characterization of mammary tumors.
XX
XX Example 9; Page 10; 26pp; English.
XX
XX The present sequence is that of human PKW gene-specific primer RTR-5. RTR
XX -5 was used in the synthesis of first strand cDNA from total RNA isolated
XX from breast tumour tissues. The resulting cDNA was amplified by PCR using

```

CC a second specific forward primer (see ABL57140). PKW nucleic acid is
CC upregulated in tumour cells, especially in mammary carcinoma cells. It
CC codes for a protein that induces tumour progression or metastasis. PKW is
CC useful as a marker in the diagnosis and characterisation of mammary
CC tumours. PKW nucleic acids, expression vectors, host cells, and
CC polypeptides are claimed. Hybridisation probes comprising a PKW nucleic
CC acid are used in a claimed process for determining whether a test sample
CC of human cells has a tumour progression potential. The invention also
CC relates to the detection of tumour cells and to gene therapy methods that
CC modulate or inhibit PKW function in tumour cells
XX

SO Sequence 19 BP; 5 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.6%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2395 CTTGAAATTAATGAAG 2412

Db 19 CTTGAAATGAATGAATG 2

RESULT 273

ADB25800

ID ADB25800 standard; DNA; 19 BP.

AC ADB25800;

DT 20-NOV-2003 (first entry)

DE Human CYP2D6-related PCR primer #21.

KW human; mutant CYP2D6 gene; drug analysis; drug testing; PCR; ss; primer.

OS Homo sapiens.

PN WO2003050282-A1.

PD 19-JUN-2003.

PF 05-DEC-2002; 2002WO-JP012748.

PR 06-DEC-2001; 2001JP-00372548.

PA (TSUR) TSUMURA & CO.

PI Taniyama M, Ogawa K, Tsuchiya N, Hibino T;

DR WPI; 2003-505401/47.

PT Genetic polymorphisms of CYP2D6 gene in human population for analysis of
PT drug effect on individual patients and testing of new drugs.

PS Example 1; Page 18; 75pp; Japanese.

CC The invention comprises mutant forms of the human CYP2D6 gene, containing
CC one or more of the following mutations G125A, C1858T, T2874C and C2875T.
CC The mutant human CYP2D6 genes of the invention are useful for analysing
CC the effect of drugs on individual patients and testing of new drugs. The
CC present DNA sequence represents a PCR primer used in an example of the
CC invention.
XX

SO Sequence 19 BP; 2 A; 11 C; 2 G; 4 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.6%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 378 CTCGAGACCTCTCTCT 395

Db 1 CTCGAGACCTCTCTCTCT 18

RESULT 274
ACF79453/C
ID ACF79453 standard; DNA; 19 BP.

AC ACF79453;

DT 18-DEC-2003 (first entry)

DE Serum amyloid A1 modified promoter GREI primer GREIR.

KW Glucocorticoid responsive element; GRE; serum amyloid A1; SAA1; promoter;
KW human; steroid responsiveness; PCR; primer; ss.

OS Homo sapiens.

OS Synthetic.

PN WO2003062792-A2.

PD 31-JUL-2003.

PF 22-JAN-2003; 2003WO-US001651.

PR 22-JAN-2002; 2002US-00045360.

PR 03-APR-2002; 2002US-0370008P.

PA (UYPE-) UNIV PENNSYLVANIA.

PI Whitehead AS, Chailberg SS, Lazar JG;

DR WPI; 2003-748014/70.

PT Determining steroid responsiveness, useful e.g. for monitoring, or
PT assessing likely success of therapy, comprises measuring relative
PT expression of responsive and non-responsive genes.

PS Example 1; Page 29; 0pp; English.

CC The present sequence is that of primer GREIR, which was used in the PCR
CC mutagenesis of the human serum amyloid A1 (SAA1) gene promoter to produce
CC construct GREI (see ACF79453). GREI was used to confirm that a putative
CC glucocorticoid responsive element of SAA1 is functional. A method for
CC determining steroid responsiveness involves determining, in a tissue,
CC body fluid or cell sample from a subject being treated with steroids, the
CC RNA expression levels of genes that are known to be, or suspected of,
CC being, respectively, responsive and non-responsive to steroids. The first
CC gene is preferably the SAA1 gene controlled by a GRB, and the second gene
CC is the SAA2 gene; the responses of only the SAA1 gene are augmented by
CC glucocorticoid administration. The method is applied to subjects being
CC treated with steroids for a very wide range of diseases (e.g.
CC inflammation, cancer, autoimmune disease, arthritic disease, coronary
CC artery disease, endocrine disease, stroke etc.), e.g. for monitoring to
CC detect loss of responsiveness, to detect response when a combination of
CC stimuli or drugs is administered and to assess side effects, to evaluate
CC subjects for transplantation or steroid therapy, and to determine
CC suitable doses of steroids
XX

SO Sequence 19 BP; 3 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.6%; Score 14.8; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1630 GGCTGACTACCTCTCT 1647

Db 18 GGCTGACTACCTCTCTCT 1

RESULT 275

ADB65548/C
ID ADB65548 standard; RNA; 19 BP.

AC ADB65548;

XX

DT 29-JAN-2004 (first entry)
XX Human c-fos transcript target sequence/siNA upper strand, SEQ ID NO:3.
DE
XX RNA interference; short interfering nucleic acid; siNA;
XX short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
XX short hairpin RNA; shRNA; expression modulation; gene therapy;
XX drug screening; diagnosis; therapeutic target identification;
XX pharmacogenomics; gene function analysis; gene mapping;
XX central nervous system disorder; Alzheimer's disease;
XX Parkinson's disease; Huntington's disease; epilepsy; dementia;
XX amyotrophic lateral sclerosis; cancer; proliferative disease; restenosis;
XX polycystic kidney disease; inflammatory disease; allergic disease;
XX viral infection; HIV infection; autoimmune disease; transplant rejection;
XX vasotropic; neurotropic; antiparkinsonian; neuroprotective; cytostatic;
XX antiinflammatory; antiallergic; virucide; anti-HIV; immunosuppressive;
XX anticonvulsant; nephrotoxic; human; c-fos; target sequence; ss.
XX
XX Homo sapiens.
OS
XX MO2003070914-A2.
PN
XX 28-AUG-2003.
PD
XX 20-FEB-2003; 2003WO-US005162.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PA
XX (SIRN-) SIRNA THERAPEUTICS INC.
PI
XX Mcswiggen J, Beigelman L;
PI
XX WPI; 2003-679877/64.
DR
XX
XX New short interfering nucleic acid downregulates expression of the c-fos
PT gene useful for treatment and diagnosis of diseases, e.g. cancer and
PT inflammation.
XX
XX
XX Example 3; SEQ ID NO 3; 145pp; English.
PS
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human c-fos gene by RNA interference. The
CC siNA may or may not comprise ribonucleotides and may be double or single
CC stranded. They further comprise sense and antisense regions, or
CC alternatively are assembled from a sense oligonucleotide and an antisense
CC oligonucleotide. Specifically, the siNA include short interfering RNA
CC (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA
CC (shRNA). The siNA can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNA are used to modulate
CC expression of the c-fos gene in cells, tissue explants or organisms
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC central nervous system lesions and injuries (e.g., Alzheimer's disease,
CC Parkinson's disease, Huntington's disease, epilepsy, dementia or
CC amyotrophic lateral sclerosis); various cancers; other proliferative
CC diseases (e.g., restenosis and polycystic kidney disease); inflammatory
CC and/or allergic diseases; viral infections (including HIV infection);
CC autoimmune diseases; and transplant rejection. The siNA are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human c-fos-
CC targeted double-stranded siNA, which is identical to the c-fos transcript
CC target sequence.

XX
SQ Sequence 19 BP; 2 A; 8 C; 9 G; 0 T; 0 U; 0 Other;
XX
XX Query Match: 0.6%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 15 GCGCCGCGCTCGCGCT 32
DB 18 GCGCCGCGCTCGCGCT 1
RESULT 276
ID ADE65664
ID ADE65664 standard; RNA; 19 BP.
AC ADE65664;
XX
XX 29-JAN-2004 (first entry)
DT
XX
XX Human c-fos siNA lower strand, SEQ ID NO:119.
DE
XX RNA interference; short interfering nucleic acid; siNA;
XX short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
XX short hairpin RNA; shRNA; expression modulation; gene therapy;
XX drug screening; diagnosis; therapeutic target identification;
XX pharmacogenomics; gene function analysis; gene mapping;
XX central nervous system disorder; Alzheimer's disease;
XX Parkinson's disease; Huntington's disease; epilepsy; dementia;
XX amyotrophic lateral sclerosis; cancer; proliferative disease; restenosis;
XX polycystic kidney disease; inflammatory disease; allergic disease;
XX viral infection; HIV infection; autoimmune disease; transplant rejection;
XX vasotropic; neurotropic; antiparkinsonian; neuroprotective; cytostatic;
XX antiinflammatory; antiallergic; virucide; anti-HIV; immunosuppressive;
XX anticonvulsant; nephrotoxic; human; c-fos; ss.
XX
XX Homo sapiens.
OS
XX MO2003070914-A2.
PN
XX 28-AUG-2003.
PD
XX 20-FEB-2003; 2003WO-US005162.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PA
XX (SIRN-) SIRNA THERAPEUTICS INC.
PI
XX Mcswiggen J, Beigelman L;
PI
XX WPI; 2003-679877/64.
DR
XX
XX New short interfering nucleic acid downregulates expression of the c-fos
PT gene useful for treatment and diagnosis of diseases, e.g. cancer and
PT inflammation.
XX
XX
XX Example 3; SEQ ID NO 119; 145pp; English.
PS
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human c-fos gene by RNA interference. The
CC siNA may or may not comprise ribonucleotides and may be double or single
CC stranded. They further comprise sense and antisense regions, or
CC alternatively are assembled from a sense oligonucleotide and an antisense
CC oligonucleotide. Specifically, the siNA include short interfering RNA
CC (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA
CC (shRNA). The siNA can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a


```
DR WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
XX Example 3; SEQ ID NO 246; 164pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) gene by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNA
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNA can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 9 A; 2 C; 2 G; 0 T; 6 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 897 TATTGCTTCAAGAAAT 914
| | | | | | | | | |
Db 18 TTTATGCTTCAAGAAAT 1
| | | | | | | | | |
XX
RESULT 279
ADE29711
ID ADE29711 standard; RNA; 19 BP.
XX
AC ADE29711;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:333.
XX
KW short interfering nucleic acid; siNA; downregulation; inhibition;
KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
XX Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
XX
XX 28-JAN-2003; 2003WO-US002510.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
XX
XX 06-JUN-2002; 2002US-0386782P.
XX
XX 29-AUG-2002; 2002US-0406784P.
XX
XX 05-SEP-2002; 2002US-0408378P.
XX
XX 09-SEP-2002; 2002US-0409293P.
XX
XX 15-JAN-2003; 2003US-0440129P.
```

```
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PA Meswigen J, Beigelman L, Usman N, Haeblerli P, Chowwira B;
XX PI WPI; 2003-689980/65.
XX
XX DR WPI; 2003-689980/65.
XX
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
XX Example 3; SEQ ID NO 333; 164pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) gene by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNA
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNA can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 1 A; 4 C; 13 G; 0 T; 1 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
OY 2300 GAGGGGGTTGGCGCGGG 2317
| | | | | | | | | |
Db 1 GAGGGGGGUGCGCGCGGG 18
| | | | | | | | | |
XX
RESULT 280
ADE29816/C
ID ADE29816 standard; RNA; 19 BP.
XX
AC ADE29816;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:438.
XX
KW short interfering nucleic acid; siNA; downregulation; inhibition;
KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
XX Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
XX
XX 28-JAN-2003; 2003WO-US002510.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
```



```
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcawiggen J, Beigelman L, Chowrira B,
XX WPI; 2003-679889/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
XX and diagnosis of leukemia and lymphoma, downregulates the breakpoint
XX cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 6; 197bp; English.
XX
XX The invention relates to a novel double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of the breakpoint
XX cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
XX (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
XX activity and may be useful for modulating expression of the BCR-ABL gene,
XX as well as for treating leukaemia or lymphoma and in diagnosis, drug
XX screening, target identification and validation, genetic engineering,
XX gene function studies and gene mapping. The current sequence is that of
XX the human BCR-targeted siRNA of the invention.
XX
XX Sequence 19 BP; 1 A; 5 C; 13 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 16 CGCCGCGGCTGGCGCTC 33
XX ||||| ||||| |||||
XX Db 18 CCGCCGCGGCGGCGCTC 1
XX
XX RESULT 283
XX ADF84593/C
XX ID ADF84593 standard; RNA; 19 BP.
XX
XX ADF84593;
XX
XX 26-FEB-2004 (first entry)
XX
XX Human ABL1-targeted siRNA - SEQ ID 887.
XX
XX short interfering nucleic acid; siNA; breakpoint cluster region;
XX v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
XX cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
XX Homo sapiens.
XX
XX WO2003070972-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005234.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 15-AUG-2002; 2002US-0404039P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 14-JAN-2003; 2003US-0439922P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcawiggen J, Beigelman L, Chowrira B,
XX WPI; 2003-679889/64.
XX
XX
```

```
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 887; 197bp; English.
XX
XX The invention relates to a novel double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of the breakpoint
XX cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
XX (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
XX activity and may be useful for modulating expression of the BCR-ABL gene,
XX as well as for treating leukaemia or lymphoma and in diagnosis, drug
XX screening, target identification and validation, genetic engineering,
XX gene function studies and gene mapping. The current sequence is that of
XX the human ABL1-targeted siRNA of the invention.
XX
XX Sequence 19 BP; 5 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 717 CATGCTATCATGGGCTG 734
XX ||||| ||||| |||||
XX Db 19 CCGGTACCATGGGCTG 2
XX
XX RESULT 284
XX ADF84274
XX ID ADF84274 standard; RNA; 19 BP.
XX
XX ADF84274;
XX
XX 26-FEB-2004 (first entry)
XX
XX Human ABL1-targeted siRNA - SEQ ID 568.
XX
XX short interfering nucleic acid; siNA; breakpoint cluster region;
XX v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
XX cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
XX Homo sapiens.
XX
XX WO2003070972-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005234.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 15-AUG-2002; 2002US-0404039P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 14-JAN-2003; 2003US-0439922P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcawiggen J, Beigelman L, Chowrira B,
XX WPI; 2003-679889/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
XX and diagnosis of leukemia and lymphoma, downregulates the breakpoint
XX cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 568; 197bp; English.
XX
XX The invention relates to a novel double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of the breakpoint
XX
```

CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
XX
SQ Sequence 19 BP; 2 A; 6 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 1.6e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 717 CATGATCATGGGCTG 734
| : : : : | : : : : | : : : : |
Db 1 CCUGGUAACCAUGGCCUCG 18

RESULT 285
ADF83975
ID ADF83975 standard; RNA; 19 BP.
XX
AC ADF83975;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human breakpoint cluster region-targeted siRNA - SEQ ID 269.
XX
KM short interfering nucleic acid, siNA; breakpoint cluster region;
KM v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KM cytostatic; leukaemia; lymphoma; human; BCR; ss; siRNA.
XX
OS Homo sapiens.
XX
FN WO2003070972-A2.
XX
PD 28-AUG-2003.
XX
PE 20-FEB-2003; 2003WO-US005234.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcawiggen J, Beigelman L, Chowrira B;
XX
DR WPI; 2003-679889/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
PS Example 7; SEQ ID NO 269; 197pp; English.
XX
CC The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human BCR-targeted siRNA of the invention.
XX

SQ Sequence 19 BP; 0 A; 13 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 16 CGCCGCGGCTCCGCGCTC 33
| : : : : | : : : : | : : : : |
Db 2 CGCCGCGGCTCCGCGCTC 19

RESULT 286
ADG34885
ID ADG34885 standard; RNA; 19 BP.
XX
AC ADG34885;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF receptor siNA oligonucleotide SEQ ID NO:237.
XX
KM RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping;
KM tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
KM antibacterial; immunosuppressive; antineoplastic; antiarthritic; anti-HIV;
KM HIV/AIDS; psoriasis; inflammation; autoimmune disease; target sequence.
XX
OS Synthetic.
XX
FN WO2003070897-A2.
XX
PD 28-AUG-2003.
XX
PE 20-FEB-2003; 2003WO-US004741.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0429359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcawiggen J, Beigelman L;
XX
DR WPI; 2003-697609/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of septic shock or rheumatoid arthritis, downregulates
PT expression of the tumor necrosis factor gene.
XX
PS Example 3; SEQ ID NO 237; 141pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF)
CC receptor gene by RNA interference. The siNAs may or may not comprise
CC ribonucleotides and may be double or single stranded. They further
CC comprise sense and antisense regions, or alternatively are assembled from
CC a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC unmodified or chemically modified, can contain deoxyribonucleotides, and
CC can be chemically synthesised, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors

CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the upper strand of a human TNF receptor-targeted double-
CC stranded siNA, which is identical to the TNF receptor transcript target
CC sequence.
SQ Sequence 19 BP; 6 A; 9 C; 2 G; 0 T; 2 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 2265 CCCCAGACCCCAAGCTTCA 2282
Db 2 CCCCAGACCCCAAGCTTCA 19
RESULT 287
ADG35008/c
ID ADG35008 standard; RNA; 19 BP.
XX
AC ADG35008;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF receptor siNA oligonucleotide SEQ ID NO:360.
XX
XX RNA interference; short interfering nucleic acid; siNA;
XX short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
XX short hairpin RNA; shRNA; expression modulation; gene therapy;
XX drug screening; diagnosis; therapeutic target identification;
XX pharmacogenomics; gene function analysis; gene mapping;
XX tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
XX antibacterial; immunosuppressive; antirheumatic; antiarthritic; anti-HIV;
XX anti-psoriatic; antiinflammatory; septic shock; rheumatoid arthritis;
XX HIV/AIDS; psoriasis; inflammation; autoimmune disease.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX WO2003070897-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US004741.
XX
XX 20-FEB-2002; 2002US-0356580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 28-NOV-2002; 2002US-0428359P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcawiggen J, Belgelman L;
XX
XX WPI; 2003-697609/66.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX diagnosis of septic shock or rheumatoid arthritis, downregulates
XX expression of the tumor necrosis factor gene.

XX
PS Example 3; SEQ ID NO 360; 141pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF)
CC receptor gene by RNA interference. The siNAs may or may not comprise
CC ribonucleotides and may be double or single stranded. They further
CC comprise sense and antisense regions, or alternatively are assembled from
CC a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC unmodified or chemically modified, can contain deoxyribonucleotides, and
CC can be chemically synthesized, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA, conjugates and/or complexes of siNA, and vectors
CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the lower strand of a human TNF receptor-targeted double-
CC stranded siNA.
XX
SQ Sequence 19 BP; 2 A; 2 C; 9 G; 0 T; 6 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2265 CCCCAGACCCCAAGCTTCA 2282
Db 18 CCCCAGACCCCAAGCTTCA 1

Search completed: August 8, 2005, 09:56:56
Job time : 10 secs

THIS PAGE BLANK (USPTO)

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
AUTHORS Shoshan, A., Maeser, A., Mintz, E., Mintz, L., and Faigler, S.
TITLE Oligonucleotide library for detecting rna transcripts and splice
variants that populate a transcriptome
JOURNAL Patent: WO 0210449-A 16614 07-FEB-2002;
CompuGen Inc. (US)
FEATURES
source location/Qualifiers
1. .60
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.5%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 2.9e-05;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1767 ACTTCTCATACAGCCCTTTATTCGACATACCCAGCTGCTGCTGCTGAAATGCA 1826
DB 60 ACTTCTCATACAGCCCTTTATTCGACATACCCAGCTGCTGCTGCTGAAATGCA 1

RESULT 2
BD181456 65 bp DNA linear PAT 15-MAY-2003
LOCUS A gene of which expression changes in psoriasis and a method for e
DEFINITION
ACCESSION BD181456
VERSION BD181456.1 GI:30792374
KEYWORDS JP 2002330770-A/4.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
AUTHORS Imai, Y., Wakimoto, K., Yamada, E., Chiba, H., and Okubo, K.
TITLE A gene of which expression changes in psoriasis and a method for e
JOURNAL Patent: JP 2002330770-A 4 19-NOV-2002;
TANABE SEIYAKU CO LTD
COMMENT OS Homo sapiens (human)
PN JP 2002330770-A/4
PD 19-NOV-2002
PF 25-MAY-2001 JP 2001156529
PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI
OKUBO
PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21 PC
PC C12N5/10, C12Q1/68,
PC G01N33/53, G01N33/56, C12N15/00, C12N5/00 CC A gene
of which expression changes in psoriasis and a method CC
for e
CC xamination directed to said gene
FH Key location/Qualifiers
FT source 1. .65
/organism="Homo sapiens (human)"
/db_xref="taxon:9606"

FEATURES
source location/Qualifiers
1. .65
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 2.5%; Score 60; DB 1; Length 65;
Best Local Similarity 100.0%; Pred. No. 3.1e-05;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2362 GATCATTCACCATTCGACATTTGTATATCCCTTGAATAATGAAGTGAATCC 2421
DB 1 GATCATTCACCATTCGACATTTGTATATCCCTTGAATAATGAAGTGAATCC 60

RESULT 3
CQ007002/c 51 bp DNA linear PAT 16-JAN-2004
LOCUS CQ007002

DEFINITION Sequence 5642 from Patent WO0147944.
ACCESSION CQ007002
VERSION CQ007002.1 GI:41013634
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE 1 Shinkens, R.A. and Leach, M.
AUTHORS Nucleic acids containing single nucleotide polymorphisms and
TITLE methods of use thereof
JOURNAL Patent: WO 0147944-A 5642 05-JUL-2001;
Curagen Corporation (US)
FEATURES
source location/Qualifiers
1. .51
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Accession number cg43983352"

Query Match 1.7%; Score 40.5; DB 1; Length 51;
Best Local Similarity 98.1%; Pred. No. 0.017; 0; Indels 1; Gaps 1;
Matches 51; Conservative 0; Mismatches 0;

QY 1390 TGAAGTGAAGCCAGCTTCGGGGCACTCCCTGAGAGAACGCTGCAATC 1441
DB 51 TGAAGTGAAGCCAG-CTTCGGGGCACTCCCTGAGAGAACGCTGCAATC 1

RESULT 4
AX697225 24 bp DNA linear PAT 02-APR-2003
LOCUS AX697225
DEFINITION Sequence 293 from Patent WO0078961.
ACCESSION AX697225
VERSION AX697225.1 GI:29498160
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Ferrara, N., Stewart, T.A., Williams, P.M., Baker, K.P., Desnoyers, L.,
Baton, D.L., Gao, W.O., Pan, J., Botstein, D., Pong, S., Goddard, A.,
Godowski, P.J., Gurney, A.L., Smith, V., Tumas, D., Wood, W.I.,
Grimaldi, C.V., Hillan, K.V., Paoni, N.F., Roy, W.A., and Watanabe, C.K.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
JOURNAL Patent: WO 0078961-A 293 28-DEC-2000;
Genentech Inc. (US)
FEATURES
source location/Qualifiers
1. .24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTTCACATCTACTCC 1064
DB 1 GCTGACCTGGTTCACATCTACTCC 24

RESULT 5
AX697226/c 24 bp DNA linear PAT 02-APR-2003
LOCUS AX697226
DEFINITION Sequence 294 from Patent WO0078961.
ACCESSION AX697226
VERSION AX697226.1 GI:29498161
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct

REFERENCE 1 other sequences; artificial sequences.

AUTHORS Ferrara, N., Stewart, T.A., Williams, P.M., Baker, K.P., Desnoyers, L., Eaton, D.L., Gao, W.Q., Pan, J., Bocstein, D., Fong, S., Goddard, A., Godowski, P.J., Gurney, A.L., Smith, V., Tumas, D., Wood, W.I., Grimaldi, C.J., Hillan, K.J., Paoni, N.F., Roy, M.A. and Watanabe, C.K.

TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same

JOURNAL Patent: WO 0078961-A 294 28-DEC-2000;

Genentech Inc. (US)

FEATURES Location/Qualifiers

source 1..24

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

Query Match 1.0%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 2.7;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 CGAAGTGTATGCGGTCTGTGCG 1486

Db 24 GGAAGTGTATGCGGTCTGTGCG 1

RESULT 6

LOCUS BD181464 22 bp DNA linear PAT 15-MAY-2003

DEFINITION A gene of which expression changes in psoriasis and a method for e

ACCESSION BD181464

VERSION BD181464.1 GI:30792382

KEYWORDS JP 2002330770-A/12.

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 22)

AUTHORS Imai, Y., Wakimoto, K., Yamada, E., Chiba, H. and Okubo, K.

TITLE A gene of which expression changes in psoriasis and a method for e

JOURNAL Patent: JP 2002330770-A 12 19-NOV-2002;

COMMENT TANABE SEIYAKU CO LTD

OS Artificial Sequence

PN JP 2002330770-A/12

PD 19-NOV-2002

PF 25-MAY-2001 JP 2001156529

PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI

OKUBO

PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21 PC

, C12N5/10, C12Q1/68,

PC GOIN33/53, GOIN33/56, C12N15/00, C12N5/00 CC

Artificially synthesized primer sequence

Key Location/Qualifiers

FT source 1..22

/organism="Artificial Sequence".

FEATURES Location/Qualifiers

source 1..22

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.9%; Score 22; DB 1; Length 22;

Best Local Similarity 100.0%; Pred. No. 4.9;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2057 CGCCACCATGAGCTAGTGGAG 2078

Db 1 CGCCACCATGAGCTAGTGGAG 22

RESULT 7

LOCUS BD181465/c 22 bp DNA linear PAT 15-MAY-2003

DEFINITION A gene of which expression changes in psoriasis and a method for e

xamination directed to said gene.

ACCESSION BD181465

VERSION BD181465.1 GI:30792383

KEYWORDS JP 2002330770-A/13.

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 22)

AUTHORS Imai, Y., Wakimoto, K., Yamada, E., Chiba, H. and Okubo, K.

TITLE A gene of which expression changes in psoriasis and a method for e

JOURNAL Patent: JP 2002330770-A 13 19-NOV-2002;

COMMENT TANABE SEIYAKU CO LTD

OS Artificial Sequence

PN JP 2002330770-A/13

PD 19-NOV-2002

PF 25-MAY-2001 JP 2001156529

PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI

OKUBO

PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21 PC

, C12N5/10, C12Q1/68,

PC GOIN33/53, GOIN33/56, C12N15/00, C12N5/00 CC

Artificially synthesized primer sequence

Key Location/Qualifiers

FT source 1..22

/organism="Artificial Sequence".

FEATURES Location/Qualifiers

source 1..22

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.9%; Score 22; DB 1; Length 22;

Best Local Similarity 100.0%; Pred. No. 4.9;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2357 GATGAGCATTCGACCATGTC 2378

Db 22 GATGAGCATTCGACCATGTC 1

RESULT 8

LOCUS BD181460/c 21 bp DNA linear PAT 15-MAY-2003

DEFINITION A gene of which expression changes in psoriasis and a method for e

ACCESSION BD181460

VERSION BD181460.1 GI:30792378

KEYWORDS JP 2002330770-A/8.

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 21)

AUTHORS Imai, Y., Wakimoto, K., Yamada, E., Chiba, H. and Okubo, K.

TITLE A gene of which expression changes in psoriasis and a method for e

JOURNAL Patent: JP 2002330770-A 8 19-NOV-2002;

COMMENT TANABE SEIYAKU CO LTD

OS Artificial Sequence

PN JP 2002330770-A/8

PD 19-NOV-2002

PF 25-MAY-2001 JP 2001156529

PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI

OKUBO

PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21 PC

, C12N5/10, C12Q1/68,

PC GOIN33/53, GOIN33/56, C12N15/00, C12N5/00 CC

Artificially synthesized primer sequence

Key Location/Qualifiers

FT source 1..21

/organism="Artificial Sequence".

FEATURES Location/Qualifiers

source 1. .21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.8%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2364 TCATTGCACGACTCAGACT 2383
Db 21 TCATTGCACGACTCAGACT 2

RESULT 9
AX476295/c 25 bp DNA linear PAT 12-AUG-2002
LOCUS Sequence 1516 from Patent WO0224750.
DEFINITION AX476295
ACCESSION AX476295.1 GI:22215580
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 1516 28-MAR-2002;
Aecmca, Inc. (US)
FEATURES
source 1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 13;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1419 CCTGAGGACGCTGCAATCA 1442
Db 25 CCTGAGGCTCTGCTGCAATCA 2

RESULT 10
AX476296/c 25 bp DNA linear PAT 12-AUG-2002
LOCUS Sequence 1517 from Patent WO0224750.
DEFINITION AX476296
ACCESSION AX476296.1 GI:22215581
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 1517 28-MAR-2002;
Aecmca, Inc. (US)
FEATURES
source 1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 13;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1419 CCTGAGGACGCTGCAATCA 1442
Db 25 CCTGAGGCTCTGCTGCAATCA 2

Db 24 CCTGAGGCTCTGCTGCAATCA 1

RESULT 11
AX838503 23 bp DNA linear PAT 15-DEC-2003
LOCUS Sequence 3 from Patent WO03076654.
DEFINITION AX838503
ACCESSION AX838503.1 GI:39922106
VERSION
KEYWORDS
SOURCE
ORGANISM synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Palecek, E. and Kosak, H.
TITLE Method for identifying, quantifying and/or characterizing an
JOURNAL analyze
PATENT: WO 03076654-A 3 18-SEP-2003;
November Aktiengesellschaft Gesellschaft fuer Molekulare Medizin
(DE)
FEATURES
source 1. .23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz:
Willkuerliche Sequenz"

Query Match 0.7%; Score 17.8; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 19;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1536 TCTTTTAAAGCAAGG 1556
Db 3 TTTTGTGAGGAGGAGG 23

RESULT 12
AR489241/c 22 bp DNA linear PAT 15-MAY-2004
LOCUS Sequence 20 from patent US 6709860.
DEFINITION AR489241
ACCESSION AR489241.1 GI:47256198
VERSION
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Enerback, S. and Carlsson, P.
TITLE Animal model
JOURNAL Patent: US 6709860-A 20 23-MAR-2004;
Location/Qualifiers
FEATURES
source 1. .22
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 239 CCTCATAGCGCTACTCGGG 260
Db 22 CCTCATAGCGCTACTCGGG 1

RESULT 13
AR299945 21 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 11680 from patent US 6537751.
DEFINITION AR299945
ACCESSION AR299945.1 GI:31687229
VERSION
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL disequilibrium map of the human genome
FEATURES Patent: US 6537751-A 11680 25-MAR-2003;
LOCATION/Qualifiers
1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1643 TCTCTTCTTCCCTTCT 1659
1 TCTCTTCTTCCCTTCT 17

Db 1 TCTCTTCTTCCCTTCT 17

RESULT 14
LOCUS AR266033 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 40 from patent US 6492171.
ACCESSION AR266033
VERSION AR266033.1 GI:29694879
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P., Gaarde,W.A., Freier,S.M. and Wanciewicz,E.
TITLE Antisense modulation of TERT expression
JOURNAL Patent: US 6492171-A 40 10-DEC-2002;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 24;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 139 GCGCGAAGCCCTGCGCCCG 158
1 GCGCGAAGCCCTGCGCCCG 1
20 GTGGGAAGCCCTGCGCCCG 1

Db 20 GTGGGAAGCCCTGCGCCCG 1

RESULT 15
LOCUS AR139944 21 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 16 from patent US 6207417.
ACCESSION AR139944
VERSION AR139944.1 GI:14482440
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE DNA encoding stem cell factor
JOURNAL Patent: US 6207417-A 16 27-MAR-2001;
FEATURES Location/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATTAATGCAAGTGAGATCC 2421

Db 2 ATTAATGCAAGTGATATCC 21
|||||

RESULT 16
LOCUS AR140263 21 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 16 from patent US 6207454.
ACCESSION AR140263
VERSION AR140263.1 GI:14482759
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method for enhancing the efficiency of gene transfer with stem cell
JOURNAL factor (SCF) polypeptide
FEATURES Patent: US 6207454-A 16 27-MAR-2001;
LOCATION/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATTAATGCAAGTGAGATCC 2421
|||||

Db 2 ATTAATGCAAGTGATATCC 21

RESULT 17
LOCUS AR140541 21 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 16 from patent US 6207802.
ACCESSION AR140541
VERSION AR140541.1 GI:14483037
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Stem cell factor and compositions
JOURNAL Patent: US 6207802-A 16 27-MAR-2001;
FEATURES Location/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATTAATGCAAGTGAGATCC 2421
|||||

Db 2 ATTAATGCAAGTGATATCC 21

RESULT 18
LOCUS AR562140 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 16 from patent US 6759215.
ACCESSION AR562140
VERSION AR562140.1 GI:53976003
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.

TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 16 06-JUL-2004;
FEATURES
source
1. .21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATAAATGCAAGTGAATCC 2421
|||||
2 ATAAATGCAAGTGAATATCC 21

RESULT 19
AR126157
LOCUS AR126157 22 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 17 from patent US 6177614.
ACCESSION AR126157
VERSION AR126157.1 GI:14112219
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 22)
AUTHORS Colasanti, J.J. and Sundaresan, V.
TITLE Control of floral induction in plants and uses therefor
JOURNAL Patent: US 6177614-A 17 23-JAN-2001;
FEATURES
source
1. .22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 85.7%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 364 GCATCCTCTCCGCCCTCCAGG 384
|||||
2 GCATCCTCTTCCCTCCAGG 22

RESULT 20
AX746091/c
LOCUS AX746091 22 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 41 from Patent WO03031459.
ACCESSION AX746091
VERSION AX746091.1 GI:30724741
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS other sequences; artificial sequences.
TITLE Hecker, M. and Wagner, A.H.
JOURNAL Modulation of the expression of genes dependent on stat-1
Avotec GmbH (DE)
Patent: WO 03031459-A 41 17-APR-2003;
FEATURES
source
1. .22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="antisense oligo"

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 589 GTGCAGAGGTCACAGTGG 608
|||||
22 GTGCAGAGATGTCTCAGTGG 3

RESULT 21
AX770442/c
LOCUS AX770442 22 bp DNA linear PAT 02-JUL-2003
DEFINITION Sequence 41 from Patent WO03030944.
ACCESSION AX770442
VERSION AX770442.1 GI:32437843
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS other sequences; artificial sequences.
TITLE Hecker, M. and Wagner, A.H.
JOURNAL Inhibition of stat-1
Patent: WO 03030944-A 41 17-APR-2003;
Avotec GmbH (DE)
FEATURES
source
1. .22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="antisense oligo"

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 589 GTGCAGAGGTCACAGTGG 608
|||||
22 GTGCAGAGATGTCTCAGTGG 3

RESULT 22
AR223394
LOCUS AR223394 21 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 39 from patent US 6436399.
ACCESSION AR223394
VERSION AR223394.1 GI:23331561
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 21)
AUTHORS Rikhiya, Y., Zhi, N. and Ohashi, N.
TITLE Nucleic acid encoding the major outer membrane protein of the
causative agent of human granulocytic ehrlichiosis and peptides
encoded thereby
JOURNAL Patent: US 6436399-A 39 20-AUG-2002;
FEATURES
source
1. .21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 563 GTTTGACTGGAACACACC 580
|||||
4 GTTTGACTGGAACACTCC 21

RESULT 23
AR240913/c
LOCUS AR240913 19 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 80 from patent US 6468791.
ACCESSION AR240913
VERSION AR240913.1 GI:27286114
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.

REFERENCE 1 (bases 1 to 19)
AUTHORS Tanzi, R.E., Schellenberg, G.D., Masco, W., Levy-Lahad, E., Bird, T.D.
and Galas, D.J.
TITLE Chromosome 1 gene and gene products related to Alzheimer's Disease
JOURNAL Patent: US 6468791-A 80-22-OCT-2002;
FEATURES
source
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1842 CCAAGGGAGAGACTGGAG 1860
DB 19 CCCAGGGAGAGCTGGAG 1

RESULT 24
LOCUS AR279716 19 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 22 from patent US 6518012.
ACCESSION AR279716
VERSION AR279716.1 GI:29714650
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Tomasi, T.B.
TITLE Method for regulating the expression of MHC antigens and CD40 by
JOURNAL Patent: US 6518012-A 22-11-FEB-2003;
FEATURES
source
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1999 GCAATGACACCTCGAGG 2017
DB 19 GCAAGACACCATCGAGG 1

RESULT 25
LOCUS AX353084 19 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 290 from Patent EP1174518.
ACCESSION AX353084
VERSION AX353084.1 GI:18618166
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Loukachov, V.V., van Gemen, B. and Goudsmit, J.
TITLE Collection of binding molecules
JOURNAL Patent: EP 1174518-A 290-23-JAN-2002;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 103"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAAGTCACT 1561
DB 1 TAAAGAGAAAAGTCACT 19

RESULT 26
LOCUS AX353089 19 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 295 from Patent EP1174518.
ACCESSION AX353089
VERSION AX353089.1 GI:18618171
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Loukachov, V.V., van Gemen, B. and Goudsmit, J.
TITLE Collection of binding molecules
JOURNAL Patent: EP 1174518-A 295-23-JAN-2002;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 103"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAAGTCACT 1561
DB 1 TAAAGAGAAAAGTCACT 19

RESULT 27
LOCUS AX362929 19 bp DNA linear PAT 15-FEB-2002
DEFINITION Sequence 290 from Patent WO0208463.
ACCESSION AX362929
VERSION AX362929.1 GI:18695069
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Loukachov, V.V., Goudsmit, J. and van Gemen, B.
TITLE Collection of binding molecules
JOURNAL Patent: WO 0208463-A 290-31-JAN-2002;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 103"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAAGTCACT 1561
DB 1 TAAAGAGAAAAGTCACT 19

RESULT 28
LOCUS AX362934 19 bp DNA linear PAT 15-FEB-2002
DEFINITION Sequence 295 from Patent WO0208463.
ACCESSION AX362934

VERSION	KEYWORDS	SYNTHETIC CONSTRUCT	SYNTHETIC CONSTRUCT	OTHER SEQUENCES	ARTIFICIAL SEQUENCES
VERSION 1	AX362934.1	GI:18695074			
SOURCE					
ORGANISM					
REFERENCE					
AUTHORS	1	Loukachov, V.V., Goudamit, J. and van Gemen, B.			
TITLE		Collection of binding molecules			
JOURNAL		Patent: WO 0208463-A 295 31-JAN-2002;			
		Amsterdam Support Diagnostics B.V. (NL)			
FEATURES					
source		1..19	/organism="synthetic construct"		
			/mol_type="unassigned DNA"		
			/db_xref="taxon:32630"		
			/note="position 103"		
Query Match	0.7%;	Score 15.8;	DB 1;	Length 19;	
Best Local Similarity	89.5%;	Pred. No. 33;			
Matches 17;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;	
OY	1543	TAGAGAGAAAAGTCAGT	1561		
DB	1	TAAAGGAAAATCAGT	19		
RESULT 29	BD196165	20 bp	DNA	linear	PAT 17-JUL-2003
LOCUS	BD196165				
DEFINITION	Antisense oligonucleotide sequences as inhibitors of				
ACCESSION	BD196165				
VERSION	BD196165.1	GI:33005935			
KEYWORDS	JP 2002514093-A/196.				
SOURCE	Escherichia coli				
ORGANISM	Escherichia coli				
	Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;				
	Enterobacteriaceae; Escherichia.				
	1 (bases 1 to 20)				
REFERENCE					
AUTHORS	1	Wright, J.A., Young, A.H. and Dugourd, D.			
TITLE		Antisense oligonucleotide sequences as inhibitors of microorganisms			
JOURNAL		Patent: JP 2002514093-A 196 14-MAY-2002;			
		GENENSENSE TECHNOLOGIES INC			
COMMENT					
	OS	Escherichia coli			
	PN	JP 2002514093-A/196			
	PD	14-MAY-2002			
	PF	10-JUL-1998	JP 1998507930		
	PI	10-JUL-1997	US 60/052160		
	PR	JIM A WRIGHT, ALPINE H YOUNG, DOMINIQUE DUGOURD	PC		
	CC	CLN15/11, CLN15/31			
		Antisense oligonucleotide sequences as inhibitors of CC			
	microorganisms				
FEATURES					
source					
	FT	1..20	/organism="Escherichia coli"		
		location/Qualifiers			
		1..20	/organism="Escherichia coli"		
			/mol_type="genomic DNA"		
			/db_xref="taxon:562"		
Query Match	0.7%;	Score 15.8;	DB 1;	Length 20;	
Best Local Similarity	89.5%;	Pred. No. 33;			
Matches 17;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;	
OY	1345	AGCACAGACCAAGTTCGG	1363		
DB	2	AGCACAGACCAAGTTCGG	20		
RESULT 30	AR261856	20 bp	DNA	linear	PAT 29-JAN-2003
LOCUS	AR261856				

DEFINITION	Sequence 8 from patent US 6323000.
ACCESSION	AR261856
VERSION	AR261856.1 GI:28073046
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified. 1 (bases 1 to 20)
AUTHORS	Briggs,C.A., Gopalakrishnan,M., McKenna,D.G., Monteggia,L.M., Roch,J.-M., Sullivan,J.P. and Touma,E.
TITLE	Variant human .alpha.7 acetylcholine receptor subunit, and methods of production and uses thereof
JOURNAL	Patent: US 6323000-A 8 27-NOV-2001;
FEATURES	location/Qualifiers 1..20 /mol_type="genomic DNA"
source	
Query Match	0.7%; Score 15.8; DB 1; Length 20; Best Local Similarity 89.5%; Pred. No. 33;
Matches	17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	819 GGCAACTTCGATGCCTG 837 Db 20 GGCAAGCTCGAATGCCGTG 2
RESULT 31	
AR382956	
LOCUS	AR382956 20 bp DNA
DEFINITION	Sequence 196 from patent US 6610539.
ACCESSION	AR382956
VERSION	AR382956.1 GI:40091769
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified. 1 (bases 1 to 20)
AUTHORS	Wright,J.A., Young,A.H. and Dugourd,D.
TITLE	Antisense oligonucleotide sequences as inhibitors of microorganisms
JOURNAL	Patent: US 6610539-A 196 26-AUG-2003;
FEATURES	location/Qualifiers 1..20 /organism="unknown" /mol_type="genomic DNA"
source	
Query Match	0.7%; Score 15.8; DB 1; Length 20; Best Local Similarity 89.5%; Pred. No. 33;
Matches	17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	1345 AGCACAGACCACGTTCCG 1363 Db 2 AGCACAGACCACGTTCCG 20
RESULT 32	
AR454983/c	
LOCUS	AR454983 20 bp DNA
DEFINITION	Sequence 8 from patent US 6683157.
ACCESSION	AR454983
VERSION	AR454983.1 GI:42689495
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified. 1 (bases 1 to 20)
AUTHORS	Briggs,C.A., Gopalakrishnan,M., Mc Kenna,D.G., Monteggia,L.M., Roch,J.-M., Sullivan,J.P. and Touma,E.
TITLE	Variant human .alpha.7 acetylcholine receptor subunit, and methods of production and use thereof
JOURNAL	Patent: US 6683157-A 8 27-JAN-2004;
FEATURES	location/Qualifiers 1..20
source	

```
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      819 GGCACTTCGATGCGCTG 837
      ||||| ||||| |||||
Db      20 GGCAAGCTCCGATGCGCTG 2

RESULT 33
AX294475/c      20 bp      DNA      linear      PAT 22-NOV-2001
DEFINITION      Sequence 6237 from Patent WO0179548.
ACCESSION      AX294475
VERSION      AX294475.1 GI:17056158
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS      Barany, F., Zivvi, M., Gerry, N.P., Favis, R. and Kliman, R.
TITLE      Method of designing addressable array for detection of nucleic acid
JOURNAL      Patent: WO 0179548-A 6237 25-OCT-2001;
CORNELIUS RESEARCH FOUNDATION, INC. (US)
FEATURES
source
1. 20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/Note="Hypothetical Probe Sequence"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1113 TGGGGCCGATGGCTCAGA 1131
      ||||| ||||| |||||
Db      19 TGGGGCTGATGCTCAGA 1

RESULT 34
BD023662/c      20 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION      Variant human alpha-7 acetylcholine receptor subunit and production
ACCESSION      BD023662
VERSION      BD023662.1 GI:22564885
KEYWORDS      JP 2001506135-A/7.
SOURCE
ORGANISM
REFERENCE
AUTHORS      Briggs, C.A., Gopalakrishnan, M., McKenna, D.G., Monteggia, L.M.,
      Roch, J.M., Sullivan, J.P. and Youna, E.
TITLE      Variant human alpha-7 acetylcholine receptor subunit and production
JOURNAL      Patent: JP 2001506135-A 7 15-MAY-2001;
ABBOTT LABORATORIES
COMMENT
PN      JP 2001506135-A/7
PD      15-MAY-2001
PF      22-DEC-1997 JP 1998528933
PR      20-DEC-1996 US 08/771737
PI      CLARK A BRIGGS, MURALI GOPALAKRISHNAN, DAVID G MCKENNA, LISA M
PI      MONTEGGIA,
PI      JEAN MARC ROCH, JAMES P SULLIVAN, EDWARD TOURNA
PC      C12N15/09, C07K14/705, C12N1/15, C12N1/19, C12N1/21, C12N5/10 PC
PC      C12Q1/02, C12Q1/68,
PC      G01N33/15, G01N33/50, G01N33/566, C12N15/00, C12N5/00 CC
Strandedness: Single;
```

```
CC Topology: Linear;
FH Key Location/Qualifiers.
FEATURES
source      1. 20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      819 GGCACTTCGATGCGCTG 837
      ||||| ||||| |||||
Db      20 GGCAAGCTCCGATGCGCTG 2

RESULT 35
BD223195/c      21 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION      Human CCR-2 gene polymorphism.
ACCESSION      BD223195
VERSION      BD223195.1 GI:33032965
KEYWORDS      JP 2002521063-A/8.
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
      Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS      Smith, J.C., Anand, R. and Morten, J.E.N.
TITLE      Human CCR-2 gene polymorphism
JOURNAL      Patent: JP 2002521063-A 8 16-JUL-2002;
ASTRAZENECA AB
COMMENT
PN      Homo sapiens (human)
PS      JP 2002521063-A/8
PD      16-JUL-2002
PF      20-JUL-1999 JP 2000562551
PR      25-JUL-1998 GB 9816193.8, 28-JAN-1999 GB 9901844.2 PI
PI      JOHN CRAIG SMITH, RAKESH ANAND, JOHN EDWARD NORRIS, MORTEN PC
PC      C12N15/09, A61K45/00, C12Q1/68, A61P19/02, A61P29/00, C12N15/00 CC
Human CCR-2 gene polymorphism
FH Key Location/Qualifiers
FT source      1. 21
/organism="Homo sapiens (human)".

FEATURES
source
1. 21
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1208 GCTGTGCTCTACTCCAG 1226
      ||||| ||||| |||||
Db      20 GCTGTGCTCTGCTCCAG 2

RESULT 36
AR529846/c      21 bp      DNA      linear      PAT 08-OCT-2004
DEFINITION      Sequence 1049 from patent US 6727063.
ACCESSION      AR529846
VERSION      AR529846.1 GI:53918283
KEYWORDS
SOURCE
ORGANISM
REFERENCE      Unclasseified.
AUTHORS      1 (bases 1 to 21)
      Lander, E.S., Carilli, M., Ireland, J.S., Bolk, S., Daley, G.O. and
      McCarthy, J.J.
TITLE      Single nucleotide polymorphisms in genes
```

JOURNAL Patent: US 6727063-A 1049 27-APR-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765
1 GTAACTTCAGTAAACAGGCCA 21

RESULT 37
ARS29850 21 bp DNA linear PAT 08-OCT-2004
LOCUS ARS29850
DEFINITION Sequence 1053 from patent US 6727063.
ACCESSION ARS29850
VERSION ARS29850.1 GI:53918287
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 1053 27-APR-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765
1 GTAACTTCAGTAAACAGGCCA 21

RESULT 38
AX095871 21 bp DNA linear PAT 30-MAR-2001
LOCUS AX095871
DEFINITION Sequence 1049 from Patent WO0118250.
ACCESSION AX095871
VERSION AX095871.1 GI:13512098
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 1049 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765

Db 1 GTAACTTCAGTAAACAGGCCA 21

RESULT 39
AX095875 21 bp DNA linear PAT 30-MAR-2001
LOCUS AX095875
DEFINITION Sequence 1053 from Patent WO0118250.
ACCESSION AX095875
VERSION AX095875.1 GI:13512102
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 1053 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765
1 GTAACTTCAGTAAACAGGCCA 21

RESULT 40
AX453141 21 bp DNA linear PAT 06-JUL-2002
LOCUS AX453141/c
DEFINITION Sequence 20 from Patent WO0242444.
ACCESSION AX453141
VERSION AX453141.1 GI:21712648
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Yoder,O., Turgeon,B.G. and Lu,S.W.
TITLE Fungal gene cluster associated with pathogenesis
JOURNAL Patent: WO 0242444-A 20 30-MAY-2002;
SYNGENTA PARTICIPATIONS AG (CH) ; CORNELL RESEARCH FOUNDATION, INC.
(US) ; Yoder, Olen (US) ; Turgeon, Barbara G. (US) ; Lu, Shen-wen
(US)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 510 ATATTTCGACGTGATTGCT 528
1 ATATTTCGACGTGATTGCT 2

RESULT 41
CO617281 17 bp DNA linear PAT 02-FEB-2004
LOCUS CO617281

DEFINITION Sequence 2021 from Patent WO0192524.
ACCESSION CQ617281
VERSION CQ617281.1 GI:41667499
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2021 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 731 CCTGGTGCTTCTGCA 747
Db 1 CCTGGTGCTTCTGCA 17

RESULT 42
LOCUS CQ618102 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2842 from Patent WO0192524.
ACCESSION CQ618102
VERSION CQ618102.1 GI:41668320
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2842 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1974 GGCCTCCAGATGAGCA 1990
Db 1 GGCCTCCAGATGAGCA 17

RESULT 43
LOCUS AR458344 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2021 from patent US 6686188.
ACCESSION AR458344
VERSION AR458344.1 GI:4263401
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
PATENT: US 6686188-A 2021 03-FEB-2004;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 731 CCTGGTGCTTCTGCA 747
Db 1 CCTGGTGCTTCTGCA 17

RESULT 44
LOCUS AR459165 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2842 from patent US 6686188.
ACCESSION AR459165
VERSION AR459165.1 GI:42694222
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
PATENT: US 6686188-A 2842 03-FEB-2004;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1974 GGCCTCCAGATGAGCA 1990
Db 1 GGCCTCCAGATGAGCA 17

RESULT 45
LOCUS AX423205 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1541 from Patent WO0188124.
ACCESSION AX423205
VERSION AX423205.1 GI:21526587
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Jarvis,T., von Carlwiltz,I., Mcswigen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1541 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1072 AGAATGAAGTCAAG 1088
| | | | | | | | | | | | | | | | | | | | | |
Db 1 AGAATGAAGTCAAG 17

RESULT 46
AX688559
LOCUS Sequence 1291 from Patent EP1281758. 17 bp DNA linear PAT 31-MAR-2003
DEFINITION AX688559
ACCESSION AX688559 GI:29411261
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C. T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 1291 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 841 TGAGGAGTACCTGATG 857
| | | | | | | | | | | | | | | | | | | | | |
Db 1 TGAGGAGTACCTGATG 17

RESULT 47
AX783426 17 bp DNA linear PAT 17-JUL-2003
LOCUS Sequence 1757 from Patent WO03050284.
DEFINITION AX783426
ACCESSION AX783426 GI:32951275
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1757 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 725 CATGGGCTGGGTGCTT 741
| | | | | | | | | | | | | | | | | | | | | |
Db 1 CCTGGGCTGGGTGCTT 17

RESULT 48
AX783428 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX783428

DEFINITION Sequence 1759 from Patent WO03050284.
ACCESSION AX783428
VERSION AX783428.1 GI:32951277
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1759 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 727 TGGGCTGGGTGCTTC 743
| | | | | | | | | | | | | | | | | | | | | |
Db 1 TGGGCTGGGTGCTTC 17

RESULT 49
AR474174 20 bp DNA linear PAT 20-FEB-2004
LOCUS AR474174
DEFINITION Sequence 2 from patent US 6689875.
ACCESSION AR474174
VERSION AR474174.1 GI:42712994
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE
AUTHORS Dierlamm, J., Baens, M. and Marijnen, P.
TITLE Molecular characterization of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis
JOURNAL Patent: US 6689875-A 2 10-FEB-2004;
Location/Qualifiers
1.20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 739 CCTTTCGCACTTCAGC 755
| | | | | | | | | | | | | | | | | | | | | |
Db 1 CCTTTCGCACTTCATC 17

RESULT 50
AX055866 20 bp DNA linear PAT 13-JAN-2001
LOCUS AX055866
DEFINITION Sequence 2 from Patent WO073500.
ACCESSION AX055866
VERSION AX055866.1 GI:12228973
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE
AUTHORS Baens, M., Marynen, P. and Dierlamm, J.
TITLE Molecular characterisation of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis
JOURNAL Patent: WO 0073500-A 2 07-DEC-2000;
Vlaams Internuiversitair Instituut voor Biotechnologie vzw. (BR)

FEATURES
source

Location/Qualifiers
1. 20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer MLT1"

Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 739 CCTTCTGCACTTCTCAGC 755
|||||
Db 1 CCTTCTGCACTTCTC 17

RESULT 51
LOCUS AR067195 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 543 from patent US 5851760.
ACCESSION AR067195
VERSION AR067195.1 GI:5998417
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Evans, G.A. and Smith, M.W.
TITLE Method for generation of sequence sampled maps of complex genomes
JOURNAL Patent: US 5851760-A 543 22-DEC-1998;
FEATURES Location/Qualifiers
1. 20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 499 TCCTCATGTACATATTCTGC 518
|||||
Db 20 TCCTCATGTACATATTCTGC 1

RESULT 52
LOCUS AR158930 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 552 from patent US 6251588.
ACCESSION AR158930
VERSION AR158930.1 GI:16221339
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Shannon, K.W., Wolber, P.K., Delenstarr, G.C., Webb, P.G. and Kincaid, R.H.
TITLE Method for evaluating oligonucleotide probe sequences
JOURNAL Patent: US 6251588-A 552 26-JUN-2001;
FEATURES Location/Qualifiers
1. 20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1543 TAAGAAGGAAAAAGTCAGTA 1562
|||||
Db 20 TAAAAAGGAAAAATCAGTA 1

RESULT 53
LOCUS AR158931 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 553 from patent US 6251588.
ACCESSION AR158931
VERSION AR158931.1 GI:16221341
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Shannon, K.W., Wolber, P.K., Delenstarr, G.C., Webb, P.G. and Kincaid, R.H.
TITLE Method for evaluating oligonucleotide probe sequences
JOURNAL Patent: US 6251588-A 553 26-JUN-2001;
FEATURES Location/Qualifiers
1. 20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1542 TTAAGAAGGAAAAAGTCAGT 1561
|||||
Db 20 TTAAGAAGGAAAAATCAGT 1

RESULT 54
LOCUS AR163820 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 18 from patent US 6271030.
ACCESSION AR163820
VERSION AR163820.1 GI:16234587
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Montla, B.P., Butler, M.M. and Wyatt, J.
TITLE Antisense inhibition of C/EBP beta expression
JOURNAL Patent: US 6271030-A 18 07-AUG-2001;
FEATURES Location/Qualifiers
1. 20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 21 CGGCTGCCCGCTCTGCTGGG 40
|||||
Db 1 CTGCTGCCCGCGCTGCCGCG 20

RESULT 55
LOCUS BD225099 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Antisense modulation of expression of tumor necrosis factor receptor-associated factor (TRAF).
ACCESSION BD225099
VERSION BD225099.1 GI:33034869
KEYWORDS JP 2002526095-A/234.
SOURCE synthetic construct
ORGANISM other sequences: artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Baker, B.F., Cowart, L.M., Montla, B.P. and Xu, X.S.
TITLE Antisense modulation of expression of tumor necrosis factor receptor-associated factor (TRAF)
JOURNAL Patent: JP 2002526095-A 234 20-AUG-2002;

COMMENT
ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002526095-A/234
PD 20-AUG-2002

PF 05-OCT-1999 JP 2000574546
PF 06-OCT-1998 US 09/167109
PI BRENDIA F BAKER, LEX M COMSERT, BRETT P MONIA, XIAOXING S XU PC
C12N15/09, A61K31/7105, A61K48/00, A61P29/00, A61P35/04, C12N15/00 CC
antisense sequence

FT Key Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
1..20
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

FEATURES
source

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 436 AGTCATCTCATGCTCCG 455
Db 1 AGGCCATCTCAGGCTTCAG 20

RESULT 56
BD235616

LOCUS BD235616 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Gene.
ACCESSION BD235616.1 GI:33045386
VERSION JP 2002522073-A/17.

KEYWORDS JP 2002522073-A/17.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1 (bases 1 to 20)
Robinson, I.C.A.F., Stoye, J.P., Flavell, D., Wells, S.E. and
Tiesler, P.L.

REFERENCE
AUTHORS
TITLE
JOURNAL
Gene
Patent: JP 2002522073-A 17 23-JUL-2002;
MEDICAL RESEARCH COUNCIL
OS Artificial Sequence
PN JP 2002522073-A/17
PD 23-JUL-2002
PF 12-AUG-1999 JP 2000565123
PR 12-AUG-1998 GB 9817566.4, 06-MAY-1999 GB 9910522.3 PI
IAIN CLIVE ANDREW FRANKLIN ROBINSON, JONATHAN PAUL STOYE, DAVID PI
FLAVELL,
PI SARA ELIZABETH WELLS, PAUL LE TISSIER
PC C12N15/09, A01K67/027, C07K14/47, C12N1/15, C12N1/19, C12N1/21, PC
C12N5/10.
PC C12P21/02, C12Q1/68, G01N33/15, G01N33/50, C12N15/00, C12N5/00 CC
Gene
FH Key Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
1..20
Location/Qualifiers
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

COMMENT

FEATURES
source

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 358 GATCAGACATCTCTCCGCC 377
Db 1 GAATCAGACATCTCTCCGCC 20

RESULT 57

LOCUS CQ764765 20 bp DNA linear PAT 03-MAR-2004
CQ764765
Sequence 3383 from Patent WO2004003201.
CQ764765
CQ764765.1 GI:44908001

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
JOURNAL
Kane, C.D.
Antisense modulation of lph1 expression
Patent: WO 2004003201-A 3383 08-JAN-2004;
Pharmacia Corporation (US)
Location/Qualifiers
1..20
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/note='Human LRH1 antisense'

FEATURES
source

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2378 CAGACTTTGCTATGCTT 2397
Db 1 CAGACTTTGCTATGACTT 20

RESULT 58
CQ786675

LOCUS CQ786675 20 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 8 from Patent WO2004020469.
ACCESSION CQ786675
VERSION CQ786675.1 GI:45721691
KEYWORDS

SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
JOURNAL
Campocharro, P.A. and Kaleko, M.
Ocular gene therapy
Patent: WO 2004020469-A 8 11-MAR-2004;
Novartis AG (CH); Novartis Pharma GmbH (AT)
Location/Qualifiers
1..20
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/note='PCR Primer'

FEATURES
source

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 518 CACTGATTGCTGCTATCG 537
Db 1 CACTGCTTACTGCTTATCG 20

RESULT 59
CQ798040
LOCUS CQ798040 20 bp DNA linear PAT 20-APR-2004
DEFINITION Sequence 8 from Patent WO2004028635.
ACCESSION CQ798040
VERSION CQ798040.1 GI:46426492
KEYWORDS

SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

AUTHORS Campochiaro, P.A. and Kaleko, M.
 TITLE Ocular gene therapy
 JOURNAL Patent: WO 2004028635-A 8 08-APR-2004;
 Novartis AG (CH); Novartis Pharma GmbH (AT)
 FEATURES
 source
 1. .20
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="PCR Primer"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 40;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 518 CACTGATTCCTGGCTCATCG 537
 Db 1 CACTGCTACTGCGCTTATCG 20

RESULT 60
 LOCUS I31301 20 bp DNA linear PAT 06-FEB-1997
 DEFINITION Sequence 213 from patent US 5582979.
 ACCESSION I31301
 VERSION I31301.1 GI:1822092
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 1 (bases 1 to 20)

REFERENCE
 AUTHORS Weber, J.L.
 TITLE Length polymorphisms in (dc-da).sub.n.(dc-dt).sub.n sequences and method of using the same
 Patent: US 5582979-A 213 10-DEC-1996;
 JOURNAL Location/Qualifiers
 FEATURES
 source
 1. .20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 40;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 660 CTGCTGAAGACACACACT 679
 Db 1 CTGCTGAATTCAACACACT 20

RESULT 61
 LOCUS AR199798 20 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 59 from patent US 6355482.
 ACCESSION AR199798
 VERSION AR199798.1 GI:20249872
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 1 (bases 1 to 20)

REFERENCE
 AUTHORS Bennett, C. Frank, and Freiler, S.M.
 TITLE Antisense inhibition of integrin beta 4 binding protein expression
 JOURNAL Patent: US 6355482-A 59 12-MAR-2002;
 FEATURES
 source
 1. .20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 40;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1633 TCAGCTAACCTCTCTTCTTC 1652

Db 20 TGAGCTGCTCTCTTCTTC 1

RESULT 62
 LOCUS AR203182 20 bp DNA linear PAT 20-JUN-2002
 DEFINITION Sequence 101 from patent US 6365354.
 ACCESSION AR203182
 VERSION AR203182.1 GI:21499505
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 1 (bases 1 to 20)

REFERENCE
 AUTHORS Bennett, C. Frank, and Wyatt, J.
 TITLE Antisense modulation of tybospholipase I expression
 Patent: US 6365354-A 101 02-APR-2002;
 JOURNAL Location/Qualifiers
 FEATURES
 source
 1. .20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 40;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4 CCGGAGCCGACGCCGCCGCG 23
 Db 20 CCGGAGGCCACGCCGCCGCG 1

RESULT 63
 LOCUS AR216033 20 bp DNA linear PAT 25-SEP-2002
 DEFINITION Sequence 80 from patent US 6410518.
 ACCESSION AR216033
 VERSION AR216033.1 GI:23314321
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 1 (bases 1 to 20)

REFERENCE
 AUTHORS Monia, B.P.
 TITLE Antisense oligonucleotide inhibition of raf gene expression
 JOURNAL Patent: US 6410518-A 80 25-JUN-2002;
 FEATURES
 source
 1. .20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 40;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1873 CCGTTGCTGAGGACAGTAG 1892
 Db 20 CAGTGCTGTGAGGACAGAG 1

RESULT 64
 LOCUS AR312819 20 bp DNA linear PAT 12-JUN-2003
 DEFINITION Sequence 3356 from patent US 6559294.
 ACCESSION AR312819
 VERSION AR312819.1 GI:31706245
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 1 (bases 1 to 20)

REFERENCE
 AUTHORS Griffiths, R., Holseth, S.K., Zagureky, R.J., Metcalf, B.J., Peek, J.A., Sankaran, B. and Fletcher, L.D.

TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559234-A 3356 06-MAY-2003;
FEATURES location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 386 CCTCTCTCTGTCACCTGCG 405
Db 1 CCTCTCTCTATCACGTTGC 20

RESULT 65
AX084397 20 bp DNA linear PAT 28-FEB-2001
LOCUS AX084397
DEFINITION Sequence 3 from Patent WO0112830.
ACCESSION AX084397
VERSION AX084397.1 GI:13185848
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Hallenbeck, P.L. and Chen, C.T.
TITLE Adenoviral vectors including dna sequences encoding angiogenic inhibitors
JOURNAL Patent: WO 0112830-A 3 22-FEB-2001;
FEATURES location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 518 CACTGATTGCTGGCTCATCG 537
Db 1 CACTGCTTACTGCTTATCG 20

RESULT 66
AX148978/c 20 bp DNA linear PAT 08-JUN-2001
LOCUS AX148978
DEFINITION Sequence 180 from Patent WO0136625.
ACCESSION AX148978
VERSION AX148978.1 GI:14347502
KEYWORDS
SOURCE
ORGANISM synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Wright, J.A., Young, A.H. and Dugourd, D.
TITLE Antisense oligonucleotide sequences derived from groel and groes as inhibitors of microorganisms
JOURNAL Patent: WO 0136625-A 180 25-MAY-2001;
FEATURES GeneSense Technologies Inc. (CA)
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense oligonucleotide"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1548 AGGAAAAGTCAATTTC 1567
Db 20 AGGAGAAAAGTAAGTATGCA 1

RESULT 67
AX204801/c 20 bp DNA linear PAT 30-AUG-2001
LOCUS AX204801
DEFINITION Sequence 20 from Patent WO0153345.
ACCESSION AX204801
VERSION AX204801.1 GI:15394138
KEYWORDS
SOURCE
ORGANISM synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Harper, S.J.
TITLE Vegf148 isoform, a truncated splice variant of vegf. Vegf heterodimers and therapeutical uses thereof
JOURNAL Patent: WO 0153345-A 20 26-JUL-2001;
FEATURES North Bristol NHS Trust (GB)
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="DNA probe"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1121 ATGGGTCGAGAGAGTTCC 1140
Db 20 ATGGACCCAGATGAATTCC 1

RESULT 68
AX253270 20 bp DNA linear PAT 10-OCT-2001
LOCUS AX253270
DEFINITION Sequence 13 from Patent WO0168907.
ACCESSION AX253270
VERSION AX253270.1 GI:16073816
KEYWORDS
SOURCE
ORGANISM synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Doehmer, J., Krebsfeagner, N., Eichelbaum, M. and Zanger, U.M.
TITLE Stable expression of polymorphous forms of human cytochrome p450 2d6 as an analytic in the pre-clinical development of medicaments
JOURNAL Patent: WO 0168907-A 13 20-SEP-2001;
FEATURES DOEHMER, Johannes (DE)
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz: oligonukleotid"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 518 CACTGATTGCTGGCTCATCG 537
Db 1 CACTGCTTACTGCTTATCG 20

RESULT 69
AX298825/c

LOCUS AX298825 20 bp DNA linear PAT 26-NOV-2001
DEFINITION Sequence 459 from Patent WO0183749.
ACCESSION AX298825
VERSION AX298825.1 GI:17128815
KEYWORDS
SOURCE Mus sp.
ORGANISM Mus sp.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
Li,X., Ohnen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
TITLE Gene and sequence variation associated with sensing carbohydrate
compounds and other sweeteners
JOURNAL Patent: WO 0183749-A 459 08-NOV-2001;
WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
(US)
FEATURES
source location/Qualifiers
1..20
/organism="Mus sp."
/mol_type="unassigned DNA"
/db_xref="taxon:10095"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1991 TGGGGCTGCAATGACACC 2010
Db 20 TGGAGTGCATGATATACC 1
RESULT 70
LOCUS AX463759 20 bp DNA linear PAT 15-JUL-2002
DEFINITION Sequence 22 from Patent WO0250111.
ACCESSION AX463759
VERSION AX463759.1 GI:21886509
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Doi,M., Thyboll,J. and Trygsvason,K.
TITLE Isolated laminin 10
JOURNAL Patent: WO 0250111-A 22 27-JUN-2002;
BIOTRATUM INC (US)
FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer Baxr"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 450 CTCGAGTGGCTCTCTCTT 469
Db 20 CCCGAGTGGATCTCTCTT 1
RESULT 71
LOCUS AX925251 20 bp DNA linear PAT 19-DEC-2003
DEFINITION Sequence 8 from Patent WO02067971.
ACCESSION AX925251
VERSION AX925251.1 GI:40243420
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS
TITLE
JOURNAL
FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:10095"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 518 CACTGATTGCTGCTATCG 537
Db 1 CACTGCTTACTGCTATCG 20
RESULT 72
LOCUS BD012251 20 bp DNA linear PAT 02-AUG-2002
DEFINITION A novel gene encoding a serine protease-like protein.
ACCESSION BD012251
VERSION BD012251.1 GI:22092440
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS
TITLE
JOURNAL
COMMENT
PN MO 0109349-A/18
PD 08-FEB-2001
PF 28-JUL-2000 WO 2000JP005062
PR 29-JUL-1999 JP 99P 248036,27-AUG-1999 JP 99P 300253 PR
11-JAN-2000 JP 00P 118776,02-MAY-2000 JP 00P 183767 PR
18-OCT-1999 US 60/159590,17-FEB-2000 US 60/183322 PI
OTA, TAKAO ISOGAI, TETSUO NISHIKAWA, KOJI HAYASHI, PI
KASHIMA
PI JUNICHI YAMAMOTO, SHIZUKO ISHII, TOMOYASU SUGIYAMA, AI WAKAMATSU,
KOJI HAYASHI, KAOJI SATO, JUNICHI YAMAMOTO, SHIZUKO ISHII, OKOYASU
SUGIYAMA, AI WAKAMATSU, KEIICHI NAGAI, TETSUJI OTSUKI, KAZUHIRO YANO,
KOJI MURAKAMI, KOJI KANZAKI, YOSHIIISA INOUE, EMI HASHIMOTO, AKIKO
KASHIMA
PI YOSHIIISA INOUE, EMI HASHIMOTO, AKIKO KASHIMA
PC C12N15/57, C12N9/64, C12N15/63, C12N5/06, C07K16/40, C12Q1/68, PC
G01N33/573,
PC A61K38/48, A61K31/7052, A61K48/00/ C12P21/08, C12N9/64, C12R1/91)
CC Description of Artificial Sequence: an artificially
synthesized primer
CC G01N33/573,
CC sequence
CC key
FEATURES
source location/Qualifiers
1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 518 CACTGATTGCTGCTATCG 537

REFERENCE 1
AUTHORS Brazzall,R.K., Campocharo,P.A. and Dixon,K.H.
TITLE Use of endostatin in the treatment of ocular neovascularization
JOURNAL Patent: WO 02067971-A 8 06-SEP-2002;
Novartis AG (CH)
FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 518 CACTGATTGCTGCTATCG 537
Db 1 CACTGCTTACTGCTATCG 20
RESULT 72
LOCUS BD012251 20 bp DNA linear PAT 02-AUG-2002
DEFINITION A novel gene encoding a serine protease-like protein.
ACCESSION BD012251
VERSION BD012251.1 GI:22092440
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS
TITLE
JOURNAL
COMMENT
PN MO 0109349-A/18
PD 08-FEB-2001
PF 28-JUL-2000 WO 2000JP005062
PR 29-JUL-1999 JP 99P 248036,27-AUG-1999 JP 99P 300253 PR
11-JAN-2000 JP 00P 118776,02-MAY-2000 JP 00P 183767 PR
18-OCT-1999 US 60/159590,17-FEB-2000 US 60/183322 PI
OTA, TAKAO ISOGAI, TETSUO NISHIKAWA, KOJI HAYASHI, PI
KASHIMA
PI JUNICHI YAMAMOTO, SHIZUKO ISHII, TOMOYASU SUGIYAMA, AI WAKAMATSU,
KOJI HAYASHI, KAOJI SATO, JUNICHI YAMAMOTO, SHIZUKO ISHII, OKOYASU
SUGIYAMA, AI WAKAMATSU, KEIICHI NAGAI, TETSUJI OTSUKI, KAZUHIRO YANO,
KOJI MURAKAMI, KOJI KANZAKI, YOSHIIISA INOUE, EMI HASHIMOTO, AKIKO
KASHIMA
PI YOSHIIISA INOUE, EMI HASHIMOTO, AKIKO KASHIMA
PC C12N15/57, C12N9/64, C12N15/63, C12N5/06, C07K16/40, C12Q1/68, PC
G01N33/573,
PC A61K38/48, A61K31/7052, A61K48/00/ C12P21/08, C12N9/64, C12R1/91)
CC Description of Artificial Sequence: an artificially
synthesized primer
CC G01N33/573,
CC sequence
CC key
FEATURES
source location/Qualifiers
1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 518 CACTGATTGCTGCTATCG 537

```

Db      1  CACTGCTACTGGCTATCG 20

RESULT 73
LOCUS   ARI95688
DEFINITION Sequence 153 from patent US 6350934.
ACCESSION ARI95688
VERSION  ARI95688.1 GI:20245125
KEYWORDS
SOURCE  Unknown.
ORGANISM
REFERENCE
AUTHORS Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
TITLE    Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
JOURNAL  Nucleic acid encoding delta-9 desaturase
FEATURES
source   1..17
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match      0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      778 AGAAGTTCGCCAGCA 792
Db      3 AGAAGTTCGCCAGCA 17

RESULT 74
LOCUS   ARI95690
DEFINITION Sequence 155 from patent US 6350934.
ACCESSION ARI95690
VERSION  ARI95690.1 GI:20245127
KEYWORDS
SOURCE  Unknown.
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 17)
TITLE    Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
JOURNAL  Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
FEATURES  Nucleic acid encoding delta-9 desaturase
          Patent: US 6350934-A 155 26-FEB-2002;
          Location/Qualifiers
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      778 AGAAGTTCGCCAGCA 792
Db      2 AGAAGTTCGCCAGCA 16

RESULT 75
LOCUS   AX783427
DEFINITION Sequence 1758 from Patent WO03050284.
ACCESSION AX783427
VERSION  AX783427.1 GI:32951276
KEYWORDS
SOURCE  Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Cranialta; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

```

```

REFERENCE
AUTHORS 1
TITLE    Guo,J.
JOURNAL  Human prostate cancer candidate protein 1
          Patent: WO 03050284-A 1758 19-JUN-2003;
          Amersham Biosciences (SV) Corp. (US)
FEATURES
source   1..17
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match      0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      727 TGGGCTGGGTGCTCT 741
Db      2 TGGGCTGGGTGCTCT 16

RESULT 76
LOCUS   BD235620
DEFINITION Gene.
ACCESSION BD235620
VERSION  BD235620.1 GI:33045390
KEYWORDS JP 2002522073-A/21.
SOURCE   synthetic construct
          other sequences; artificial sequences.
REFERENCE
AUTHORS 1 (bases 1 to 18)
          Robinson,I.C.A.F., Stoye,J.P., Flavell,D., Wells,S.E. and
          Tisler,P.L.
TITLE    Gene
JOURNAL  Patent: JP 2002522073-A 21 23-JUL-2002;
COMMENT  MEDICAL RESEARCH COUNCIL
          OS Artificial Sequence
          PN JP 2002522073-A/21
          PD 23-JUL-2002 JP 2000565123
          PF 12-AUG-1999 JP 9817566.4,06-MAY-1999 GB 9910522.3 PI
          PR 12-AUG-1998 GB 9817566.4,06-MAY-1999 GB 9910522.3 PI
          IAIN CLIVE ANDREW FRANKLIN ROBINSON,JONATHAN PAUL STOYE,DAVID PI
          FLAVELL,
          PI SARA ELIZABETH WELLS,PAUL LE TISSIER
          PC C12N15/09,A01K67/027,C07K14/47,C12N1/15,C12N1/19,C12N1/21, PC
          C12N5/10,
          C12N5/10,C12Q1/68,G01N33/15,G01N33/50,C12N15/00,C12N5/00 CC
          Gene
          FH Key Location/Qualifiers
          FT source 1..18
              /organism="Artificial Sequence".
          Location/Qualifiers
            1..18
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

FEATURES
source   1..18
          /organism="Artificial Sequence".
          Location/Qualifiers
            1..18
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

Query Match      0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      281 GGCCGAGGCTGACCGAG 298
Db      1 GGCCGAGGCTGACCGAG 18

RESULT 77
LOCUS   CQ771686/c
DEFINITION Sequence 113 from Patent WO2003100423.
ACCESSION CQ771686
VERSION  CQ771686.1 GI:45125676
KEYWORDS

```


SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1
AUTHORS Cuzin, M., Mandrand, B., Cleuziat, P. and Abaibou, H.
TITLE Better organised biochip
JOURNAL Patent: WO 2003/100423-A 113 04-DEC-2003;
Aptbio (FR)

FEATURES
source
1. .18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2052 GATGCCGCCACCATGAGC 2069
DB 18 GCTGCCCCACCATGAGC 1

RESULT 78
LOCUS CQ798833 18 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 12 from Patent WO2004031237.
ACCESSION CQ798833
VERSION CQ798833.1 GI:46847870
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
OTHER SEQUENCES; artificial sequences.

REFERENCE 1
AUTHORS Nakamura, Y. and Katagiri, T.
TITLE Genes and polypeptides relating to human myeloid leukemia
JOURNAL Patent: WO 2004031237-A 12 15-APR-2004;
Oncotherapy Science, Inc. (JP); Japan as represented by the
President of the university of Tokyo (JP)

FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Artificially synthesized S-oligonucleotides for
Antisense"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 668 GACACACACCTGCTGAC 685
DB 18 GACACACCTACCTGCAGAC 1

RESULT 79
LOCUS 114363 18 bp DNA linear PAT 26-SEP-1995
DEFINITION Sequence 5 from patent US 5449609.
ACCESSION 114363
VERSION 114363.1 GI:996854
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Younkin, D. P. and Pleasure, D.
TITLE Methode for screening for neurotoxicity using a clonal human
JOURNAL Patent: US 5449609-A 5 12-SEP-1995;
Location/Qualifiers

source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGCGAGACCGCAG 1010
DB 1 AACCTGCGAGACCGCAG 18

RESULT 80
LOCUS AR490327 18 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 1 from patent US 6713247.
ACCESSION AR490327
VERSION AR490327.1 GI:47257699
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Sah, D. W. Y., Gage, F. H. and Ray, J.
TITLE Human CNS cell lines and methods of use therefor
JOURNAL Patent: US 6713247-A 1 30-MAR-2004;
Location/Qualifiers

FEATURES
source
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGCGAGACCGCAG 1010
DB 1 AACCTGCGAGACCGCAG 18

RESULT 81
LOCUS BD104248 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104248
VERSION BD104248.1 GI:22649822
KEYWORDS WO 0192572-A/352.
SOURCE synthetic construct
ORGANISM synthetic construct
OTHER SEQUENCES; artificial sequences.

REFERENCE 1 (bases 1 to 18)
AUTHORS Inoko, H., Kagiya, T., Ichihara, T., Matsumura, Y., Moriya, S. and
Nishida, M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 352 06-DEC-2001;
NISHIDA INDUSTRIES INC., SYSTEM RESEARCH INC., HIDETOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA

COMMENT
OS Artificial Sequence
PN WO 0192572-A/352
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI
MATSUMURA,
PI SHOGO MORIYA, MICHIO NISHIDA
PC C1201/68, C12M1/00, C12N15/09, G01N31/53
CC Description of Artificial Sequence: capture
FH Key
FT source
1. .18
/organism="Artificial Sequence".
Location/Qualifiers

[illegible]

DEFINITION	Sequence 22 from patent US 6153189.
ACCESSION	AB119350
VERSION	AB119350.1
KEYWORDS	GI:14102049
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 19)
TITLE	Prestra,L.G., Shelton,D.L. and Ufer,R.
JOURNAL	Human TRK receptors and neurotrophic factor inhibitors
FEATURES	Patent: US 6153189-A 22-28-NOV-2000; Location/Qualifiers 1..19 /organism="unknown" /mol_type="unassigned DNA"
source	
Query Match	0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity	88.9%; Pred. No. 44;
Matches	16; Conservative 0; Mismatches 2; Indels 0; Gaps 0
Qy	2124 CTCAGCCTGAGCTGAG 2141
Db	19 CTCACCTTGAGCTGAGC 2
RESULT 85	
BD196861	19 bp DNA linear PAT 17-JUL-2002
LOCUS	BD196861
DEFINITION	Prostatic cancer gene.
ACCESSION	BD196861
VERSION	BD196861.1
KEYWORDS	GI:33006631
SOURCE	JP 2002516657-A/450.
ORGANISM	Homo sapiens (human)
REFERENCE	Homo sapiens
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL	1 (bases 1 to 19)
COMMENT	Cohen,D., Blumenfeld,M., Chumakov,I. and Bougueleret,L. Prostatic cancer gene Patent: JP 2002516657-A 450 11-JUN-2002; GENSET
OS	Homo sapiens (human)
PN	JP 2002516657-A/450
PD	11-JUN-2002
PF	22-DEC-1998 JP 2000525562
PR	22-DEC-1997 US 08/996306, 09-SEP-1998 US 60/099658 PI
DANIEL COHEN, MARIA BLUMENFELD, ILYA CHUMAKOV, LYDIE BOUGUELERET	PC
C12N15/09, C12N15/09, A01K67/027, C07K4/47, C07K46/18, C12N1/15, PC	
C12N1/19,	
PC C12N1/21, C12N5/10, C12N5/10, C12P21/08, C12Q1/68, G01N33/50 PC	
, C12N15/00, C12N5/00,	
PC C12N5/00, C12N15/00	
CC microsequencing oligo for 99-140-130.m1s1	
FH Key	Location/Qualifiers
FT primer bind	1..19.
FEATURES	Location/Qualifiers
source	1..19
Query Match	0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity	88.9%; Pred. No. 44;
Matches	16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy	424 AAAAGCAGCTACAGTCA 441
Db	2 AAAAGCAGCTACAGCCA 19
RESULT 86	
LOCUS	E051122 19 bp DNA linear PAT 29-SEP-1997
E051122/c	

DEFINITION Primer.
ACCESSION E05122
VERSION E05122.1 GI:2172315
KEYWORDS JP 1993184400-A/5.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Komata,M. and Ebata,T.
TITLE CHRONICALLY ACTIVE HEPATITIS B VIRUS AND METHOD FOR DETECTING THE
JOURNAL Patent: JP 1993184400-A 5 27-JUL-1993;
TSUMURA & CO
COMMENT
OS Artificial gene
OC Artificial sequence; Genes.
PN JP 1993184400-A/5
PD 27-JUL-1993
PF 17-JAN-1992 JP 1992025887
PI KOMATA MASAO, EBATA TOSHIKI
PC C12Q1/70, C12N7/00, C12Q1/68, G01N33/50//A61B10/00, A61K39/29, PC
C12N15/00.
PC C12N15/51;
CC strandedness: Single;
CC topology: Linear.
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1828 GACGAGTTCTCTGCCAA 1845
Db 18 GACGAGTTCTCTGCCAA 1

RESULT 87
E05126 19 bp DNA linear PAT 29-SEP-1997
LOCUS
DEFINITION Primer.
ACCESSION E05126
VERSION E05126.1 GI:2172319
KEYWORDS JP 1993184400-A/5.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Komata,M. and Ebata,T.
TITLE CHRONICALLY ACTIVE HEPATITIS B VIRUS AND METHOD FOR DETECTING THE
JOURNAL Patent: JP 1993184400-A 9 27-JUL-1993;
TSUMURA & CO
COMMENT
OS Artificial gene
OC Artificial sequence; Genes.
PN JP 1993184400-A/9
PD 27-JUL-1993
PF 17-JAN-1992 JP 1992025887
PI KOMATA MASAO, EBATA TOSHIKI
PC C12Q1/70, C12N7/00, C12Q1/68, G01N33/50//A61B10/00, A61K39/29, PC
C12N15/00.
PC C12N15/51;
CC strandedness: Single;
CC topology: Linear.
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1828 GACGAGTTCTCTGCCAA 1845
Db 2 GACGAGTTCTCTGCCAA 19

RESULT 88
AR493023/c 19 bp DNA linear PAT 15-MAY-2004
LOCUS
DEFINITION Sequence 55 from patent US 6720137.
ACCESSION AR493023
VERSION AR493023.1 GI:47264371
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Roder,M., Plaschke,J. and Ganai,M.
TITLE Microsatellite markers for plants of the species Triticum aestivum
JOURNAL and Tribe triticeae and the use of said markers
Patent: US 6720137-A 55 13-APR-2004;
Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCCCTTCTGCCACCC 1935
Db 18 ATCTCCCTTCTGCCACCC 1

RESULT 89
AX130953 19 bp DNA linear PAT 15-MAY-2001
LOCUS
DEFINITION Sequence 2171 from Patent WO0130362.
ACCESSION AX130953
VERSION AX130953.1 GI:14137258
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Robins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL diseases
Patent: WO 0130362-A 2171 03-MAY-2001;
IMMUSOL, INC. (US)
Location/Qualifiers
1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin B ribozyme binding site"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 877 TCAGCCGGGACACCAATAG 894
Db 18 TCAGCCGGGACACCAATAG 1

RESULT 90
AX304853 19 bp DNA linear PAT 11-DEC-2001
LOCUS
DEFINITION Sequence 8 from Patent EP1158001.
ACCESSION AX304853

```

VERSION      AX304853.1  GI:17644532
KEYWORDS     .
SOURCE       synthetic construct
ORGANISM     synthetic construct
REFERENCE    1 other sequences; artificial sequences.
AUTHORS      Kaul,S., Preherr,J. and Weidle,U.
TITLE        A nucleic acid which is upregulated in human tumor cells, a protein
JOURNAL      encoded thereby and a process for tumor diagnosis
              Patent: EP 1158001-A 8-28-NOV-2001;
              F. HOFFMANN-LA ROCHE AG (CH)
FEATURES     Location/Qualifiers
              1..19
              source
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="primer RTR-5"

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2395 CTTGAAATTAATGAAG 2412
        |||||||
        19 CTTGAAATGAATGAATG 2

RESULT 91
AX823814/c      19 bp      DNA      linear      PAT 11-DEC-2003
LOCUS           AX823814
DEFINITION      Sequence 4 from Patent WO03070269.
ACCESSION       AX823814
VERSION         AX823814.1  GI:39750134
KEYWORDS        .
SOURCE          synthetic construct
ORGANISM        synthetic construct
REFERENCE        other sequences; artificial sequences.
AUTHORS         1 Schraermeyer,U.
TITLE           Treatment for diseases of the eye, inner ear and central nervous
JOURNAL         system
                Patent: WO 03070269-A 4-28-AUG-2003;
                Schraermeyer, Ulrich (DE)
FEATURES        Location/Qualifiers
                1..19
                source
                  /organism="synthetic construct"
                  /mol_type="unassigned DNA"
                  /db_xref="taxon:32630"
                  /note="primer"

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1273 AGCACCCAGCCAGCAAG 1290
        |||||||
        19 ACCACCCAGCCAGCAAG 2

Db

```

Search completed: August 8, 2005, 09:54:52
 Job time : 3 secs


```
107 13.8 0.6 18 1 US-09-422-978-5061 Sequence 5061, Ap
108 13.8 0.6 18 1 US-09-422-978-11430 Sequence 11430, A
109 13.8 0.6 18 1 US-09-371-772B-3984 Sequence 3984, Ap
C 110 13.8 0.6 18 1 US-09-354-736A-117 Sequence 117, Appl
C 111 13.8 0.6 18 1 US-09-155-885A-247 Sequence 247, Appl
112 13.8 0.6 18 1 US-10-071-411A-22 Sequence 22, Appl
113 13.8 0.6 18 1 US-09-685-664B-3984 Sequence 3984, A
C 114 13.8 0.6 18 1 PCT-US93-12603-11 Sequence 11, Appl
115 13.4 0.6 15 1 US-08-363-240A-622 Sequence 622, App
C 116 13.4 0.6 15 1 US-08-585-684B-91 Sequence 91, Appl
C 117 13.4 0.6 15 1 US-09-038-073-91 Sequence 91, Appl
C 118 13.4 0.6 17 1 US-08-233-608-25 Sequence 25, Appl
C 119 13.4 0.6 17 1 US-08-887-480-25 Sequence 25, Appl
C 120 13.4 0.6 17 1 US-08-722-187-25 Sequence 25, Appl
C 121 13.4 0.6 17 1 US-08-985-162-53 Sequence 53, Appl
122 13.4 0.6 17 1 US-08-985-162-326 Sequence 326, App
123 13.4 0.6 17 1 US-09-474-432B-487 Sequence 487, App
124 13.4 0.6 17 1 US-09-474-432B-691 Sequence 487, App
125 13.4 0.6 17 1 US-09-371-772B-4986 Sequence 4986, Ap
126 13.4 0.6 17 1 US-09-371-772B-4987 Sequence 4987, Ap
127 13.4 0.6 17 1 US-09-476-387-486 Sequence 486, App
128 13.4 0.6 17 1 US-09-476-387-690 Sequence 690, App
C 129 13.4 0.6 17 1 US-09-401-063-53 Sequence 53, Appl
C 130 13.4 0.6 17 1 US-09-401-063-326 Sequence 326, App
C 131 13.4 0.6 17 1 US-09-866-108A-797 Sequence 797, App
C 132 13.4 0.6 17 1 US-09-866-108A-800 Sequence 800, App
133 13.4 0.6 17 1 US-09-866-108A-1293 Sequence 1293, Ap
134 13.4 0.6 17 1 US-09-866-108A-1296 Sequence 1296, Ap
135 13.4 0.6 17 1 US-09-866-108A-2823 Sequence 2823, Ap
136 13.4 0.6 17 1 US-09-866-108A-2840 Sequence 2840, Ap
137 13.4 0.6 17 1 US-09-866-108A-2844 Sequence 2844, Ap
138 13.4 0.6 17 1 US-09-866-108A-6040 Sequence 6040, Ap
139 13.4 0.6 17 1 US-09-866-108A-6041 Sequence 6041, Ap
140 13.4 0.6 17 1 US-09-866-108A-6042 Sequence 6042, Ap
C 141 13.4 0.6 17 1 US-09-866-108A-6607 Sequence 6607, Ap
C 142 13.4 0.6 17 1 US-09-866-108A-6610 Sequence 6610, Ap
143 13.4 0.6 17 1 US-09-866-108A-10512 Sequence 10512, A
144 13.4 0.6 17 1 US-09-866-108A-10513 Sequence 10513, A
145 13.4 0.6 17 1 US-09-866-108A-10514 Sequence 10514, A
C 146 13.4 0.6 17 1 US-09-404-912-151 Sequence 151, App
C 147 13.4 0.6 17 1 PCT-US95-04712-25 Sequence 25, Appl
```

ALIGNMENTS

```
RESULT 1
US-09-396-196G-52073/C
; Sequence 52073, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittlemann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52073
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-52073
```

```
Query Match 0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 7.1;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1311 ATGTACATGAGCGCCCTGTGAG 1334
|||||
Db 25 ATGTACTTGAGAGACCTGTGTAG 2
```

```
RESULT 2
US-09-587-945-20/C
; Sequence 20, Application US/09587945
; Patent No. 6709860
; GENERAL INFORMATION:
; APPLICANT: Enerback, Sven
; APPLICANT: Carlsson, Peter
; TITLE OF INVENTION: Animal Model
; FILE REFERENCE: 10806-117A
; CURRENT APPLICATION NUMBER: US/09/587,945
; CURRENT FILING DATE: 2000-06-06
; PRIOR APPLICATION NUMBER: US 60/190,692
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/085,380
; PRIOR FILING DATE: 1998-05-26
; PRIOR APPLICATION NUMBER: SE 9701963-2
; PRIOR FILING DATE: 1997-05-26
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 3' primer
US-09-587-945-20
```

```
Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 16;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 239 CCTCATGCGCGCTACTCCGCG 260
|||||
Db 22 CCTATTGGCGGCTACTCAGG 1
```

```
RESULT 3
US-09-422-978-11680
; Sequence 11680, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSRT 0200C1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11680
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-22404 for SEQ 3815, in complem
US-09-422-978-11680
```

```
Query Match 0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

OY 1643 TCTCTCTCCCTCTCT 1659
DB 1 TCTCTCTCTCTCTCT 17

RESULT 4

US-09-733-294A-40/c
Sequence 40, Application US/09733294A
Patent No. 6492171
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: William Gaarde
APPLICANT: Susan M. Preler
APPLICANT: Edward V. Manciewicz
TITLE OF INVENTION: ANTISENSE MODULATION OF TEXT EXPRESSION
FILE REFERENCE: ISPH-0527
CURRENT APPLICATION NUMBER: US/09/733,294A
CURRENT FILING DATE: 2000-12-07
PRIOR APPLICATION NUMBER: 09/572,423
PRIOR FILING DATE: 2000-05-16
NUMBER OF SEQ ID NOS: 108
SEQ ID NO 40
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-733-294A-40

Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 17;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 139 GCGGAGCCCTGCGCCCG 158
DB 20 GTGGAGCCCTGCGCCCG 1

RESULT 5

US-08-482-918-16
Sequence 16, Application US/08482918
Patent No. 6207417
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
APPLICANT: Bosseiman, Robert A.
APPLICANT: Suggs, Sidney V.
APPLICANT: Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,918
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/33005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448

TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-482-918-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2402 ATAAATGAAGTGAATCC 2421
DB 2 ATAAATGAAGTGAATCC 21

RESULT 6

US-09-224-681-16
Sequence 16, Application US/09224681
Patent No. 6207454
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
APPLICANT: Bosseiman, Robert A.
APPLICANT: Suggs, Sidney V.
APPLICANT: Martin, Francis H.
TITLE OF INVENTION: Method for Enhancing the Efficiency of Gene
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/224,681
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/005,893
FILING DATE: 12-JAN-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/449,653
FILING DATE: 24-MAY-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/589,701
FILING DATE: 01-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107

REFERENCE/DOCKET NUMBER: 01017/35199
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX:
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-224-681-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATAAATGCAAGTGAATCC 2421
DB 2 ATAAATGCAAGTGAATCC 21

RESULT 7
US-08-336-728A-16
Sequence 16, Application US/08336728A
Patent No. 6207802
GENERAL INFORMATION:
APPLICANT: Zeebo, Krisztina M.
Bosselman, Robert A.
Suggs, Sidney V.
APPLICANT: Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSER: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/336,728A
FILING DATE: 09-NOV-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/589,701
FILING DATE: 01-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/32956
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856

INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-336-728A-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATAAATGCAAGTGAATCC 2421
DB 2 ATAAATGCAAGTGAATCC 21

RESULT 8
US-09-635-251-16
Sequence 16, Application US/09635251
Patent No. 6759215
GENERAL INFORMATION:
APPLICANT: Zeebo, Krisztina M.
Bosselman, Robert A.
Suggs, Sidney V.
Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSER: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/635,251
FILING DATE: 07-AUG-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/449,182
FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 04-OCT-1991
APPLICATION NUMBER: 07/589,701
FILING DATE: 01-OCT-1990
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/32957A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-635-251-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATAAATGAAAGTGAGATCC 2421
DB 2 ATAAATGCAAGTGATATCC 21

RESULT 9
US-09-056-226-17
Sequence 17, Application US/09056226B
Patent No. 6177614
GENERAL INFORMATION:
APPLICANT: Colasanti, Joseph J.
APPLICANT: Sundaresan, Venkatesan
TITLE OF INVENTION: Control of Floral Induction in Plants
FILE REFERENCE: CSHL94-04A4
CURRENT APPLICATION NUMBER: US/09/056,226B
CURRENT FILING DATE: 1998-04-07
EARLIER APPLICATION NUMBER: US 09/000,640
EARLIER FILING DATE: 1997-12-30
EARLIER APPLICATION NUMBER: US 08/804,104
EARLIER FILING DATE: 1997-02-20
EARLIER APPLICATION NUMBER: PCT/US96/03466
EARLIER FILING DATE: 1996-03-15
EARLIER APPLICATION NUMBER: US 08/406,186
EARLIER FILING DATE: 1995-03-16
NUMBER OF SEQ ID NOS: 20
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 17
LENGTH: 22
TYPE: DNA
ORGANISM: Zea mays
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(16)
OTHER INFORMATION: 'N' at position 16 represents an insertion of 3
OTHER INFORMATION: nucleotides, producing a mutation.
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(22)
OTHER INFORMATION: n = A,T,C or G
US-09-056-226-17

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 85.7%; Pred. No. 19;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 364 GCATCTCTCGCCCTCCAGG 384
DB 2 GCATCTCTCTCCCTCCAGG 22

RESULT 10
US-09-467-082-10/c
Sequence 10, Application US/09467082
GENERAL INFORMATION:
APPLICANT: Brett P. Monti
APPLICANT: Lex M. Cowseart
TITLE OF INVENTION: ANTISENSE MODULATION OF PKA CATALYTIC SUBUNIT C-ALPHA EXPRESSION
FILE REFERENCE: RTS-0088
CURRENT APPLICATION NUMBER: US/09/467,082
CURRENT FILING DATE: 1999-12-17
NUMBER OF SEQ ID NOS: 49

SEQ ID NO 10
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-467-082-10

Query Match 0.7%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 68 CTGGCCCGCCGCGCAGC 85
DB 20 CGGCGCCGCGCGCAGC 3

RESULT 11
US-09-288-339-39
Sequence 39, Application US/09288339
Patent No. 6436399
GENERAL INFORMATION:
APPLICANT: Rikihisa, Yasuko
APPLICANT: Zhi, Ning
TITLE OF INVENTION: Nucleic Acid Encoding the Major Outer Membrane Protein of
TITLE OF INVENTION: The Causative Agent of Human Granulocytic Ehrlichiosis
TITLE OF INVENTION: and Peptides Encoded Thereby
FILE REFERENCE:
CURRENT APPLICATION NUMBER: US/09/288,339
CURRENT FILING DATE: 1999-04-08
NUMBER OF SEQ ID NOS: 44
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 39
LENGTH: 21
TYPE: DNA
ORGANISM: Primer pnf12
US-09-288-339-39

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 563 GTTGACTGGAACACACC 580
DB 4 GTTGACTGGAACACTCC 21

RESULT 12
US-08-791-883-5
Sequence 5, Application US/08791883
Patent No. 5879890
GENERAL INFORMATION:
APPLICANT: LAKEN, STEVE
APPLICANT: GRUBER, STEPHEN
APPLICANT: PETERS, GIORIA
APPLICANT: KINZLER, KENNETH
APPLICANT: VOGELSTEIN, BERT
TITLE OF INVENTION: APC MUTATION ASSOCIATED WITH
TITLE OF INVENTION: FAMILIAL COLORECTAL CANCER IN ASHKENAZI JEWS
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: 1001 G Street, N.W.
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20001
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0

```

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/791,883
FILING DATE: 31-JAN-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A
REGISTRATION NUMBER: 32,145
REFERENCE/DOCKET NUMBER: 01107.03734
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299
TELEX: 97430 BMB UT
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-791-883-5

```

```

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1040 AGCTGACCTGGTCCCATC 1058
DB      1 AGCTGACCTAGTTCATC 19

```

```

RESULT 13
US-09-023-673-5
Sequence 5, Application US/09023673
Patent No. 6033461
GENERAL INFORMATION:
APPLICANT: LAKEN, STEVE
APPLICANT: GRUBER, STEPHEN
APPLICANT: PETERSEN, GLORIA
APPLICANT: KINZLER, KENNETH
APPLICANT: VOGELSTEIN, BERT
TITLE OF INVENTION: APC MUTATION ASSOCIATED WITH
TITLE OF INVENTION: FAMILIAL COLORECTAL CANCER IN ASHKENAZI JEWS
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSER: Banner & Witcoff, Ltd.
STREET: 1001 G Street, N.W.
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20001
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/023,673
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/791,883
FILING DATE: 31-JAN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A
REGISTRATION NUMBER: 32,145
REFERENCE/DOCKET NUMBER: 01107.03734
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299
TELEX: 97430 BMB UT
INFORMATION FOR SEQ ID NO: 5:

```

```

SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-023-673-5

```

```

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1040 AGCTGACCTGGTCCCATC 1058
DB      1 AGCTGACCTAGTTCATC 19

```

```

RESULT 14
US-09-375-318-80/c
Sequence 80, Application US/09375318
Patent No. 6468791
GENERAL INFORMATION:
APPLICANT: Tanzi, Rudolph E.
Schellenberg, Gerard D.
Masco, Wilma
Levy-Ishad, Ephrat
Bird, Thomas D.
Galas, David J.
TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO
ALZHEIMER'S DISEASE
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSER: SEED AND BERRY LLP
STREET: 701 Fifth Ave, Suite 6300
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/375,318
FILING DATE: 16-Aug-1999
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Verna, James M.
REGISTRATION NUMBER: 33,287
REFERENCE/DOCKET NUMBER: 920010.571C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4800
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 80:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 80:
US-09-375-318-80

```

```

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1842 CCAAGGAGAGAGAGAGAGAG 1860
DB      19 CCCAGGGGAGAGAGAGAGAG 1

```

```

RESULT 15
US-09-540-257B-22/c

```

```
; Sequence 22, Application US/09540257B
; Patent No. 6518012
; GENERAL INFORMATION:
; APPLICANT: Tomasi, Thomas
; TITLE OF INVENTION: Method for Regulating the Expression of MHC Antigens and
; FILE REFERENCE: CD40 by Inhibitors of Histone Deacetylation
; CURRENT APPLICATION NUMBER: US/09/540,257B
; PRIOR FILING DATE: 2000-03-31
; PRIOR FILING DATE: 1999-07-29; 1999-04-02
; NUMBER OF SEQ ID NOS: 26
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Forward primer for Mouse CD40
US-09-540-257B-22

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1999 GCAATGACACCTGACAGG 2017
Db      19  GCAGAGACACATGCGG 1

RESULT 16
US-09-344-001-19
; Sequence 19, Application US/09344001
; Patent No. 6054440
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF JUN N-TERMINAL KINASE KINASE-2 EXPRESSION
; FILE REFERENCE: RTS-0067
; CURRENT APPLICATION NUMBER: US/09/344,001
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-001-19

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2045 CAGGAGATGCCGCCACC 2063
Db      1  CAGGAGAGCGCCGCCATC 19

RESULT 17
US-09-344-001-20
; Sequence 20, Application US/09344001
; Patent No. 6054440
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF JUN N-TERMINAL KINASE KINASE-2 EXPRESSION
; FILE REFERENCE: RTS-0067
; CURRENT APPLICATION NUMBER: US/09/344,001
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-001-20

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2043 TCCAGGAGATGCCGCCA 2061
Db      1  TCCAGGAGAGCGCCGCCA 19

RESULT 18
US-08-771-737-8/c
; Sequence 8, Application US/08771737
; Patent No. 6323000
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murali
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Sullivan, James P.
; APPLICANT: Touma, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; FILE REFERENCE: 6017.US.01
; CURRENT APPLICATION NUMBER: US/08/771,737
; CURRENT FILING DATE: 1996-12-20
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-08-771-737-8

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      819 GCGAAGCTCCGATGCTG 837
Db      20  GCGAAGCTCCGATGCTG 2

RESULT 19
US-09-112-580-196
; Sequence 196, Application US/09112580
; Patent No. 6610539
; GENERAL INFORMATION:
; APPLICANT: Wright, Jim A.
; APPLICANT: Young, Aiping
; APPLICANT: DUGOURD, Dominique
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE SEQUENCES AS INHIBITORS OF
; FILE REFERENCE: 032396-016
; CURRENT APPLICATION NUMBER: US/09/112,580
; CURRENT FILING DATE: 1998-07-09
; EARLIER APPLICATION NUMBER: US 60/052,160
; EARLIER FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 265
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Escherichia coli
US-09-112-580-196

Query Match      0.7%; Score 15.8; DB 1; Length 20;
```

Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1345 AGCACAGACCAATTCGG 1363
Db 2 AGCACAGACCAATTCGG 20

RESULT 20

US-09-954-936-8/C
; Sequence 8, Application US/09954936
; Patent No. 6683157
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murali
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Sullivan, James P.
; APPLICANT: Touma, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USES THEREOF
; FILE REFERENCE: 6017, US, 01
; CURRENT APPLICATION NUMBER: US/09/954,936
; CURRENT FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: 08/771,737
; PRIOR FILING DATE: 1996-12-20
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-09-954-936-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 819 GGCACCTCCGAATGCTG 837
Db 20 GGCACCTCCGAATGCTG 2

RESULT 21

US-09-657-472-1049
; Sequence 1049, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolik, Stacey
; APPLICANT: Daley, George O.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825,1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1049
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-1049

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 28;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 745 GCACTTCAGACAGAGGCCA 765
Db 1 GTAACCTCAGTAACAGGCCA 21

RESULT 22

US-09-657-472-1053
; Sequence 1053, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolik, Stacey
; APPLICANT: Daley, George O.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825,1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1053
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-1053

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 28;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 745 GCACTTCAGACAGAGGCCA 765
Db 1 GTAACCTCAGTAACAGGCCA 21

RESULT 23

US-09-866-108A-2021
; Sequence 2021, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Shangang
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmeca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2021
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2021

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

731 CCTGGGTCCTCTGCA 747
1 CCTGGGTCCTCTGCA 17

RESULT 24
US-09-866-108A-2842
; Sequence 2842, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmeca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2842
; LENGTH: 17
; TYPE: DNA
```

```

; ORGANISM: Homo sapiens
US-09-866-108A-2842

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1974 GGCTCCAGATGAGCA 1990
1 GGCTCCAGATGAGCA 17

RESULT 25
US-09-433-699-12
; Sequence 12, Application US/09433699B
; Patent No. 6165786
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowart
; TITLE OF INVENTION: ANTISENSE MODULATION OF NUCLEOLIN EXPRESSION
; FILE REFERENCE: RTS-0109
; CURRENT APPLICATION NUMBER: US/09/433,699B
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-433-699-12

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1120 GATGGTCAGAGAAG 1136
2 GATGGTCAGAGAAG 18

RESULT 26
US-09-579-692B-2
; Sequence 2, Application US/09579692B
; Patent No. 6689875
; GENERAL INFORMATION:
; APPLICANT: Vlaams Internationaal Instituut voor Biotechnol
; TITLE OF INVENTION: Molecular characterisation of chromosome translocation t(11;18)
; FILE REFERENCE: PMA/MALT/V043; 2676-4080.1
; CURRENT APPLICATION NUMBER: US/09/579,692B
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/138,834
; PRIOR FILING DATE: 1999-06-09
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer Mult1
US-09-579-692B-2

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

739 CCTTGTGCACTTCAAC 755
1 CCTTGTGCACTTCAAC 17
```

RESULT 27
US-08-222-177A-213
; Sequence 213, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dewitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865,601
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 213:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: mfd56p1
; US-08-222-177A-213
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 660 CTGGTGAAGACACACACT 679
|||||
Db 1 CTGTGAATTCAACACACT 20

RESULT 28
US-08-117-952-543/c
; Sequence 543, Application US/08117952
; Patent No. 5851760
; GENERAL INFORMATION:
; APPLICANT: Evans, Glen A.
; APPLICANT: Smith, Michael W.
; TITLE OF INVENTION: METHOD FOR GENERATION OF SEQUENCE
; TITLE OF INVENTION: SAMPLED MAPS OF COMPLEX GENOMES
; NUMBER OF SEQUENCES: 797
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,952
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/078,471
; FILING DATE: 15-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: P41 9423
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-546-4737
; TELEFAX: 619-546-9392
; INFORMATION FOR SEQ ID NO: 543:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Oligonucleotide
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; US-08-117-952-543
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 499 TCCATGATACATATCTGC 518
|||||
Db 20 TCTTATGTCACCATTTGTC 1

RESULT 29
US-09-021-701-552/c
; Sequence 552, Application US/09021701
; Patent No. 6251588
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; APPLICANT: Delenstarr, Glenda C.
; APPLICANT: Webb, Peter G.
; APPLICANT: Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; TITLE OF INVENTION: probe sequences
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company W/S 20
; STREET: 3000 Hanover Street
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,701
; FILING DATE: 10-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 552:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-021-701-552

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAAGTCAGTA 1562
DB 20 TAAAAAGAAAATCAGTA 1

RESULT 30
US-09-021-701-553/C
Sequence 553, Application US/09021701
Patent No. 6251588
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSER: Records Manager, Legal Department, Hewlett-Packard Company W/S 20
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,701
FILING DATE: 10-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 553:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-021-701-553

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1542 TTAAGAGAAAAGTCAGT 1561
DB 20 TAAAAAGAAAATCAGT 1

RESULT 31
US-09-593-711A-18
Sequence 18, Application US/09593711A
Patent No. 6271030
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Madeline M. Butler
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
FILE REFERENCE: RTS-0118
CURRENT APPLICATION NUMBER: US/09/593,711A
CURRENT FILING DATE: 2000-06-14
NUMBER OF SEQ ID NOS: 244
SEQ ID NO 18
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-18

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 21 CGGCTGCCGCTCTGCTGGG 40
DB 1 CTGCTGCCGCTCTGCTGGG 20

RESULT 32
US-09-716-161A-59/C
Sequence 59, Application US/09716161A
Patent No. 6355482
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Susan M. Freiler
TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN BETA 4 BINDING PROTEIN EXPRESSION
FILE REFERENCE: RTS-0176
CURRENT APPLICATION NUMBER: US/09/716,161A
CURRENT FILING DATE: 2000-11-07
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 59
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-716-161A-59

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1633 TCAGTAACCTCTCTTCTTC 1652
DB 20 TGAGCTGTCTCTCTTCTTC 1

RESULT 33
US-09-629-645A-101/C
Sequence 101, Application US/09629645A
Patent No. 6365354
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF LYSOPHOSPHOLIPASE I EXPRESSION
FILE REFERENCE: RTS-0137

```

; CURRENT APPLICATION NUMBER: US/09/629,645A
; CURRENT FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 164
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-645A-101

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      4 CCGGAACGCCAGGCCGCGG 23
Db      20 CCGGAAGCCACCGCGCGG 1

RESULT 34
US-09-506-073-80/C
; Sequence 80, Application US/09506073
; Patent No. 6410518
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/506,073
; CURRENT FILING DATE: 2000-02-18
; EARLIER APPLICATION NUMBER: US 09/143,214
; EARLIER FILING DATE: 1998-08-28
; EARLIER APPLICATION NUMBER: PCT/US98/13961
; EARLIER FILING DATE: 1998-07-06
; EARLIER APPLICATION NUMBER: US 08/888,982
; EARLIER FILING DATE: 1997-07-07
; EARLIER APPLICATION NUMBER: US 08/756,806
; EARLIER FILING DATE: 1996-11-26
; EARLIER APPLICATION NUMBER: PCT/US95/07111
; EARLIER FILING DATE: 1995-05-31
; EARLIER APPLICATION NUMBER: US 08/250,856
; EARLIER FILING DATE: 1994-05-31
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-506-073-80

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1873 CCGTGTGTGAGGCGAGTAG 1892
Db      20 CAGTGTGTGAGGCGAGCAG 1

RESULT 35
US-09-198-452A-3356
; Sequence 3356, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
```

```

; SEQ ID NO 3356
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3356

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      386 CCTCTTCTCTGTCACCTGCG 405
Db      1 CCTCTTCTCTATCAGCTTGC 20

RESULT 36
US-08-679-645-153
; Sequence 153, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwigen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 153:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-153

Query Match      0.6%; Score 15; DB 1; Length 17;
```


Best Local Similarity 86.7%; Pred. No. 31;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 AGAAGTCCCGACCA 792

DB 3 AGAAGTCCCGACCA 17

RESULT 37

US-08-679-645-155

Sequence 155, Application US/08679645

Patent No. 6350934

GENERAL INFORMATION:

APPLICANT: Zwick, Michael G.

APPLICANT: Edington, Brent E.

APPLICANT: McSwiggen, James A.

APPLICANT: Merlo, Patricia Ann Owens

APPLICANT: Guo, Lining

APPLICANT: Skokut, Thomas A.

APPLICANT: Folkerth, Otto

APPLICANT: Merlo, Donald J.

TITLE OF INVENTION: COMPOSITION AND METHODS FOR

TITLE OF INVENTION: MODULATION OF GENE EXPRESSION

TITLE OF INVENTION: IN PLANTS

NUMBER OF SEQUENCES: 1263

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/679,645

FILING DATE: July 12, 1996

CLASSIFICATION: 800

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/001,135

FILING DATE: July 13, 1995

APPLICATION NUMBER: 08/300,726

FILING DATE: September 2, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 219/247

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 155:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-679-645-155

Query Match

Best Local Similarity 86.7%; Pred. No. 31;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 AGAAGTCCCGACCA 792

DB 2 AGAAGTCCCGACCA 16

RESULT 38
US-08-189-199A-5

Sequence 5, Application US/08189199A

Patent No. 5449609

GENERAL INFORMATION:

APPLICANT: Younk, Donald P.

APPLICANT: Pleasure, David

TITLE OF INVENTION: Methods for Screening for Neurotoxicity

TITLE OF INVENTION: Using a Clonal Human Teratocarcinoma Cell Line

NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5449609x1e

STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: USA

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: IBM PC compatible

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/189,199A

FILING DATE:

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Gaumond, Rebecca R.

REGISTRATION NUMBER: 35,152

REFERENCE/DOCKET NUMBER: CH-0407

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-564-3439

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-189-199A-5

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGCGAAGCGAAG 1010

DB 1 AACCTGCGAAGCGAAG 18

RESULT 39

US-09-213-719-65

Sequence 65, Application US/09213719B

Patent No. 6150162

GENERAL INFORMATION:

APPLICANT: C. Frank Bennett

APPLICANT: Lex M. Cowsett

TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION

FILE REFERENCE: RTS-0006

CURRENT APPLICATION NUMBER: US/09/213,719B

CURRENT FILING DATE: 1998-12-17

NUMBER OF SEQ ID NOS: 91

SEQ ID NO 65

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Antisense Oligonucleotide

US-09-213-719-65

Query Match

0.6%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 502 TCATGACATATTCTGCA 519
Db 1 TCATGTCACATCTCTGCA 18

RESULT 40

US-08-711-628-1
Sequence 1, Application US/08711628
Patent No. 6713247
GENERAL INFORMATION:
APPLICANT: Sah, Dinah W.Y.
APPLICANT: Gage, Fred H.
APPLICANT: Ray, Jasodhara
TITLE OF INVENTION: HUMAN CNS CELL LINES AND METHODS OF USE
TITLE OF INVENTION: THEREFOR
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/711,628
FILING DATE: 03-SEP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 860098.415
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-711-628-1

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTCGGACCGCAG 1010
Db 1 AACCTGACAGACCGCAG 18

RESULT 41

US-08-359-705B-22/C
Sequence 22, Application US/08359705B
Patent No. 5844092
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Ufer, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco

STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/359,705B

FILING DATE: 20-Dec-1994

CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/286846

FILING DATE: 08/10/94

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/215139

FILING DATE: 03/18/94

ATTORNEY/AGENT INFORMATION:
NAME: Torchia, PhD., Timothy E.

REGISTRATION NUMBER: 36,700

REFERENCE/DOCKET NUMBER: P0873P2

TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674

TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: linear
US-08-359-705B-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTGGCCGCGAG 2141
Db 19 CTCACCTTGCGCTGCGC 2

RESULT 42

US-08-286-846A-22/C
Sequence 22, Application US/08286846A
Patent No. 5877016
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Ufer, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/286,846A
FILING DATE: 05-Aug-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, PhD., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P0873P1
TELECOMMUNICATION INFORMATION:

TELEPHONE: 415/225-8674
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-286-846A-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCCCTGGAG 2141
DB 19 CTCACCTTGCCCTGGCG 2

RESULT 43
US-08-457-880A-22/C
Sequence 22, Application US/08457880A
GENERAL INFORMATION:
PATENT No. 5910574
APPLICANT: Leonard G. Presta
APPLICANT: David L. Shelton
APPLICANT: Roman Ulfert
TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/457,880A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/444,622
FILING DATE: 19-May-1995
APPLICATION NUMBER: 08/286846
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, Ph.D., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P0873P1C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-457-880A-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCCCTGGAG 2141
DB 19 CTCACCTTGCCCTGGCG 2

DB 19 CTCACCTTGCCCTGGCG 2

RESULT 44
US-08-444-622A-22/C
Sequence 22, Application US/08444622A
Patent No. 6025166
GENERAL INFORMATION:
APPLICANT: Leonard G. Presta
APPLICANT: David L. Shelton
APPLICANT: Roman Ulfert
TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/444,622A
FILING DATE: 19-May-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/286846
FILING DATE: 5
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, Ph.D., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P0873P1C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-444-622A-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCCCTGGAG 2141
DB 19 CTCACCTTGCCCTGGCG 2

RESULT 45
US-08-942-562-22/C
Sequence 22, Application US/08942562
Patent No. 6027927
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Ulfert, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA

ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/942,562
FILING DATE: 01-OCT-1997
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/444,597
FILING DATE: 19-May-1995
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, Phd., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P0873P1C2
TELEPHONE: 415/225-8674
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-942-562-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCCCTGGAG 2141
DB 19 CTCACCTTGCCCTGGCG 2

RESULT 46
US-09-156-923-22/c
Sequence 22, Application US/09156923
Patent No. 6153189
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Urfert, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knodbe, Martens, Olsson & Bear
STREET: 620 Newport Center Drive 16th Floor
CITY: Newport Beach
STATE: California
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/156,923
FILING DATE: 18-SEP-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/359,705
FILING DATE: 20-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/286846
FILING DATE: 10-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/215139
FILING DATE: 18-MAR-1994

ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: GENENT.33CP2C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 949/760-0404
TELEFAX: 949/760-9502
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-156-923-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCCCTGGAG 2141
DB 19 CTCACCTTGCCCTGGCG 2

RESULT 47
US-09-338-907-476
Sequence 476, Application US/09338907
Patent No. 6265346
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bougueteloret, Lydie
TITLE OF INVENTION: PROSTATE CANCER GENE
FILE REFERENCE: GENSET.18CP1C
CURRENT APPLICATION NUMBER: US/09/338,907
EARLIER FILING DATE: 1999-06-23
EARLIER APPLICATION NUMBER: 08/996,306
EARLIER FILING DATE: 1997-12-22
EARLIER APPLICATION NUMBER: 607/099,658
EARLIER FILING DATE: 1998-09-09
EARLIER APPLICATION NUMBER: 09/218,207
EARLIER FILING DATE: 1998-12-22
NUMBER OF SEQ ID NOS: 578
SOFTWARE: Patent.pm
SEQ ID NO 476
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..15
OTHER INFORMATION: microsequencing oligo for 99-140-130.misl
US-09-338-907-476

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 424 AAAAGCAGCTACAGGTCA 441
DB 2 AAAAGCAGCTACAGACCA 19

RESULT 48
US-09-218-207-476
Sequence 476, Application US/09218207
Patent No. 6346381
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bougueteloret, Lydie

;; TITLE OF INVENTION: Prostate cancer gene
;; FILE REFERENCE: GENSET.018CPI
;; CURRENT APPLICATION NUMBER: US/09/218,207
;; CURRENT FILING DATE: 1998-12-22
;; EARLIER APPLICATION NUMBER: 08/996,306
;; EARLIER FILING DATE: 1997-12-22
;; EARLIER APPLICATION NUMBER: 60/099,658
;; EARLIER FILING DATE: 1998-09-09
;; NUMBER OF SEQ ID NOS: 578
;; SOFTWARE: Patent.pm
;; SEQ ID NO 476
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Homo Sapiens
;; FEATURE:
;; NAME/KEY: misc.feature
;; LOCATION: 1..19
;; OTHER INFORMATION: microsequencing oligo for 99-140-130.m1s1
US-09-218-207-476

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 424 AAAGCAGCTACAGTCA 441
Db 2 AAAGCAGCTACAGCA 19

RESULT 49
US-08-983-605-55/c
;; Sequence 55, Application US/08983605A
;; Patent No. 6720137
;; GENERAL INFORMATION:
;; APPLICANT: Roder, Marion
;; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
;; TITLE OF INVENTION: Trifolium aestivum and the Use of
;; TITLE OF INVENTION: Said Markers
;; FILE REFERENCE: 2936.10400
;; CURRENT APPLICATION NUMBER: US/08/983,605A
;; CURRENT FILING DATE: 1998-05-01
;; EARLIER APPLICATION NUMBER: DE 195 25 284.5
;; EARLIER FILING DATE: 1995-06-28
;; NUMBER OF SEQ ID NOS: 466
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 55
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Trifolium aestivum
US-08-983-605-55

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1918 ATCTCCCTTCGCCACCC 1935
Db 18 ATCTCCCTTCGCCACCC 1

RESULT 50
US-09-696-791-2171/c
;; Sequence 2171, Application US/09696791
;; Patent No. 6770633
;; GENERAL INFORMATION:
;; APPLICANT: Robbins, Joan M.
;; APPLICANT: Trlez, Richard
;; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;; TITLE OF INVENTION: SKIN AND EYE DISEASES
;; FILE REFERENCE: 480124.407
;; CURRENT APPLICATION NUMBER: US/09/696,791
;; CURRENT FILING DATE: 2000-10-25
;; NUMBER OF SEQ ID NOS: 4523

;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 2171
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Homo sapiens
;; FEATURE:
;; OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-696-791-2171

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 877 TCAGCCGAGACCATAG 894
Db 18 TCAGCCGAGACCATAG 1

RESULT 51
US-08-464-514-9
;; Sequence 9, Application US/08464514
;; Patent No. 6265173
;; GENERAL INFORMATION:
;; APPLICANT: EVANS, RONALD M.
;; APPLICANT: MCKEOWN, MICHAEL B.
;; APPLICANT: ORO, ANTHONY E.
;; APPLICANT: SGRAVES, WILLIAM A.
;; APPLICANT: YAO, TSO-PANG
;; TITLE OF INVENTION: MULTIMERIC FORMS OF MEMBERS OF THE
;; TITLE OF INVENTION: STEROID/THYROID SUPERFAMILY OF RECEPTORS WITH THE
;; TITLE OF INVENTION: ULTRASPIRACLE RECEPTOR
;; NUMBER OF SEQUENCES: 29
;; CORRESPONDENCE ADDRESS:
;; ADDRESSER: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
;; STREET: 444 South Flower Street, Suite 2000
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: United States
;; ZIP: 90071

;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/464,514
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/907,908
;; FILING DATE:

;; ATTORNEY/AGENT INFORMATION:
;; NAME: Reiter, Stephen B.
;; REGISTRATION NUMBER: 31192
;; REFERENCE/DOCKET NUMBER: P41 9321
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (619) 546-4737
;; TELEFAX: (619) 546-9392
;; INFORMATION FOR SEQ ID NO: 9:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 16 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear

US-08-464-514-9

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 587 AGGTGACGAGAGTCA 602
Db 1 AGGTGACGAGAGTCA 16

RESULT 52
US-08-486-403-9
Sequence 9, Application US/08486403
Patent No. 6281330
GENERAL INFORMATION:
APPLICANT: EVANS, RONALD M.
APPLICANT: MCKEOWN, MICHAEL B.
APPLICANT: ORO, ANTHONY E.
APPLICANT: SEGRAVES, WILLIAM A.
APPLICANT: YAO, TSO-PANG
TITLE OF INVENTION: MULTIMERIC FORMS OF MEMBERS OF THE
TITLE OF INVENTION: STEROID/THYROID SUPERFAMILY OF RECEPTORS WITH THE
TITLE OF INVENTION: ULTRASPIRACLE RECEPTOR
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
STREET: 444 South Flower Street, Suite 2000
CITY: Los Angeles
STATE: California
COUNTRY: United States
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,403
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/907,908
FILING DATE: 02-JUL-1992
ATTORNEY/AGENT INFORMATION:
NAME: Reiter, Stephen E.
REGISTRATION NUMBER: 31192
REFERENCE/DOCKET NUMBER: P41 9321
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 546-4737
TELEFAX: (619) 546-9392
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-486-403-9

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 587 AGTGGCAGAGGTCA 602
DB 1 AGTGCACAGAGGTCA 16

RESULT 53
US-07-672-530C-39
Sequence 39, Application US/07672530C
Patent No. 6492137
GENERAL INFORMATION:
APPLICANT: SUICOV, HENRY M
APPLICANT: EVANS, RONALD M
APPLICANT: UMESONO, KAZUHIKO
TITLE OF INVENTION: RESPONSE ELEMENT COMPOSITIONS AND ASSAYS EMPLOYING SAME
FILE REFERENCE: 088802/1552
CURRENT APPLICATION NUMBER: US/07/672,530C
CURRENT FILING DATE: 1991-03-19
PRIOR APPLICATION NUMBER: 07/438,757
PRIOR FILING DATE: 1989-11-16

NUMBER OF SEQ ID NOS: 51
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 39
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
US-07-672-530C-39

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 587 AGTGGCAGAGGTCA 602
DB 1 AGTGCACAGAGGTCA 16

RESULT 54
US-09-479-005A-1/c
Sequence 1, Application US/09479005A
Patent No. 6656731
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
FILE REFERENCE: MBIB00-884-C
CURRENT APPLICATION NUMBER: US/09/479,005A
CURRENT FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 09/444,209
PRIOR FILING DATE: 1999-11-19
PRIOR APPLICATION NUMBER: US 09/159,274
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: US 60/059,473
PRIOR FILING DATE: 1997-09-22
NUMBER OF SEQ ID NOS: 1208
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-479-005A-1

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CGCCGCGCTGCCGCC 31
DB 16 CGCCGCGCGCGCGCC 1

RESULT 55
US-08-758-306-147/c
Sequence 147, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

```

; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Fastseq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 147:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-758-306-147

Query Match
Best Local Similarity 0.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1379 GGTCTGTGAGGTGAC 1394
Db 16 GGTCTGTGAGGTGAC 1

RESULT 56
US-09-866-108A-798/c
; Sequence 798, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER-OF SEQ ID NOS: 15755
; SOFTWARE: Aeoica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 798
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
;
US-09-866-108A-798

Query Match
Best Local Similarity 0.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1400 CAGCTTCGGGGCCAA 1415
Db 17 CAGCTTCGGGGCCAA 2

RESULT 57
US-09-866-108A-799/c
; Sequence 799, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeoica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 799
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
;
US-09-866-108A-799

Query Match
Best Local Similarity 0.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1400 CAGCTTCGGGGCCAA 1415
Db 17 CAGCTTCGGGGCCAA 2
```

Db 16 CAGCTTCGGGGCCAA 1

RESULT 58
US-09-866-108A-1294
Sequence 1294, Application US/09866108A
Patent No. 6686188

GENERAL INFORMATION:
APPLICANT: GU Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Shatton G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

PATENT NO. 6686188

SEQ ID NO 1294

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-1294

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1086 AAGCAGTGATCTTCG 1101
|||||

Db 2 AAGCAGTGATCTTCG 17
|||||

RESULT 59
US-09-866-108A-1295
Sequence 1295, Application US/09866108A
Patent No. 6686188

GENERAL INFORMATION:
APPLICANT: GU Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Shatton G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

PATENT NO. 6686188

SEQ ID NO 1295

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-1295

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1086 AAGCAGTGATCTTCG 1101
|||||

Db 1 AAGCAGTGATCTTCG 16
|||||

RESULT 60
US-09-866-108A-2020
Sequence 2020, Application US/09866108A
Patent No. 6686188

GENERAL INFORMATION:
APPLICANT: GU Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Shatton G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668


```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2020
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2020

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      731 CTTGGGTGCTTCTGC 746
Db      2 CTTGGGTGCTTCTGC 17

RESULT 61
US-09-866-108A-2022
; Sequence 2022, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2022
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2022

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      732 CTTGGGTGCTTCTGCA 747
```

```

Db      1 CTTGGGTGCTTCTGCA 16

RESULT 62
US-09-866-108A-2841
; Sequence 2841, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2841
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2841

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1974 GGCTCCAGATGAGG 1989
Db      2 GGCTCCAGATGAGG 17

RESULT 63
US-09-866-108A-2843
; Sequence 2843, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```

```

; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2843
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2843

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1975 GCCTCCAGATGAGGA 1990
DB      1 GCCTCCAGATGAGGA 16

RESULT 64
US-09-866-108A-6608/c
; Sequence 6608, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6609
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6609

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6608
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6608

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1975 GCCTCCAGATGAGGA 1990
DB      17 GCCTCCAGATGAGGA 2
```

```

RESULT 65
US-09-866-108A-6609/c
; Sequence 6609, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6609
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6609

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 1975 GCCTCCGAGATGAGA 1990
Db 16 GCCTCCGAGATGAGA 1

RESULT 66
US-08-758-306-523/C
Sequence 523, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 523:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-523

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 44;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1379 GGTCCTGAGGTGAG 1394
Db 18 GGTCCTGAGGTGAG 3

RESULT 67
US-09-177-359-15/C
Sequence 15, Application US/09177359B
Patent No. 6183963
GENERAL INFORMATION:
APPLICANT: SINNETT, Daniel
APPLICANT: LABUDA, Damian
TITLE OF INVENTION: DETECTION OF CYP1A1, CYP3A4, CYP2D6 AND
TITLE OF INVENTION: NAT2 VARIANTS BY PCR-ALBELE-SPECIFIC OLIGONUCLEOTIDE (ASO)

TITLE OF INVENTION: ASSAY
FILE REFERENCE: 12667-17"US" FC/1d
CURRENT APPLICATION NUMBER: US/09/177,359B
CURRENT FILING DATE: 1998-10-23
NUMBER OF SEQ ID NOS: 37
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 15
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: cDNA for use as primers
US-09-177-359-15

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 44;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 TCCAAGTGAAGC 429
Db 16 TCCAAGTGAAGC 1

RESULT 68
US-09-474-922A-46/C
Sequence 46, Application US/09474922A
Patent No. 6187586
GENERAL INFORMATION:
APPLICANT: Bretz P. Monia
APPLICANT: Lex M. Cowart
APPLICANT: Richard A. Roth
TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION
FILE REFERENCE: RTS-0036
CURRENT APPLICATION NUMBER: US/09/474,922A
CURRENT FILING DATE: 1999-12-29
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 46
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-474-922A-46

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 44;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1068 GGAGAGAAATGAAGTGT 1083
Db 16 GGAGAGAAATGAATGTGT 1

RESULT 69
US-08-974-549A-479
Sequence 479, Application US/08974549A
Patent No. 6166178
GENERAL INFORMATION:
APPLICANT: Cech, Thomas R.
APPLICANT: Linsmer, Joachim
APPLICANT: Nakamura, Toru
APPLICANT: Chapman, Karen B.
APPLICANT: Morlin, Gregg B.
APPLICANT: Harley, Calvin B.
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Human Telomerase Catalytic Subunit
NUMBER OF SEQUENCES: 727
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA

```

ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/974,549A
FILING DATE: 19-NOV-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/724,643
FILING DATE: 01-OCT-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/844,419
FILING DATE: 18-APR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/846,017
FILING DATE: 25-APR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/851,843
FILING DATE: 06-MAY-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/854,050
FILING DATE: 09-MAY-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/911,312
FILING DATE: 14-AUG-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/912,951
FILING DATE: 14-AUG-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/915,503
FILING DATE: 14-AUG-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: NO PCT/US97/17618
FILING DATE: 01-OCT-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/US97/17885
FILING DATE: 01-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Apple, Randolph T.
REGISTRATION NUMBER: 36,429
REFERENCE/DOCKET NUMBER: 015389-002610US
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 479:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY:
LOCATION: 1..17
OTHER INFORMATION: /note="Nam2 primer"
US-08-974-549A-479

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 145 AGCCTGGCCCCG 158
DB 1 AGCCTGGCCCCG 14

```

```

GENERAL INFORMATION:
APPLICANT: Cech, Thomas R.
APPLICANT: Lingner, Joachim
APPLICANT: Nakamura, Toru
APPLICANT: Chapman, Karen B.
APPLICANT: Morin, Gregg B.
APPLICANT: Harley, Calvin
APPLICANT: Andrews, William H.
TITLE OF INVENTION: HUMAN TELOMERASE CATALYTIC SUBUNIT:
TITLE OF INVENTION: THERAPEUTIC METHODS
NUMBER OF SEQUENCES: 335
CORRESPONDENCE ADDRESS:
ADDRESS: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: San Francisco
STATE: California
COUNTRY: United States of America
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/912,951
FILING DATE: 14-AUG-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/854,050
FILING DATE: 09-MAY-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/851,843
FILING DATE: 06-MAY-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/846,017
FILING DATE: 25-APR-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/844,419
FILING DATE: 18-APR-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/724,643
FILING DATE: 01-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Apple, Randolph T.
REGISTRATION NUMBER: 36,429
REFERENCE/DOCKET NUMBER: 015389-002600US
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 246:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-912-951-246

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 145 AGCCTGGCCCCG 158
DB 1 AGCCTGGCCCCG 14

```

RESULT 71

RESULT 70
US-08-912-951-246
; Sequence 246, Application US/08912951
; Patent No. 6475789

US-09-402-181B-479
Sequence 479, Application US/09402181B
Patent No. 6610839
GENERAL INFORMATION:
APPLICANT: Cech, Thomas R.
Lingner, Joachim
Nakamura, Toru
Chapman, Karen B.
Morin, Gregg B.
Harley, Calvin B.
Andrews, William H.
TITLE OF INVENTION: Human Telomerase Catalytic Subunit
NUMBER OF SEQUENCES: 633
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/402,181B
FILING DATE: 29-Sep-1997
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/724,643
FILING DATE: 01-OCT-1996
APPLICATION NUMBER: US 08/844,419
FILING DATE: 18-APR-1997
APPLICATION NUMBER: US 08/846,017
FILING DATE: 25-APR-1997
APPLICATION NUMBER: US 08/851,843
FILING DATE: 06-MAY-1997
APPLICATION NUMBER: US 08/854,050
FILING DATE: 09-MAY-1997
APPLICATION NUMBER: US 08/911,312
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: US 08/912,951
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: US 08/915,503
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: WO PCT/US97/17885
FILING DATE: 01-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Ausenhub, Scott L.
REGISTRATION NUMBER: 42,271
REFERENCE/DOCKET NUMBER: 015389-002620US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 479:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: -
LOCATION: 1..17
OTHER INFORMATION: /note= "Nam2 primer"
SEQUENCE DESCRIPTION: SEQ ID NO: 479:
US-09-402-181B-479
Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

09 145 AGCCCTGGCCCCGG 158
Db 145 AGCCCTGGCCCCGG 14
RESULT 72
US-09-721-456-479
Sequence 479, Application US/09721456
Patent No. 6617110
GENERAL INFORMATION:
APPLICANT: Cech, Thomas R.
Lingner, Joachim
Nakamura, Toru
Chapman, Karen B.
Morin, Gregg B.
Harley, Calvin B.
Andrews, William H.
TITLE OF INVENTION: Human Telomerase Catalytic Subunit
NUMBER OF SEQUENCES: 727
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/721,456
FILING DATE: 22-No. 6617110-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/974,549A
FILING DATE: 19-NOV-1997
APPLICATION NUMBER: US 08/724,643
FILING DATE: 01-OCT-1996
APPLICATION NUMBER: US 08/844,419
FILING DATE: 18-APR-1997
APPLICATION NUMBER: US 08/846,017
FILING DATE: 25-APR-1997
APPLICATION NUMBER: US 08/851,843
FILING DATE: 06-MAY-1997
APPLICATION NUMBER: US 08/854,050
FILING DATE: 09-MAY-1997
APPLICATION NUMBER: US 08/911,312
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: US 08/912,951
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: US 08/915,503
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: WO PCT/US97/17618
FILING DATE: 01-OCT-1997
APPLICATION NUMBER: WO PCT/US97/17885
FILING DATE: 01-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Apple, Randolph Ted
REGISTRATION NUMBER: 36,429
REFERENCE/DOCKET NUMBER: 015389-002610US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 479:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:

```

; NAME/KEY: -
; LOCATION: 1..17
; OTHER INFORMATION: /note="Nam2 primer"
; SEQUENCE DESCRIPTION: SEQ ID NO: 479:
US-09-721-456-479

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY 145 AGCCTTGCCCCGG 158
|||||
1 AGCCTTGCCCCGG 14

RESULT 73
US-09-866-108A-1534
; Sequence 1534, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1534
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1534

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1205 GGGGCTGGTGCCCT 1218
|||||
4 GGGGCTGGTGCCCT 17

RESULT 74
US-09-866-108A-1535
; Sequence 1535, Application US/09866108A

```

```

/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Shatron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aeomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1535
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-1535

Query Match      0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1205 GGGGCTGTGGCCCT 1218
      |||||RR|||||
Db      3 GGGGCTGTGGCCCT 16

RESULT 75
US-09-866-108A-1536
/ Sequence 1536, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Shatron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aeomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1535
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-1535

```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1536

Query Match      0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1205 GGGGCTGTGTCCT 1218
DB      2 GGGGCTGTGTCCT 15

RESULT 76
US-09-866-108A-1537
; Sequence 1537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
```

```

; Patent No. 6686188
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1537

Query Match      0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1205 GGGGCTGTGTCCT 1218
DB      1 GGGGCTGTGTCCT 14

RESULT 77
US-08-129-719-18/c
; Sequence 18, Application US/08129719
; Patent No. 5556755
; GENERAL INFORMATION:
; APPLICANT: Timothy F. Murphy
; TITLE OF INVENTION: Vaccine for Brannhamella catarrhalis
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One Mt Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 720 Kb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft windows 3.1
; SOFTWARE: Wordperfect for windows 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/129,719
; FILING DATE: September 29, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 11520, 0050
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; ORIGINAL SOURCE:
; ORGANISM: Brannhamella catarrhalis
; STRAIN: 25240
; FEATURE:
; LOCATION: CD gene region, 1048-1064
; IDENTIFICATION METHOD: By experiment
; OTHER INFORMATION: hybridizes to Brannhamella catarrhalis gene region
US-08-129-719-18

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1327 TGGTGAAGCTCTTCGAC 1343
DB      17 TGGCGAAGCTCTTCTAC 1

RESULT 78
US-08-306-871-18/c
; Sequence 18, Application US/08306871
```

```
Patent No. 5712118
GENERAL INFORMATION:
APPLICANT: Timothy F. Murphy
TITLE OF INVENTION: Vaccine For Brannhamella catarrhalis
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
STREET: 1800 One Mkt Plaza
CITY: Buffalo
STATE: New York
COUNTRY: United States
ZIP: 14203-2391
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS/ Microsoft Windows 3.1
SOFTWARE: Wordperfect for Windows 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/306,871
FILING DATE: 20-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/129,719
FILING DATE: September 29, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, M. Bud
REGISTRATION NUMBER: 35,300
REFERENCE/DOCKET NUMBER: 11520.0053
TELECOMMUNICATION INFORMATION:
TELEPHONE: (716) 856-4000
TELEFAX: (716) 849-0349
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
ORIGINAL SOURCE:
ORGANISM: Brannhamella catarrhalis
STRAIN: 25240
FEATURE:
LOCATION: CD gene region, 1048-1064
IDENTIFICATION METHOD: by experiment
OTHER INFORMATION: hybridizes to Brannhamella catarrhalis gene region
US-08-306-871-18

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1327 TGGTGAAGCTCTTCGAC 1343
DB      17 TGGCGAAGCTCTTCTAC 1

RESULT 79
US-08-569-959-18/c
Sequence 18, Application US/08569959
Patent No. 5725862
GENERAL INFORMATION:
APPLICANT: Timothy F. Murphy
TITLE OF INVENTION: Vaccine For Brannhamella catarrhalis
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
STREET: 1800 One Mkt Plaza
CITY: Buffalo
STATE: New York
COUNTRY: United States
ZIP: 14203-2391
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS/ Microsoft Windows 3.1
```

```
SOFTWARE: Wordperfect for Windows 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/569,959
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: U.S. 08/129,719
FILING DATE: September 29, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, M. Bud
REGISTRATION NUMBER: 35,300
REFERENCE/DOCKET NUMBER: 11520.0053
TELECOMMUNICATION INFORMATION:
TELEPHONE: (716) 856-4000
TELEFAX: (716) 849-0349
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
ORIGINAL SOURCE:
ORGANISM: Brannhamella catarrhalis
STRAIN: 25240
FEATURE:
LOCATION: CD gene region, 1048-1064
IDENTIFICATION METHOD: by experiment
OTHER INFORMATION: hybridizes to Brannhamella
OTHER INFORMATION: catarrhalis gene region
US-08-569-959-18

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1327 TGGTGAAGCTCTTCGAC 1343
DB      17 TGGCGAAGCTCTTCTAC 1

RESULT 80
US-08-985-162-52/c
Sequence 52, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
```


FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-52

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1539 TTTTAAAGAGAAAA 1555
DB 17 TCTTAAGAGAAAGA 1

RESULT 81
US-08-584-040-7266/c
Sequence 7266, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7266:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7266

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 854 GATGCTGGAGGTATCT 870
DB 17 GATGTAGGAGGTATCT 1

RESULT 82
US-08-584-040-7471
Sequence 7471, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7471:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7471

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 613 GAAGTGGAGCTGTGTGG 629
DB 1 GAAGTGGAGCTGTGTGG 17

RESULT 83

US-09-474-432B-322/C
; Sequence 322, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adams, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MEB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 322
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-322

Query Match

Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 173 GCCAGGGCGCGGGGTG 189
DB 17 GCCGGGGCGCGGGGTG 1

RESULT 84

US-09-371-772B-3075/C
; Sequence 3075, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3075

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 854 GATGCTGGAGGTATCT 870
DB 17 GATGTAGGAGGTATCT 1

RESULT 85

US-09-371-772B-3277
; Sequence 3277, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3277
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3277

Query Match

Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 613 GAACTGGGCTGTCTGG 629
DB 1 GAAACUGUCUGUGUG 17

RESULT 86

US-09-371-772B-4985
; Sequence 4985, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4985
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4985

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;


```
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO: 230
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-230

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1247 AGAGCCATCACCATCC 1263
Db      1 AGAGCCCTCACCATCC 17

RESULT 91
US-09-866-108A-2018
Sequence 2018, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
```

```
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO: 2018
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-2018

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      728 GGGCTGGTGCTCTCT 744
Db      1 GGGCTGGTGCTCTCT 17

RESULT 92
US-09-866-108A-2019
Sequence 2019, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
```

Patent No. 6686188
SEQ ID NO 2019
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-2019

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 729 GGCCTGGGCTGCTCTG 745
DB 1 GCCCTGGGCTGCTCTG 17

RESULT 93
US-09-685-664B-3075/C
Sequence 3075, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3075
LENGTH: 17
TYPE: RNA
ORGANISM: Mus musculus
US-09-685-664B-3075

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 854 GATGCTGGAGGTATCT 870
DB 17 GATGAGGAGGTATCT 1

RESULT 94
US-09-685-664B-3277
Sequence 3277, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08

PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3277
LENGTH: 17
TYPE: RNA
ORGANISM: Mus musculus
US-09-685-664B-3277

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 613 GAACCTGGGCTGCTG 629
DB 1 GAACCTGGGCTGCTG 17

RESULT 95
US-08-050-073-148
Sequence 148, Application US/08050073
Patent No. 5567809
GENERAL INFORMATION:
APPLICANT: Apple, Raymond J.
APPLICANT: Begovich, Ann B.
APPLICANT: Bugawan, Teodorica L.
APPLICANT: Erlich, Henry A.
APPLICANT: Griffith, Robert L.
APPLICANT: Schaff, Stephen J.
TITLE OF INVENTION: Methods and Reagents for HLA DRbeta DNA
TITLE OF INVENTION: Typing
NUMBER OF SEQUENCES: 315
CORRESPONDENCE ADDRESS:
ADDRESSER: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/050,073
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8769
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 148:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
US-08-050-073-148

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1970 GACTGCGCTCCAGATG 1986
DB 2 GCTGCTCCAGATG 18

RESULT 96
US-08-210-762E-45/C
Sequence 45, Application US/08210762E
Patent No. 5837441
GENERAL INFORMATION:
APPLICANT: Hjelte, Brian
APPLICANT: Jensen, Steve
TITLE OF INVENTION: Molecular Clones Producing Recombinant DNA Antigens of
TITLE OF INVENTION: the HARDS virus.
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffman, Masson & Giller
STREET: 2361 Jefferson Davis Highway
CITY: Arlington
STATE: Virginia
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 500 Kb storage
COMPUTER: Accel 486
OPERATING SYSTEM: Windows 3.1
SOFTWARE: Wordperfect 6.1 for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/210,762E
FILING DATE: 22-MAR-94
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/141,035
FILING DATE: 26-OCT-93
APPLICATION NUMBER: 08/120,096
FILING DATE: 13-SEP-93
APPLICATION NUMBER: 08/111,519
FILING DATE: 25-AUG-93
ATTORNEY/AGENT INFORMATION:
NAME: Bultm1, Jean A.
REGISTRATION NUMBER: 24,236
REFERENCE/DOCKET NUMBER: A4710CIP3.SL3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)415-0100
TELEFAX: (703)418-2768
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA viral
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Four Corners Hantavirus
INDIVIDUAL ISOLATE: 3H226
IMMEDIATE SOURCE:
LIBRARY:
CLONE:
PUBLICATION INFORMATION:
AUTHORS: Hjelte, Brian
AUTHORS: Jensen, Steven
AUTHORS: Torres-Martinez, No. 5837441ah
AUTHORS: Yamada, Takashi
AUTHORS: No. 5837441te, Kurt
AUTHORS: Zummalt, Ross
AUTHORS: MacInnes, Kersti
AUTHORS: Myers, Gerald
TITLE: A No. 5837441el Hantavirus Associated with an Outbreak of Fatal Respirat
TITLE: Disease in the Southwestern United States: Evolutionary Relationships to
TITLE: Hantaviruses-Running Title: Hantavirus-associated ARDS
JOURNAL: Journal of Virology
VOLUME: 68
PAGES: in press
DATE: 1994
RELEVANT RESIDUES IN SEQ ID NO: 1: FROM 1 TO 18

US-08-210-762E-45
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2025 CTGCCCCCATGCACCA 2041
Db 17 CTGAGCCCCATGCACCA 1
RESULT 97
US-09-161-015-9/C
Sequence 9, Application US/09161015A
Patent No. 5965370
GENERAL INFORMATION:
APPLICANT: Lex M. Cowart
TITLE OF INVENTION: ANTISENSE MODULATION OF RHOG EXPRESSION
FILE REFERENCE: RTS-0015
CURRENT APPLICATION NUMBER: US/09/161,015A
CURRENT FILING DATE: 1998-09-25
NUMBER OF SEQ ID NOS: 47
SEQ ID NO 9
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-015-9
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1118 CCGATGGGTCCAGAGA 1134
Db 17 CAGAGGGGTCCAGAGA 1

RESULT 98
US-09-205-860-10
Sequence 10, Application US/09205860
Patent No. 5981732
GENERAL INFORMATION:
APPLICANT: Lex M. Cowart
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION
FILE REFERENCE: RTS-0031
CURRENT APPLICATION NUMBER: US/09/205,860
CURRENT FILING DATE: 1998-12-04
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 10
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-860-10
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 17 GCCGGCGCTGCCGCTC 33
Db 1 GCCGGCGCTGCCGCTC 17
RESULT 99
US-09-200-141-40/C
Sequence 40, Application US/09200141
Patent No. 5985663
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett

```

; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF Interleukin-15 EXPRESSION
; FILE REFERENCE: RTS-0022
; CURRENT APPLICATION NUMBER: US/09/200,141
; CURRENT FILING DATE: 1998-11-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 40
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-200-141-40

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1563 TTTCAGTCTTCTTCACT 1579
DB      17 TTACAGTATTCTTCACT 1

RESULT 100
US-09-106-038A-85
; Sequence 85, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 MB
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-106-038A-85

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      757 CAGAGCCACAGAGTG 773
DB      2 CAGAGGCACAGAGTG 18

RESULT 101
```

```

US-09-358-381-23
; Sequence 23, Application US/09358381
; Patent No. 6020199
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
; FILE REFERENCE: RTS-0079
; CURRENT APPLICATION NUMBER: US/09/358,381
; CURRENT FILING DATE: 1999-07-21
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-358-381-23

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1456 TAAATTGGAGTGCA 1472
DB      2 TAAATTGGCGGTGCA 18

RESULT 102
US-09-577-902-23
; Sequence 23, Application US/09577902
; Patent No. 6284538
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowseart
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
; FILE REFERENCE: ISPH-0463
; CURRENT APPLICATION NUMBER: US/09/577,902
; CURRENT FILING DATE: 2000-05-24
; PRIOR APPLICATION NUMBER: US 09/358,381
; PRIOR FILING DATE: 1999-07-21
; PRIOR APPLICATION NUMBER: PCT/US99/29594,
; PRIOR FILING DATE: 1999-12-14
; NUMBER OF SEQ ID NOS: 51
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-577-902-23

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1456 TAAATTGGAGTGCA 1472
DB      2 TAAATTGGCGGTGCA 18

RESULT 103
US-09-106-075A-45/c
; Sequence 45, Application US/09106075A
; Patent No. 6316250
; GENERAL INFORMATION:
; APPLICANT: Hjelte MD, Brian
; APPLICANT: Jensen, Steve
; TITLE OF INVENTION: Molecular Clones Producing Recombinant DNA Antigens of
; FILE REFERENCE: 10312-8U1, Hjelte et al. (210312.0009)
; CURRENT APPLICATION NUMBER: US/09/106,075A
```

```

; CURRENT FILING DATE: 1998-06-29
; PRIOR APPLICATION NUMBER: 08/210,762
; PRIOR FILING DATE: 1994-03-22
; PRIOR APPLICATION NUMBER: 08/141,035
; PRIOR FILING DATE: 1993-10-26
; PRIOR APPLICATION NUMBER: 08/120,096
; PRIOR FILING DATE: 1993-09-13
; PRIOR APPLICATION NUMBER: 08/111,519
; PRIOR FILING DATE: 1993-08-25
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Prospect Hill virus
US-09-106-075A-45

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2025 CTGCCCCCATGCACCA 2041
Db      17 CTGAGCCCCATGCACCA 1

RESULT 104
US-08-584-040-8326
; Sequence 8326, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wairburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 8326:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8326

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 64.7%; Pred. No. 58;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      613 GAAACTGGGCTGTGG 629
Db      2 GAACTGUCUCUCUGG 18

RESULT 105
US-09-387-341-152/c
; Sequence 152, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowser, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; CURRENT FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; EARLIER FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 152
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-387-341-152

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1118 CCGATGGGTCGAGAGA 1134
Db      17 CAGAGGGGTCGAGAGA 1

RESULT 106
US-09-422-978-4223
; Sequence 4223, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CG1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4223
```



```
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: 1..18
/ OTHER INFORMATION: upstream amplification primer 99-14013 for SEQ 289,
US-09-422-978-4223

Query Match
Best Local Similarity 88.2%; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2344 TCCTGATCTCTGATG 2360
DB 2 TCTGTATCCTTGATG 18

RESULT 107
US-09-422-978-5061
/ Sequence 5061, Application US/09422978
/ Patent No. 6537751
/ GENERAL INFORMATION:
/ APPLICANT: Cohen, Daniel
/ APPLICANT: Blumenfeld, Marla
/ APPLICANT: Chumakov, Ilya
/ TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
/ FILE REFERENCE: GENSET.020CPI
/ CURRENT APPLICATION NUMBER: US/09/422,978
/ EARLIER FILING DATE: 1999-10-20
/ EARLIER APPLICATION NUMBER: US 09/298,850
/ EARLIER FILING DATE: 1999-04-21
/ EARLIER APPLICATION NUMBER: US 60/109,732
/ EARLIER FILING DATE: 1998-11-23
/ EARLIER APPLICATION NUMBER: US 60/082,614
/ NUMBER OF SEQ ID NOS: 11796
/ SEQ ID NO 5061
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: 1..18
/ OTHER INFORMATION: upstream amplification primer 99-2058 for SEQ 1127,
US-09-422-978-5061

Query Match
Best Local Similarity 88.2%; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1381 TCCTGAGGTGAAGTGA 1397
DB 1 TCCTGAGGTGAAGTGA 17

RESULT 108
US-09-422-978-11430
/ Sequence 11430, Application US/09422978
/ Patent No. 6537751
/ GENERAL INFORMATION:
/ APPLICANT: Cohen, Daniel
/ APPLICANT: Blumenfeld, Marla
/ APPLICANT: Chumakov, Ilya
/ TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
/ FILE REFERENCE: GENSET.020CPI
/ CURRENT APPLICATION NUMBER: US/09/422,978
/ EARLIER FILING DATE: 1999-10-20
/ EARLIER APPLICATION NUMBER: US 09/298,850
/ EARLIER FILING DATE: 1999-04-21
/ EARLIER APPLICATION NUMBER: US 60/109,732
/ EARLIER FILING DATE: 1998-11-23
/ EARLIER APPLICATION NUMBER: US 60/082,614
```

```
/ EARLIER FILING DATE: 1998-04-21
/ NUMBER OF SEQ ID NOS: 11796
/ SEQ ID NO 11430
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: 1..18
/ OTHER INFORMATION: downstream amplification primer 99-5987 for SEQ 3565, in compleme
US-09-422-978-11430

Query Match
Best Local Similarity 88.2%; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 699 ATCTTGATACCAACC 715
DB 2 ATCTTGATGCCACAC 18

RESULT 109
US-09-371-772B-3984
/ Sequence 3984, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Favco, Pam
/ APPLICANT: McSwigen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Secobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ EARLIER FILING DATE: 1999-08-10
/ EARLIER APPLICATION NUMBER: US 60/005,974
/ EARLIER FILING DATE: 1995-10-26
/ EARLIER APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: Patencin version 3.0
/ SEQ ID NO 3984
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Mus sp.
/ OTHER INFORMATION: Mus sp.
US-09-371-772B-3984

Query Match
Best Local Similarity 64.7%; DB 1; Length 18;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 613 GAACCTGGCTGTGTGG 629
DB 2 GAACCTGGCTGTGTGG 18

RESULT 110
US-09-954-736A-17/C
/ Sequence 17, Application US/09954736A
/ Patent No. 6689744
/ GENERAL INFORMATION:
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Koepfen, Hartmut
/ APPLICANT: Ross, Sarajane
/ APPLICANT: Shou, Jianyong
/ TITLE OF INVENTION: NOTCH RECEPTOR AGONISTS AND USES
/ FILE REFERENCE: P1848R1
/ CURRENT APPLICATION NUMBER: US/09/954,736A
/ EARLIER FILING DATE: 2001-09-17
/ EARLIER APPLICATION NUMBER: US 60/234,674
/ PRIOR FILING DATE: 2000-09-22
/ NUMBER OF SEQ ID NOS: 21
```

SEQ ID NO 17
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-954-736A-17

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 TGCCTTCTGCACTCA 753
Db 18 TGCCTTCTGCACTCA 2

RESULT 111
US-09-155-885A-247/c
Sequence 247, Application US/09155885A
Patent No. 6709812
GENERAL INFORMATION:
APPLICANT: STOVER, LIEVEN
ROSSAU, RUDI
MAERTENS, GEERT

TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
NUMBER OF SEQUENCES: 313
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHIVE P.C.
STREET: 1100 NORTH GLEBE ROAD
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/155,885A
FILING DATE: 08-Oct-1998
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP97/02002
FILING DATE: 21-APR-1997
APPLICATION NUMBER: EP 96870053.4
FILING DATE: 19-APR-1996

ATTORNEY/AGENT INFORMATION:
NAME: SADOFF, B.J.
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 2551-5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100

INFORMATION FOR SEQ ID NO: 247:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 247:
US-09-155-885A-247

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1302 TACCAACATGTACAT 1318
Db 1302 TACCAACATGTACAT 1318

Db 18 TACCAACATGTACAT 2

RESULT 112
US-10-071-411A-22
Sequence 22, Application US/10071411A
Patent No. 6797475
GENERAL INFORMATION:
APPLICANT: Glenn Barnes
APPLICANT: Joanne Meyer

TITLE OF INVENTION: Detection of Polymorphisms in the Human
FILE REFERENCE: MRI-021
CURRENT APPLICATION NUMBER: US/10/071,411A
CURRENT FILING DATE: 2002-02-07
PRIOR APPLICATION NUMBER: 60/267,515
PRIOR FILING DATE: 2001-02-08
PRIOR APPLICATION NUMBER: 60/314,248
PRIOR FILING DATE: 2001-08-21

NUMBER OF SEQ ID NOS: 66
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 18
TYPE: DNA

ORGANISM: Homo sapiens
US-10-071-411A-22

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2018 GAAAGACTGCCCCCA 2034
Db 1 GAAAGACTGCCCCCA 17

RESULT 113
US-09-685-664B-3984
Sequence 3984, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggan, Jim
APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
FILE REFERENCE: MBH800-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
CURRENT FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: Patent In version 3.0
SEQ ID NO 3984
LENGTH: 18
TYPE: RNA

ORGANISM: Mus musculus
US-09-685-664B-3984

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 64.7%; Pred. No. 58;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 613 GAAACGTGGCTGTGG 629
Db 2 GAAACGTGGCTGTGG 18

RESULT 114
PCT-US93-12603-11/C
Sequence 11, Application PC/TUS9312603
GENERAL INFORMATION:
APPLICANT: Denner, Larry A
APPLICANT: Rege, Ajay A
APPLICANT: Dixon, Richard AF
TITLE OF INVENTION: ANTISENSE MOLECULES DIRECTED AGAINST
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dressler, Goldsmith, Shore & Milnamov, Ltd.
STREET: 180 North Steetson, Suite 4700
CITY: Chicago
STATE: IL
COUNTRY: USA
ZIP: 60601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/12603
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Katz, Martin L.
REGISTRATION NUMBER: 25,011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312)616-5400
TELEFAX: (312)616-5460
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US93-12603-11

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 CCCCGTGTGTGAGGC 1887
DB 17 CCCAGTGTGTGAGGC 1

RESULT 115
US-08-363-240A-622
Sequence 622, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwigen, James
APPLICANT: Bisgaler, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION, AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 622:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-622

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 56;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 361 CCAGCATCTCTCCG 375
DB 1 CCAGCAUCCUCCAG 15

RESULT 116
US-08-585-684B-91/C
Sequence 91, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Steinhcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: PasteQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 91:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-91

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 56;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 766 CAGAGTGAGCAAGA 780
DB 15 CAGAGTGAGCAAGA 1

RESULT 117
US-09-038-073-91/c
Sequence 91, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 91:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-91

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 56;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 766 CAGAGTGAGCAAGA 780
DB 15 CAGAGTGAGCAAGA 1

RESULT 118
US-08-233-608-25/c
Sequence 25, Application US/08233608
Patent No. 5585238
GENERAL INFORMATION:
APPLICANT: Ligon, James M
APPLICANT: Beck, James J
TITLE OF INVENTION: Detection of Fungal Pathogens Using the
TITLE OF INVENTION: Polymerase Chain Reaction
NUMBER OF SEQUENCES: 49
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cliba-Geigy Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: NY
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/233,608
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Spruill, W. Murray
REGISTRATION NUMBER: 32,943
REFERENCE/DOCKET NUMBER: CGC 1739
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8615
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-233-608-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAAGTGCCCCCGA 2270
DB 15 GCAAGTGCCCCCGA 1

RESULT 119
US-08-887-480-25/c
Sequence 25, Application US/08887480
Patent No. 5814453
GENERAL INFORMATION:
APPLICANT: Beck, James J
TITLE OF INVENTION: Detection of Fungal Pathogens Using the
TITLE OF INVENTION: Polymerase Chain Reaction
NUMBER OF SEQUENCES: 96
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5814453artis Corporation
STREET: 520 White Plains Road
CITY: Tarrytown
STATE: NY

COUNTRY: USA
ZIP: 10591
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/887,480
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/722,187
FILING DATE: 15-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Meigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: CGC 1739/PCT/CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULAR TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHEICAL: NO
ANTI-SENSE: NO
US-08-887-480-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAGGTGCCCCCGA 2270
DB 15 GCAGGTGCCCCCGA 1

RESULT 120
US-08-722-187-25/C
Sequence 25, Application US/08722187
Patent No. 5955274
GENERAL INFORMATION:
APPLICANT: Ligon, James M
APPLICANT: Beck, James J
TITLE OF INVENTION: Detection of Fungal Pathogens Using the
NUMBER OF INVENTIONS: Polymerase Chain Reaction
NUMBER OF SEQUENCES: 86
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ciba-Geigy Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: NY
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/722,187
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/233,608
FILING DATE: 04-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Walsh, Andrea C.

REGISTRATION NUMBER: 34,988
REFERENCE/DOCKET NUMBER: CGC 1739
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8666
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULAR TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHEICAL: NO
ANTI-SENSE: NO
US-08-722-187-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAGGTGCCCCCGA 2270
DB 15 GCAGGTGCCCCCGA 1

RESULT 121
US-08-985-162-53/C
Sequence 53, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Bell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STREET: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELFX: 67-3510
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

```

;
; TOPOLOGY: linear
US-08-985-162-53

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1539 TTTTAAAGAGGAAA 1553
Db      16 TCTTTAAGAGGAAA 2

RESULT 122
US-08-985-162-326
; Sequence 326, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akheer, Saghir
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 326:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-326

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 65;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      853 TGATGCTGAGGTA 867
Db      3 UGAUGUCUGAGCUA 17

RESULT 123
US-09-474-432B-487
```

```

; Sequence 487, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 691
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-691

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      2021 AGAGTCCCCCAT 2035
Db      3 AGUAGUCGCCCCCAU 17

RESULT 124
US-09-474-432B-691
; Sequence 691, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 691
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-691
```

```

Best Local Similarity 66.7%; Pred. No. 65;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1824 GCAGGACCAGTTTCT 1838
      ||||| |||||:::|
Db      1 GCAGGCCAGUUCU 15

RESULT 127
US-09-476-387-486
; Sequence 486, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleoside Triphosphate and their Incorporation into Oli
; FILE REFERENCE: MEHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524

```

```

; SOFTWARE: Patent.in version 3.0
; SEQ ID NO 486
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-486

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2021 AGGACTGCCCCCAT 2035
        |||:|||||:
Db       3 AGUACUGCCCCCAU 17

RESULT 128
US-09-476-387-690
; Sequence 690, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Rbozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beautyd, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic.
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Olig
; FILE REFERENCE: MBHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28

```

; PRIOR APPLICATION NUMBER: 09/186,675
 ; PRIOR FILING DATE: 1998-11-04

THIS PAGE BLANK (USPTO)

; PRIOR APPLICATION NUMBER: 60/083,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; NUMBER OF SEQ ID NOS: 1524
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 690
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-476-387-690

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 73.3%; Pred. No. 65;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 33 CTGCTGGGCTCTAGG 47
 1 CUGCUGGGGUCCAGG 15

RESULT 129

US-09-401-063-53/c
 ; Sequence 53, Application US/09401063
 ; Patent No. 6623962

; GENERAL INFORMATION:
 ; APPLICANT: Akhtar, Saghir
 ; APPLICANT: Fell, Patricia
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT
 ; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; TITLE OF INVENTION: FACTOR RECEPTORS
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066

; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq for Windows 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/401,063
 ; FILING DATE:

; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/985,162
 ; FILING DATE: 04 December 1997
 ; APPLICATION NUMBER: 60/036,476
 ; FILING DATE: 31 January 1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 230/107
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 53:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 US-09-401-063-53

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 65;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1539 TTTTAAAGAGAA 1553
 16 TCTTAAAGAGAA 2

RESULT 130

US-09-401-063-326
 ; Sequence 326, Application US/09401063
 ; Patent No. 6623962

; GENERAL INFORMATION:
 ; APPLICANT: Akhtar, Saghir
 ; APPLICANT: Fell, Patricia
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT
 ; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; TITLE OF INVENTION: FACTOR RECEPTORS
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066

; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq for Windows 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/401,063
 ; FILING DATE:

; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/985,162
 ; FILING DATE: 04 December 1997
 ; APPLICATION NUMBER: 60/036,476
 ; FILING DATE: 31 January 1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 230/107
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 326:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 US-09-401-063-326

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 60.0%; Pred. No. 65;
 Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 853 TGATGCTGGAGTA 867
 3 UGAUGUCUGGAGCUA 17

RESULT 131

US-09-866-108A-797/c
 ; Sequence 797, Application US/09866108A

THIS PAGE BLANK (USPTO)

```
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 797
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-797

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1401 AGCTTCGGGGCCAA 1415
Db 17 AGCTTCGGGGCCAA 3

RESULT 132
US-09-866-108A-800/c
Sequence 800, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1401 AGCTTCGGGGCCAA 1415
Db 17 AGCTTCGGGGCCAA 3

RESULT 132
US-09-866-108A-800/c
Sequence 800, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
```

```
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 800
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-800

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1400 CAGCTTCGGGGCCCA 1414
Db 15 CAGCTTCGGGGCCCA 1

RESULT 133
US-09-866-108A-1293
Sequence 1293, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
```

THIS PAGE BLANK (USPTO)

; Patent No. 6686188
; SEQ ID NO 1293
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1293

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1086 AAGCAGGTGATCTTC 1100
|||||
Db 3 AAGCAGGTGAGCTTC 17

RESULT 134

US-09-866-108A-1296
; Sequence 1296, Application US/09866108A
; Patent No. 6686188

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine

; Patent No. 6686188
; SEQ ID NO 1296

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1296

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1087 AGCAGGTGATCTTC 1101
|||||
Db 1 AGCAGGTGAGCTTC 15

RESULT 135

US-09-866-108A-2023

; Sequence 2023, Application US/09866108A

; Patent No. 6686188
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine

; Patent No. 6686188
; SEQ ID NO 2023

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2023

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 TCGGTGCTTCTGCA 747
|||||
Db 1 TCGGTGCTTCTGCA 15

RESULT 136

US-09-866-108A-2840

; Sequence 2840, Application US/09866108A
; Patent No. 6686188

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

THIS PAGE BLANK (USPTO)

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2840
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2840

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1974 GCCTCCAGGATGAG 1988
DB 3 GCCTCCAGGATGAG 17

RESULT 137
US-09-866-108A-2844
; Sequence 2844, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2840
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2840

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1974 GCCTCCAGGATGAG 1988
DB 3 GCCTCCAGGATGAG 17

RESULT 137
US-09-866-108A-2844
; Sequence 2844, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2844
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2844

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1976 CCTCCAGGATGAGGA 1990
DB 1 CCTCCAGGATGAGGA 15

RESULT 138
US-09-866-108A-6040
; Sequence 6040, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6040
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6040

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 629 GCGCTACTTTCGAGA 643
DB 3 GTGCTACTTTCGAGA 17

RESULT 139
```

THIS PAGE BLANK (USPTO)

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

RESULT 140
/ US/09-866-108A-6042
/ Sequence 6042, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYO2IN-LIKE GENE EXPRESSION
/ FILE REFERENCE: A60MCA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT PTLING CASE...: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,450
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 242663.6

```

```
Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 141
US-09-866-108A-6607/c
Sequence 6607, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: A6OMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.

THIS PAGE BLANK (USPTO)

NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6607
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6607

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1976 CCTCCAGGATGAGGA 1990

Db 17 CCTCCAGGATGTGGA 3

RESULT 142

US-09-866-108A-6610/c
; Sequence 6610, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6610
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-6610
; Sequence 6610, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6610
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-6610

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1975 GCCTCAGGATGAGG 1989

Db 15 GCCTCAGGATGTGG 1

RESULT 143

US-09-866-108A-10512
; Sequence 10512, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10512
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-10512

US-09-866-108A-10513

US-09-866-108A-10514

US-09-866-108A-10515

US-09-866-108A-10516

US-09-866-108A-10517

US-09-866-108A-10518

US-09-866-108A-10519

US-09-866-108A-10520

US-09-866-108A-10521

US-09-866-108A-10522

US-09-866-108A-10523

US-09-866-108A-10524

US-09-866-108A-10525

US-09-866-108A-10526

US-09-866-108A-10527

US-09-866-108A-10528

US-09-866-108A-10529

US-09-866-108A-10530

US-09-866-108A-10531

US-09-866-108A-10532

US-09-866-108A-10533

US-09-866-108A-10534

US-09-866-108A-10535

US-09-866-108A-10536

US-09-866-108A-10537

US-09-866-108A-10538

US-09-866-108A-10539

US-09-866-108A-10540

US-09-866-108A-10541

US-09-866-108A-10542

US-09-866-108A-10543

US-09-866-108A-10544

US-09-866-108A-10545

US-09-866-108A-10546

US-09-866-108A-10547

US-09-866-108A-10548

US-09-866-108A-10549

US-09-866-108A-10550

US-09-866-108A-10551

US-09-866-108A-10552

US-09-866-108A-10553

US-09-866-108A-10554

US-09-866-108A-10555

US-09-866-108A-10556

US-09-866-108A-10557

US-09-866-108A-10558

US-09-866-108A-10559

US-09-866-108A-10560

US-09-866-108A-10561

US-09-866-108A-10562

US-09-866-108A-10563

US-09-866-108A-10564

US-09-866-108A-10565

US-09-866-108A-10566

US-09-866-108A-10567

US-09-866-108A-10568

US-09-866-108A-10569

US-09-866-108A-10570

US-09-866-108A-10571

US-09-866-108A-10572

US-09-866-108A-10573

US-09-866-108A-10574

US-09-866-108A-10575

THIS PAGE BLANK (USPTO)

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10513
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-10513

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2309 GGGCCGGGGAGGAAA 2323
Db 2 GGGACGGGGAGGAAA 16

RESULT 145
US-09-866-108A-10514
; Sequence 10514, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10514
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-10514

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2309 GGGCCGGGGAGGAAA 2323
Db 1 GGGACGGGGAGGAAA 15

RESULT 146
US-09-404-912-151/c
; Sequence 151, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; PRIOR FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 151
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
; US-09-404-912-151

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 TTGGAGAGAAATGAA 1079
Db 15 TTGGAGAGAAATTA 1

RESULT 147
PCT-US95-04712-25/c
; Sequence 25, Application PC/TUS9504712
; GENERAL INFORMATION:
; APPLICANT: Ligon, James M
; APPLICANT: Beck, James J
; TITLE OF INVENTION: Detection of Fungal Pathogens Using the
; TITLE OF INVENTION: Polymerase Chain Reaction
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ciba-Geigy Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

THIS PAGE BLANK (USPTO)

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/04712
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/233,608
FILING DATE: 04-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Walsh, Andrea C.
REGISTRATION NUMBER: 34,988
REFERENCE/DOCKET NUMBER: CGC 1739
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8666
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US95-04712-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAGGTGCCCCCGA 2270
|||
Db 15 GCAGGTGCCCCCGA 1

Search completed: August 8, 2005, 09:59:24
Job time : 4 secs

THIS PAGE BLANK (USPTO)